PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Evgrafov, OV; Mersiyanova, I; Irobi, J; Van Den Bosch, L; Dierick, I; Leung, CL; Schagina, O; Verpoorten, N; Van Impe, K; Fedotov, V; Dadali, E; Auer-Grumbach, M; Windpassinger, C; Wagner, K; Mitrovic, Z; Hilton-Jones, D; Talbot, K; Martin, JJ; Vasserman, N; Tverskaya, S; Polyakov, A; Liem, RKH; Gettemans, J; Robberecht, W; De Jonghe, P; Timmerman, V				Evgrafov, OV; Mersiyanova, I; Irobi, J; Van Den Bosch, L; Dierick, I; Leung, CL; Schagina, O; Verpoorten, N; Van Impe, K; Fedotov, V; Dadali, E; Auer-Grumbach, M; Windpassinger, C; Wagner, K; Mitrovic, Z; Hilton-Jones, D; Talbot, K; Martin, JJ; Vasserman, N; Tverskaya, S; Polyakov, A; Liem, RKH; Gettemans, J; Robberecht, W; De Jonghe, P; Timmerman, V			Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy	NATURE GENETICS			English	Article							ALPHA-B-CRYSTALLIN; SPINAL MUSCULAR-ATROPHY; MISSENSE MUTATION; UP-REGULATION; HSP27; PROTEIN; TYPE-2; MAPS; GENE; MYOPATHY	Charcot-Marie-Tooth disease (CMT) is the most common inherited neuromuscular disease and is characterized by considerable clinical and genetic heterogeneity(1). We previously reported a Russian family with autosomal dominant axonal CMT and assigned the locus underlying the disease (CMT2F; OMIM 606595) to chromosome 7q11-q21 (ref. 2). Here we report a missense mutation in the gene encoding 27-kDa small heat-shock protein 131 (HSPB1, also called HSP27) that segregates in the family with CMT2F Screening for mutations in HSPB1 in 301 individuals with CMT and 115 individuals with distal hereditary motor neuropathies (distal HMNs) confirmed the previously observed mutation and identified four additional missense mutations. We observed the additional HSPB1 mutations in four families with distal HMN and in one individual with CMT neuropathy. Four mutations are located in the Hsp20-alpha-crystallin domain, and one mutation is in the C-terminal part of the HSP27 protein. Neuronal cells transfected with mutated HSPB1 were less viable than cells expressing the wild-type protein. Cotransfection of neurofilament light chain (NEFL) and mutant HSPB1 resulted in altered neurofilament assembly in cells devoid of cytoplasmic intermediate filaments.	New York State Psychiat Inst & Hosp, Res Fdn Mental Hyg, Dept Psychiat, Unit 28, New York, NY 10032 USA; Russian Acad Med Sci, Med Genet Res Ctr, DNA Diagnost Lab, Moscow, Russia; Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium; Katholieke Univ Leuven, Dept Expt Neurol, Neurobiol Lab, Louvain, Belgium; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; Ctr Diagnost, Genet Counseling Dept, Voronezh, Russia; Med Univ Graz, Inst Med Biol & Human Genet, Graz, Austria; Univ Zagreb, Sch Med, Clin Hosp Ctr, Dept Neurol,Ctr Neuromuscular Dis, Zagreb 41001, Croatia; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 2JD, England; Univ Antwerp, Born Bunge Fdn, B-2020 Antwerp, Belgium; Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium	New York State Psychiatry Institute; Research Centre for Medical Genetics; Russian Academy of Medical Sciences; Flanders Institute for Biotechnology (VIB); University of Antwerp; KU Leuven; Columbia University; Flanders Institute for Biotechnology (VIB); Ghent University; Medical University of Graz; University of Zagreb; Radcliffe Infirmary; University of Oxford; University of Antwerp; University of Antwerp	Evgrafov, OV (corresponding author), New York State Psychiat Inst & Hosp, Res Fdn Mental Hyg, Dept Psychiat, Unit 28, 1051 Riverside Dr, New York, NY 10032 USA.	Evgrafo@pi.cpmc.columbia.edu	Dadali, Elena/AFG-0883-2022; Timmerman, Vincent/O-7283-2019; Van Den Bosch, Ludo/B-7258-2012; Talbot, Kevin/F-7361-2011; Shchagina, Olga/W-4835-2018	Dadali, Elena/0000-0001-5602-2805; Timmerman, Vincent/0000-0002-2162-0933; Shchagina, Olga/0000-0003-4905-1303; Van Den Bosch, Ludo/0000-0003-0104-4067; Talbot, Kevin/0000-0001-5490-1697				Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; Batulan Z, 2003, J NEUROSCI, V23, P5789; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Bera S, 2002, BIOCHEMISTRY-US, V41, P12421, DOI 10.1021/bi0204140; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; Fontaine JM, 2003, CELL STRESS CHAPERON, V8, P62, DOI 10.1379/1466-1268(2003)8<62:TSODFP>2.0.CO;2; HARDING AE, 1980, J NEUROL SCI, V45, P337, DOI 10.1016/0022-510X(80)90177-X; HARDING AE, 1980, BRAIN, V103, P259, DOI 10.1093/brain/103.2.259; IROBI J, 2004, NAT GENET; Ismailov SM, 2001, EUR J HUM GENET, V9, P646, DOI 10.1038/sj.ejhg.5200686; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Klein CJ, 2003, NEUROLOGY, V60, P1151, DOI 10.1212/01.WNL.0000055900.30217.EA; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; Nelis E, 2004, J MED GENET, V41, P193, DOI 10.1136/jmg.2003.012633; Perez-Olle R, 2002, J CELL SCI, V115, P4937, DOI 10.1242/jcs.00148; Perng MD, 1999, J CELL SCI, V112, P2099; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Tang BS, 2004, HUM GENET, V114, P527, DOI 10.1007/s00439-004-1102-1; Verhoeven K, 2003, AM J HUM GENET, V72, P722, DOI 10.1086/367847; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	30	459	490	1	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2004	36	6					602	606		10.1038/ng1354	http://dx.doi.org/10.1038/ng1354			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15122254	Bronze			2022-12-25	WOS:000221763700017
J	Martinez, D; Larrondo, LF; Putnam, N; Gelpke, MDS; Huang, K; Chapman, J; Helfenbein, KG; Ramaiya, P; Detter, JC; Larimer, F; Coutinho, PM; Henrissat, B; Berka, R; Cullen, D; Rokhsar, D				Martinez, D; Larrondo, LF; Putnam, N; Gelpke, MDS; Huang, K; Chapman, J; Helfenbein, KG; Ramaiya, P; Detter, JC; Larimer, F; Coutinho, PM; Henrissat, B; Berka, R; Cullen, D; Rokhsar, D			Genome sequence of the lignocellulose degrading fungus Phanerochaete chrysosporium strain RP78	NATURE BIOTECHNOLOGY			English	Article							LIGNIN PEROXIDASE GENES; PHANEROCHAETE-CHRYSOSPORIUM; GLYOXAL OXIDASE; FILAMENTOUS FUNGUS; ORGANIZATION; IDENTIFICATION; SPECIFICITIES; PHEROMONE; ELEMENTS; CLUSTER	White rot fungi efficiently degrade lignin, a complex aromatic polymer in wood that is among the most abundant natural materials on earth. These fungi use extracellular oxidative enzymes that are also able to transform related aromatic compounds found in explosive contaminants, pesticides and toxic waste. We have sequenced the 30-million base-pair genome of Phanerochaete chrysosporium strain RP78 using a whole genome shotgun approach. The P. chrysosporium genome reveals an impressive array of genes encoding secreted oxidases, peroxidases and hydrolytic enzymes that cooperate in wood decay. Analysis of the genome data will enhance our understanding of lignocellulose degradation, a pivotal process in the global carbon cycle, and provide a framework for further development of bioprocesses for biomass utilization, organopollutant degradation and fiber bleaching. This genome provides a high quality draft sequence of a basidiomycete, a major fungal phylum that includes important plant and animal pathogens.	US Forest Serv, USDA, Forest Prod Lab, Madison, WI 53726 USA; US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Mol Genet & Microbiol, Santiago, Chile; Millennium Inst Fundamental & Appl Biol, Santiago, Chile; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Novozymes Biotech, Davis, CA 95616 USA; Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; CNRS, UMR 6098, F-13402 Marseille, France; Univ Aix Marseille 1, F-13402 Marseille, France; Univ Aix Marseille 2, F-13402 Marseille, France; Amer Museum Nat Hist, New York, NY 10027 USA	United States Department of Agriculture (USDA); United States Forest Service; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; Pontificia Universidad Catolica de Chile; University of California System; University of California Berkeley; Novozymes; United States Department of Energy (DOE); Oak Ridge National Laboratory; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; American Museum of Natural History (AMNH)	Cullen, D (corresponding author), US Forest Serv, USDA, Forest Prod Lab, 1 Gifford Pinchot Dr, Madison, WI 53726 USA.	dcullen@facstaff.wisc.edu; DSRokhsar@lbl.gov	Putnam, Nicholas/B-9968-2008; Cullen, Daniel/AAN-5484-2020; Henrissat, Bernard/J-2475-2012; Coutinho, Pedro M/C-4473-2008; Larrondo, Luis/J-1086-2016	Putnam, Nicholas/0000-0002-1315-782X; Henrissat, Bernard/0000-0002-3434-8588; Larrondo, Luis/0000-0002-8832-7109; Rokhsar, Daniel/0000-0002-8704-2224				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ander P, 1997, J BIOTECHNOL, V53, P115, DOI 10.1016/S0168-1656(97)01680-5; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Berbee ML, 2001, MYCOTA, V7, P229; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; BLANCHETTE RA, 1991, ANNU REV PHYTOPATHOL, V29, P381, DOI 10.1146/annurev.py.29.090191.002121; BURDSALL H H JR, 1974, Mycotaxon, V1, P123; Burset M, 1996, GENOMICS, V34, P353, DOI 10.1006/geno.1996.0298; CASSELTON LA, 1995, CAN J BOT, V73, pS266, DOI 10.1139/b95-256; Coutinho PM, 2003, TRENDS PLANT SCI, V8, P563, DOI 10.1016/j.tplants.2003.10.002; COVERT SF, 1992, APPL ENVIRON MICROB, V58, P2168, DOI 10.1128/AEM.58.7.2168-2175.1992; Detter JC, 2002, GENOMICS, V80, P691, DOI 10.1006/geno.2002.7020; Eriksson K.-E., 1990, MICROBIAL ENZYMATIC; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; GASKELL J, 1991, NUCLEIC ACIDS RES, V19, P599, DOI 10.1093/nar/19.3.599; GASKELL J, 1994, BIO-TECHNOL, V12, P1372, DOI 10.1038/nbt1294-1372; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goodwin TJD, 2000, GENOME RES, V10, P174, DOI 10.1101/gr.10.2.174; Guigo R, 2000, GENOME RES, V10, P1631, DOI 10.1101/gr.122800; Halsall JR, 2000, GENETICS, V154, P1115; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; ISAYA G, 1995, GENOMICS, V28, P450, DOI 10.1006/geno.1995.1174; Kempken F, 1998, BIOESSAYS, V20, P652, DOI 10.1002/(SICI)1521-1878(199808)20:8&lt;652::AID-BIES8&gt;3.0.CO;2-K; KERSTEN PJ, 1990, P NATL ACAD SCI USA, V87, P2936, DOI 10.1073/pnas.87.8.2936; KERSTEN PJ, 1987, J BACTERIOL, V169, P2195, DOI 10.1128/jb.169.5.2195-2201.1987; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Kues U, 2001, CURR GENET, V39, P16, DOI 10.1007/s002940000176; Larrondo LF, 2003, APPL ENVIRON MICROB, V69, P6257, DOI 10.1128/AEM.69.10.6257-6263.2003; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mannhaupt G, 2003, NUCLEIC ACIDS RES, V31, P1944, DOI 10.1093/nar/gkg293; Martinez AT, 2002, ENZYME MICROB TECH, V30, P425, DOI 10.1016/S0141-0229(01)00521-X; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; O'Shea SF, 1998, GENETICS, V148, P1081; RAEDER U, 1989, MOL MICROBIOL, V3, P911, DOI 10.1111/j.1365-2958.1989.tb00240.x; Schulte U, 2002, J BIOTECHNOL, V94, P3, DOI 10.1016/S0168-1656(01)00415-1; Stewart P, 1999, J BACTERIOL, V181, P3427, DOI 10.1128/JB.181.11.3427-3432.1999; Stewart P, 2000, APPL ENVIRON MICROB, V66, P1629, DOI 10.1128/AEM.66.4.1629-1633.2000; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; Whittaker MM, 1999, J BIOL CHEM, V274, P36226, DOI 10.1074/jbc.274.51.36226; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Wostemeyer J, 2002, CURR GENET, V41, P189, DOI 10.1007/s00294-002-0306-y; Xu Y, 1997, J COMPUT BIOL, V4, P325, DOI 10.1089/cmb.1997.4.325	46	635	687	1	122	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					695	700		10.1038/nbt967	http://dx.doi.org/10.1038/nbt967			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15122302	hybrid			2022-12-25	WOS:000221785300030
J	Pearse, DD; Pereira, FC; Marcillo, AE; Bates, ML; Berrocal, YA; Filbin, MT; Bunge, MB				Pearse, DD; Pereira, FC; Marcillo, AE; Bates, ML; Berrocal, YA; Filbin, MT; Bunge, MB			cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; ADENYLATE-CYCLASE; MESSENGER-RNA; RATING-SCALE; REGENERATION; ACTIVATION; INHIBITION; APOPTOSIS	Central neurons regenerate axons if a permissive environment is provided; after spinal cord injury, however, inhibitory molecules are present that make the local environment nonpermissive. A promising new strategy for inducing neurons to overcome inhibitory signals is to activate cAMP signaling. Here we show that cAMP levels fall in the rostral spinal cord, sensorimotor cortex and brainstem after spinal cord contusion. Inhibition of cAMP hydrolysis by the phosphodiesterase IV inhibitor rolipram prevents this decrease and when combined with Schwann cell grafts promotes significant supraspinal and proprioceptive axon sparing and myelination. Furthermore, combining rolipram with an injection of db-cAMP near the graft not only prevents the drop in cAMP levels but increases them above those in uninjured controls. This further enhances axonal sparing and myelination, promotes growth of serotonergic fibers into and beyond grafts, and significantly improves locomotion. These findings show that cAMP levels are key for protection, growth and myelination of injured CNS axons in vivo and recovery of function.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Sao Paulo, Inst Biomed Sci, Dept Anat, BR-05508900 Sao Paulo, Brazil; CUNY Hunter Coll, Dept Biol, New York, NY 10021 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA	University of Miami; Universidade de Sao Paulo; City University of New York (CUNY) System; Hunter College (CUNY); University of Miami; University of Miami	Pearse, DD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	dpearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Berrocal, Yerko/0000-0002-1089-6563	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038665, R01NS009923] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bunge MB, 2002, PROG BRAIN RES, V137, P275; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge MB, 2001, NEUROSCIENTIST, V7, P325, DOI 10.1177/107385840100700409; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed., DOI DOI 10.4324/9780203771587; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Howe DG, 2000, J NEUROSCI, V20, P3513, DOI 10.1523/JNEUROSCI.20-10-03513.2000; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LUDWIN SK, 1978, LAB INVEST, V39, P597; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nijjar MS, 2000, INT J MOL MED, V6, P377; NUYDENS R, 1993, NEUROREPORT, V4, P179, DOI 10.1097/00001756-199302000-00016; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; SCHULTZ JE, 1988, PHARMACOPSYCHIATRY, V21, P83, DOI 10.1055/s-2007-1014653; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; Takami T, 2002, J NEUROSCI, V22, P6670; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; VIALA D, 1969, BRAIN RES, V12, P437, DOI 10.1016/0006-8993(69)90011-0; WEST NR, 1989, J NEUROPATH EXP NEUR, V48, P94, DOI 10.1097/00005072-198901000-00008; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; Zidek Z, 1999, EUR CYTOKINE NETW, V10, P319	50	560	592	3	64	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					610	616		10.1038/nm1056	http://dx.doi.org/10.1038/nm1056			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156204				2022-12-25	WOS:000221759600026
J	Barac, T; Taghavi, S; Borremans, B; Provoost, A; Oeyen, L; Colpaert, JV; Vangronsveld, J; van der Lelie, D				Barac, T; Taghavi, S; Borremans, B; Provoost, A; Oeyen, L; Colpaert, JV; Vangronsveld, J; van der Lelie, D			Engineered endophytic bacteria improve phytoremediation of water-soluble, volatile, organic pollutants	NATURE BIOTECHNOLOGY			English	Article							PLASMID; RESISTANCE; SELECTION; PLANTS	Phytoremediation of highly water soluble and volatile organic xenobiotics is often inefficient because plants do not completely degrade these compounds through their rhizospheres. This results in phytotoxicity and/or volatilization of chemicals through the leaves, which can cause additional environmental problems. We demonstrate that endophytic bacteria equipped with the appropriate degradation pathway improve the in planta degradation of toluene. We introduced the pTOM toluene-degradation plasmid of Burkholderia cepacia G4 into B. cepacia L. S. 2.4, a natural endophyte of yellow lupine. After surface-sterilized lupine seeds were successfully inoculated with the recombinant strain, the engineered endophytic bacteria strongly degraded toluene, resulting in a marked decrease in its phytotoxicity, and a 50-70% reduction of its evapotranspiration through the leaves. This strategy promises to improve the efficiency of phytoremediating volatile organic contaminants.	Flemish Inst Technol Res, Environm Technol Expertise Ctr, B-2400 Mol, Belgium; Limburgs Univ Ctr, Dept Environm Biol, B-3590 Diepenbeek, Belgium; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	VITO; Hasselt University; United States Department of Energy (DOE); Brookhaven National Laboratory	van der Lelie, D (corresponding author), Flemish Inst Technol Res, Environm Technol Expertise Ctr, Boeretang 200, B-2400 Mol, Belgium.	vdlelied@bnl.gov	Vangronsveld, Jaco/ABE-5907-2020	Vangronsveld, Jaco/0000-0003-4423-8363; Colpaert, Jan V/0000-0003-1610-1861				Bent E, 2002, APPL ENVIRON MICROB, V68, P4650, DOI 10.1128/AEM.68.9.4650-4652.2002; Burken JG, 1999, INT J PHYTOREMEDIAT, V1, P139, DOI 10.1080/15226519908500012; CUNNINGHAM SD, 1993, IN VITRO CELL DEV-PL, V29P, P207, DOI 10.1007/BF02632036; Doucette WJ, 1998, FIRST INTERNATIONAL CONFERENCE ON REMEDIATION OF CHLORINATED AND RECALCITRANT COMPOUNDS, VOL 4, P251; Elvira-Recuenco M, 2000, CAN J MICROBIOL, V46, P1036, DOI 10.1139/cjm-46-11-1036; FROMMEL MI, 1991, PLANT PHYSIOL, V96, P928, DOI 10.1104/pp.96.3.928; GERMAINE K, 2004, IN PRESS FEMS MICROB; Harvey PJ, 2002, ENVIRON SCI POLLUT R, V9, P29, DOI 10.1007/BF02987315; HEYMAN J, 2004, INT J SYST EVOL MI 1, V54, P47; James EK, 1998, CRIT REV PLANT SCI, V17, P77, DOI 10.1016/S0735-2689(98)00357-8; Lodewyckx C, 2001, INT J PHYTOREMEDIAT, V3, P173, DOI 10.1080/15226510108500055; Lodewyckx C, 2002, CRIT REV PLANT SCI, V21, P583, DOI 10.1080/0735-260291044377; Ma XM, 2003, ENVIRON SCI TECHNOL, V37, P2534, DOI 10.1021/es026055d; MCCRADY JK, 1987, J EXP BOT, V38, P1875, DOI 10.1093/jxb/38.11.1875; MERGEAY M, 1985, J BACTERIOL, V162, P328, DOI 10.1128/JB.162.1.328-334.1985; MISAGHI IJ, 1990, PHYTOPATHOLOGY, V80, P808, DOI 10.1094/Phyto-80-808; Reiter B, 2003, CAN J MICROBIOL, V49, P549, DOI 10.1139/W03-070; SCHLEGEL HG, 1961, ARCH MIKROBIOL, V38, P209, DOI 10.1007/BF00422356; SCHNOOR JL, 1995, ENVIRON SCI TECHNOL, V29, pA318, DOI [10.1021/es00007a002, 10.1021/es00007a747]; Schwitzguebel Jean-Paul, 2002, Journal of Soils and Sediments, V2, P91, DOI 10.1007/BF02987877; Sharp RR, 1998, BIOTECHNOL BIOENG, V57, P287; SHIELDS MS, 1995, APPL ENVIRON MICROB, V61, P1352, DOI 10.1128/AEM.61.4.1352-1356.1995; SHIELDS MS, 1992, APPL ENVIRON MICROB, V58, P3977, DOI 10.1128/AEM.58.12.3977-3983.1992; Siciliano SD, 2001, APPL ENVIRON MICROB, V67, P2469, DOI 10.1128/AEM.67.6.2469-2475.2001; Taghavi S, 2001, APPL ENVIRON MICROB, V67, P1015, DOI 10.1128/AEM.67.2.1015-1019.2001; Trapp S., 2001, Journal of Soils and Sediments, V1, P71, DOI 10.1007/BF02987712; Trapp S, 2000, ARCH ENVIRON CON TOX, V39, P154, DOI 10.1007/s002440010091; van der Lelie D, 2001, ENVIRON SCI TECHNOL, V35, p446A, DOI 10.1021/es012543u	28	390	421	8	161	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					583	588		10.1038/nbt960	http://dx.doi.org/10.1038/nbt960			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15077119	Green Published			2022-12-25	WOS:000221159700027
J	Binz, HK; Amstutz, P; Kohl, A; Stumpp, MT; Briand, C; Forrer, P; Grutter, MG; Pluckthun, A				Binz, HK; Amstutz, P; Kohl, A; Stumpp, MT; Briand, C; Forrer, P; Grutter, MG; Pluckthun, A			High-affinity binders selected from designed ankyrin repeat protein libraries	NATURE BIOTECHNOLOGY			English	Article							STRUCTURAL BASIS; BINDING-SITES; EVOLUTION; RECOGNITION; ANTIBODIES; SCAFFOLDS; AFFIBODY; PROGRAM; DISPLAY	We report here the evolution of ankyrin repeat (AR) proteins in vitro for specific, high-affinity target binding. Using a consensus design strategy, we generated combinatorial libraries of AR proteins of varying repeat numbers with diversified binding surfaces. Libraries of two and three repeats, flanked by 'capping repeats, ' were used in ribosome-display selections against maltose binding protein (MBP) and two eukaryotic kinases. We rapidly enriched target-specific binders with affinities in the low nanomolar range and determined the crystal structure of one of the selected AR proteins in complex with MBP at 2.3 Angstrom resolution. The interaction relies on the randomized positions of the designed AR protein and is comparable to natural, heterodimeric protein-protein interactions. Thus, our AR protein libraries are valuable sources for binding molecules and, because of the very favorable biophysical properties of the designed AR proteins, an attractive alternative to antibody libraries.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gruetter@bioc.unizh.ch; plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Binz, Hans Kaspar/0000-0003-0702-2280; Forrer, Patrik/0000-0002-9717-0991				Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; Eklund M, 2002, PROTEINS, V48, P454, DOI 10.1002/prot.10169; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; Forrer P, 1998, BIOL CHEM, V379, P1101, DOI 10.1515/bchm.1998.379.8-9.1101; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3191, DOI 10.1073/pnas.0436100100; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobe B, 2000, TRENDS BIOCHEM SCI, V25, P509, DOI 10.1016/S0968-0004(00)01667-4; Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Marcotte EM, 1999, J MOL BIOL, V293, P151, DOI 10.1006/jmbi.1999.3136; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nygren PA, 1997, CURR OPIN STRUC BIOL, V7, P463, DOI 10.1016/S0959-440X(97)80108-X; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; Rubin SM, 2002, J MOL BIOL, V322, P425, DOI 10.1016/S0022-2836(02)00739-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.3.CO;2-0; Skerra A, 2003, CURR OPIN CHEM BIOL, V7, P683, DOI 10.1016/j.cbpa.2003.10.012; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; Wahlberg E, 2003, P NATL ACAD SCI USA, V100, P3185, DOI 10.1073/pnas.0436086100; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Wodak SJ, 2003, ADV PROTEIN CHEM, V61, P9; Xu LH, 2002, CHEM BIOL, V9, P933, DOI 10.1016/S1074-5521(02)00187-4; Yang F, 2000, NAT STRUCT BIOL, V7, P230; Zeytun A, 2003, NAT BIOTECHNOL, V21, P1473, DOI 10.1038/nbt911	50	503	588	4	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					575	582		10.1038/nbt962	http://dx.doi.org/10.1038/nbt962			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15097997				2022-12-25	WOS:000221159700026
J	Morris, RJ; Liu, YP; Marles, L; Yang, ZX; Trempus, C; Li, SL; Lin, JS; Sawicki, JA; Cotsarelis, G				Morris, RJ; Liu, YP; Marles, L; Yang, ZX; Trempus, C; Li, SL; Lin, JS; Sawicki, JA; Cotsarelis, G			Capturing and profiling adult hair follicle stem cells	NATURE BIOTECHNOLOGY			English	Article							LABEL-RETAINING CELLS; DIFFERENTIAL EXPRESSION; BASAL CELLS; IN-VIVO; GROWTH; BULGE; KERATINOCYTES; INDUCTION; SYSTEM; OLIGONUCLEOTIDE	The hair follicle bulge possesses putative epithelial stem cells. Characterization of these cells has been hampered by the inability to target bulge cells genetically. Here, we use a Keratin1-15 (Krt1-15, also known as K15) promoter to target mouse bulge cells with an inducible Cre recombinase construct or with the gene encoding enhanced green fluorescent protein (EGFP), which allow for lineage analysis and for isolation of the cells. We show that bulge cells in adult mice generate all epithelial cell types within the intact follicle and hair during normal hair follicle cycling. After isolation, adult Krt1-15-EGFP-positive cells reconstituted all components of the cutaneous epithelium and had a higher proliferative potential than Krt1-15-EGFP-negative cells. Genetic profiling of hair follicle stem cells revealed several known and unknown receptors and signaling pathways important for maintaining the stem cell phenotype. Ultimately, these findings provide potential targets for the treatment of hair loss and other disorders of skin and hair.	Univ Penn, Sch Med, Dept Dermatol, Kligman Labs, Philadelphia, PA 19104 USA; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; NIEHS, Canc Biol Grp, Natl Ctr Toxicogenom, Res Triangle Pk, NC 27709 USA; Lankenau Inst Med Res, Wynnewood, PA 19096 USA	University of Pennsylvania; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Lankenau Medical Center; Lankenau Institute for Medical Research	Cotsarelis, G (corresponding author), Univ Penn, Sch Med, Dept Dermatol, Kligman Labs, Philadelphia, PA 19104 USA.	cotsarel@mail.med.upenn.edu	Lin, Jamie/F-4278-2015	Lin, Jamie/0000-0002-7073-9658	NATIONAL CANCER INSTITUTE [R01CA097957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046837] Funding Source: NIH RePORTER; NCI NIH HHS [CA97957] Funding Source: Medline; NIAMS NIH HHS [AR46837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERNSTEIN ID, 1994, BLOOD CELLS, V20, P15; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; BUHL AE, 1993, J INVEST DERMATOL, V101, pS148, DOI 10.1111/1523-1747.ep12363290; Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; Cotsarelis G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; Gilmour SK, 2001, J INVEST DERMATOL, V117, P1674, DOI 10.1046/j.0022-202x.2001.01597.x; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ito M, 2001, J INVEST DERMATOL, V116, P956, DOI 10.1046/j.0022-202x.2001.01369.x; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JAHODA CAB, 1993, J INVEST DERMATOL, V101, P584, DOI 10.1111/1523-1747.ep12366039; JAWORSKY C, 1992, BRIT J DERMATOL, V127, P239, DOI 10.1111/j.1365-2133.1992.tb00121.x; Kamimura J, 1997, J INVEST DERMATOL, V109, P534, DOI 10.1111/1523-1747.ep12336704; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; Lavker RM, 2003, J INVEST DERM SYMP P, V8, P28, DOI 10.1046/j.1523-1747.2003.12169.x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Lyle S, 1998, J CELL SCI, V111, P3179; Meier N, 1999, MECH DEVELOP, V89, P215, DOI 10.1016/S0925-4773(99)00218-X; MORRIS RJ, 1990, CELL TISSUE KINET, V23, P587, DOI 10.1111/j.1365-2184.1990.tb01348.x; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Panteleyev AA, 2001, J CELL SCI, V114, P3419; PAUS R, 1989, LAB INVEST, V60, P365; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; Potten CS, 2002, J INVEST DERMATOL, V119, P888, DOI 10.1046/j.1523-1747.2002.00020.x; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; Xu XW, 2003, AM J PATHOL, V163, P969, DOI 10.1016/S0002-9440(10)63456-6; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	45	974	1043	3	98	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2004	22	4					411	417		10.1038/nbt950	http://dx.doi.org/10.1038/nbt950			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	809AR	15024388				2022-12-25	WOS:000220610100029
J	Chae, TH; Kim, S; Marz, KE; Hanson, PI; Walsh, CA				Chae, TH; Kim, S; Marz, KE; Hanson, PI; Walsh, CA			The hyh mutation uncovers roles for alpha Snap in apical protein localization and control of neural cell fate	NATURE GENETICS			English	Article							DROSOPHILA NEUROBLAST; ASYMMETRIC DIVISIONS; COMPLEX; MOUSE; TRAFFICKING; FUSION; GENE; PROLIFERATION; HYDROCEPHALUS; CHROMOSOME-7	The hyh (hydrocephalus with hop gait) mouse shows a markedly small cerebral cortex at birth and dies postnatally from progressive enlargement of the ventricular system(1,2). Here we show that the small hyh cortex reflects altered cell fate. Neural progenitor cells withdraw prematurely from the cell cycle, producing more early-born, deep-layer cerebral cortical neurons but depleting the cortical progenitor pool, such that late-born, upper-layer cortical neurons are underproduced, creating a small cortex. hyh mice carry a hypomorphic missense mutation in the gene Napa encoding solubleN- ethylmaleimide-sensitive factor (NSF) attachment protein alpha (alphaSnap), involved in SNAP receptor (SNARE)- mediated vesicle fusion in many cellular contexts. A targeted null Napa mutation is embryonically lethal. Altered neural cell fate is accompanied by abnormal localization of many apical proteins implicated in regulation of neural cell fate, including E-cadherin, beta-catenin, atypical protein kinase C (aPKC) and INADL(inactivation-no-afterpotential D-like, also known as protein associated with Lin7, or Pals1). Apical localization of the SNARE Vamp7 is also disrupted. Thus, Snap is essential for apical protein localization and cell fate determination in neuroepithelial cells.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Washington University (WUSTL)	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Beth Israel Deaconess Med Ctr, HIM 816,4 Blackfan Circle, Boston, MA 02115 USA.	cwalsh@bidmc.harvard.edu	Hanson, Phyllis/E-9420-2012	Walsh, Christopher/0000-0002-0156-2238				Bogdanovic A, 2002, BIOCHEM J, V368, P29, DOI 10.1042/BJ20020845; BRONSON RT, 1990, DEV BRAIN RES, V54, P131, DOI 10.1016/0165-3806(90)90073-8; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; CAVINESS VS, 1995, BRAIN DEV-JPN, V17, P159, DOI 10.1016/0387-7604(95)00029-B; Chae TH, 2002, MAMM GENOME, V13, P239, DOI 10.1007/s00335-001-2144-5; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Coco S, 1999, J NEUROSCI, V19, P9803; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; Ferland RJ, 2003, J COMP NEUROL, V460, P266, DOI 10.1002/cne.10654; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Jimenez AJ, 2001, J NEUROPATH EXP NEUR, V60, P1105, DOI 10.1093/jnen/60.11.1105; Kolehmainen J, 2003, AM J HUM GENET, V72, P1359, DOI 10.1086/375454; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Le Borgne R, 2002, CURR BIOL, V12, P95, DOI 10.1016/S0960-9822(01)00648-0; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; Marz KE, 2003, J BIOL CHEM, V278, P27000, DOI 10.1074/jbc.M302003200; McEvilly RJ, 2002, SCIENCE, V295, P1528, DOI 10.1126/science.1067132; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pearlman A L, 1996, Prog Brain Res, V108, P117; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; PUSCHEL AW, 1994, FEBS LETT, V347, P55, DOI 10.1016/0014-5793(94)00505-2; REH TA, 1989, J NEUROSCI, V9, P4179; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; TAKAHASHI T, 1994, P NATL ACAD SCI USA, V91, P375, DOI 10.1073/pnas.91.1.375; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	30	130	132	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					264	270		10.1038/ng1302	http://dx.doi.org/10.1038/ng1302			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14758363	Bronze			2022-12-25	WOS:000189250400015
J	Sini, P; Cannas, A; Koleske, AJ; Di Fiore, PP; Scita, G				Sini, P; Cannas, A; Koleske, AJ; Di Fiore, PP; Scita, G			Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation	NATURE CELL BIOLOGY			English	Article							C-ABL; KINASE-ACTIVITY; FACTOR RECEPTOR; TRANSFORMING ACTIVITY; ACTIN CYTOSKELETON; RHO-GTPASES; SH3 DOMAIN; PROTEIN; EXCHANGE; EPS8	The non-receptor tyrosine kinase Abl participates in receptor tyrosine kinase (RTK)-induced actin cytoskeleton remodelling, a signalling pathway in which the function of Rac is pivotal. More importantly, the activity of Rac is indispensable for the leukaemogenic ability of the BCR-Abl oncoprotein. Thus, Rac might function downstream of Abl and be activated by it. Here, we elucidate the molecular mechanisms through which Abl signals to Rac in RTK-activated pathways. We show that Sos-1, a dual guanine nucleotide-exchange factor (GEF), is phosphorylated on tyrosine, after activation of RTKs, in an Abl-dependent manner. Sos-1 and Abl interact in vivo, and Abl-induced tyrosine phosphorylation of Sos-1 is sufficient to elicit its Rac-GEF activity in vitro. Genetic or pharmacological interference with Abl (and the related kinase Arg) resulted in a marked decrease in Rac activation induced by physiological doses of growth factors. Thus, our data identify the molecular connections of a pathway RTKs-Abl-Sos-1-Rac that is involved in signal transduction and actin remodelling.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM, FIRC Inst Mol Oncol, I-20134 Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Ondontoiatria, I-20122 Milan, Italy; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan; Yale University	Scita, G (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.it; gscita@ieo.it	Di Fiore, Pier Paolo/K-2130-2012; Scita, Giorgio/J-9670-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Scita, Giorgio/0000-0001-7984-1889	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039475] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039475] Funding Source: Medline; Telethon [D.090] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SASTRY L, 1995, ONCOGENE, V11, P1107; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014	28	103	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					268	274		10.1038/ncb1096	http://dx.doi.org/10.1038/ncb1096			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039778				2022-12-25	WOS:000189363000019
J	Sumazaki, R; Shiojiri, N; Isoyama, S; Masu, M; Keino-Masu, K; Osawa, M; Nakauchi, H; Kageyama, R; Matsui, A				Sumazaki, R; Shiojiri, N; Isoyama, S; Masu, M; Keino-Masu, K; Osawa, M; Nakauchi, H; Kageyama, R; Matsui, A			Conversion of biliary system to pancreatic tissue in Hes1-deficient mice	NATURE GENETICS			English	Article							LOOP-HELIX FACTORS; ALAGILLE-SYNDROME; CELL LINEAGES; HUMAN JAGGED1; DIFFERENTIATION; NEUROGENIN3; HES-1; NOTCH; GENE; MORPHOGENESIS	The biliary system, pancreas and liver all develop from the nearby foregut at almost the same time in mammals. The molecular mechanisms that determine the identity of each organ in this complex area are unknown. Hes1 encodes the basic helix-loop-helix protein Hes1 (ref. 1), which represses positive basic helix-loop-helix genes(2) such as Neurog3 (ref. 3). Expression of Hes1 is controlled by the evolutionarily conserved Notch pathway(4). Hes1 operates as a general negative regulator of endodermal endocrine differentiation(5,6), and defects in Notch signaling lead to accelerated pancreatic endocrine differentiation(7,8). Mutations in JAG1, encoding a Notch ligand, cause the Alagille syndrome in humans(9,10), characterized by poor development of the biliary system(11), suggesting that the Notch pathway is also involved in normal biliary development. Here we show that Hes1 is expressed in the extrahepatic biliary epithelium throughout development and that Hes1-deficient mice 2 have gallbladder agenesis and severe hypoplasia of extrahepatic bile ducts. Biliary epithelium in Hes1(-/-) mice ectopically expresses the proendocrine gene Neurog3 (refs. 12,13), differentiates into endocrine and exocrine cells and forms acini and islet-like structures in the mutant bile ducts. Thus, biliary epithelium has the potential for pancreatic differentiation and Hes1 determines biliary organogenesis by preventing the pancreatic differentiation program, probably by directly repressing transcription of Neurog3	Univ Tsukuba, Inst Clin Med, Dept Child Hlth, Tsukuba, Ibaraki 305, Japan; Shizuoka Univ, Fac Sci, Inst Biol, Shizuoka, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Mol Neurobiol, Tsukuba, Ibaraki 305, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Lab Stem Cell Therapy, Tokyo, Japan; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan	University of Tsukuba; Shizuoka University; University of Tsukuba; University of Tokyo; Kyoto University	Sumazaki, R (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Child Hlth, Tsukuba, Ibaraki 305, Japan.	rsuma@md.tsukuba.ac.jp						Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; ELLIOTT WM, 1993, ANAT REC, V237, P271, DOI 10.1002/ar.1092370214; GOLOSOW N, 1962, DEV BIOL, V4, P242, DOI 10.1016/0012-1606(62)90042-8; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; SHIOJIRI N, 1988, ANAT EMBRYOL, V178, P15, DOI 10.1007/BF00305009; Skipper M, 2000, NAT GENET, V24, P3, DOI 10.1038/71653; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3	28	173	181	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2004	36	1					83	87		10.1038/ng1273	http://dx.doi.org/10.1038/ng1273			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702043	Bronze			2022-12-25	WOS:000187666800018
J	Assadi, AH; Zhang, GC; Beffert, U; McNeil, RS; Renfro, AL; Niu, S; Quattrocchi, CC; Antalffy, BA; Sheldon, M; Armstrong, DD; Wynshaw-Boris, A; Herz, J; D'Arcangelo, G; Clark, GD				Assadi, AH; Zhang, GC; Beffert, U; McNeil, RS; Renfro, AL; Niu, S; Quattrocchi, CC; Antalffy, BA; Sheldon, M; Armstrong, DD; Wynshaw-Boris, A; Herz, J; D'Arcangelo, G; Clark, GD			Interaction of reelin signaling and Lis1 in brain development	NATURE GENETICS			English	Article							NEURONAL MIGRATION; TYROSINE PHOSPHORYLATION; LISSENCEPHALY GENE; VLDL RECEPTOR; RADIAL GLIA; PROTEIN; COMPLEX; FAMILY; DAB1; LOCALIZATION	Loss-of-function mutations in RELN (encoding reelin) or PAFAH1B1 (encoding LIS1) cause lissencephaly, a human neuronal migration disorder(1). In the mouse, homozygous mutations in Reln result in the reeler phenotype, characterized by ataxia and disrupted cortical layers(2). Pafah1b1(+/-) mice have hippocampal layering defects, whereas homozygous mutants are embryonic lethal(3). Reln encodes an extracellular protein that regulates layer formation by interacting with VLDLR and ApoER2 (Lrp8) receptors(4-6), thereby phosphorylating the Dab1 signaling molecule(7-10). Lis1 associates with microtubules and modulates neuronal migration(11). We investigated interactions between the reelin signaling pathway and Lis1 in brain development. Compound mutant mice with disruptions in the Reln pathway and heterozygous Pafah1b1 mutations had a higher incidence of hydrocephalus and enhanced cortical and hippocampal layering defects. Dab1 and Lis1 bound in a reelin-induced phosphorylation-dependent manner. These data indicate genetic and biochemical interaction between the reelin signaling pathway and Lis1.	Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Brescia, Program Neurosci, I-25121 Brescia, Italy; Baylor Coll Med, Div Hematol Oncol, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Univ Calif San Diego, Dept Pediat & Med, San Diego, CA 92103 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Brescia; Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; University of California System; University of California San Diego; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Clark, GD (corresponding author), Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA.	gclark@bcm.tmc.edu		Beffert, Uwe/0000-0001-5877-922X; D'Arcangelo, Gabriella/0000-0003-1575-1010; Quattrocchi, Carlo Cosimo/0000-0001-6823-7707	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Brich J, 2003, J NEUROSCI, V23, P187; Clark GD, 1997, J NEUROPATH EXP NEUR, V56, P1044, DOI 10.1097/00005072-199709000-00009; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DArcangelo G, 1996, MOL BRAIN RES, V39, P234, DOI 10.1016/0169-328X(96)00046-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Luque JM, 2003, DEV BRAIN RES, V140, P195, DOI 10.1016/S0165-3806(02)00604-1; Miller MW, 2000, BRAIN RES, V852, P355, DOI 10.1016/S0006-8993(99)02176-9; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Sweeney KJ, 2000, MECH DEVELOP, V92, P263, DOI 10.1016/S0925-4773(00)00242-2; Tramontin AD, 2003, CEREB CORTEX, V13, P580, DOI 10.1093/cercor/13.6.580; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Yan W, 2003, P NATL ACAD SCI USA, V100, P7189, DOI 10.1073/pnas.1236145100	30	167	178	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					270	276		10.1038/ng1257	http://dx.doi.org/10.1038/ng1257			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14578885				2022-12-25	WOS:000186273300024
J	Coffield, VM; Jiang, Q; Su, LS				Coffield, VM; Jiang, Q; Su, LS			A genetic approach to inactivating chemokine receptors using a modified viral protein	NATURE BIOTECHNOLOGY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; LYMPHOCYTE CHEMOATTRACTANT; BONE-MARROW; VPU PROTEIN; STEM-CELLS; SDF-1; FACTOR-1; CLONING; DEGRADATION; LESTR/FUSIN	We have developed a genetic system, called degrakine, that specifically and stably inactivates chemokine receptors (CKR) by redirecting the ability of the HIV-1 protein, Vpu, to degrade CD4 in the endoplasmic reticulum (ER) via the host proteasome machinery. To harness Vpu's proteolytic targeting capability to degrade new receptors, we fused a chemokine with the C terminal region of Vpu. The fusion protein, or degrakine, accumulates in the ER, trapping and functionally inactivating its target CKR. We have demonstrated that degrakines based on SDF-1 (CXCL12), MDC (CCL22) and RANTES (CCL5) specifically inactivate their respective receptor functions. Using a retroviral vector expressing the SDF-1 degrakine, we have established that CXCR4 is required for the homing of hematopoietic stem/progenitor cells (HSPC) to the bone marrow immediately after transplantation. Thus the degrakine provides an effective genetic tool to dissect receptor functions in a number of biological systems in vitro and in vivo.	Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Ctr 22 048, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Su, LS (corresponding author), Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.	lsu@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022; Ariel, Pablo/AGJ-4118-2022		NHLBI NIH HHS [HL72240, R21 HL072240] Funding Source: Medline; NIAID NIH HHS [R21 AI053804, R01 AI041356, AI53804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL072240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053804, R01AI041356] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chantry D, 1999, BLOOD, V94, P1890; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Cheng LZ, 1998, BLOOD, V92, P83, DOI 10.1182/blood.V92.1.83.413k09_83_92; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Cullen BR, 2002, NAT IMMUNOL, V3, P597, DOI 10.1038/ni0702-597; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Engel BC, 2000, MOL THER, V1, P165, DOI 10.1006/mthe.2000.0026; Hardy J, 2001, EXP HEMATOL, V29, P1353, DOI 10.1016/S0301-472X(01)00756-1; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marsal J, 2002, EUR J IMMUNOL, V32, P3488, DOI 10.1002/1521-4141(200212)32:12<3488::AID-IMMU3488>3.0.CO;2-E; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Szilvassy SJ, 2001, BLOOD, V98, P2108, DOI 10.1182/blood.V98.7.2108; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TISCORNIA G, 2003, P NATL ACAD SCI USA, V27, P27; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Vilen BJ, 2002, J IMMUNOL, V168, P4344, DOI 10.4049/jimmunol.168.9.4344; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	43	27	30	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1321	1327		10.1038/nbt889	http://dx.doi.org/10.1038/nbt889			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14555957	Green Published, Green Accepted			2022-12-25	WOS:000186320000033
J	Gretarsdottir, S; Thorleifsson, G; Reynisdottir, ST; Manolescu, A; Jonsdottir, S; Jonsdottir, T; Gudmundsdottir, T; Bjarnadottir, SM; Einarsson, OB; Gudjonsdottir, HM; Hawkins, M; Gudmundsson, G; Gudmundsdottir, H; Andrason, H; Gudmundsdottir, AS; Sigurdardottir, M; Chou, TT; Nahmias, J; Goss, S; Sveinbjornsdottir, S; Valdimarsson, EM; Jakobsson, F; Agnarsson, U; Gudnason, V; Thorgeirsson, G; Fingerle, J; Gurney, M; Gudbjartsson, D; Frigge, ML; Kong, A; Stefansson, K; Gulcher, JR				Gretarsdottir, S; Thorleifsson, G; Reynisdottir, ST; Manolescu, A; Jonsdottir, S; Jonsdottir, T; Gudmundsdottir, T; Bjarnadottir, SM; Einarsson, OB; Gudjonsdottir, HM; Hawkins, M; Gudmundsson, G; Gudmundsdottir, H; Andrason, H; Gudmundsdottir, AS; Sigurdardottir, M; Chou, TT; Nahmias, J; Goss, S; Sveinbjornsdottir, S; Valdimarsson, EM; Jakobsson, F; Agnarsson, U; Gudnason, V; Thorgeirsson, G; Fingerle, J; Gurney, M; Gudbjartsson, D; Frigge, ML; Kong, A; Stefansson, K; Gulcher, JR			The gene encoding phosphodiesterase 4D confers risk of ischemic stroke	NATURE GENETICS			English	Article							SMOOTH-MUSCLE CELLS; DEPENDENT PROTEIN-KINASE; COORDINATED REGULATION; PDE4D ACTIVITY; IN-VIVO; CAMP; ACTIVATION; PROLIFERATION; MUTATIONS; PHOSPHORYLATION	We previously mapped susceptibility to stroke to chromosome 5q12. Here we finely mapped this locus and tested it for association with stroke. We found the strongest association in the gene encoding phosphodiesterase 4D (PDE4D), especially for carotid and cardiogenic stroke, the forms of stroke related to atherosclerosis. Notably, we found that haplotypes can be classified into three distinct groups: wild-type, at-risk and protective. We also observed a substantial disregulation of multiple PDE4D isoforms in affected individuals. We propose that PDE4D is involved in the pathogenesis of stroke, possibly through atherosclerosis, which is the primary pathological process underlying ischemic stroke.	deCODE Genet, IS-101 Reykjavik, Iceland; Natl Univ Hosp Reykjavik, Reykjavik, Iceland; Iceland Heart Assoc Heart Prevent Clin, Reykjavik, Iceland; Hoffmann La Roche AG, Div Pharma, Preclin Res, Basel, Switzerland	Landspitali National University Hospital; Roche Holding	Gretarsdottir, S (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.		Stefansson, Kari/AAE-7187-2019; Manolescu, Andrei/G-4565-2014; Gudnason, Vilmundur/AAE-7126-2019; Gudnason, Vilmundur/K-6885-2015	Manolescu, Andrei/0000-0002-0713-4664; Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason, Vilmundur/0000-0001-5696-0084; Gudbjartsson, Daniel/0000-0002-5222-9857				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ALBERTS MJ, 1999, GENETICS CEREBROVASC; Baillie G, 2001, MOL PHARMACOL, V60, P1100, DOI 10.1124/mol.60.5.1100; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BRASS LM, 1995, BAILLIERE CLIN NEUR, V4, P221; Caplan LR., 2000, CAPLANS STROKE CLIN, V3rd ed., P34; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; DEMPSTER AB, 1971, J MOL SPECTROSC, V39, P1, DOI 10.1016/0022-2852(71)90269-4; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; Fukumoto S, 1999, CIRC RES, V85, P985; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; Hassan A, 2000, BRAIN, V123, P1784, DOI 10.1093/brain/123.9.1784; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Indolfi C, 1997, NAT MED, V3, P775, DOI 10.1038/nm0797-775; Indolfi C, 2000, J AM COLL CARDIOL, V36, P288, DOI 10.1016/S0735-1097(00)00679-3; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Laberge-le Couteulx S, 1999, NAT GENET, V23, P189, DOI 10.1038/13815; Landells LJ, 2001, BRIT J PHARMACOL, V133, P722, DOI 10.1038/sj.bjp.0704120; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEWONTIN RC, 1964, GENETICS, V49, P49; Leys D, 2002, J NEUROL, V249, P507, DOI 10.1007/s004150200057; Liu HG, 2000, J BIOL CHEM, V275, P26615, DOI 10.1074/jbc.M001634200; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; Palmer D, 1998, CIRC RES, V82, P852; PALSDOTTIR A, 1988, LANCET, V2, P603; PAN XL, 1994, BIOCHEM PHARMACOL, V48, P827, DOI 10.1016/0006-2952(94)90062-0; RICE JA, 1995, MATH STAT DATA ANAL, P308; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Sacco RL, 1997, STROKE, V28, P1507, DOI 10.1161/01.STR.28.7.1507; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; STELZNER TJ, 1989, J CELL PHYSIOL, V139, P157, DOI 10.1002/jcp.1041390122; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839	42	462	511	1	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					131	138		10.1038/ng1245	http://dx.doi.org/10.1038/ng1245			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	14517540				2022-12-25	WOS:000185625300009
J	Park, KS; Lee, DK; Lee, H; Lee, Y; Jang, YS; Kim, YH; Yang, HY; Lee, SI; Seol, W; Kim, JS				Park, KS; Lee, DK; Lee, H; Lee, Y; Jang, YS; Kim, YH; Yang, HY; Lee, SI; Seol, W; Kim, JS			Phenotypic alteration of eukaryotic cells using randomized libraries of artificial transcription factors	NATURE BIOTECHNOLOGY			English	Article							ZINC-FINGER PROTEINS; CONTROLLING GENE-EXPRESSION; FUNCTIONAL GENOMICS APPROACH; DNA-BINDING SPECIFICITY; CANDIDA-ALBICANS; BUILDING-BLOCKS; HIGH-AFFINITY; TARGET SITES; SELECTION; RECOGNITION	We have developed a method in which randomized libraries of zinc finger-containing artificial transcription factors are used to induce phenotypic variations in yeast and mammalian cells. By linking multiple zinc-finger domains together, we constructed more than 100,000 zinc-finger proteins with diverse DNA-binding specificities and fused each of them to either a transcription activation or repression domain. The resulting transcriptional regulatory proteins were expressed individually in cells, and the transfected cells were screened for various phenotypic changes, such as drug resistance, thermotolerance or osmotolerance in yeast, and differentiation in mammalian cells. Genes associated with the selected phenotypes were also identified. Our results show that randomized libraries of artificial transcription factors are useful tools for functional genomics and phenotypic engineering.	Toolgen Inc, Taejon 305390, South Korea		Kim, JS (corresponding author), Toolgen Inc, 461-6 Jeonmin Dong, Taejon 305390, South Korea.		KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bae KH, 2003, NAT BIOTECHNOL, V21, P275, DOI 10.1038/nbt796; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; CAMPLING BG, 1988, LEUKEMIA RES, V12, P823, DOI 10.1016/0145-2126(88)90036-7; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; De Backer MD, 2001, NAT BIOTECHNOL, V19, P235, DOI 10.1038/85677; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; Gordon CL, 2000, MICROBIOL-UK, V146, P415, DOI 10.1099/00221287-146-2-415; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kang JS, 2000, J BIOL CHEM, V275, P8742, DOI 10.1074/jbc.275.12.8742; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566; Lee DK, 2003, CURR TOP MED CHEM, V3, P645, DOI 10.2174/1568026033452384; Lee JH, 1999, P NATL ACAD SCI USA, V96, P5873, DOI 10.1073/pnas.96.10.5873; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; Morii E, 2002, J BIOL CHEM, V277, P8566, DOI 10.1074/jbc.M110392200; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pierce ML, 1998, NUCLEIC ACIDS RES, V26, P5093, DOI 10.1093/nar/26.22.5093; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sanchez JP, 2002, PLANT CELL PHYSIOL, V43, P1465, DOI 10.1093/pcp/pcf186; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x; TAYLOR WE, 1995, BIOCHEMISTRY-US, V34, P3222, DOI 10.1021/bi00010a011; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Vanden Bossche H, 1998, MED MYCOL, V36, P119; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	44	116	146	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1208	1214		10.1038/nbt868	http://dx.doi.org/10.1038/nbt868			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	12960965				2022-12-25	WOS:000185647200033
J	Wuchty, S; Oltvai, ZN; Barabasi, AL				Wuchty, S; Oltvai, ZN; Barabasi, AL			Evolutionary conservation of motif constituents in the yeast protein interaction network	NATURE GENETICS			English	Article							GENE DISPENSABILITY; CELLULAR NETWORKS; ORGANIZATION; DATABASE	Understanding why some cellular components are conserved across species but others evolve rapidly is a key question of modern biology(1-3). Here we show that in Saccharomyces cerevisiae, proteins organized in cohesive patterns of interactions are conserved to a substantially higher degree than those that do not participate in such motifs. We find that the conservation of proteins in distinct topological motifs correlates with the interconnectedness and function of that motif and also depends on the structure of the overall interactome topology. These findings indicate that motifs may represent evolutionary conserved topological units of cellular networks molded in accordance with the specific biological function in which they participate.	Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	University of Notre Dame; Northwestern University	Barabasi, AL (corresponding author), Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA.	zno008@northwestern.edu; alb@nd.edu	Barabasi, Albert-Laszlo/S-6474-2017	Barabasi, Albert/0000-0002-4028-3522				Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hirsh AE, 2003, NATURE, V421, P497, DOI 10.1038/421497a; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; Hurst LD, 1999, CURR BIOL, V9, P747, DOI 10.1016/S0960-9822(99)80334-0; Jordan IK, 2002, GENOME RES, V12, P962, DOI 10.1101/gr.87702; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Oltvai ZN, 2002, SCIENCE, V298, P763, DOI 10.1126/science.1078563; Pal C, 2003, NATURE, V421, P496, DOI 10.1038/421496b; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Rives AW, 2003, P NATL ACAD SCI USA, V100, P1128, DOI 10.1073/pnas.0237338100; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Snel B, 2002, P NATL ACAD SCI USA, V99, P5890, DOI 10.1073/pnas.092632599; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303	22	292	305	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					176	179		10.1038/ng1242	http://dx.doi.org/10.1038/ng1242			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12973352				2022-12-25	WOS:000185625300015
J	Beil, M; Micoulet, A; von Wichert, G; Paschke, S; Walther, P; Omary, MB; Van Veldhoven, PP; Gern, U; Wolff-Hieber, E; Eggermann, J; Waltenberger, J; Adler, G; Spatz, J; Seufferlein, T				Beil, M; Micoulet, A; von Wichert, G; Paschke, S; Walther, P; Omary, MB; Van Veldhoven, PP; Gern, U; Wolff-Hieber, E; Eggermann, J; Waltenberger, J; Adler, G; Spatz, J; Seufferlein, T			Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells	NATURE CELL BIOLOGY			English	Article							INTERMEDIATE-FILAMENTS; G-PROTEIN; MECHANICAL-PROPERTIES; LIVING CELLS; IN-VITRO; MIGRATION; DISEASE; REORGANIZATION; IDENTIFICATION; ORGANIZATION	Sphingosylphosphorylcholine (SPC) is a naturally occurring bioactive lipid that is present in high density lipoproteins (HDL) particles and found at increased levels in blood and malignant ascites of patients with ovarian cancer. Here, we show that incubation of human epithelial tumour cells with SPC induces a perinuclear reorganization of intact keratin 8-18 filaments. This effect is specific for SPC, largely independent of F-actin and microtubules, and is accompanied by keratin phosphorylation. In vivo visco-elastic probing of single cancer cells demonstrates that SPC increases cellular elasticity. Accordingly, SPC stimulates migration of cells through size-limited pores in a more potent manner than lysophosphatidic acid (LPA). LPA induces actin stress fibre formation, but does not reorganize keratins in cancer cells and hence increases cellular stiffness. We propose that reorganization of keratin by SPC may facilitate biological phenomena that require a high degree of elasticity, such as squeezing of cells through membranous pores during metastasis.	Univ Ulm, Dept Internal Med 1, D-89071 Ulm, Germany; Univ Ulm, Dept Electron Microscopy, D-89071 Ulm, Germany; Univ Ulm, Dept Internal Med 2, D-89071 Ulm, Germany; Heidelberg Univ, Dept Chem Phys, Biophys Chem Sect, D-69120 Heidelberg, Germany; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Stanford Univ, Palo Alto, CA 94304 USA; VA Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA 94304 USA; Katholieke Univ Leuven, Afdeling Farmakol, B-3000 Louvain, Belgium	Ulm University; Ulm University; Ulm University; Ruprecht Karls University Heidelberg; Columbia University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; KU Leuven	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, D-89071 Ulm, Germany.	thomas.seufferlein@medizin.uni-ulm.de	, Van Veldhoven Paul/U-6359-2019; Mordwinkin, Nicholas M/A-4347-2010; Spatz, Joachim P/A-1107-2017; Seufferlein, Thomas TW/P-7147-2018; Waltenberger, Johannes/I-1813-2013	, Van Veldhoven Paul/0000-0002-4478-2564; Spatz, Joachim P/0000-0003-3419-9807; Omary, Bishr/0000-0002-8624-2347; Waltenberger, Johannes/0000-0002-2417-9880				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Boguslawski G, 2000, BIOCHEM BIOPH RES CO, V272, P603, DOI 10.1006/bbrc.2000.2822; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; DECEUSTER P, 1995, BIOCHEM J, V311, P139, DOI 10.1042/bj3110139; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; Hesse M, 2000, EMBO J, V19, P5060, DOI 10.1093/emboj/19.19.5060; Hofmann I, 1997, EUR J CELL BIOL, V72, P122; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Ma LL, 2001, NAT CELL BIOL, V3, P503, DOI 10.1038/35074576; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Omary M B, 1998, Subcell Biochem, V31, P105; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Rumenapp U, 2000, N-S ARCH PHARMACOL, V361, P1, DOI 10.1007/s002109900159; SANTINI D, 1994, GASTROENTEROLOGY, V106, P1326; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; Thoumine O, 1997, J CELL SCI, V110, P2109; Toivola DM, 1997, J CELL SCI, V110, P23; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; Wakita H, 1998, J INVEST DERMATOL, V110, P253, DOI 10.1046/j.1523-1747.1998.00120.x; Windoffer R, 1999, J CELL SCI, V112, P4521; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada S, 2002, MOL BIOL CELL, V13, P382, DOI 10.1091/mbc.01-10-0522; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	35	201	208	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					803	811		10.1038/ncb1037	http://dx.doi.org/10.1038/ncb1037			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12942086				2022-12-25	WOS:000185059000013
J	Roubertoux, PL; Sluyter, F; Carlier, M; Marcet, B; Maarouf-Veray, F; Cherif, C; Marican, C; Arrechi, P; Godin, F; Jamon, M; Verrier, B; Cohen-Salmon, C				Roubertoux, PL; Sluyter, F; Carlier, M; Marcet, B; Maarouf-Veray, F; Cherif, C; Marican, C; Arrechi, P; Godin, F; Jamon, M; Verrier, B; Cohen-Salmon, C			Mitochondrial DNA modifies cognition in interaction with the nuclear genome and age in mice	NATURE GENETICS			English	Article							BRAIN; DYSFUNCTION; EFFICIENT; DISEASE; DECAY; MOUSE	Several lines of evidence indicate an association between mitochondrial DNA (mtDNA) and the functioning of the nervous system. As neuronal development(1,2) and structure(3-5) as well as axonal and synaptic activity(6,7) involve mitochondrial genes, it is not surprising that most mtDNA diseases are associated with brain disorders(8,9). Only one study has suggested an association between mtDNA and cognition(10), however. Here we provide direct evidence of mtDNA involvement in cognitive functioning. Total substitution of mtDNA was achieved by 20 repeated backcrosses in NZB/BINJ (N) and CBA/H (H) mice with different mtDNA origins. All 13 mitochondrial genes were expressed in the brains of the congenic quartet. In interaction with nuclear DNA (nDNA), mtDNA modified learning, exploration, sensory development and the anatomy of the brain. The effects of mtDNA substitution persisted with age, increasing in magnitude as the mice got older. We observed different effects with input of mtDNA from N versus H mice, varying according to the phenotypes. Exchanges of mtDNA may produce phenotypes outside the range of scores observed in the original mitochondrial and nuclear combinations. These findings show that mitochondrial polymorphisms are not as neutral as was previously believed.	CNRS, INPC, F-13402 Marseille, France; CNRS Genet Neurogenet Comportement, Orleans, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Roubertoux, PL (corresponding author), CNRS, INPC, 31 Chemin Joseph Aiguer, F-13402 Marseille, France.	rouber@lnf.cnrs-mrs.fr	Marcet, Brice/Q-1218-2016	Marcet, Brice/0000-0001-5015-2297				Atamna H, 2002, P NATL ACAD SCI USA, V99, P14807, DOI 10.1073/pnas.192585799; Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Carey MR, 2002, NEURON, V35, P223, DOI 10.1016/S0896-6273(02)00771-7; CARLIER M, 1983, PHYSIOL BEHAV, V30, P837, DOI 10.1016/0031-9384(83)90245-7; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; Freeman FM, 2000, PHARMACOL BIOCHEM BE, V67, P355, DOI 10.1016/S0091-3057(00)00373-7; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Le Roy I, 1998, BEHAV BRAIN RES, V95, P135, DOI 10.1016/S0166-4328(97)00218-0; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Martin-Romero FJ, 2002, J NEUROCHEM, V82, P705, DOI 10.1046/j.1471-4159.2002.01023.x; Nagao Y, 1998, GENES GENET SYST, V73, P21, DOI 10.1266/ggs.73.21; Roubertoux PL, 1996, BEHAV GENET, V26, P427, DOI 10.1007/BF02359487; *SAS I, 1989, SAS STAT US GUID VER; Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1; SIMIAND J, 1984, PSYCHOPHARMACOLOGY, V84, P48, DOI 10.1007/BF00432023; SKUDER P, 1995, INTELLIGENCE, V21, P1, DOI 10.1016/0160-2896(95)90035-7; Sluyter F, 1999, BRAIN RES, V835, P68, DOI 10.1016/S0006-8993(99)01385-2; Wahlsten D, 2003, J NEUROSCI METH, V123, P207, DOI 10.1016/S0165-0270(02)00359-X; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; YONEKAWA H, 1982, DIFFERENTIATION, V22, P222, DOI 10.1111/j.1432-0436.1982.tb01255.x; Zenisek D, 2000, NEURON, V25, P229, DOI 10.1016/S0896-6273(00)80885-5; Zini R, 2002, LIFE SCI, V71, P3091, DOI 10.1016/S0024-3205(02)02161-6	29	169	172	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2003	35	1					65	69		10.1038/ng1230	http://dx.doi.org/10.1038/ng1230			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12923532				2022-12-25	WOS:000185018500012
J	Isaacs, FJ; Dwyer, DJ; Ding, CM; Pervouchine, DD; Cantor, CR; Collins, JJ				Isaacs, FJ; Dwyer, DJ; Ding, CM; Pervouchine, DD; Cantor, CR; Collins, JJ			Engineered riboregulators enable post-transcriptional control of gene expression	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; IN-VITRO SELECTION; ANTISENSE RNA; ESCHERICHIA-COLI; TRANSLATION; BACTERIA; IDENTIFICATION; TRANSCRIPTION; THERMOSENSOR; COMPUTATION	Recent studies have demonstrated the important enzymatic, structural and regulatory roles of RNA in the cell. Here we present a post-transcriptional regulation system in Escherichia coli that uses RNA to both silence and activate gene expression. We inserted a complementary cis sequence directly upstream of the ribosome binding site in a target gene. Upon transcription, this cis-repressive sequence causes a stem-loop structure to form at the 5'-untranslated region of the mRNA. The stem-loop structure interferes with ribosome binding, silencing gene expression. A small noncoding RNA that is expressed in trans targets the cis-repressed RNA with high specificity, causing an alteration in the stem-loop structure that activates expression. Such engineered riboregulators may lend insight into mechanistic actions of endogenous RNA-based processes and could serve as scalable components of biological networks, able to function with any promoter or gene to directly control gene expression.	Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University; Boston University; Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Ctr Biodynam, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu	Pervouchine, Dmitri/AAE-2178-2020; Pervouchine, Dmitri/AAU-5399-2021; Pervouchine, Dmitri/H-5252-2015; Ding, Chunming/B-2593-2008	Pervouchine, Dmitri/0000-0003-0543-9760; Pervouchine, Dmitri/0000-0003-0543-9760; Ding, Chunming/0000-0002-2063-5594				Altuvia S, 2000, P NATL ACAD SCI USA, V97, P9824, DOI 10.1073/pnas.97.18.9824; Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Atkins J.F, 1999, RNA WORLD; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Court D. L., 1993, CONTROL MESSENGER RN, P71; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Engdahl HM, 2001, ANTISENSE NUCLEIC A, V11, P29, DOI 10.1089/108729001750072100; Faulhammer D, 2000, P NATL ACAD SCI USA, V97, P1385, DOI 10.1073/pnas.97.4.1385; Franch T, 1999, J MOL BIOL, V294, P1115, DOI 10.1006/jmbi.1999.3306; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Gelfand MS, 1999, TRENDS GENET, V15, P439, DOI 10.1016/S0168-9525(99)01856-9; Good L, 2003, CELL MOL LIFE SCI, V60, P854, DOI 10.1007/s00018-003-3045-4; Gottesman S, 2002, GENE DEV, V16, P2829, DOI 10.1101/gad.1030302; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P571, DOI 10.1093/nar/23.4.571; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; Johansson J, 2002, CELL, V110, P551, DOI 10.1016/S0092-8674(02)00905-4; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; Joyce GF, 2002, NATURE, V418, P214, DOI 10.1038/418214a; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Lease RA, 2000, P NATL ACAD SCI USA, V97, P9919, DOI 10.1073/pnas.170281497; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Majdalani N, 2002, MOL MICROBIOL, V46, P813, DOI 10.1046/j.1365-2958.2002.03203.x; Mandal M, 2003, CELL, V113, P577, DOI 10.1016/S0092-8674(03)00391-X; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; Morita MT, 1999, GENE DEV, V13, P655, DOI 10.1101/gad.13.6.655; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; Rivas E, 2001, CURR BIOL, V11, P1369, DOI 10.1016/S0960-9822(01)00401-8; Robertson MP, 1999, NAT BIOTECHNOL, V17, P62, DOI 10.1038/5236; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith HO, 2003, P NATL ACAD SCI USA, V100, P15440, DOI 10.1073/pnas.2237126100; STEWARD P, 1981, P NATL ACAD SCI USA, V78, P6008; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Tabor JJ, 2003, NAT BIOTECHNOL, V21, P1013, DOI 10.1038/nbt0903-1013; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wagner EGH, 2002, TRENDS GENET, V18, P223, DOI 10.1016/S0168-9525(02)02658-6; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	49	390	473	5	119	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					841	847		10.1038/nbt986	http://dx.doi.org/10.1038/nbt986			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15208640				2022-12-25	WOS:000222533000024
J	Nakamura, Y; Itoh, T; Matsuda, H; Gojobori, T				Nakamura, Y; Itoh, T; Matsuda, H; Gojobori, T			Biased biological functions of horizontally transferred genes in prokaryotic genomes	NATURE GENETICS			English	Article							PATHOGENICITY ISLANDS; EVOLUTION; BACTERIA; NEISSERIA; SEQUENCE; EXCHANGE	Horizontal gene transfer is one of the main mechanisms contributing to microbial genome diversification(1-3). To clarify the overall picture of interspecific gene flow among prokaryotes, we developed a new method for detecting horizontally transferred genes and their possible donors by Bayesian inference with training models for nucleotide composition. Our method gives the average posterior probability ( horizontal transfer index) for each gene sequence, with a low horizontal transfer index indicating recent horizontal transfer. We found that 14% of open reading frames in 116 prokaryotic complete genomes were subjected to recent horizontal transfer. Based on this data set, we quantitatively determined that the biological functions of horizontally transferred genes, except mobile element genes, are biased to three categories: cell surface, DNA binding and pathogenicity-related functions. Thus, the transferability of genes seems to depend heavily on their functions.	Res Org Informat & Syst, Natl Inst Genet, Ctr Informat Biol, Shizuoka 4118540, Japan; Res Org Informat & Syst, Natl Inst Genet, DNA Data Bank Japan, Shizuoka 4118540, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Natl Inst Agrobiol Sci, Genome Res Dept, Tsukuba, Ibaraki 3058602, Japan; Osaka Univ, Grad Sch Informat Sci & Technol, Dept Bioinformat Engn, Osaka 5608531, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Agrobiological Sciences - Japan; Osaka University	Gojobori, T (corresponding author), Res Org Informat & Syst, Natl Inst Genet, Ctr Informat Biol, 1111 Yata, Shizuoka 4118540, Japan.	tgojobor@genes.nig.ac.jp	asif, huma/C-1441-2012	Matsuda, Hideo/0000-0002-4701-3779; Itoh, Takeshi/0000-0002-6291-4233				AMABILECUEVAS CF, 1992, CELL, V70, P189, DOI 10.1016/0092-8674(92)90095-T; BORODOVSKY M, 1995, NUCLEIC ACIDS RES, V23, P3554, DOI 10.1093/nar/23.17.3554; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; Charlebois RL, 2003, NATURE, V421, P217, DOI 10.1038/421217a; Davis J, 2001, J BACTERIOL, V183, P4626, DOI 10.1128/JB.183.15.000-000.2001; de la Cruz F, 2000, TRENDS MICROBIOL, V8, P128, DOI 10.1016/S0966-842X(00)01703-0; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Genereux DP, 2003, TRENDS GENET, V19, P191, DOI 10.1016/S0168-9525(03)00055-6; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; Karlin S, 1998, MOL MICROBIOL, V29, P1341, DOI 10.1046/j.1365-2958.1998.01008.x; Kroll JS, 1998, P NATL ACAD SCI USA, V95, P12381, DOI 10.1073/pnas.95.21.12381; Kurland CG, 2003, P NATL ACAD SCI USA, V100, P9658, DOI 10.1073/pnas.1632870100; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lawrence JG, 2002, THEOR POPUL BIOL, V61, P449, DOI 10.1006/tpbi.2002.1587; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Peterson JD, 2001, NUCLEIC ACIDS RES, V29, P123, DOI 10.1093/nar/29.1.123; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang B, 2001, J MOL EVOL, V53, P244, DOI 10.1007/s002390010214; Yap WH, 1999, J BACTERIOL, V181, P5201, DOI 10.1128/JB.181.17.5201-5209.1999	27	336	356	4	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					760	766		10.1038/ng1381	http://dx.doi.org/10.1038/ng1381			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15208628	Bronze			2022-12-25	WOS:000222354100029
J	Zeidler, MP; Tan, C; Bellaiche, Y; Cherry, S; Hader, S; Gayko, U; Perrimon, N				Zeidler, MP; Tan, C; Bellaiche, Y; Cherry, S; Hader, S; Gayko, U; Perrimon, N			Temperature-sensitive control of protein activity by conditionally splicing inteins	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; DROSOPHILA; YEAST; SITES; MUTATIONS; VECTORS; SUBUNIT; ATPASE; MODEL	Conditional or temperature-sensitive (TS) alleles represent useful tools with which to investigate gene function. Indeed, much of our understanding of yeast has relied on temperature-sensitive mutations which, when available, also provide important insights into other model systems. However, the rarity of temperature- sensitive alleles and difficulty in identifying them has limited their use. Here we describe a system to generate temperature- sensitive alleles based on conditionally active inteins. We have identified temperature-sensitive splicing variants of the yeast Saccharomyces cerevisiae vacuolar ATPase subunit (VMA) intein inserted within Gal4 and transferred these into Gal80. We show that Gal80-intein(TS) is able to efficiently provide temporal regulation of the Gal4/upstream activation sequence (UAS) system in a temperature- dependent manner in Drosophila melanogaster. Given the minimal host requirements necessary for temperature- sensitive intein splicing, this technique has the potential to allow the generation and use of conditionally active inteins in multiple host proteins and model systems, thereby widening the use of temperature- sensitive alleles for functional protein analysis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	perrimon@receptor.med.harvard.edu	Zeidler, Martin/E-6209-2010; Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644; cherry, sara/0000-0003-3956-6610; Tan, Change/0000-0001-8291-3337; Perrimon, Norbert/0000-0001-7542-472X; Zeidler, Martin/0000-0003-2942-1135				Adam E, 2002, J MOL MICROB BIOTECH, V4, P479; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennan K, 1999, DEV BIOL, V216, P210, DOI 10.1006/dbio.1999.9502; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Fukasawa T, 1989, Biotechnology, V13, P1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARRIS SD, 1992, J MOL BIOL, V225, P53, DOI 10.1016/0022-2836(92)91025-K; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lukacsovich T, 2001, GENETICS, V157, P727; Muller B, 2000, DEVELOPMENT, V127, P2999; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Tian J, 2003, DEVELOPMENT, V130, P3331, DOI 10.1242/dev.00544; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu W, 2002, NUCLEIC ACIDS RES, V30, P4864, DOI 10.1093/nar/gkf621; YOCUM RR, 1984, GENE, V32, P75, DOI 10.1016/0378-1119(84)90034-9	27	141	149	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					871	876		10.1038/nbt979	http://dx.doi.org/10.1038/nbt979			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15184905	Green Published			2022-12-25	WOS:000222533000029
J	Merad, M; Hoffmann, P; Ranheim, E; Slaymaker, S; Manz, MG; Lira, SA; Charo, I; Cook, DN; Weissman, IL; Strober, S; Engleman, EG				Merad, M; Hoffmann, P; Ranheim, E; Slaymaker, S; Manz, MG; Lira, SA; Charo, I; Cook, DN; Weissman, IL; Strober, S; Engleman, EG			Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease	NATURE MEDICINE			English	Article							DENDRITIC CELLS; LYMPH-NODES; PERIPHERAL LYMPH; STEADY-STATE; TOLERANCE; RESPONSES; MICE	Skin is the most commonly affected organ in graft-versus-host disease (GVHD). To explore the role of Langerhans cells in GVHD, the principal dendritic cells of the skin, we studied the fate of these cells in mice transplanted with allogeneic bone marrow. In contrast to other dendritic cells, host Langerhans cells were replaced by donor Langerhans cells only when donor T cells were administered along with bone marrow, and the extent of Langerhans cell chimerism correlated with the dose of donor T cells injected. Donor T cells depleted host Langerhans cells through a Fas-dependent pathway and induced the production in skin of CCL20, which was required for the recruitment of donor Langerhans cells. Administration of donor T cells to bone marrow-chimeric mice with persistent host Langerhans cells, but not to mice whose Langerhans cells had been replaced, resulted in marked skin GVHD. These findings indicate a crucial role for donor T cells in host Langerhans cell replacement, and show that host dendritic cells can persist in nonlymphoid tissue for the duration of an animal's life and can trigger GVHD despite complete blood chimerism.	Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94104 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94104 USA; CUNY Mt Sinai Sch Med, Dept Immunobiol, New York, NY 10029 USA; Duke Univ, Med Ctr, Dept Med, Div Pulm & Crit Care, Durham, NC 27710 USA	Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Duke University	Merad, M (corresponding author), CUNY Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA.	miriam.merad@mssm.edu	Manz, Markus G/C-7588-2011; Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755; Manz, Markus/0000-0002-4676-7931	NHLBI NIH HHS [HL57443, P01 HL057443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Belz GT, 2002, J EXP MED, V196, P1099, DOI 10.1084/jem.20020861; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; CVETOVICCVRLJE M, 2001, BLOOD, V98, P1607; DREXHAGE HA, 1979, CELL TISSUE RES, V202, P407, DOI 10.1007/BF00220434; Emile JF, 1997, BRIT J HAEMATOL, V98, P480, DOI 10.1046/j.1365-2141.1997.2293046.x; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; FRELINGER JG, 1979, NATURE, V282, P321, DOI 10.1038/282321a0; Goker H, 2001, EXP HEMATOL, V29, P259, DOI 10.1016/S0301-472X(00)00677-9; Hemmi H, 2001, INT IMMUNOL, V13, P695, DOI 10.1093/intimm/13.5.695; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KATZ SI, 1987, AM J DERMATOPATH, V9, P343; KELLY RH, 1978, ANAT RECORD, V190, P5, DOI 10.1002/ar.1091900103; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; PERREAULT C, 1985, BRIT J HAEMATOL, V60, P253, DOI 10.1111/j.1365-2141.1985.tb07411.x; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Teshima T, 2002, SEMIN HEMATOL, V39, P15, DOI 10.1053/shem.2002.29246; Vogelsang GB, 2001, BLOOD, V97, P1196, DOI 10.1182/blood.V97.5.1196; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073; Zeng DF, 1997, BLOOD, V90, P453; Zhang Y, 2002, J IMMUNOL, V169, P7111, DOI 10.4049/jimmunol.169.12.7111; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	37	257	265	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					510	517		10.1038/nm1038	http://dx.doi.org/10.1038/nm1038			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098028	Green Accepted			2022-12-25	WOS:000221242400029
J	Vulliamy, T; Marrone, A; Szydlo, R; Walne, A; Mason, PJ; Dokal, I				Vulliamy, T; Marrone, A; Szydlo, R; Walne, A; Mason, PJ; Dokal, I			Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC	NATURE GENETICS			English	Article							SMALL NUCLEOLAR RNAS; APLASTIC-ANEMIA; CELLS; COMPONENT; LENGTH	Telomerase is a ribonucleoprotein complex that is required to synthesize DNA repeats at the ends of each chromosome. The RNA component of this reverse transcriptase is mutated in the bone marrow failure syndrome autosomal dominant dyskeratosis congenita. Here we show that disease anticipation is observed in families with this disease and that this is associated with progressive telomere shortening.	Hammersmith Hosp, Imperial Coll London, Dept Haematol, Div Invest Sci, London W12 0NN, England	Imperial College London	Mason, PJ (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Campus Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	PMason@im.wustl.edu	Szydlo, Richard/C-6678-2012; Mason, Philip J/B-1087-2008	Szydlo, Richard/0000-0003-1102-8298; Dokal, Inderjeet/0000-0003-4462-4782				Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Dokal I, 2000, BRIT J HAEMATOL, V110, P768, DOI 10.1046/j.1365-2141.2000.02109.x; Fu D, 2003, MOL CELL, V11, P1361, DOI 10.1016/S1097-2765(03)00196-5; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hathcock KS, 2002, P NATL ACAD SCI USA, V99, P3591, DOI 10.1073/pnas.012549799; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Lindblad K, 1999, SEMIN NEUROL, V19, P289, DOI 10.1055/s-2008-1040845; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6	15	336	348	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					447	449		10.1038/ng1346	http://dx.doi.org/10.1038/ng1346			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15098033	Bronze			2022-12-25	WOS:000221183000014
J	Ide, T; Shimano, H; Yahagi, N; Matsuzaka, T; Nakakuki, M; Yamamoto, T; Nakagawa, Y; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Fukamizu, A; Yamada, N				Ide, T; Shimano, H; Yahagi, N; Matsuzaka, T; Nakakuki, M; Yamamoto, T; Nakagawa, Y; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Fukamizu, A; Yamada, N			SREBPs suppress IRS-2-mediated insulin signalling in the liver	NATURE CELL BIOLOGY			English	Letter							ELEMENT-BINDING PROTEIN-1; TRANSCRIPTION FACTOR FKHR; RECEPTOR SUBSTRATE-2; TRANSGENIC MICE; KINASE-B; IRS-2; GENE; EXPRESSION; RESISTANCE; MOUSE	Insulin receptor substrate 2 (IRS-2) is the main mediator of insulin signalling in the liver, controlling insulin sensitivity. Sterol regulatory element binding proteins (SREBPs) have been established as transcriptional regulators of lipid synthesis. Here, we show that SREBPs directly repress transcription of IRS-2 and inhibit hepatic insulin signalling. The IRS-2 promoter is activated by forkhead proteins through an insulin response element (IRE). Nuclear SREBPs effectively replace and interfere in the binding of these transactivators, resulting in inhibition of the downstream PI(3)K/Akt pathway, followed by decreased glycogen synthesis. These data suggest a molecular mechanism for the physiological switching from glycogen synthesis to lipogenesis and hepatic insulin resistance that is associated with hepatosteatosis.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Internal Med, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba	Shimano, H (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Yahagi, Naoya/D-2360-2014; Sone, Hirohito/ABC-9346-2021; fukamizu, akiyoshi/J-5350-2012; Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Sone, Hirohito/0000-0003-1263-2817; fukamizu, akiyoshi/0000-0002-8786-6020; Shimano, Hitoshi/0000-0002-5562-5572				Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Vassen L, 1999, DIABETES, V48, P1877, DOI 10.2337/diabetes.48.9.1877; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; YAMAMOTO T, 2004, J BIOL CHEM; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	30	262	283	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					351	357		10.1038/ncb1111	http://dx.doi.org/10.1038/ncb1111			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048126				2022-12-25	WOS:000220587600017
J	Karpowicz, P; Cohen, CB; van der Kooy, D				Karpowicz, P; Cohen, CB; van der Kooy, D			It is ethical to transplant human stem cells into nonhuman embryos	NATURE MEDICINE			English	Editorial Material							CHIMERAS; TISSUE; SHEEP	Human/nonhuman stem cell chimeras will be increasingly applied to study human cells in developing nonhuman animals. Such experiments raise a number of issues that may create further controversy in the stem cell field. Here we outline the scientific value and ethical ramifications of such studies, and suggest how such experiments may be conducted ethically.	Univ Toronto, Inst Med Sci, Toronto, ON M5R 1A8, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5R 1A8, Canada; Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA	University of Toronto; University of Toronto; Georgetown University	Karpowicz, P (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5R 1A8, Canada.	phillip.karpowicz@utoronto.ca	Karpowicz, Phillip/C-3334-2016	Karpowicz, Phillip/0000-0002-3116-4804				[Anonymous], J MEC THEOR APPL; BALABAN E, 1988, SCIENCE, V241, P1339, DOI 10.1126/science.3413496; Bazopoulou-Kyrkanidou E, 2001, AM J MED GENET, V100, P66; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Check E, 2003, NATURE, V421, P4, DOI [10.1038/421004b, 10.1038/421004a]; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Cohen CB, 2003, AM J BIOETHICS, V3, pW3; Cohen CB, 1999, J MED PHILOS, V24, P288, DOI 10.1076/jmep.24.3.288.2525; DESOUSA R, 1980, ZYGON, V15, P169, DOI 10.1111/j.1467-9744.1980.tb00384.x; DESOUSA R, 1984, CAN J PHILOS, V14, P561; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; Heeger R, 2001, J AGR ENVIRON ETHIC, V14, P241, DOI 10.1023/A:1011319921159; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KANT I, 1964, METAPHYSICAL PRINC 2, P1; Karpowicz P, 2003, AM J BIOETHICS, V3, pW17; KASS L, 2002, LIFE LIBERTY DEFENSE, P120; KASS L, 1985, MORE NATURAL SCI BIO, P249; Kaufmann R, 1993, Exp Dermatol, V2, P209, DOI 10.1111/j.1600-0625.1993.tb00035.x; Kornack DR, 1998, P NATL ACAD SCI USA, V95, P1242, DOI 10.1073/pnas.95.3.1242; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; PAPAIOANNOU VE, 1984, CHIMERAS DEV BIOL, P3; POLZIN VJ, 1987, J ANIM SCI, V65, P325, DOI 10.2527/jas1987.651325x; Raychaudhuri SP, 2001, BRIT J DERMATOL, V144, P931, DOI 10.1046/j.1365-2133.2001.04178.x; Robert JS, 2003, AM J BIOETHICS, V3, P1, DOI 10.1162/15265160360706417; Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827; Stout J., 1988, ETHICS BABEL LANGUAG, P145; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; WELLS HG, 1996, ISLAND MOREAU, P1; ZANJANI ED, 1991, BLOOD CELLS, V17, P349	32	53	54	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					331	335		10.1038/nm0404-331	http://dx.doi.org/10.1038/nm0404-331			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15057220				2022-12-25	WOS:000220587000014
J	Knight, JC; Keating, BJ; Kwiatkowski, DP				Knight, JC; Keating, BJ; Kwiatkowski, DP			Allele-specific repression of lymphotoxin-alpha activated B cell factor-1	NATURE GENETICS			English	Article							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; GENE POLYMORPHISM; FACTOR-BETA; SEVERE SEPSIS; AMINO-ACID; BINDING; PROTEINS; ENHANCER; ASTHMA	Genetic variation at the human LTA locus, encoding lymphotoxin-alpha, is associated with susceptibility to myocardial infarction, asthma and other diseases. By detailed haplotypic analysis of the locus, we identified a single-nucleotide polymorphism (SNP) at LTA + 80 as a main predictor of LTA protein production by human B cells. We found that activated B-cell factor-1 (ABF-1) binds to this site in vitro and suppresses reporter gene expression, but only in the presence of the LTA +80A allele. Using haplotype-specific chromatin immunoprecipitation, we confirmed that ABF-1 is preferentially recruited to the low-producer allele in vivo. These findings provide a molecular model of how LTA expression may be genetically regulated by allele-specific recruitment of the transcriptional repressor ABF-1.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Knight, JC (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	julian@well.ox.ac.uk	Knight, Julian/C-7242-2009; Knight, Julian Charles/W-2399-2019	Knight, Julian/0000-0002-0377-5536; Knight, Julian Charles/0000-0002-0377-5536; Kwiatkowski, Dominic/0000-0002-5023-0176				Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; BADENHOOP K, 1992, J CLIN ENDOCR METAB, V74, P287, DOI 10.1210/jc.74.2.287; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Demeter J, 1997, BRIT J HAEMATOL, V97, P107, DOI 10.1046/j.1365-2141.1997.9912636.x; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Lee SH, 1997, LUPUS, V6, P603, DOI 10.1177/096120339700600708; Majetschak M, 1999, ANN SURG, V230, P207, DOI 10.1097/00000658-199908000-00011; Massari ME, 1998, MOL CELL BIOL, V18, P3130, DOI 10.1128/MCB.18.6.3130; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PICOT F, 1993, EUR J IMMUNOL, V23, P224; Roach DR, 2001, J EXP MED, V193, P239, DOI 10.1084/jem.193.2.239; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHIMURA T, 1994, CANCER, V73, P1184, DOI 10.1002/1097-0142(19940215)73:4<1184::AID-CNCR2820730410>3.0.CO;2-Y; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; Takahashi Y, 2000, GENE DEV, V14, P804; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Whichelow CE, 1996, EUR J IMMUNOGENET, V23, P425, DOI 10.1111/j.1744-313X.1996.tb00133.x; Wong J, 2001, DNA CELL BIOL, V20, P465, DOI 10.1089/104454901316976091; Yamaguchi E, 2001, CHEST, V119, P753, DOI 10.1378/chest.119.3.753	30	94	97	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					394	399		10.1038/ng1331	http://dx.doi.org/10.1038/ng1331			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15052269	Bronze			2022-12-25	WOS:000220647200024
J	Krakow, D; Robertson, SP; King, LM; Morgan, T; Sebald, ET; Bertolotto, C; Wachsmann-Hogiu, S; Acuna, D; Shapiro, SS; Takafuta, T; Aftimos, S; Kim, CA; Firth, H; Steiner, CE; Cormier-Daire, V; Superti-Furga, A; Bonafe, L; Graham, JM; Grix, A; Bacino, CA; Allanson, J; Bialer, MG; Lachman, RS; Rimoin, DL; Cohn, DH				Krakow, D; Robertson, SP; King, LM; Morgan, T; Sebald, ET; Bertolotto, C; Wachsmann-Hogiu, S; Acuna, D; Shapiro, SS; Takafuta, T; Aftimos, S; Kim, CA; Firth, H; Steiner, CE; Cormier-Daire, V; Superti-Furga, A; Bonafe, L; Graham, JM; Grix, A; Bacino, CA; Allanson, J; Bialer, MG; Lachman, RS; Rimoin, DL; Cohn, DH			Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis	NATURE GENETICS			English	Article							SPONDYLOCARPOTARSAL SYNOSTOSIS; PRENATAL-DIAGNOSIS; LARSENS-SYNDROME; PROTEIN; DISLOCATIONS; MIGRATION; DYSPLASIA; NEURONS	The filamins are cytoplasmic proteins that regulate the structure and activity of the cytoskeleton by cross-linking actin into three-dimensional networks, linking the cell membrane to the cytoskeleton and serving as scaffolds on which intracellular signaling and protein trafficking pathways are organized (reviewed in refs. 1,2). We identified mutations in the gene encoding filamin B in four human skeletal disorders. We found homozygosity or compound heterozygosity with respect to stop-codon mutations in autosomal recessive spondylocarpotarsal syndrome (SCT, OMIM 272460) and missense mutations in individuals with autosomal dominant Larsen syndrome (OMIM 150250) and the perinatal lethal atelosteogenesis I and III phenotypes (AOI, OMIM 108720; AOIII, OMIM 108721). We found that filamin B is expressed in human growth plate chondrocytes and in the developing vertebral bodies in the mouse. These data indicate an unexpected role in vertebral segmentation, joint formation and endochondral ossification for this ubiquitously expressed cytoskeletal protein.	Cedars Sinai Res Inst, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; Cedars Sinai Res Inst, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA; Univ Otago, Dept Paediat & Child Hlth, Dunedin, New Zealand; Cedars Sinai Res Inst, MIST, Los Angeles, CA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Yamanashi Med Univ, Dept Clin & Lab Med, Yamanashi, Japan; No Reg Genet Serv, Auckland, New Zealand; Univ Sao Paulo, Inst Crianca, Fac Med, BR-05508 Sao Paulo, Brazil; Addenbrookes Hosp, Dept Med Genet, Cambridge, England; Univ Estadual Campinas, Dept Med Genet, Sch Med Sci, Campinas, SP, Brazil; Hop Necker Enfants Malad, Dept Med Genet, Paris, France; CHU Vaudois, Div Mol Paediat, Lausanne, Switzerland; Baylor Coll Med, Dept Mol & Human Genet, Los Angeles, CA USA; Eastern Ontario Reg Genet Program, Ottawa, ON, Canada; N Shore NYU Med Ctr, Schneider Childrens Hosp, Dept Pediat, Manhasset, NY USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA USA; Permanente Med Grp Inc, Sacramento, CA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Otago; Cedars Sinai Medical Center; Jefferson University; University of Yamanashi; Universidade de Sao Paulo; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidade Estadual de Campinas; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Permanente Medical Groups	Krakow, D (corresponding author), Cedars Sinai Res Inst, Dept Obstet & Gynecol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	deborah.krakow@cshs.org; stephen.robertson@stonebow.otago.ac.nz	Graham, John M./J-1429-2019; Steiner, Carlos E/B-9319-2014; superti-furga, andrea/E-9162-2015; cormier-daire, valerie/H-6520-2017	Steiner, Carlos E/0000-0001-5148-3063; superti-furga, andrea/0000-0002-3543-7531; cormier-daire, valerie/0000-0002-2839-9856; Kim, Chong/0000-0002-1754-1300; Robertson, Stephen/0000-0002-5181-7809				Chakarova C, 2000, HUM GENET, V107, P597, DOI 10.1007/s004390000414; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Himmel M, 2003, BIOCHEMISTRY-US, V42, P430, DOI 10.1021/bi026501+; Honeywell C, 2002, AM J MED GENET, V109, P318, DOI 10.1002/ajmg.10383; LARSEN LJ, 1950, J PEDIATR-US, V37, P574, DOI 10.1016/S0022-3476(50)80268-8; LATTA RJ, 1971, J PEDIATR-US, V78, P291, DOI 10.1016/S0022-3476(71)80014-8; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Maquat LE, 2000, COLD SPRING HARBOR M, V39, P849; MARQUES MDT, 1980, J GENET HUM, V28, P83; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; Nishimura G, 1997, AM J MED GENET, V73, P132; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; Schultz C, 1999, AM J MED GENET, V83, P28, DOI 10.1002/(SICI)1096-8628(19990305)83:1<28::AID-AJMG7>3.0.CO;2-G; Sheen VL, 2001, HUM MOL GENET, V10, P1775, DOI 10.1093/hmg/10.17.1775; Sheen VL, 2002, HUM MOL GENET, V11, P2845, DOI 10.1093/hmg/11.23.2845; Sillence D, 1997, PEDIATR RADIOL, V27, P388, DOI 10.1007/s002470050154; Steiner CE, 2000, AM J MED GENET, V91, P131, DOI 10.1002/(SICI)1096-8628(20000313)91:2<131::AID-AJMG10>3.3.CO;2-7; STEINER CE, IN PRESS J MED GENET; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; VUJIC M, 1995, AM J HUM GENET, V57, P1104; Wessels MW, 2003, AM J MED GENET A, V122A, P148, DOI 10.1002/ajmg.a.20239	24	189	193	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					405	410		10.1038/ng1319	http://dx.doi.org/10.1038/ng1319			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	14991055	Bronze			2022-12-25	WOS:000220647200026
J	Strawn, LA; Shen, TX; Shulga, N; Goldfarb, DS; Wente, SR				Strawn, LA; Shen, TX; Shulga, N; Goldfarb, DS; Wente, SR			Minimal nuclear pore complexes define FG repeat domains essential for transport	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR ARCHITECTURE; PROTEOMIC ANALYSIS; YEAST NUCLEOPORIN; PROTEIN IMPORT; BINDING; PATHWAY; REGIONS; NUP116P; KAP95P	Translocation through nuclear pore complexes (NPCs) requires interactions between receptor-cargo complexes and phenylalanine-glycine (FG) repeats in multiple FG domain-containing NPC proteins (FG-Nups). We have systematically deleted the FG domains of 11 Saccharomyces cerevisiae FG-Nups in various combinations. All five asymmetrically localized FG domains deleted together were non-essential. However, specific combinations of symmetrically localized FG domains were essential. Over half the total mass of FG domains could be deleted without loss of viability or the NPC's normal permeability barrier. Significantly, symmetric deletions caused mild reductions in Kap95-Kap60-mediated import rates, but virtually abolished Kap104 import. These results suggest the existence of multiple translocation pathways.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	Vanderbilt University; University of Rochester	Wente, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, 3120A MRBIII,465 21st Ave S, Nashville, TN 37232 USA.	susan.wente@vanderbilt.edu			NIGMS NIH HHS [R01 GM67838, R01 GM51219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, R01GM067838] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Allen NPC, 2002, MOL CELL PROTEOMICS, V1, P930, DOI 10.1074/mcp.T200012-MCP200; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Fabre E, 1995, COLD SPRING HARB SYM, V60, P677, DOI 10.1101/SQB.1995.060.01.073; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Hood JK, 2000, J CELL SCI, V113, P1471; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pyhtila B, 2003, J BIOL CHEM, V278, P42699, DOI 10.1074/jbc.M307135200; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rosenblum JS, 1997, J CELL BIOL, V139, P1655, DOI 10.1083/jcb.139.7.1655; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2003, TRENDS CELL BIOL, V13, P622, DOI 10.1016/j.tcb.2003.10.007; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schlaich NL, 1997, MOL BIOL CELL, V8, P33, DOI 10.1091/mbc.8.1.33; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Shulga N, 2003, MOL CELL BIOL, V23, P534, DOI 10.1128/MCB.23.2.534-542.2003; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Walther TC, 2002, J CELL BIOL, V158, P63, DOI 10.1083/jcb.200202088; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705	50	296	311	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					197	206		10.1038/ncb1097	http://dx.doi.org/10.1038/ncb1097			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039779				2022-12-25	WOS:000189363000010
J	Song, MS; Song, SJ; Ayad, NG; Chang, JS; Lee, JH; Hong, HK; Lee, H; Choi, N; Kim, J; Kim, H; Kim, JW; Choi, EJ; Kirschner, MW; Lim, DS				Song, MS; Song, SJ; Ayad, NG; Chang, JS; Lee, JH; Hong, HK; Lee, H; Choi, N; Kim, J; Kim, H; Kim, JW; Choi, EJ; Kirschner, MW; Lim, DS			The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; EPIGENETIC INACTIVATION; CHROMOSOME SEGREGATION; MITOTIC REGULATOR; CELL-CYCLE; CPG ISLAND; PROTEIN; CDC20; MAD2; PROTEOLYSIS	The tumour suppressor gene RASSF1A is frequently silenced in lung cancer and other sporadic tumours as a result of hypermethylation of a CpG island in its promoter(1-6). However, the precise mechanism by which RASSF1A functions in cell cycle regulation and tumour suppression has remained unknown. Here we show that RASSF1A regulates the stability of mitotic cyclins and the timing of mitotic progression. RASSF1A localizes to microtubules during interphase and to centrosomes and the spindle during mitosis. The overexpression of RASSF1A induced stabilization of mitotic cyclins and mitotic arrest at prometaphase. RASSF1A interacts with Cdc20, an activator of the anaphase-promoting complex (APC), resulting in the inhibition of APC activity. Although RASSF1A does not contribute to either the Mad2-dependent spindle assembly checkpoint or the function of Emi1 (ref. 1), depletion of RASSF1A by RNA interference accelerated the mitotic cyclin degradation and mitotic progression as a result of premature APC activation. It also caused a cell division defect characterized by centrosome abnormalities and multipolar spindles. These findings implicate RASSF1A in the regulation of both APC - Cdc20 activity and mitotic progression.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Samsung Med Ctr, Seoul 135230, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea University; Harvard University; Harvard Medical School; Sungkyunkwan University (SKKU); Samsung Medical Center	Lim, DS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseoung D, Taejon 305701, South Korea.	daesiklim@kaist.ac.kr	Lim, Dae-Sik/C-1599-2011; Lee, Joo-Hyeon/AAM-2777-2020; KIM, JIN WOO/C-1655-2011	Lim, Dae-Sik/0000-0003-2356-7555; Lee, Joo-Hyeon/0000-0002-7364-6422; KIM, JIN WOO/0000-0003-0767-1918	Wellcome Trust [107633] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lo KW, 2001, CANCER RES, V61, P3877; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	30	260	281	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					129	+		10.1038/ncb1091	http://dx.doi.org/10.1038/ncb1091			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743218				2022-12-25	WOS:000188668300012
J	Chen, CD; Welsbie, DS; Tran, C; Baek, SH; Chen, R; Vessella, R; Rosenfeld, MG; Sawyers, CL				Chen, CD; Welsbie, DS; Tran, C; Baek, SH; Chen, R; Vessella, R; Rosenfeld, MG; Sawyers, CL			Molecular determinants of resistance to antiandrogen therapy	NATURE MEDICINE			English	Article							HUMAN ANDROGEN RECEPTOR; INDEPENDENT PROSTATE-CANCER; DNA-BINDING DOMAIN; ESTROGEN-RECEPTOR; STRUCTURAL BASIS; IN-VITRO; GENE; EXPRESSION; PHOSPHORYLATION; CELLS	Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Tran, Chau/GRX-4633-2022; Sawyers, Charles/G-5327-2016					Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DePrimo SE, 2002, GENOME BIOL, V3; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Ellis WJ, 1996, CLIN CANCER RES, V2, P1039; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Glass CK, 2000, GENE DEV, V14, P121; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang ZQ, 2002, MOL ENDOCRINOL, V16, P924, DOI 10.1210/me.16.5.924; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kinoshita H, 2000, CANCER RES, V60, P3623; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Lobaccaro JM, 1996, MOL CELL ENDOCRINOL, V116, P137, DOI 10.1016/0303-7207(95)03709-8; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RAFFO AJ, 1995, CANCER RES, V55, P4438; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Schellhammer PF, 1997, J UROLOGY, V157, P1731, DOI 10.1016/S0022-5347(01)64846-8; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	49	1570	1723	8	94	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					33	39		10.1038/nm972	http://dx.doi.org/10.1038/nm972			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702632				2022-12-25	WOS:000187743600036
J	Windrem, MS; Nunes, MC; Rashbaum, WK; Schwartz, TH; Goodman, RA; Mckhann, G; Roy, NS; Goldman, SA				Windrem, MS; Nunes, MC; Rashbaum, WK; Schwartz, TH; Goodman, RA; Mckhann, G; Roy, NS; Goldman, SA			Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; SUBCORTICAL WHITE-MATTER; SHIVERER MUTANT MICE; TRANSPLANTED OLIGODENDROCYTES; EXTENSIVE MYELINATION; STEM-CELLS; IDENTIFICATION; PRECURSORS; FOREBRAIN; TOLERANCE	Both late-gestation and adult human forebrain both contain large numbers of oligodendrocyte progenitor cells (OPCs). These cells may be identified by their A2B5(+)PSA-NCAM(-) phenotype (positive for the early oligodendrocyte marker A2B5 and negative for the polysialylated neural cell adhesion molecule). We used dual-color fluorescence-activated cell sorting (FACS) to extract OPCs from 21- to 23-week-old fetal human forebrain, and A2B5 selection to extract these cells from adult white matter. When xenografted to the forebrains of newborn shiverer mice, fetal OPCs dispersed throughout the white matter and developed into oligodendrocytes and astrocytes. By 12 weeks, the host brains showed extensive myelin production, compaction and axonal myelination. Isolates of OPCs derived from adult human white matter also myelinated shiverer mouse brain, but much more rapidly than their fetal counterparts, achieving widespread and dense myelin basic protein (MBP) expression by 4 weeks after grafting. Adult OPCs generated oligodendrocytes more efficiently than fetal OPCs, and ensheathed more host axons per donor cell than fetal cells. Both fetal and adult OPCS phenotypes mediated the extensive and robust myelination of congenitally dysmyelinated host brain, although their differences suggested their use for different disease targets.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Obstet & Gynecol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Neurosurg, New York, NY 10021 USA; Columbia Univ, Sch Med, Dept Neurosurg, New York, NY 10032 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA	Cornell University; Cornell University; Cornell University; Columbia University; University of Rochester	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, 1300 York Ave, New York, NY 10021 USA.		Schwartz, Theodore/AAK-3320-2020; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Goldman, Steven/0000-0002-5498-4303; Nunes, Marta/0000-0003-3788-878X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039559, R01NS033106] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS33106, R01NS39559] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; Franklin RJM, 1997, J ANAT, V190, P23, DOI 10.1046/j.1469-7580.1997.19010023.x; GANSMULLER A, 1986, DEV NEUROSCI-BASEL, V8, P197, DOI 10.1159/000112253; GOLDMAN SA, 1993, GLIA, V8, P150, DOI 10.1002/glia.440080303; GUMPEL M, 1987, ANN NY ACAD SCI, V495, P71, DOI 10.1111/j.1749-6632.1987.tb23666.x; GUMPEL M, 1989, DEV NEUROSCI-BASEL, V11, P132, DOI 10.1159/000111894; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; Lachapelle F, 1983, DEV NEUROSCI, V6, P326; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; OLeary MT, 1997, J NEUROSCI RES, V48, P159, DOI 10.1002/(SICI)1097-4547(19970415)48:2<159::AID-JNR8>3.0.CO;2-B; Piper DR, 2001, J NEUROSCI RES, V66, P356, DOI 10.1002/jnr.1228; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROSER BJ, 1989, IMMUNOL REV, V107, P179, DOI 10.1111/j.1600-065X.1989.tb00009.x; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhang SC, 1999, P NATL ACAD SCI USA, V96, P4089, DOI 10.1073/pnas.96.7.4089	25	320	342	0	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					93	97		10.1038/nm974	http://dx.doi.org/10.1038/nm974			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702638				2022-12-25	WOS:000187743600044
J	Adams, G; Vessillier, S; Dreja, H; Chernajovsky, Y				Adams, G; Vessillier, S; Dreja, H; Chernajovsky, Y			Targeting cytokines to inflammation sites	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR-BETA; COLLAGEN-INDUCED ARTHRITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TGF-BETA; GENE-THERAPY; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; DIRECTED MUTAGENESIS; MULTIPLE-SCLEROSIS; CYSTEINE RESIDUES	To increase the half-life of a cytokine and target its activation specifically to disease sites, we have engineered a latent cytokine using the latency-associated protein (LAP) of transforming growth factor-beta (TGF-beta1) fused via a matrix metalloproteinase (MMP) cleavage site to interferon (IFN)-beta at either its N or C terminus. The configuration LAP-MMP-IFN-beta resembles native TGF-beta and lacks biological activity until cleaved by MMPs, whereas the configuration IFN-beta-MMP-LAP is active. LAP provides for a disulfide-linked shell hindering interaction of the cytokine with its cellular receptors, conferring a very long half-life of 55 h in vivo. Mutations of the disulfide bonds in LAP abolish this latency. Samples of cerebrospinal fluid (CSF) or synovial fluid from patients with inflammatory diseases specifically activate the latent cytokine, whereas serum samples do not. Intramuscular injection in arthritic mice of plasmid DNA encoding these constructs demonstrated a greater therapeutic effect of the latent as compared to the active forms.	Univ London, Queen Mary, St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst,Bone & Joint Res Unit, London EC1M 6BQ, England	University of London; Queen Mary University London	Chernajovsky, Y (corresponding author), Univ London, Queen Mary, St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst,Bone & Joint Res Unit, Charterhouse Sq, London EC1M 6BQ, England.		Vessillier, Sandrine/E-2502-2013	Vessillier, Sandrine/0000-0002-9697-1834				Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; AULITZKY WE, 1994, DRUGS, V48, P667, DOI 10.2165/00003495-199448050-00002; Baugh MD, 1999, GASTROENTEROLOGY, V117, P814, DOI 10.1016/S0016-5085(99)70339-2; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; Chernajovsky Y, 1997, GENE THER, V4, P553, DOI 10.1038/sj.gt.3300436; CHERNAJOVSKY Y, 1984, DNA-J MOLEC CELL BIO, V3, P297, DOI 10.1089/dna.1.1984.3.297; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Croxford JL, 1998, J IMMUNOL, V160, P5181; DECLERCK YA, 1992, CANCER RES, V52, P701; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Dreja H, 2000, ARTHRITIS RHEUM-US, V43, P1698, DOI 10.1002/1529-0131(200008)43:8<1698::AID-ANR5>3.0.CO;2-8; Golab J, 1999, INT J MOL MED, V3, P537; Goldman MH, 1997, CYTOTECHNOLOGY, V23, P103, DOI 10.1023/A:1007947130709; Gordon EM, 1997, HUM GENE THER, V8, P1385, DOI 10.1089/hum.1997.8.11-1385; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Han B, 1997, PROTEIN EXPRES PURIF, V11, P169, DOI 10.1006/prep.1997.0784; Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; Kubo Y, 1997, BONE MARROW TRANSPL, V20, P27, DOI 10.1038/sj.bmt.1700837; Leppert D, 1998, BRAIN, V121, P2327, DOI 10.1093/brain/121.12.2327; Libby P, 1998, Vasc Med, V3, P225, DOI 10.1177/1358836X9800300309; Lode HN, 1998, PHARMACOL THERAPEUT, V80, P277, DOI 10.1016/S0163-7258(98)00033-3; Louis E, 2000, CLIN EXP IMMUNOL, V120, P241, DOI 10.1046/j.1365-2249.2000.01227.x; Margolin KA, 2000, SEMIN ONCOL, V27, P194; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Masure S, 1997, EUR J BIOCHEM, V244, P21, DOI 10.1111/j.1432-1033.1997.00021.x; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Peng KW, 1997, HUM GENE THER, V8, P729, DOI 10.1089/hum.1997.8.6-729; Pepinsky RB, 2001, J PHARMACOL EXP THER, V297, P1059; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SATO Y, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P79; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; Triantaphyllopoulos KA, 1998, GENE THER, V5, P253, DOI 10.1038/sj.gt.3300570; Triantaphyllopoulos KA, 1999, ARTHRITIS RHEUM, V42, P90, DOI 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; Vodovotz Y, 1999, CANCER RES, V59, P2142; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; Yu Q, 2000, GENE DEV, V14, P163	53	53	58	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1314	1320		10.1038/nbt888	http://dx.doi.org/10.1038/nbt888			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14528315				2022-12-25	WOS:000186320000032
J	Marin, M; Rose, KM; Kozak, SL; Kabat, D				Marin, M; Rose, KM; Kozak, SL; Kabat, D			HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VIF; REVERSE TRANSCRIPTION; BOX MOTIF; DNA; VIRIONS; RNA; COMPLEX; CELLS; IDENTIFICATION	The viral infectivity factor (Vif) encoded by HIV-1 neutralizes a potent antiviral pathway that occurs in human T lymphocytes and several leukemic T-cell lines termed nonpermissive, but not in other cells termed permissive. In the absence of Vif, this antiviral pathway efficiently inactivates HIV-1. It was recently reported that APOBEC3G (also known as CEM-15), a cytidine deaminase nucleic acid-editing enzyme, confers this antiviral phenotype on permissive cells. Here we describe evidence that Vif binds APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions. Studies of Vif mutants imply that it contains two domains, one that binds APOBEC3G and another with a conserved SLQ(Y/F)LA motif that mediates APOBEC3G degradation by a proteasome-dependent pathway. These results provide promising approaches for drug discovery.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97239 USA.				NIAID NIH HHS [AI49729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049729, R21AI049729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; Madani N, 2000, J VIROL, V74, P5982, DOI 10.1128/JVI.74.13.5982-5987.2000; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760; Ochsenbauer C, 1997, J GEN VIROL, V78, P627, DOI 10.1099/0022-1317-78-3-627; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; Platt EJ, 2001, J VIROL, V75, P12266, DOI 10.1128/JVI.75.24.12266-12278.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	40	654	673	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1398	1403		10.1038/nm946	http://dx.doi.org/10.1038/nm946			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528301				2022-12-25	WOS:000186319700030
J	Pantalacci, S; Tapon, N; Leopold, P				Pantalacci, S; Tapon, N; Leopold, P			The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila	NATURE CELL BIOLOGY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; REGULATING APOPTOSIS; IAP DEGRADATION; TNF SUPERFAMILY; PROTEIN-KINASE; DIAP1; REAPER; GENE; MELANOGASTER; MECHANISMS	Tissue growth during animal development is tightly controlled so that the organism can develop harmoniously(1). The salvador (sav) gene, which encodes a scaffold protein, has been shown to restrict cell number by coordinating cell-cycle exit and apoptosis during Drosophila development(2,3). Here we identify Hippo (Hpo), the Drosophila orthologue of the mammalian MST1 and MST2 serine/threonine kinases, as a partner of Sav. Loss of hpo function leads to sav-like phenotypes, whereas gain of hpo function results in the opposite phenotype. Whereas Sav and Hpo normally restrict cellular quantities of the Drosophila inhibitor of apoptosis protein DIAP1, overexpression of Hpo destabilizes DIAP1 in cell culture. We show that DIAP1 is phosphorylated in a Hpo-dependent manner in S2 cells and that Hpo can phosphorylate DIAP1 in vitro. Thus, Hpo may promote apoptosis by reducing cellular amounts of DIAP1. In addition, we show that Sav is an unstable protein that is stabilized by Hpo. We propose that Hpo and Sav function together to restrict tissue growth in vivo.	Univ Nice, Ctr Biochim, CNRS, UMR 6543,Inst Signalling Dev Biol & Canc Res, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Tapon, N (corresponding author), Canc Res UK London Res Inst, Apoptosis & Proliferat Control Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.			Tapon, Nicolas/0000-0001-5267-6510				Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Ditzel M, 2002, TRENDS CELL BIOL, V12, P449, DOI 10.1016/S0962-8924(02)02366-8; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; Giordano E, 2002, GENETICS, V160, P637; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Pignoni F, 1997, DEVELOPMENT, V124, P271; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RING JM, 1993, DEVELOPMENT, P251; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Wang HCR, 2000, J BIOL CHEM, V275, P25850, DOI 10.1074/jbc.M000818200; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; XU TA, 1995, DEVELOPMENT, V121, P1053; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	30	439	455	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					921	927		10.1038/ncb1051	http://dx.doi.org/10.1038/ncb1051			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14502295				2022-12-25	WOS:000185647400019
J	Lin, SP; Youngson, N; Takada, S; Seitz, H; Reik, W; Paulsen, M; Cavaille, J; Ferguson-Smith, ACF				Lin, SP; Youngson, N; Takada, S; Seitz, H; Reik, W; Paulsen, M; Cavaille, J; Ferguson-Smith, ACF			Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12	NATURE GENETICS			English	Article							UNIPARENTAL DISOMY; GENES; DOMAIN; GTL2; DELETION; H19; IDENTIFICATION; EXPRESSION; DNMT3L; LOCUS	Genomic imprinting causes parental origin specific gene expression(1). Cis-acting regulatory elements that control imprinting are not fully understood but involve regions that become differentially methylated on the two parental chromosomes during male and female gametogenesis(2-4). Understanding properties of maternally and paternally inherited imprints provides insight into the mechanisms and evolution of genomic imprinting. Previously we identified an intergenic germline-derived differentially methylated region (IG-DMR) that is a candidate control element for an imprinted domain on distal mouse chromosome 12 (ref. 5). The 1-Mb cluster contains the paternally expressed protein-coding genes Dlk1 (refs. 6,7) and Dio3 (ref. 8,9) and several maternally expressed non-coding RNAs, including Gtl2 (refs. 6,7,10) and C/D snoRNAs(11). A retrotransposon-like gene (Rtl1) is expressed from the paternal chromosome and has an antisense transcript expressed from the maternal chromosome containing two microRNAs with full complementarity to Rtl1 (ref. 12). Here we show that deletion of the IG-DMR from the maternally inherited chromosome causes bidirectional loss of imprinting of all genes in the cluster. When the deletion is transmitted from the father, imprinting is unaltered. These results prove that the IG-DMR is a control element for all imprinted genes on the maternal chromosome only and indicate that the two parental chromosomes control allele-specific gene expression differently.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Toulouse 3, CNRS, UMR 5099, LBME, F-31062 Toulouse, France; Babraham Inst, Lab Dev Genet & Imprinting, Dev Genet Programme, Cambridge CB2 4AT, England	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Lin, SP (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Youngson, Neil/AAB-7389-2019; Ferguson-Smith, Anne C/G-7534-2011; Reik, Wolf/I-6794-2012; cavaille, jerome/AAM-8047-2020; Seitz, Hervé/AAE-6487-2019; Paulsen, Martina/G-2262-2010	Seitz, Hervé/0000-0001-8172-5393; Youngson, Neil/0000-0003-0690-4580; Lin, Shau-Ping/0000-0003-3423-991X; CAVAILLE, Jerome/0000-0003-2833-6836; Takada, Shuji/0000-0002-9406-4683; Reik, Wolf/0000-0003-0216-9881; Ferguson-Smith, Anne/0000-0002-7608-5894				Arney KL, 2003, TRENDS GENET, V19, P17, DOI 10.1016/S0168-9525(02)00004-5; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Buiting K, 2003, AM J HUM GENET, V72, P571, DOI 10.1086/367926; Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527; Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Georges M, 2003, TRENDS GENET, V19, P248, DOI 10.1016/S0168-9525(03)00082-9; Georgiades P, 2000, DEVELOPMENT, V127, P4719; Georgiades P, 2001, P NATL ACAD SCI USA, V98, P4522, DOI 10.1073/pnas.081540898; Hata K, 2002, DEVELOPMENT, V129, P1983; Mancini-DiNardo D, 2003, HUM MOL GENET, V12, P283, DOI 10.1093/hmg/ddg024; Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x; Mundt C, 2001, J EXP MED, V193, P435, DOI 10.1084/jem.193.4.435; Paulsen M, 2001, GENOME RES, V11, P2085, DOI 10.1101/gr.206901; Schmidt JV, 2000, GENE DEV, V14, P1997; Schuster-Gossler K, 1998, DEV DYNAM, V212, P214, DOI 10.1002/(SICI)1097-0177(199806)212:2<214::AID-AJA6>3.0.CO;2-K; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tsai CE, 2002, CURR BIOL, V12, P1221, DOI 10.1016/S0960-9822(02)00951-X; WANG JCC, 1991, AM J HUM GENET, V48, P1069; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; Yevtodiyenko A, 2002, MAMM GENOME, V13, P633, DOI 10.1007/s00335-002-2208-1	29	379	410	1	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2003	35	1					97	102		10.1038/ng1233	http://dx.doi.org/10.1038/ng1233			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12937418				2022-12-25	WOS:000185018500017
J	Ortega, S; Prieto, I; Odajima, J; Martin, A; Dubus, P; Sotillo, R; Barbero, JL; Malumbres, M; Barbacid, M				Ortega, S; Prieto, I; Odajima, J; Martin, A; Dubus, P; Sotillo, R; Barbero, JL; Malumbres, M; Barbacid, M			Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice	NATURE GENETICS			English	Article							CYCLIN-DEPENDENT KINASES; HISTONE GENE-TRANSCRIPTION; CHROMOSOME SYNAPSIS; MEIOTIC PROPHASE; CENTROSOME DUPLICATION; RETINOBLASTOMA PROTEIN; CDK2 KINASE; S-PHASE; MOUSE; PHOSPHORYLATION	We targeted the locus encoding the cyclin-dependent kinase 2 (CDK2) by homologous recombination in mouse embryonic stem (ES) cells. Embryonic fibroblasts lacking CDK2 proliferate normally and become immortal after continuous passage in culture. Elimination of a conditional Cdk2 allele in immortal cells does not have a significant effect on proliferation. Cdk2(-/-) mice are viable and survive for up to two years, indicating that CDK2 is also dispensable for proliferation and survival of most cell types. But CDK2 is essential for completion of prophase I during meiotic cell division in male and female germ cells, an unforeseen role for this cell cycle kinase.	Ctr Nacl Invest Oncol, Mol Oncol Program, E-28029 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28029 Madrid, Spain; Univ Bordeaux 2, EA 2406, F-33076 Bordeaux, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UDICE-French Research Universities; Universite de Bordeaux	Ortega, S (corresponding author), Ctr Nacl Invest Oncol, Mol Oncol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.		Malumbres, Marcos/E-8834-2011; Barbero, Jose Luis/J-9833-2014	Malumbres, Marcos/0000-0002-0829-6315; Dubus, Pierre/0000-0003-1803-4711; Sotillo, Rocio/0000-0002-0855-7917; Martin, Alberto/0000-0003-3427-7684; BARBERO, JOSE LUIS/0000-0002-1226-0323				Ashley T, 2001, J CELL SCI, V114, P685; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Eaker S, 2002, DEV BIOL, V249, P85, DOI 10.1006/dbio.2002.0708; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; GENG Y, IN PRESS CELL; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hanks MC, 1998, DEVELOPMENT, V125, P4521; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; HULTEN MA, 2001, HUMAN CYTOGENETICS C, P211; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; Kneitz B, 2000, GENE DEV, V14, P1085; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Lane ME, 2000, GENETICS, V155, P233; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARISI T, IN PRESS EMBO J; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	52	668	686	1	59	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					25	31		10.1038/ng1232	http://dx.doi.org/10.1038/ng1232			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12923533				2022-12-25	WOS:000185018500007
J	Nguyen, MD; Shu, TZ; Sanada, K; Lariviere, RC; Tseng, HC; Park, SK; Julien, JP; Tsai, LH				Nguyen, MD; Shu, TZ; Sanada, K; Lariviere, RC; Tseng, HC; Park, SK; Julien, JP; Tsai, LH			A NUDEL-dependent mechanism of neurofilament assembly regulates the integrity of CNS neurons	NATURE CELL BIOLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MUTANT SUPEROXIDE-DISMUTASE; INTERMEDIATE-FILAMENTS; NERVOUS-SYSTEM; MOUSE MODEL; MICROTUBULE ORGANIZATION; CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; GENE-EXPRESSION; SOD1 MUTATION	The cytoskeleton controls the architecture and survival of central nervous system (CNS) neurons by maintaining the stability of axons and dendrites. Although neurofilaments (NFs) constitute the main cytoskeletal network in these structures, the mechanism that underlies subunit incorporation into filaments remains a mystery. Here we report that NUDEL, a mammalian homologue of the Aspergillus nidulans nuclear distribution molecule NudE, is important for NF assembly, transport and neuronal integrity. NUDEL facilitates the polymerization of NFs through a direct interaction with the NF light subunit (NF-L). Knockdown of NUDEL by RNA interference (RNAi) in a neuroblastoma cell line, primary cortical neurons or post-natal mouse brain destabilizes NF-L and alters the homeostasis of NFs. This results in NF abnormalities and morphological changes reminiscent of neurodegeneration. Furthermore, variations in levels of NUDEL correlate with disease progression and NF defects in a mouse model of neurodegeneration. Thus, NUDEL contributes to the integrity of CNS neurons by regulating NF assembly.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; McGill University	Nguyen, MD (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,New Res Bldg,Room 856-8, Boston, MA 02115 USA.	minh-dang_nguyen@hms.harvard.edu; li-huei_tsai@hms.harvard.edu	SANADA, YOSHIKADO/G-5014-2014	Sanada, Kamon/0000-0002-0280-8957				Beaulieu JM, 1999, BIOCHEM CELL BIOL, V77, P41, DOI 10.1139/bcb-77-1-41; Beaulieu JM, 2000, J NEUROSCI, V20, P5321, DOI 10.1523/JNEUROSCI.20-14-05321.2000; BENNETT GS, 1985, J CELL BIOL, V100, P1799, DOI 10.1083/jcb.100.5.1799; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BLACK MM, 1986, J NEUROSCI, V6, P1004; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; Couillard-Despres S, 1998, P NATL ACAD SCI USA, V95, P9626, DOI 10.1073/pnas.95.16.9626; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Fujita Y, 2000, J NEUROL SCI, V174, P137, DOI 10.1016/S0022-510X(00)00265-3; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; Helfand BT, 2003, ANNU REV CELL DEV BI, V19, P445, DOI 10.1146/annurev.cellbio.19.111401.092306; HILL WD, 1993, J COMP NEUROL, V329, P328, DOI 10.1002/cne.903290304; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; Julien JP, 1999, CURR OPIN NEUROBIOL, V9, P554, DOI 10.1016/S0959-4388(99)00004-5; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Jung C, 1998, CELL MOTIL CYTOSKEL, V40, P44, DOI 10.1002/(SICI)1097-0169(1998)40:1<44::AID-CM5>3.0.CO;2-F; Kong JM, 2000, NEUROSCI LETT, V281, P72, DOI 10.1016/S0304-3940(00)00808-9; KOST SA, 1992, BRAIN RES, V595, P270, DOI 10.1016/0006-8993(92)91060-R; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; Lariviere RC, 2003, NEUROBIOL DIS, V13, P158, DOI 10.1016/S0969-9961(03)00036-6; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; MCLACHLAN DRC, 1988, MOL BRAIN RES, V3, P255, DOI 10.1016/0169-328X(88)90048-4; Menzies FM, 2002, J NEUROCHEM, V82, P1118, DOI 10.1046/j.1471-4159.2002.01045.x; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Morrison BM, 2000, EXP NEUROL, V165, P207, DOI 10.1006/exnr.2000.7457; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Rao MV, 2002, J CELL BIOL, V159, P279, DOI 10.1083/JCB.200205062; Rouleau GA, 1996, ANN NEUROL, V39, P128, DOI 10.1002/ana.410390119; Roy S, 2000, J NEUROSCI, V20, P6849, DOI 10.1523/JNEUROSCI.20-18-06849.2000; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; Shah JV, 2000, MOL BIOL CELL, V11, P3495, DOI 10.1091/mbc.11.10.3495; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169; Wang L, 2000, NAT CELL BIOL, V2, P137, DOI 10.1038/35004008; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yabe JT, 1999, J CELL SCI, V112, P3799; Yuan AD, 2003, J NEUROSCI, V23, P9452; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	48	76	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					595	608		10.1038/ncb1139	http://dx.doi.org/10.1038/ncb1139			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15208636				2022-12-25	WOS:000222434900014
J	Qing, GL; Ma, LC; Khorchid, A; Swapna, GVT; Mal, TK; Takayama, MM; Xia, B; Phadtare, S; Ke, HP; Acton, T; Montelione, GT; Ikura, M; Inouye, M				Qing, GL; Ma, LC; Khorchid, A; Swapna, GVT; Mal, TK; Takayama, MM; Xia, B; Phadtare, S; Ke, HP; Acton, T; Montelione, GT; Ikura, M; Inouye, M			Cold-shock induced high-yield protein production in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article							NMR-SPECTROSCOPY; CSPA; IDENTIFICATION; DOWNSTREAM; EXPRESSION; ELEMENT	Overexpression of proteins in Escherichia coli at low temperature improves their solubility and stability(1,2). Here, we apply the unique features of the cspA gene to develop a series of expression vectors, termed pCold vectors, that drive the high expression of cloned genes upon induction by cold-shock. Several proteins were produced with very high yields, including E. coli EnvZ ATP-binding domain (EnvZ-B) and Xenopus laevis calmodulin (CaM). The pCold vector system can also be used to selectively enrich target proteins with isotopes to study their properties in cell lysates using NMR spectroscopy. We have cloned 38 genes from a range of prokaryotic and eukaryotic organisms into both pCold and pET14 (ref. 3) systems, and found that pCold vectors are highly complementary to the widely used pET vectors.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, NE Struct Genom Consortium, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Takara Bio Inc, Shiga 5202193, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Takara Bio Inc.	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@umdnj.edu	Mal, Tapas K/A-9453-2011	Mal, Tapas K/0000-0002-0625-2095; Montelione, Gaetano/0000-0002-9440-3059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM067061, P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50-GM62413, R21-GM067061] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almeida FCL, 2001, J MAGN RESON, V148, P142, DOI 10.1006/jmre.2000.2213; Bae W, 1997, J BACTERIOL, V179, P7081, DOI 10.1128/jb.179.22.7081-7088.1997; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erbel PJA, 2003, J BACTERIOL, V185, P1995, DOI 10.1128/JB.185.6.1995-2004.2003; Etchegaray JP, 1999, J BIOL CHEM, V274, P10079, DOI 10.1074/jbc.274.15.10079; Gronenborn AM, 1996, PROTEIN SCI, V5, P174; Jansson M, 1996, J BIOMOL NMR, V7, P131; Mitta M, 1997, MOL MICROBIOL, V26, P321, DOI 10.1046/j.1365-2958.1997.5771943.x; MONTELIONE GT, 1999, BIOL MAGN RESON, V17, P81; Palmer A. G., 1996, PROTEIN NMR SPECTROS; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHIRANO Y, 1990, FEBS LETT, V271, P128; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUNDERLICH Z, 2004, IN PRESS PROTEIN TAR; Xia B, 2001, J BIOL CHEM, V276, P35581, DOI 10.1074/jbc.M103871200; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	18	245	311	6	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					877	882		10.1038/nbt984	http://dx.doi.org/10.1038/nbt984			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15195104				2022-12-25	WOS:000222533000030
J	Ting, AH; Jair, KW; Suzuki, H; Yen, RWC; Baylin, SB; Schuebel, KE				Ting, AH; Jair, KW; Suzuki, H; Yen, RWC; Baylin, SB; Schuebel, KE			CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1	NATURE GENETICS			English	Article							METHYLATION; GENES; PROTEIN	The role of the primary mammalian DNA methyltransferase, DNMT1, in maintaining CpG island methylation in human colon cancer cells has recently been questioned. This controversy has arisen from discrepancies between genetic knockout and RNA interference-mediated knockdown studies. Here, we re-examined the RNA interference-based approach and found that hypermethylation of single-copy genes is maintained in cells transiently and stably depleted of DNMT1.	Johns Hopkins Univ, Program Cellular & Mol Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Canc Biol Div, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Baylin, SB (corresponding author), Johns Hopkins Univ, Program Cellular & Mol Med, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu; kornels@jhmi.edu						Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Myohanen SK, 1998, CANCER RES, V58, P591; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; SEDIVY JM, 1999, SCIENCE, V283, P9, DOI DOI 10.1126/SCIENCE.283.5398.9A); Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892	15	77	79	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					582	584		10.1038/ng1365	http://dx.doi.org/10.1038/ng1365			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15156141	Bronze			2022-12-25	WOS:000221763700014
J	Qi, Y; Takahashi, N; Hileman, SM; Patel, HR; Berg, AH; Pajvani, UB; Scherer, PE; Ahima, RS				Qi, Y; Takahashi, N; Hileman, SM; Patel, HR; Berg, AH; Pajvani, UB; Scherer, PE; Ahima, RS			Adiponectin acts in the brain to decrease body weight	NATURE MEDICINE			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; UNCOUPLING PROTEIN; LEPTIN; EXPRESSION; ADIPOSITY; ACRP30; AGOUTI	Adiponectin (ADP) is an adipocyte hormone involved in glucose and lipid metabolism. We detected a rise in ADP in cerebrospinal fluid after intravenous (i.v.) injection, consistent with brain transport. In contrast to leptin, intracerebroventricular (i.c.v.) administration of ADP decreased body weight mainly by stimulating energy expenditure. Full-length ADP, mutant ADP with Cys39 replaced with serine, and globular ADP were effective, whereas the collagenous tail fragment was not. Lep(ob/ob) mice were especially sensitive to i.c.v. and systemic ADP, which resulted in increased thermogenesis, weight loss and reduction in serum glucose and lipid levels. ADP also potentiated the effect of leptin on thermogenesis and lipid levels. While both hormones increased expression of hypothalamic corticotropin-releasing hormone (CRH), ADP had no substantial effect on other neuropeptide targets of leptin. In addition, ADP induced distinct Fos immunoreactivity. Agouti (A(y)/a) mice did not respond to ADP or leptin, indicating the melanocortin pathway may be a common target. These results show that ADP has unique central effects on energy homeostasis.	Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Penn Diabet Ctr, Philadelphia, PA 19104 USA; W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	University of Pennsylvania; University of Pennsylvania; West Virginia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ahima, RS (corresponding author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	ahima@mail.med.upenn.edu	Scherer, Philipp E/K-7819-2012; Ahima, Rexford/W-1394-2019	Scherer, Philipp E/0000-0003-0680-3392; Takahashi, Nobuhiko/0000-0003-2028-5405	NIDDK NIH HHS [R01-DK62348, R01-DK55758, P30-DK19525] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK055758, R01DK062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahima RS, 2000, REGUL PEPTIDES, V92, P1, DOI 10.1016/S0167-0115(00)00142-7; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Ahima RS, 2002, DIABETES, V51, P2099, DOI 10.2337/diabetes.51.7.2099; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Elias CF, 2000, J COMP NEUROL, V423, P261; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Masaki T, 2003, DIABETES, V52, P2266, DOI 10.2337/diabetes.52.9.2266; Masaki T, 2003, ENDOCRINOLOGY, V144, P3547, DOI 10.1210/en.2003-0301; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; PAXINOS G, 1997, MOUSE BRAIN STEREOTA, P36; STE ML, 2000, P NATL ACAD SCI USA, V97, P12339; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	25	641	678	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					524	529		10.1038/nm1029	http://dx.doi.org/10.1038/nm1029			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15077108				2022-12-25	WOS:000221242400031
J	Ruggero, D; Montanaro, L; Ma, L; Xu, W; Londei, P; Cardon-Cardo, C; Pandolfi, PP				Ruggero, D; Montanaro, L; Ma, L; Xu, W; Londei, P; Cardon-Cardo, C; Pandolfi, PP			The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis	NATURE MEDICINE			English	Article							INITIATION-FACTOR 4E; PROTEIN; TRANSFORMATION; FIBROBLASTS; EXPRESSION; APOPTOSIS; PTEN	The mammalian target of rapamycin, mTOR, regulates cell growth and proliferation. Here we show that the initiation factor of translation (eIF-4E), a downstream effector of mTOR, has oncogenic effects in vivo and cooperates with c-Myc in B-cell lymphomagenesis. We found that c-Myc overrides eIF-4E-induced cellular senescence, whereas eIF-4E antagonizes c-Myc-dependent apoptosis in vivo. Our results implicate activation of eIF-4E as a key event in oncogenic transformation by phosphoinositide-3 kinase and Akt.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Univ Bari, Dipartimento Biochim Med & Biol Med, I-70124 Bari, Italy	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Universita degli Studi di Bari Aldo Moro	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Montanaro, Lorenzo/I-4236-2019; Ma, Li/GQR-1313-2022	Montanaro, Lorenzo/0000-0001-9776-9518; Ma, Li/0000-0001-9965-989X				Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seki N, 2002, CLIN CANCER RES, V8, P3046; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	15	463	478	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					484	486		10.1038/nm1042	http://dx.doi.org/10.1038/nm1042			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098029				2022-12-25	WOS:000221242400025
J	Bottini, N; Musumeci, L; Alonso, A; Rahmouni, S; Nika, K; Rostamkhani, M; MacMurray, J; Meloni, GF; Lucarelli, P; Pellecchia, M; Eisenbarth, GS; Comings, D; Mustelin, T				Bottini, N; Musumeci, L; Alonso, A; Rahmouni, S; Nika, K; Rostamkhani, M; MacMurray, J; Meloni, GF; Lucarelli, P; Pellecchia, M; Eisenbarth, GS; Comings, D; Mustelin, T			A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes	NATURE GENETICS			English	Article							SUSCEPTIBILITY GENES; KINASE; P50(CSK); SEARCH; GENOME	We report that a single-nucleotide polymorphism ( SNP) in the gene (PTPN22) encoding the lymphoid protein tyrosine phosphatase (LYP), a suppressor of T-cell activation, is associated with type 1 diabetes mellitus (T1D). The variants encoded by the two alleles, 1858C and 1858T, differ in a crucial amino acid residue involved in association of LYP with the negative regulatory kinase Csk. Unlike the variant encoded by the more common allele 1858C, the variant associated with T1D does not bind Csk.	Burnham Inst, Canc Res Ctr, Program Signal Transduct, La Jolla, CA 92037 USA; City Hope Natl Med Ctr, Dept Med Genet, Duarte, CA 91010 USA; Univ Sassari, Dept Pediat, I-07100 Sassari, Italy; Italian Natl Res Council, Rome, Italy; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	Sanford Burnham Prebys Medical Discovery Institute; City of Hope; University of Sassari; Consiglio Nazionale delle Ricerche (CNR); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mustelin, T (corresponding author), Burnham Inst, Canc Res Ctr, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burham-inst.org	Meloni, Gianfranco G.F./E-9426-2012; Alonso, Andrés/L-7523-2014; Pellecchia, Maurizio/Y-7072-2018; Ingegnoli, Francesca/B-6226-2017	Meloni, Gianfranco G.F./0000-0002-0604-8924; Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840; Ingegnoli, Francesca/0000-0002-6727-1273; Nika, Konstantina/0000-0002-9620-0263				Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bottini N, 2002, ARCH IMMUNOL THER EX, V50, P95; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Ghose R, 2001, NAT STRUCT BIOL, V8, P998, DOI 10.1038/nsb1101-998; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; IIVANAINEN AV, 1990, EUR J IMMUNOL, V20, P2509, DOI 10.1002/eji.1830201123; Jawaheer D, 2003, ARTHRITIS RHEUM-US, V48, P906, DOI 10.1002/art.10989; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD918, DOI 10.2741/musteli1; Mustelin T, 2002, MOL PATHOLOGY AUTOIM, P127; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024	15	1067	1108	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					337	338		10.1038/ng1323	http://dx.doi.org/10.1038/ng1323			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15004560	Bronze			2022-12-25	WOS:000220647200015
J	Garcia-Cao, M; O'Sullivan, R; Peters, AHFM; Jenuwein, T; Blasco, MA				Garcia-Cao, M; O'Sullivan, R; Peters, AHFM; Jenuwein, T; Blasco, MA			Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases	NATURE GENETICS			English	Article							CHROMOSOMAL INSTABILITY; H3; HETEROCHROMATIN; METHYLATION; FUSIONS; REPEATS; MICE	Telomeres are capping structures at the ends of eukaryotic chromosomes composed of TTAGGG repeats bound to an array of specialized proteins(1-3). Telomeres are heterochromatic regions. Yeast and flies with defects in activities that modify the state of chromatin also have abnormal telomere function(4-6), but the putative role of chromatin-modifying activities in regulating telomeres in mammals is unknown. Here we report on telomere length and function in mice null with respect to both the histone methyltransferases (HMTases) Suv39h1 and Suv39h2 (called SUV39DN mice). Suv39h1 and Suv39h2 govern methylation of histone H3 Lys9 (H3-Lys9) in heterochromatic regions(7). We show that primary cells derived from SUV39DN mice have abnormally long telomeres relative to wild-type controls. Using chromatin immunoprecipitation (ChIP) analysis, we found that telomeres were enriched in di- and trimethylated H3-Lys9 but that telomeres of SUV39DN cells had less dimethylated and trimethylated H3-Lys9 but more monomethylated H3-Lys9. Concomitant with the decrease in H3-Lys9 methylation, telomeres in SUV39DN cells had reduced binding of the chromobox proteins Cbx1, Cbx3 and Cbx5, homologs of Drosophila melanogaster heterochromatin protein 1 (HP1). These findings indicate substantial changes in the state of telomeric heterochromatin in SUV39DN cells, which are associated with abnormal telomere elongation. Taken together, the results indicate epigenetic regulation of telomere length in mammals by Suv39h1 and Suv39h2.	Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria; Spanish Natl Canc Ctr CNIO, Mol Oncol Program, E-28029 Madrid, Spain	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Oncol Program, E-28029 Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Peters, Antoine/0000-0002-0311-1887				Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cenci G, 2003, NAT CELL BIOL, V5, P82, DOI 10.1038/ncb902; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Koering CE, 2002, EMBO REP, V3, P1055, DOI 10.1093/embo-reports/kvf215; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; McIlrath J, 2001, CANCER RES, V61, P912; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; PEREZBURGOS L, IN PRESS METHODS ENZ; PETERS AH, IN PRESS MOL CELL; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0	29	429	453	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2004	36	1					94	99		10.1038/ng1278	http://dx.doi.org/10.1038/ng1278			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702045	Bronze			2022-12-25	WOS:000187666800020
J	Shimbo, I; Nakajima, R; Yokoyama, S; Sumikura, K				Shimbo, I; Nakajima, R; Yokoyama, S; Sumikura, K			Patent protection for protein structure analysis	NATURE BIOTECHNOLOGY			English	Editorial Material							BIOINFORMATIC INVENTIONS; EMERGING TRENDS	Three national patent offices have consulted on patents that cover protein three-dimensional structural data and pharmacophores, with significant implications for the biotechnology industry.	RIKEN, Intellectual Property & Technol Transfer Off, Wako, Saitama 3510198, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa, Japan; RIKEN GSC & Harima Inst, Wako, Saitama, Japan; Univ Tokyo, Tokyo, Japan; Natl Grad Inst Policy Studies, Tokyo, Japan	RIKEN; RIKEN; RIKEN; University of Tokyo; National Graduate Institute for Policy Studies	Shimbo, I (corresponding author), RIKEN, Intellectual Property & Technol Transfer Off, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				[Anonymous], 1996, FED REGISTER, V61, P7478; *EPO, 2000, GUID EX EPO C, pCH3; Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd1034; Hultquist SJ, 2002, NAT BIOTECHNOL, V20, P743, DOI 10.1038/nbt0702-743; Hultquist SJ, 2002, NAT BIOTECHNOL, V20, P517, DOI 10.1038/nbt0502-517; JPO, 2001, EX GUID PAT UT MOD 7; *TRIL PROJ WM4, 2002, COMP STUD NEW TECHN	7	0	0	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					109	113		10.1038/nbt0104-109	http://dx.doi.org/10.1038/nbt0104-109			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704710				2022-12-25	WOS:000187745400035
J	Hommel, JD; Sears, RM; Georgescu, D; Simmons, DL; DiLeone, RJ				Hommel, JD; Sears, RM; Georgescu, D; Simmons, DL; DiLeone, RJ			Local gene knockdown in the brain using viral-mediated RNA interference	NATURE MEDICINE			English	Article							DOUBLE-STRANDED-RNA; TYROSINE-HYDROXYLASE; PARKINSONS-DISEASE; MAMMALIAN-CELLS; EXPRESSION; MICE; DROSOPHILA; DOPAMINE; VECTORS; ELEGANS	Conditional mutant techniques that allow spatial and temporal control over gene expression can be used to create mice with restricted genetic modifications. These mice serve as powerful disease models in which gene function in adult tissues can be specifically dissected. Current strategies for conditional genetic manipulation are inefficient, however, and often lack sufficient spatial control. Here we use viral- mediated RNA interference (RNAi) to generate a specific knockdown of Th, the gene encoding the dopamine synthesis enzyme tyrosine hydroxylase, within midbrain neurons of adult mice. This localized gene knockdown resulted in behavioral changes, including a motor performance deficit and reduced response to a psychostimulant. These results underscore the potential of using viral- mediated RNAi for the rapid production and testing of new genetic disease models. Similar strategies may be used in other model species, and may ultimately find applications in human gene therapy.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DiLeone, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Hommel, Jonathan/0000-0001-8305-3746; DiLeone, Ralph/0000-0002-4770-2590; , robert/0000-0001-5688-1853				Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Chamberlin NL, 1998, BRAIN RES, V793, P169, DOI 10.1016/S0006-8993(98)00169-3; CHUANG D, 1975, MOL PHARMACOL, V11, P784; COLOTLA VA, 1990, NEUROTOXICOL TERATOL, V12, P405, DOI 10.1016/0892-0362(90)90061-G; DiLeone RJ, 1998, GENETICS, V148, P401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fitzsimons HL, 2001, GENE THER, V8, P1675, DOI 10.1038/sj.gt.3301582; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Georgescu D, 2003, J NEUROSCI, V23, P3106; Gibb WRG, 1997, EUR NEUROL, V38, P21, DOI 10.1159/000113472; Girod A, 1999, NAT MED, V5, P1052, DOI 10.1038/12491; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; HAN VKM, 1987, J NEUROSCI RES, V17, P11, DOI 10.1002/jnr.490170103; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MCGEER EG, 1971, J NEUROCHEM, V18, P1647, DOI 10.1111/j.1471-4159.1971.tb03738.x; MOORE KE, 1977, BIOL PSYCHIAT, V12, P451; Paxinos G, 2000, MOUSE BRAIN STEREOTA; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rozas G, 1998, J NEUROSCI METH, V83, P165, DOI 10.1016/S0165-0270(98)00078-8; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	36	278	306	0	16	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1539	1544		10.1038/nm964	http://dx.doi.org/10.1038/nm964			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14634645				2022-12-25	WOS:000186845400039
J	Zhou, XY; Shibusawa, N; Naik, K; Porras, D; Temple, K; Ou, HS; Kaihara, K; Roe, MW; Brady, MJ; Wondisford, FE				Zhou, XY; Shibusawa, N; Naik, K; Porras, D; Temple, K; Ou, HS; Kaihara, K; Roe, MW; Brady, MJ; Wondisford, FE			Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein	NATURE MEDICINE			English	Article							GENE-TRANSCRIPTION; COACTIVATOR PGC-1; RESISTANCE; RECEPTOR; GROWTH; MICE; CBP	Hepatic gluconeogenesis is essential for maintenance of normal blood glucose concentrations and is regulated by opposing stimulatory (cyclic adenosine monophosphate, cAMP) and inhibitory (insulin) signaling pathways(1). The cAMP signaling pathway leads to phosphorylation of cAMP response element-binding (CREB) protein, resulting in recruitment of the coactivators CREB-binding protein (CBP) and p300 and subsequent activation of gluconeogenesis(2-5). Insulin signaling leads to phosphorylation of CBP at serine 436, a residue near its CREB-interacting domain, but it is unknown whether this event modulates cAMP signaling(6). Here, we show in vitro and in 'knock-in' mice that a mutant CBP (S436A) is aberrantly recruited to CREB protein, resulting in inappropriate activation of gluconeogenesis in the fed state and glucose intolerance resulting from increased hepatic glucose production. We propose that insulin signaling may directly regulate many cAMP signaling pathways at the transcriptional level by controlling CBP recruitment.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Div Biol Sci, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Wondisford, FE (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	fwondisf@medicine.bsd.uchicago.edu		Kaihara, Kelly/0000-0002-1277-6418	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK063349] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60-DK20595, R01 DK-63349] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boileau P, 2002, DIABETES, V51, pS343, DOI 10.2337/diabetes.51.2007.S343; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; Fisher SJ, 2003, J CLIN INVEST, V111, P463, DOI 10.1172/JCI16426; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	20	112	114	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					633	637		10.1038/nm1050	http://dx.doi.org/10.1038/nm1050			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146178				2022-12-25	WOS:000221759600029
J	Bachtrog, D				Bachtrog, D			Evidence that positive selection drives Y-chromosome degeneration in Drosophila miranda	NATURE GENETICS			English	Article							NEO-Y; EVOLUTION; ACCUMULATION; HITCHHIKING; ADAPTATION; PATTERN; GENES	Why does the Y chromosome harbor so few functional loci? Evolutionary theory predicts that Y chromosomes degenerate because they lack genetic recombination(1). Both positive(2) and negative(1) selection models have been invoked to explain this degeneration, as both can result in the recurrent fixation of linked deleterious mutations on a nonrecombining Y chromosome. To distinguish between these models, I investigated patterns of nucleotide variability along 37 kb of the recently formed neo-Y chromosome in Drosophila miranda. Levels of nucleotide variability on this chromosome are 30 times lower than in highly recombining portions of the genome. Both positive and negative selection models can result in reduced variability levels, but their effects on the frequency spectrum of mutations differ. Using coalescent simulations, I show that the patterns of nucleotide variability on the neo-Y chromosome are unlikely under deleterious mutation models (including background selection and Muller's ratchet) but are expected under recent positive selection. These results implicate positive selection as an important force driving the degeneration of Y chromosomes; adaptation at a few loci, possibly increasing male fitness, occurs at the cost of most other genes on this chromosome.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Cornell Univ, Dept Genet & Mol Biol, Ithaca, NY 14853 USA	University of Edinburgh; Cornell University	Bachtrog, D (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	Doris.Bachtrog@cornell.edu						Andolfatto P, 2001, GENETICS, V158, P657; Bachtrog D, 2003, GENETICS, V165, P1221; Bachtrog D, 2003, NAT GENET, V34, P215, DOI 10.1038/ng1164; Bachtrog D, 2003, MOL BIOL EVOL, V20, P173, DOI 10.1093/molbev/msg035; Bachtrog D, 2002, NATURE, V416, P323, DOI 10.1038/416323a; Carvalho AB, 2002, CURR OPIN GENET DEV, V12, P664, DOI 10.1016/S0959-437X(02)00356-8; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; CHARLESWORTH D, 1995, GENETICS, V141, P1619; Drake JW, 1998, GENETICS, V148, P1667; Gordo I, 2002, GENETICS, V161, P835; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; Hudson Richard R., 1994, P140; MUKAI T, 1972, GENETICS, V72, P335; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; RICE WR, 1987, GENETICS, V116, P161; SIMONSEN KL, 1995, GENETICS, V141, P413; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Steinemann M, 1998, GENETICA, V102-3, P409, DOI 10.1023/A:1017058119760; Tachida H, 2000, GENE, V261, P3, DOI 10.1016/S0378-1119(00)00475-3; TAJIMA F, 1989, GENETICS, V123, P585; Yi SJ, 2003, GENETICS, V164, P1369	24	90	91	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					518	522		10.1038/ng1347	http://dx.doi.org/10.1038/ng1347			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107853	Bronze			2022-12-25	WOS:000221183000027
J	Belting, M; Dorrell, MI; Sandgren, S; Aguilar, E; Ahamed, J; Dorfleutner, A; Carmeliet, P; Mueller, BM; Friedlander, M; Ruf, W				Belting, M; Dorrell, MI; Sandgren, S; Aguilar, E; Ahamed, J; Dorfleutner, A; Carmeliet, P; Mueller, BM; Friedlander, M; Ruf, W			Regulation of angiogenesis by tissue factor cytoplasmic domain signaling	NATURE MEDICINE			English	Article							PROTEASE-ACTIVATED RECEPTORS; ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; GROWTH-FACTOR; FACTOR VIIA; IN-VITRO; INHIBITORS; DISEASE; MICE; PDGF	Hemostasis initiates angiogenesis-dependent wound healing, and thrombosis is frequently associated with advanced cancer. Although activation of coagulation generates potent regulators of angiogenesis, little is known about how this pathway supports angiogenesis in vivo. Here we show that the tissue factor (TF)-VIIa protease complex, independent of triggering coagulation, can promote tumor and developmental angiogenesis through protease-activated receptor-2 (PAR-2) signaling. In this context, the TF cytoplasmic domain negatively regulates PAR-2 signaling. Mice from which the TF cytoplasmic domain has been deleted (TFDeltaCT mice) show enhanced PAR-2-dependent angiogenesis, in synergy with platelet-derived growth factor BB (PDGF-BB). Ocular tissue from diabetic patients shows PAR-2 colocalization with phosphorylated TF specifically on neovasculature, suggesting that phosphorylation of the TF cytoplasmic domain releases its negative regulatory control of PAR-2 signaling in angiogenesis. Targeting the TF-VIIa signaling pathway may thus enhance the efficacy of angiostatic treatments for cancer and neovascular eye diseases.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Lund Univ, Biomed Ctr, SE-22184 Lund, Sweden; Katholieke Univ Leuven VIB, B-3000 Leuven, Belgium; La Jolla Inst Mol Med, Div Canc Biol, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Lund University; Flanders Institute for Biotechnology (VIB); KU Leuven	Friedlander, M (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	friedlan@scripps.edu; ruf@scripps.edu	Carmeliet, Peter/AAQ-5140-2020; Dorfleutner, Andrea/AAG-5504-2021; Dorrell, Michael I/U-8648-2019	Carmeliet, Peter/0000-0001-7961-1821; Dorfleutner, Andrea/0000-0003-4406-2986; Dorrell, Michael I/0000-0002-7258-6288; Belting, Mattias/0000-0003-1585-5434	NATIONAL CANCER INSTITUTE [R01CA085405] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011254] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL060742] Funding Source: NIH RePORTER; NCI NIH HHS [CA-85405] Funding Source: Medline; NEI NIH HHS [EY-11254] Funding Source: Medline; NHLBI NIH HHS [HL-60742, CHL-16411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; AHAMED J, J BIOL CHEM; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Buschmann I, 2003, MICROCIRCULATION, V10, P371, DOI 10.1038/sj.mn.7800199; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Dorfleutner A, 2003, BLOOD, V102, P3998, DOI 10.1182/blood-2003-04-1149; Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hembrough TA, 2003, CANCER RES, V63, P2997; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Melis E, 2001, BIOCHEM BIOPH RES CO, V286, P580, DOI 10.1006/bbrc.2001.5425; Milia AF, 2002, CIRC RES, V91, P346, DOI 10.1161/01.RES.0000031958.92781.9E; Mody RS, 1997, BIOCHEMISTRY-US, V36, P7869, DOI 10.1021/bi9701235; NICOSIA RF, 1990, LAB INVEST, V63, P115; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Ruf W, 2003, J THROMB HAEMOST, V1, P1495, DOI 10.1046/j.1538-7836.2003.00300.x; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	44	292	306	0	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2004	10	5					502	509		10.1038/nm1037	http://dx.doi.org/10.1038/nm1037			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15098027	Green Published			2022-12-25	WOS:000221242400028
J	Prince, JT; Carlson, MW; Wang, R; Lu, P; Marcotte, EM				Prince, JT; Carlson, MW; Wang, R; Lu, P; Marcotte, EM			The need for a public proteomics repository	NATURE BIOTECHNOLOGY			English	Editorial Material							COMPLEX PROTEIN MIXTURES; MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; MICROARRAY DATA; YEAST PROTEOME; MESSENGER-RNA; EXPRESSION; IDENTIFICATION; NORMALIZATION; TECHNOLOGY		Univ Texas, Ctr Syst & Synthet Biol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Prince, JT (corresponding author), Univ Texas, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.	marcotte@icmb.utexas.edu; marcotte@icmb.utexas.edu	Prince, John/AAD-3010-2019; Prince, John/F-2487-2014	Prince, John/0000-0001-9820-4252; Prince, John/0000-0001-9820-4252; Marcotte, Edward/0000-0001-8808-180X				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Alter O, 2001, PROC SPIE, V4266, P171, DOI 10.1117/12.427986; Boguski MS, 2003, NATURE, V422, P233, DOI 10.1038/nature01515; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hermjakob H, 2004, NAT BIOTECHNOL, V22, P177, DOI 10.1038/nbt926; Jensen PK, 2000, ELECTROPHORESIS, V21, P1372, DOI 10.1002/(SICI)1522-2683(20000401)21:7<1372::AID-ELPS1372>3.3.CO;2-P; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Lu P, 2003, P NATL ACAD SCI USA, V100, P10370, DOI 10.1073/pnas.1832361100; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pevzner PA, 2001, GENOME RES, V11, P290, DOI 10.1101/gr.154101; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Taylor CF, 2003, NAT BIOTECHNOL, V21, P247, DOI 10.1038/nbt0303-247; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	25	123	132	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2004	22	4					471	472		10.1038/nbt0404-471	http://dx.doi.org/10.1038/nbt0404-471			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	809AR	15085804				2022-12-25	WOS:000220610100042
J	Bouwmeester, T; Bauch, A; Ruffner, H; Angrand, PO; Bergamini, G; Croughton, K; Cruciat, C; Eberhard, D; Gagneur, J; Ghidelli, S; Hopf, C; Huhse, B; Mangano, R; Michon, AM; Schirle, M; Schlegl, J; Schwab, M; Stein, MA; Bauer, A; Casari, G; Drewes, G; Gavin, AC; Jackson, DB; Joberty, G; Neubauer, G; Rick, J; Kuster, B; Superti-Furga, G				Bouwmeester, T; Bauch, A; Ruffner, H; Angrand, PO; Bergamini, G; Croughton, K; Cruciat, C; Eberhard, D; Gagneur, J; Ghidelli, S; Hopf, C; Huhse, B; Mangano, R; Michon, AM; Schirle, M; Schlegl, J; Schwab, M; Stein, MA; Bauer, A; Casari, G; Drewes, G; Gavin, AC; Jackson, DB; Joberty, G; Neubauer, G; Rick, J; Kuster, B; Superti-Furga, G			A physical and functional map of the human TNF-alpha NF-kappa B signal transduction pathway	NATURE CELL BIOLOGY			English	Article							PROTEIN; GENERATION; ACTIVATION; KINASE; P52	Signal transduction pathways are modular composites of functionally interdependent sets of proteins that act in a coordinated fashion to transform environmental information into a phenotypic response. The pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha triggers a signalling cascade, converging on the activation of the transcription factor NF-kappaB, which forms the basis for numerous physiological and pathological processes. Here we report the mapping of a protein interaction network around 32 known and candidate TNF-alpha/ NF-kappaB pathway components by using an integrated approach comprising tandem affinity purification, liquid-chromatography tandem mass spectrometry, network analysis and directed functional perturbation studies using RNA interference. We identified 221 molecular associations and 80 previously unknown interactors, including 10 new functional modulators of the pathway. This systems approach provides significant insight into the logic of the TNF-alpha/NF-kappaB pathway and is generally applicable to other pathways relevant to human disease.	Cellzome AG, D-69117 Heidelberg, Germany	GlaxoSmithKline; Cellzome GmbH	Bouwmeester, T (corresponding author), Cellzome AG, Meyerhofstr 1, D-69117 Heidelberg, Germany.	tewis.bouwmeester@cellzome.com; giulio.superti-furga@cellzome.com	Kuster, Bernhard/Q-6031-2016; Superti-Furga, Giulio/F-4755-2015; Angrand, Pierre-Olivier/N-1863-2019; Superti-Furga, Giulio/AAE-5681-2019; Hopf, Carsten/A-3275-2015	Kuster, Bernhard/0000-0002-9094-1677; Superti-Furga, Giulio/0000-0002-0570-1768; Drewes, Gerard/0000-0003-0575-6766; Gagneur, Julien/0000-0002-8924-8365; Hopf, Carsten/0000-0003-0802-6451; ANGRAND, Pierre-Olivier/0000-0002-9509-4796; Gavin, Anne-Claude/0000-0003-4917-2340; Bauch, Angela/0000-0002-8712-4414; Bergamini, Giovanna/0000-0002-9662-9502				Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Fong A, 2002, J BIOL CHEM, V277, P40697, DOI 10.1074/jbc.M205330200; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	25	791	855	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					97	+		10.1038/ncb1086	http://dx.doi.org/10.1038/ncb1086			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743216				2022-12-25	WOS:000188668300008
J	Johnson, EN; Seasholtz, TM; Waheed, AA; Kreutz, B; Suzuki, N; Kozasa, T; Jones, TLZ; Brown, JH; Druey, KM				Johnson, EN; Seasholtz, TM; Waheed, AA; Kreutz, B; Suzuki, N; Kozasa, T; Jones, TLZ; Brown, JH; Druey, KM			RGS16 inhibits signalling through the G alpha 13-Rho axis	NATURE CELL BIOLOGY			English	Letter							GTPASE-ACTIVATING PROTEIN; TERMINAL CYSTEINE RESIDUES; G-ALPHA-Q; FUNCTIONAL-CHARACTERIZATION; P115 RHOGEF; G-ALPHA(12); REGULATORS; PALMITOYLATION; MEMBRANES; KINASE	Galpha13 stimulates the guanine nucleotide exchange factors (GEFs) for Rho, such as p115Rho-GEF(1). Activated Rho induces numerous cellular responses, including actin polymerization, serum response element (SRE)-dependent gene transcription and transformation(2). p115Rho-GEF contains a Regulator of G protein Signalling domain (RGS box) that confers GTPase activating protein (GAP) activity towards Galpha12 and Galpha13 (ref. 3). In contrast, classical RGS proteins (such as RGS16 and RGS4) exhibit RGS domain-dependent GAP activity on Galphai and Galphaq, but not Galpha12 or Galpha13 (ref 4). Here, we show that RGS16 inhibits Galpha13-mediated, RhoA-dependent reversal of stellation and SRE activation. The RGS16 amino terminus binds Galpha13 directly, resulting in translocation of Galpha13 to detergent-resistant membranes (DRMs) and reduced p115Rho-GEF binding. RGS4 does not bind Galpha13 or attenuate Galpha13-dependent responses, and neither RGS16 nor RGS4 affects Galpha12-mediated signalling. These results elucidate a new mechanism whereby a classical RGS protein regulates Galpha13-mediated signal transduction independently of the RGS box.	NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Druey, KM (corresponding author), NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA.	kdruey@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000746, ZIAAI000746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36927] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Ingi T, 1998, J NEUROSCI, V18, P7178; Johnson EN, 2002, J BIOL CHEM, V277, P16768, DOI 10.1074/jbc.M200751200; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Nagata Y, 2001, BLOOD, V97, P3051, DOI 10.1182/blood.V97.10.3051; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; SEIZINGER BR, 1997, P NATL ACAD SCI USA, V94, P7868; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Wells C, 2002, METHOD ENZYMOL, V345, P371	30	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1095	1103		10.1038/ncb1065	http://dx.doi.org/10.1038/ncb1065			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634662	Green Published			2022-12-25	WOS:000186892900016
J	Perepelitsa-Belancio, V; Deininger, P				Perepelitsa-Belancio, V; Deininger, P			RNA truncation by premature polyadenylation attenuates human mobile element activity	NATURE GENETICS			English	Article							TRANSPOSABLE ELEMENT; LINE-1; EXPRESSION; MOUSE; RETROTRANSPOSONS; MECHANISM	Long interspersed elements (LINE-1s, also called L1s) are the only active members of the autonomous, non long terminal repeat (LTR) retrotransposon family, which reshapes mammalian genomes in many different ways(1-5). LINE-1 expression is low in most differentiated cells but high in some cancer cells, in testis and during embryonic development(6-12). To minimize the negative impact on their hosts genomes,, many mobile elements strategically limit their amplification potential, particularly in somatic cells(13-15). Here we show that the A-rich coding strand of the human LINE-1 contains multiple functional canonical and noncanonical polyadenylation (poly(A)) signals, resulting in truncation of full-length transcripts by premature polyadenylation. This attenuation lowers the rate of retrotransposition in assays using HeLa cells. It probably also increases the negative effects of LINE-1 insertions into genes(16).	Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Environm Hlth Sci, New Orleans, LA 70112 USA	Tulane University; Tulane University	Deininger, P (corresponding author), Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, SL66,1430 Tulane Ave, New Orleans, LA 70112 USA.	pdeinin@tulane.edu		Deininger, Prescott/0000-0002-1067-3028				Asch HL, 1996, ONCOL RES, V8, P239; Benihoud K, 2002, ONCOGENE, V21, P5593, DOI 10.1038/sj.onc.1205730; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BRATTHAUER GL, 1994, CANCER, V73, P2333, DOI 10.1002/1097-0142(19940501)73:9<2333::AID-CNCR2820730915>3.0.CO;2-4; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lerat E, 2002, J MOL EVOL, V54, P625, DOI 10.1007/s00239-001-0059-0; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Medstrand P, 2002, GENOME RES, V12, P1483, DOI 10.1101/gr.388902; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; Tabaska JE, 1999, GENE, V231, P77, DOI 10.1016/S0378-1119(99)00104-3; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	29	178	182	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2003	35	4					363	366		10.1038/ng1269	http://dx.doi.org/10.1038/ng1269			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14625551				2022-12-25	WOS:000186791000018
J	Uhlik, MT; Abell, AN; Johnson, NL; Sun, WY; Cuevas, BD; Lobel-Rice, KE; Horne, EA; Dell'Acqua, ML; Johnson, GL				Uhlik, MT; Abell, AN; Johnson, NL; Sun, WY; Cuevas, BD; Lobel-Rice, KE; Horne, EA; Dell'Acqua, ML; Johnson, GL			Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock	NATURE CELL BIOLOGY			English	Letter							KINASE KINASE KINASE; PROTEIN-KINASE; OSMOTIC-STRESS; FRET MICROSCOPY; 2-HYBRID SYSTEM; MEK KINASES; PATHWAY; YEAST; CELLS; CYTOSKELETON	Sensing the osmolarity of the environment is a critical response for all organisms. Whereas bacteria will migrate away from high osmotic conditions, most eukaryotic cells are not motile and use adaptive metabolic responses for survival(1-5). The p38 MAPK pathway is a crucial mediator of survival during cellular stress(6-9). We have discovered a novel scaffold protein that binds to actin, the GTPase Rac, and the upstream kinases MEKK3 and MKK3 in the p38 MAPK phospho-relay module. RNA interference (RNAi) demonstrates that MEKK3 and the scaffold protein are required for p38 activation in response to sorbitol-induced hyperosmolarity. FRET identifies a cytoplasmic complex of the MEKK3 scaffold protein that is recruited to dynamic actin structures in response to sorbitol treatment. Through its ability to bind actin, relocalize to Rac-containing membrane ruffles and its obligate requirement for p38 activation in response to sorbitol, we have termed this protein osmosensing scaffold for MEKK3 (OSM). The Rac-OSM-MEKK3-MKK3 complex is the mammalian counterpart of the CDC42-STE50-STE11-Pbs2 complex in Saccharomyces cerevisiae that is required for the regulation of p38 activity.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.	gary_johnson@med.unc.edu		Dell'Acqua, Mark/0000-0003-3798-3461	NIDDK NIH HHS [DK37871, DK68820] Funding Source: Medline; NIGMS NIH HHS [GM30324, R01 GM068820] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068820, R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040701] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL AN, IN PRESS J CELL SCI; Allen WE, 1997, J CELL SCI, V110, P707; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Garmyn M, 2001, J INVEST DERMATOL, V117, P1290, DOI 10.1046/j.0022-202x.2001.01553.x; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Landry J, 1999, BIOCHEM SOC SYMP, P79; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Waldegger S, 1998, J MEMBRANE BIOL, V162, P95, DOI 10.1007/s002329900346; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	30	298	308	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1104	1110		10.1038/ncb1071	http://dx.doi.org/10.1038/ncb1071			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634666				2022-12-25	WOS:000186892900017
J	Ooi, SL; Shoemaker, DD; Boeke, JD				Ooi, SL; Shoemaker, DD; Boeke, JD			DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; REPLICATION FORK PROGRESSION; HOMOLOGOUS RECOMBINATION; YEAST SGS1; SRS2; REQUIREMENT; ABSENCE; MUTANTS; PURIFICATION; CHECKPOINT	We describe a new synthetic lethality analysis by microarray (SLAM) technique that uses 4,600 Saccharomyces cerevisiae haploid deletion mutants with molecular bar codes (TAGs). We used SGS1 and SRS2, two 3' --> 5' DNA helicase genes, as queries to identify their redundant and unique biological functions. We introduced these query mutations into a haploid deletion pool by integrative transformation to disrupt the query gene in every cell, generating a double mutant pool. Optimization of integrative transformation efficiency was essential to the success of SLAM. Synthetic interactions defined a DNA helicase genetic network and predicted a role for SRS2 in processing damaged replication forks but, unlike SGS1, not in rDNA replication, DNA topology or lagging strand synthesis. SGS1 and SRS2 have synthetic defects with MRC1 but not RAD9, suggesting that SGS1 and SRS2 function in a parallel pathway with MRC1 to transduce the DNA replication stress signal to the general DNA damage checkpoint pathway. Both helicase genes have rad51-reversible synthetic defects with 5 3 DNA helicase RRM3, suggesting that RRM3 helps prevent formation of toxic recombination intermediates. SLAM detects synthetic lethality efficiently and ranks candidate genetic interactions, making it an especially useful method.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Merck & Co Inc, San Diego, CA 92121 USA	Johns Hopkins University; Merck & Company	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 617 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.			Boeke, Jef/0000-0001-5322-4946				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; AGUILERA A, 1988, GENETICS, V119, P779; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r22; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; DOBZHANSKY T, 1946, GENETICS, V31, P269; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Frei C, 2000, GENE DEV, V14, P81; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Mankouri HW, 2002, NUCLEIC ACIDS RES, V30, P1103, DOI 10.1093/nar/30.5.1103; Morrow DM, 1997, GENETICS, V147, P371; Mullen JR, 2001, GENETICS, V157, P103; NOVICK P, 1989, GENETICS, V121, P659; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; RONG L, 1993, J BIOL CHEM, V268, P1252; Schmidt KH, 2002, J BIOL CHEM, V277, P45331, DOI 10.1074/jbc.M207263200; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	36	159	165	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					277	286		10.1038/ng1258	http://dx.doi.org/10.1038/ng1258			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14566339				2022-12-25	WOS:000186273300025
J	Wakabayashi, N; Itoh, K; Wakabayashi, J; Motohashi, H; Noda, S; Takahashi, S; Imakado, S; Kotsuji, T; Otsuka, F; Roop, DR; Harada, T; Engel, JD; Yamamoto, M				Wakabayashi, N; Itoh, K; Wakabayashi, J; Motohashi, H; Noda, S; Takahashi, S; Imakado, S; Kotsuji, T; Otsuka, F; Roop, DR; Harada, T; Engel, JD; Yamamoto, M			Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR; LAMELLAR ICHTHYOSIS; OXIDATIVE STRESS; DROSOPHILA KELCH; DEFICIENT MICE; KNOCKOUT MICE; IN-VITRO; PROTEIN; GENES; EXPRESSION	Transcription factor Nrf2 (encoded by Nfe2l2) regulates a battery of detoxifying and antioxidant genes, and Keap1 represses Nrf2 function. When we ablated Keap1, Keap1-deficient mice died postnatally, probably from malnutrition resulting from hyperkeratosis in the esophagus and forestomach. Nrf2 activity affects the expression levels of several squamous epithelial genes. Biochemical data show that, without Keap1, Nrf2 constitutively accumulates in the nucleus to stimulate transcription of cytoprotective genes. Breeding to Nrf2-deficient mice reversed the phenotypic Keap1 deficiencies. These experiments show that Keap1 acts upstream of Nrf2 in the cellular response to oxidative and xenobiotic stress.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, ERATO, JST, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Clin Med Sci, Tsukuba, Ibaraki 3058577, Japan; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Inst Environm Toxicol, Mitsukaido, Ibaraki 3030043, Japan; Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; University of Tsukuba; University of Tsukuba; Baylor College of Medicine; Baylor College of Medicine; University of Michigan System; University of Michigan	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.	masi@tara.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010; Motohashi, Hozumi/AAZ-2628-2020	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; 				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Li NX, 2000, METHOD ENZYMOL, V319, P273; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Parmentier L, 1996, HUM MOL GENET, V5, P555, DOI 10.1093/hmg/5.4.555; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Takahashi K, 1998, GENOMICS, V53, P170, DOI 10.1006/geno.1998.5476; Thiele JJ, 1999, J INVEST DERMATOL, V113, P335, DOI 10.1046/j.1523-1747.1999.00693.x; TIEMANN F, 1994, ONCOGENE, V9, P1907; Virolainen E, 2000, AM J HUM GENET, V66, P1132, DOI 10.1086/302813; WILLIAMS ML, 1985, ARCH DERMATOL, V121, P477, DOI 10.1001/archderm.121.4.477; Wojcik SM, 2000, MOL CELL BIOL, V20, P5248, DOI 10.1128/MCB.20.14.5248-5255.2000; Wojcik SM, 2001, J CELL BIOL, V154, P619, DOI 10.1083/jcb.200102079; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	36	649	675	6	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					238	245		10.1038/ng1248	http://dx.doi.org/10.1038/ng1248			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14517554				2022-12-25	WOS:000186273300019
J	Clarke, DJ; Segal, M; Andrews, CA; Rudyak, SG; Jensen, S; Smith, K; Reed, SI				Clarke, DJ; Segal, M; Andrews, CA; Rudyak, SG; Jensen, S; Smith, K; Reed, SI			S-phase checkpoint controls mitosis via an APC-independent Cdc20p function	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; HUMAN CANCERS; PDS1; INHIBITOR; PROTEOLYSIS; UBIQUITIN; PROTEINS	Cells divide with remarkable fidelity, allowing complex organisms to develop and possess longevity. Checkpoint controls contribute by ensuring that genome duplication and segregation occur without error so that genomic instability, associated with developmental abnormalities and a hallmark of most human cancers(1-5), is avoided. S-phase checkpoints prevent cell division while DNA is replicating(6-8). Budding yeast Mec1p and Rad53p, homologues of human checkpoint kinases ATM/ATR and Chk2, are needed for this control system. How Mec1p and Rad53p prevent mitosis in S phase is not known. Here we provide evidence that budding yeasts avoid mitosis during S phase by regulating the anaphase-promoting complex (APC) specificity factor Cdc20p: Mec1p and Rad53p repress the accumulation of Cdc20p in S phase. Because precocious Cdc20p accumulation causes anaphase onset and aneuploidy, Cdc20p concentrations must be precisely regulated during each and every cell cycle. Catastrophic mitosis induced by Cdc20p in S phase occurs even in the absence of core APC components. Thus, Cdc20p can function independently of the APC.	Scripps Res Inst, La Jolla, CA 92037 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Scripps Research Institute; University of Minnesota System; University of Minnesota Twin Cities	Reed, SI (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Rudyak, Stanislav/U-1781-2017	Armbrust, Karen/0000-0001-9381-4756; Segal, Marisa/0000-0003-1848-9388; Clarke, Duncan/0000-0002-7795-3294	NATIONAL CANCER INSTITUTE [R01CA099033, R01CA085487] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA85487-02, 1R01CA99033-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Clarke DJ, 1999, CURR BIOL, V9, P365, DOI 10.1016/S0960-9822(99)80163-8; Clarke DJ, 2001, NAT CELL BIOL, V3, P619, DOI 10.1038/35083009; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; COLLART MA, 1993, CURRENT PROTOCOLS MO, V13, P12; Haase SB, 2002, CELL CYCLE, V1, P132, DOI 10.4161/cc.1.2.114; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jensen S, 2001, J CELL BIOL, V152, P27, DOI 10.1083/jcb.152.1.27; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kramer KM, 1998, EMBO J, V17, P498, DOI 10.1093/emboj/17.2.498; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Schott EJ, 1998, GENETICS, V148, P599; Segal M, 1998, J CELL BIOL, V143, P135, DOI 10.1083/jcb.143.1.135; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Tsongalis GJ, 1998, CANCER INVEST, V16, P485, DOI 10.3109/07357909809011703; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	27	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					928	935		10.1038/ncb1046	http://dx.doi.org/10.1038/ncb1046			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14502293				2022-12-25	WOS:000185647400020
J	Dewannieux, M; Esnault, C; Heidmann, T				Dewannieux, M; Esnault, C; Heidmann, T			LINE-mediated retrotransposition of marked Alu sequences	NATURE GENETICS			English	Article							HIGH-FREQUENCY RETROTRANSPOSITION; SIGNAL RECOGNITION PARTICLE; RIBONUCLEOPROTEIN-PARTICLES; INDICATOR GENE; L1 RETROTRANSPOSITION; REVERSE TRANSCRIPTION; MAMMALIAN-CELLS; ORF1 PROTEIN; HUMAN GENOME; RNA-BINDING	Alu elements are the most successful transposons in humans. They are 300-bp non-coding sequences transcribed by RNA polymerase III (Pol III) and are expected to retrotranspose with the aid of reverse transcriptases of cellular origin. We previously showed that human LINEs can generate cDNA copies of any mRNA transcript by means of a retroposition process involving reverse transcription and integration by the LINE-encoded endonuclease and reverse transcriptase. Here we show mobility of marked Alu sequences in human HeLa cells with the canonical features of a retrotransposition process, including splicing out of an autocatalytic intron introduced into the marked sequence, target site duplications of varying lengths and integrations into consensus A-rich sequences. We further show that the poly-A stretch at the Alu 3' end is essential for mobility, that LINEs are required for transposition and that the rate of retroposition is 100 1,000 times higher for Alu transcripts than for control mRNAs, thus accounting for the high mutational activity of these elements observed in humans.	Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	heidmann@igr.fr		Dewannieux, Marie/0000-0003-3918-2414				Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Boeke J. D., 1997, P343; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; Bovia F, 1996, J CELL SCI, V109, P2601; BOVIA F, 1995, MOL BIOL CELL, V6, P471, DOI 10.1091/mbc.6.4.471; Chaboissier MC, 2000, NUCLEIC ACIDS RES, V28, P2467, DOI 10.1093/nar/28.13.2467; CHANG DY, 1995, MOL CELL BIOL, V15, P2109; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Deininger PL, 1989, MOBILE DNA, P619; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Esnault C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.11.e49; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kajikawa M, 2002, CELL, V111, P433, DOI 10.1016/S0092-8674(02)01041-3; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; Kimberland ML, 1999, HUM MOL GENET, V8, P1557, DOI 10.1093/hmg/8.8.1557; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; Muddashetty RS, 2002, J MOL BIOL, V321, P433, DOI 10.1016/S0022-2836(02)00655-1; QUENTIN Y, 1992, NUCLEIC ACIDS RES, V20, P487, DOI 10.1093/nar/20.3.487; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; Roy AM, 2000, J MOL BIOL, V302, P17, DOI 10.1006/jmbi.2000.4027; Roy-Engel AM, 2002, GENOME RES, V12, P1333, DOI 10.1101/gr.384802; Sarrowa J, 1997, MOL CELL BIOL, V17, P1144, DOI 10.1128/MCB.17.3.1144; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; SINNETT D, 1991, J BIOL CHEM, V266, P8675; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; TCHENIO T, 1995, J VIROL, V69, P1079; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WEINER AM, 1980, CELL, V22, P209, DOI 10.1016/0092-8674(80)90169-5; West NC, 2002, J MOL BIOL, V321, P423, DOI 10.1016/S0022-2836(02)00542-9; Willoughby DA, 2000, J BIOL CHEM, V275, P759, DOI 10.1074/jbc.275.2.759	49	730	758	2	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					41	48		10.1038/ng1223	http://dx.doi.org/10.1038/ng1223			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12897783				2022-12-25	WOS:000185018500009
J	Edinger, M; Hoffmann, P; Ermann, J; Drago, K; Fathman, CG; Strober, S; Negrin, RS				Edinger, M; Hoffmann, P; Ermann, J; Drago, K; Fathman, CG; Strober, S; Negrin, RS			CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation	NATURE MEDICINE			English	Article							IN-VITRO; LEUKEMIA; ACTIVATION; INDUCTION; MECHANISM; DEPLETION	Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation. Suppression of GVHD with maintenance of GVT activity is a desirable outcome for clinical transplantation. We have previously shown that donor-derived CD4(+)CD25(+) regulatory T cells inhibit lethal GVHD after allogeneic bone marrow transplantation across major histocompatibility complex (MHC) class I and II barriers in mice. Here we demonstrate that in host mice with leukemia and lymphoma, CD4(+)CD25(+) regulatory T cells suppress the early expansion of alloreactive donor T cells, their interleukin-2-receptor (IL-2R) alpha-chain expression and their capacity to induce GVHD without abrogating their GVT effector function, mediated primarily by the perforin lysis pathway. Thus, CD4(+)CD25(+) T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells.	Stanford Univ, Sch Med, Dept Med, Div Bone Marrow Transplantat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Univ Hosp Regensburg, Dept Hematol & Oncol, D-93053 Regensburg, Germany	Stanford University; Stanford University; University of Regensburg	Negrin, RS (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Bone Marrow Transplantat, 300 Pasteur Dr, Stanford, CA 94305 USA.	negrs@stanford.edu	Ermann, Joerg/ABE-4495-2021	Ermann, Joerg/0000-0003-3836-9404; Edinger, Matthias/0000-0003-2889-2533	NCI NIH HHS [CA92225, R01S CA8006, P01-CA49605, CA65237] Funding Source: Medline; NHLBI NIH HHS [HL57443, HL58520] Funding Source: Medline; NIAID NIH HHS [AI49903] Funding Source: Medline; NIDDK NIH HHS [DK61925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092225, R01CA065237, P01CA049605] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK061925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ailles L, 2002, MOL THER, V6, P615, DOI 10.1006/mthe.2002.0720; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Curtis RE, 1999, BLOOD, V94, P2208; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Edinger M, 2003, BLOOD, V101, P640, DOI 10.1182/blood-2002-06-1751; Edinger Matthias, 1999, Neoplasia (New York), V1, P303, DOI 10.1038/sj.neo.7900048; Ermann J, 2001, J IMMUNOL, V167, P4271, DOI 10.4049/jimmunol.167.8.4271; FERRARA J, 1997, GRAFT HOST DIS; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; Field EH, 2001, IMMUNOL REV, V182, P99, DOI 10.1034/j.1600-065X.2001.1820108.x; HAKIM FT, 1997, GRAFT VS HOST DIS, P257; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; HOROWITZ MM, 1990, BLOOD, V75, P555; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; MARTIN PJ, 1985, BLOOD, V66, P664; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Murakami M, 2002, P NATL ACAD SCI USA, V99, P8832, DOI 10.1073/pnas.132254399; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Shevach EM, 1998, CIBA F SYMP, V215, P200; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SIADAK M, 1994, BLOOD REV, V8, P154, DOI 10.1016/0268-960X(94)90076-T; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Truitt R L, 1995, Biol Blood Marrow Transplant, V1, P61; WARNKE RA, 1979, J IMMUNOL, V123, P1181; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Zeng DF, 2002, BLOOD, V99, P1449, DOI 10.1182/blood.V99.4.1449	44	991	1033	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1144	1150		10.1038/nm915	http://dx.doi.org/10.1038/nm915			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925844				2022-12-25	WOS:000185061600026
J	Roberts, SC; Gosling, LM				Roberts, SC; Gosling, LM			Genetic similarity and quality interact in mate choice decisions by female mice	NATURE GENETICS			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; HOUSE MICE; SEXUAL SELECTION; ODOR PREFERENCES; MUS-DOMESTICUS; LEK PARADOX; MHC; EVOLUTION; RESOLUTION	Females express mate preferences for genetically dissimilar males(1), especially with respect to the major histocompatibility complex, MHC2,3, and for males whose sexually selected signals indicate high genetic quality(4,5). The balance of selection pressure on each trait will depend on how females weight these desirable qualities under different conditions(6), but this has not been tested empirically. Here we show in mice that although MHC dissimilarity and a 'good genes' indicator (investment in scent-marking) both have a role in determining female preference, their relative influence can vary depending on the degree of variability in each trait among available males. Such interactions between condition-dependent and disassortative mate choice criteria suggest a mechanism by which female choice can contribute to maintenance of additive genetic variance in both the MHC and condition-dependent traits, even under consistent directional selection.	Univ Newcastle Upon Tyne, Sch Biol, Evolut & Behav Res Grp, Newcastle Upon Tyne NE1 4HH, Tyne & Wear, England	Newcastle University - UK	Roberts, SC (corresponding author), Univ Newcastle Upon Tyne, Sch Biol, Evolut & Behav Res Grp, Framlington Pl, Newcastle Upon Tyne NE1 4HH, Tyne & Wear, England.		Roberts, S./A-2040-2009; Roberts, Craig/E-6919-2011	Roberts, Craig/0000-0002-9641-6101; Gosling, Leonard Morris/0000-0002-2028-3488				BROWN JL, 1994, AM NAT, V143, P435, DOI 10.1086/285612; Colegrave N, 2002, EVOL ECOL RES, V4, P911; DESJARDINS C, 1973, SCIENCE, V182, P939, DOI 10.1126/science.182.4115.939; DRICKAMER LC, 1992, ANIM BEHAV, V43, P868, DOI 10.1016/S0003-3472(05)80212-X; Edwards SV, 1998, TRENDS ECOL EVOL, V13, P305, DOI 10.1016/S0169-5347(98)01416-5; Eggert Frank, 1996, Physiology and Behavior, V59, P57, DOI 10.1016/0031-9384(95)02029-2; Gosling LM, 2000, BEHAV ECOL SOCIOBIOL, V48, P328, DOI 10.1007/s002650000242; Gosling LM, 2001, ADV STUD BEHAV, V30, P169, DOI 10.1016/S0065-3454(01)80007-3; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; HAYASHI S, 1990, ZOOL SCI, V7, P889; Horne TJ, 1998, EVOLUTION, V52, P894, DOI [10.2307/2411284, 10.1111/j.1558-5646.1998.tb03714.x]; Isles AR, 2001, NATURE, V409, P783, DOI 10.1038/35057323; Jordan WC, 1998, HEREDITY, V81, P239, DOI 10.1038/sj.hdy.6884280; Kotiaho JS, 2001, NATURE, V410, P684, DOI 10.1038/35070557; Mossman CA, 1996, J COMP PSYCHOL, V110, P131, DOI 10.1037/0735-7036.110.2.131; NOVOTNY M, 1990, EXPERIENTIA, V46, P109, DOI 10.1007/BF01955433; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; Penn DJ, 1999, AM NAT, V153, P145, DOI 10.1086/303166; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; POTTS WK, 1993, TRENDS GENET, V9, P408, DOI 10.1016/0168-9525(93)90103-O; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; Rich TJ, 1998, ANIM BEHAV, V56, P727, DOI 10.1006/anbe.1998.0803; Von Schantz T, 1997, HEREDITAS, V127, P133, DOI 10.1111/j.1601-5223.1997.t01-1-00133.x; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; YAMAGUCHI M, 1981, P NATL ACAD SCI-BIOL, V78, P5817, DOI 10.1073/pnas.78.9.5817; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	30	157	159	0	63	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					103	106		10.1038/ng1231	http://dx.doi.org/10.1038/ng1231			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12937417				2022-12-25	WOS:000185018500018
J	Guo, DW; Hazbun, TR; Xu, XJ; Ng, SL; Fields, S; Kuo, MH				Guo, DW; Hazbun, TR; Xu, XJ; Ng, SL; Fields, S; Kuo, MH			A tethered catalysis, two-hybrid system to identify protein-protein interactions requiring post-translational modifications	NATURE BIOTECHNOLOGY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; IN-VIVO; YEAST; PHOSPHORYLATION; TRANSCRIPTION; ACETYLATION; ACTIVATION; BINDING; GROWTH	We have modified the yeast two-hybrid system to enable the detection of protein-protein interactions that require a specific post-translational modification, using the acetylation of histones and the phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II as test modifications. In this tethered catalysis assay, constitutive modification of the protein to be screened for interactions is achieved by fusing it to its cognate modifying enzyme, with the physical linkage resulting in efficient catalysis. This catalysis maintains substrate modification even in the presence of antagonizing enzyme activities. A catalytically inactive mutant of the enzyme is fused to the substrate as a control such that the modification does not occur; this construct enables the rapid identification of modification-independent interactions. We identified proteins with links to chromatin functions that interact with acetylated histones, and proteins that participate in RNA polymerase II functions and in CTD phosphorylation regulation that interact preferentially with the phosphorylated CTD.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Program Mol & Cell Biol, E Lansing, MI 48824 USA; Michigan State Univ, Genet Program, E Lansing, MI 48824 USA; Univ Washington, Dept Genome Sci, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Med, Howard Hughes Med Inst, Seattle, WA 98195 USA	Michigan State University; Michigan State University; Michigan State University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Kuo, MH (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	kuom@msu.edu	Hazbun, Tony/K-2597-2019	Hazbun, Tony/0000-0003-0675-8093	NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NIGMS NIH HHS [R01 GM62282] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062282] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; James P, 1996, GENETICS, V144, P1425; KASSENBROCK CK, 1995, MOL CELL BIOL, V15, P4763; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Recht J, 1996, MOL CELL BIOL, V16, P2545; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tucker CL, 2001, TRENDS CELL BIOL, V11, P102, DOI 10.1016/S0962-8924(00)01902-4; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yamada M, 2001, J BIOCHEM-TOKYO, V130, P157, DOI 10.1093/oxfordjournals.jbchem.a002955	30	50	51	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					888	892		10.1038/nbt985	http://dx.doi.org/10.1038/nbt985			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15208639				2022-12-25	WOS:000222533000032
J	Kim, MS; Park, JY; Namkoong, C; Jang, PG; Ryu, JW; Song, HS; Yun, JY; Namgoong, IS; Ha, J; Park, IS; Lee, IK; Viollet, B; Youn, JH; Lee, HK; Lee, KU				Kim, MS; Park, JY; Namkoong, C; Jang, PG; Ryu, JW; Song, HS; Yun, JY; Namgoong, IS; Ha, J; Park, IS; Lee, IK; Viollet, B; Youn, JH; Lee, HK; Lee, KU			Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; GLUCOSE-TRANSPORT; BODY-WEIGHT; INTRACEREBROVENTRICULAR INFUSION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MALONYL-COA; EXPRESSION; LEPTIN	AMP-activated protein kinase (AMPK) functions as a fuel sensor in the cell and is activated when cellular energy is depleted. Here we report that alpha-lipoic acid (alpha-LA), a cofactor of mitochondrial enzymes, decreases hypothalamic AMPK activity and causes profound weight loss in rodents by reducing food intake and enhancing energy expenditure. Activation of hypothalamic AMPK reverses the effects of alpha-LA on food intake and energy expenditure. Intracerebroventricular (i.c.v.) administration of glucose decreases hypothalamic AMPK activity, whereas inhibition of intracellular glucose utilization through the administration of 2-deoxyglucose increases hypothalamic AMPK activity and food intake. The 2-deoxyglucose-induced hyperphagia is reversed by inhibiting hypothalamic AMPK. Our findings indicate that hypothalamic AMPK is important in the central regulation of food intake and energy expenditure and that alpha-LA exerts anti-obesity effects by suppressing hypothalamic AMPK activity.	Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Kyung Hee Univ, Coll Med, Dept Mol Biol, Seoul 130701, South Korea; Inha Univ, Coll Med, Dept Anat, Inchon 400103, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700310, South Korea; Univ Paris 05, CNR, INSERM, Inst Cochin,Dept Genet Dev & Mol Pathol, F-75014 Paris, France; Univ So Calif, Dept Physiol & Biophys, Keck Sch Med, Los Angeles, CA 90089 USA; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea	University of Ulsan; University of Ulsan; Kyung Hee University; Inha University; Keimyung University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southern California; Seoul National University (SNU)	Lee, KU (corresponding author), Univ Ulsan, Coll Med, Dept Internal Med, 138-736 Poongnap Dong, Seoul 138736, South Korea.	kulee@amc.seoul.kr	Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; NAM-GOONG, IL SEONG/0000-0002-0492-0467; NamKoong, Cherl/0000-0002-1869-4405				Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Benoit SC, 2003, INT J OBESITY, V27, P550, DOI 10.1038/sj.ijo.0802280; BROWN NF, 1994, J BIOL CHEM, V269, P26438; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596; DAVIS JD, 1981, SCIENCE, V212, P81, DOI 10.1126/science.7193909; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Henriksen EJ, 1997, LIFE SCI, V61, P805, DOI 10.1016/S0024-3205(97)00562-6; Jacob S, 1996, DIABETES, V45, P1024, DOI 10.2337/diabetes.45.8.1024; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; Niimi M, 1999, J NEUROENDOCRINOL, V11, P605; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ryu JW, 2003, BIOCHEM BIOPH RES CO, V303, P726, DOI 10.1016/S0006-291X(03)00409-1; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SMITH GP, 1969, AM J PHYSIOL, V217, P1083, DOI 10.1152/ajplegacy.1969.217.4.1083; Tritos NA, 1998, ENDOCRINOLOGY, V139, P4634, DOI 10.1210/en.139.11.4634; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Yaworsky K, 2000, DIABETOLOGIA, V43, P294, DOI 10.1007/s001250050047; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603; ZIMMER G, 1991, ARCH BIOCHEM BIOPHYS, V288, P609, DOI 10.1016/0003-9861(91)90243-C	36	421	447	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					727	733		10.1038/nm1061	http://dx.doi.org/10.1038/nm1061			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195087				2022-12-25	WOS:000222460400027
J	Liu, D; Safari, A; O'Connor, MS; Chan, DW; Laegeler, A; Qin, J; Zhou, SY				Liu, D; Safari, A; O'Connor, MS; Chan, DW; Laegeler, A; Qin, J; Zhou, SY			PTOP interacts with POT1 and regulates its localization to telomeres	NATURE CELL BIOLOGY			English	Article							END-BINDING-PROTEIN; PROTECTION; LENGTH; YEAST; CDC13; RECOGNITION; ELONGATION; TANKYRASE	Telomere maintenance has been implicated in cancer and ageing, and requires cooperation between a multitude of telomeric factors, including telomerase, TRF1, TRF2, RAP1, TIN2, Tankyrase, PINX1 and POT1 (refs 1-12). POT1 belongs to a family of oligonucleotide-binding (OB)-fold-containing proteins that include Oxytricha nova TEBP, Cdc13, and spPot1, which specifically recognize telomeric single-stranded DNA (ssDNA)(10,13-19). In human cells, the loading of POT1 to telomeric ssDNA controls telomerase-mediated telomere elongation(12). Surprisingly, a human POT1 mutant lacking an OB fold is still recruited to telomeres. However, the exact mechanism by which this recruitment occurs remains unclear. Here we identify a novel telomere protein, PTOP, which interacts with both POT1 and TIN2. PTOP binds to the carboxyl terminus of POT1 and recruits it to telomeres. Inhibition of PTOP by RNA interference (RNAi) or disruption of the PTOP-POT1 interaction hindered the localization of POT1 to telomeres. Furthermore, expression of the respective interaction domains on PTOP and POT1 alone extended telomere length in human cells. Therefore, PTOP heterodimerizes with POT1 and regulates POT1 telomeric recruitment and telomere length.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; LOAYZA D, 2004, J BIOL CHEM, V7; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Rodriguez M, 2004, J BIOL CHEM, V279, P8802, DOI 10.1074/jbc.M311886200; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	30	334	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					673	680		10.1038/ncb1142	http://dx.doi.org/10.1038/ncb1142			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15181449				2022-12-25	WOS:000222434900023
J	Mukai, J; Liu, H; Burt, RA; Swor, DE; Lai, WS; Karayiorgou, M; Gogos, JA				Mukai, J; Liu, H; Burt, RA; Swor, DE; Lai, WS; Karayiorgou, M; Gogos, JA			Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia	NATURE GENETICS			English	Article							INTRON RETENTION; SUSCEPTIBILITY; ASSOCIATION; EXPRESSION; HAPLOTYPE; LOCUS	Using a relatively dense genetic map of 72 single-nucleotide polymorphisms (SNPs) distributed across the entire 1.5-Mb locus on chromosome 22q11 associated with susceptibilit to schizophrenia(1,2), we previously identified two subregions that were consistently associated with the disease(3,4). In the distal subregion, we detected an association signal with five neighboring SNPs distributed over a haplotypic block of 80 kb encompassing six known genes(4). One of these five SNPs, rs175174, had the strongest association of all 72 SNPs that we tested. Here we show that rs175174 regulates the level of the fully functional transcript by modulating the retention of intron 4 of the gene ZDHHC8, which encodes a putative transmembrane palmitoyltransferase. Zdhhc8-knockout mice had a sexually dimorphic deficit in prepulse inhibition, a gene dosage dependent decrease in exploratory activity in a new environment and a decreased sensitivity to the locomotor stimulatory effects of the psychomimetic drug dizocilpine (MK801). SNP rs175174 shows differences in transmission distortion between sexes in individuals with schizophrenia. Our results indicate that there is an unexpected connection between impaired palmitate modification of neuronal proteins and the psychiatric phenotypes associated with microdeletions of chromosome 22q11.	Rockefeller Univ, Human Neurogenet Lab, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Rockefeller University; Columbia University; Columbia University	Karayiorgou, M (corresponding author), Rockefeller Univ, Human Neurogenet Lab, 1230 York Ave, New York, NY 10021 USA.	karayim@rockefeller.edu; jag90@columbia.edu	Burt, Rachel/I-7874-2012	Burt, Rachel/0000-0001-8827-8266; Lai, Wen-Sung/0000-0001-6918-5531; Mukai, Jun/0000-0003-2065-4784				Aleman A, 2003, ARCH GEN PSYCHIAT, V60, P565, DOI 10.1001/archpsyc.60.6.565; Bassett AS, 2003, AM J PSYCHIAT, V160, P1580, DOI 10.1176/appi.ajp.160.9.1580; Bateman JF, 2003, HUM MOL GENET, V12, P217, DOI 10.1093/hmg/ddg054; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; D'Souza DN, 1999, NEUROSCIENCE, V93, P1539, DOI 10.1016/S0306-4522(99)00229-8; DIRKSEN WP, 1995, J BIOL CHEM, V270, P5346, DOI 10.1074/jbc.270.10.5346; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Gogos JA, 1999, NAT GENET, V21, P434, DOI 10.1038/7777; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; Hennah W, 2003, HUM MOL GENET, V12, P3151, DOI 10.1093/hmg/ddg341; Huang YQ, 1996, MOL CELL BIOL, V16, P6046; Jacquet H, 2002, HUM MOL GENET, V11, P2243, DOI 10.1093/hmg/11.19.2243; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Kienzle N, 1999, J VIROL, V73, P1195, DOI 10.1128/JVI.73.2.1195-1204.1999; Konnecke R, 2000, SCHIZOPHR RES, V44, P81, DOI 10.1016/S0920-9964(99)00139-5; Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3; Li T, 2004, AM J MED GENET B, V129B, P13, DOI 10.1002/ajmg.b.30049; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Liu H, 2002, P NATL ACAD SCI USA, V99, P16859, DOI 10.1073/pnas.232186099; Liu H, 2002, P NATL ACAD SCI USA, V99, P3717, DOI 10.1073/pnas.042700699; LOBO S, 2002, J BIOL CHEM, V277, P41628; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Shifman S, 2002, AM J HUM GENET, V71, P1296, DOI 10.1086/344514; Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326	29	244	258	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					725	731		10.1038/ng1375	http://dx.doi.org/10.1038/ng1375			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15184899	Bronze			2022-12-25	WOS:000222354100023
J	Townsley, FM; Cliffe, A; Bienz, M				Townsley, FM; Cliffe, A; Bienz, M			Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function	NATURE CELL BIOLOGY			English	Article							APC TUMOR-SUPPRESSOR; BETA-CATENIN; PHD-FINGER; NEGATIVE REGULATION; DROSOPHILA HOMOLOG; WINGLESS SIGNAL; TCF COMPLEX; PROTEIN; LOCALIZATION; EXPORT	Wnt signalling controls the transcription of genes that function during normal and malignant development(1,2). Stimulation by canonical Wnt ligands activates beta-catenin (or Drosophila melanogaster Armadillo) by blocking its phosphorylation, resulting in its stabilization and translocation to the nucleus. Here, Armadillo/beta-catenin binds to TCF/LEF transcription factors and recruits chromatin-modifying and -remodelling complexes to transcribe Wnt target genes(3-6). The transcriptional activity of Armadillo/beta-catenin depends on two conserved nuclear proteins recently discovered in Drosophila, Pygopus (Pygo) and Legless/BCL-9 (Lgs)(7-10). Lgs functions as an adaptor between Pygo and Armadillo/beta-catenin(7), but how Armadillo/beta-catenin is controlled by Pygo and Lgs is not known. Here, we show that the nuclear localization of Lgs entirely depends on Pygo, which itself is constitutively localized to the nucleus; thus, Pygo functions as a nuclear anchor. Pygo is also required for high nuclear Armadillo levels during Wingless signalling, and together with Lgs increases the transcriptional activity of beta-catenin in APC mutant cancer cells. Notably, linking Armadillo to a nuclear localization sequence rescues pygo and lgs mutant fly embryos. This indicates that Pygo and Lgs function in targeting Armadillo/beta-catenin to the nucleus, thus ensuring its availability to TCF during Wnt signalling.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mb2@mrc-lmb.cam.ac.uk						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahmed Y, 2002, DEVELOPMENT, V129, P1751; Akong K, 2002, DEV BIOL, V250, P91, DOI 10.1006/dbio.2002.0776; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cox RT, 1999, DEVELOPMENT, V126, P1327; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Pai LM, 1997, DEVELOPMENT, V124, P2255; Parker DS, 2002, DEVELOPMENT, V129, P2565; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Thompson BJ, 2004, CURR BIOL, V14, P458, DOI 10.1016/j.cub.2004.02.026; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Townsley FM, 2004, J BIOL CHEM, V279, P5177, DOI 10.1074/jbc.M309722200; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	37	177	180	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					626	633		10.1038/ncb1141	http://dx.doi.org/10.1038/ncb1141			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15208637				2022-12-25	WOS:000222434900017
J	Brandenberger, R; Wei, H; Zhang, S; Lei, S; Murage, J; Fisk, GJ; Li, Y; Xu, CH; Fang, R; Guegler, K; Rao, MS; Mandalam, R; Lebkowski, J; Stanton, LW				Brandenberger, R; Wei, H; Zhang, S; Lei, S; Murage, J; Fisk, GJ; Li, Y; Xu, CH; Fang, R; Guegler, K; Rao, MS; Mandalam, R; Lebkowski, J; Stanton, LW			Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELLS; EXPRESSION; LINES; IDENTIFICATION; GENERATION; PATTERNS; ENHANCER; DATABASE; CULTURE; MURINE	Human embryonic stem (hES) cells hold promise for generating an unlimited supply of cells for replacement therapies. To characterize hES cells at the molecular level, we obtained 148,453 expressed sequence tags (ESTs) from undifferentiated hES cells and three differentiated derivative subpopulations. Over 32,000 different transcripts expressed in hES cells were identified, of which more than 16,000 do not match closely any gene in the UniGene public database. Queries to this EST database revealed 532 significantly upregulated and 140 significantly downregulated genes in undifferentiated hES cells. These data highlight changes in the transcriptional network that occur when hES cells differentiate. Among the differentially regulated genes are several components of signaling pathways and transcriptional regulators that likely play key roles in hES cell growth and differentiation. The genomic data presented here may facilitate the derivation of clinically useful cell types from hES cells.	Geron Corp, Menlo Pk, CA 94025 USA; Celera Genom, Rockville, MD 20850 USA; NIA, Baltimore, MD 21224 USA	Geron Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brandenberger, R (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.	rbrandenberger@geron.com			NATIONAL INSTITUTE ON AGING [ZIAAG000324, Z01AG000324] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Claverie JM, 1999, HUM MOL GENET, V8, P1821, DOI 10.1093/hmg/8.10.1821; Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Ewing RM, 1999, GENOME RES, V9, P950, DOI 10.1101/gr.9.10.950; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Lebkowski JS, 2001, CANCER J, V7, pS83; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 2001, GENOME BIOL, V2, P3005; Pop Mihai, 2004, Methods Mol Biol, V255, P279; Purandare SM, 2002, DEVELOPMENT, V129, P2293; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schuringa JJ, 2002, EXP CELL RES, V274, P119, DOI 10.1006/excr.2001.5454; Smith TPL, 2000, BIOTECHNIQUES, V29, P698, DOI 10.2144/00294bm05; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tang K, 2002, BIOCHEM BIOPH RES CO, V293, P167, DOI 10.1016/S0006-291X(02)00215-2; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; [No title captured]	47	269	317	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					707	716		10.1038/nbt971	http://dx.doi.org/10.1038/nbt971			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15146197				2022-12-25	WOS:000221785300032
J	Min, DH; Tang, WJ; Mrksich, M				Min, DH; Tang, WJ; Mrksich, M			Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor	NATURE BIOTECHNOLOGY			English	Article							SELF-ASSEMBLED MONOLAYERS; PROTEIN-KINASE KINASE; FLUORESCENCE POLARIZATION; PROTECTIVE ANTIGEN; CRYSTAL-STRUCTURE; IDENTIFICATION; ASSAYS; RECEPTOR; BINDING; TOXIN	Mass spectrometry (MS) analysis is applicable to a broad range of biological analytes and has the important advantage that it does not require analytes to be labeled. A drawback of MS methods, however, is the need for chromatographic steps to prepare the analyte, precluding MS from being used in chemical screening and rapid analysis. Here, we report that surfaces that are chemically tailored for characterization by matrix-assisted laser-desorption ionization time-of-flight MS eliminate the need for sample processing and make this technique adaptable to parallel screening experiments. The tailored substrates are based on self-assembled monolayers that present ligands that interact with target proteins and enzymes. We apply this method to screen a chemical library against protease activity of anthrax lethal factor, and report a compound that inhibits lethal factor activity with a K-i of 1.1 muM and blocks the cleavage of MEK1 in 293 cells.	Univ Chicago, Dept Chem, Inst Biophys Dynam, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Mrksich, M (corresponding author), Univ Chicago, Dept Chem, Inst Biophys Dynam, 5735 S Ellis Ave, Chicago, IL 60637 USA.	mmrksich@uchicago.edu	Mrksich, Milan/G-2469-2011; Min, Dal-Hee/AAP-1298-2020	Mrksich, Milan/0000-0002-4964-796X; Tang, Wei-Jen/0000-0002-8267-8995; Min, Dal-Hee/0000-0001-8623-6716				Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Cacace A, 2003, DRUG DISCOV TODAY, V8, P785, DOI 10.1016/S1359-6446(03)02809-5; Cummings RT, 2002, P NATL ACAD SCI USA, V99, P6603, DOI 10.1073/pnas.062171599; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fowler A, 2002, ANAL BIOCHEM, V308, P223, DOI 10.1016/S0003-2697(02)00245-2; Friedlander AM, 2001, NATURE, V414, P160, DOI 10.1038/35102660; Guo ZH, 2000, SCIENCE, V288, P2042, DOI 10.1126/science.288.5473.2042; Houseman BT, 2002, NAT BIOTECHNOL, V20, P270, DOI 10.1038/nbt0302-270; Houseman BT, 2003, LANGMUIR, V19, P1522, DOI 10.1021/la0262304; Houseman BT, 2002, CHEM BIOL, V9, P443, DOI 10.1016/S1074-5521(02)00124-2; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Khandurina J, 2002, CURR OPIN CHEM BIOL, V6, P359, DOI 10.1016/S1367-5931(02)00323-X; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Levine LM, 1997, ANAL BIOCHEM, V247, P83, DOI 10.1006/abio.1997.2047; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moy FJ, 2001, ANAL CHEM, V73, P571, DOI 10.1021/ac0006270; Mrksich M, 1997, ACS SYM SER, V680, P361; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Parker GJ, 2000, J BIOMOL SCREEN, V5, P77, DOI 10.1177/108705710000500204; Pellizzari R, 2000, INT J MED MICROBIOL, V290, P421; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Salisbury CM, 2002, J AM CHEM SOC, V124, P14868, DOI 10.1021/ja027477q; Shogren-Knaak MA, 2001, ANNU REV CELL DEV BI, V17, P405, DOI 10.1146/annurev.cellbio.17.1.405; Sigal GB, 1998, J AM CHEM SOC, V120, P3464, DOI 10.1021/ja970819l; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Su J, 2002, ANGEW CHEM INT EDIT, V41, P4715, DOI 10.1002/anie.200290026; Tawa P, 2001, CELL DEATH DIFFER, V8, P30, DOI 10.1038/sj.cdd.4400769; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Trevor JL, 1998, LANGMUIR, V14, P1664, DOI 10.1021/la971136m; Varughese M, 1999, INFECT IMMUN, V67, P1860; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	35	127	134	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					717	723		10.1038/nbt973	http://dx.doi.org/10.1038/nbt973			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15146199				2022-12-25	WOS:000221785300033
J	Rosenbauer, F; Wagner, K; Kutok, JL; Iwasaki, H; Le Beau, MM; Okuno, Y; Akashi, K; Fiering, S; Tenen, DG				Rosenbauer, F; Wagner, K; Kutok, JL; Iwasaki, H; Le Beau, MM; Okuno, Y; Akashi, K; Fiering, S; Tenen, DG			Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1	NATURE GENETICS			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; C/EBP-ALPHA; TRANSGENIC MICE; DIFFERENTIATION; MUTATIONS; GENE; PROGENITORS; MYC; ABNORMALITIES	Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis(1), and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated(2). However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development(3,4). We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.	Harvard Univ, Inst Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Immunol & AIDS, Boston, MA 02115 USA; Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Hanover, NH 03756 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Dartmouth College	Tenen, DG (corresponding author), Harvard Univ, Inst Med, Room 954,77 Ave Louis Pasteur, Boston, MA 02115 USA.	dtenen@bidmc.harvard.edu		Fiering, Steven/0000-0003-0624-974X; Tenen, Daniel/0000-0002-6423-3888; Rosenbauer, Frank/0000-0001-7977-9421	NCI NIH HHS [P30 CA023108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Duprez EA, 2002, BLOOD, V100, p61A; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Iwasaki-Arai J, 2002, BLOOD, V100, p61A; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	30	404	411	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					624	630		10.1038/ng1361	http://dx.doi.org/10.1038/ng1361			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15146183	Bronze			2022-12-25	WOS:000221763700021
J	Zou, YZ; Akazawa, H; Qin, YJ; Sano, M; Takano, H; Minamino, T; Makita, N; Iwanaga, K; Zhu, WD; Kudoh, S; Toko, H; Tamura, K; Kihara, M; Nagai, T; Fukamizu, A; Umemura, S; Iiri, T; Fujita, T; Komuro, I				Zou, YZ; Akazawa, H; Qin, YJ; Sano, M; Takano, H; Minamino, T; Makita, N; Iwanaga, K; Zhu, WD; Kudoh, S; Toko, H; Tamura, K; Kihara, M; Nagai, T; Fukamizu, A; Umemura, S; Iiri, T; Fujita, T; Komuro, I			Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II	NATURE CELL BIOLOGY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CARDIAC MYOCYTES; RANDOMIZED-TRIAL; IN-VIVO; PROTEIN; STRETCH; HEART; EXPRESSION; PATHWAY; KINASE	The angiotensin II type 1 (AT1) receptor has a crucial role in load-induced cardiac hypertrophy. Here we show that the AT1 receptor can be activated by mechanical stress through an angiotensin-II-independent mechanism. Without the involvement of angiotensin II, mechanical stress not only activates extracellular-signal-regulated kinases and increases phosphoinositide production in vitro, but also induces cardiac hypertrophy in vivo. Mechanical stretch induces association of the AT1 receptor with Janus kinase 2, and translocation of G proteins into the cytosol. All of these events are inhibited by the AT1 receptor blocker candesartan. Thus, mechanical stress activates AT1 receptor independently of angiotensin II, and this activation can be inhibited by an inverse agonist of the AT1 receptor.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Kanazawa Med Univ, Dept Cardiol, Kawakita, Ishikawa 9200265, Japan; Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, Kanagawa 2360004, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan	Chiba University; University of Tokyo; Kanazawa Medical University; Yokohama City University; University of Tsukuba	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Minamino, Tohru/P-8145-2018; fukamizu, akiyoshi/J-5350-2012	Minamino, Tohru/0000-0003-1627-6151; fukamizu, akiyoshi/0000-0002-8786-6020; Akazawa, Hiroshi/0000-0002-3574-9607				Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Bader J, 2001, J MOL MED, V79, P76, DOI 10.1007/s001090100210; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BERNSTEIN KE, 1992, ENDOCR REV, V13, P381, DOI 10.1210/er.13.2.381; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Campbell DJ, 2004, HYPERTENSION, V43, P854, DOI 10.1161/01.HYP.0000119190.06968.f1; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Inagami T, 1999, J AM SOC NEPHROL, V10, pS2; Ishida JJ, 1999, INT J MOL MED, V3, P263; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; LEE MA, 1993, CIRCULATION, V87, P7; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Malhotra R, 1999, CIRC RES, V85, P137, DOI 10.1161/01.RES.85.2.137; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mazzolai L, 2000, HYPERTENSION, V35, P985, DOI 10.1161/01.HYP.35.4.985; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wei CC, 2002, AM J PHYSIOL-HEART C, V282, pH2254, DOI 10.1152/ajpheart.00191.2001; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	48	491	514	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					499	506		10.1038/ncb1137	http://dx.doi.org/10.1038/ncb1137			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15146194				2022-12-25	WOS:000221759400009
J	van der Hoek, L; Pyrc, K; Jebbink, MF; Vermeulen-Oost, W; Berkhout, RJM; Wolthers, KC; Wertheim-van Dillen, PME; Kaandorp, J; Spaargaren, J; Berkhout, B				van der Hoek, L; Pyrc, K; Jebbink, MF; Vermeulen-Oost, W; Berkhout, RJM; Wolthers, KC; Wertheim-van Dillen, PME; Kaandorp, J; Spaargaren, J; Berkhout, B			Identification of a new human coronavirus	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING; SARS-CORONAVIRUS; ORGAN CULTURES; SPIKE PROTEIN; S-GENE; VIRUS; DISEASE; GENOME; OC43	Three human coronaviruses are known to exist: human coronavirus 229E (HCoV-229E), HCoV-OC43 and severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). Here we report the identification of a fourth human coronavirus, HCoV-NL63, using a new method of virus discovery. The virus was isolated from a 7-month-old child suffering from bronchiolitis and conjunctivitis. The complete genome sequence indicates that this virus is not a recombinant, but rather a new group 1 coronavirus. The in vitro host cell range of HCoV-NL63 is notable because it replicates on tertiary monkey kidney cells and the monkey kidney LLC-MK2 cell line. The viral genome contains distinctive features, including a unique N-terminal fragment within the spike protein. Screening of clinical specimens from individuals suffering from respiratory illness identified seven additional HCoV-NL63-infected individuals, indicating that the virus was widely spread within the human population.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Municipal Hlth Serv, Publ Hlth Lab, NL-1018 WT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol Clin Virol, NL-1105 AZ Amsterdam, Netherlands; Slotervaart Hosp, Dept Pediat, NL-1066 EC Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.berkhout@amc.uva.nl	Wolthers, Katja C./E-5140-2018; van der Hoek, Lia/Y-6412-2019	Wolthers, Katja C./0000-0003-1617-7049; Spaargaren, Joke/0000-0001-8728-316X				Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; Boivin G, 2003, EMERG INFECT DIS, V9, P634; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767; Chen LL, 2003, BIOCHEM BIOPH RES CO, V307, P382, DOI 10.1016/S0006-291X(03)01192-6; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058; GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Guy JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000; Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562; HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734; HENDLEY JO, 1972, AM REV RESPIR DIS, V105, P805; Holmes KV, 1996, FIELDS VIROLOGY, P1075; Jubelt B, 2001, NEUROLOGY, V57, P945, DOI 10.1212/WNL.57.6.945; Krempl C, 2000, J GEN VIROL, V81, P489, DOI 10.1099/0022-1317-81-2-489; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360; Lai MMC, 2003, J BIOMED SCI, V10, P664, DOI [10.1007/BF02256318, 10.1159/000074077]; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502; MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933; MOUNIR S, 1993, ADV EXP MED BIOL, V342, P61; MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sawicki S G, 1995, Adv Exp Med Biol, V380, P499; Shingadia D, 2002, LANCET INFECT DIS, V2, P310, DOI 10.1016/S1473-3099(02)00265-7; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9; Stohlman SA, 2001, BRAIN PATHOL, V11, P92; Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273; TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; VAUGHN EM, 1995, J VIROL, V69, P3176, DOI 10.1128/JVI.69.5.3176-3184.1995	41	915	971	8	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					368	373		10.1038/nm1024	http://dx.doi.org/10.1038/nm1024			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034574	Bronze, Green Published			2022-12-25	WOS:000220587000027
J	Yeh, E; Cunningham, M; Arnold, H; Chasse, D; Monteith, T; Ivaldi, G; Hahn, WC; Stukenberg, PT; Shenolikar, S; Uchida, T; Counter, CM; Nevins, JR; Means, AR; Sears, R				Yeh, E; Cunningham, M; Arnold, H; Chasse, D; Monteith, T; Ivaldi, G; Hahn, WC; Stukenberg, PT; Shenolikar, S; Uchida, T; Counter, CM; Nevins, JR; Means, AR; Sears, R			A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells	NATURE CELL BIOLOGY			English	Article							TRANSACTIVATION DOMAIN; PROTEIN STABILITY; PHOSPHORYLATION; PIN1; ELEMENTS; BINDING; MICE; GENE; DIFFERENTIATION; PROLIFERATION	The stability of c-Myc is regulated by multiple Ras effector pathways. Phosphorylation at Ser 62 stabilizes c-Myc, whereas subsequent phosphorylation at Thr 58 is required for its degradation. Here we show that Ser 62 is dephosphorylated by protein phosphatase 2A (PP2A) before ubiquitination of c-Myc, and that PP2A activity is regulated by the Pin1 prolyl isomerase. Furthermore, the absence of Pin1 or inhibition of PP2A stabilizes c-Myc. A stable C-MyC(T58A) mutant that cannot bind Pin1 or be dephosphorylated by PP2A replaces SV40 small T antigen in human cell transformation and tumorigenesis assays. Therefore, small T antigen, which inactivates PP2A, exerts its oncogenic potential by preventing dephosphorylation of c-Myc, resulting in c-Myc stabilization. Thus, Ras-dependent signalling cascades ensure transient and self-limiting accumulation of c-Myc, disruption of which contributes to human cell oncogenesis.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Med Oncol & Med, Boston, MA 02115 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Oregon Health & Science University; Duke University; Duke University; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of Virginia; Tohoku University	Sears, R (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	searsr@ohsu.edu	ivaldi, giovanni/R-1106-2016; ivaldi, giovanni/AAB-7547-2019	ivaldi, giovanni/0000-0002-7280-5698; ivaldi, giovanni/0000-0002-7280-5698; Stukenberg, Todd/0000-0002-6788-2111; Counter, Christopher M/0000-0003-0748-3079; Uchida, Takafumi/0000-0003-3665-4906	NATIONAL CANCER INSTITUTE [R01CA082845, R01CA100855, K01CA086957] Funding Source: NIH RePORTER; NCI NIH HHS [CA-82845, CA 100855, CA 86957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P104; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	38	605	619	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					308	318		10.1038/ncb1110	http://dx.doi.org/10.1038/ncb1110			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048125				2022-12-25	WOS:000220587600012
J	Chen, W; Zhang, DH				Chen, W; Zhang, DH			Kinetochore fibre dynamics outside the context of the spindle during anaphase	NATURE CELL BIOLOGY			English	Article							CRANE-FLY SPERMATOCYTES; CHROMOSOME MOVEMENT; ULTRAVIOLET MICROBEAM; MICROTUBULE DYNAMICS; POLEWARD; MITOSIS; END; MOTION; FORCE; FLUX	Chromosomes move polewards as kinetochore fibres shorten during anaphase. Fibre dynamics and force production have been studied extensively(1-10), but little is known about these processes in the absence of the spindle matrix. Here we show that laser-microbeam-severed kinetochore fibres in the cytoplasm of grasshopper spermatocytes maintain a constant length while turning over in a polarized manner. Tubulin incorporates at or near the kinetochore and translocates towards severed ends without shortening the fibre. Consequently, the chromosome cannot move polewards unless the severed fibre reattaches to the pole through microtubules. A potential seclusion artefact has been ruled out, as fibres severed inside spindles behave identically despite being surrounded by the spindle matrix. Our data suggest that kinetochore microtubules constantly treadmill(11) during anaphase in insect cells. Treadmilling is an intrinsic property of microtubules in the kinetochore fibre, independent of the context and attachment of the spindle. The machinery that depolymerizes minus ends of kinetochore microtubules is functional in a non-spindle context. Attachment to the pole, however, is required to cause net kinetochore fibre shortening to generate polewards forces during anaphase.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Zhang, DH (corresponding author), Oregon State Univ, Dept Zool, 3029 Cordley Hall, Corvallis, OR 97331 USA.	zhangd@science.oregonstate.edu						Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Forer A, 2003, CELL MOTIL CYTOSKEL, V56, P173, DOI 10.1002/cm.10144; FORER A, 1965, J CELL BIOL, V25, P95, DOI 10.1083/jcb.25.1.95; FUGE H, 1989, BIOL CELL, V66, P209, DOI 10.1016/0248-4900(89)90173-1; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Johansen KM, 2002, CELL CYCLE, V1, P312, DOI 10.4161/cc.1.5.144; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; King JM, 2000, J CELL SCI, V113, P3815; LaFountain JR, 2002, J CELL SCI, V115, P1541; Maddox P, 2003, J CELL BIOL, V162, P377, DOI 10.1083/jcb.200301088; Maddox P, 2002, CURR BIOL, V12, P1670, DOI 10.1016/S0960-9822(02)01183-1; Maiato H, 2003, CELL CYCLE, V2, P511, DOI 10.4161/cc.2.6.576; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; MCINTOSH JR, 1969, NATURE, V224, P659, DOI 10.1038/224659a0; McIntosh JR, 2002, ANNU REV CELL DEV BI, V18, P193, DOI 10.1146/annurev.cellbio.18.032002.132412; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1982, J CELL BIOL, V95, P91, DOI 10.1083/jcb.95.1.91; Pickett-Heaps JD, 2001, PROTOPLASMA, V215, P16, DOI 10.1007/BF01280300; PICKETTHEAPS JD, 1982, CELL, V29, P729, DOI 10.1016/0092-8674(82)90435-4; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Scholey JM, 2001, J CELL BIOL, V154, P261, DOI 10.1083/jcb.200101097; SHELDEN E, 1992, J CELL BIOL, V116, P1409, DOI 10.1083/jcb.116.6.1409; Walczak CE, 2003, MOL CELL, V11, P286, DOI 10.1016/S1097-2765(03)00067-4; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; WILSON PJ, 1994, J CELL SCI, V107, P3015; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	32	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					227	231		10.1038/ncb1104	http://dx.doi.org/10.1038/ncb1104			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039774				2022-12-25	WOS:000189363000013
J	Rizzoti, K; Brunelli, S; Carmignac, D; Thomas, PQ; Robinson, IC; Lovell-Badge, R				Rizzoti, K; Brunelli, S; Carmignac, D; Thomas, PQ; Robinson, IC; Lovell-Badge, R			SOX3 is required during the formation of the hypothalamo-pituitary axis	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; X-CHROMOSOME; MOUSE; HORMONE; GENES; EXPRESSION; GROWTH; ORGANOGENESIS; PROTEIN; SRY	The pituitary develops from the interaction of the infundibulum, a region of the ventral diencephalon, and Rathke's pouch, a derivative of oral ectoderm. Postnatally, its secretory functions are controlled by hypothalamic neurons, which also derive from the ventral diencephalon. In humans, mutations affecting the X-linked transcription factor SOX3 are associated with hypopituitarism and mental retardation, but nothing is known of their etiology. We find that deletion of Sox3 in mice leads to defects of pituitary function and of specific central nervous system (CNS) midline structures. Cells in the ventral diencephalon, where Sox3 is usually highly expressed, have altered properties in mutant embryos, leading to abnormal development of Rathke's pouch, which does not express the gene. Pituitary and hypothalamic defects persist postnatally, and SOX3 may also function in a subset of hypothalamic neurons. This study shows how sensitive the pituitary is to subtle developmental defects and how one gene can act at several levels in the hypothalamic-pituitary axis.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Mol Endocrinol, London NW7 1AA, England; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Lovell-Badge, R (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Mill Hill, London NW7 1AA, England.	rlovell@nimr.mrc.ac.uk	Thomas, Paul Q/K-4497-2012; Brunelli, Silvia/J-3248-2014; Brunelli, Silvia/P-3853-2019; Rizzoti, Karine/AAW-1090-2021	Brunelli, Silvia/0000-0003-1753-5346; Brunelli, Silvia/0000-0003-1753-5346; Rizzoti, Karine/0000-0003-0711-5452; Lovell-Badge, Robin/0000-0001-9364-4179	MRC [MC_U117562207] Funding Source: UKRI; Medical Research Council [MC_U117562207] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Avilion AA, 2000, GENESIS, V27, P76, DOI 10.1002/1526-968X(200006)27:2<76::AID-GENE40>3.0.CO;2-A; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Cochran W.G., 1967, STAT METHODS; Collignon J, 1996, DEVELOPMENT, V122, P509; COLLIGNON J, 1992, STUDY NEW FAMILY GEN; Dasen JS, 2001, ANNU REV NEUROSCI, V24, P327, DOI 10.1146/annurev.neuro.24.1.327; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Ericson J, 1998, DEVELOPMENT, V125, P1005; Flavell DM, 1996, EMBO J, V15, P3871, DOI 10.1002/j.1460-2075.1996.tb00761.x; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; JONES CM, 1991, ANN NY ACAD SCI, V642, P339; Kaufman MH, 1994, ATLAS MOUSE DEV; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Laumonnier F, 2002, AM J HUM GENET, V71, P1450, DOI 10.1086/344661; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2; Martinez-Barbera JP, 2001, DEVELOPMENT, V128, P4789; Mayo KE, 2000, RECENT PROG HORM RES, V55, P237; McGuinness L, 2003, ENDOCRINOLOGY, V144, P720, DOI 10.1210/en.2002-220847; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Overton PM, 2002, DEVELOPMENT, V129, P4219; PARSONS M, 1997, FUNCTIONAL ANAL SOX3; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Shibusawa N, 2000, MOL ENDOCRINOL, V14, P137, DOI 10.1210/me.14.1.137; Solomon NM, 2002, GENOMICS, V79, P553, DOI 10.1006/geno.2002.6741; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Weiss J, 2003, MOL CELL BIOL, V23, P8084, DOI 10.1128/MCB.23.22.8084-8091.2003; Wood HB, 1999, MECH DEVELOP, V86, P197, DOI 10.1016/S0925-4773(99)00116-1; Zernicka-Goetz M, 2001, METHODS, V24, P55, DOI 10.1006/meth.2001.1157; Zucchi I, 1999, GENOMICS, V57, P209, DOI 10.1006/geno.1999.5768	40	211	217	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					247	255		10.1038/ng1309	http://dx.doi.org/10.1038/ng1309			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981518	Bronze			2022-12-25	WOS:000189250400013
J	Hermjakob, H; Montecchi-Palazzi, L; Bader, G; Wojcik, R; Salwinski, L; Ceol, A; Moore, S; Orchard, S; Sarkans, U; von Mering, C; Roechert, B; Poux, S; Jung, E; Mersch, H; Kersey, P; Lappe, M; Li, YX; Zeng, R; Rana, D; Nikolski, M; Husi, H; Brun, C; Shanker, K; Grant, SGN; Sander, C; Bork, P; Zhu, WM; Pandey, A; Brazma, A; Jacq, B; Vidal, M; Sherman, D; Legrain, P; Cesareni, G; Xenarios, L; Eisenberg, D; Steipe, B; Hogue, C; Apweiler, R				Hermjakob, H; Montecchi-Palazzi, L; Bader, G; Wojcik, R; Salwinski, L; Ceol, A; Moore, S; Orchard, S; Sarkans, U; von Mering, C; Roechert, B; Poux, S; Jung, E; Mersch, H; Kersey, P; Lappe, M; Li, YX; Zeng, R; Rana, D; Nikolski, M; Husi, H; Brun, C; Shanker, K; Grant, SGN; Sander, C; Bork, P; Zhu, WM; Pandey, A; Brazma, A; Jacq, B; Vidal, M; Sherman, D; Legrain, P; Cesareni, G; Xenarios, L; Eisenberg, D; Steipe, B; Hogue, C; Apweiler, R			The HUPOPSI's Molecular Interaction format - a community standard for the representation of protein interaction data	NATURE BIOTECHNOLOGY			English	Article							EXCHANGING PROTEOMICS DATA; COMMON STANDARDS; SYSTEMS BIOLOGY; DATA-BANK; BIND	A major goal of proteomics is the complete description of the protein interaction network underlying cell physiology. A large number of small scale and, more recently, large-scale experiments have contributed to expanding our understanding of the nature of the interaction network. However, the necessary data integration across experiments is currently hampered by the fragmentation of publicly available protein interaction data, which exists in different formats in databases, on authors' websites or sometimes only in print publications. Here, we propose a community standard data model for the representation and exchange of protein interaction data. This data model has been jointly developed by members of the Proteomics Standards Initiative (PSI), a work group of the Human Proteome Organization (HUPO), and is supported by major protein interaction data providers, in particular the Biomolecular Interaction Network Database (BIND), Cellzome (Heidelberg, Germany), the Database of Interacting Proteins (DIP), Dana Farber Cancer Institute (Boston, MA, USA), the Human Protein Reference Database (HPRD), Hybrigenics (Paris, France), the European Bioinformatics Institute's (EMBL-EBI, Hinxton, UK) IntAct, the Molecular Interactions (MINT, Rome, Italy) database, the Protein-Protein Interaction Database (PPID, Edinburgh, UK) and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, EMBL, Heidelberg, Germany).	European Bioinformat Inst, EBI Hinxton, Cambridge CB10 1SD, England; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; Hybrigen SA, F-75012 Paris, France; Univ Calif Los Angeles, Howard Hughes Med Inst, DOE Inst Gen & Prote, Los Angeles, CA 90095 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; European Mol Biol Lab, Struct & Computat Biol Program, D-69117 Heidelberg, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13092 Berlin, Germany; Swiss Inst Bioinformat, CH-1211 Geneva, Switzerland; LG Informat, Aventis Pharma Deutschland, D-65812 Bad Soden, Germany; Univ Bielefeld, Fac Technol, D-33615 Bielefeld, Germany; Chinese Acad Sci, Shanghai Inst Biol Sci, Bioinformat Ctr, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Prote Ctr, Shanghai 200031, Peoples R China; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; CNRS, Lab Genet & Physiol Dev, IBDM, F-13402 Marseille 9, France; Univ Edinburgh, Div Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland; Inst Bioinformat, Bangalore 560066, Karnataka, India; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21287 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; CNRS, Lab Bordelais Rech Informat, UMR 5800, F-33405 Talence, France; Serono Int SA, CH-1228 Geneva, Switzerland; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	European Molecular Biology Laboratory (EMBL); University of Rome Tor Vergata; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Swiss Institute of Bioinformatics; Sanofi-Aventis; University of Bielefeld; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Edinburgh; Johns Hopkins University; Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Merck & Company; Serono International S.A.; University of Toronto; University of Toronto	Hermjakob, H (corresponding author), European Bioinformat Inst, EBI Hinxton, Wellcome Trust Genome Campus, Cambridge CB10 1SD, England.	hhe@ebi.ac.uk	von Mering, Christian/B-3300-2008; Brun, Christine/B-4922-2008; Steipe, Boris/ABE-3813-2020; Bader, Gary/C-1176-2009; Hermjakob, Henning/AFM-3497-2022; Hogue, Christopher W V/AAZ-3934-2020; Sander, Chris/H-1452-2011; Lappe, Michael/A-5505-2008; Pandey, Akhilesh/B-4127-2009; Hogue, Christopher/B-6726-2008; Ceol, Arnaud/H-3386-2012; Bork, Peer/F-1813-2013; Kalyana-Sundaram, Shanker/F-6860-2012; Orchard, Sandra/ABC-1609-2020	von Mering, Christian/0000-0001-7734-9102; Brun, Christine/0000-0002-5563-6765; Steipe, Boris/0000-0002-1134-6758; Bader, Gary/0000-0003-0185-8861; Hermjakob, Henning/0000-0001-8479-0262; Hogue, Christopher W V/0000-0002-3107-5246; Sander, Chris/0000-0001-6059-6270; Pandey, Akhilesh/0000-0001-9943-6127; Ceol, Arnaud/0000-0001-9533-4246; Bork, Peer/0000-0002-2627-833X; Orchard, Sandra/0000-0002-8878-3972; Grant, Seth/0000-0001-8732-8735; Xenarios, Ioannis/0000-0002-3413-6841; Salwinski, Lukasz/0000-0003-4522-1969; Apweiler, Rolf/0000-0001-7078-200X; Kalyana-Sundaram, Shanker/0000-0002-7309-3848; Kersey, Paul/0000-0002-7054-800X; Brazma, Alvis/0000-0001-5988-7409; Sarkans, Ugis/0000-0001-9227-8488; Poux, Sylvain/0000-0001-7299-6685; Sherman, David James/0000-0002-2316-1005	Telethon [GTF02011] Funding Source: Medline	Telethon(Fondazione Telethon)		Ashburner M, 2001, GENOME RES, V11, P1425; Bader GD, 2000, BIOINFORMATICS, V16, P465, DOI 10.1093/bioinformatics/16.5.465; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Ball CA, 2002, SCIENCE, V298, P539; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Deane CM, 2002, MOL CELL PROTEOMICS, V1, P349, DOI 10.1074/mcp.M100037-MCP200; Garavelli JS, 2003, NUCLEIC ACIDS RES, V31, P499, DOI 10.1093/nar/gkg038; Hermjakob H, 2004, NUCLEIC ACIDS RES, V32, pD452, DOI 10.1093/nar/gkh052; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; HUSI H, 2002, NEUROSCIENCE DATABAS, P1; Kaiser J, 2002, SCIENCE, V296, P827, DOI 10.1126/science.296.5569.827; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Miyazaki S, 2003, NUCLEIC ACIDS RES, V31, P13, DOI 10.1093/nar/gkg088; Orchard S, 2003, PROTEOMICS, V3, P1374, DOI 10.1002/pmic.200300496; Orchard S, 2003, COMP FUNCT GENOM, V4, P203, DOI 10.1002/cfg.279; Orchard S, 2003, COMP FUNCT GENOM, V4, P16, DOI 10.1002/cfg.232; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Spellman PT, 2002, GENOME BIOL, V3; Stoesser G, 2003, NUCLEIC ACIDS RES, V31, P17, DOI 10.1093/nar/gkg021; Taylor CF, 2003, NAT BIOTECHNOL, V21, P247, DOI 10.1038/nbt0303-247; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Westbrook J, 2003, NUCLEIC ACIDS RES, V31, P489, DOI 10.1093/nar/gkg068; Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8	29	437	454	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					177	183		10.1038/nbt926	http://dx.doi.org/10.1038/nbt926			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14755292				2022-12-25	WOS:000188730500016
J	Nicot, C; Dundr, M; Johnson, JM; Fullen, JR; Alonzo, N; Fukumoto, R; Princler, GL; Derse, D; Misteli, T; Franchini, G				Nicot, C; Dundr, M; Johnson, JM; Fullen, JR; Alonzo, N; Fukumoto, R; Princler, GL; Derse, D; Misteli, T; Franchini, G			HTLV-1-encoded p30(II) is a post-transcriptional negative regulator of viral replication	NATURE MEDICINE			English	Article							HTLV-I; LYMPHOTROPIC VIRUS; PX; PROTEINS; GENE; TAX; REV; EXPRESSION; CELLS; REQUIREMENT	Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) persists despite a vigorous virus-specific host immune response, and causes adult T-cell leukemia and lymphoma in approximately 2% of infected individuals. Here we report that HTLV-1 has evolved a genetic function to restrict its own replication by a novel post-transcriptional mechanism. The HTLV-1-encoded p30(II) is a nuclear-resident protein that binds to, and retains in the nucleus, the doubly spliced mRNA encoding the Tax and Rex proteins. Because Tex and Rex are positive regulators of viral gene expression(1,2), their inhibition by p30(II) reduces virion production. p30(II) inhibits virus expression by reducing Tax and Rex protein expression.	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; NCI, Basic Res Lab, Ctr Canc Res, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645, Z01BC010003, ZIABC010003, ZIABC010309, Z01BC010309] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P38, DOI 10.1073/pnas.83.1.38; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Derse D, 1996, J ACQ IMMUN DEF SYND, V12, P1, DOI 10.1097/00042560-199605010-00001; DIMAIO D, 1996, FIELDS VIROLOGY, P119; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MUCHARDT C, 1992, NEW BIOL, V4, P541; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; WACHSMAN W, 1985, SCIENCE, V228, P1534, DOI 10.1126/science.2990032	30	139	148	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					197	201		10.1038/nm984	http://dx.doi.org/10.1038/nm984			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14730358				2022-12-25	WOS:000188719600041
J	Sen, G; Wehrman, TS; Myers, JW; Blau, HM				Sen, G; Wehrman, TS; Myers, JW; Blau, HM			Restriction enzyme-generated siRNA (REGS) vectors and libraries	NATURE GENETICS			English	Article							SHORT-INTERFERING RNAS; DOUBLE-STRANDED-RNA; GENE-EXPRESSION; STEM-CELLS; HAIRPIN RNAS; DIFFERENTIATION; MESSENGER; SYSTEM	Small interfering RNA (siRNA) technology facilitates the study of loss of gene function in mammalian cells and animal models, but generating multiple siRNA vectors using oligonucleotides is slow, inefficient and costly. Here we describe a new, enzyme-mediated method for generating numerous functional siRNA constructs from any gene of interest or pool of genes. To test our restriction enzyme generated siRNA (REGS) system, we silenced a transgene and two endogenous genes and obtained the predicted phenotypes. REGS generated on average 34 unique siRNAs per kilobase of sequence. REGS enabled us to create enzymatically a complex siRNA library (>4x10(5) clones) from double-stranded cDNA encompassing known and unknown genes with 96% of the clones containing inserts of the appropriate size.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, 269 Campus Dr,CCSR 4225A, Stanford, CA 94305 USA.	hblau@stanford.edu						BOYD AC, 1986, NUCLEIC ACIDS RES, V14, P5255, DOI 10.1093/nar/14.13.5255; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Detter JC, 2002, GENOMICS, V80, P691, DOI 10.1006/geno.2002.7020; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	28	117	133	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					183	189		10.1038/ng1288	http://dx.doi.org/10.1038/ng1288			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14704668	Bronze			2022-12-25	WOS:000188542700022
J	Baxendale, S; Davison, C; Muxworthy, C; Wolff, C; Ingham, PW; Roy, S				Baxendale, S; Davison, C; Muxworthy, C; Wolff, C; Ingham, PW; Roy, S			The B-cell maturation factor Blimp-1 specifies vertebrate slow-twitch muscle fiber identity in response to Hedgehog signaling	NATURE GENETICS			English	Article							ZEBRAFISH EMBRYO; SOMITE FORMATION; SONIC HEDGEHOG; PLASMA-CELLS; EXPRESSION; REPRESSION; DIFFERENTIATION; PROTEIN; IDENTIFICATION; INDUCTION	Vertebrate skeletal muscles comprise distinct fiber types that differ in their morphology, contractile function, mitochondrial content and metabolic properties. Recent studies identified the transcriptional coactivator PGC-1 as a key mediator of the physiological stimuli that modulate fiber-type plasticity in postembryonic development(1). Although myoblasts become fated to differentiate into distinct kinds of fibers early in development, the identities of regulatory proteins that determine embryonic fiber-type specification are still obscure. Here we show that the gene u-boot (ubo), a mutation in which disrupts the induction of embryonic slow-twitch fibers(2), encodes the zebrafish homolog of Blimp-1, a SET domain containing transcription factor that promotes the terminal differentiation of B lymphocytes in mammals(3). Expression of ubo is induced by Hedgehog (Hh) signaling in prospective slow muscle precursors, and its activity alone is sufficient to direct slow-twitch fiber specific development by naive myoblasts. Our data provide the first molecular insight into the mechanism by which a specific group of muscle precursors is driven along a distinct pathway of fiber-type differentiation in response to positional cues in the vertebrate embryo.	Univ Sheffield, Sch Med & Biomed Sci, Ctr Dev Genet, MRC Intecellular Signaling Grp, Sheffield S10 2TN, S Yorkshire, England; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Sheffield; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ingham, PW (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Ctr Dev Genet, MRC Intecellular Signaling Grp, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Ingham, Philip W/G-9903-2011; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958; Baxendale, Sarah/0000-0002-6760-9457	MRC [G0100151] Funding Source: UKRI; Medical Research Council [G0100151] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barresi MJF, 2000, DEVELOPMENT, V127, P2189; Blagden CS, 1997, GENE DEV, V11, P2163, DOI 10.1101/gad.11.17.2163; Borycki AG, 1998, DEVELOPMENT, V125, P777; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Coutelle O, 2001, DEV BIOL, V236, P136, DOI 10.1006/dbio.2001.0193; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; de Souza FSJ, 1999, EMBO J, V18, P6062, DOI 10.1093/emboj/18.21.6062; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Du SJ, 1997, J CELL BIOL, V139, P145, DOI 10.1083/jcb.139.1.145; Glasgow E, 1998, MECH DEVELOP, V76, P175, DOI 10.1016/S0925-4773(98)00121-X; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lewis KE, 1999, DEV BIOL, V216, P469, DOI 10.1006/dbio.1999.9519; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roy S, 2001, GENE DEV, V15, P1563, DOI 10.1101/gad.195801; Talbot WS, 1999, METHOD CELL BIOL, V60, P259; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Wolff C, 2003, CURR BIOL, V13, P1169, DOI 10.1016/S0960-9822(03)00461-5; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	29	147	150	1	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					88	93		10.1038/ng1280	http://dx.doi.org/10.1038/ng1280			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702044	Bronze			2022-12-25	WOS:000187666800019
J	Katayama, H; Sasai, K; Kawai, H; Yuan, ZM; Bondaruk, J; Suzuki, F; Fujii, S; Arlinghaus, RB; Czerniak, BA; Sen, S				Katayama, H; Sasai, K; Kawai, H; Yuan, ZM; Bondaruk, J; Suzuki, F; Fujii, S; Arlinghaus, RB; Czerniak, BA; Sen, S			Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53	NATURE GENETICS			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; TUMOR AMPLIFIED KINASE; PROLYL ISOMERASE PIN1; CENTROSOME AMPLIFICATION; CELL-DIVISION; DNA-BINDING; PROTEIN; GENE; REGULATOR; REQUIRES	Aurora kinase A (also called STK15 and BTAK) is overexpressed in many human cancers. Ectopic overexpression of aurora kinase A in mammalian cells induces centrosome amplification, chromosome instability and oncogenic transformation, a phenotype characteristic of loss-of-function mutations of p53. Here we show that aurora kinase A phosphorylates p53 at Ser315, leading to its ubiquitination by Mdm2 and proteolysis. p53 is not degraded in the presence of inactive aurora kinase A or ubiquitination-defective Mdm2. Destabilization of p53 by aurora kinase A is abrogated in the presence of mutant Mdm2 that is unable to bind p53 and after repression of Mdm2 by RNA interference. Silencing of aurora kinase A results in less phosphorylation of p53 at Ser315, greater stability of p53 and cell-cycle arrest at G2-M. Cells depleted of aurora kinase A are more sensitive to cisplatin-induced apoptosis, and elevated expression of aurora kinase A abolishes this response. In a sample of bladder tumors with wildtype p53, elevated expression of aurora kinase A was correlated with low p53 concentration. We conclude that aurora kinase A is a key regulatory component of the p53 pathway and that overexpression of aurora kinase A leads to increased degradation of p53, causing downregulation of checkpoint-response pathways and facilitating oncogenic transformation of cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Radiobiol, Hiroshima 7348553, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard T.H. Chan School of Public Health; Hiroshima University; University of Texas System; UTMD Anderson Cancer Center	Sen, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ssen@mail.mdanderson.org	高, 雨莉/HGU-8187-2022	Kawai, Hidehiko/0000-0003-2213-7166				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; CHAN CSM, 1993, GENETICS, V135, P677; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu JX, 1996, MOL CELL BIOL, V16, P998; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Sen S, 1997, P NATL ACAD SCI USA, V94, P6164, DOI 10.1073/pnas.94.12.6164; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Tanaka T, 1999, CANCER RES, V59, P2041; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	48	474	502	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2004	36	1					55	62		10.1038/ng1279	http://dx.doi.org/10.1038/ng1279			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702041	Bronze			2022-12-25	WOS:000187666800014
J	Kim, S; Lim, YT; Soltesz, EG; De Grand, AM; Lee, J; Nakayama, A; Parker, JA; Mihaljevic, T; Laurence, RG; Dor, DM; Cohn, LH; Bawendi, MG; Frangioni, JV				Kim, S; Lim, YT; Soltesz, EG; De Grand, AM; Lee, J; Nakayama, A; Parker, JA; Mihaljevic, T; Laurence, RG; Dor, DM; Cohn, LH; Bawendi, MG; Frangioni, JV			Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping	NATURE BIOTECHNOLOGY			English	Article							BIOPSY	The use of near-infrared or infrared photons is a promising approach for biomedical imaging in living tissue(1). This technology often requires exogenous contrast agents with combinations of hydrodynamic diameter, absorption, quantum yield and stability that are not possible with conventional organic fluorophores. Here we show that the fluorescence emission of type II2,3 quantum dots can be tuned into the near infrared while preserving absorption cross-section, and that a polydentate phosphine coating renders them soluble, disperse and stable in serum. We then demonstrate that these quantum dots allow a major cancer surgery, sentinel lymph node mapping(4-6), to be performed in large animals under complete image guidance. Injection of only 400 pmol of near-infrared quantum dots permits sentinel lymph nodes 1 cm deep to be imaged easily in real time using excitation fluence rates of only 5 mW/cm(2). Taken together, the chemical, optical and in vivo data presented in this study demonstrate the potential of near-infrared quantum dots for biomedical imaging.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Frangioni, JV (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.		Kim, sungjee/F-5822-2013	Kim, Sungjee/0000-0002-1289-1926	NIBIB NIH HHS [R21 EB000673-01, R21 EB-00673, R33 EB000673-02, R33 EB000673, R21 EB000673] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000673, R33EB000673] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bonnema J, 2002, ANN ONCOL, V13, P1531, DOI 10.1093/annonc/mdf319; DEGRAND AM, 2003, IN PRESS TECHNOL CAN; DREW MGB, 1986, INORG CHIM ACTA, V118, P165, DOI 10.1016/S0020-1693(00)81380-8; Hatami F, 1998, PHYS REV B, V57, P4635, DOI 10.1103/PhysRevB.57.4635; Jakub JW, 2003, ONCOLOGIST, V8, P59, DOI 10.1634/theoncologist.8-1-59; Kim S, 2003, J AM CHEM SOC, V125, P11466, DOI 10.1021/ja0361749; KIM SJ, 2003, IN PRESS J AM CHEM S; Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282; Manna L, 2002, J AM CHEM SOC, V124, P7136, DOI 10.1021/ja025946i; MIKULEC FV, 1999, THESIS MIT CAMBRIGE; Nakayama Akira, 2002, Mol Imaging, V1, P365, DOI 10.1162/153535002321093972; Nakayama Akira, 2003, Mol Imaging, V2, P37, DOI 10.1162/153535003765276273; Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x; Sevick-Muraca EM, 2002, CURR OPIN CHEM BIOL, V6, P642, DOI 10.1016/S1367-5931(02)00356-3; Thompson J F, 2001, Expert Rev Anticancer Ther, V1, P446, DOI 10.1586/14737140.1.3.446; UREN RF, 2003, TXB MELANOMA, pCH30; US Department of Energy, RISK ASS INF SYST; Wang Y, 2003, J AM CHEM SOC, V125, P2830, DOI 10.1021/ja029231r	18	1784	1899	11	591	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					93	97		10.1038/nbt920	http://dx.doi.org/10.1038/nbt920			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14661026	Green Accepted			2022-12-25	WOS:000187745400032
J	Moffat, J; Andrews, B				Moffat, J; Andrews, B			Late-G1 cyclin-CDK activity is essential for control of cell morphogenesis in budding yeast	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; EXCHANGE FACTOR CDC24P; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; POLARIZED GROWTH; G1 CYCLINS; PHO85; PHOSPHORYLATION; COMPLEX; CDC42P	The accurate spatial and temporal coordination of cell polarization with DNA replication and segregation guarantees the fidelity of genetic transmission. Here we report that in Saccharomyces cerevisiae, a build-up or burst of G1 cyclin-dependent kinase (CDK) activity through activation of the cyclin genes CLN1,2 and PCL1,2 is essential for cell morphogenesis, but not for other events associated with the G1-S-phase transition, including DNA replication. Strains lacking a burst of late-G1 cyclin-CDK activity (LG1C(-)) undergo a catastrophic morphogenesis and halt the nuclear cycle at the morphogenesis checkpoint in G2 phase. Consistent with a role in morphogenesis, the Pho85 G1 cyclins Pcl1 and Pcl2 show a unique pattern of localization to sites of polarized cell growth, and strains lacking PCL1 and PCL2 show genetic interactions with the cell polarity GTPase Cdc42, its regulators and downstream effectors. Our data suggest that inability to assemble a septin ring and localize the GTP exchange factor Cdc24 at the incipient bud site may be the primary morphogenetic defects in LG1C-depleted cells. We conclude that a burst of late G1 cyclin-CDK activity is essential for establishing cell polarity and development of the cleavage apparatus.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Andrews, B (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle,Rm 4287,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		Moffat, Jason/AAC-1110-2020	Moffat, Jason/0000-0002-5663-8586				Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; Edgington NP, 2001, J CELL SCI, V114, P4599; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Jaquenoud M, 2000, MOL CELL BIOL, V20, P6244, DOI 10.1128/MCB.20.17.6244-6258.2000; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Lenburg ME, 2001, GENETICS, V157, P39; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Miller ME, 2000, MOL CELL BIOL, V20, P542, DOI 10.1128/MCB.20.2.542-555.2000; Miller ME, 2001, MOL CELL BIOL, V21, P6292, DOI 10.1128/MCB.21.18.6292-6311.2001; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; Pruyne D, 2000, J CELL SCI, V113, P365; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Tennyson CN, 1998, MOL MICROBIOL, V28, P69, DOI 10.1046/j.1365-2958.1998.00773.x; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 2000, YEAST NUCL FRONTIERS, P58	30	74	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					59	U15		10.1038/ncb1078	http://dx.doi.org/10.1038/ncb1078			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14688790				2022-12-25	WOS:000187802600014
J	Rosok, O; Sioud, M				Rosok, O; Sioud, M			Systematic identification of sense-antisense transcripts in mammalian cells	NATURE BIOTECHNOLOGY			English	Article							MESSENGER-RNA; GENE-EXPRESSION; HUMAN GENOME	In prokaryotes, a number of endogenous antisense RNAs have been detected and found to exert various biological functions(1,2). In eukaryotes antisense RNAs have been found(3-7); however, a lack of experimental methodologies that permit the identification of overlapping transcripts in cells presents a barrier to a more systematic identification of antisense RNA. Here we have developed an experimental strategy that allows systematic identification of endogenous mRNAs with long complementary regions to other transcripts. The method was applied to human normal mammary epithelial and breast cancer cells. Experimental validation of the presence of the sense and antisense transcripts by various techniques (e. g., northern blots, RT-PCR) supports the specificity of the method. When the antisense RNAs were specifically targeted, their corresponding mRNA levels significantly altered, a result consistent with a regulatory role for the identified antisense RNAs.	Norwegian Radium Hosp, Inst Canc Res, Dept Immunol, Mol Med Grp, N-0310 Oslo, Norway	University of Oslo	Sioud, M (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Immunol, Mol Med Grp, N-0310 Oslo, Norway.	mosioud@ulrik.uio.no						AASHEIM HC, 1997, METHODS MOL BIOL, V69; Capaccioli S, 1996, ONCOGENE, V13, P105; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delihas N, 1997, NAT BIOTECHNOL, V15, P751, DOI 10.1038/nbt0897-751; DOLNICK BJ, 1993, NUCLEIC ACIDS RES, V21, P1747, DOI 10.1093/nar/21.8.1747; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Li AW, 2000, MOL CELL ENDOCRINOL, V170, P231, DOI 10.1016/S0303-7207(00)00440-8; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Podlowski S, 2002, J CELL BIOCHEM, V85, P198, DOI 10.1002/jcb.10116; Sioud M, 1996, EUR J IMMUNOL, V26, P1026, DOI 10.1002/eji.1830260511; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	18	84	143	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					104	108		10.1038/nbt925	http://dx.doi.org/10.1038/nbt925			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704709				2022-12-25	WOS:000187745400034
J	Sato, N; Meijer, L; Skaltsounis, L; Greengard, P; Brivanlou, AH				Sato, N; Meijer, L; Skaltsounis, L; Greengard, P; Brivanlou, AH			Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor	NATURE MEDICINE			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; SELF-RENEWAL; ES CELLS; HUMAN BLASTOCYSTS; COLON-CARCINOMA; AXIS FORMATION; POU-DOMAIN; DIFFERENTIATION; EXPRESSION	Human and mouse embryonic stem cells (HESCs and MESCs, respectively) self-renew indefinitely while maintaining the ability to generate all three germ-layer derivatives. Despite the importance of ESCs in developmental biology and their potential impact on tissue replacement therapy, the molecular mechanism underlying ESC self-renewal is poorly understood. Here we show that activation of the canonical Wnt pathway is sufficient to maintain self-renewal of both HESCs and MESCs. Although Stat-3 signaling is involved in MESC self-renewal, stimulation of this pathway does not support self-renewal of HESCs. Instead we find that Wnt pathway activation by 6-bromoindirubin-3'-oxime (BIO), a specific pharmacological inhibitor of glycogen synthase kinase-3 (GSK-3), maintains the undifferentiated phenotype in both types of ESCs and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. Wnt signaling is endogenously activated in undifferentiated MESCs and is downregulated upon differentiation. In addition, BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both HESCs and MESCs. These results suggest that the use of GSK-3-specific inhibitors such as BIO may have practical applications in regenerative medicine.	Rockefeller Univ, Lab Mol Vertebrate Embryol, New York, NY 10021 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; CNRS, Biol Stn, Cell Cycle Grp, F-29680 Roscoff, France; Univ Athens, Dept Pharmacognosy, Athens, Greece	Rockefeller University; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); National & Kapodistrian University of Athens	Brivanlou, AH (corresponding author), Rockefeller Univ, Lab Mol Vertebrate Embryol, 1230 York Ave, New York, NY 10021 USA.		skaltsounis, alexios leandros/AAE-9617-2019	, laurent/0000-0003-3511-4916				Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kubo F, 2003, DEVELOPMENT, V130, P587, DOI 10.1242/dev.00244; Lloyd S, 2003, GENE EXPR PATTERNS, V3, P309, DOI 10.1016/S1567-133X(03)00046-2; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEIJER L, IN PRESS CHEM BIOL; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vonica A, 2002, DEV BIOL, V250, P112, DOI 10.1006/dbio.2002.0786; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971	47	1623	1865	1	176	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					55	63		10.1038/nm979	http://dx.doi.org/10.1038/nm979			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702635				2022-12-25	WOS:000187743600039
J	Moatti, JP; N'Doye, I; Hammer, SM; Hale, P; Kazatchkine, M				Moatti, JP; N'Doye, I; Hammer, SM; Hale, P; Kazatchkine, M			Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm	NATURE MEDICINE			English	Editorial Material							COST-EFFECTIVENESS; RISK BEHAVIOR; THERAPY; ACCESS; AIDS; TRANSMISSION; ADHERENCE; AFRICA; HAART; CARE	Scaling up access to antiretroviral drugs (ARVs) for HIV- infected adults and children in developing countries can no longer be refused for medical or economic reasons, or on the grounds of inequality, lack of infrastructure, risk of viral resistance or alternative priorities. Access to ARVs is an appropriate, rational and cost- effective investment choice in developing countries.	Univ Mediterrannee, F-13008 Marseille, France; INSERM, Res Unit 379, F-13008 Marseille, France; SIDA, Programme Natl Lutte, Dakar, Senegal; Columbia Univ, Div Infect Dis, New York, NY 10032 USA; Hop Europeen Georges Pompidou, INSERM, Res Unit 430, F-75908 Paris, France; Univ Paris 05, F-75013 Paris, France; Agence Natl Rech SIDA, F-75013 Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Moatti, JP (corresponding author), Univ Mediterrannee, F-13008 Marseille, France.	moatti@marseille.inserm.fr						Ainsworth M, 2000, LANCET, V356, P55, DOI 10.1016/S0140-6736(00)02440-5; Bouhnik AD, 2002, J EPIDEMIOL COMMUN H, V56, P349, DOI 10.1136/jech.56.5.349; Boulle A, 2002, SAMJ S AFR MED J, V92, P811; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005; Castro-Leal F, 2000, B WORLD HEALTH ORGAN, V78, P66; Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Cohen J, 2003, SCIENCE, V301, P1658, DOI 10.1126/science.301.5640.1658; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; DYER G, 2003, FINANCIAL TIMES 0715; *ECOWAS CEDEAO ACC, 2002, M MIN HLTH SUBR OBS; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Garber AM, 2000, HANDB ECON, V17, P181; Guimaraes MDC, 2001, INT J STD AIDS, V12, P334, DOI 10.1258/0956462011923057; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Hertogs K, 2000, AIDS, V14, P1203, DOI 10.1097/00002030-200006160-00018; Hogg RS, 2002, AIDS, V16, P787, DOI 10.1097/00002030-200203290-00015; Katzenstein D, 2003, AIDS, V17, pS1, DOI 10.1097/00002030-200317003-00001; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001; Lopez-Casasnovas G, 2000, HEALTH POLICY, V54, P87, DOI 10.1016/S0168-8510(00)00100-7; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018; MOATTI JP, 2003, EC AIDS ACCESS HIV A, P121; MSELLATI P, 2001, ACCES TRAITEMENTS VI, P233; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; OVER M, 2003, CURRENT ISSUES EC HI; Rosen S, 2003, HARVARD BUS REV, V81, P80; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Skordis J, 2002, J HEALTH ECON, V21, P405, DOI 10.1016/S0167-6296(01)00133-3; *UNAIDS, 2003, PROGR REP GLOB RESP; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; *WHO, 2002, ESS DRUGS MED POL PI; *WHO HIV AIDS DEP, 2002, SCAL ANT THER RES LT; Wolff M, 2001, REV MED CHILE, V129, P886	39	28	29	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1449	1452		10.1038/nm1203-1449	http://dx.doi.org/10.1038/nm1203-1449			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14647513				2022-12-25	WOS:000186845400014
J	Foss, GS; Rogne, S				Foss, GS; Rogne, S			Gene medication or genetic modification? The devil is in the details	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Bergen, Dept Publ Hlth, N-5020 Bergen, Norway; Agr Univ Norway, Dept Nat Conservat, N-1432 As, Norway	University of Bergen; Norwegian University of Life Sciences								BOUCHIE A, 2003, NAT BIOTECHNOL, V21, P11; *BRIT AGR ENV BIOT, 2002, AN BIOT; *PEW IN FOOD BIOT, 2003, FUT FISH ISS SCI REG; Sato M, 2002, MOL REPROD DEV, V61, P49, DOI 10.1002/mrd.1130	4	8	9	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1280	1281		10.1038/nbt1103-1280	http://dx.doi.org/10.1038/nbt1103-1280			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14595352				2022-12-25	WOS:000186320000016
J	Lee, OK; Frese, KK; James, JS; Chadda, D; Chen, ZH; Javier, RT; Cho, KO				Lee, OK; Frese, KK; James, JS; Chadda, D; Chen, ZH; Javier, RT; Cho, KO			Discs-Large and Strabismus are functionally linked to plasma membrane formation	NATURE CELL BIOLOGY			English	Letter							TISSUE POLARITY; DROSOPHILA EYE; CELL POLARITY; GOLGI STACKS; PDZ PROTEINS; HOMOLOG; GENE; LOCALIZATION; DISRUPTION; JUNCTIONS	During early embryogenesis in Drosophila melanogaster, extensive vesicle transport occurs to build cell boundaries for 6,000 nuclei. Here we show that this important process depends on a functional complex formed between the tumour suppressor and adaptor protein Discs-Large (Dlg)(1) and the integral membrane protein Strabismus (Stbm)/Van Gogh (Vang)(2,3). In support of this idea, embryos with mutations in either dlg or stbm displayed severe defects in plasma membrane formation. Conversely, overexpression of Dlg and Stbm synergistically induced excessive plasma membrane formation. In addition, ectopic co-expression of Stbm (which associated with post-Golgi vesicles) and the mammalian Dlg homologue SAP97/hDlg(4,5) promoted translocation of SAP97 from the cytoplasm to both post-Golgi vesicles and the plasma membrane. This effect was dependent on the interaction between Stbm and SAP97. These findings suggest that the Dlg-Stbm complex recruits membrane-associated proteins and lipids from internal membranes to sites of new plasma membrane formation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cho, KO (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Cho, Kyung-Ok/C-1705-2011	Cho, Kyung-Ok/0000-0002-0760-2560	NATIONAL CANCER INSTITUTE [R01CA058541, T32CA009197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035532] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058541, T32 CA009197] Funding Source: Medline; NINDS NIH HHS [R29 NS35532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Burgess RW, 1997, J CELL BIOL, V138, P861, DOI 10.1083/jcb.138.4.861; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Foe Victoria E., 1993, P149; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kondylis V, 2001, MOL BIOL CELL, V12, P2308, DOI 10.1091/mbc.12.8.2308; Lecuit T, 2000, J CELL BIOL, V150, P849, DOI 10.1083/jcb.150.4.849; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mendoza C, 2003, J NEUROSCI, V23, P2093; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; PERRIMON N, 1988, DEV BIOL, V127, P382; Rao A, 1998, J NEUROSCI, V18, P1217; Rawls AS, 2003, DEVELOPMENT, V130, P1877, DOI 10.1242/dev.00411; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; Strutt D, 2002, CURR BIOL, V12, P813, DOI 10.1016/S0960-9822(02)00841-2; Taylor J, 1998, GENETICS, V150, P199; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Wolff T, 1998, DEVELOPMENT, V125, P1149; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	37	69	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					987	993		10.1038/ncb1055	http://dx.doi.org/10.1038/ncb1055			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14562058	Green Accepted			2022-12-25	WOS:000186273100015
J	Lipford, JR; Deshaies, RJ				Lipford, JR; Deshaies, RJ			Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation	NATURE CELL BIOLOGY			English	Article							ESTROGEN-RECEPTOR-ALPHA; 26S PROTEASOME; DEGRADATION; PROTEIN; DEUBIQUITINATION; RECRUITMENT; INHIBITION; SUBCOMPLEX; COMPLEXES; TURNOVER	A growing literature points to a fundamental role for the ubiquitin - proteasome degradation system ( UPS) in transcription. Four recent publications add significant insight to our understanding of the connections between these processes. Each provides evidence that some aspect of the UPS can stimulate the activity of transcriptional activators. UPS might promote transcription by several mechanisms, and in some cases, even the final step of the UPS - proteolysis - might enhance activator function.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Lipford, JR (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	rlipford@caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				Ansari AZ, 2002, P NATL ACAD SCI USA, V99, P14706, DOI 10.1073/pnas.232573899; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Nelson C, 2003, NATURE, V421, P187, DOI 10.1038/nature01243; Nishiyama A, 2000, GENE DEV, V14, P2344, DOI 10.1101/gad.823200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	38	150	155	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					845	850		10.1038/ncb1003-845	http://dx.doi.org/10.1038/ncb1003-845			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14523392				2022-12-25	WOS:000185647400002
J	Perez, JM; Rathz, DA; Petrashevskaya, NN; Hahn, HS; Wagoner, LE; Schwartz, A; Dorn, GW; Liggett, SB				Perez, JM; Rathz, DA; Petrashevskaya, NN; Hahn, HS; Wagoner, LE; Schwartz, A; Dorn, GW; Liggett, SB			beta(1)-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure	NATURE MEDICINE			English	Article							CARDIAC-HYPERTROPHY; EXERCISE CAPACITY; DOWN-REGULATION; GI-ALPHA; OVEREXPRESSION; DESENSITIZATION; EXPRESSION; INCREASE; CYCLASE; KINASE	Catecholamines stimulate cardiac contractility through beta(1)-adrenergic receptors (beta(1)-ARs), which in humans are polymorphic at amino acid residue 389 (Arg/Gly). We used cardiac-targeted transgenesis in a mouse model to delineate mechanisms accounting for the association of Arg389 with human heart failure phenotypes. Hearts from young Arg389 mice had enhanced receptor function and contractility compared with Gly389 hearts. Older Arg389 mice displayed a phenotypic switch, with decreased beta-agonist signaling to adenylyl cyclase and decreased cardiac contractility compared with Gly 389 hearts. Arg389 hearts had abnormal expression of fetal and hypertrophy genes and calcium-cycling proteins, decreased adenylyl cyclase and Galpha(s) expression, and fibrosis with heart failure This phenotype was recapitulated in homozygous, end-stage, failing human hearts. In addition, hemodynamic responses to beta-receptor blockade were greater in Arg389 mice, and homozygosity for Arg389 was associated with improvement in ventricular function during carvedilol treatment in heart failure patients. Thus the human Arg389 variant predisposes to heart failure by instigating hyperactive signaling programs leading to depressed receptor coupling and ventricular dysfunction, and influences the therapeutic response to beta-receptor blockade.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Inst Mol Pharmacol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012; MIALET-PEREZ, Jeanne/Y-7487-2018	MIALET-PEREZ, Jeanne/0000-0002-1765-0283; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL22619, HL52318] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bengtsson K, 2001, CIRCULATION, V104, P187, DOI 10.1161/01.CIR.104.2.187; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1992, HYPERTENSION, V20, P103, DOI 10.1161/01.HYP.20.1.103; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; ESCHENHAGEN T, 1992, CIRC RES, V70, P688, DOI 10.1161/01.RES.70.4.688; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; Givertz MM, 2000, NEW ENGL J MED, V342, P1120, DOI 10.1056/NEJM200004133421509; Liggett SB, 2000, CIRCULATION, V101, P1707; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Moore MM, 1999, MUTAGENESIS, V14, P271, DOI 10.1093/mutage/14.3.271; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rathz DA, 2003, J BIOL CHEM, V278, P10784, DOI 10.1074/jbc.M206054200; Serikov VB, 2001, CIRC RES, V88, P9, DOI 10.1161/01.RES.88.1.9; Small KM, 2002, METHOD ENZYMOL, V343, P459; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Tepe NM, 1999, BIOCHEMISTRY-US, V38, P16706, DOI 10.1021/bi991619k; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; van Campen LCMC, 1998, J CARDIOVASC PHARM, V32, pS31, DOI 10.1097/00005344-199806321-00006; Wagoner LE, 2002, AM HEART J, V144, P840, DOI 10.1067/mhj.2002.125325; Wagoner LE, 2000, CIRC RES, V86, P834, DOI 10.1161/01.RES.86.8.834; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719	29	165	175	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1300	1305		10.1038/nm930	http://dx.doi.org/10.1038/nm930			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502278				2022-12-25	WOS:000185669700042
J	Xing, HR; Cordon-Cardo, C; Deng, XZ; Tong, W; Campodonico, L; Fuks, Z; Kolesnick, R				Xing, HR; Cordon-Cardo, C; Deng, XZ; Tong, W; Campodonico, L; Fuks, Z; Kolesnick, R			Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer	NATURE MEDICINE			English	Article							KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; CELLS	Inhibition of the kinase suppressor of ras-1 (KSR1) gene by continuous infusion of phosphorothioate antisense oligonucleotides (ODNs) prevented growth of K-Ras-dependent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma xenografts in nude mice, effected regression of established PANC-1 tumors and inhibited A549 lung metastases, all without apparent toxicity. These studies suggest KSR1 antisense ODNs as a treatment for Ras-dependent human malignancies, in particular pancreatic cancer, which lacks effective curative therapy.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Clin Chem Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1989, CANCER RES, V49, P4682; Huron DR, 2003, CLIN CANCER RES, V9, P1267; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; XING RH, 2003, CLIN CANCER RES, V9, P1267	9	45	52	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1266	1268		10.1038/nm927	http://dx.doi.org/10.1038/nm927			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960962				2022-12-25	WOS:000185669700036
J	Buaas, FW; Kirsh, AL; Sharma, M; McLean, DJ; Morris, JL; Griswold, MD; de Rooij, DG; Braun, RE				Buaas, FW; Kirsh, AL; Sharma, M; McLean, DJ; Morris, JL; Griswold, MD; de Rooij, DG; Braun, RE			Plzf is required in adult male germ cells for stem cell self-renewal	NATURE GENETICS			English	Article							ZINC-FINGER PROTEIN; PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; MOUSE; DIFFERENTIATION; PROLIFERATION; EMBRYO; BMI-1; MAP	Adult germline stem cells are capable of self-renewal, tissue regeneration and production of large numbers of differentiated progeny. We show here that the classical mouse mutant luxoid affects adult germline stem cell self-renewal. Young homozygous luxoid mutant mice produce limited numbers of normal spermatozoa and then progressively lose their germ line after birth. Transplantation studies showed that germ cells from mutant mice did not colonize recipient testes, suggesting that the defect is intrinsic to the stem cells. We determined that the luxoid mutant contains a nonsense mutation in the gene encoding Plzf, a transcriptional repressor that regulates the epigenetic state of undifferentiated cells, and showed that Plzf is coexpressed with Oct4 in undifferentiated spermatogonia. This is the first gene shown to be required in germ cells for stem cell self-renewal in mammals.	Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA; Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Fac Biol, Dept Endocrinol, NL-3584 CH Utrecht, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Washington State University; University of Washington; University of Washington Seattle; Utrecht University; Utrecht University	Braun, RE (corresponding author), Univ Washington, Sch Med, Dept Genome Sci, Box 357730,1705 NE Pacific St, Seattle, WA 98195 USA.	braun@u.washington.edu	de Rooij, D.G./AAW-1195-2021	de Rooij, Dirk/0000-0003-3932-4419; McLean, Derek/0000-0001-6151-2796				BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; de Rooij DG, 2001, REPRODUCTION, V121, P347, DOI 10.1530/rep.0.1210347; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FORSTHOEFEL PAULINUS FREDERICK, 1958, J MORPH, V102, P247, DOI 10.1002/jmor.1051020203; GREEN MARGARET C., 1955, JOUR HEREDITY, V46, P91; Hawe N, 1996, BLOOD, V88, P1151; JOHNSON DR, 1971, J EMBRYOL EXP MORPH, V25, P223; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Nadler JJ, 2000, GENESIS, V27, P117, DOI 10.1002/1526-968X(200007)27:3<117::AID-GENE40>3.0.CO;2-7; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; OBRIEN DA, 1980, DEV BIOL, V75, P405, DOI 10.1016/0012-1606(80)90172-4; Ohmura M, 2003, BIOL REPROD, V68, P2304, DOI 10.1095/biolreprod.102.013276; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; TEGELENBOSCH RAJ, 1993, MUTAT RES, V290, P193; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	29	651	689	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					647	652		10.1038/ng1366	http://dx.doi.org/10.1038/ng1366			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15156142	Green Submitted, Bronze			2022-12-25	WOS:000221763700025
J	Majumder, PK; Febbo, PG; Bikoff, R; Berger, R; Xue, Q; McMahon, LM; Manola, J; Brugarolas, J; McDonnell, TJ; Golub, TR; Loda, M; Lane, HA; Sellers, WR				Majumder, PK; Febbo, PG; Bikoff, R; Berger, R; Xue, Q; McMahon, LM; Manola, J; Brugarolas, J; McDonnell, TJ; Golub, TR; Loda, M; Lane, HA; Sellers, WR			mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways	NATURE MEDICINE			English	Article							TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; CANCER CELLS; BCL-2; EXPRESSION; PHOSPHORYLATION; TARGET; GENE; TSC2; PROLIFERATION	Loss of PTEN function leads to activation of phosphoinositide 3-kinase (PI3K) signaling and Akt. Clinical trials are now testing whether mammalian target of rapamycin (mTOR) inhibition is useful in treating PTEN-null cancers. Here, we report that mTOR inhibition induced apoptosis of epithelial cells and the complete reversal of a neoplastic phenotype in the prostate of mice expressing human AKT1 in the ventral prostate. Induction of cell death required the mitochondrial pathway, as prostate-specific coexpression of BCL2 blocked apoptosis. Thus, there is an mTOR-dependent survival signal required downstream of Akt. Bcl2 expression, however, only partially restored intraluminal cell growth in the setting of mTOR inhibition. Expression profiling showed that Hif-1alpha targets, including genes encoding most glycolytic enzymes, constituted the dominant transcriptional response to AKT activation and mTOR inhibition. These data suggest that the expansion of AKT-driven prostate epithelial cells requires mTOR-dependent survival signaling and activation of HIF-1alpha, and that clinical resistance to mTOR inhibitors may emerge through BCL2 expression and/or upregulation of HIF-1alpha activity.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Novartis; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Novartis	Sellers, WR (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	william_sellers@dfci.harvard.edu		Brugarolas, James/0000-0002-8575-499X	NATIONAL CANCER INSTITUTE [P01CA089021] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA89021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Baltaci S, 2000, BJU INT, V85, P155, DOI 10.1046/j.1464-410x.2000.00388.x; Bruckheimer EM, 2000, ONCOGENE, V19, P2404, DOI 10.1038/sj.onc.1203571; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; delPeso L, 1997, SCIENCE, V278, P687; DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Friedland D, 1999, SEMIN ONCOL, V26, P19; Furuya Y, 1996, CLIN CANCER RES, V2, P389; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Krajewska M, 1996, AM J PATHOL, V148, P1567; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McMenamin ME, 1999, CANCER RES, V59, P4291; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morris MJ, 2002, CLIN CANCER RES, V8, P679; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nashan B, 2002, THER DRUG MONIT, V24, P53, DOI 10.1097/00007691-200202000-00010; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; SELLERS WR, 2002, PROSTATE CANC PRINCI; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Suzuki H, 1998, CANCER RES, V58, P204; Taesch S, 1994, Transpl Int, V7 Suppl 1, pS263; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhong H, 2000, CANCER RES, V60, P1541	50	800	853	2	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					594	601		10.1038/nm1052	http://dx.doi.org/10.1038/nm1052			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156201				2022-12-25	WOS:000221759600024
J	Ye, JZS; de Lange, T				Ye, JZS; de Lange, T			TIN2 is a tankyrase 1 PARP modulator in the TRF1 telomere length control complex	NATURE GENETICS			English	Article							POLY(ADP-RIBOSE) POLYMERASE; REGULATOR	Telomere length in humans is partly controlled by a feedback mechanism in which telomere elongation by telomerase is limited by the accumulation of the TRF1 complex at chromosome ends(1-5). TRF1 itself can be inhibited by the poly(ADP-ribose) polymerase (PARP) activity of its interacting partner tankyrase 1, which abolishes its DNA binding activity in vitro and removes the TRF1 complex from telomeres in vivo. Here we report that the inhibition of TRF1 by tankyrase is in turn controlled by a second TRF1-interacting factor, TIN2 (ref. 6). Partial knockdown of TIN2 by small hairpin RNA in a telomerase-positive cell line resulted in telomere elongation, which is typical of reduced TRF1 function. Transient inhibition of TIN2 with small interfering RNA led to diminished telomeric TRF1 signals. This effect could be reversed with the PARP inhibitor 3-aminobenzamide and did not occur in cells overexpressing a PARP-dead mutant of tankyrase 1. TIN2 formed a ternary complex with TRF1 and tankyrase 1 and stabilized their interaction, an effect also observed with the PARP-dead mutant of tankyrase 1. In vitro, TIN2 protected TRF1 from poly(ADP-ribosyl)ation by tankyrase 1 without affecting tankyrase 1 automodification. These data identify TIN2 as a PARP modulator in the TRF1 complex and can explain how TIN2 contributes to the regulation of telomere length.	Rockefeller Univ, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center	de Lange, T (corresponding author), NYU, Sch Med, Div Hematol, Dept Med, 550 1St Ave, New York, NY 10016 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; De Rycker M, 2003, BIOCHEM J, V372, P87, DOI 10.1042/BJ20021450; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Iwano T, 2004, J BIOL CHEM, V279, P1442, DOI 10.1074/jbc.M309138200; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; MARSISCHKY GT, 1995, J BIOL CHEM, V270, P3247, DOI 10.1074/jbc.270.7.3247; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	20	146	155	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					618	623		10.1038/ng1360	http://dx.doi.org/10.1038/ng1360			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15133513	Bronze			2022-12-25	WOS:000221763700020
J	Mall, M; Grubb, BR; Harkema, JR; O'Neal, WK; Boucher, RC				Mall, M; Grubb, BR; Harkema, JR; O'Neal, WK; Boucher, RC			Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice	NATURE MEDICINE			English	Article							NEUTROPHIL ELASTASE; SALT CONTROVERSY; SODIUM-CHANNELS; ION-TRANSPORT; EXPRESSION; GENE; CFTR; SECRETIONS; LIQUID; MUCUS	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in defective epithelial cAMP-dependent Cl- secretion and increased airway Na+ absorption. The mechanistic links between these altered ion transport processes and the pathogenesis of cystic fibrosis lung disease, however, are unclear. To test the hypothesis that accelerated Na+ transport alone can produce cystic fibrosis-like lung disease, we generated mice with airway-specific overexpression of epithelial Na+ channels (ENaC). Here we show that increased airway Na+ absorption in vivo caused airway surface liquid (ASL) volume depletion, increased mucus concentration, delayed mucus transport and mucus adhesion to airway surfaces. Defective mucus transport caused a severe spontaneous lung disease sharing features with cystic fibrosis, including mucus obstruction, goblet cell metaplasia, neutrophilic inflammation and poor bacterial clearance. We conclude that increasing airway Na+ absorption initiates cystic fibrosis-like lung disease and produces a model for the study of the pathogenesis and therapy of this disease.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Michigan State Univ, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Michigan State University	Mall, M (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7011 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	mmall@med.unc.edu; rboucher@med.unc.edu	Mall, Marcus A./AAA-1498-2022	Mall, Marcus A./0000-0002-4057-2199				Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Berger M, 2002, AM J RESP CRIT CARE, V165, P857, DOI 10.1164/ajrccm.165.7.2202030a; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BREUER R, 1987, AM REV RESPIR DIS, V136, P698, DOI 10.1164/ajrccm/136.3.698; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; Grubb BR, 2004, AM J PHYSIOL-LUNG C, V286, pL588, DOI 10.1152/ajplung.00302.2003; Grubb BR, 2001, AM J PHYSIOL-CELL PH, V281, pC615, DOI 10.1152/ajpcell.2001.281.2.C615; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; HACKETT BP, 1992, P NATL ACAD SCI USA, V89, P9079, DOI 10.1073/pnas.89.19.9079; Ibanez-Tallon I, 2002, HUM MOL GENET, V11, P715, DOI 10.1093/hmg/11.6.715; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM CS, 1986, J APPL PHYSIOL, V60, P901, DOI 10.1152/jappl.1986.60.3.901; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MATTHEWS LW, 1963, AM REV RESPIR DIS, V88, P199; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1; PUCHELLE E, 1995, RESPIRATION, V62, P2; Sims DE, 1997, AM J PHYSIOL-LUNG C, V273, pL1036; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZUELZER WW, 1949, PEDIATRICS, V4, P53	50	683	707	2	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					487	493		10.1038/nm1028	http://dx.doi.org/10.1038/nm1028			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15077107				2022-12-25	WOS:000221242400026
J	Inoue, K; Khajavi, M; Ohyama, T; Hirabayashi, S; Wilson, J; Reggin, JD; Mancias, P; Butler, IJ; Wilkinson, MF; Wegner, M; Lupski, JR				Inoue, K; Khajavi, M; Ohyama, T; Hirabayashi, S; Wilson, J; Reggin, JD; Mancias, P; Butler, IJ; Wilkinson, MF; Wegner, M; Lupski, JR			Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR SOX10; WAARDENBURG-HIRSCHSPRUNG-DISEASE; MESSENGER-RNA DECAY; CHRONIC INTESTINAL PSEUDOOBSTRUCTION; NONSENSE-MEDIATED DECAY; MARIE-TOOTH-DISEASE; REGULATORY MECHANISM; CLINICAL PHENOTYPES; FUNCTIONAL-ANALYSIS; P-0 MUTATIONS	The molecular mechanisms by which different mutations in the same gene can result in distinct disease phenotypes remain largely unknown. Truncating mutations of SOX10 cause either a complex neurocristopathy designated PCWH or a more restricted phenotype known as Waardenburg-Shah syndrome (WS4; OMIM 277580). Here we report that although all nonsense and frameshift mutations that cause premature termination of translation generate truncated SOX10 proteins with potent dominant-negative activity, the more severe disease phenotype, PCWH, is realized only when the mutant mRNAs escape the nonsense-mediated decay (NMD) pathway. We observe similar results for truncating mutations of MPZ that convey distinct myelinopathies. Our experiments show that triggering NMD and escaping NMD may cause distinct neurological phenotypes.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Nagano Childrens Hosp, Div Pediat Neurol, Nagano, Japan; Great Ormond St Hosp Children, Dept Neurol, London WC1N 3JH, England; Meritcare Neurosci Clin, Fargo, ND USA; Univ Texas, Sch Med, Dept Neurol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA	Baylor College of Medicine; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; University of Erlangen Nuremberg; Baylor College of Medicine; Baylor College of Medicine	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,Room 604B, Houston, TX 77030 USA.	jlupski@bcm.tmc.edu		Ohyama, Tomoko/0000-0003-1697-1138; Wegner, Michael/0000-0002-4586-3294				BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; Bondurand N, 1999, HUM MOL GENET, V8, P1785, DOI 10.1093/hmg/8.9.1785; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Byers PH, 2002, J CLIN INVEST, V109, P3, DOI 10.1172/JCI14841; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; FORGET BG, 1974, NATURE, V247, P379, DOI 10.1038/247379a0; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Inoue K, 2002, ANN NEUROL, V52, P836, DOI 10.1002/ana.10404; Inoue K, 1999, ANN NEUROL, V46, P313, DOI 10.1002/1531-8249(199909)46:3<313::AID-ANA6>3.0.CO;2-7; JACOBS JM, 1992, ACTA NEUROPATHOL, V83, P670, DOI 10.1007/BF00299420; Kerr TP, 2001, HUM GENET, V109, P402, DOI 10.1007/s004390100598; Korkko J, 1998, AM J HUM GENET, V62, P98, DOI 10.1086/301689; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Medghalchi SM, 2001, HUM MOL GENET, V10, P99, DOI 10.1093/hmg/10.2.99; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; OMENN GS, 1979, AM J MED GENET, V3, P217, DOI 10.1002/ajmg.1320030302; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Pingault V, 2000, ANN NEUROL, V48, P671, DOI 10.1002/1531-8249(200010)48:4<671::AID-ANA17>3.0.CO;2-8; Pingault V, 2002, HUM GENET, V111, P198, DOI 10.1007/s00439-002-0765-8; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Saifi GM, 2003, J INVEST MED, V51, P261, DOI 10.1136/jim-51-05-14; Schrijver I, 2002, AM J HUM GENET, V71, P223, DOI 10.1086/341581; Sham MH, 2001, J MED GENET, V38, DOI 10.1136/jmg.38.9.e30; Shames I, 2003, J NEUROPATH EXP NEUR, V62, P751, DOI 10.1093/jnen/62.7.751; Snead MP, 1999, J MED GENET, V36, P353; Sonnenberg-Riethmacher E, 2001, MECH DEVELOP, V109, P253, DOI 10.1016/S0925-4773(01)00547-0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Southard-Smith EM, 1999, GENOME RES, V9, P215; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Toki F, 2003, PEDIATR SURG INT, V19, P725, DOI 10.1007/s00383-003-1057-7; Touraine RL, 2000, AM J HUM GENET, V66, P1496, DOI 10.1086/302895; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; Wong MH, 1996, J CELL BIOL, V134, P1531, DOI 10.1083/jcb.134.6.1531; Yoshida M, 2001, NEUROCHEM RES, V26, P703, DOI 10.1023/A:1010999622760	44	320	334	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					361	369		10.1038/ng1322	http://dx.doi.org/10.1038/ng1322			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15004559	Bronze			2022-12-25	WOS:000220647200019
J	Lindgren, G; Backstrom, N; Swinburne, J; Hellborg, L; Einarsson, A; Sandberg, K; Cothran, G; Vila, C; Binns, M; Ellegren, H				Lindgren, G; Backstrom, N; Swinburne, J; Hellborg, L; Einarsson, A; Sandberg, K; Cothran, G; Vila, C; Binns, M; Ellegren, H			Limited number of patrilines in horse domestication	NATURE GENETICS			English	Article							HUMAN Y-CHROMOSOME; SEQUENCE VARIATION; ORIGINS; DIVERSITY; LINEAGES	Genetic studies using mitochondrial DNA ( mtDNA) have identified extensive matrilinear diversity among domestic horses. Here, we show that this high degree of polymorphism is not matched by a corresponding patrilinear diversity of the male-specific Y chromosome. In fact, a screening for single-nucleotide polymorphisms (SNPs) in 14.3 kb of noncoding Y chromosome sequence among 52 male horses of 15 different breeds did not identify a single segregation site. These observations are consistent with a strong sex-bias in the domestication process, with few stallions contributing genetically to the domestic horse.	Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, SE-75236 Uppsala, Sweden; Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England; Swedish Univ Agr Sci, Dept Anim Breeding & Genet, SE-75007 Uppsala, Sweden; Univ Kentucky, Dept Vet Sci, Lexington, KY 40546 USA	Uppsala University; Animal Health Trust; Swedish University of Agricultural Sciences; University of Kentucky	Ellegren, H (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, Norbyvagen 18D, SE-75236 Uppsala, Sweden.	Hans.Ellegren@ebc.uu.se	Vila, Carles/H-4893-2013; Backström, Niclas/C-8425-2012	Vila, Carles/0000-0002-4206-5246; Lindgren, Gabriella/0000-0001-6046-9669				Clutton-Brock J, 1999, NATURAL HIST DOMESTI; Cunningham EP, 2001, ANIM GENET, V32, P360, DOI 10.1046/j.1365-2052.2001.00785.x; Hammer MF, 2003, GENETICS, V164, P1495; Hammer MF, 2001, MOL BIOL EVOL, V18, P1189, DOI 10.1093/oxfordjournals.molbev.a003906; Jansen T, 2002, P NATL ACAD SCI USA, V99, P10905, DOI 10.1073/pnas.152330099; Levine MA, 1999, J ANTHROPOL ARCHAEOL, V18, P29, DOI 10.1006/jaar.1998.0332; Lister A.M., 1998, ANCIENT BIOMOLECULES, V2, P267; MacHugh DE, 2001, P NATL ACAD SCI USA, V98, P5382, DOI 10.1073/pnas.111163198; Olsen S. L., 1996, HORSES TIME; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Shen PD, 2000, P NATL ACAD SCI USA, V97, P7354, DOI 10.1073/pnas.97.13.7354; Stumpf MPH, 2001, SCIENCE, V291, P1738, DOI 10.1126/science.291.5509.1738; Vila C, 2001, SCIENCE, V291, P474, DOI 10.1126/science.291.5503.474; Wallner B, 2003, ANIM GENET, V34, P453, DOI 10.1046/j.0268-9146.2003.01044.x; Zeder MA, 2000, SCIENCE, V287, P2254, DOI 10.1126/science.287.5461.2254	15	115	122	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					335	336		10.1038/ng1326	http://dx.doi.org/10.1038/ng1326			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15034578	Bronze, Green Published			2022-12-25	WOS:000220647200014
J	Nishimura, T; Kato, K; Yamaguchi, T; Fukata, Y; Ohno, S; Kaibuchi, K				Nishimura, T; Kato, K; Yamaguchi, T; Fukata, Y; Ohno, S; Kaibuchi, K			Role of the PAR-3-KIF3 complex in the establishment of neuronal polarity	NATURE CELL BIOLOGY			English	Letter							CULTURED HIPPOCAMPAL-NEURONS; KINESIN SUPERFAMILY; CELL POLARITY; PROTEIN; MOTOR; TRANSPORT; 3-KINASE; VESICLES; KIF3A; AXON	Neurons polarize to form elaborate multiple dendrites and one long axon. The establishment and maintenance of axon/dendrite polarity are fundamentally important for neurons. Recent studies have demonstrated that the polarity complex PAR-3-PAR-6-atypical protein kinase C (aPKC) is involved in polarity determination in many tissues and cells. The function of the PAR-3-PAR-6-aPKC protein complex depends on its subcellular localization in polarized cells. PAR-3 accumulates at the tip of growing axons in cultured rat hippocampal neurons, but the molecular mechanism of this localization remains unknown. Here we identify a direct interaction between PAR-3 and KIF3A, a plus-end-directed microtubule motor protein, and show that aPKC can associate with KIF3A through its interaction with PAR-3. The expression of dominant-negative PAR-3 and KIF3A fragments that disrupt PAR-3-KIF3A binding inhibited the accumulation of PAR-3 and aPKC at the tip of the neurites and abolished neuronal polarity. These results suggest that PAR-3 is transported to the distal tip of the axon by KIF3A and that the proper localization of PAR-3 is required to establish neuronal polarity.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Nagoya University; Yokohama City University	Kato, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, 65 Tsurumai, Aichi 4668550, Japan.	kaibuchi@med.nagoya-u.ac.jp	Yamaguchi, Tomoya/AAN-7524-2020; Kato, Katsuhiro/AAV-8356-2020; Ohno, Shigeo/B-1768-2010; Nishimura, Takashi/AAQ-9299-2020; Nishimura, Takashi/D-7672-2017	Yamaguchi, Tomoya/0000-0001-6933-543X; Ohno, Shigeo/0000-0002-1294-5269; Nishimura, Takashi/0000-0002-6773-0302; Nishimura, Takashi/0000-0002-6773-0302; Fukata, Yuko/0000-0001-7724-8643				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Muresan V, 1998, MOL BIOL CELL, V9, P637, DOI 10.1091/mbc.9.3.637; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Yang ZH, 1998, MOL BIOL CELL, V9, P249, DOI 10.1091/mbc.9.2.249	23	230	240	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					328	334		10.1038/ncb1118	http://dx.doi.org/10.1038/ncb1118			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048131				2022-12-25	WOS:000220587600014
J	Wadia, JS; Stan, RV; Dowdy, SF				Wadia, JS; Stan, RV; Dowdy, SF			Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL; ENDOCYTOSIS; DELIVERY; SURFACE; INTERNALIZATION; DOMAINS; MACROPHAGES; CAVEOLAE; PATHWAY	The TAT protein transduction domain (PTD) has been used to deliver a wide variety of biologically active cargo for the treatment of multiple preclinical disease models, including cancer and stroke. However, the mechanism of transduction remains unknown. Because of the TAT PTD's strong cell-surface binding, early assumptions regarding cellular uptake suggested a direct penetration mechanism across the lipid bilayer by a temperature- and energy-independent process. Here we show, using a transducible TAT-Cre recombinase reporter assay on live cells, that after an initial ionic cell-surface interaction, TAT-fusion proteins are rapidly internalized by lipid raft-dependent macropinocytosis. Transduction was independent of interleukin-2 receptor/raft-, caveolar- and clathrin-mediated endocytosis and phagocytosis. Using this information, we developed a transducible, pH-sensitive, fusogenic dTAT-HA2 peptide that markedly enhanced TAT-Cre escape from macropinosomes. Taken together, these observations provide a scientific basis for the development of new, biologically active, transducible therapeutic molecules.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Dowdy, SF (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	sdowdy@ucsd.edu	wadia, jay/AAQ-9944-2021; Stan, Radu/AAE-7574-2021	Stan, Radu/0000-0003-2969-1725	NATIONAL CANCER INSTITUTE [R01CA096098] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065418] Funding Source: NIH RePORTER; NCI NIH HHS [CA96098, R01 CA096098] Funding Source: Medline; NHLBI NIH HHS [R01 HL065418-01A1, R01 HL065418-02, R01 HL065418-03, HL065418, R01 HL065418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Cao GD, 2002, J NEUROSCI, V22, P5423; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OLIVER JM, 1984, METHOD ENZYMOL, V108, P336; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Skehel JJ, 2001, BIOCHEM SOC T, V29, P623, DOI 10.1042/BST0290623; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731	30	1347	1503	2	208	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					310	315		10.1038/nm996	http://dx.doi.org/10.1038/nm996			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770178				2022-12-25	WOS:000189297700045
J	Tanaka, M; Machida, Y; Niu, SY; Ikeda, T; Jana, NR; Doi, H; Kurosawa, M; Nekooki, M; Nukina, N				Tanaka, M; Machida, Y; Niu, SY; Ikeda, T; Jana, NR; Doi, H; Kurosawa, M; Nekooki, M; Nukina, N			Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED CAG REPEAT; CELL-DEATH; IN-VITRO; AGGREGATION; MICE; INHIBITION; DISORDERS; GENE; FIBRILLOGENESIS	Inhibition of polyglutamine-induced protein aggregation could provide treatment options for polyglutamine diseases such as Huntington disease. Here we showed through in vitro screening studies that various disaccharides can inhibit polyglutamine-mediated protein aggregation. We also found that various disaccharides reduced polyglutamine aggregates and increased survival in a cellular model of Huntington disease. Oral administration of trehalose, the most effective of these disaccharides, decreased polyglutamine aggregates in cerebrum and liver, improved motor dysfunction and extended lifespan in a transgenic mouse model of Huntington disease. We suggest that these beneficial effects are the result of trehalose binding to expanded polyglutamines and stabilizing the partially unfolded polyglutamine-containing protein. Lack of toxicity and high solubility, coupled with efficacy upon oral administration, make trehalose promising as a therapeutic drug or lead compound for the treatment of polyglutamine diseases. The saccharide-polyglutamine interaction identified here thus provides a new therapeutic strategy for polyglutamine diseases.	RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	RIKEN	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab Struct Neuropathol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nukina@brain.riken.jp	Tanaka, Motomasa/N-5064-2015; Nukina, Nobuyuki/GPP-6265-2022	Tanaka, Motomasa/0000-0002-2994-7703; Jana, Nihar/0000-0002-6549-4211				Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FARRER LA, 1985, CLIN GENET, V27, P62; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Guo N, 2000, NAT BIOTECHNOL, V18, P168, DOI 10.1038/72616; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Hurlbert MS, 1999, DIABETES, V48, P649, DOI 10.2337/diabetes.48.3.649; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	39	578	614	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					148	154		10.1038/nm985	http://dx.doi.org/10.1038/nm985			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14730359				2022-12-25	WOS:000188719600033
J	Wang, LH; Yang, XY; Zhang, XH; Mihalic, K; Fan, YX; Xiao, WH; Howard, OMZ; Appella, E; Maynard, AT; Farrar, WL				Wang, LH; Yang, XY; Zhang, XH; Mihalic, K; Fan, YX; Xiao, WH; Howard, OMZ; Appella, E; Maynard, AT; Farrar, WL			Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor	NATURE MEDICINE			English	Article							CELL-CYCLE PROGRESSION; DNA-BINDING DOMAIN; NUCLEOCAPSID PROTEIN; MOLECULAR-MECHANISMS; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; TRICHOSTATIN-A; TUMOR-GROWTH; MCF-7 CELLS; NUDE-MICE	Current antiestrogen therapy for breast cancer is limited by the mixed estrogenic and antiestrogenic activity of selective estrogen receptor modulators. Here we show that the function of zinc fingers in the estrogen receptor DNA-binding domain (DBD) is susceptible to chemical inhibition by electrophilic disulfide benzamide and benzisothiazolone derivatives, which selectively block binding of the estrogen receptor to its responsive element and subsequent transcription. These compounds also significantly inhibit estrogen-stimulated cell proliferation, markedly reduce tumor mass in nude mice bearing human MCF-7 breast cancer xenografts, and interfere with cell-cycle and apoptosis regulatory gene expression. Functional assays and computational analysis support a molecular mechanism whereby electrophilic agents preferentially disrupt the vulnerable C-terminal zinc finger, thus suppressing estrogen receptor-mediated breast carcinoma progression. Our results provide the proof of principle for a new strategy to inhibit breast cancer at the level of DNA binding, rather than the classical antagonism of estrogen binding.	NCI, Basic Res Program, SAIC Frederick, NIH, Frederick, MD 21702 USA; NCI, Cytokine Mol Mech Sect, NIH, Frederick, MD 21702 USA; US FDA, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, LH (corresponding author), NCI, Basic Res Program, SAIC Frederick, NIH, POB B, Frederick, MD 21702 USA.		Xiao, Weihua/N-2775-2013; Howard, O M Zack/B-6117-2012	Xiao, Weihua/0000-0001-9102-6326; Howard, O M Zack/0000-0002-0505-7052	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; Ju YH, 2002, CANCER RES, V62, P2474; KYPRIANOU N, 1991, CANCER RES, V51, P162; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee SH, 2001, ANTIOXID REDOX SIGN, V3, P531, DOI 10.1089/15230860152542907; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Maynard AT, 2001, J AM CHEM SOC, V123, P1047, DOI 10.1021/ja0011616; Maynard AT, 1998, P NATL ACAD SCI USA, V95, P11578, DOI 10.1073/pnas.95.20.11578; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Ngwenya S, 2003, ENDOCRINOLOGY, V144, P1675, DOI 10.1210/en.2002-0009; Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Whittal RM, 2000, BIOCHEMISTRY-US, V39, P8406, DOI 10.1021/bi000282f; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	45	73	79	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					40	47		10.1038/nm969	http://dx.doi.org/10.1038/nm969			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702633				2022-12-25	WOS:000187743600037
J	Irwin, WA; Bergamin, N; Sabatelli, P; Reggiani, C; Megighian, A; Merlini, L; Braghetta, P; Columbaro, M; Volpin, D; Bressan, GM; Bernardi, P; Bonaldo, P				Irwin, WA; Bergamin, N; Sabatelli, P; Reggiani, C; Megighian, A; Merlini, L; Braghetta, P; Columbaro, M; Volpin, D; Bressan, GM; Bernardi, P; Bonaldo, P			Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency	NATURE GENETICS			English	Article							PERMEABILITY TRANSITION; MECHANISM; CHANNELS; RELEASE; FIBERS; ONSET; CA2+	Collagen VI is an extracellular matrix protein that forms a microfilamentous network in skeletal muscles and other organs(1-3). Inherited mutations in genes encoding collagen VI in humans cause two muscle diseases, Bethlem myopathy and Ullrich congenital muscular dystrophy(4,5). We previously generated collagen VI deficient (Col6a1(-/-)) mice and showed that they have a muscle phenotype that strongly resembles Bethlem myopathy(6). The pathophysiological defects and mechanisms leading to the myopathic disorder were not known. Here we show that Col6a1(-/-) muscles have a loss of contractile strength associated with ultrastructural alterations of sarcoplasmic reticulum (SR) and mitochondria and spontaneous apoptosis. We found a latent mitochondrial dysfunction in myofibers of Col6a1(-/-) mice on incubation with the selective F1FO-ATPase inhibitor oligomycin, which caused mitochondrial depolarization, Ca2+ deregulation and increased apoptosis. These defects were reversible, as they could be normalized by plating Col6a1(-/-) myofibers on collagen VI or by addition of cyclosporin A (CsA), the inhibitor of mitochondrial permeability transition pore (PTP). Treatment of Col6a1(-/-) mice with CsA rescued the muscle ultrastructural defects and markedly decreased the number of apoptotic nuclei in vivo. These findings indicate that collagen VI myopathies have an unexpected mitochondrial pathogenesis that could be exploited for therapeutic intervention.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy; ITOI CNR IOR, I-40136 Bologna, Italy; Univ Padua, Dept Human Anat, I-35121 Padua, Italy; Univ Padua, Dept Physiol, I-35121 Padua, Italy; Orthoped Inst Rizzoli, I-40136 Bologna, Italy	University of Padua; University of Padua; University of Padua; University of Padua	Bernardi, P (corresponding author), Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy.	bernardi@bio.unipd.it; bonaldo@bio.unipd.it	Megighian, Aram/G-6478-2014; Bergamin, Natascha/A-9315-2010; Sabatelli, Patrizia/C-7479-2019; Bernardi, Paolo/C-3656-2008; Braghetta, Paola/K-5478-2016; Columbaro, Marta/C-6960-2019; Merlini, Luciano/N-6478-2019; MEGIGHIAN, ARAM/I-8146-2019	Megighian, Aram/0000-0002-7971-5310; Sabatelli, Patrizia/0000-0003-2345-5094; Bernardi, Paolo/0000-0001-9187-3736; Braghetta, Paola/0000-0003-2547-8679; Merlini, Luciano/0000-0002-1108-1198; MEGIGHIAN, ARAM/0000-0002-7971-5310; Columbaro, Marta/0000-0002-4439-8976; Bonaldo, Paolo/0000-0002-9571-8140	Telethon [GP0229Y01, GGP02123] Funding Source: Medline	Telethon(Fondazione Telethon)		Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; Bowser DN, 2002, FASEB J, V16, P1105, DOI 10.1096/fj.01-0828fje; Bowser DN, 1998, BIOPHYS J, V75, P2004, DOI 10.1016/S0006-3495(98)77642-8; Camacho V.O., 2001, P NATL ACAD SCI USA, V98, P7516, DOI DOI 10.1073/PNAS.121027598; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Germinario E, 2002, J APPL PHYSIOL, V92, P2045, DOI 10.1152/japplphysiol.00673.2001; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Howell SJ, 1998, EXP CELL RES, V241, P230, DOI 10.1006/excr.1998.4051; Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Plant DR, 2002, J PHYSIOL-LONDON, V543, P169, DOI 10.1113/jphysiol.2002.022418; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Rossi R, 2001, AM J PHYSIOL-CELL PH, V281, pC585, DOI 10.1152/ajpcell.2001.281.2.C585; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; Tews DS, 2002, NEUROMUSCULAR DISORD, V12, P613, DOI 10.1016/S0960-8966(02)00030-5; TIMPL R, 1994, EXTRACELLULAR MATRIX, P208; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	26	383	392	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2003	35	4					367	371		10.1038/ng1270	http://dx.doi.org/10.1038/ng1270			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14625552				2022-12-25	WOS:000186791000019
J	Min-Oo, G; Fortin, A; Tam, MF; Nantel, A; Stevenson, MM; Gros, P				Min-Oo, G; Fortin, A; Tam, MF; Nantel, A; Stevenson, MM; Gros, P			Pyruvate kinase deficiency in mice protects against malaria	NATURE GENETICS			English	Article							PLASMODIUM-FALCIPARUM MALARIA; RECOMBINANT CONGENIC STRAINS; GENETIC-CONTROL; MOUSE MALARIA; SUSCEPTIBILITY; RESISTANCE; CELL; INFECTION; LOCUS; HOST	The global health impact of malaria is enormous, with an estimated 300-500 million clinical cases and 1 million annual deaths(1). In humans, initial susceptibility to infection with Plasmodium species, disease severity and ultimate outcome of malaria (self-healing or lethal) are under complex genetic control. Alleles associated with sickle cell anemia, beta-thalassemia and deficiency in glucose-6-phosphate dehydrogenase have a protective effect against malaria and may have been retained by positive selection in areas of endemic malaria(2). Likewise, genetic variations in erythrocyte antigens and levels of host cytokines affect type and severity of disease(3,4). A mouse model of infection with Plasmodium chabaudi was used to study the genetic component of malaria susceptibility. Segregation analyses in informative F-2 crosses derived from resistant C57BL/6J and susceptible A/J, C3H and SJL strains using extent of blood stage replication of the parasite and survival as traits mapped three P. chabaudi resistance ( Char) loci on chromosomes 9 (Char1), 8 (Char2) and 17 (Char3, MHC-linked)(5-7). Recombinant congenic strains AcB55 and AcB61 are unusually resistant to malaria despite carrying susceptibility alleles at Char1 and Char2. Malaria resistance in AcB55 and AcB61 is associated with splenomegaly and constitutive reticulocytosis, is inherited in an autosomal recessive fashion and is controlled by a locus on chromosome 3 (Char4)(8). Sequencing of candidate genes from the Char4 region identified a loss-of-function mutation (269T-->A, resulting in the amino acid substitution I90N) in the pyruvate kinase gene (Pklr) that underlies the malaria resistance in AcB55 and AcB61. These results suggest that pyruvate kinase deficiency may similarly protect humans against malaria.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Gen Hosp, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	McGill University; McGill University; National Research Council Canada	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Burt RA, 1999, IMMUNOGENETICS, V50, P278, DOI 10.1007/s002510050603; Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577; Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065; Foote SJ, 1997, NAT GENET, V17, P380, DOI 10.1038/ng1297-380; Fortin A, 1997, NAT GENET, V17, P382, DOI 10.1038/ng1297-382; Fortin A, 2002, GENES IMMUN, V3, P177, DOI 10.1038/sj.gene.6363841; Fortin A, 2002, HUM MOL GENET, V11, P2469, DOI 10.1093/hmg/11.20.2469; Fortin A, 2001, P NATL ACAD SCI USA, V98, P10793, DOI 10.1073/pnas.191288998; Fortin A, 2001, GENOMICS, V74, P21, DOI 10.1006/geno.2001.6528; Jacobasch G, 1996, MOL ASPECTS MED, V17, P143, DOI 10.1016/0098-2997(96)88345-2; Kemp SJ, 1997, NAT GENET, V16, P194, DOI 10.1038/ng0697-194; Lee SH, 2001, NAT GENET, V28, P42, DOI 10.1038/ng0501-42; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556; OELSHLEGEL FJ, 1975, NATURE, V255, P345, DOI 10.1038/255345a0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROTH E, 1990, BLOOD CELLS, V16, P453; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; SAMBROOK J, 2001, MOL CLONING LAB MANU, V1; STEVENSON MM, 1982, INFECT IMMUN, V38, P80, DOI 10.1128/IAI.38.1.80-88.1982; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; vanSolinge WW, 1997, BLOOD, V90, P1197; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Vladimirov V, 2003, INFECT IMMUN, V71, P2041, DOI 10.1128/IAI.71.4.2041-2046.2003; Weatherall D, 2002, GENES IMMUN, V3, P331, DOI 10.1038/sj.gene.6363878; WILLCOX M, 1983, ANN TROP MED PARASIT, V77, P239, DOI 10.1080/00034983.1983.11811704; Zanella A, 2000, BEST PRACT RES CL HA, V13, P57, DOI 10.1053/beha.1999.0057	29	96	99	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2003	35	4					357	362		10.1038/ng1260	http://dx.doi.org/10.1038/ng1260			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14595440				2022-12-25	WOS:000186791000017
J	Thornton, BR; Toczyski, DP				Thornton, BR; Toczyski, DP			Securin and B-cyclin/CDK are the only essential targets of the APC	NATURE CELL BIOLOGY			English	Letter							ANAPHASE-PROMOTING COMPLEX; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DEPENDENT PROTEOLYSIS; RE-REPLICATION; MITOTIC EXIT; KINASE; MITOSIS; DEGRADATION	The anaphase-promoting complex/cyclosome (APC) is a highly conserved ubiquitin ligase that controls passage through the cell cycle by targeting many proteins for proteolysis'. The complex is composed of at least thirteen core subunits(2), eight of which are essential(1,3-5), and two activating subunits, Cdc20 (essential) and Cdh1/Hct1 (non-essential)(6,7). Previously, it was not known which APC targets are sufficient to explain the essential nature of the complex. Here, we show that each of the eight normally essential APC subunits is rendered non-essential ('bypass-suppressed') by the simultaneous removal/inhibition of the APC substrates securin (Pds1) and B-type cyclin/CDK (Clb/CDK). In strains lacking the APC, levels of Clb2 and Clb3 remain constant, but Clb/CDK activity oscillates as cells cycle. This suggests that in the absence of B-type cyclin destruction, oscillation of the Clb/CDK-inhibitor Sic1 is sufficient to trigger the feedback loops necessary for the bi-stable nature of Clb/CDK activity. These results strongly suggest that securin and B-type cyclin/CDK activity are the only obligatory targets of the APC in Saccharomyces cerevisiae.	Univ Calif San Francisco, Canc Res Inst, Dept Biochem & Biophys S332, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Toczyski, DP (corresponding author), Univ Calif San Francisco, Canc Res Inst, Dept Biochem & Biophys S332, 2340 Sutter St, San Francisco, CA 94115 USA.	toczyski@cc.ucsf.edu			NIGMS NIH HHS [GM59691-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Blilou I, 2002, GENE DEV, V16, P2566, DOI 10.1101/gad.237302; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Geymonat M, 2002, CURR BIOL, V12, pR482, DOI 10.1016/S0960-9822(02)00963-6; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	30	144	149	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1090	1094		10.1038/ncb1066	http://dx.doi.org/10.1038/ncb1066			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634663				2022-12-25	WOS:000186892900015
J	Amsellem, S; Pflumio, F; Bardinet, D; Izac, B; Charneau, P; Romeo, PH; Dubart-Kupperschmitt, A; Fichelson, S				Amsellem, S; Pflumio, F; Bardinet, D; Izac, B; Charneau, P; Romeo, PH; Dubart-Kupperschmitt, A; Fichelson, S			Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein	NATURE MEDICINE			English	Article							NOD/SCID-REPOPULATING CELLS; IN-VIVO; PROGENITOR CELLS; EXPRESSION; HOMEODOMAIN; THROMBOPOIETIN; PROLIFERATION; PURIFICATION; RECEPTOR	Expansion of human hematopoietic stem cells (HSCs) is a major challenge in cellular therapy, and currently relies on the use of recombinant cytokines or on gene transfer of transcription factors. Of these, the HOXB4 homeoprotein protein is of particular interests as it promotes the expansion of mouse HSCs without inducing the development of leukemia. To eliminate any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes. Here we show that when cultured on stromal cells genetically engineered to secrete HOXB4, human long-term culture-initiating cells (LTC-ICs) and nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mouse repopulating cells (SRCs) were expanded by more than 20- and 2.5-fold, respectively, over their input numbers. This expansion was associated with enhanced stem cell repopulating capacity in vivo and maintenance of pluripotentiality. This method provides a basis for developing cell therapy strategies using expanded HSCs that are not genetically modified.	Univ Paris 05, Inst Cochin, Dept Hematol, CNRS UMR 8104,INSERM,U567, F-75014 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75015 Paris, France; Hop Cochin, AP HP, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Fichelson, S (corresponding author), Univ Paris 05, Inst Cochin, Dept Hematol, CNRS UMR 8104,INSERM,U567, 123 Bd Port Royal, F-75014 Paris, France.		Romeo, Paul-Henri/L-5989-2017; Dubart-Kupperschmitt, Anne/AAE-9408-2020; CHARNEAU, Pierre/M-1565-2017; Dubart-Kupperschmitt, Anne/G-8191-2015; Pflumio, Francoise/E-2074-2017	Romeo, Paul-Henri/0000-0002-8294-0367; Dubart-Kupperschmitt, Anne/0000-0002-9326-4413; CHARNEAU, Pierre/0000-0003-1184-5773; Dubart-Kupperschmitt, Anne/0000-0002-9326-4413; Pflumio, Francoise/0000-0001-8995-596X				[Anonymous], J MEC THEOR APPL; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; ISSAAD C, 1993, BLOOD, V81, P2916; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Maizel A, 1999, DEVELOPMENT, V126, P3183; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Woods NB, 2000, BLOOD, V96, P3725, DOI 10.1182/blood.V96.12.3725.h8003725_3725_3733; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	24	218	243	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1423	1427		10.1038/nm953	http://dx.doi.org/10.1038/nm953			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14578882				2022-12-25	WOS:000186319700035
J	Duchaud, E; Rusniok, C; Frangeul, L; Buchrieser, C; Givaudan, A; Taourit, S; Bocs, S; Boursaux-Eude, C; Chandler, M; Charles, JF; Dassa, E; Derose, R; Derzelle, S; Freyssinet, G; Gaudriault, S; Medigue, C; Lanois, A; Powell, K; Siguier, P; Vincent, R; Wingate, V; Zouine, M; Glaser, P; Boemare, N; Danchin, A; Kunst, F				Duchaud, E; Rusniok, C; Frangeul, L; Buchrieser, C; Givaudan, A; Taourit, S; Bocs, S; Boursaux-Eude, C; Chandler, M; Charles, JF; Dassa, E; Derose, R; Derzelle, S; Freyssinet, G; Gaudriault, S; Medigue, C; Lanois, A; Powell, K; Siguier, P; Vincent, R; Wingate, V; Zouine, M; Glaser, P; Boemare, N; Danchin, A; Kunst, F			The genome sequence of the entomopathogenic bacterium Photorhabdus luminescens	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; YERSINIA-PESTIS; EXTRACELLULAR LIPASE; GENE CLONING; XENORHABDUS; PURIFICATION; CLASSIFICATION; SECRETION; ELEMENTS; PROPOSAL	Photorhabdus luminescens is a symbiont of nematodes and a broad-spectrum insect pathogen. The complete genome sequence of strain TT01 is 5,688,987 base pairs (bp) long and contains 4,839 predicted protein-coding genes. Strikingly, it encodes a large number of adhesins, toxins, hemolysins, proteases and lipases, and contains a wide array of antibiotic synthesizing genes. These proteins are likely to play a role in the elimination of competitors, host colonization, invasion and bioconversion of the insect cadaver, making P. luminescens a promising model for the study of symbiosis and host-pathogen interactions. Comparison with the genomes of related bacteria reveals the acquisition of virulence factors by extensive horizontal transfer and provides clues about the evolution of an insect pathogen. Moreover, newly identified insecticidal proteins may be effective alternatives for the control of insect pests.	Inst Pasteur, Lab Genom Microorganismes Pathogenes, F-75724 Paris 15, France; Inst Pasteur, Genopole Plate Forme Integrat & Anal Genom, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Genomes Bacteriens, F-75724 Paris 15, France; Inst Pasteur, Unite Programmat Mol & Toxicol Genet, F-75724 Paris 15, France; Univ Montpellier 2, Lab EMIP, IFR122, Inst Natl Rech Agron,UMR 1133, F-34095 Montpellier 5, France; Genoscope CNRS UMR 8030, Atelier Genom Comparat, F-91006 Evry 15, France; CNRS, Lab Microbiol & Genet Mol, F-31062 Toulouse, France; Bayer CropSci, F-91058 Evry, France; Bayer CropSci, Res Triangle Pk, NC 27709 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Bayer AG; Bayer CropScience; Bayer AG; Bayer CropScience	Kunst, F (corresponding author), Inst Pasteur, Lab Genom Microorganismes Pathogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	fkunst@pasteur.fr	Frangeul, Lionel/G-3617-2015; , Gaudriault/AAK-9152-2021; Glaser, Philippe/O-2641-2015	, Gaudriault/0000-0003-2789-4959; Glaser, Philippe/0000-0003-4156-2782; Derzelle, Sylviane/0000-0002-2302-2291; Buchrieser, Carmen/0000-0003-3477-9190; Chandler, Michael/0000-0002-0292-6662; Siguier, Patricia/0000-0003-1620-6495; Lionel, Frangeul/0000-0002-0992-8775; Danchin, Antoine/0000-0002-6350-5001				Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; AKATSUKA H, 1994, J BACTERIOL, V176, P1949, DOI 10.1128/jb.176.7.1949-1956.1994; AVICHEZER D, 1992, J BIOL CHEM, V267, P23023; Basset A, 2003, EMBO REP, V4, P205, DOI 10.1038/sj.embor.embor730; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; BOEMARE NE, 1993, INT J SYST BACTERIOL, V43, P249, DOI 10.1099/00207713-43-2-249; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Bowen D, 2000, INSECT BIOCHEM MOLEC, V30, P69, DOI 10.1016/S0965-1748(99)00098-3; Brillard J, 2002, J BACTERIOL, V184, P3871, DOI 10.1128/JB.184.14.3871-3878.2002; Buchrieser C, 1999, INFECT IMMUN, V67, P4851, DOI 10.1128/IAI.67.9.4851-4861.1999; Caldas C, 2002, APPL ENVIRON MICROB, V68, P1297, DOI 10.1128/AEM.68.3.1297-1304.2002; Choo DW, 1998, APPL ENVIRON MICROB, V64, P486; Ciche TA, 2001, J BACTERIOL, V183, P3117, DOI 10.1128/JB.183.10.3117-3126.2001; Daborn PJ, 2002, P NATL ACAD SCI USA, V99, P10742, DOI 10.1073/pnas.102068099; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; DUCHAUD E, 2002, Patent No. 0301238; Ffrench-Constant R, 2003, FEMS MICROBIOL REV, V26, P433, DOI 10.1111/j.1574-6976.2003.tb00625.x; Ffrench-Constant RH, 2000, APPL ENVIRON MICROB, V66, P3310, DOI 10.1128/AEM.66.8.3310-3329.2000; Fischer-Le Saux M, 1999, INT J SYST BACTERIOL, V49, P1645, DOI 10.1099/00207713-49-4-1645; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Forst S, 1997, ANNU REV MICROBIOL, V51, P47, DOI 10.1146/annurev.micro.51.1.47; Frangeul L, 1999, MICROBIOL-SGM, V145, P2625, DOI 10.1099/00221287-145-10-2625; FRANGEUL L, IN PRESS BIOINFORMAT; Fullner KJ, 2000, EMBO J, V19, P5315, DOI 10.1093/emboj/19.20.5315; Gustavsson A, 2002, J CELL SCI, V115, P2669; Hinnebusch BJ, 2002, SCIENCE, V296, P733, DOI 10.1126/science.1069972; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; Joyce SA, 2003, MOL MICROBIOL, V47, P1445, DOI 10.1046/j.1365-2958.2003.03389.x; LI XY, 1995, APPL ENVIRON MICROB, V61, P2674, DOI 10.1128/AEM.61.7.2674-2680.1995; Marokhazi J, 2003, J BACTERIOL, V185, P4648, DOI 10.1128/JB.185.15.4648-4656.2003; Miller VL, 2001, MOL MICROBIOL, V41, P1053, DOI 10.1046/j.1365-2958.2001.02575.x; Minet AD, 2000, GENE, V257, P87, DOI 10.1016/S0378-1119(00)00388-7; Moellenbeck DJ, 2001, NAT BIOTECHNOL, V19, P668, DOI 10.1038/90282; NAGAMATSU T, 1993, CHEM PHARM BULL, V41, P362, DOI 10.1248/cpb.41.362; O'Neill KH, 2002, J BACTERIOL, V184, P3096, DOI 10.1128/JB.184.11.3096-3105.2002; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Schmiel DH, 1998, INFECT IMMUN, V66, P3941, DOI 10.1128/IAI.66.8.3941-3951.1998; Sha J, 2002, INFECT IMMUN, V70, P1924, DOI 10.1128/IAI.70.4.1924-1935.2002; Sharma S, 2002, FEMS MICROBIOL LETT, V214, P241, DOI 10.1111/j.1574-6968.2002.tb11354.x; Srimanote P, 2002, INFECT IMMUN, V70, P3094, DOI 10.1128/IAI.70.6.3094-3100.2002; Thaler JO, 1998, APPL ENVIRON MICROB, V64, P2367; Valens M, 2002, MICROBIOL-SGM, V148, P2427, DOI 10.1099/00221287-148-8-2427; Vermunt AMW, 1998, INSECT MOL BIOL, V7, P327, DOI 10.1046/j.1365-2583.1998.740327.x; Waterfield NR, 2002, TRENDS MICROBIOL, V10, P541, DOI 10.1016/S0966-842X(02)02463-0; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Wong EFS, 1996, J BIOL CHEM, V271, P16399, DOI 10.1074/jbc.271.27.16399; XU SY, 1994, BIOTECHNIQUES, V17, P57; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhao H, 1997, MOL MICROBIOL, V23, P1009, DOI 10.1046/j.1365-2958.1997.2791645.x	50	464	1241	3	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1307	1313		10.1038/nbt886	http://dx.doi.org/10.1038/nbt886			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14528314	Green Published, hybrid			2022-12-25	WOS:000186320000031
J	Repping, S; Skaletsky, H; Brown, L; van Daalen, SKM; Korver, CM; Pyntikova, T; Kuroda-Kawaguchi, T; de Vries, JWA; Oates, RD; Silber, S; van der Veen, F; Page, DC; Rozen, S				Repping, S; Skaletsky, H; Brown, L; van Daalen, SKM; Korver, CM; Pyntikova, T; Kuroda-Kawaguchi, T; de Vries, JWA; Oates, RD; Silber, S; van der Veen, F; Page, DC; Rozen, S			Polymorphism for a 1.6-Mb deletion of the human Y chromosome persists through balance between recurrent mutation and haploid selection	NATURE GENETICS			English	Article							INTRACHROMOSOMAL RECOMBINATION; HUMAN-POPULATIONS; INFERTILE MEN; COPY NUMBER; AZFC REGION; DAZ GENES; MICRODELETIONS; MARKER; MALES; YQ11	Many human Y-chromosomal deletions are thought to severely impair reproductive fitness, which precludes their transmission to the next generation and thus ensures their rarity in the population. Here we report a 1.6-Mb deletion that persists over generations and is sufficiently common to be considered a polymorphism. We hypothesized that this deletion might affect spermatogenesis because it removes almost half of the Y chromosome's AZFc region, a gene-rich segment that is critical for sperm production(1,2). An association study established that this deletion, called gr/gr, is a significant risk factor for spermatogenic failure. The gr/gr deletion has far lower penetrance with respect to spermatogenic failure than previously characterized Y-chromosomal deletions; it is often transmitted from father to son. By studying the distribution of gr/gr-deleted chromosomes across the branches of the Y chromosome's genealogical tree, we determined that this deletion arose independently at least 14 times in human history. We suggest that the existence of this deletion as a polymorphism reflects a balance between haploid selection, which culls gr/gr-deleted Y chromosomes from the population, and homologous recombination, which continues to generate new gr/gr deletions.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, Dept Obstet & Gynecol, NL-1105 AZ Amsterdam, Netherlands; Ichikawa Gen Hosp, Tokyo Dent Coll, Reprod Ctr, Chiba, Japan; Boston Univ, Med Ctr, Dept Urol, Boston, MA 02118 USA; St Lukes Hosp, Infertil Ctr, St Louis, MO 63017 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Amsterdam; Academic Medical Center Amsterdam; Tokyo Dental College; Boston University; Saint Luke's Hospital - Missouri	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	; Rozen, Steven G./J-5939-2013	Oates, Robert/0000-0003-2330-6697; Rozen, Steven G./0000-0002-4288-0056; Repping, Sjoerd/0000-0002-6959-149X				Bienvenu T, 2001, ANN GENET-PARIS, V44, P125, DOI 10.1016/S0003-3995(01)01078-4; Blanco P, 2000, J MED GENET, V37, P752, DOI 10.1136/jmg.37.10.752; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; de Vries JWA, 2002, FERTIL STERIL, V77, P68, DOI 10.1016/S0015-0282(01)02935-1; Ellis N, 2002, GENOME RES, V12, P339; Ewis AA, 2002, J HUM GENET, V47, P257, DOI 10.1007/s100380200035; Fernandes S, 2002, MOL HUM REPROD, V8, P286, DOI 10.1093/molehr/8.3.286; Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403; Hammer MF, 2001, MOL BIOL EVOL, V18, P1189, DOI 10.1093/oxfordjournals.molbev.a003906; Jobling MA, 1996, HUM MOL GENET, V5, P1767, DOI 10.1093/hmg/5.11.1767; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; Kamp C, 2000, HUM MOL GENET, V9, P2563, DOI 10.1093/hmg/9.17.2563; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Ke YH, 2001, SCIENCE, V292, P1151, DOI 10.1126/science.1060011; Kuroki Y, 1999, J HUM GENET, V44, P289, DOI 10.1007/s100380050162; Oates RD, 2002, HUM REPROD, V17, P2813, DOI 10.1093/humrep/17.11.2813; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Repping S, 2002, AM J HUM GENET, V71, P906, DOI 10.1086/342928; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Soucie JM, 1998, AM J HEMATOL, V59, P288, DOI 10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I; Sun C, 2000, HUM MOL GENET, V9, P2291, DOI 10.1093/oxfordjournals.hmg.a018920; Tilford CA, 2001, NATURE, V409, P943, DOI 10.1038/35057170; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; World Health Organization, 1992, WHO LAB MAN EX HUM S; Yen P, 2001, NAT GENET, V29, P243, DOI 10.1038/ng1101-243	28	308	333	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					247	251		10.1038/ng1250	http://dx.doi.org/10.1038/ng1250			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14528305				2022-12-25	WOS:000186273300020
J	Wang, XF; Zhou, CX; Shi, QX; Yuan, YY; Yu, MK; Ajonuma, LC; Ho, LS; Lo, PS; Tsang, LL; Liu, Y; Lam, SY; Chan, LN; Zhao, WC; Chung, YW; Chan, HC				Wang, XF; Zhou, CX; Shi, QX; Yuan, YY; Yu, MK; Ajonuma, LC; Ho, LS; Lo, PS; Tsang, LL; Liu, Y; Lam, SY; Chan, LN; Zhao, WC; Chung, YW; Chan, HC			Involvement of CFTR in uterine bicarbonate secretion and the fertilizing capacity of sperm	NATURE CELL BIOLOGY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; MOUSE SPERMATOZOA; CERVICAL MUCUS; HCO3; EXPRESSION; ION; INFERTILITY; EPITHELIUM; TRANSPORT	Cystic fibrosis transmembrane conductance regulator ( CFTR) is a cAMP-activated chloride channel expressed in a wide variety of epithelial cells, mutations of which are responsible for the hallmark defective chloride secretion observed in cystic fibrosis (CF). Although CFTR has been implicated in bicarbonate secretion, its ability to directly mediate bicarbonate secretion of any physiological significance has not been shown. We demonstrate here that endometrial epithelial cells possess a CFTR-mediated bicarbonate transport mechanism. Co-culture of sperm with endometrial cells treated with antisense oligonucleotide against CFTR, or with bicarbonate secretion-defective CF epithelial cells, resulted in lower sperm capacitation and egg-fertilizing ability. These results are consistent with a critical role of CFTR in controlling uterine bicarbonate secretion and the fertilizing capacity of sperm, providing a link between defective CFTR and lower female fertility in CF.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res, Shatin, Hong Kong, Peoples R China; Zhejiang Acad Med Sci, Hangzhou 310013, Peoples R China	Chinese University of Hong Kong; Zhejiang Academy of Medical Sciences	Chan, HC (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res, Shatin, Hong Kong, Peoples R China.		Chan, Hsiao Chang/E-1507-2016					Chan HC, 1997, BBA-MOL CELL RES, V1356, P140, DOI 10.1016/S0167-4889(96)00171-1; Chan LN, 2002, J MEMBRANE BIOL, V185, P165, DOI 10.1007/s00232-001-0117-y; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Cheng HS, 1998, J MEMBRANE BIOL, V164, P155, DOI 10.1007/s002329900401; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Epelboin S, 2001, FERTIL STERIL, V76, P1280, DOI 10.1016/S0015-0282(01)02896-5; FRASER LR, 1983, J REPROD FERTIL, V69, P419, DOI 10.1530/jrf.0.0690419; Hug MJ, 2003, NEWS PHYSIOL SCI, V18, P38, DOI 10.1152/nips.01412.2002; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; KOPITO LE, 1973, FERTIL STERIL, V24, P512; MADDEN ME, 1988, PANCREAS, V3, P512, DOI 10.1097/00006676-198810000-00003; OPPENHEIMER EA, 1970, AM J OBSTET GYNECOL, V108, P673; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Quinton PM, 2001, NAT MED, V7, P292, DOI 10.1038/85429; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Schultz BD, 1999, PHYSL REV S, V79, P109; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SHI QX, 1995, BIOL REPROD, V52, P540, DOI 10.1095/biolreprod52.3.540; TIZZANO EF, 1994, AM J PATHOL, V144, P906; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Visconti PE, 1998, J ANDROL, V19, P242; VISHWAKARMA P, 1962, FERTIL STERIL, V13, P481; Wang XF, 2002, BIOL REPROD, V66, P1846, DOI 10.1095/biolreprod66.6.1846; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8	25	90	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					902	906		10.1038/ncb1047	http://dx.doi.org/10.1038/ncb1047			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14515130				2022-12-25	WOS:000185647400016
J	Woodruff, ML; Wang, ZY; Chung, HY; Redmond, TM; Fain, GL; Lem, J				Woodruff, ML; Wang, ZY; Chung, HY; Redmond, TM; Fain, GL; Lem, J			Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis	NATURE GENETICS			English	Article							PIGMENT ACTIVATES TRANSDUCTION; EQUIVALENT-LIGHT HYPOTHESIS; VITAMIN-A; VISUAL PIGMENT; MOUSE MODEL; RETINITIS-PIGMENTOSA; SALAMANDER RODS; BINDING PROTEIN; NIGHT BLINDNESS; RPE65 GENE	Mutations in Rpe65 disrupt synthesis of the opsin chromophore ligand 11-cis- retinal and cause Leber congenital amaurosis (LCA), a severe, early-onset retinal dystrophy. To test whether light-independent signaling by unliganded opsin causes the degeneration, we used Rpe65 - null mice, a model of LCA. Dark-adapted Rpe65(-/-) mice behaved as if light adapted, exhibiting reduced circulating current, accelerated response turn-off, and diminished intracellular calcium. A genetic block of transducin signaling completely rescued degeneration irrespective of an elevated level of retinyl ester. These studies clearly show that activation of sensory transduction by unliganded opsin, and not the accumulation of retinyl esters, causes light-independent retinal degeneration in LCA. A similar mechanism may also be responsible for degeneration induced by vitamin A deprivation.	Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Genet Program, Boston, MA 02111 USA; Tufts Univ, Sch Med, Tufts Ctr Vis Res, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of California System; University of California Los Angeles; Tufts University; Tufts University	Lem, J (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 5045, Boston, MA 02111 USA.			Redmond, T. Michael/0000-0002-1813-5291; Fain, Gordon/0000-0002-9813-0342	NATIONAL EYE INSTITUTE [ZIAEY000260, Z01EY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CARTERDAWSON L, 1986, DEV BIOL, V116, P431, DOI 10.1016/0012-1606(86)90144-2; CERVETTO L, 1986, J PHYSIOL-LONDON, V370, P91, DOI 10.1113/jphysiol.1986.sp015924; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; CORNWALL MC, 1995, J GEN PHYSIOL, V106, P543, DOI 10.1085/jgp.106.3.543; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; Fain GL, 1999, INVEST OPHTH VIS SCI, V40, P2770; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Felius J, 2002, ARCH OPHTHALMOL-CHIC, V120, P55; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984; Jin SN, 2003, NAT NEUROSCI, V6, P731, DOI 10.1038/nn1070; JONES GJ, 1993, J GEN PHYSIOL, V102, P483, DOI 10.1085/jgp.102.3.483; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Matthews HR, 2002, J PHYSIOL-LONDON, V542, P829, DOI 10.1113/jphysiol.2001.013218; MATTHEWS HR, IN PRESS J PHYSL; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Mendez A, 2003, J NEUROSCI, V23, P3124; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Rohrer B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/iovs.02-0567; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Surya A, 1997, J BIOL CHEM, V272, P21745, DOI 10.1074/jbc.272.35.21745; TANG G, 1993, J NUTR BIOCHEM, V4, P58, DOI 10.1016/0955-2863(93)90021-N; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987	42	149	154	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					158	164		10.1038/ng1246	http://dx.doi.org/10.1038/ng1246			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	14517541				2022-12-25	WOS:000185625300012
J	Benson, KF; Li, FQ; Person, RE; Albani, D; Duan, ZJ; Wechsler, J; Meade-White, K; Williams, K; Acland, GM; Niemeyer, G; Lothrop, CD; Horwitz, M				Benson, KF; Li, FQ; Person, RE; Albani, D; Duan, ZJ; Wechsler, J; Meade-White, K; Williams, K; Acland, GM; Niemeyer, G; Lothrop, CD; Horwitz, M			Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase	NATURE GENETICS			English	Article							HERMANSKY-PUDLAK-SYNDROME; CATHEPSIN-G; BETA-3A SUBUNIT; SORTING SIGNALS; PROTEIN COMPLEX; AP-3 ADAPTER; DISTINCT; IDENTIFICATION; TRAFFICKING; MEMBRANES	Cyclic hematopoiesis is a stem cell disease in which the number of neutrophils and other blood cells oscillates in weekly phases. Autosomal dominant mutations of ELA2, encoding the protease neutrophil elastase(1), found in lysosome-like granules, cause cyclic hematopoiesis(2) and most cases of the pre-leukemic disorder severe congenital neutropenia (SCN; ref. 3) in humans. Over 20 different mutations of neutrophil elastase have been identified, but their consequences are elusive, because they confer no consistent effects on enzymatic activity(4). The similar autosomal recessive disease of dogs, canine cyclic hematopoiesis(5), is not caused by mutations in ELA2 ( data not shown). Here we show that homozygous mutation of the gene encoding the dog adaptor protein complex 3 (AP3) beta-subunit, directing trans-Golgi export of transmembrane cargo proteins to lysosomes, causes canine cyclic hematopoiesis. C-terminal processing of neutrophil elastase exposes an AP3 interaction signal responsible for redirecting neutrophil elastase trafficking from membranes to granules. Disruption of either neutrophil elastase or AP3 perturbs the intracellular trafficking of neutrophil elastase. Most mutations in ELA2 that cause human cyclic hematopoiesis prevent membrane localization of neutrophil elastase, whereas most mutations in ELA2 that cause SCN lead to exclusive membrane localization.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA; Auburn Univ, Coll Vet Med, Auburn, AL 36849 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cornell University; Auburn University System; Auburn University	Horwitz, M (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, Box 357720,1705 NE Pacific St,HSB-K236B, Seattle, WA 98195 USA.	horwitz@u.washington.edu		Horwitz, Marshall/0000-0002-1683-1680				Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; ALLEN DH, 1995, J BIOL CHEM, V270, P1408, DOI 10.1074/jbc.270.3.1408; Bainton DF, 1999, J IMMUNOL METHODS, V232, P153, DOI 10.1016/S0022-1759(99)00173-8; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P54; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CLARK JM, 1980, J CELL BIOL, V84, P102, DOI 10.1083/jcb.84.1.102; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; FUKS A, 1983, BIOCHIM BIOPHYS ACTA, V755, P195, DOI 10.1016/0304-4165(83)90203-9; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Horwitz M, 2003, CURR OPIN HEMATOL, V10, P49, DOI 10.1097/00062752-200301000-00008; Huizing M, 2002, PEDIATR RES, V51, P150, DOI 10.1203/00006450-200202000-00006; Kaup M, 2002, BIOL CHEM, V383, P1011, DOI 10.1515/BC.2002.108; KJELDSEN L, 1993, BLOOD, V82, P3183; Kolkenbrock H, 2000, BIOL CHEM, V381, P49, DOI 10.1515/BC.2000.007; Li FQ, 2001, J BIOL CHEM, V276, P14230, DOI 10.1074/jbc.M010279200; LOTHROP CD, 1987, ENDOCRINOLOGY, V120, P1027, DOI 10.1210/endo-120-3-1027; Mardones G, 2003, J IMMUNOL METHODS, V275, P169, DOI 10.1016/S0022-1759(03)00015-2; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; PAIGEN K, 1989, PROG NUCLEIC ACID RE, V37, P155; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Vita F, 1996, EXP CELL RES, V227, P367, DOI 10.1006/excr.1996.0286; Yang W, 2000, J CELL SCI, V113, P4077	29	129	133	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2003	35	1					90	96		10.1038/ng1224	http://dx.doi.org/10.1038/ng1224			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12897784				2022-12-25	WOS:000185018500016
J	Olsson, B; Andersson, PO; Jernas, M; Jacobsson, S; Carlsson, B; Carlsson, LMS; Wadenvik, H				Olsson, B; Andersson, PO; Jernas, M; Jacobsson, S; Carlsson, B; Carlsson, LMS; Wadenvik, H			T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura	NATURE MEDICINE			English	Article							AUTOANTIBODIES; ANTIBODIES; RECEPTORS	Chronic idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder that is characterized by increased platelet destruction and is believed to be autoantibody mediated. In this study, CD3(+) T cells from ITP patients had increased expression of genes involved in cell-mediated cytotoxicity. In addition, cytotoxic cell-mediated lysis of autologous platelets was shown in active ITP. Our data suggest that T-cell-mediated cytotoxicity is an alternative mechanism for platelet destruction in ITP.	Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, Sect Hematol & Coagulat, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Andersson, PO (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, Sect Hematol & Coagulat, SE-41345 Gothenburg, Sweden.		Carlsson, Lena/F-7570-2018	Carlsson, Lena/0000-0003-4145-6242; Olsson, Bob/0000-0002-6368-6172				BERCHTOLD P, 1993, BLOOD, V81, P1246; Boyington JC, 2001, IMMUNOL REV, V181, P66, DOI 10.1034/j.1600-065X.2001.1810105.x; Brighton TA, 1996, BLOOD, V88, P194; Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; Hopkins Leann M., 2002, Human Immunology, V63, pS5, DOI 10.1016/S0198-8859(02)00534-7; IMBACH P, 1991, J PEDIATR-US, V118, P535, DOI 10.1016/S0022-3476(05)83373-6; OZSOYLU S, 1991, AM J HEMATOL, V36, P82, DOI 10.1002/ajh.2830360203; Semple JW, 1996, BLOOD, V87, P4245, DOI 10.1182/blood.V87.10.4245.bloodjournal87104245; Stockelberg D, 1996, EUR J HAEMATOL, V56, P72; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Warner MN, 1999, BRIT J HAEMATOL, V104, P442, DOI 10.1046/j.1365-2141.1999.01218.x	12	471	519	0	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1123	1124		10.1038/nm921	http://dx.doi.org/10.1038/nm921			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937414				2022-12-25	WOS:000185061600022
J	Oikawa, T; Yamaguchi, H; Itoh, T; Kato, M; Ijuin, T; Yamazaki, D; Suetsugu, S; Takenawa, T				Oikawa, T; Yamaguchi, H; Itoh, T; Kato, M; Ijuin, T; Yamazaki, D; Suetsugu, S; Takenawa, T			PtdIns(3,4,5)P-3 binding is necessary for WAVE2-induced formation of lamellipodia	NATURE CELL BIOLOGY			English	Letter							CELL-MIGRATION; RHO GTPASES; NEUTROPHIL CHEMOTAXIS; ACTIN-FILAMENTS; DISTINCT ROLES; KEY MOLECULES; RAC; POLARITY; WAVE; ACTIVATION	Polarized cell movement is triggered by the development of a PtdIns(3,4,5)P-3 gradient at the membrane, which is followed by rearrangement of the actin cytoskeleton. The WASP family verprolin homologous protein (WAVE) is essential for lamellipodium formation at the leading edge by activating the Arp2/3 complex downstream of Rac GTPase. Here, we report that WAVE2 binds to Ptdlns(3,4,5)P-3 through its basic domain. The amino-terminal portion of WAVE2, which includes the Ptdlns(3,4,5)P-3-binding sequence, was localized at the leading edge of lamellipodia induced by an active form of Rac (RacDA) or by treatment with platelet-derived growth factor (PDGF). Production of Ptdlns(3,4,5)P-3 at the cell membrane by myristoylated phosphatidylinositol-3-OH kinase (PION is sufficient to recruit WAVE2 in the presence of dominant-negative Rac and latrunculin, demonstrating that Ptdlns(3,4,5)P-3 alone is able to recruit WAVE2. Expression of a full-length mutant of WAVE2 that lacks the lipid-binding activity inhibited proper formation of lamellipodia induced by RacDA. These results suggest that one of the products of PI(3)K, Ptdlns(3,4,5)P-3, recruits WAVE2 to the polarized membrane and that this recruitment is essential for lamellipodium formation at the leading edge.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Canc Gen, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Suetsugu, Shiro/B-3300-2010; Oikawa, Tsukasa/B-7718-2013; Suetsugu, Shiro/ABB-6033-2020; Ijuin, Takeshi/H-7016-2017; Suetsugu, Shiro/AAF-4427-2019	Suetsugu, Shiro/0000-0002-4612-0628; Oikawa, Tsukasa/0000-0003-2694-2699; Ijuin, Takeshi/0000-0002-0618-1776; Suetsugu, Shiro/0000-0002-4612-0628; Yamaguchi, Hideki/0000-0003-2125-9655				Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Cross GH, 2003, BIOSENS BIOELECTRON, V19, P383, DOI 10.1016/S0956-5663(03)00203-3; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Takenawa T, 2001, J CELL SCI, V114, P1801; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; Wang JX, 2002, INT J MOL SCI, V3, P4, DOI 10.3390/i3010004; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350	30	184	185	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					420	+		10.1038/ncb1125	http://dx.doi.org/10.1038/ncb1125			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15107862				2022-12-25	WOS:000221432600012
J	He, ZN; Russell, JE				He, ZN; Russell, JE			Antisickling effects of an endogenous human alpha-like globin	NATURE MEDICINE			English	Article							EMBRYONIC ZETA-GLOBIN; NF-KAPPA-B; GENE; EXPRESSION; PROMOTER; CHAINS	Gene replacement or gene reactivation therapies for sickle-cell disease (SCD) typically target the mutant beta(S)-globin subunits of hemoglobin-S (alpha(2)beta(2)(S)) for substitution by nonpathological beta-like globins. Here we show, in vitro and in vivo in a transgenic mouse model of SCD, that the adverse properties of hemoglobin-S can be reversed by exchanging its normal alpha-globin subunits for zeta-globin, an endogenous, developmentally silenced, non-beta-like globin.	Univ Penn, Sch Med, Dept Med Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat Hematol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Russell, JE (corresponding author), Univ Penn, Sch Med, Dept Med Hematol Oncol, Philadelphia, PA 19104 USA.	jeruss@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067118, R01HL061399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61399, HL67118, R01 HL067118, R01 HL061399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bunn H, 1986, HEMOGLOBIN MOL GENET, P502; Chang J, 1996, BLOOD, V88, P1846; CHUI DHK, 1986, NEW ENGL J MED, V314, P76, DOI 10.1056/NEJM198601093140203; EDELSTEIN SJ, 1981, J MOL BIOL, V150, P557, DOI 10.1016/0022-2836(81)90381-8; HE Z, 2002, ANAL BIOCHEM, P349; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; Liu JJ, 2003, J BIOL CHEM, V278, P19534, DOI 10.1074/jbc.M212278200; PAPAYANNOPOULOU T, 1991, BLOOD, V77, P2569; PASTZY C, 1997, SCIENCE, V278, P876; TANG WZ, 1993, BLOOD, V81, P1636; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218	12	13	13	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					365	367		10.1038/nm1022	http://dx.doi.org/10.1038/nm1022			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034572				2022-12-25	WOS:000220587000026
J	Li, A; Blow, JJ				Li, A; Blow, JJ			Non-proteolytic inactivation of geminin requires CDK-dependent ubiquitination.	NATURE CELL BIOLOGY			English	Article							REPLICATION LICENSING SYSTEM; XENOPUS EGG EXTRACTS; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE REGULATION; DNA-REPLICATION; INHIBITOR; DESTRUCTION; INITIATION; COMPONENT; PROTEINS	In late mitosis and G1, a complex of the essential initiation proteins Mcm2-7 are assembled onto replication origins to 'license' them for initiation. At other times licensing is inhibited by cyclin-dependent kinases (CDKs) and geminin, thus ensuring that origins fire only once per cell cycle. Here we show that, paradoxically, CDKs are also required to inactivate geminin and activate the licensing system. On exit from metaphase in Xenopus laevis egg extracts, CDK-dependent activation of the anaphase-promoting complex (APC/C) results in the transient polyubiquitination of geminin. This ubiquitination triggers geminin inactivation without requiring ubiquitin-dependent proteolysis, and is essential for replication origins to become licensed. This reveals an unexpected role for CDKs and ubiquitination in activating chromosomal DNA replication.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.	j.j.blow@dundee.ac.uk	Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849	Cancer Research UK [A3135] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Bach I, 2003, TRENDS BIOCHEM SCI, V28, P189, DOI 10.1016/S0968-0004(03)00055-0; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Chong JPJ, 1997, METHOD ENZYMOL, V283, P549; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishiyama A, 2000, GENE DEV, V14, P2344, DOI 10.1101/gad.823200; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	30	66	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					260	267		10.1038/ncb1100	http://dx.doi.org/10.1038/ncb1100			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	14767479	Green Accepted			2022-12-25	WOS:000189363000018
J	Nagaki, K; Cheng, ZK; Ouyang, S; Talbert, PB; Kim, M; Jones, KM; Henikoff, S; Buell, CR; Jiang, JM				Nagaki, K; Cheng, ZK; Ouyang, S; Talbert, PB; Kim, M; Jones, KM; Henikoff, S; Buell, CR; Jiang, JM			Sequencing of a rice centromere uncovers active genes	NATURE GENETICS			English	Article							CENP-A; CHROMATIN IMMUNOPRECIPITATION; TRANSPOSABLE ELEMENT; SATELLITE REPEAT; DNA ELEMENT; ORGANIZATION; NEOCENTROMERE; KINETOCHORE; REGIONS; COMPLEX	Centromeres are the last frontiers of complex eukaryotic genomes, consisting of highly repetitive sequences that resist mapping, cloning and sequencing. The centromere of rice Chromosome 8 (Cen8) has an unusually low abundance of highly repetitive satellite DNA, which allowed us to determine its sequence. A region of similar to750 kb in Cen8 binds rice CENH3, the centromere-specific H3 histone. CENH3 binding is contained within a larger region that has abundant dimethylation of histone H3 at Lys9 (H3-Lys9), consistent with Cen8 being embedded in heterochromatin. Fourteen predicted and at least four active genes are interspersed in Cen8, along with CENH3 binding sites. The retrotransposons located in and outside of the CENH3 binding domain have similar ages and structural dynamics. These results suggest that Cen8 may represent an intermediate stage in the evolution of centromeres from genic regions, as in human neocentromeres, to fully mature centromeres that accumulate megabases of homogeneous satellite arrays.	Inst Genom Res, Rockville, MD 20850 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	J. Craig Venter Institute; University of Wisconsin System; University of Wisconsin Madison; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buell, CR (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	rbuell@tigr.org; jjiang1@wisc.edu	Nagaki, Kiyotaka/B-2519-2011; Jiang, Jiming/V-6060-2019; Jiang, Jiming/A-9614-2009	Jiang, Jiming/0000-0002-6435-6140; Jiang, Jiming/0000-0002-6435-6140; Buell, C Robin/0000-0002-6727-4677; Henikoff, Steven/0000-0002-7621-8685				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Cheng ZK, 2002, PLANT CELL, V14, P1691, DOI 10.1105/tpc.003079; Cheng ZK, 2001, CHROMOSOMA, V110, P24, DOI 10.1007/s004120000126; CHLEBOWICZSLEDZIEWSKA E, 1985, GENE, V39, P25, DOI 10.1016/0378-1119(85)90103-9; Choo KHA, 2001, DEV CELL, V1, P165, DOI 10.1016/S1534-5807(01)00028-4; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; DEVLIN RH, 1990, GENETICS, V125, P129; Dong FG, 1998, P NATL ACAD SCI USA, V95, P8135, DOI 10.1073/pnas.95.14.8135; Gaut BS, 1996, P NATL ACAD SCI USA, V93, P10274, DOI 10.1073/pnas.93.19.10274; Gindullis F, 2001, GENOME RES, V11, P253, DOI 10.1101/gr.162301; Greil F, 2003, GENE DEV, V17, P2825, DOI 10.1101/gad.281503; Hosouchi T, 2002, DNA RES, V9, P117, DOI 10.1093/dnares/9.4.117; Hudakova S, 2001, NUCLEIC ACIDS RES, V29, P5029, DOI 10.1093/nar/29.24.5029; Jiang JM, 1996, P NATL ACAD SCI USA, V93, P14210, DOI 10.1073/pnas.93.24.14210; Kaszas E, 1998, GENETICS, V150, P1683; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; Lo AWI, 2001, GENOME RES, V11, P448, DOI 10.1101/gr.GR-1676R; Lo AWI, 2001, EMBO J, V20, P2087, DOI 10.1093/emboj/20.8.2087; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Malik HS, 2002, CURR OPIN GENET DEV, V12, P711, DOI 10.1016/S0959-437X(02)00351-9; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Motohashi R, 1996, MOL GEN GENET, V250, P148, DOI 10.1007/BF02174173; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Nagaki K, 2003, GENETICS, V163, P1221; Nagaki K, 2003, GENETICS, V163, P759; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PEREIRA A, 1986, EMBO J, V5, P835, DOI 10.1002/j.1460-2075.1986.tb04292.x; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Saffery R, 2003, MOL CELL, V12, P509, DOI 10.1016/S1097-2765(03)00279-X; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; Satinover DL, 2001, CHROMOSOMA, V110, P275, DOI 10.1007/s004120100143; Schueler MG, 2001, SCIENCE, V294, P109, DOI 10.1126/science.1065042; Sun XP, 2003, GENOME RES, V13, P182, DOI 10.1101/gr.681703; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Talbert PB, 2002, PLANT CELL, V14, P1053, DOI 10.1105/tpc.010425; TALBERT PB, 2000, ANN DROS RES C, V41, pC247; Tolchkov EV, 2000, GENETICS, V154, P1611; Tyler-Smith C, 1999, AM J HUM GENET, V64, P1440, DOI 10.1086/302380; Vafa O, 1999, CHROMOSOMA, V108, P367, DOI 10.1007/s004120050388; Ventura M, 2001, GENOME RES, V11, P595, DOI 10.1101/gr.152101; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wong LH, 2001, GENOME RES, V11, P513, DOI 10.1101/gr.183901; Wu JZ, 2002, PLANT CELL, V14, P525, DOI 10.1105/tpc.010274; Yu HG, 1997, J CELL BIOL, V139, P831, DOI 10.1083/jcb.139.4.831; Yuan Q, 2002, MOL GENET GENOMICS, V267, P713, DOI 10.1007/s00438-002-0706-1; Zhong CX, 2002, PLANT CELL, V14, P2825, DOI 10.1105/tpc.006106; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	50	411	455	2	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					138	145		10.1038/ng1289	http://dx.doi.org/10.1038/ng1289			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14716315	Bronze			2022-12-25	WOS:000188542700014
J	Boehning, D; Patterson, RL; Sedaghat, L; Glebova, NO; Kurosaki, T; Snyder, SH				Boehning, D; Patterson, RL; Sedaghat, L; Glebova, NO; Kurosaki, T; Snyder, SH			Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis	NATURE CELL BIOLOGY			English	Article							RESONANCE ENERGY-TRANSFER; 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; DOWN-REGULATION; CELL-DEATH; RELEASE; MITOCHONDRIA; ACTIVATION; ASSOCIATION; BILIRUBIN	Mitochondrial cytochrome c release and inositol (1,4,5) trisphosphate receptor (InsP(3)R)-mediated calcium release from the endoplasmic reticulum mediate apoptosis in response to specific stimuli. Here we show that cytochrome c binds to the InsP(3)R during apoptosis. Addition of 1 nM cytochrome c blocks calcium-dependent inhibition of InsP(3)R function. Early in apoptosis, cytochrome c translocates to the endoplasmic reticulum where it selectively binds InsP(3)R, resulting in sustained, oscillatory cytosolic calcium increases. These calcium events are linked to the coordinate release of cytochrome c from all mitochondria. Our findings identify a feed-forward mechanism whereby early cytochrome c release increases InsP(3)R function, resulting in augmented cytochrome c release that amplifies the apoptotic signal.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; RIKEN Res Ctr Allergy & Immunol, Lab Lymphocyte, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; RIKEN; Kansai Medical University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Kurosaki, Tomohiro/D-1306-2009; Boehning, Darren/I-8539-2015	Kurosaki, Tomohiro/0000-0002-6352-304X; Boehning, Darren/0000-0001-7920-6922	NIDA NIH HHS [DA-000266, DA-00074] Funding Source: Medline; NIH HHS [NH65090] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [NS-043850] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Ferrara C, 2002, PEDIATR RADIOL, V32, P413, DOI 10.1007/s00247-001-0617-z; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Okazaki M, 1998, BIOCHEM BIOPH RES CO, V243, P131, DOI 10.1006/bbrc.1997.7979; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	32	498	518	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1051	1061		10.1038/ncb1063	http://dx.doi.org/10.1038/ncb1063			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14608362				2022-12-25	WOS:000186892900010
J	Tour, O; Meijer, RM; Zacharias, DA; Adams, SR; Tsien, RY				Tour, O; Meijer, RM; Zacharias, DA; Adams, SR; Tsien, RY			Genetically targeted chromophore-assisted light inactivation	NATURE BIOTECHNOLOGY			English	Article							LASER INACTIVATION; SINGLET OXYGEN; PROTEIN; CELLS; CALI	Studies of protein function would be facilitated by a general method to inactivate selected proteins in living cells noninvasively with high spatial and temporal precision. Chromophore- assisted light inactivation (CALI)(1) uses photochemically generated, reactive oxygen species to inactivate proteins acutely, but its use has been limited by the need to microinject dye- labeled nonfunction- blocking antibodies. We now demonstrate CALI of connexin43 (Cx43) and alpha(1C) L- type calcium channels, each tagged with one or two small tetracysteine (TC) motifs(2) that specifically bind the membrane- permeant, red biarsenical dye, ReAsH3,4. ReAsH-based CALI is genetically targeted, requires no antibodies or microinjection, and inactivates each protein by similar to 90% in <30 s of widefield illumination. Similar light doses applied to Cx43 or &alpha;(1C) tagged with green fluorescent protein (GFP) had negligible to slight effects with or without ReAsH exposure, showing the expected molecular specificity. ReAsH- mediated CALI acts largely via singlet oxygen because quenchers or enhancers of singlet oxygen respectively inhibit or enhance CALI.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Falk MM, 2000, J CELL SCI, V113, P4109; Foote C. S., 1995, ACTIVE OXYGEN CHEM, V2, P105; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; Jay DG, 1999, BBA-REV CANCER, V1424, pM39, DOI 10.1016/S0304-419X(99)00022-0; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; Marek KW, 2002, NEURON, V36, P805, DOI 10.1016/S0896-6273(02)01068-1; MOAN J, 1990, J PHOTOCH PHOTOBIO B, V6, P343, DOI 10.1016/1011-1344(90)85104-5; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Piedras-Renteria ES, 2001, J NEUROSCI, V21, P9185, DOI 10.1523/JNEUROSCI.21-23-09185.2001; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Surrey T, 1998, P NATL ACAD SCI USA, V95, P4293, DOI 10.1073/pnas.95.8.4293; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	19	165	188	1	36	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1505	1508		10.1038/nbt914	http://dx.doi.org/10.1038/nbt914			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14625562				2022-12-25	WOS:000186845200030
J	Bernstein, E; Kim, SY; Carmell, MA; Murchison, EP; Alcorn, H; Li, MZ; Mills, AA; Elledge, SJ; Anderson, KV; Hannon, GJ				Bernstein, E; Kim, SY; Carmell, MA; Murchison, EP; Alcorn, H; Li, MZ; Mills, AA; Elledge, SJ; Anderson, KV; Hannon, GJ			Dicer is essential for mouse development	NATURE GENETICS			English	Article							RNA-INTERFERENCE	To address the biological function of RNA interference (RNAi) related pathways in mammals, we disrupted the gene Dicer1 in mice. Loss of Dicer1 lead to lethality early in development, with Dicer1 - null embryos depleted of stem cells. Coupled with our inability to generate viable Dicer1 - null embryonic stem (ES) cells, this suggests a role for Dicer, and, by implication, the RNAi machinery, in maintaining the stem cell population during early mouse development.	Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA; Sloan Kettering Inst, Dev Biol Program, New York, NY 10021 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Hannon, GJ (corresponding author), Watson Sch Biol Sci, Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.org	Hannon, Gregory/AAB-3568-2019	Kim, Sang Yong/0000-0001-7326-7505; Anderson, Kathryn/0000-0003-1657-2161; Murchison, Elizabeth Proby/0000-0001-7462-8907				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; HUTVAGNER G, 2002, SCIENCE, V1, P1; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Yeom YI, 1996, DEVELOPMENT, V122, P881; Zhang PM, 2002, NAT GENET, V30, P31, DOI 10.1038/ng797	15	1443	1548	3	68	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					215	217		10.1038/ng1253	http://dx.doi.org/10.1038/ng1253			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14528307				2022-12-25	WOS:000186273300014
J	Padua, RA; Larghero, J; Robin, M; le Pogam, C; Schlageter, MH; Muszlak, S; Fric, J; West, R; Rousselot, P; Phan, TH; Mudde, L; Teisserenc, H; Carpentier, AF; Kogan, S; Degos, L; Pla, M; Bishop, JM; Stevenson, F; Charron, D; Chomienne, C				Padua, RA; Larghero, J; Robin, M; le Pogam, C; Schlageter, MH; Muszlak, S; Fric, J; West, R; Rousselot, P; Phan, TH; Mudde, L; Teisserenc, H; Carpentier, AF; Kogan, S; Degos, L; Pla, M; Bishop, JM; Stevenson, F; Charron, D; Chomienne, C			PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; B-CELL LYMPHOMA; RETINOIC ACID; HYBRID PROTEIN; FUSION REGION; FRAGMENT-C; ALPHA; CANCER; MICE; TRANSLOCATION	Despite improved molecular characterization of malignancies and development of targeted therapies, acute leukemia is not curable and few patients survive more than 10 years after diagnosis. Recently, combinations of different therapeutic strategies (based on mechanisms of apoptosis, differentiation and cytotoxicity) have significantly increased survival. To further improve outcome, we studied the potential efficacy of boosting the patient's immune response using specific immunotherapy. In an animal model of acute promyelocytic leukemia, we developed a DNA-based vaccine by fusing the human promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) oncogene to tetanus fragment C (FrC) sequences. We show for the first time that a DNA vaccine specifically targeted to an oncoprotein can have a pronounced effect on survival, both alone and when combined with all-trans retinoic acid (ATRA). The survival advantage is concomitant with time-dependent antibody production and an increase in interferon-gamma (IFN-gamma). We also show that ATRA therapy on its own triggers an immune response in this model. When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia.	Hop St Louis, LBCH INSERM E0 03, U 462, Inst Univ Hematol,AP HP, F-75010 Paris, France; Hop St Louis, LBCH INSERM E0 03, U 396, Inst Univ Hematol,AP HP, F-75010 Paris, France; Kings Coll London, Dept Med Hematol, London SE5 9NU, England; Cardiff Univ, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Southampton, Tenovus, Southampton SO16 6YD, Hants, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; King's College London; Cardiff University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southampton	Padua, RA (corresponding author), Hop St Louis, LBCH INSERM E0 03, U 462, Inst Univ Hematol,AP HP, F-75010 Paris, France.	rose.padua@kcl.ac.uk	Muszlak, Sacha/AAV-6110-2020; Moins-Teisserenc, helene/AAL-1566-2021; Frič, Jan/P-7444-2018; Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019; Fric, Jan/O-5441-2015	Muszlak, Sacha/0000-0001-5739-8564; Moins-Teisserenc, helene/0000-0003-1602-7534; Frič, Jan/0000-0001-6642-797X; PADUA, Rose Ann/0000-0001-9964-7864; Fric, Jan/0000-0001-6642-797X; CHOMIENNE, Christine/0000-0001-5513-5752; Robin, Marie/0000-0003-1388-9876; Stevenson, Freda/0000-0002-0933-5021; Kogan, Scott/0000-0002-2395-8479; Carpentier, Antoine/0000-0003-2926-0060				Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; Chen SA, 2000, CLIN CANCER RES, V6, P4381; Delva L, 1999, MOL CELL BIOL, V19, P7158; Dermime S, 1996, CLIN CANCER RES, V2, P593; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DRESSER DW, 1968, NATURE, V217, P527, DOI 10.1038/217527a0; Finn OJ, 2002, CURR OPIN IMMUNOL, V14, P172, DOI 10.1016/S0952-7915(02)00317-5; Forni G, 2000, CANCER RES, V60, P2571; GAMBACORTIPASSERINI C, 1993, BLOOD, V81, P1369; HU J, 1993, J EXP MED, V177, P1681, DOI 10.1084/jem.177.6.1681; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUST JA, 1981, J EXP MED, V154, P306, DOI 10.1084/jem.154.2.306; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Parrado A, 2001, NUCLEIC ACIDS RES, V29, P4901, DOI 10.1093/nar/29.24.4901; Rice J, 2001, J IMMUNOL, V167, P1558, DOI 10.4049/jimmunol.167.3.1558; Sambrook J., 2002, MOL CLONING LAB MANU; Spellerberg MB, 1997, J IMMUNOL, V159, P1885; Stephensen CB, 2002, J IMMUNOL, V168, P4495, DOI 10.4049/jimmunol.168.9.4495; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Westervelt P, 2002, P NATL ACAD SCI USA, V99, P9468, DOI 10.1073/pnas.132657799; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	30	60	69	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1413	1417		10.1038/nm949	http://dx.doi.org/10.1038/nm949			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566333				2022-12-25	WOS:000186319700033
J	Baker, DJ; Jeganathan, KB; Cameron, JD; Thompson, M; Juneja, S; Kopecka, A; Kumar, R; Jenkins, RB; de Groen, PC; Roche, P; van Deursen, JM				Baker, DJ; Jeganathan, KB; Cameron, JD; Thompson, M; Juneja, S; Kopecka, A; Kumar, R; Jenkins, RB; de Groen, PC; Roche, P; van Deursen, JM			BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice	NATURE GENETICS			English	Article							MITOTIC CHECKPOINT GENES; CANCER; DEFICIENT; AGE	Faithful segregation of replicated chromosomes is essential for maintenance of genetic stability and seems to be monitored by several mitotic checkpoints. Various components of these checkpoints have been identified in mammals, but their physiological relevance is largely unknown. Here we show that mutant mice with low levels of the spindle assembly checkpoint protein BubR1 develop progressive aneuploidy along with a variety of progeroid features, including short lifespan, cachectic dwarfism, lordokyphosis, cataracts, loss of subcutaneous fat and impaired wound healing. Graded reduction of BubR1 expression in mouse embryonic fibroblasts causes increased aneuploidy and senescence. Male and female mutant mice have defects in meiotic chromosome segregation and are infertile. Natural aging of wild-type mice is marked by decreased expression of BubR1 in multiple tissues, including testis and ovary. These results suggest a role for BubR1 in regulating aging and infertility.	Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	van Deursen, JM (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	vandeursen.jan@mayo.edu		Baker, Darren/0000-0001-9006-1939; Jeganathan, KARTHIK/0000-0001-5587-1266; Kumar, Rajiv/0000-0003-3497-3057; Juneja, Subhash/0000-0002-8536-5724	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK065830, R01DK025409] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065830, R01 DK058546, R01 DK025409] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Eskenazi B, 2003, HUM REPROD, V18, P447, DOI 10.1093/humrep/deg107; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Ford WCL, 2000, HUM REPROD, V15, P1703, DOI 10.1093/humrep/15.8.1703; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kang-Decker N, 2001, SCIENCE, V294, P1531, DOI 10.1126/science.1063665; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Koomen M, 2002, HUM MOL GENET, V11, P273, DOI 10.1093/hmg/11.3.273; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Shichiri M, 2002, CANCER RES, V62, P13; Thomas NS, 2001, HUM MOL GENET, V10, P243, DOI 10.1093/hmg/10.3.243; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	28	559	575	2	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					744	749		10.1038/ng1382	http://dx.doi.org/10.1038/ng1382			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15208629	Bronze			2022-12-25	WOS:000222354100026
J	Dos Santos, C; Essioux, L; Teinturier, C; Tauber, M; Goffin, V; Bougneres, P				Dos Santos, C; Essioux, L; Teinturier, C; Tauber, M; Goffin, V; Bougneres, P			A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone	NATURE GENETICS			English	Article							CRYSTAL-STRUCTURE; EXPRESSION; COMPLEX; DIVERSITY; MUTATION; CHILDREN; ISOFORM; HEIGHT; GH	Growth hormone is used to increase height in short children who are not deficient in growth hormone, but its efficacy varies largely across individuals. The genetic factors responsible for this variation are entirely unknown. In two cohorts of short children treated with growth hormone, we found that an isoform of the growth hormone receptor gene that lacks exon 3 (d3-GHR) was associated with 1.7 to 2 times more growth acceleration induced by growth hormone than the full-length isoform (P < 0.0001). In transfection experiments, the transduction of growth hormone signaling through d3-GHR homo- or heterodimers was similar to 30% higher than through full-length GHR homodimers (P < 0.0001). One-half of Europeans are hetero- or homozygous with respect to the allele encoding the d3-GHR isoform, which is dominant over the full-length isoform. These observations suggest that the polymorphism in exon 3 of GHR is important in growth hormone pharmacogenetics.	Univ Paris 05, St Vincent de Paul Hosp, INSERM, U561, F-75014 Paris, France; Univ Paris 05, St Vincent de Paul Hosp, Dept Pediat Endocrinol, F-75014 Paris, France; Childrens Hosp, Unite Endocrinol, Toulouse, France; Univ Paris 05, INSERM, U584, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bougneres, P (corresponding author), Univ Paris 05, St Vincent de Paul Hosp, INSERM, U561, 82 Ave Denfert Rochereau, F-75014 Paris, France.	bougneres@paris5.inserm.fr	GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086; DOS SANTOS MENGUY, Christine/0000-0002-6748-5183				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; Bryant J, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD004440, 10.1002/14651858.CD004440]; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Hintz RL, 1999, NEW ENGL J MED, V340, P502, DOI 10.1056/NEJM199902183400702; ITHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Ochoa R, 2003, HORM RES, V60, P68, DOI 10.1159/000071873; Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200; Pantel J, 2003, J CLIN ENDOCR METAB, V88, P1705, DOI 10.1210/jc.2002-021667; SOBRIER ML, 1993, FEBS LETT, V319, P16, DOI 10.1016/0014-5793(93)80028-S; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Stead JDH, 2000, HUM MOL GENET, V9, P713, DOI 10.1093/hmg/9.5.713; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; URBANEK M, 1993, J BIOL CHEM, V268, P19025	18	258	271	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					720	724		10.1038/ng1379	http://dx.doi.org/10.1038/ng1379			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15208626	Bronze			2022-12-25	WOS:000222354100022
J	Peltekova, VD; Wintle, RF; Rubin, LA; Amos, CI; Huang, QQ; Gu, XJ; Newman, B; Van Oene, M; Cescon, D; Greenberg, G; Griffiths, AM; St George-Hyslop, PH; Siminovitch, KA				Peltekova, VD; Wintle, RF; Rubin, LA; Amos, CI; Huang, QQ; Gu, XJ; Newman, B; Van Oene, M; Cescon, D; Greenberg, G; Griffiths, AM; St George-Hyslop, PH; Siminovitch, KA			Functional variants of OCTN cation transporter genes are associated with Crohn disease	NATURE GENETICS			English	Article							ORGANIC CATION/CARNITINE TRANSPORTER; TISSUE DISTRIBUTION PATTERN; INFLAMMATORY-BOWEL-DISEASE; CARNITINE TRANSPORT; SUSCEPTIBILITY LOCI; ULCERATIVE-COLITIS; TRANSCRIPTION; LOCALIZATION; EXPRESSION; ALLELES	Crohn disease is a chronic, inflammatory disease of the gastrointestinal tract. A locus of similar to250 kb at 5q31 (IBD5)(1,2) was previously associated with susceptibility to Crohn disease, as indicated by increased prevalence of a risk haplotype of 11 single-nucleotide polymorphisms(3) among individuals with Crohn disease, but the pathogenic lesion in the region has not yet been identified. We report here that two variants in the organic cation transporter cluster at 5q31 ( a missense substitution in SLC22A4 and a G-->C transversion in the SLC22A5 promoter) form a haplotype associated with susceptibility to Crohn disease. These variants alter transcription and transporter functions of the organic cation transporters and interact with variants in another gene associated with Crohn disease, CARD15, to increase risk of Crohn disease. These results suggest that SLC22A4, SLC22A5 and CARD15 act in a common pathogenic pathway to cause Crohn disease.	Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Immunol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med Genet & Microbiol, Toronto, ON M5G 1X5, Canada; Toronto Gen Res Inst, Toronto, ON, Canada; Ellipsis Biotherapeut Corp, Toronto, ON M5G 1Z6, Canada; St Michaels Hosp, Div Rheumatol, Toronto, ON M5B 1W8, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Siminovitch, KA (corresponding author), Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada.	ksimin@ellipsisbiotherapeutics.com	Siminovitch, Katherine/K-1475-2013; Greenberg, Gordon/C-4620-2015	Wintle, Richard/0000-0003-1987-1095; Newman, William/0000-0002-6382-4678; St George-Hyslop, Peter/0000-0003-0796-7209				BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; CONLON RA, 1992, DEVELOPMENT, V116, P357; Duran JM, 2002, J MEMBRANE BIOL, V185, P65, DOI 10.1007/s00232-001-0110-5; Elimrani I, 2003, AM J PHYSIOL-GASTR L, V284, pG863, DOI 10.1152/ajpgi.00220.2002; Giallourakis C, 2003, AM J HUM GENET, V73, P205, DOI 10.1086/376417; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lamhonwah AM, 2003, BIOCHEM BIOPH RES CO, V301, P98, DOI 10.1016/S0006-291X(02)02946-7; Ma YH, 1999, INFLAMM BOWEL DIS, V5, P271, DOI 10.1097/00054725-199911000-00005; Mirza MM, 2003, AM J HUM GENET, V72, P1018, DOI 10.1086/373880; Newman B, 2004, AM J GASTROENTEROL, V99, P306, DOI 10.1111/j.1572-0241.2004.04038.x; Newman B, 2003, J RHEUMATOL, V30, P305; Ng PC, 2000, BIOINFORMATICS, V16, P760, DOI 10.1093/bioinformatics/16.9.760; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Rioux JD, 2000, AM J HUM GENET, V66, P1863, DOI 10.1086/302913; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; ROEDIGER WEW, 1986, BRIT J EXP PATHOL, V67, P773; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Seth P, 1999, J BIOL CHEM, V274, P33388, DOI 10.1074/jbc.274.47.33388; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	27	596	624	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					471	475		10.1038/ng1339	http://dx.doi.org/10.1038/ng1339			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107849	Bronze			2022-12-25	WOS:000221183000018
J	Friedrich, TC; Dodds, EJ; Yant, LJ; Vojnov, L; Rudersdorf, R; Cullen, C; Evans, DT; Desrosiers, RC; Mothe, BR; Sidney, J; Sette, A; Kunstman, K; Wolinsky, S; Piatak, M; Lifson, J; Hughes, AL; Wilson, N; O'Connor, DH; Watkins, DI				Friedrich, TC; Dodds, EJ; Yant, LJ; Vojnov, L; Rudersdorf, R; Cullen, C; Evans, DT; Desrosiers, RC; Mothe, BR; Sidney, J; Sette, A; Kunstman, K; Wolinsky, S; Piatak, M; Lifson, J; Hughes, AL; Wilson, N; O'Connor, DH; Watkins, DI			Reversion of CTL escape-variant immunodeficiency viruses in vivo	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; PEPTIDE-BINDING-SPECIFICITY; CELLULAR IMMUNE-RESPONSES; ACUTE-PHASE; DISEASE PROGRESSION; PRIMARY INFECTION; TYPE-1 INFECTION; VIRAL ESCAPE; HIV; VIREMIA	Engendering cytotoxic T-lymphocyte (CTL) responses is likely to be an important goal of HIV vaccines. However, CTLs select for viral variants that escape immune detection. Maintenance of such escape variants in human populations could pose an obstacle to HIV vaccine development. We first observed that escape mutations in a heterogeneous simian immunodeficiency virus (SIV) isolate were lost upon passage to new animals. We therefore infected macaques with a cloned SIV bearing escape mutations in three immunodominant CTL epitopes, and followed viral evolution after infection. Here we show that each mutant epitope sequence continued to evolve in vivo, often re-establishing the original, CTL-susceptible sequence. We conclude that escape from CTL responses may exact a cost to viral fitness. In the absence of selective pressure upon transmission to new hosts, these original escape mutations can be lost. This suggests that some HIV CTL epitopes will be maintained in human populations.	Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Calif State Univ San Marcos, San Marcos, CA 92096 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; NCI, AIDS Vaccine Program, Frederick, MD 21702 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of Wisconsin System; University of Wisconsin Madison; California State University System; California State University San Marcos; La Jolla Institute for Immunology; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Watkins, DI (corresponding author), Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.	watkins@primate.wisc.edu	Wolinsky, Steven/B-2893-2012; Sette, Alessandro/AFO-8916-2022; Yant, Levi/ABH-1275-2020	Vojnov, Lara/0000-0003-0488-1012; o'connor, david/0000-0003-2139-470X; Wolinsky, Steven/0000-0002-9625-6697; Yant, Levi/0000-0003-3442-0217; Friedrich, Thomas/0000-0001-9831-6895	NCRR NIH HHS [P51 RR001676-43] Funding Source: Medline; NIAID NIH HHS [R01-AI-46366, R01-AI-49120, R01-AI-52056, N01-AI-95362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049120, R01AI052056, N01AI095362, R01AI046366] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; FRIEDRICH TC, IN PRESS J VIROL; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Ho DD, 2002, CELL, V110, P135, DOI 10.1016/S0092-8674(02)00832-2; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Knapp LA, 1997, TISSUE ANTIGENS, V50, P170, DOI 10.1111/j.1399-0039.1997.tb02856.x; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Mothe BR, 2002, J VIROL, V76, P875, DOI 10.1128/JVI.76.2.875-884.2002; Mothe BR, 2002, J IMMUNOL, V169, P210, DOI 10.4049/jimmunol.169.1.210; O'Connor DH, 2003, J VIROL, V77, P9029, DOI 10.1128/JVI.77.16.9029-9040.2003; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Peyerl FW, 2003, J VIROL, V77, P12572, DOI 10.1128/JVI.77.23.12572-12578.2003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rue SM, 2003, J VIROL, V77, P8009, DOI 10.1128/JVI.77.14.8009-8018.2003; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Sidney J, 2000, J IMMUNOL, V165, P6387, DOI 10.4049/jimmunol.165.11.6387; Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	38	314	327	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					275	281		10.1038/nm998	http://dx.doi.org/10.1038/nm998			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966520	Bronze			2022-12-25	WOS:000189297700039
J	Inoue, H; Ogawa, W; Ozaki, M; Haga, S; Matsumoto, M; Furukawa, K; Hashimoto, N; Kido, Y; Mori, T; Sakaue, H; Teshigawara, K; Jin, SY; Iguchi, H; Hiramatsu, R; LeRoith, D; Takeda, K; Akira, S; Kasuga, M				Inoue, H; Ogawa, W; Ozaki, M; Haga, S; Matsumoto, M; Furukawa, K; Hashimoto, N; Kido, Y; Mori, T; Sakaue, H; Teshigawara, K; Jin, SY; Iguchi, H; Hiramatsu, R; LeRoith, D; Takeda, K; Akira, S; Kasuga, M			Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo	NATURE MEDICINE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN SENSITIVITY; GLUCOSE; INTERLEUKIN-6; EXPRESSION; ACTIVATION; GLUCOSE-6-PHOSPHATASE; OVEREXPRESSION; INHIBITION; RECEPTOR	The transcription factor, signal transducer and activator of transcription-3 (STAT-3) contributes to various physiological processes. Here we show that mice with liver-specific deficiency in STAT-3, achieved using the Cre-loxP system, show insulin resistance associated with increased hepatic expression of gluconeogenic genes. Restoration of hepatic STAT-3 expression in these mice, using adenovirus-mediated gene transfer, corrected the metabolic abnormalities and the alterations in hepatic expression of gluconeogenic genes. Overexpression of STAT-3 in cultured hepatocytes inhibited gluconeogenic gene expression independently of peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha), an upstream regulator of gluconeogenic genes. Liver-specific expression of a constitutively active form of STAT-3, achieved by infection with an adenovirus vector, markedly reduced blood glucose, plasma insulin concentrations and hepatic gluconeogenic gene expression in diabetic mice. Hepatic STAT-3 signaling is thus essential for normal glucose homeostasis and may provide new therapeutic targets for diabetes mellitus.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan; Natl Res Inst Child Hlth & Dev, Dept Onnovat Surg, Bioengn Lab, Tokyo 1548567, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Food & Hlth Sci, Okayama 7008558, Japan; Sumitomo Pharmaceut Co Ltd, Genom Sci Labs, Takarazuka, Hyogo 6650051, Japan; NIDDKD, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan	Kobe University; National Center for Child Health & Development - Japan; Okayama University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; Inoue, Hiroshi/0000-0002-7724-6637				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Christ B, 2000, HEPATOLOGY, V31, P461, DOI 10.1002/hep.510310228; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Metzger S, 1997, AM J PHYSIOL-ENDOC M, V273, pE262, DOI 10.1152/ajpendo.1997.273.2.E262; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; STRASSMANN G, 1993, CYTOKINE, V5, P285, DOI 10.1016/1043-4666(93)90058-D; Sun Y, 2002, J BIOL CHEM, V277, P23301, DOI 10.1074/jbc.M200964200; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Vgontzas AN, 1997, J CLIN ENDOCR METAB, V82, P1313, DOI 10.1210/jc.82.5.1313; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	37	287	300	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					168	174		10.1038/nm980	http://dx.doi.org/10.1038/nm980			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716305				2022-12-25	WOS:000188719600036
J	Sereda, MW; Horste, GMZ; Suter, U; Uzma, N; Nave, KA				Sereda, MW; Horste, GMZ; Suter, U; Uzma, N; Nave, KA			Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)	NATURE MEDICINE			English	Letter							PERIPHERAL MYELIN PROTEIN-22; SCHWANN-CELLS; GENE-EXPRESSION; BREAST-CANCER; MOUSE MODEL; DUPLICATION; RECEPTOR; RAT; 1A; DIFFERENTIATION	Charcot- Marie- Tooth disease (CMT) is the most common inherited neuropathy. The predominant subtype, CMT- 1A, accounts for more than 50% of all cases(1) and is associated with an interstitial chromosomal duplication of 17p12 (refs. 2,3). We have generated a model of CMT- 1A by introducing extra copies of the responsible disease gene, Pmp22 (encoding the peripheral myelin protein of 22 kDa), into transgenic rats(4). Here, we used this model to test whether progesterone, a regulator of the myelin genes Pmp22 and myelin protein zero (Mpz) in cultured Schwann cells, can modulate the progressive neuropathy caused by moderate overexpression of Pmp22. Male transgenic rats (n = 84) were randomly assigned into three treatment groups: progesterone, progesterone antagonist (onapristone) and placebo control. Daily administration of progesterone elevated the steady- state levels of Pmp22 and Mpz mRNA in the sciatic nerve, resulting in enhanced Schwann cell pathology and a more progressive clinical neuropathy. In contrast, administration of the selective progesterone receptor antagonist reduced overexpression of Pmp22 and improved the CMT phenotype, without obvious side effects, in wild- type or transgenic rats. Taken together, these data provide proof of principle that the progesterone receptor of myelin- forming Schwann cells is a promising pharmacological target for therapy of CMT- 1A.	Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany; ETH Honggerberg, Swiss Fed Inst Technol, Dept Biol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Max Planck Society; University of Gottingen; University of Gottingen; Swiss Federal Institutes of Technology Domain; ETH Zurich	Nave, KA (corresponding author), Max Planck Inst Expt Med, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Horste, Gerd Meyer zu/O-9549-2016; Nave, Klaus-Armin/C-8883-2011; Suter, Ueli/A-1624-2010	Horste, Gerd Meyer zu/0000-0002-4341-4719; 				Berger P, 2002, NEUROGENETICS, V4, P1, DOI 10.1007/s10048-002-0130-z; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; GARCIA CA, 1995, NEUROLOGY, V45, P2090, DOI 10.1212/WNL.45.11.2090; Gopalkrishnan K, 2003, BIOL REPROD, V68, P1959, DOI 10.1095/biolreprod.102.007963; Graham JD, 2002, BREAST CANCER RES, V4, P187, DOI 10.1186/bcr450; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Jung-Testas I, 1999, J STEROID BIOCHEM, V69, P97, DOI 10.1016/S0960-0760(98)00149-6; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Lin RJ, 1998, COLD SPRING HARB SYM, V63, P577, DOI 10.1101/sqb.1998.63.577; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Magyar JP, 1996, J NEUROSCI, V16, P5351; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Michna H, 1996, Cancer Treat Res, V83, P191; Niemann S, 2000, J NEUROSCI, V20, P4120; Perea J, 2001, HUM MOL GENET, V10, P1007, DOI 10.1093/hmg/10.10.1007; POLLOCK M, 1982, NEUROLOGY, V32, P1311, DOI 10.1212/WNL.32.11.1311; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; Robertson JFR, 1999, EUR J CANCER, V35, P214, DOI 10.1016/S0959-8049(98)00388-8; RUDNIKSCHONEBORN S, 1993, NEUROLOGY, V43, P2011, DOI 10.1212/WNL.43.10.2011; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; SUTER U, 1994, J BIOL CHEM, V269, P25795; Thomas PK, 1997, BRAIN, V120, P465, DOI 10.1093/brain/120.3.465	27	215	232	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1533	1537		10.1038/nm957	http://dx.doi.org/10.1038/nm957			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14608378				2022-12-25	WOS:000186845400038
J	Carrolo, M; Giordano, S; Cabrita-Santos, L; Corso, S; Vigario, AM; Silva, S; Leiriao, P; Carapau, D; Armas-Portela, R; Comoglio, PM; Rodriguez, A; Mota, MM				Carrolo, M; Giordano, S; Cabrita-Santos, L; Corso, S; Vigario, AM; Silva, S; Leiriao, P; Carapau, D; Armas-Portela, R; Comoglio, PM; Rodriguez, A; Mota, MM			Hepatocyte growth factor and its receptor are required for malaria infection	NATURE MEDICINE			English	Article							SCATTER-FACTOR; PLASMODIUM SPOROZOITES; MET; FALCIPARUM; YOELII; HGF; TRANSFORMATION; PROTEOGLYCANS; PROTOONCOGENE; MECHANISM	Plasmodium, the causative agent of malaria, must first infect hepatocytes to initiate a mammalian infection. Sporozoites migrate through several hepatocytes, by breaching their plasma membranes, before infection is finally established in one of them. Here we show that wounding of hepatocytes by sporozoite migration induces the secretion of hepatocyte growth factor (HGF), which renders hepatocytes susceptible to infection. Infection depends on activation of the HGF receptor, MET, by secreted HGF. The malaria parasite exploits MET not as a primary binding site, but as a mediator of signals that make the host cell susceptible to infection. HGF/MET signaling induces rearrangements of the host-cell actin cytoskeleton that are required for the early development of the parasites within hepatocytes. Our findings identify HGF and MET as potential targets for new approaches to malaria prevention.	Gulbenkian Inst Sci, P-2780156 Oeiras, Portugal; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, E-28049 Madrid, Spain	New York University; University of Turin; Autonomous University of Madrid	Mota, MM (corresponding author), Gulbenkian Inst Sci, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	mmota@igc.gulbenkian.pt	Carrolo, Margarida/AAM-2938-2020; Mota, Maria/AAF-2048-2019; Giordano, Silvia/J-9858-2018; Carapau, Daniel/J-3966-2012; Carrolo, Margarida/C-4781-2009	Giordano, Silvia/0000-0003-1854-1086; Carapau, Daniel/0000-0001-8888-6333; Mota, Maria Manuel/0000-0002-2858-1041; Vigario, Ana Margarida/0000-0001-5679-1196; Comoglio, Paolo/0000-0002-7056-5328; Carrolo, Margarida/0000-0002-6866-9515; CORSO, Simona/0000-0002-5069-1503; Rodriguez, Ana/0000-0002-0060-3405	NIAID NIH HHS [AI49432, AI53698] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053698, R01AI049432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; CALVOCALLE JM, 1994, EXP PARASITOL, V79, P362, DOI 10.1006/expr.1994.1098; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gohda Eiichi, 2002, Nihon Yakurigaku Zasshi, V119, P287; Jeffers M, 1996, ONCOGENE, V13, P853; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; Ljubimova JY, 1997, J HISTOCHEM CYTOCHEM, V45, P79, DOI 10.1177/002215549704500111; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MCNEIL PL, 1999, CURRENT PROTOCOLS S, V2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; Mota MM, 2000, EXP PARASITOL, V96, P257, DOI 10.1006/expr.2000.4570; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NALDINI L, 1991, ONCOGENE, V6, P501; NAOUMOV NV, 1994, GUT, V35, P1013, DOI 10.1136/gut.35.8.1013; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Prat M, 1998, J CELL SCI, V111, P237; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Serghides L, 2002, LANCET, V359, P1404, DOI 10.1016/S0140-6736(02)08360-5; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; THURSZ MR, 1995, NAT MED, V1, P374, DOI 10.1038/nm0495-374; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; ZARNEGAR R, 1999, BIOCHEM BIOPH RES CO, V177, P559	35	110	122	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1363	1369		10.1038/nm947	http://dx.doi.org/10.1038/nm947			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14556002				2022-12-25	WOS:000186319700025
J	Li, MA; Alls, JD; Avancini, RM; Koo, K; Godt, D				Li, MA; Alls, JD; Avancini, RM; Koo, K; Godt, D			The large Maf factor Traffic Jam controls gonad morphogenesis in Drosophila	NATURE CELL BIOLOGY			English	Letter							CELL-DEVELOPMENT; FASCICLIN-III; ADHESION; DIFFERENTIATION; CADHERIN; GENE; TRANSCRIPTION; SEGMENTATION; MELANOGASTER; RECOGNITION	Interactions between somatic and germline cells are critical for the normal development of egg and sperm. Here we show that the gene traffic jam (tj) produces a soma-specific factor that controls gonad morphogenesis and is required for female and male fertility. tj encodes the only large Maf factor in Drosophila melanogaster, an orthologue of the atypical basic Leu zipper transcription factors c-Maf and MafB/Kreisler in vertebrates. Expression of tj occurs in somatic gonadal cells that are in direct contact with germline cells throughout development. In tj mutant gonads, somatic cells fail to inter-mingle and properly envelop germline cells, causing an early block in germ cell differentiation. In addition, tj mutant somatic cells show an increase in the level of expression for several adhesion molecules. We propose that tj is a critical modulator of the adhesive properties of somatic cells, facilitating germline-soma interactions that are essential for germ cell differentiation.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada	University of Toronto	Godt, D (corresponding author), Univ Toronto, Dept Zool, 25 Harbord St, Toronto, ON M5S 3G5, Canada.							BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; Cooke JE, 2001, DEVELOPMENT, V128, P571; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; Dobens LL, 2000, DEV DYNAM, V218, P80, DOI 10.1002/(SICI)1097-0177(200005)218:1<80::AID-DVDY7>3.0.CO;2-8; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; Godt D, 2003, CURR BIOL, V13, pR683, DOI 10.1016/S0960-9822(03)00609-2; GODT D, 1995, DEVELOPMENT, V121, P173; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Jenkins AB, 2003, DEVELOPMENT, V130, P4417, DOI 10.1242/dev.00639; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; King R. C., 1970, OVARIAN DEV DROSOPHI; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Lopez-Schier H, 2003, BIOESSAYS, V25, P781, DOI 10.1002/bies.10309; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; POWERS PA, 1991, GENETICS, V129, P133; Sadl VS, 2002, DEV BIOL, V249, P16, DOI 10.1006/dbio.2002.0751; SCHUPBACH T, 1991, GENETICS, V129, P1119; Starz-Gaiano M, 2001, MECH DEVELOP, V105, P5, DOI 10.1016/S0925-4773(01)00392-6; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Veraksa A, 2000, DEVELOPMENT, V127, P4023; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365	32	189	191	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					994	1000		10.1038/ncb1058	http://dx.doi.org/10.1038/ncb1058			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14578908				2022-12-25	WOS:000186273100016
J	Anholt, RRH; Dilda, CL; Chang, S; Fanara, JJ; Kulkarni, NH; Ganguly, I; Rollmann, SM; Kamdar, KP; Mackay, TFC				Anholt, RRH; Dilda, CL; Chang, S; Fanara, JJ; Kulkarni, NH; Ganguly, I; Rollmann, SM; Kamdar, KP; Mackay, TFC			The genetic architecture of odor-guided behavior in Drosophila: epistasis and the transcriptome	NATURE GENETICS			English	Article							OLFACTORY BEHAVIOR; BINDING PROTEINS; CHANNEL; FAMILY; IMMUNITY; GROWTH; SEX	We combined transcriptional profiling and quantitative genetic analysis to elucidate the genetic architecture of olfactory behavior in Drosophila melanogaster. We applied whole-genome expression analysis to five coisogenic smell-impaired (smi) mutant lines and their control. We used analysis of variance to partition variation in transcript abundance between males and females and between smi genotypes and to determine the genotype-by-sex interaction. A total of 666 genes showed sexual dimorphism in transcript abundance, and 530 genes were coregulated in response to one or more smi mutations, showing considerable epistasis at the level of the transcriptome in response to single mutations. Quantitative complementation tests of mutations at these coregulated genes with the smi mutations showed that in most cases (67%) epistatic interactions for olfactory behavior mirrored epistasis at the level of transcription, thus identifying new candidate genes regulating olfactory behavior.	N Carolina State Univ, Dept Zool, Raleigh, NC 27695 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; N Carolina State Univ, WM Keck Ctr Behav Biol, Raleigh, NC 27695 USA; Torrey Mesa Res Inst, La Jolla, CA USA; Univ Buenos Aires, Dept Ecol Genet & Evolut, Buenos Aires, DF, Argentina	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of Buenos Aires	Anholt, RRH (corresponding author), N Carolina State Univ, Dept Zool, Raleigh, NC 27695 USA.	anholt@ncsu.edu	Anholt, Robert/S-5977-2019					Anholt RRH, 1996, GENETICS, V143, P293; BALAKRISHNAN R, 1991, J EXP BIOL, V157, P161; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Fedorowicz GM, 1998, GENETICS, V148, P1885; Fujii S, 2002, EMBO J, V21, P5353, DOI 10.1093/emboj/cdf556; Gaines P, 2000, GENETICS, V154, P1627; Galindo K, 2001, GENETICS, V159, P1059; Ganguly I, 2003, GENETICS, V164, P1447; Greenspan RJ, 2001, NAT REV GENET, V2, P383, DOI 10.1038/35072018; Hekmat-Scafe DS, 2002, GENOME RES, V12, P1357, DOI 10.1101/gr.239402; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kim MS, 1998, GENETICS, V150, P711; Kulkarni NH, 2002, GENETICS, V161, P1507; Kuniyoshi H, 2002, GENETICS, V162, P1775; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; Munier AI, 2002, EMBO REP, V3, P1195, DOI 10.1093/embo-reports/kvf242; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; Raghavan S, 2000, CURR BIOL, V10, P269, DOI 10.1016/S0960-9822(00)00364-X; Roche JP, 2002, J NEUROSCI, V22, P6471, DOI 10.1523/jneurosci.22-15-06471.2002; Sokolowski MB, 2001, NAT REV GENET, V2, P879, DOI 10.1038/35098592; Stortkuhl KF, 1999, J NEUROSCI, V19, P4839; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wang JW, 2002, J NEUROGENET, V16, P45, DOI 10.1080/01677060213106; Wang Q, 1999, J BIOL CHEM, V274, P10309, DOI 10.1074/jbc.274.15.10309; Wu LP, 2001, GENETICS, V159, P189	30	112	118	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					180	184		10.1038/ng1240	http://dx.doi.org/10.1038/ng1240			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12958599				2022-12-25	WOS:000185625300016
J	Colvin, VL				Colvin, VL			The potential environmental impact of engineered nanomaterials	NATURE BIOTECHNOLOGY			English	Article							WATER-SOLUBLE FULLERENE; ULTRAFINE PARTICLES; IN-VITRO; PHOTOINDUCED CYTOTOXICITY; COLLOIDAL DISPERSIONS; C-60; SIZE; POLYETHYLENE; DEBRIS; WEAR	With the increased presence of nanomaterials in commercial products, a growing public debate is emerging on whether the environmental and social costs of nanotechnology outweigh its many benefits. To date, few studies have investigated the toxicological and environmental effects of direct and indirect exposure to nanomaterials and no clear guidelines exist to quantify these effects.	Rice Univ, Dept Chem, CBEN, Houston, TX 77005 USA; Rice Univ, Dept Chem Engn, CBEN, Houston, TX 77005 USA	Rice University; Rice University	Colvin, VL (corresponding author), Rice Univ, Dept Chem, CBEN, MS-60 6100 Main St, Houston, TX 77005 USA.	colvin@rice.edu						Alargova RG, 2001, J AM CHEM SOC, V123, P10460, DOI 10.1021/ja010202a; Andrievsky GV, 2002, CHEM PHYS LETT, V364, P8, DOI 10.1016/S0009-2614(02)01305-2; Arnall A. H., 2003, FUTURE TECHNOLOGIES; Bahnemanna DW, 2002, APPL CATAL B-ENVIRON, V36, P161, DOI 10.1016/S0926-3373(01)00301-0; Benz EB, 2001, BIOMATERIALS, V22, P2835, DOI 10.1016/S0142-9612(01)00027-8; Bolton JD, 2002, KEY ENG MAT, V230-2, P447, DOI 10.4028/www.scientific.net/KEM.230-232.447; Borm PJA, 2002, INHAL TOXICOL, V14, P311, DOI 10.1080/08958370252809086; Boynton EL, 2000, J BIOMED MATER RES, V52, P239, DOI 10.1002/1097-4636(200011)52:2<239::AID-JBM1>3.0.CO;2-R; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Carter LC, 2000, J ADHESION, V74, P53, DOI 10.1080/00218460008034524; Castranova V, 2000, INHAL TOXICOL, V12, P7, DOI 10.1080/08958378.2000.11463226; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chen HHC, 1997, FULLERENE SCI TECHN, V5, P1387, DOI 10.1080/15363839708013327; Chen HHC, 1998, TOXICOL PATHOL, V26, P143, DOI 10.1177/019262339802600117; Chew NYK, 2002, J AEROSOL MED, V15, P325, DOI 10.1089/089426802760292672; Courrier HM, 2002, CRIT REV THER DRUG, V19, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40; Cusan C, 2002, EUR J ORG CHEM, V2002, P2928; Da Ros T, 1999, CHEM COMMUN, P663; Dagani R, 2003, CHEM ENG NEWS, V81, P30, DOI 10.1021/cen-v081n017.p030; Deguchi S, 2001, LANGMUIR, V17, P6013, DOI 10.1021/la010651o; DeHeer DH, 2001, J BIOMED MATER RES, V54, P12, DOI 10.1002/1097-4636(200101)54:1<12::AID-JBM2>3.0.CO;2-X; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 2000, PHILOS T ROY SOC A, V358, P2741, DOI 10.1098/rsta.2000.0681; Dunford R, 1997, FEBS LETT, V418, P87, DOI 10.1016/S0014-5793(97)01356-2; Edwards MF, 2001, POWDER TECHNOL, V119, P9, DOI 10.1016/S0032-5910(01)00399-0; ETC Group, 2003, NO SMALL MATT 2 CAS; FERIN J, 1991, J AEROSOL MED, V4, P57, DOI 10.1089/jam.1991.4.57; Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006-291X(02)00445-X; Henry C, 2003, CHEM ENG NEWS, V81, P10; Hidaka H, 1997, J PHOTOCH PHOTOBIO A, V111, P205, DOI 10.1016/S1010-6030(97)00229-3; HIRAKAWA K, 1996, CLIN ORTHOP RELAT R, V331, P151; Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219; Kai Y, 2003, FULLER NANOTUB CAR N, V11, P79, DOI 10.1081/FST-120018664; KAN AT, 1990, ENVIRON TOXICOL CHEM, V9, P253, DOI 10.1002/etc.5620090302; Kawashima Y, 1998, PHARM RES-DORDR, V15, P1748, DOI 10.1023/A:1011916930655; Kersting AB, 1999, NATURE, V397, P56, DOI 10.1038/16231; Kleeman MJ, 2000, ENVIRON SCI TECHNOL, V34, P1132, DOI 10.1021/es981276y; Kraft CN, 2003, J BONE JOINT SURG BR, V85B, P133, DOI 10.1302/0301-620X.85B1.12749; Lademann J, 1999, SKIN PHARMACOL APPL, V12, P247, DOI 10.1159/000066249; LAM C, 2003, IN PRESS TOXICOL SCI; LEE JM, 1992, J BONE JOINT SURG BR, V74, P380, DOI 10.1302/0301-620X.74B3.1587882; LESHER S, 2003, HILL            0507; LIDDLE R, 2003, GUARDIAN        0730; Malato S, 2002, APPL CATAL B-ENVIRON, V37, P1, DOI 10.1016/S0926-3373(01)00315-0; Matsunaga T, 2000, BIOTECHNOL BIOENG, V70, P704, DOI 10.1002/1097-0290(20001220)70:6<704::AID-BIT14>3.0.CO;2-E; Matsunaga T, 2000, J BIOSCI BIOENG, V90, P1; Mchedlov-Petrossyan NO, 1997, J CHEM SOC FARADAY T, V93, P4343, DOI 10.1039/a705494g; McMurry PH, 2002, J AEROSOL MED, V15, P169, DOI 10.1089/089426802320282293; Miyaguchi M, 2002, J BIOMED MATER RES, V62, P331, DOI 10.1002/jbm.10331; Monti D, 2000, BIOCHEM BIOPH RES CO, V277, P711, DOI 10.1006/bbrc.2000.3715; Moriguchi T, 1999, FULLERENE SCI TECHN, V7, P195, DOI 10.1080/10641229909350279; Murphy SAM, 1999, OCCUP ENVIRON MED, V56, P813, DOI 10.1136/oem.56.12.813; Nakajima N, 1996, FULLERENE SCI TECHN, V4, P1, DOI 10.1080/10641229608001533; Nemmar A, 2001, AM J RESP CRIT CARE, V164, P1665, DOI 10.1164/ajrccm.164.9.2101036; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Okamura Y, 2000, APPL BIOCHEM BIOTECH, V84-6, P441, DOI 10.1385/ABAB:84-86:1-9:441; Olivier V, 2003, CELL BIOL TOXICOL, V19, P145, DOI 10.1023/A:1024723326036; Picatonotto T, 2001, J DISPER SCI TECHNOL, V22, P381, DOI 10.1081/DIS-100106943; Rajagopalan P, 1996, ANTIMICROB AGENTS CH, V40, P2262, DOI 10.1128/AAC.40.10.2262; Ricci A, 2003, PHOTOCH PHOTOBIO SCI, V2, P487, DOI 10.1039/b212815b; Rossatto V, 2003, J DISPER SCI TECHNOL, V24, P259, DOI 10.1081/DIS-120019977; Sabokbar A, 2003, J MATER SCI-MATER M, V14, P731, DOI 10.1023/A:1025088418878; Sakai A, 1999, FULLERENE SCI TECHN, V7, P743, DOI 10.1080/10641229909351375; Schulz J, 2002, ADV DRUG DELIVER REV, V54, pS157, DOI 10.1016/S0169-409X(02)00120-5; Shefer S, 2001, J COSMET SCI, V52, P350; Smith S, 2001, AEROSOL SCI TECH, V35, P697, DOI 10.1080/02786820152546743; SPIERTZ C, 1995, J DERMATOL TREAT, V6, P155, DOI 10.3109/09546639509097173; Tremblay JF, 2003, CHEM ENG NEWS, V81, P13, DOI 10.1021/cen-v081n012.p013; Tremblay JF, 2002, CHEM ENG NEWS, V80, P16; Tsao N, 1999, ANTIMICROB AGENTS CH, V43, P2273, DOI 10.1128/AAC.43.9.2273; Tsuchiya T, 1996, FEBS LETT, V393, P139, DOI 10.1016/0014-5793(96)00812-5; Ueng TH, 1997, TOXICOL LETT, V93, P29, DOI 10.1016/S0378-4274(97)00071-4; US FDA, 1999, FED REGISTER, V64, P27666; VISURI T, 1991, ORTHOPEDICS, V14, P137; Wang IC, 1999, J MED CHEM, V42, P4614, DOI 10.1021/jm990144s; Warheit DB, 1997, J EXPO ANAL ENV EPID, V7, P313; Warheit DB, 1995, SCAND J WORK ENV HEA, V21, P19; WARHEIT DB, 2003, IN PRESS TOXICOL SCI; WICHMANN HE, 2000, ROLE PARTICLE NUMBER, V98; WIESNER M, 1998, METALS SURFACE WATER; Wooley PH, 1996, CLIN ORTHOP RELAT R, P63; Xu Z, 1998, PROG BIOCHEM BIOPHYS, V25, P130; Yang A, 2002, CELL BIOL TOXICOL, V18, P97, DOI 10.1023/A:1015328100876; Yang XL, 2002, TOXICOL IN VITRO, V16, P41, DOI 10.1016/S0887-2333(01)00102-3; 2003, GUARDIAN        0428	85	1642	1751	8	513	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1166	1170		10.1038/nbt875	http://dx.doi.org/10.1038/nbt875			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	14520401				2022-12-25	WOS:000185647200027
J	Palstra, RJ; Tolhuis, B; Splinter, E; Nijmeijer, R; Grosveld, F; de Laat, W				Palstra, RJ; Tolhuis, B; Splinter, E; Nijmeijer, R; Grosveld, F; de Laat, W			The beta-globin nuclear compartment in development and erythroid differentiation	NATURE GENETICS			English	Article							LOCUS-CONTROL REGION; HYPERSENSITIVE SITE; TARGETED DELETION; GENE CLUSTERS; IN-VIVO; TRANSCRIPTION; VISUALIZATION; ORGANIZATION; EXPRESSION; DYNAMICS	Efficient transcription of genes requires a high local concentration of the relevant trans - acting factors. Nuclear compartmentalization can provide an effective means to locally increase the concentration of rapidly moving trans - acting factors; this may be achieved by spatial clustering of chromatin-associated binding sites for such factors(1-5). Here we analyze the structure of an erythroid-specific spatial cluster of cis regulatory elements and active beta-globin genes, the active chromatin hub (ACH; ref. 6), at different stages of development and in erythroid progenitors. We show, in mice and humans, that a core ACH is developmentally conserved and consists of the hypersensitive sites (HS1-HS6) of the locus control region (LCR), the upstream 5' HS 60/-62 and downstream 3' HS1. Globin genes switch their interaction with this cluster during development, correlating with the switch in their transcriptional activity(7). In mouse erythroid progenitors that are committed to but do not yet express beta-globin, only the interactions between 5' HS 60/-62, 3' HS1 and hypersensitive sites at the 5 side of the LCR are stably present. After induction of differentiation, these sites cluster with the rest of the LCR and the gene that is activated. We conclude that during erythroid differentiation, cis - regulatory DNA elements create a developmentally conserved nuclear compartment dedicated to RNA polymerase II transcription of beta-globin genes.	ErasmusMC, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	de Laat, W (corresponding author), ErasmusMC, Dept Cell Biol & Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Palstra, Robert-Jan/0000-0003-4600-2303; de Laat, Wouter/0000-0002-6393-595X				Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bulger M, 2000, P NATL ACAD SCI USA, V97, P14560, DOI 10.1073/pnas.97.26.14560; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chubb JR, 2003, CELL, V112, P403, DOI 10.1016/S0092-8674(03)00078-3; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Droge P, 2001, BIOESSAYS, V23, P179, DOI 10.1002/1521-1878(200102)23:2<179::AID-BIES1025>3.0.CO;2-6; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; Farrell CM, 2000, P NATL ACAD SCI USA, V97, P14554, DOI 10.1073/pnas.97.26.14554; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; HARDISON R, 1993, MOL BIOL EVOL, V10, P73; Hug BA, 1996, MOL CELL BIOL, V16, P2906; Imam AMA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e65; Isogai Y, 2003, CURR OPIN CELL BIOL, V15, P296, DOI 10.1016/S0955-0674(03)00052-8; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Wai AWK, 2003, EMBO J, V22, P4489, DOI 10.1093/emboj/cdg437; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	28	419	443	0	28	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					190	194		10.1038/ng1244	http://dx.doi.org/10.1038/ng1244			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	14517543				2022-12-25	WOS:000185625300018
J	Sledz, CA; Holko, M; de Veer, MJ; Silverman, RH; Williams, BRG				Sledz, CA; Holko, M; de Veer, MJ; Silverman, RH; Williams, BRG			Activation of the interferon system by short-interfering RNAs	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; MAMMALIAN-CELLS; PHOSPHORYLATION	RNA interference (RNAi) is a powerful tool used to manipulate gene expression or determine gene function(1,2). One technique of expressing the short double-stranded (ds) RNA intermediates required for interference in mammalian systems is the introduction of short-interfering (si) RNAs3-6. Although RNAi strategies are reliant on a high degree of specificity, little attention has been given to the potential non-specific effects that might be induced. Here, we found that transfection of siRNAs results in interferon (IFN)-mediated activation of the Jak-Stat pathway and global upregulation of IFN-stimulated genes. This effect is mediated by the dsRNA-dependent protein kinase, PKR, which is activated by 21-base-pair (bp) siRNAs and required for upregulation of IFN-beta in response to siRNAs. In addition, we show by using cell lines deficient in specific components mediating IFN action that the RNAi mechanism itself is independent of the interferon system. Thus, siRNAs have broad and complicating effects beyond the selective silencing of target genes when introduced into cells. This is of critical importance, as siRNAs are currently being explored for their potential therapeutic use(7,8).	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Mol Virol Program, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA62220] Funding Source: Medline; NIAID NIH HHS [R01 AI34039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; WILLIAMS BRG, 1979, NUCLEIC ACIDS RES, V6, P1335, DOI 10.1093/nar/6.4.1335; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; ZHOU A, 1997, EMBO J, V16, P3297; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	23	1131	1248	3	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					834	839		10.1038/ncb1038	http://dx.doi.org/10.1038/ncb1038			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12942087				2022-12-25	WOS:000185059000017
J	Ghadessy, FJ; Ramsay, N; Boudsocq, F; Loakes, D; Brown, A; Iwai, S; Vaisman, A; Woodgate, R; Holliger, P				Ghadessy, FJ; Ramsay, N; Boudsocq, F; Loakes, D; Brown, A; Iwai, S; Vaisman, A; Woodgate, R; Holliger, P			Generic expansion of the substrate spectrum of a DNA polymerase by directed evolution	NATURE BIOTECHNOLOGY			English	Article							GENETIC ALPHABET; ERROR-PRONE; ACTIVE-SITE; REPLICATION; FIDELITY; BYPASS; ETA; PCR	DNA polymerases recognize their substrates with exceptionally high specificity(1,2), restricting the use of unnatural nucleotides and the applications they enable. We describe a strategy to expand the substrate range of polymerases. By selecting for the extension of distorting 3' mismatches, we obtained mutants of Taq DNA polymerase that not only promiscuously extended mismatches, but had acquired a generic ability to process a diverse range of noncanonical substrates while maintaining high catalytic turnover, processivity and fidelity. Unlike the wild-type enzyme, they bypassed blocking lesions such as an abasic site, a thymidine dimer or the base analog 5-nitroindol(3) and performed PCR amplification with complete substitution of all four nucleotide triphosphates with phosphorothioates(4) or the substitution of one with the equivalent fluorescent dye-labeled nucleotide triphosphate. Such 'unfussy' polymerases have immediate utility, as we demonstrate by the generation of microarray probes with up to 20-fold brighter fluorescence.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; NICHHD, Sect DNA Replicat Repair & Mutagenesis, Lab Genom Integr, NIH, Bethesda, MD 20892 USA; BioRobotics, Haslingfield CB3 7LW, England; Univ Tokyo, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Tokyo	Holliger, P (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	phl@mrc-lmb.cam.ac.uk	Vaisman, Alexandra/C-3766-2013	Vaisman, Alexandra/0000-0002-2521-1467; Woodgate, Roger/0000-0001-5581-4616; Ghadessy, Farid/0000-0001-8559-903X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Debbie P, 1997, NUCLEIC ACIDS RES, V25, P4825, DOI 10.1093/nar/25.23.4825; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Jestin JL, 1999, ANGEW CHEM INT EDIT, V38, P1124, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1124::AID-ANIE1124>3.0.CO;2-W; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kool ET, 2000, CURR OPIN CHEM BIOL, V4, P602, DOI 10.1016/S1367-5931(00)00141-1; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Loakes D, 2001, NUCLEIC ACIDS RES, V29, P2437, DOI 10.1093/nar/29.12.2437; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; Tae EJL, 2001, J AM CHEM SOC, V123, P7439, DOI 10.1021/ja010731e; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; Xia G, 2002, P NATL ACAD SCI USA, V99, P6597, DOI 10.1073/pnas.102577799; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	27	127	139	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					755	759		10.1038/nbt974	http://dx.doi.org/10.1038/nbt974			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15156154				2022-12-25	WOS:000221785300038
J	Ng, D; Thakker, N; Corcoran, CM; Donnai, D; Perveen, R; Schneider, A; Hadley, DW; Tifft, C; Zhang, LQ; Wilkie, AOM; van der Smagt, JJ; Gorlin, RJ; Burgess, SM; Bardwell, VJ; Black, GCM; Biesecker, LG				Ng, D; Thakker, N; Corcoran, CM; Donnai, D; Perveen, R; Schneider, A; Hadley, DW; Tifft, C; Zhang, LQ; Wilkie, AOM; van der Smagt, JJ; Gorlin, RJ; Burgess, SM; Bardwell, VJ; Black, GCM; Biesecker, LG			Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; GERMINAL-CENTER FORMATION; DENTAL OFCD SYNDROME; B-CELL LYMPHOMAS; GENE; BCL-6; TRANSLOCATIONS; LOCALIZATION; INFLAMMATION; COREPRESSOR	Lenz microphthalmia is inherited in an X-linked recessive pattern and comprises microphthalmia, mental retardation, and skeletal and other anomalies. Two loci associated with this syndrome, MAA ( microphthalmia with associated anomalies) and MAA2, are situated respectively at Xq27-q28 (refs. 1,2) and Xp11.4-p21.2 (ref. 3). We identified a substitution, nt 254C --> T; P85L, in BCOR (encoding BCL-6-interacting corepressor, BCOR 4) in affected males from the family with Lenz syndrome previously used to identify the MAA2 locus 3. Oculofaciocardiodental syndrome (OFCD; OMIM 300166) is inherited in an X-linked dominant pattern with presumed male lethality and comprises microphthalmia, congenital cataracts, radiculomegaly, and cardiac and digital abnormalities. Given their phenotypic overlap, we proposed that OFCD and MAA2 - associated Lenz microphthalmia were allelic, and we found different frameshift, deletion and nonsense mutations in BCOR in seven families affected with OFCD. Like wild-type BCOR, BCOR P85L and an OFCD-mutant form of BCOR can interact with BCL-6 and efficiently repress transcription. This indicates that these syndromes are likely to result from defects in alternative functions of BCOR, such as interactions with transcriptional partners other than BCL-6. We cloned the zebrafish (Danio rerio) ortholog of BCOR and found that knock-down of this ortholog caused developmental perturbations of the eye, skeleton and central nervous system consistent with the human syndromes, confirming that BCOR is a key transcriptional regulator during early embryogenesis.	St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England; St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; Univ Minnesota, Ctr Canc, Minneapolis, MN USA; Albert Einstein Med Ctr, Dept Genet, Philadelphia, PA 19141 USA; NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet Dev & Dis Res Branch, NIH, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Div Genet, Washington, DC 20010 USA; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Utrecht, Med Ctr, Dept Med Genet, NL-3508 AB Utrecht, Netherlands; Univ Minnesota, Dept Oral Pathol & Genet, Sch Dent, Minneapolis, MN USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Ctr Mol Med, Manchester, Lancs, England; Cent Manchester & Manchester Childrens Univ Hosp, Manchester Royal Eye Hosp, Manchester, Lancs, England	University of Manchester; University of Manchester; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Children's National Health System; University of Oxford; Utrecht University; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Manchester; Manchester Royal Eye Hospital	Black, GCM (corresponding author), St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England.	gblack@man.ac.uk	Wilkie, Andrew/AAC-3820-2020; wei, wei/HHR-8613-2022; Black, Graeme/K-7374-2015	Wilkie, Andrew/0000-0002-2972-5481; Burgess, Shawn/0000-0003-1147-0596; Thakker, Nalin/0000-0002-8664-1508; Black, Graeme/0000-0001-8727-6592	NATIONAL CANCER INSTITUTE [R01CA071540] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200328, Z01HG000181, Z01HG000183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA071540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aalfs CM, 1996, CLIN DYSMORPHOL, V5, P93, DOI 10.1097/00019605-199604000-00001; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Brown J, 1996, GENOMICS, V37, P200, DOI 10.1006/geno.1996.0543; Chen Q, 2002, J BIOL CHEM, V277, P24081, DOI 10.1074/jbc.M201821200; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Epstein JA, 2003, NATURE, V426, P238, DOI 10.1038/426238a; Forrester S, 2001, AM J MED GENET, V98, P92; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gorlin RJ, 1996, AM J MED GENET, V63, P290; GRAHAM CA, 1991, OPHTHALMIC PAED GEN, V12, P43, DOI 10.3109/13816819109023084; Graw J, 2003, NAT REV GENET, V4, P876, DOI 10.1038/nrg1202; Hedera P, 2003, AM J MED GENET A, V123A, P261, DOI 10.1002/ajmg.a.20444; Huynh KD, 2000, GENE DEV, V14, P1810; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kubota T, 1999, HUM GENET, V104, P49, DOI 10.1007/s004390050909; MIKI T, 1994, BLOOD, V83, P217; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Ng D, 2002, AM J MED GENET, V110, P308, DOI 10.1002/ajmg.10484; Schulze BRB, 1999, AM J MED GENET, V82, P429, DOI 10.1002/(SICI)1096-8628(19990219)82:5<429::AID-AJMG13>3.0.CO;2-S; Srinivasan RS, 2003, ONCOGENE, V22, P3395, DOI 10.1038/sj.onc.1206361; van Genderen MM, 2000, BRIT J OPHTHALMOL, V84, P1177, DOI 10.1136/bjo.84.10.1177; Wilkie A O, 1993, Clin Dysmorphol, V2, P114; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732	26	228	233	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					411	416		10.1038/ng1321	http://dx.doi.org/10.1038/ng1321			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15004558	Bronze			2022-12-25	WOS:000220647200027
J	Chen, WSV; Delrow, J; Corrin, PD; Frazier, JP; Soriano, P				Chen, WSV; Delrow, J; Corrin, PD; Frazier, JP; Soriano, P			Identification and validation of PDGF transcriptional targets by microarray-coupled gene-trap mutagenesis	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; MESSENGER-RNA; DEVELOPMENTAL GENES; EXPRESSION PATTERNS; FUNCTIONAL-ANALYSIS; GROWTH-FACTORS; MOUSE GENOME; MUTANT MICE; IN-VITRO; SCREEN	We developed a versatile, high-throughput genetic screening strategy by coupling gene mutagenesis and expression profiling technologies. Using a retroviral gene-trap vector optimized for efficient mutagenesis and cloning, we randomly disrupted genes in mouse embryonic stem (ES) cells and amplified them to construct a cDNA microarray. With this gene-trap array, we show that transcriptional target genes of platelet-derived growth factor (PDGF) can be efficiently and reliably identified in physiologically relevant cells and are immediately accessible to genetic studies to determine their in vivo roles and relative contributions to PDGF-regulated developmental processes. The same platform can be used to search for genes of specific biological relevance in a broad array of experimental settings, providing a fast track from gene identification to functional validation.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Div Basic Sci, Seattle, WA 98109 USA; Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Fred Hutchinson Cancer Center; University of Michigan System; University of Michigan	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, Div Basic Sci, Seattle, WA 98109 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				Abuin A, 2002, TRENDS BIOTECHNOL, V20, P36, DOI 10.1016/S0167-7799(01)01843-1; Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bonaldo P, 1998, EXP CELL RES, V244, P125, DOI 10.1006/excr.1998.4208; Chen WSV, 2003, METHOD ENZYMOL, V365, P367; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Hamilton TG, 2003, MOL CELL BIOL, V23, P4013, DOI 10.1128/MCB.23.11.4013-4025.2003; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Komada M, 2000, GENE DEV, V14, P1332; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lahoud MH, 2001, GENOME RES, V11, P1327, DOI 10.1101/gr.168801; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100	42	89	96	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					304	312		10.1038/ng1306	http://dx.doi.org/10.1038/ng1306			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981515	Bronze			2022-12-25	WOS:000189250400022
J	Glebov, OO; Nichols, BJ				Glebov, OO; Nichols, BJ			Lipid raft proteins have a random distribution during localized activation of the T-cell receptor	NATURE CELL BIOLOGY			English	Article							RESONANCE ENERGY-TRANSFER; GPI-ANCHORED PROTEINS; YELLOW FLUORESCENT PROTEIN; MEMBRANE MICRODOMAINS; SIGNALING ASSEMBLIES; PLASMA-MEMBRANE; LIVE CELLS; MICROSCOPY; DOMAINS; SURFACE	The extent to which lipid raft proteins are organized in functional clusters within the plasma membrane is central to the debate on structure and function of rafts(1-3). Glycosylphosphatidylinositol (GPI)-linked proteins are characteristic components of biochemically defined rafts(1,4,5). Several studies report a function for rafts in T-cell stimulation(6-8), but it is unclear whether molecules involved in T-cell receptor (TCR) signalling are recruited to (or excluded from) T-cell synapses through asymmetric distribution of raft microdomains or through specific protein-protein interactions(9,10). Here we used FRET analysis(11) in live cells to determine whether GPI-linked proteins are clustered in the plasma membrane of unstimulated cells, and at regions where TCR signalling has been activated using antibody-coated beads. Multiple criteria suggested that FRET between different GPI-linked fluorescent proteins in COS-7 or unstimulated Jurkat T-cells is generated by a random, un-clustered distribution. Stimulation of TCR signalling in Jurkat cells resulted in localized increases in fluorescence of GPI-linked fluorescent proteins and cholera toxin B-subunit (CTB)(12). However, measurements of FRET and ratio imaging showed that there was no detectable clustering and no overall enrichment of GPI-linked proteins or CTB in these regions.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Nichols, BJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ben@mrc-lmb.cam.ac.uk		Glebov, Oleg/0000-0002-3312-5470				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; EDIDIN M, 2003, ANNU REV BIOPH BIOM, V32, P417; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; JOVIN TM, 1989, ANNU REV BIOPHYS BIO, V18, P271, DOI 10.1146/annurev.bb.18.060189.001415; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pizzo P, 2003, CURR OPIN IMMUNOL, V15, P255, DOI 10.1016/S0952-7915(03)00038-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	33	167	170	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					238	243		10.1038/ncb1103	http://dx.doi.org/10.1038/ncb1103			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	14767481				2022-12-25	WOS:000189363000015
J	Parks, AL; Cook, KR; Belvin, M; Dompe, NA; Fawcett, R; Huppert, K; Tan, LR; Winter, CG; Bogart, KP; Deal, JE; Deal-Herr, ME; Grant, D; Marcinko, M; Miyazaki, WY; Robertson, S; Shaw, KJ; Tabios, M; Vysotskaia, V; Zhao, L; Andrade, RS; Edgar, KA; Howie, E; Killpack, K; Milash, B; Norton, A; Thao, D; Whittaker, K; Winner, MA; Friedman, L; Margolis, J; Singer, MA; Kopczynski, C; Curtis, D; Kaufman, TC; Plowman, GD; Duyk, G; Francis-Lang, HL				Parks, AL; Cook, KR; Belvin, M; Dompe, NA; Fawcett, R; Huppert, K; Tan, LR; Winter, CG; Bogart, KP; Deal, JE; Deal-Herr, ME; Grant, D; Marcinko, M; Miyazaki, WY; Robertson, S; Shaw, KJ; Tabios, M; Vysotskaia, V; Zhao, L; Andrade, RS; Edgar, KA; Howie, E; Killpack, K; Milash, B; Norton, A; Thao, D; Whittaker, K; Winner, MA; Friedman, L; Margolis, J; Singer, MA; Kopczynski, C; Curtis, D; Kaufman, TC; Plowman, GD; Duyk, G; Francis-Lang, HL			Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome	NATURE GENETICS			English	Article							CHROMOSOME REARRANGEMENTS; RECOMBINATION	In fruit fly research, chromosomal deletions are indispensable tools for mapping mutations, characterizing alleles and identifying interacting loci. Most widely used deletions were generated by irradiation or chemical mutagenesis. These methods are labor-intensive, generate random breakpoints and result in unwanted secondary mutations that can confound phenotypic analyses. Most of the existing deletions are large, have molecularly undefined endpoints and are maintained in genetically complex stocks. Furthermore, the existence of haplolethal or haplosterile loci makes the recovery of deletions of certain regions exceedingly difficult by traditional methods, resulting in gaps in coverage. Here we describe two methods that address these problems by providing for the systematic isolation of targeted deletions in the D. melanogaster genome. The first strategy used a P element based technique to generate deletions that closely flank haploinsufficient genes and minimize undeleted regions. This deletion set has increased overall genomic coverage by 5-7%. The second strategy used FLP recombinase and the large array of FRT-bearing insertions described in the accompanying paper(1) to generate 519 isogenic deletions with molecularly defined endpoints. This second deletion collection provides 56% genome coverage so far. The latter methodology enables the generation of small custom deletions with predictable endpoints throughout the genome and should make their isolation a simple and routine task.	Indiana Univ, Dept Biol, Bloomington Drosophila Stock Ctr, Bloomington, IN 47405 USA; Exelixis, San Francisco, CA 94083 USA	Indiana University System; Indiana University Bloomington; Exelixis, Inc.	Cook, KR (corresponding author), Indiana Univ, Dept Biol, Bloomington Drosophila Stock Ctr, 1001 E 3rd St, Bloomington, IN 47405 USA.	kcook@bio.indiana.edu	PLOWMAN, Greg D/E-2012-2011	Cook, Kevin/0000-0001-9260-364X; Huppert, Kari A./0000-0003-0842-1937; Parks, Annette/0000-0002-4619-2277; Plowman, Gregory D/0000-0002-6465-309X	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014106] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR014106] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashburner M., 1989, DROSOPHILA LAB HDB; BERG R, 1980, SCIENCE, V210, P427, DOI 10.1126/science.6776625; COOLEY L, 1990, P NATL ACAD SCI USA, V87, P3170, DOI 10.1073/pnas.87.8.3170; Golic KG, 1996, GENETICS, V144, P1693; Gray YHM, 1996, GENETICS, V144, P1601; Preston CR, 1996, GENETICS, V144, P1623; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; THIBAULT ST, 2004, NAT GENET       0222; TOWER J, 1993, GENETICS, V133, P347	9	586	599	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					288	292		10.1038/ng1312	http://dx.doi.org/10.1038/ng1312			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981519	Bronze			2022-12-25	WOS:000189250400019
J	Singer, M; Martin, LD; Vargaftig, BB; Park, J; Gruber, AD; Li, YH; Adler, KB				Singer, M; Martin, LD; Vargaftig, BB; Park, J; Gruber, AD; Li, YH; Adler, KB			A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS; SECRETION; MICE; PHOSPHORYLATION; RELEASE; MUCIN; LEUKOTRIENES; RECRUITMENT; EXOCYTOSIS	Mucus hypersecretion is a crucial feature of pulmonary diseases such as asthma, chronic bronchitis and cystic fibrosis. Despite much research, there is still no effective therapy for this condition. Recently, we showed that the myristoylated, alanine-rich C-kinase substrate (MARCKS) protein is required for mucus secretion by human bronchial epithelial cells in culture 1. Having synthesized a peptide corresponding to the N-terminal domain of MARCKS, we now show that the intratracheal instillation of this peptide blocks mucus hypersecretion in a mouse model of asthma. A missense peptide with the same amino acid composition has no effect. Based on quantitative histochemical analysis of the mouse airways, the peptide seems to act by blocking mucus release from goblet cells, possibly by inhibiting the attachment of MARCKS to membranes of intracellular mucin granules. These results support a pivotal role for MARCKS protein, specifically its N-terminal region, in modulating this secretory process in mammalian airways. Intratracheal administration of this MARCKS-related peptide could therapeutically reduce mucus secretion in the airways of human patients with asthma, chronic bronchitis and cystic fibrosis.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Inst Pasteur, Unite Pharmacol Cellulaire, F-75724 Paris 15, France; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Hannover Sch Vet Med, Dept Pathol, D-30559 Hannover, Germany	University of North Carolina; North Carolina State University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade de Sao Paulo; University of Veterinary Medicine Hannover, Foundation	Adler, KB (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	Kenneth_Adler@ncsu.edu	Gruber, Achim D./ABA-4514-2021; Vargaftig, Bernardo Boris B.B.J./C-3323-2013		NHLBI NIH HHS [R01-HL36982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Haile S, 1999, AM J RESP CELL MOL, V20, P891, DOI 10.1165/ajrcmb.20.5.3446; Hartness ME, 2001, EUR J NEUROSCI, V13, P925, DOI 10.1046/j.0953-816x.2001.01466.x; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; Salli U, 2000, BIOL REPROD, V63, P12, DOI 10.1095/biolreprod63.1.12; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; Singer M, 2002, AM J RESP CELL MOL, V26, P74, DOI 10.1165/ajrcmb.26.1.4618; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V285, pL808, DOI 10.1152/ajplung.00377.2002; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V284, pL260, DOI 10.1152/ajplung.00226.2002; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Wu TT, 1997, J CELL SCI, V110, P1533	18	127	140	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					193	196		10.1038/nm983	http://dx.doi.org/10.1038/nm983			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716307				2022-12-25	WOS:000188719600040
J	Deidda, G; Rossi, N; Tocchini-Valentini, GP				Deidda, G; Rossi, N; Tocchini-Valentini, GP			An archaeal endoribonuclease catalyzes cis- and trans-nonspliceosomal splicing in mouse cells	NATURE BIOTECHNOLOGY			English	Article							UNFOLDED PROTEIN RESPONSE; TRANSFER-RNA LIGASE; GENE; RECOGNITION; MECHANISM; SYSTEM	The tRNA endonuclease from the archaebacterium Methanococcus jannaschii (MJ endonuclease) can cleave RNAs forming specific bulge- helix- bulge (BHB) structures recognized by the enzyme (1). The resulting cleavage products are subsequently joined together by an endogenous ligase. We demonstrate the potential of using this strategy for repairing RNA in higher organisms by expressing the enzyme in mouse cells. Reporter target mRNAs modified with 17- nucleotide introns, flanked by sequences capable of forming BHB structures in cis, were expressed in mouse cells. RNA molecules that can form BHB substrates in trans with targeted mRNAs were also designed. Co- transfection of mouse cells with plasmids expressing these RNAs and the MJ endonuclease led to formation of RNA chimeras in which the target and exogenous RNA were recombined across the BHB. This technology is not limited to mRNA, but could in principle be used to destroy, modify or restore the function of a vast repertoire of RNA species or to join selectable tags to target RNAs.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, RM, Italy	Consiglio Nazionale delle Ricerche (CNR)	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Via E Ramarini 32,Campus A Buzzati Traverso, I-00016 Monterotondo, RM, Italy.	gtocchini@ibc.cnr.it		DEIDDA, GIANCARLO/0000-0002-0828-5800				Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Dahlberg JE, 2003, RNA, V9, P1, DOI 10.1261/rna.2121703; Diener JL, 1998, MOL CELL, V1, P883, DOI 10.1016/S1097-2765(00)80087-8; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; LYKKEANDERSEN J, 1994, J MOL BIOL, V243, P846, DOI 10.1006/jmbi.1994.1687; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; Moore M. J., 1993, RNA WORLD; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820	27	22	23	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1499	1504		10.1038/nbt908	http://dx.doi.org/10.1038/nbt908			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14595336				2022-12-25	WOS:000186845200029
J	Fu, X; Albermann, C; Jiang, JQ; Liao, JC; Zhang, CS; Thorson, JS				Fu, X; Albermann, C; Jiang, JQ; Liao, JC; Zhang, CS; Thorson, JS			Antibiotic optimization via in vitro glycorandomization	NATURE BIOTECHNOLOGY			English	Article							VANCOMYCIN; GLYCOSYLATION; CYCLOADDITION; GLYCOPEPTIDES; NATURES; ANALOGS	In nature, the attachment of sugars to small molecules is often used to mediate targeting, mechanism of action and/ or pharmacology. As an alternative to pathway engineering or total synthesis, we report a useful method, in vitro glycorandomization (IVG), to diversify the glycosylation patterns of complex natural products. We have used flexible glycosyltransferases on nucleotide diphosphosugar (NDP-sugar) libraries to generate glycorandomized natural products and then applied chemoselective ligation to produce monoglycosylated vancomycins that rival vancomycin.	Univ Wisconsin, Sch Pharm, Lab Biosynthet Chem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Thorson, JS (corresponding author), Univ Wisconsin, Sch Pharm, Lab Biosynthet Chem, 777 Highland Ave, Madison, WI 53705 USA.		Thorson, Jon S/L-3696-2013; Zhang, Changsheng/B-5965-2012	Thorson, Jon S/0000-0002-7148-0721; Zhang, Changsheng/0000-0003-2349-3138	NATIONAL CANCER INSTITUTE [R01CA084374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058196] Funding Source: NIH RePORTER; NCI NIH HHS [CA84374] Funding Source: Medline; NIAID NIH HHS [AI52218] Funding Source: Medline; NIGMS NIH HHS [GM58196] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; Hang HC, 2001, ACCOUNTS CHEM RES, V34, P727, DOI 10.1021/ar9901570; HLASTA DJ, 1994, J ORG CHEM, V59, P6184, DOI 10.1021/jo00100a019; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5; Losey HC, 2001, BIOCHEMISTRY-US, V40, P4745, DOI 10.1021/bi010050w; Losey HC, 2002, CHEM BIOL, V9, P1305, DOI 10.1016/S1074-5521(02)00270-3; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; Nicolaou KC, 2001, CHEM-EUR J, V7, P3798, DOI 10.1002/1521-3765(20010903)7:17<3798::AID-CHEM3798>3.0.CO;2-6; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; Thorson JS, 2001, CURR ORG CHEM, V5, P139, DOI 10.2174/1385272013375706; THORSON JS, IN PRESS CHEMBIOCHEM; Wang Q, 2003, J AM CHEM SOC, V125, P3192, DOI 10.1021/ja021381e; WeymouthWilson AC, 1997, NAT PROD REP, V14, P99, DOI 10.1039/np9971400099	15	195	214	0	44	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1467	1469		10.1038/nbt909	http://dx.doi.org/10.1038/nbt909			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14608364				2022-12-25	WOS:000186845200023
J	Hevener, AL; He, WM; Barak, Y; Le, J; Bandyopadhyay, G; Olson, P; Wilkes, J; Evans, RM; Olefsky, J				Hevener, AL; He, WM; Barak, Y; Le, J; Bandyopadhyay, G; Olson, P; Wilkes, J; Evans, RM; Olefsky, J			Muscle-specific Pparg deletion causes insulin resistance	NATURE MEDICINE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; ADIPOSE-TISSUE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; ANTIDIABETIC AGENT; ORPHAN RECEPTORS; SKELETAL-MUSCLE; NIDDM PATIENTS	Thiazolidinediones (TZDs) are insulin- sensitizing drugs and are potent agonists of the nuclear peroxisome proliferator- activated receptor-gamma (PPAR-gamma). Although muscle is the major organ responsible for insulin- stimulated glucose disposal, PPAR-gamma is more highly expressed in adipose tissue than in muscle. To address this issue, we used the Cre- loxP system to knock out Pparg, the gene encoding PPAR-gamma, in mouse skeletal muscle. As early as 4 months of age, mice with targeted disruption of PPAR-gamma in muscle showed glucose intolerance and progressive insulin resistance. Using the hyperinsulinemic- euglycemic clamp technique, the in vivo insulin- stimulated glucose disposal rate (IS- GDR) was reduced by similar to80% and was unchanged by 3 weeks of TZD treatment. These effects reveal a crucial role for muscle PPAR-gamma in the maintenance of skeletal muscle insulin action, the etiology of insulin resistance and the action of TZDs.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Calif San Diego, Howard Hughes Med Inst, Salk Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Jackson Laboratory; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Olefsky, J (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NHLBI NIH HHS [HL56989] Funding Source: Medline; NIDDK NIH HHS [2T32 DK07044-23, DK-60484, DK57978-24, DK-33651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060484, R37DK057978, T32DK007044, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; ELKEBBI IM, 1994, METABOLISM, V43, P953, DOI 10.1016/0026-0495(94)90173-2; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FRAYN KN, 1980, J LIPID RES, V21, P139; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; GAVRILOVA O, IN PRESS J BIOL CHEM; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kumar S, 1996, DIABETOLOGIA, V39, P701; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Loviscach M, 2000, DIABETOLOGIA, V43, P304, DOI 10.1007/s001250050048; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Meigs JB, 2002, AM J MANAG CARE, V8, pS283; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OGOMAN S, 1997, P NATL ACAD SCI USA, V94, P14602; Reaven G, 2002, CIRCULATION, V106, P286, DOI 10.1161/01.CIR.0000019884.36724.D9; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SMITH D, 1987, METABOLISM, V36, P1176; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wilkes JJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE912, DOI 10.1152/ajpendo.2000.279.4.E912; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087	49	391	410	0	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1491	1497		10.1038/nm956	http://dx.doi.org/10.1038/nm956			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625542				2022-12-25	WOS:000186845400032
J	Shah, MM; Fujiyama, K; Flynn, CR; Joshi, L				Shah, MM; Fujiyama, K; Flynn, CR; Joshi, L			Sialylated endogenous glycoconjugates in plant cells	NATURE BIOTECHNOLOGY			English	Article							N-GLYCOLYLNEURAMINIC ACIDS; LINKED OLIGOSACCHARIDES; LIQUID-CHROMATOGRAPHY; GLYCOPROTEINS	Bioengineered plants are emerging as promising systems for the production of therapeutically valuable proteins. It has been commonly accepted that plants do not perform mammalian-like post- translational modifications, particularly sialylation of glycoconjugates, and no evidence has previously been reported to suggest that they have such capabilities. Here we report the presence of sialylated glycoconjugates in suspension- cultured cells of Arabidopsis thaliana and suggest that a genetic and enzymatic basis for sialylation exists in plants.	Arizona State Univ, Harrington Dept Bioengn, Tempe, AZ 85287 USA; Arizona State Univ, Arizona BioDesign Inst, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Joshi, L (corresponding author), Arizona State Univ, Harrington Dept Bioengn, POB 879709, Tempe, AZ 85287 USA.		Flynn, Charles/M-3895-2015	Flynn, Charles/0000-0002-3749-0598; Joshi, Lokesh/0000-0002-3612-0747				ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; FAYE L, 1985, ANAL BIOCHEM, V149, P218, DOI 10.1016/0003-2697(85)90498-1; Giddings G, 2001, CURR OPIN BIOTECH, V12, P450, DOI 10.1016/S0958-1669(00)00244-5; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; MATSUMOTO S, 1995, PLANT MOL BIOL, V27, P1163, DOI 10.1007/BF00020889; REUTER G, 1994, METHOD ENZYMOL, V230, P168; Rosenberg A, 1995, BIOL SIALIC ACIDS; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; VARKI A, 1995, ESSENTIALS GLYCOBIOL, P195; WANG WC, 1988, J BIOL CHEM, V263, P4576	12	69	82	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1470	1471		10.1038/nbt912	http://dx.doi.org/10.1038/nbt912			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14608367				2022-12-25	WOS:000186845200024
J	Corn, PG; McDonald, ER; Herman, JG; El-Deiry, WS				Corn, PG; McDonald, ER; Herman, JG; El-Deiry, WS			Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENE; RENAL-CARCINOMA; REGULATE HIF; COMPLEX; MUTATIONS; DISEASE; IDENTIFICATION; PROTEOLYSIS; FAMILY; PVHL	von Hippel Lindau (VHL) gene inactivation occurs in von Hippel Lindau (VHL) disease. The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1alpha for proteasomal degradation during normoxia. We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome. TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 in vivo. Overexpression of TBP-1 promotes degradation of Hif1 in a pVHL-dependent manner that requires the ATPase domain of TBP-1. Blockade of TBP-1 expression by small interfering RNA ( siRNA) causes prolonged degradation kinetics of Hif1alpha. Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1. A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1alpha, but not TBP-1, and does not promote degradation of Hif1alpha. Thus, the ability of pVHL to degrade Hif1alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1alpha stabilization in some pVHL-deficient tumors.	Univ Penn, Howard Hughes Med Inst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Medicine	El-Deiry, WS (corresponding author), Univ Penn, Howard Hughes Med Inst, Dept Med, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hoyle J, 1997, HUM GENET, V99, P285, DOI 10.1007/s004390050356; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Liu CW, 2002, J BIOL CHEM, V277, P26815, DOI 10.1074/jbc.M201782200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nakamura T, 1998, BBA-GENE STRUCT EXPR, V1399, P93, DOI 10.1016/S0167-4781(98)00105-5; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, GENE DEV, V14, P1983; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	38	61	63	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					229	237		10.1038/ng1254	http://dx.doi.org/10.1038/ng1254			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14556007				2022-12-25	WOS:000186273300018
J	Li, HW; Liu, H; Heller, S				Li, HW; Liu, H; Heller, S			Pluripotent stem cells from the adult mouse inner ear	NATURE MEDICINE			English	Article							HAIR-CELLS; REGENERATIVE PROLIFERATION; NERVOUS-SYSTEM; GROWTH-FACTORS; EXPRESSION; GENE; GENERATION; CULTURE; MATH1; MICE	In mammals, the permanence of acquired hearing loss is mostly due to the incapacity of the cochlea to replace lost mechanoreceptor cells, or hair cells. In contrast, damaged vestibular organs can generate new hair cells, albeit in limited numbers. Here we show that the adult utricular sensory epithelium contains cells that display the characteristic features of stem cells. These inner ear stem cells have the capacity for self-renewal, and form spheres that express marker genes of the developing inner ear and the nervous system. Inner ear stem cells are pluripotent and can give rise to a variety of cell types in vitro and in vivo, including cells representative of ectodermal, endodermal and mesodermal lineages. Our observation that these stem cells are capable of differentiating into hair cell-like cells implies a possible use of such cells for the replacement of lost inner-ear sensory cells.	Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Heller, S (corresponding author), Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006167] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC006167] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; BODINE DM, 1991, BLOOD, V78, P914; Chen P, 2002, DEVELOPMENT, V129, P2495; Chen P, 1999, DEVELOPMENT, V126, P1581; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Cohen M. M., 1995, HEREDITARY HEARING L, P9; CORWIN JT, 1995, ASS RES OT ABSTR, V18, P87; Davis AC, 1993, HEARING SCI HEARING, P35; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gritti A, 1996, J NEUROSCI, V16, P1091; Groves AK, 2000, DEVELOPMENT, V127, P3489; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Helms AW, 2000, DEVELOPMENT, V127, P1185; HUDSPETH AJ, 1985, SCIENCE, V230, P745, DOI 10.1126/science.2414845; Kopke RD, 2001, P NATL ACAD SCI USA, V98, P5886, DOI 10.1073/pnas.101120898; LAMBERT PR, 1994, LARYNGOSCOPE, V104, P701; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; LUMPKIN EA, IN PRESS GENE EXPRES; Malgrange B, 2002, MECH DEVELOP, V112, P79, DOI 10.1016/S0925-4773(01)00642-6; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Morsli H, 1999, DEVELOPMENT, V126, P2335; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; *NAT CTR HLTH STAT, 2002, VIT HLTH STAT, V10; Oh SH, 1996, J NEUROSCI, V16, P6463; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAART G, 1989, DEVELOPMENT, V107, P585; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zheng JL, 1999, J NEUROCYTOL, V28, P901, DOI 10.1023/A:1007078307638; Zheng JL, 1997, J NEUROSCI, V17, P216, DOI 10.1523/JNEUROSCI.17-01-00216.1997; Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8	43	353	439	4	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1293	1299		10.1038/nm925	http://dx.doi.org/10.1038/nm925			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12949502				2022-12-25	WOS:000185669700041
J	Stager, S; Alexander, J; Kirby, AC; Botto, M; Van Rooijen, N; Smith, DF; Brombacher, F; Kaye, PM				Stager, S; Alexander, J; Kirby, AC; Botto, M; Van Rooijen, N; Smith, DF; Brombacher, F; Kaye, PM			Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8(+) T-cell responses	NATURE MEDICINE			English	Article							DENDRITIC CELL; LEISHMANIA-DONOVANI; DEFICIENT MICE; IN-VIVO; B-CELLS; VISCERAL LEISHMANIASIS; PROTECTIVE IMMUNITY; ACQUIRED-IMMUNITY; BONE-MARROW; LINK INNATE	CD8(+) T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8(+) T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8(+) T cells, and we defined the primary source of IL-4 as a CD11b(+)CD11c(lo) phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8(+) T-cell priming was seen in C1qa(-/-) mice. These results identify a new pathway by which immune complex-mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; Univ London Imperial Coll Sci & Technol, Fac Med, Rheumatol Sect, London W12 0NN, England; Vrije Univ Amsterdam, Dept Mol Cell Biol, NL-1081 B5 Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England; Univ Cape Town, Sch Med, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of Strathclyde; Imperial College London; Vrije Universiteit Amsterdam; Imperial College London; University of Cape Town	Kaye, PM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.		Alexander, James/A-4238-2009	Kaye, Paul/0000-0002-8796-4755; Kirby, Alun/0000-0001-5663-2961	Wellcome Trust [061343] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alce TM, 1999, MOL BIOCHEM PARASIT, V102, P191, DOI 10.1016/S0166-6851(99)00074-2; Ato M, 2002, NAT IMMUNOL, V3, P1185, DOI 10.1038/ni861; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Boes M, 1998, J IMMUNOL, V160, P4776; BONA C, 1980, J EXP MED, V151, P224, DOI 10.1084/jem.151.1.224; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166; Coffman RL, 1997, J EXP MED, V185, P373, DOI 10.1084/jem.185.3.373; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gicheru MM, 2001, INFECT IMMUN, V69, P245, DOI 10.1128/IAI.69.1.245-251.2001; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7; Haas KM, 2002, IMMUNITY, V17, P713, DOI 10.1016/S1074-7613(02)00483-1; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; Hayashi N, 1999, J IMMUNOL, V163, P6702; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King C, 2001, NAT MED, V7, P206, DOI 10.1038/84659; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Lutz C, 1998, NATURE, V393, P797, DOI 10.1038/31716; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Mohrs M, 1999, J IMMUNOL, V162, P7302; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Murphy ML, 1998, J IMMUNOL, V161, P4153; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Keeffe M, 2003, BLOOD, V101, P1453, DOI 10.1182/blood-2002-03-0974; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Qi H, 2001, J IMMUNOL, V167, P4534, DOI 10.4049/jimmunol.167.8.4534; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reid RR, 1997, J IMMUNOL, V159, P970; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; Schuler T, 2001, J EXP MED, V194, P1767, DOI 10.1084/jem.194.12.1767; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; Stager S, 2000, J IMMUNOL, V165, P7064, DOI 10.4049/jimmunol.165.12.7064; Suresh M, 2003, J IMMUNOL, V170, P788, DOI 10.4049/jimmunol.170.2.788; SWAIN SL, 1988, IMMUNOL REV, V102, P77, DOI 10.1111/j.1600-065X.1988.tb00742.x; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wardemann H, 2002, J EXP MED, V195, P771, DOI 10.1084/jem.20011140; Yamaguchi M, 2001, INT IMMUNOL, V13, P843, DOI 10.1093/intimm/13.7.843; Yoshida A, 2001, VACCINE, V19, P4297, DOI 10.1016/S0264-410X(01)00146-3	50	167	173	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1287	1292		10.1038/nm933	http://dx.doi.org/10.1038/nm933			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502281				2022-12-25	WOS:000185669700040
J	During, MJ; Cao, L; Zuzga, DS; Francis, JS; Fitzsimons, HL; Jiao, XY; Bland, RJ; Klugmann, M; Banks, WA; Drucker, DJ; Haile, CN				During, MJ; Cao, L; Zuzga, DS; Francis, JS; Fitzsimons, HL; Jiao, XY; Bland, RJ; Klugmann, M; Banks, WA; Drucker, DJ; Haile, CN			Glucagon-like peptide-1 receptor is involved in learning and neuroprotection	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; BLOOD-BRAIN; EXPRESSION; INSULIN; CELLS; PANCREAS; DEGRADATION; EXENDIN-4; RELEASE	Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.	Univ Auckland, Dept Mol Med & Pathol, Auckland 86716, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, CNS Gene Therapy Ctr, Philadelphia, PA 19107 USA; St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63106 USA; St Louis Univ, Sch Med, Vet Affiars Med Ctr St Louis, GRECC, St Louis, MO 63106 USA; Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Auckland; Jefferson University; Saint Louis University; Geriatric Research Education & Clinical Center; Saint Louis University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	During, MJ (corresponding author), Univ Auckland, Dept Mol Med & Pathol, Private Bag 92019, Auckland 86716, New Zealand.		Cao, Lei/H-3185-2019; Banks, William A/K-1330-2017; Drucker, Daniel J/A-4092-2010; Cao, Lei/E-2841-2011; During, Matthew/AAC-1388-2020	Banks, William A/0000-0002-0496-3619; Haile, Colin/0000-0001-8293-7291; Cao, Lei/0000-0003-0322-4985; Fitzsimons, Helen/0000-0001-7825-3911				Alvarez E, 1996, J NEUROCHEM, V66, P920; Banks WA, 2002, J PHARMACOL EXP THER, V302, P1062, DOI 10.1124/jpet.102.036129; Banks WA, 1999, PEPTIDES, V20, P373, DOI 10.1016/S0196-9781(99)00045-5; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cashion MF, 1999, BRAIN RES, V822, P26, DOI 10.1016/S0006-8993(99)01069-0; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; DEWIED D, 1971, NATURE, V232, P58, DOI 10.1038/232058a0; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Gallwitz B, 2000, REGUL PEPTIDES, V86, P103, DOI 10.1016/S0167-0115(99)00095-6; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; JIN SLC, 1988, J COMP NEUROL, V271, P519, DOI 10.1002/cne.902710405; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Kern W, 1999, DIABETES, V48, P557, DOI 10.2337/diabetes.48.3.557; Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Perfetti R, 2000, ENDOCRINOLOGY, V141, P4600, DOI 10.1210/en.141.12.4600; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ramanathan M, 1998, PSYCHOPHARMACOLOGY, V135, P361, DOI 10.1007/s002130050523; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; SANTUCCI AC, 1990, BEHAV NEURAL BIOL, V53, P321, DOI 10.1016/0163-1047(90)90184-8; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Setlow B, 2000, LEARN MEMORY, V7, P187, DOI 10.1101/lm.7.3.187; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Tseng CC, 1999, AM J PHYSIOL-ENDOC M, V276, pE1049, DOI 10.1152/ajpendo.1999.276.6.E1049; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VENABLE N, 1990, PSYCHOPHARMACOLOGY, V100, P215, DOI 10.1007/BF02244409; WEATHERLY LS, 1996, BRAIN RES, V716, P29; Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	40	614	676	1	63	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1173	1179		10.1038/nm919	http://dx.doi.org/10.1038/nm919			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925848				2022-12-25	WOS:000185061600030
J	Shichiri, M; Ishimaru, S; Ota, T; Nishikawa, T; Isogai, T; Hirata, Y				Shichiri, M; Ishimaru, S; Ota, T; Nishikawa, T; Isogai, T; Hirata, Y			Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities	NATURE MEDICINE			English	Article							ONSET TORSION DYSTONIA; SMOOTH-MUSCLE-CELLS; RECEPTOR GPR14; GROWTH-FACTOR; UROTENSIN-II; ENDOTHELIN-1; PROTEIN; ADRENOMEDULLIN; EXPRESSION; APOPTOSIS	The discovery of endogenous bioactive peptides has typically required a lengthy identification process. Computer-assisted analysis of cDNA and genomic DNA sequence information can markedly shorten the process. A bioinformatic analysis of full-length, enriched human cDNA libraries searching for previously unidentified bioactive peptides resulted in the identification and characterization of two related peptides of 28 and 20 amino acids, which we designated salusin-alpha and salusin-beta. Salusins are translated from an alternatively spliced mRNA of TOR2A, a gene encoding a protein of the torsion dystonia family. Intravenous administration of salusin-alpha or salusin-beta to rats causes rapid, profound hypotension and bradycardia. Salusins increase intracellular Ca2+, upregulate a variety of genes and induce cell mitogenesis. Salusin-beta stimulates the release of argininevasopressin from rat pituitary. Expression of TOR2A mRNA and its splicing into preprosalusin are ubiquitous, and immunoreactive salusin-alpha and salusin-beta are detected in many human tissues, plasma and urine, suggesting that salusins are endocrine and/or paracrine factors.	Tokyo Med & Dent Univ, Hosp Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, Tokyo 1138519, Japan; Helix Res Inst Inc, Chiba 2920812, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shichiri, M (corresponding author), Tokyo Med & Dent Univ, Hosp Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Shichiri, Masayoshi/0000-0002-5704-1378; ISOGAI, TAKAO/0000-0002-1970-4556				Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Doi M, 2000, HYPERTENS RES, V23, P643, DOI 10.1291/hypres.23.643; Eatman D, 1998, EUR J PHARMACOL, V361, P207, DOI 10.1016/S0014-2999(98)00700-6; EIPPER BA, 1993, ANN NY ACAD SCI, V680, P147, DOI 10.1111/j.1749-6632.1993.tb19681.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Ishimaru S, 2001, HYPERTENS RES, V24, P119, DOI 10.1291/hypres.24.119; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Iwasaki H, 2001, ENDOCR J, V48, P261, DOI 10.1507/endocrj.48.261; JUNG LJ, 1993, RECENT PROG HORM RES, V48, P415; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Matsushita M, 2001, J HYPERTENS, V19, P2185, DOI 10.1097/00004872-200112000-00011; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OTA T, 1988, MICROB COMP GENOMI C, V87; Ozelius LJ, 1999, GENOMICS, V62, P377, DOI 10.1006/geno.1999.6039; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PROUTY SM, 1993, ONCOGENE, V8, P899; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHICHIRI M, 1989, BIOCHEM BIOPH RES CO, V163, P1332, DOI 10.1016/0006-291X(89)91124-8; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; Shichiri M, 2003, GENE THER, V10, P827, DOI 10.1038/sj.gt.3301953; Shichiri M, 2002, CANCER RES, V62, P13; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3	32	145	170	1	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1166	1172		10.1038/nm913	http://dx.doi.org/10.1038/nm913			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910263				2022-12-25	WOS:000185061600029
J	Crawford, DC; Bhangale, T; Li, N; Hellenthal, G; Rieder, MJ; Nickerson, DA; Stephens, M				Crawford, DC; Bhangale, T; Li, N; Hellenthal, G; Rieder, MJ; Nickerson, DA; Stephens, M			Evidence for substantial fine-scale variation in recombination rates across the human genome	NATURE GENETICS			English	Article							MEIOTIC RECOMBINATION; LINKAGE-DISEQUILIBRIUM; HAPLOTYPE BLOCKS; HOT; POLYMORPHISM; RECONSTRUCTION; DIVERSITY; HOTSPOTS; ORIGIN; SPOTS	Characterizing fine-scale variation in human recombination rates is important, both to deepen understanding of the recombination process(1) and to aid the design of disease association studies(2,3). Current genetic maps show that rates vary on a megabase scale, but studying finer-scale variation using pedigrees is difficult. Sperm-typing experiments(4-6) have characterized regions where crossovers cluster into 1-2-kb hot spots, but technical difficulties limit the number of studies(7). An alternative is to use population variation to infer fine-scale characteristics of the recombination process. Several surveys(8-10) reported block-like patterns of diversity, which may reflect fine-scale recombination rate variation(11-13), but limitations of available methods made this impossible to assess. Here, we applied a new statistical method, which overcomes these limitations, to infer patterns of fine-scale recombination rate variation in 74 genes. We found extensive rate variation both within and among genes. In particular, recombination hot spots are a common feature of the human genome: 47% (35 of 74) of genes showed substantive evidence for a hot spot, and many more showed evidence for some rate variation. No primary sequence characteristics are consistently associated with precise hot-spot location, although G+C content and nucleotide diversity are correlated with local recombination rate.	Univ Washington, Dept Stat, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stephens, M (corresponding author), Univ Washington, Dept Stat, Box 354322, Seattle, WA 98195 USA.	stephens@stat.washington.edu	Crawford, Dana/O-5578-2019; Crawford, Dana/C-1054-2012	Crawford, Dana/0000-0002-6437-6248; 				Arnheim N, 2003, AM J HUM GENET, V73, P5, DOI 10.1086/376419; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Clark AG, 2003, AM J HUM GENET, V73, P285, DOI 10.1086/377138; Cullen M, 2002, AM J HUM GENET, V71, P759, DOI 10.1086/342973; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; de Massy B, 2003, TRENDS GENET, V19, P514, DOI 10.1016/S0168-9525(03)00201-4; Frisse L, 2001, AM J HUM GENET, V69, P831, DOI 10.1086/323612; Fullerton SM, 2000, MOL BIOL EVOL, V17, P179, DOI 10.1093/oxfordjournals.molbev.a026230; Fullerton SM, 2001, MOL BIOL EVOL, V18, P1139, DOI 10.1093/oxfordjournals.molbev.a003886; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Li N, 2003, GENETICS, V165, P2213; LI N, 2003, THESIS U WASHINGTON; Nachman MW, 1998, GENETICS, V150, P1133; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Phillips MS, 2003, NAT GENET, V33, P382, DOI 10.1038/ng1100; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; PTAK SE, IN PRESS GENETICS; PTAK SE, IN PRESS PLOS BIOL; Schneider JA, 2002, HUM MOL GENET, V11, P207, DOI 10.1093/hmg/11.3.207; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Wall JD, 2003, AM J HUM GENET, V73, P502, DOI 10.1086/378099; Wall JD, 2003, AM J HUM GENET, V73, P1330, DOI 10.1086/380311; Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398	30	219	239	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					700	706		10.1038/ng1376	http://dx.doi.org/10.1038/ng1376			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15184900	Bronze			2022-12-25	WOS:000222354100019
J	Lipkin, SM; Rozek, LS; Rennert, G; Yang, W; Chen, PC; Hacia, J; Hunt, N; Shin, B; Fodor, S; Kokoris, M; Greenson, JK; Fearon, E; Lynch, H; Collins, F; Gruber, SB				Lipkin, SM; Rozek, LS; Rennert, G; Yang, W; Chen, PC; Hacia, J; Hunt, N; Shin, B; Fodor, S; Kokoris, M; Greenson, JK; Fearon, E; Lynch, H; Collins, F; Gruber, SB			The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer	NATURE GENETICS			English	Article							MISMATCH-REPAIR; MICROSATELLITE INSTABILITY; MSH6 MUTATIONS; COLON-CANCER; MUTL; EXPRESSION; GENE; IDENTIFICATION; ASHKENAZI; FAMILIES	Most susceptibility to colorectal cancer (CRC) is not accounted for by known risk factors. Because MLH1, MSH2 and MSH6 mutations underlie high-penetrance CRC susceptibility in hereditary nonpolyposis colon cancer (HNPCC), we hypothesized that attenuated alleles might also underlie susceptibility to sporadic CRC. We looked for gene variants associated with HNPCC in Israeli probands with familial CRC unstratified with respect to the microsatellite instability (MSI) phenotype. Association studies identified a new MLH1 variant (415G-->C, resulting in the amino acid substitution D132H) in similar to1.3% of Israeli individuals with CRC self-described as Jewish, Christian and Muslim. MLH1 415C confers clinically significant susceptibility to CRC. In contrast to classic HNPCC, CRCs associated with MLH1 415C usually do not have the MSI defect, which is important for clinical mutation screening. Structural and functional analyses showed that the normal ATPase function of MLH1 is attenuated, but not eliminated, by the MLH1 415G-->C mutation. The new MLH1 variant confers a high risk of CRC and identifies a previously unrecognized mechanism in microsatellite-stable tumors. These studies suggest that variants of mismatch repair proteins with attenuated function may account for a higher proportion of susceptibility to sporadic microsatellite-stable CRC than previously assumed.	Univ Calif Irvine, Dept Med, Div Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Epidemiol, Irvine, CA 92697 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Haifa, Israel; NIDDKD, Mol Struct Sect, Bethesda, MD 20892 USA; Univ So Calif, Inst Med Genet, Los Angeles, CA 90089 USA; Affymetrix Corp, Santa Clara, CA 95051 USA; BioCaptus, Bothell, WA 99164 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE USA; NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Southern California; Affymetrix; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Creighton University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Lipkin, SM (corresponding author), Univ Calif Irvine, Dept Med, Div Oncol, Irvine, CA 92697 USA.	slipkin@uci.edu; sgruber@med.umich.edu	Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Rennert, Gad/0000-0002-8512-068X; Chen, Peng-Chieh ( Jessica )/0000-0002-2060-1765				Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Boland CR, 1998, CANCER RES, V58, P5248; Charames GS, 2000, HUM GENET, V107, P623, DOI 10.1007/s004390000417; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; Foulkes WD, 2002, AM J HUM GENET, V71, P1395, DOI 10.1086/345075; Gazzoli I, 2003, MOL CELL BIOL, V23, P7992, DOI 10.1128/MCB.23.22.7992-8007.2003; Greenson JK, 2003, AM J SURG PATHOL, V27, P563, DOI 10.1097/00000478-200305000-00001; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Hacia JG, 1998, NUCLEIC ACIDS RES, V26, P3865, DOI 10.1093/nar/26.16.3865; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kokoris M, 2000, MOL DIAGN, V5, P329; Kolodner RD, 1999, CANCER RES, V59, P5068; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; Liu ZJ, 1999, MAR BIOTECHNOL, V1, P437, DOI 10.1007/PL00011800; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Peterlongo P, 2003, INT J CANCER, V107, P571, DOI 10.1002/ijc.11415; Quaresima B, 2003, BIOCHEM J, V371, P183, DOI 10.1042/BJ20021205; Samowitz WS, 2002, J CLIN ONCOL, V20, P3178, DOI 10.1200/JCO.2002.20.14.3178; Scartozzi M, 2002, J CLIN ONCOL, V20, P1203, DOI 10.1200/JCO.20.5.1203; Scholz B, 2003, NUCLEIC ACIDS RES, V31, P1426, DOI 10.1093/nar/gkg229; Shiri-Sverdlov R, 2000, HUM MUTAT, V16, P491, DOI 10.1002/1098-1004(200012)16:6<491::AID-HUMU6>3.3.CO;2-A; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; Szabo CI, 2004, CANCER RES, V64, P840, DOI 10.1158/0008-5472.CAN-03-2678; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773	30	83	89	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					694	699		10.1038/ng1374	http://dx.doi.org/10.1038/ng1374			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15184898	Bronze			2022-12-25	WOS:000222354100018
J	Zhu, L; Lee, HO; Jordan, CRS; Cantrell, VA; Southard-Smith, EM; Shin, MK				Zhu, L; Lee, HO; Jordan, CRS; Cantrell, VA; Southard-Smith, EM; Shin, MK			Spatiotemporal regulation of endothelin receptor-B by SOX10 in neural crest-derived enteric neuron precursors	NATURE GENETICS			English	Article							MOUSE MODEL; DOMINANT-MEGACOLON; AGANGLIONIC BOWEL; PROGENITOR CELLS; MIGRATION; GENE; RET; MUTATION; EDNRB; HAPLOINSUFFICIENCY	Hirschsprung disease (HSCR) is a multigenic, congenital disorder that affects 1 in 5,000 newborns and is characterized by the absence of neural crest derived enteric ganglia in the colon(1). One of the primary genes affected in HSCR encodes the G protein coupled endothelin receptor-B (EDNRB)(2,3). The expression of Ednrb is required at a defined time period during the migration of the precursors of the enteric nervous system (ENS) into the colon(4). In this study, we describe a conserved spatiotemporal ENS enhancer of Ednrb. This 1-kb enhancer is activated as the ENS precursors approach the colon, and partial deletion of this enhancer at the endogenous Ednrb locus results in pigmented mice that die postnatally from megacolon. We identified binding sites for SOX10, an SRY-related transcription factor associated with HSCR5, in the Ednrb ENS enhancer, and mutational analyses of these sites suggested that SOX10 may have multiple roles in regulating Ednrb in the ENS.	Fox Chase Canc Ctr, Cellular & Dev Biol Program, Philadelphia, PA 19111 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Med Genet, Nashville, TN 37232 USA	Fox Chase Cancer Center; Princeton University; Vanderbilt University	Shin, MK (corresponding author), Fox Chase Canc Ctr, Cellular & Dev Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	Myung.Shin@fccc.edu	Southard-Smith, Michelle/C-3488-2012	Southard-Smith, E Michelle/0000-0003-4718-5869	NIDDK NIH HHS [R01 DK060047-03, R01 DK060047-01A1, R01 DK060047, R01 DK060047-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060047] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlow A, 2003, NEURON, V40, P905, DOI 10.1016/S0896-6273(03)00730-X; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Carrasquillo MM, 2002, NAT GENET, V32, P237, DOI 10.1038/ng998; CHAKRAVARTI A, 2001, METABOLIC MOL BASES, P6231; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Hearn CJ, 1998, DEV BIOL, V197, P93, DOI 10.1006/dbio.1998.8876; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Iwashita T, 2003, SCIENCE, V301, P972, DOI 10.1126/science.1085649; KAPUR RP, 1995, DEVELOPMENT, V121, P3787; Kapur RP, 1996, DEV BIOL, V174, P360, DOI 10.1006/dbio.1996.0080; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kruger GM, 2003, NEURON, V40, P917, DOI 10.1016/S0896-6273(03)00727-X; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; Leibl MA, 1999, GUT, V44, P246, DOI 10.1136/gut.44.2.246; Mollaaghababa R, 2003, ONCOGENE, V22, P3024, DOI 10.1038/sj.onc.1206442; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Newgreen DF, 1995, ACTA ANAT, V154, P243; Paratore C, 2002, HUM MOL GENET, V11, P3075, DOI 10.1093/hmg/11.24.3075; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROTHMAN TP, 1993, DEV BIOL, V159, P559, DOI 10.1006/dbio.1993.1264; Rothman TP, 1996, DEV BIOL, V178, P498, DOI 10.1006/dbio.1996.0234; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Southard-Smith EM, 1999, GENOME RES, V9, P215; Wu JJ, 1999, DEVELOPMENT, V126, P1161	30	95	99	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					732	737		10.1038/ng1371	http://dx.doi.org/10.1038/ng1371			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15170213	Bronze			2022-12-25	WOS:000222354100024
J	Jimi, E; Aoki, K; Saito, H; D'Acquisto, F; May, MJ; Nakamura, I; Sudo, T; Kojima, T; Okamoto, F; Fukushima, H; Okabe, K; Ohya, K; Ghosh, S				Jimi, E; Aoki, K; Saito, H; D'Acquisto, F; May, MJ; Nakamura, I; Sudo, T; Kojima, T; Okamoto, F; Fukushima, H; Okabe, K; Ohya, K; Ghosh, S			Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo	NATURE MEDICINE			English	Article							RECEPTOR ACTIVATOR; KINASE INHIBITOR; TNF-ALPHA; RANK; DIFFERENTIATION; PEPTIDE; NEMO; MECHANISMS; ARTHRITIS; LIGAND	Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-kappaB (NF-kappaB) has a crucial role in osteoclast differentiation, and blocking NF-kappaB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IkappaB-kinase complex, a crucial component of signal transduction pathways to NF-kappaB. The peptide inhibited RANKL-stimulated NF-kappaB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-alpha and interleukin-1beta, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-kappaB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Pharmacol Sect, Tokyo 1138549, Japan; Yugawara Kosei Nenkin Hosp, Dept Orthoped Surg, Kanagawa 2590314, Japan; Toray Industries Ltd, Basic Res Labs, Kamakura, Kanagawa 2480036, Japan; Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sect Cellular Physiol, Fukuoka 8140193, Japan	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Tokyo Medical & Dental University (TMDU); Toray Industries, Inc.; Fukuoka Dental College (FDC)	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu	AOKI, Kazuhiro/GRO-6475-2022; D'Acquisto, Fulvio/E-7204-2018	AOKI, Kazuhiro/0000-0001-6643-6315; D'Acquisto, Fulvio/0000-0002-4513-1608; May, Michael/0000-0002-2485-3716; Saito, Hiroaki/0000-0002-8130-0624	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; BAROUKH B, 1991, J PERIODONTAL RES, V26, P161, DOI 10.1111/j.1600-0765.1991.tb01640.x; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Feldmann M, 2002, ANN RHEUM DIS, V61, P13; Feldmann M, 2001, CURR DIRECT AUTOIMMU, V3, P188; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HOROWITZ SM, 1995, CALCIFIED TISSUE INT, V57, P301, DOI 10.1007/BF00298886; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2002, ANN RHEUM DIS, V61, P82; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Luross JA, 2001, IMMUNOLOGY, V103, P407, DOI 10.1046/j.1365-2567.2001.01267.x; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Manolagas SC, 1998, AGING-CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281-200305000-00016; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Seetharaman R, 1999, J IMMUNOL, V163, P1577; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521	42	423	457	8	72	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					617	624		10.1038/nm1054	http://dx.doi.org/10.1038/nm1054			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156202				2022-12-25	WOS:000221759600027
J	Remold, SK; Lenski, RE				Remold, SK; Lenski, RE			Pervasive joint influence of epistasis and plasticity on mutational effects in Escherichia coli	NATURE GENETICS			English	Article							TERM EXPERIMENTAL EVOLUTION; ENVIRONMENT INTERACTIONS; DELETERIOUS MUTATIONS; ADAPTATION; GENERATIONS; POPULATIONS; DIVERGENCE; GENOTYPE; BACTERIA; FITNESS	The effects of mutations on phenotype and fitness may depend on the environment (phenotypic plasticity), other mutations ( genetic epistasis) or both. Here we examine the fitness effects of 18 random insertion mutations in E. coli in two resource environments and five genetic backgrounds. We tested each mutation for plasticity and epistasis by comparing its fitness effects across these ecological and genetic contexts. Some mutations had no measurable effect in any of these contexts. None of the mutations had effects on phenotypic plasticity that were independent of genetic background. However, half the mutations had epistatic interactions such that their effects differed among genetic backgrounds, usually in an environment-dependent manner. Also, the pattern of mutational effects across backgrounds indicated that epistasis had been shaped primarily by unique events in the evolutionary history of a population rather than by repeatable events associated with shared environmental history.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University	Remold, SK (corresponding author), Yale Univ, Dept Ecol & Evolut Biol, Osborn Mem Labs, 165 Prospect St, New Haven, CT 06520 USA.	susanna.remold@yale.edu		Lenski, Richard/0000-0002-1064-8375				DEAN AM, 1995, GENETICS, V139, P19; DEVISSER JAG, 1996, EVOLUTION, V51, P1499; DYKHUIZEN DE, 1983, GENETICS, V105, P1; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Elena SF, 2001, EVOLUTION, V55, P1746; Elena SF, 1998, GENETICA, V102-3, P349, DOI 10.1023/A:1017031008316; Fedorowicz GM, 1998, GENETICS, V148, P1885; Hansen TF, 2001, GENETICS, V158, P477; Kishony Roy, 2003, J Biol, V2, P14, DOI 10.1186/1475-4924-2-14; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; Kondrashov FA, 2001, P NATL ACAD SCI USA, V98, P12089, DOI 10.1073/pnas.211214298; Lenski R. E., 2004, PLANT BREED REV, V24, P225, DOI DOI 10.1002/9780470650288.CH8; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Lenski RE, 2003, J MOL EVOL, V56, P498, DOI 10.1007/s00239-002-2423-0; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LENSKI RE, 1994, MOL ECOL, V3, P127, DOI 10.1111/j.1365-294X.1994.tb00113.x; LEVIN BR, 1977, AM NAT, V111, P3, DOI 10.1086/283134; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; PODLICH DW, 1998, SIMULATED EVOLUTION, P171; Remold SK, 2001, P NATL ACAD SCI USA, V98, P11388, DOI 10.1073/pnas.201140198; Schmalhausen II, 1949, FACTORS EVOLUTION TH; Sokal RR, 1995, BIOMETRY; Travisano M, 1997, GENETICS, V146, P471; Travisano M, 1996, GENETICS, V143, P15; Wade Michael J., 2000, P213; Wade MJ, 1998, EVOLUTION, V52, P1537, DOI 10.1111/j.1558-5646.1998.tb02235.x; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125	29	100	100	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					423	426		10.1038/ng1324	http://dx.doi.org/10.1038/ng1324			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15072075	Bronze			2022-12-25	WOS:000220647200029
J	Puertollano, R; Bonifacino, JS				Puertollano, R; Bonifacino, JS			Interactions of GGA3 with the ubiquitin sorting machinery	NATURE CELL BIOLOGY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; TRANS-GOLGI NETWORK; GAMMA-ADAPTIN; VHS DOMAINS; ENDOSOMAL TRAFFICKING; DOWN-REGULATION; EGF RECEPTOR; BINDING; PROTEINS; COMPLEX	The Golgi-localized, gamma-ear-containing, Arf-binding (GGA) proteins constitute a family of clathrin adaptors that are mainly associated with the trans-Golgi network (TGN)(1-3) and mediate the sorting of mannose 6-phosphate receptors(4-6). This sorting is dependent on the interaction of the VHS domain of the GGAs with acidic-cluster-dileucine signals in the cytosolic tails of the receptors(4,5). Here we demonstrate the existence of another population of GGAs that are associated with early endosomes. RNA interference (RNAi) of GGA3 expression results in accumulation of the cation-independent mannose 6-phosphate receptor and internalized epidermal growth factor (EGF) within enlarged early endosomes. This perturbation impairs the degradation of internalized EGF, a process that is normally dependent on the sorting of ubiquitinated EGF receptors (EGFRs) to late endosomes. Protein interaction analyses show that the GGAs bind ubiquitin. The VHS and GAT domains of GGA3 are responsible for this binding, as well as for interactions with TSG101, a component of the ubiquitin-dependent sorting machinery. Thus, GGAs may have additional roles in sorting of ubiquitinated cargo.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Ghosh P, 2003, J CELL BIOL, V163, P755, DOI 10.1083/jcb.200308038; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mizuno E, 2003, MOL BIOL CELL, V14, P3675, DOI 10.1091/mbc.E02-12-0823; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; SHIBA Y, IN PRESS J BIOL CHEM; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Wakasugi M, 2003, BIOCHEM BIOPH RES CO, V306, P687, DOI 10.1016/S0006-291X(03)01032-5; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	34	186	196	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					244	251		10.1038/ncb1106	http://dx.doi.org/10.1038/ncb1106			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039775				2022-12-25	WOS:000189363000016
J	Scott, PM; Bilodeau, PS; Zhdankina, O; Winistorfer, SC; Hauglund, MJ; Allaman, MM; Kearney, WR; Robertson, AD; Boman, AL; Piper, RC				Scott, PM; Bilodeau, PS; Zhdankina, O; Winistorfer, SC; Hauglund, MJ; Allaman, MM; Kearney, WR; Robertson, AD; Boman, AL; Piper, RC			GGA proteins bind ubiquitin to facilitate sorting at the trans-Golgi network	NATURE CELL BIOLOGY			English	Article							AMINO-ACID PERMEASE; SACCHAROMYCES-CEREVISIAE; ESCRT-I; YEAST; RECEPTORS; COMPLEX; DEGRADATION; TRAFFICKING; PATHWAY; DOMAINS	Ubiquitination functions as a sorting signal for lysosomal degradation of cell-surface proteins by facilitating their internalization from the plasma membrane and incorporation into lumenal vesicles of multivesicular bodies (MVBs)(1). Ubiquitin may also mediate sorting of proteins from the trans-Golgi network (TGN) to the endosome, thereby preventing their appearance on the cell surface and hastening their degradation in the lysosome-vacuole(2-6). Substantiation of a direct ubiquitin-dependent TGN sorting pathway relies in part on identifying candidate machinery that may function as a ubiquitin-sorting 'receptor' at the TGN. Members of the GGA family of coat proteins localize to the TGN and promote the incorporation of proteins into clathrin-coated vesicles destined for transport to endosomes(7,8). We show that the GGA coat proteins bind directly to ubiquitin through their GAT domain and demonstrate that this interaction is required for the ubiquitin-dependent sorting of the Gap1 amino acid transporter from the TGN to endosomes. Thus, GGA proteins fulfill the role of ubiquitin sorting receptors at the TGN.	Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, NMR Facil, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Minnesota System; University of Minnesota Duluth; University of Iowa; University of Iowa; University of Iowa	Scott, PM (corresponding author), Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA.	pscott@d.umn.edu; Robert-Piper@uiowa.edu	Allaman, Margaret/GNO-9854-2022	Piper, Robert/0000-0001-9995-5699; Allaman, Margaret M./0000-0002-2803-1365	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046869, R01GM058202] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46869, R01 GM058202, GM58202] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev D, 2003, CHEMBIOCHEM, V4, P894, DOI 10.1002/cbic.200300699; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Boman AL, 2002, MOL BIOL CELL, V13, P3078, DOI 10.1091/mbc.E02-02-0078; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Ghosh P, 2003, J CELL BIOL, V163, P755, DOI 10.1083/jcb.200308038; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2001, MOL BIOL CELL, V12, P3573, DOI 10.1091/mbc.12.11.3573; Hoshikawa C, 2003, P NATL ACAD SCI USA, V100, P11505, DOI 10.1073/pnas.1933153100; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; SHIBA Y, 2003, J BIOL CHEM; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Sivaraman T, 2001, NAT STRUCT BIOL, V8, P331, DOI 10.1038/86208; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Sundd M, 2002, BIOCHEMISTRY-US, V41, P7586, DOI 10.1021/bi025571d; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5	28	130	132	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					252	259		10.1038/ncb1107	http://dx.doi.org/10.1038/ncb1107			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039776				2022-12-25	WOS:000189363000017
J	Wada, T; Joza, N; Cheng, HYM; Sasaki, T; Kozieradzki, I; Bachmaier, K; Katada, T; Schreiber, M; Wagner, EF; Nishina, H; Penninger, JM				Wada, T; Joza, N; Cheng, HYM; Sasaki, T; Kozieradzki, I; Bachmaier, K; Katada, T; Schreiber, M; Wagner, EF; Nishina, H; Penninger, JM			MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE SAPK/JNK; EMBRYONIC STEM-CELLS; C-JUN; TERMINAL PHOSPHORYLATION; SYNERGISTIC ACTIVATION; TRANSDUCTION PATHWAY; CDC2 GENE; APOPTOSIS; JNK; DEATH	During the development of multicellular organisms, concerted actions of molecular signalling networks determine whether cells undergo proliferation, differentiation, death or ageing. Here we show that genetic inactivation of the stress signalling kinase, MKK7, a direct activator of JNKs in mice, results in embryonic lethality and impaired proliferation of hepatocytes. Beginning at passage 4-5, mkk7(-/-) mouse embryonic fibroblasts (MEFs) display impaired proliferation, premature senescence and G2/M cell cycle arrest. Similarly, loss of c-Jun or expression of a c-JunAA mutant in which the JNK phosphorylation sites were replaced with alanine results in a G2/M cell-cycle block. The G2/M cell-cycle kinase CDC2 was identified as a target for the MKK7-JNK-c-Jun pathway. These data show that the MKK7-JNK-c-Jun signalling pathway couples developmental and environmental cues to CDC2 expression, G2/M cell cycle progression and cellular senescence in fibroblasts.	Austrian Acad Sci, IMBA Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Toronto, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Vienna, Sch Med, Dept Obstet & Gynecol, A-1090 Vienna, Austria; IMP Res Inst Mol Pathol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Tokyo; University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Penninger, JM (corresponding author), Austrian Acad Sci, IMBA Inst Mol Biotechnol, Dr Bohrgasse 3-5, A-1030 Vienna, Austria.	josef.penninger@oeaw.ac.at	Martin, Schreiber/F-2175-2013; Bachmaier, Kurt/AHC-5491-2022; Bachmaier, Kurt/B-6331-2014; Penninger, Josef M/I-6860-2013	Martin, Schreiber/0000-0003-1102-7789; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Penninger, Josef M/0000-0002-8194-3777; Sasaki, Takehiko/0000-0003-1837-3748; Wagner, Erwin F/0000-0001-7872-0196				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DIDINSKY JB, 1981, J CELL PHYSIOL, V109, P171, DOI 10.1002/jcp.1041090119; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; Nishina H, 1999, DEVELOPMENT, V126, P505; Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Toussaint O, 2000, ANN NY ACAD SCI, V908, P85, DOI 10.1111/j.1749-6632.2000.tb06638.x; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I	45	120	124	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					215	226		10.1038/ncb1098	http://dx.doi.org/10.1038/ncb1098			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039780				2022-12-25	WOS:000189363000012
J	Bottcher, RT; Pollet, N; Delius, H; Niehrs, C				Bottcher, RT; Pollet, N; Delius, H; Niehrs, C			The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling	NATURE CELL BIOLOGY			English	Article							XENOPUS MESODERM INDUCTION; ENERGY-TRANSFER BRET; INDUCED ANTAGONIST; CRYSTAL-STRUCTURE; HEAD INDUCTION; MAP KINASE; EXPRESSION; EMBRYOS; IDENTIFICATION; DIMERIZATION	Fibroblast growth factors (FGFs) signal through high-affinity tyrosine kinase receptors to regulate a diverse range of cellular processes, including cell growth, differentiation and migration, as well as cell death(1-4). Here we identify XFLRT3, a member of a leucine-rich-repeat transmembrane protein family, as a novel modulator of FGF signalling. XFLRT3 is co-expressed with FGFs, and its expression is both induced after activation and downregulated after inhibition of FGF signalling. In gain- and loss-of function experiments, FLRT3 and FLRT2 phenocopy FGF signalling in Xenopus laevis. XFLRT3 signalling results in phosphorylation of ERK and is blocked by MAPK phosphatase 1, but not by expression of a dominant-negative phosphatidyl inositol 3-OH kinase (PI(3)K) mutant. XFLRT3 interacts with FGF receptors (FGFRs) in co-immunoprecipitation experiments in vitro and in bioluminescence resonance energy transfer assays in vivo. The results indicate that XFLRT3 is a transmembrane modulator of FGF-MAP kinase signalling in vertebrates.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	Niehrs@DKFZ-Heidelberg.DE	Pollet, Nicolas/A-4746-2013	Pollet, Nicolas/0000-0002-9975-9644				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Carballada R, 2001, DEVELOPMENT, V128, P35; Christen B, 1997, DEV BIOL, V192, P455, DOI 10.1006/dbio.1997.8732; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Groth C, 2002, INT J DEV BIOL, V46, P393; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; ISAACS HV, 1992, DEVELOPMENT, V114, P711; Lacy SE, 1999, GENOMICS, V62, P417, DOI 10.1006/geno.1999.6033; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Niehrs C, 2002, NATURE, V417, P35, DOI 10.1038/417035a; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slack JMW, 1996, BIOCHEM SOC SYMP, P1; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	29	134	139	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					38	U8		10.1038/ncb1082	http://dx.doi.org/10.1038/ncb1082			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14688794				2022-12-25	WOS:000187802600011
J	Ruel, L; Rodriguez, R; Gallet, A; Lavenant-Staccini, L; Therond, PP				Ruel, L; Rodriguez, R; Gallet, A; Lavenant-Staccini, L; Therond, PP			Stability and association of Smoothened, Costal2 and Fused with Cubitus interruptus are regulated by Hedgehog	NATURE CELL BIOLOGY			English	Article							KINESIN-RELATED PROTEIN; STEROL-SENSING DOMAIN; SIGNAL-TRANSDUCTION; VESICULAR TRAFFICKING; DROSOPHILA; GENE; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; RECEPTOR	The mechanisms involved in transduction of the Hedgehog (Hh) signal are of considerable interest to developmental and cancer biologists. Stabilization of the integral membrane protein Smoothened (Smo) at the plasma membrane is a crucial step in Hh signalling but the molecular events immediately downstream of Smo remain to be elucidated. We have shown previously that the transcriptional mediator Cubitus interruptus (Ci) is associated in a protein complex with at least two other proteins, the kinesin-like Costal2 (Cos2) and the serine - threonine kinase Fused (Fu). This protein complex governs the access of Ci to the nucleus. Here we show that, consequent on the stabilization of Smo, Cos2 and Fu are destabilized. Moreover, we find that the Cos2 - Fu - Ci protein complex is associated with Smo in membrane fractions both in vitro and in vivo. We also show that Cos2 binding on Smo is necessary for the Hh-dependent dissociation of Ci from this complex. We propose that the association of the Cos2 protein complex with Smo at the plasma membrane controls the stability of the complex and allows Ci activation, eliciting its nuclear translocation.	CNRS, Ctr Biochim, Inst Signaling Dev Biol & Canc Res, UMR 6543, F-06108 Nice 02, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Therond, PP (corresponding author), CNRS, Ctr Biochim, Inst Signaling Dev Biol & Canc Res, UMR 6543, Parc Valrose, F-06108 Nice 02, France.		Therond, pascal/AAE-4811-2019; GALLET, Armel/B-4251-2012					Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Gallet A, 2003, DEV CELL, V4, P191, DOI 10.1016/S1534-5807(03)00031-5; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; Monnier Veronique, 2002, BMC Dev Biol, V2, P4, DOI 10.1186/1471-213X-2-4; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Strigini M, 1997, DEVELOPMENT, V124, P4697; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	32	163	170	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					907	913		10.1038/ncb1052	http://dx.doi.org/10.1038/ncb1052			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14523402				2022-12-25	WOS:000185647400017
J	Innocenti, M; Zucconi, A; Disanza, A; Frittoli, E; Areces, LB; Steffen, A; Stradal, TEB; Di Fiore, PP; Carlier, MF; Scita, G				Innocenti, M; Zucconi, A; Disanza, A; Frittoli, E; Areces, LB; Steffen, A; Stradal, TEB; Di Fiore, PP; Carlier, MF; Scita, G			Abi1 is essential for the formation and activation of a WAVE2 signalling complex	NATURE CELL BIOLOGY			English	Letter							ABL TRANSFORMING ACTIVITY; BINDING PROTEIN RAC; HUMAN NAP1 NCKAP1; MOLECULAR-CLONING; ACTIN-FILAMENTS; ARP2/3 COMPLEX; CYTOSKELETON; RETARDATION; NUCLEATION; EXPRESSION	WAVE2 belongs to a family of proteins that mediates actin reorganization by relaying signals from Rac to the Arp2/3 complex, resulting in lamellipodia protrusion. WAVE2 displays Arp2/3-dependent actin nucleation activity in vitro, and does not bind directly to Rac. Instead, it forms macromolecular complexes that have been reported to exert both positive and negative modes of regulation. How these complexes are assembled, localized and activated in vivo remains to be established. Here we use tandem mass spectrometry to identify an Abil-based complex containing WAVE2, Nap1 (Nck-associated protein) and PIR121. Abil interacts directly with the WHD domain of WAVE2, increases WAVE2 actin polymerization activity and mediates the assembly of a WAVE2-Abi1-Nap1-PIR121 complex. The WAVE2-Abi1-Nap1-PIR121 complex is as active as the WAVE2-Abi1 sub-complex in stimulating Arp2/3, and after Rac activation it is re-localized to the leading edge of ruffles in vivo. Consistently, inhibition of Abil by RNA interference (RNAi) abrogates Rac-dependent lamellipodia protrusion. Thus, Abil orchestrates the proper assembly of the WAVE2 complex and mediates its activation at the leading edge in vivo.	IFOM, Ist FIRC Oncol Mol, I-20134 Milan, Italy; Univ Milan, Sch Med, I-20122 Milan, Italy; Ist Europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNRS, Dynam Cytosquelette Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; German Res Ctr Biotechnol GBF, Dept Cell Biol, D-38124 Braunschweig, Germany	IFOM - FIRC Institute of Molecular Oncology; University of Milan; IRCCS European Institute of Oncology (IEO); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Helmholtz Association; Helmholtz-Center for Infection Research	Scita, G (corresponding author), IFOM, Ist FIRC Oncol Mol, Via Adamello 16, I-20134 Milan, Italy.	gscita@ifom-firc.it	Di Fiore, Pier Paolo/K-2130-2012; Scita, Giorgio/J-9670-2012; Innocenti, Metello/X-2182-2019	Di Fiore, Pier Paolo/0000-0002-2252-0950; Innocenti, Metello/0000-0002-7455-2559; Disanza, Andrea/0000-0001-5101-2907; Steffen, Anika/0000-0002-2933-0543; Stradal, Theresia/0000-0002-0352-9474; Scita, Giorgio/0000-0001-7984-1889	Telethon [D.090] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams JC, 2002, J CELL SCI, V115, P257; Allen PG, 2003, NAT CELL BIOL, V5, P972, DOI 10.1038/ncb1059; Benachenhou N, 2002, GENE, V290, P131, DOI 10.1016/S0378-1119(02)00560-7; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Schenck A, 2001, P NATL ACAD SCI USA, V98, P8844, DOI 10.1073/pnas.151231598; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Soto MC, 2002, GENE DEV, V16, P620, DOI 10.1101/gad.955702; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Suzuki T, 2000, GENOMICS, V63, P246, DOI 10.1006/geno.1999.6053; Takenawa T, 2001, J CELL SCI, V114, P1801; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Yamamoto A, 2001, GENE, V271, P159, DOI 10.1016/S0378-1119(01)00521-2	30	309	318	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					319	327		10.1038/ncb1105	http://dx.doi.org/10.1038/ncb1105			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048123				2022-12-25	WOS:000220587600013
J	Haagmans, BL; Kuiken, T; Martina, BE; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; van Riel, D; de Jong, T; Itamura, S; Chan, KH; Tashiro, M; Osterhaus, ADME				Haagmans, BL; Kuiken, T; Martina, BE; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; van Riel, D; de Jong, T; Itamura, S; Chan, KH; Tashiro, M; Osterhaus, ADME			Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; REOVIRUS 1/L INDUCTION; DISTRESS-SYNDROME; LUNG PATHOLOGY; VIRUS; IDENTIFICATION; PNEUMONIA; OUTBREAK; FIBROSIS; MICE	The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1-7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d. p. i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN- yielded intermediate results. We therefore suggest that pegylated IFN-alpha protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy	Erasmus Med Ctr, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Erasmus Med Ctr, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Natl Inst Infect Dis, Dept Viral Dis & Vaccine Control, Tokyo 2080011, Japan; Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; National Institute of Infectious Diseases (NIID); University of Hong Kong	Osterhaus, ADME (corresponding author), Erasmus Med Ctr, Dept Virol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.osterhaus@erasmusmc.nl	Haagmans, Bart/E-9791-2015; Fouchier, Ron A/A-1911-2014; Chan, Kwok Hung/ABD-5399-2021	Haagmans, Bart/0000-0001-6221-2015; Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; van Riel, Debby/0000-0001-9753-3564				BEDROSSIAN CWM, 1984, AM J CLIN PATHOL, V82, P148, DOI 10.1093/ajcp/82.2.148; Bellum SC, 1997, AM J PATHOL, V150, P2243; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; FINTER NB, 1985, INTERFERONS IN VIVO, V4; Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; London L, 2002, CLIN IMMUNOL, V103, P284, DOI 10.1006/clim.2002.5214; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Pei JW, 2001, J INTERF CYTOK RES, V21, P1071, DOI 10.1089/107999001317205204; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SMITH AL, 1987, ANTIVIR RES, V8, P239, DOI 10.1016/S0166-3542(87)80002-5; TSNAG KW, 2003, NEW ENGL J MED, V348, P1977; TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443; Van Gool AR, 2003, PSYCHIAT RES, V119, P125, DOI 10.1016/S0165-1781(03)00113-6; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WILLIAMS MC, 1990, ELECT MICROSCOPY LUN, P121	29	301	323	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					290	293		10.1038/nm1001	http://dx.doi.org/10.1038/nm1001			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981511	Bronze, Green Published			2022-12-25	WOS:000189297700041
J	Wang, XD; Chamberlin, HM				Wang, XD; Chamberlin, HM			Evolutionary innovation of the excretory system in Caenorhabditis elegans	NATURE GENETICS			English	Article							REGULATORY EVOLUTION; DROSOPHILA; GENE	The evolution of complexity relies on changes that result in new gene functions. Here we show that the unique morphological and functional features of the excretory duct cell in C. elegans result from the gain of expression of a single gene. Our results show that innovation can be achieved by altered expression of a transcription factor without coevolution of all target genes.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Chamberlin, HM (corresponding author), Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA.	chamberlin.27@osu.edu	Chamberlin, Helen/L-4206-2019	Chamberlin, Helen/0000-0001-7203-2691				Gompel N, 2003, NATURE, V424, P931, DOI 10.1038/nature01787; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; LYNCH AS, 1995, NAT GENET, V11, P309, DOI 10.1038/ng1195-309; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Sucena E, 2003, NATURE, V424, P935, DOI 10.1038/nature01768; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; Tautz D, 2000, CURR OPIN GENET DEV, V10, P575, DOI 10.1016/S0959-437X(00)00130-1; Wang XD, 2002, GENE DEV, V16, P2345, DOI 10.1101/gad.996302; Wittkopp PJ, 2002, CURR BIOL, V12, P1547, DOI 10.1016/S0960-9822(02)01113-2	12	48	50	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2004	36	3					231	232		10.1038/ng1301	http://dx.doi.org/10.1038/ng1301			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14758362	Bronze			2022-12-25	WOS:000189250400010
J	Asano, Y; Takashima, S; Asakura, M; Shintani, Y; Liao, YL; Minamino, T; Asanuma, H; Sanada, S; Kim, J; Ogai, A; Fukushima, T; Oikawa, Y; Okazaki, Y; Kaneda, Y; Sato, M; Miyazaki, J; Kitamura, S; Tomoike, H; Kitakaze, M; Hori, M				Asano, Y; Takashima, S; Asakura, M; Shintani, Y; Liao, YL; Minamino, T; Asanuma, H; Sanada, S; Kim, J; Ogai, A; Fukushima, T; Oikawa, Y; Okazaki, Y; Kaneda, Y; Sato, M; Miyazaki, J; Kitamura, S; Tomoike, H; Kitakaze, M; Hori, M			Lamr1 functional retroposon causes right ventricular dysplasia in mice	NATURE GENETICS			English	Article							II HISTONE DEACETYLASES; HETEROCHROMATIN PROTEIN-1; LONG ARM; CARDIOMYOPATHY; GENE; EXPRESSION; LOCUS; DNA; LOCALIZATION; METHYLATION	Arrhythmogenic right ventricular dysplasia (ARVD) is a hereditary cardiomyopathy that causes sudden death in the young. We found a line of mice with inherited right ventricular dysplasia (RVD) caused by a mutation of the gene laminin receptor 1 (Lamr1). This locus contained an intron-processed retroposon that was transcribed in the mice with RVD. Introduction of a mutated Lamr1 gene into normal mice by breeding or by direct injection caused susceptibility to RVD, which was similar to that seen in the RVD mice. An in vitro study of cardiomyocytes expressing the product of mutated Lamr1 showed early cell death accompanied by alteration of the chromatin architecture. We found that heterochromatin protein 1 ( HP1) bound specifically to mutant LAMR1. HP1 is a dynamic regulator of heterochromatin sites, suggesting that mutant LAMR1 impairs a crucial process of transcriptional regulation. Indeed, mutant LAMR1 caused specific changes to gene expression in cardiomyocytes, as detected by gene chip analysis. Thus, we concluded that products of the Lamr1 retroposon interact with HP1 to cause degeneration of cardiomyocytes. This mechanism may also contribute to the etiology of human ARVD.	Natl Cardiovasc Ctr, Cardiovasc Div Internal Med, Osaka 5658565, Japan; Osaka Univ, Dept Internal Med & Therapeut, Grad Sch Med, Osaka 5650871, Japan; RIKEN, Lab Genome, Explorat Res Grp, Yokohama Inst,Genom Sci Ctr, Kanagawa 2300045, Japan; Osaka Univ, Dept Gene Therapy Sci, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Dept Nutr & Physiol Chem, Grad Sch Med, Osaka 5650871, Japan	National Cerebral & Cardiovascular Center - Japan; Osaka University; RIKEN; Osaka University; Osaka University	Kitakaze, M (corresponding author), Natl Cardiovasc Ctr, Cardiovasc Div Internal Med, 5-7-1 Fujishirodai, Osaka 5658565, Japan.	takasima@medone.med.osaka-u.ac.jp; kitakaze@zf6.so-net.ne.jp	Miyazaki, Jun-ichi/N-1976-2015; Liao, Yulin/AAP-6315-2021	Miyazaki, Jun-ichi/0000-0003-2475-589X; Shintani, Yasunori/0000-0001-9579-0727; Okazaki, Yasushi/0000-0003-3241-5502				Ahmad F, 1998, CIRCULATION, V98, P2791, DOI 10.1161/01.CIR.98.25.2791; BRIGHT JM, 1995, J AM VET MED ASSOC, V207, P64; Burke AP, 1998, CIRCULATION, V97, P1571, DOI 10.1161/01.CIR.97.16.1571; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cranefield PF, 1975, CONDUCTION CARDIAC I; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fox PR, 2000, CIRCULATION, V102, P1863; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; ISHIKAWA S, 1977, ARCH PATHOL LAB MED, V101, P388; Kaneda Y, 1998, CELL DEATH DIFFER, V5, P20, DOI 10.1038/sj.cdd.4400315; Kondo K., 1957, B EXP ANIM, V6, P107; Li DX, 2000, AM J HUM GENET, V66, P148, DOI 10.1086/302713; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; Nakamura M, 1967, Diabetologia, V3, P212, DOI 10.1007/BF01222198; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nasir K, 2003, PACE, V26, P1955, DOI 10.1046/j.1460-9592.2003.00302.x; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Peters S, 2003, ANN NONINVAS ELECTRO, V8, P238, DOI 10.1046/j.1542-474X.2003.08312.x; Protonotarios N, 2001, J AM COLL CARDIOL, V38, P1477, DOI 10.1016/S0735-1097(01)01568-6; Rampazzo A, 1997, GENOMICS, V45, P259, DOI 10.1006/geno.1997.4927; Richardson MP, 1998, GENE, V206, P145, DOI 10.1016/S0378-1119(97)00586-6; Sato M, 1996, BIOCHEM BIOPH RES CO, V229, P896, DOI 10.1006/bbrc.1996.1899; Severini GM, 1996, GENOMICS, V31, P193, DOI 10.1006/geno.1996.0031; SIMPSON KW, 1994, J VET INTERN MED, V8, P306, DOI 10.1111/j.1939-1676.1994.tb03240.x; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Steenman M, 2003, PHYSIOL GENOMICS, V12, P97, DOI 10.1152/physiolgenomics.00148.2002; Thiene G, 1997, TRENDS CARDIOVAS MED, V7, P84, DOI 10.1016/S1050-1738(97)00011-X; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002	36	41	42	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					123	130		10.1038/ng1294	http://dx.doi.org/10.1038/ng1294			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14730304	Bronze			2022-12-25	WOS:000188542700012
J	Ihmels, J; Levy, R; Barkai, N				Ihmels, J; Levy, R; Barkai, N			Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae	NATURE BIOTECHNOLOGY			English	Article							GENE-EXPRESSION; ORGANIZATION; GENOME	Cellular networks are subject to extensive regulation, which modifies the availability and efficiency of connections between components in response to external conditions. Thus far, studies of large-scale networks have focused on their connectivity, but have not considered how the modulation of this connectivity might also determine network properties. To address this issue, we analyzed how the coordinated expression of enzymes shapes the metabolic network of Saccharomyces cerevisiae. By integrating large-scale expression data with the structural description of the metabolic network, we systematically characterized the transcriptional regulation of metabolic pathways. The analysis revealed recurrent patterns, which may represent design principles of metabolic gene regulation. First, we find that transcription regulation biases metabolic flow toward linearity by coexpressing only distinct branches at metabolic branchpoints. Second, individual isozymes were often separately coregulated with distinct processes, providing a means of reducing crosstalk between pathways using a common reaction. Finally, transcriptional regulation defined a hierarchical organization of metabolic pathways into groups of varying expression coherence. These results emphasize the utility of incorporating regulatory information when analyzing properties of large-scale cellular networks.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Barkai, N (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	naama.barkai@weizmann.ac.il			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI050562, R21AI050562] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50562] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bergmann S, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031902; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	25	189	195	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					86	92		10.1038/nbt918	http://dx.doi.org/10.1038/nbt918			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14647306				2022-12-25	WOS:000187745400031
J	Lappe, M; Holm, L				Lappe, M; Holm, L			Unraveling protein interaction networks with near-optimal efficiency	NATURE BIOTECHNOLOGY			English	Article							COMPLEXES	The functional characterization of genes and their gene products is the main challenge of the genomic era. Examining interaction information for every gene product is a direct way to assemble the jigsaw puzzle of proteins into a functional map. Here we demonstrate a method in which the information gained from pull-down experiments, in which single proteins act as baits to detect interactions with other proteins, is maximized by using a network-based strategy to select the baits. Because of the scale-free distribution of protein interaction networks, we were able to obtain fast coverage by focusing on highly connected nodes (hubs) first. Unfortunately, locating hubs requires prior global information about the network one is trying to unravel. Here, we present an optimized 'pay-as-you-go' strategy that identifies highly connected nodes using only local information that is collected as successive pull-down experiments are performed. Using this strategy, we estimate that 90% of the human interactome can be covered by 10,000 pull-down experiments, with 50% of the interactions confirmed by reciprocal pull-down experiments.	European Bioinformat Inst, EMBL Outstn, Cambridge CB10 1SD, England; Univ Helsinki, Inst Biotechnol, FI-00014 Helsinki, Finland	European Molecular Biology Laboratory (EMBL); University of Helsinki	Lappe, M (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.	lappe@ebi.ac.uk	Lappe, Michael/A-5505-2008					Aloy P, 2002, FEBS LETT, V530, P253, DOI 10.1016/S0014-5793(02)03427-0; Bader GD, 2000, BIOINFORMATICS, V16, P465, DOI 10.1093/bioinformatics/16.5.465; CORMEN TH, 1999, INTRO ALGORITHMS, P916; Deane CM, 2002, MOL CELL PROTEOMICS, V1, P349, DOI 10.1074/mcp.M100037-MCP200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Karp R.M., 1972, PROC S COMPLEXITY CO, P85, DOI 10.1007/978-1-4684-2001-2_9.; Lappe M, 2001, Bioinformatics, V17 Suppl 1, pS149; Maslov S, 2002, FEBS LETT, V530, P255, DOI 10.1016/S0014-5793(02)03428-2; Mrowka R, 2003, NAT GENET, V33, P15, DOI 10.1038/ng0103-15; Orchard S, 2003, COMP FUNCT GENOM, V4, P203, DOI 10.1002/cfg.279; Rung J, 2002, BIOINFORMATICS, V18, pS202, DOI 10.1093/bioinformatics/18.suppl_2.S202; Saito R, 2003, BIOINFORMATICS, V19, P756, DOI 10.1093/bioinformatics/btg070; Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vazquez A, 2003, NAT BIOTECHNOL, V21, P697, DOI 10.1038/nbt825; Vendruscolo M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061910; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289	23	67	68	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					98	103		10.1038/nbt921	http://dx.doi.org/10.1038/nbt921			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14661027				2022-12-25	WOS:000187745400033
J	Liu, G; Parant, JM; Lang, G; Chau, P; Chavez-Reyes, A; El-Naggar, AK; Multani, A; Chang, S; Lozano, G				Liu, G; Parant, JM; Lang, G; Chau, P; Chavez-Reyes, A; El-Naggar, AK; Multani, A; Chang, S; Lozano, G			Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice	NATURE GENETICS			English	Article							P53-DEPENDENT APOPTOSIS; GENETIC INSTABILITY; GENOMIC INSTABILITY; V(D)J RECOMBINATION; P53-DEFICIENT MICE; IN-VIVO; P53; ACTIVATION; GROWTH; RADIATION	The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream genes(1-3). At the cellular level, p53 induces apoptosis, cell cycle arrest and senescence. A rare mutant form of p53 with the amino acid substitution R175P, found in human tumors, is completely defective in initiating apoptosis but still induces cell cycle arrest(4,5). To decipher the functional importance of these pathways in spontaneous tumorigenesis, we used homologous recombination to generate mice with mutant p53-R172P ( the mouse equivalent of R175P in humans). Mice inheriting two copies of this mutation (Trp53(515C/515C)) escape the early onset of thymic lymphomas that characterize Trp53-null mice. At 7 months of age, 90% of Trp53-null mice had died, but 85% of Trp53(515C/515C) mice were alive and tumor-free, indicating that p53-dependent apoptosis was not required for suppression of early onset of spontaneous tumors. The lymphomas and sarcomas that eventually developed in Trp53(515C/515C) mice retained a diploid chromosome number, in sharp contrast to aneuploidy observed in tumors and cells from Trp53 null mice. The ability of mutant p53-R172P to induce a partial cell cycle arrest and retain chromosome stability are crucial for suppression of early onset tumorigenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Chavez-Reyes, Arturo/ABG-1231-2020	Chavez-Reyes, Arturo/0000-0002-6655-815X; Chau, Gilda/0000-0002-7907-3290				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tlsty TD, 1996, CANCER SURV, V28, P217; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	30	263	266	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					63	68		10.1038/ng1282	http://dx.doi.org/10.1038/ng1282			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702042	Bronze			2022-12-25	WOS:000187666800015
J	Parsons, AB; Brost, RL; Ding, HM; Li, ZJ; Zhang, CY; Sheikh, B; Brown, GW; Kane, PM; Hughes, TR; Boone, C				Parsons, AB; Brost, RL; Ding, HM; Li, ZJ; Zhang, CY; Sheikh, B; Brown, GW; Kane, PM; Hughes, TR; Boone, C			Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways	NATURE BIOTECHNOLOGY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; SENSITIVE MUTANTS; SANT DOMAIN; YEAST-CELLS; DRUG; GENOME; DELETION; REPLICATION; CALCINEURIN	Bioactive compounds can be valuable research tools and drug leads, but it is often difficult to identify their mechanism of action or cellular target. Here we investigate the potential for integration of chemical-genetic and genetic interaction data to reveal information about the pathways and targets of inhibitory compounds. Taking advantage of the existing complete set of yeast haploid deletion mutants, we generated drug-hypersensitivity (chemical-genetic) profiles for 12 compounds. In addition to a set of compound-specific interactions, the chemical-genetic profiles identified a large group of genes required for multidrug resistance. In particular, yeast mutants lacking a functional vacuolar H+-ATPase show multidrug sensitivity, a phenomenon that may be conserved in mammalian cells. By filtering chemical-genetic profiles for the multidrug-resistant genes and then clustering the compound-specific profiles with a compendium of large-scale genetic interaction profiles, we were able to identify target pathways or proteins. This method thus provides a powerful means for inferring mechanism of action.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada; SUNY Syracuse, Upstate Med Univ, Dept Biochem, Syracuse, NY 13210 USA	University of Toronto; University of Toronto; University of Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Boone, C (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada.	charlie.boone@utoronto.ca		Brown, Grant/0000-0002-9002-5003	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barstead R, 2001, CURR OPIN CHEM BIOL, V5, P63, DOI 10.1016/S1367-5931(00)00173-3; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Bellaoui M, 2003, EMBO J, V22, P4304, DOI 10.1093/emboj/cdg406; Ben-Aroya S, 2003, P NATL ACAD SCI USA, V100, P9906, DOI 10.1073/pnas.1633757100; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Brachmann CB, 1998, YEAST, V14, P115; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r22; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; FALCO SC, 1985, GENETICS, V109, P21; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HSIANG YH, 1989, CANCER RES, V49, P5077; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MA LD, 1992, BIOCHEM BIOPH RES CO, V182, P675, DOI 10.1016/0006-291X(92)91785-O; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Mukhopadhyay K, 2002, ANTIMICROB AGENTS CH, V46, P3695, DOI 10.1128/AAC.46.12.3695-3705.2002; Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; RITTBERG DAH, 1989, BIOCHEM CELL BIOL, V67, P352, DOI 10.1139/o89-055; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; THOMAS JH, 1985, GENETICS, V111, P715; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; TURI TG, 1992, J BIOL CHEM, V267, P2046; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	42	486	504	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					62	69		10.1038/nbt919	http://dx.doi.org/10.1038/nbt919			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14661025				2022-12-25	WOS:000187745400028
J	Uetz, P; Pankratz, MJ				Uetz, P; Pankratz, MJ			Protein interaction maps on the fly	NATURE BIOTECHNOLOGY			English	Editorial Material							YEAST; NETWORK	A protein interaction map for the fruit fly Drosophila melanogaster promises to facilitate functional analysis of many eukaryotic proteins.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Uetz, P (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, Box 3640, D-76021 Karlsruhe, Germany.		Uetz, Peter/A-7119-2012	Uetz, Peter/0000-0001-6194-4927				Bader JS, 2004, NAT BIOTECHNOL, V22, P78, DOI 10.1038/nbt924; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jonsson ZO, 2001, J BIOL CHEM, V276, P16279, DOI 10.1074/jbc.M011523200; Kelley BP, 2003, P NATL ACAD SCI USA, V100, P11394, DOI 10.1073/pnas.1534710100; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	8	20	22	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					43	44		10.1038/nbt0104-43	http://dx.doi.org/10.1038/nbt0104-43			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704704				2022-12-25	WOS:000187745400019
J	Chua, BT; Volbracht, C; Tan, KO; Li, R; Yu, VC; Li, P				Chua, BT; Volbracht, C; Tan, KO; Li, R; Yu, VC; Li, P			Mitochondrial translocation of cofilin is an early step in apoptosis induction	NATURE CELL BIOLOGY			English	Letter							ACTIN DYNAMICS; CYTOCHROME-C; POLYACRYLAMIDE-GELS; RETINOIC ACID; PHOSPHORYLATION; PROTEINS; BINDING; FAMILY; DEATH; DIFFERENTIATION	Increasing evidence suggests that movement of key proteins in or out of mitochondria during apoptosis is essential for the regulation of apoptosis. Here, we report identification of the actin-binding protein cofilin by a proteomic approach, as such a factor translocated from cytosol into mitochondria after induction of apoptosis. We found that after induction of apoptosis, cofilin was translocated to mitochondria before release of cytochrome c. Reduction of cofilin protein levels with small-interfering RNA (siRNA) resulted in inhibition of both cytochrome c release and apoptosis. Only dephosphorylated cofilin was translocated to mitochondria, and the cofilin S3D mutant, which mimicks the phosphorylated form, suppressed mitochondrial translocation and apoptosis. Translocation was achieved through exposure of an amino-terminal mitochondrial targeting signal in combination with carboxy-terminal sequences. When correctly targeted to mitochondria, cofilin induced massive apoptosis. The apoptosis-inducing ability of cofilin, but not its mitochondrial localization, was dependent on the functional actin-binding domain. Thus, domains involved in mitochondrial targeting and actin binding are indispensable for its pro-apoptotic function. Our data suggest that cofilin has an important function during the initiation phase of apoptosis.	Natl Inst Singapore, Lab Apoptosis Regulat, Singapore 117609, Singapore; Natl Inst Singapore, Lab Mech Apoptosis Mammalian Cells, Singapore 117609, Singapore; Natl Inst Singapore, Lab Proteom, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Pharmacol, Singapore 119260, Singapore; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Hong Kong University of Science & Technology	Li, P (corresponding author), Natl Inst Singapore, Lab Apoptosis Regulat, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015	Yu, Victor/0000-0003-3270-4734; Tan, Kuan/0000-0002-0947-7337; Volbracht, Christiane/0000-0002-5748-9981				Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Drayson MT, 2001, EXP CELL RES, V266, P126, DOI 10.1006/excr.2001.5200; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SPECTOR DL, 1997, CELLS LAB MANUAL; Wang XD, 2001, GENE DEV, V15, P2922; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079	23	253	265	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1083	1089		10.1038/ncb1070	http://dx.doi.org/10.1038/ncb1070			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634665				2022-12-25	WOS:000186892900014
J	Tang, M; Wang, G; Lu, P; Karas, RH; Aronovitz, M; Heximer, SP; Kaltenbronn, KM; Blumer, KJ; Siderovski, DP; Zhu, Y; Mendelsohn, ME				Tang, M; Wang, G; Lu, P; Karas, RH; Aronovitz, M; Heximer, SP; Kaltenbronn, KM; Blumer, KJ; Siderovski, DP; Zhu, Y; Mendelsohn, ME			Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure	NATURE MEDICINE			English	Article							COUPLED RECEPTOR KINASES; LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE SYNTHASE; MYOSIN PHOSPHATASE; THROMBOXANE RECEPTOR; THROMBIN RECEPTOR; HUMAN PLATELETS; MICE LACKING; RAT AORTA; I-BETA	Nitric oxide (NO) inhibits vascular contraction by activating cGMP- dependent protein kinase I-alpha (PKGI-alpha), which causes dephosphorylation of myosin light chain (MLC) and vascular smooth muscle relaxation. Here we show that PKGI-alpha attenuates signaling by the thrombin receptor protease- activated receptor- 1 (PAR- 1) through direct activation of regulator of G- protein signaling- 2 (RGS- 2). NO donors and cGMP cause cGMP- mediated inhibition of PAR- 1 and membrane localization of RGS- 2. PKGI-alpha binds directly to and phosphorylates RGS- 2, which significantly increases GTPase activity of G(q), terminating PAR- 1 signaling. Disruption of the RGS- 2- PKGI-alpha interaction reverses inhibition of PAR- 1 signaling by nitrovasodilators and cGMP. Rgs2(-/-) mice develop marked hypertension, and their blood vessels show enhanced contraction and decreased cGMP-mediated relaxation. Thus, PKGI-alpha binds to, phosphorylates and activates RGS- 2, attenuating receptor- mediated vascular contraction. Our study shows that RGS- 2 is required for normal vascular function and blood pressure and is a new drug development target for hypertension.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Tufts Medical Center; Tufts University; Tufts University; Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.		Siderovski, David Peter/AAA-9603-2019; Blumer, Kendall J/C-5268-2012	Siderovski, David Peter/0000-0002-0688-8210; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063494, R29HL056235, R01HL055309, R01HL056069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM062338] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56235, R01 HL56069, P50 HL63494, R01 HL55309] Funding Source: Medline; NIGMS NIH HHS [P01 GM65533, R01 GM62338] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Beinborn M, 1998, J BIOL CHEM, V273, P14146, DOI 10.1074/jbc.273.23.14146; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Hartshorne DJ, 1999, MOL CELL BIOCHEM, V190, P79, DOI 10.1023/A:1006917032557; HAYNES WG, 1993, LANCET, V342, P931, DOI 10.1016/0140-6736(93)91981-Q; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2003, J CLIN INVEST, V111, P1259, DOI 10.1172/JCI200318099C; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HIRATA M, 1990, J BIOL CHEM, V265, P1268; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; INGI T, 1999, J NEUROSCI, V274, P19639; ISHII K, 1994, J BIOL CHEM, V269, P1125; Le TH, 2003, J CLIN INVEST, V111, P441, DOI 10.1172/JCI200317836; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lincoln T.M., 1994, CYCLIC GMP BIOCH PHY, P97; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	46	291	307	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1506	1512		10.1038/nm958	http://dx.doi.org/10.1038/nm958			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14608379				2022-12-25	WOS:000186845400034
J	Hu, W; Yan, Q; Shen, DK; Liu, F; Zhu, ZD; Song, HD; Xu, XR; Wang, ZJ; Rong, YP; Zeng, LC; Wu, J; Zhang, X; Wang, JJ; Xu, XN; Wang, SY; Fu, G; Zhang, XL; Wang, ZQ; Brindley, PJ; McManus, DP; Xue, CL; Feng, Z; Chen, Z; Han, ZG				Hu, W; Yan, Q; Shen, DK; Liu, F; Zhu, ZD; Song, HD; Xu, XR; Wang, ZJ; Rong, YP; Zeng, LC; Wu, J; Zhang, X; Wang, JJ; Xu, XN; Wang, SY; Fu, G; Zhang, XL; Wang, ZQ; Brindley, PJ; McManus, DP; Xue, CL; Feng, Z; Chen, Z; Han, ZG			Evolutionary and biomedical implications of a Schistosoma japonicum complementary DNA resource	NATURE GENETICS			English	Article							COMPARATIVE GENOMICS; SEX DETERMINATION; SEQUENCE; EXPRESSION; MANSONI; PROTEIN; CLONING; HOST	Schistosoma japonicum causes schistosomiasis in humans and livestock in the Asia-Pacific region. Knowledge of the genome of this parasite should improve understanding of schistosome-host interactions, biomedical aspects of schistosomiasis and invertebrate evolution. We assigned 43,707 expressed sequence tags ( ESTs) derived from adult S. japonicum and their eggs to 13,131 gene clusters. Of these, 35% shared no similarity with known genes and 75% had not been reported previously in schistosomes. Notably, S. japonicum encoded mammalian-like receptors for insulin, progesterone, cytokines and neuropeptides, suggesting that host hormones, or endogenous parasite homologs, could orchestrate schistosome development and maturation and that schistosomes modulate anti-parasite immune responses through inhibitors, molecular mimicry and other evasion strategies.	Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Ctr Dis Control & Prevent, Inst Parasit Dis, Shanghai 200025, Peoples R China; Shanghai Med Univ 2, Dept Parasitol, Shanghai 200025, Peoples R China; Shanghai Med Univ 2, Rui Jin Hosp, State Key Lab Med Genom, Shanghai 200025, Peoples R China; Tulane Univ, Hlth Sci Ctr, Dept Trop Med, New Orleans, LA 70112 USA; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Australian Ctr Int Hlth & Nutr, Brisbane, Qld 4029, Australia	Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Tulane University; QIMR Berghofer Medical Research Institute	Han, ZG (corresponding author), Chinese Natl Human Genome Ctr Shanghai, 351 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.	hanzg@chgc.sh.cn	HU, Wei/F-1004-2012; Wang, Zhaojun/GKS-9141-2022; McManus, Donald P./G-2678-2013; McManus, Don/AAC-5394-2020; Song, Huai-Dong/G-8961-2011	Wang, Zhaojun/0000-0003-2853-1850; McManus, Don/0000-0001-6443-1449; Brindley, Paul J./0000-0003-1765-0002; Han, Ze-Guang/0000-0002-1018-1752				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; Ashburner M, 2001, GENOME RES, V11, P1425; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; Blair JE, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-7; Boag PR, 2001, ADV PARASIT, V50, P153, DOI 10.1016/S0065-308X(01)50031-7; Bostic JR, 1996, MOL BIOCHEM PARASIT, V79, P79, DOI 10.1016/0166-6851(96)02640-0; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; BUEDING E, 1982, J PARASITOL, V68, P208, DOI 10.2307/3281177; CAMACHO M, 1995, J PARASITOL, V81, P637, DOI 10.2307/3283866; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; Davies SJ, 2001, SCIENCE, V294, P1358, DOI 10.1126/science.1064462; de Mendonca RL, 2000, PARASITOL TODAY, V16, P233, DOI 10.1016/S0169-4758(00)01641-0; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; Halton DW, 1997, INT J PARASITOL, V27, P693, DOI 10.1016/S0020-7519(97)00011-8; Hoffmann KF, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-8-research0041; Holland PWH, 1999, NATURE, V402, pC41, DOI 10.1038/35011536; Imase A, 2001, PARASITOLOGY, V123, P163, DOI 10.1017/S0031182001008198; Johnston DA, 1999, BIOESSAYS, V21, P131, DOI 10.1002/(SICI)1521-1878(199902)21:2<131::AID-BIES7>3.0.CO;2-I; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kuwabara PE, 1998, DEV BIOL, V204, P251, DOI 10.1006/dbio.1998.9062; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Le TH, 2002, TRENDS PARASITOL, V18, P206, DOI 10.1016/S1471-4922(02)02252-3; Li L, 2003, GENOME RES, V13, P443, DOI 10.1101/gr.693203; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Lipman DJ, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-20; Lum DH, 2000, GENE DEV, V14, P3153; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; Morand S, 2000, PARASITOLOGY, V120, P45, DOI 10.1017/S0031182099005235; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; PULTZ MA, 1995, DEVELOPMENT, V121, P99; Ravindran B, 2001, TRENDS PARASITOL, V17, P70, DOI 10.1016/S1471-4922(00)01835-3; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Ross AGP, 2001, CLIN MICROBIOL REV, V14, P270, DOI 10.1128/CMR.14.2.270-295.2001; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Salzet M, 2000, PARASITOL TODAY, V16, P536, DOI 10.1016/S0169-4758(00)01787-7; Santos TM, 1999, MOL BIOCHEM PARASIT, V103, P79, DOI 10.1016/S0166-6851(99)00100-0; Skelly PJ, 1996, P NATL ACAD SCI USA, V93, P3642, DOI 10.1073/pnas.93.8.3642; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; Sokol SB, 2000, GENE DEV, V14, P901; Thornton JW, 2000, ANNU REV GENOM HUM G, V1, P41, DOI 10.1146/annurev.genom.1.1.41; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	46	261	298	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					139	147		10.1038/ng1236	http://dx.doi.org/10.1038/ng1236			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12973349				2022-12-25	WOS:000185625300010
J	Verjovski-Almeida, S; DeMarco, R; Martins, EAL; Guimaraes, PEM; Ojopi, EPB; Paquola, ACM; Piazza, JP; Nishiyama, MY; Kitajima, JP; Adamson, RE; Ashton, PD; Bonaldo, MF; Coulson, PS; Dillon, GP; Farias, LP; Gregorio, SP; Ho, PL; Leite, RA; Malaquias, LCC; Marques, RCP; Miyasato, PA; Nascimento, ALTO; Ohlweiler, FP; Reis, EM; Ribeiro, MA; Sa, RG; Stukart, GC; Soares, MB; Gargioni, C; Kawano, T; Rodrigues, V; Madeira, AMBN; Wilson, RA; Menck, CFM; Setubal, JC; Leite, LCC; Dias-Neto, E				Verjovski-Almeida, S; DeMarco, R; Martins, EAL; Guimaraes, PEM; Ojopi, EPB; Paquola, ACM; Piazza, JP; Nishiyama, MY; Kitajima, JP; Adamson, RE; Ashton, PD; Bonaldo, MF; Coulson, PS; Dillon, GP; Farias, LP; Gregorio, SP; Ho, PL; Leite, RA; Malaquias, LCC; Marques, RCP; Miyasato, PA; Nascimento, ALTO; Ohlweiler, FP; Reis, EM; Ribeiro, MA; Sa, RG; Stukart, GC; Soares, MB; Gargioni, C; Kawano, T; Rodrigues, V; Madeira, AMBN; Wilson, RA; Menck, CFM; Setubal, JC; Leite, LCC; Dias-Neto, E			Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni	NATURE GENETICS			English	Article							GENE-EXPRESSION; RNA INTERFERENCE; CDNA LIBRARIES; LIFE-SPAN; GENOME; SEQUENCE; PROTEINS; MEMBRANE; INVERTEBRATES; CONSTRUCTION	Schistosoma mansoni is the primary causative agent of schistosomiasis, which affects 200 million individuals in 74 countries. We generated 163,000 expressed-sequence tags ( ESTs) from normalized cDNA libraries from six selected developmental stages of the parasite, resulting in 31,000 assembled sequences and 92% sampling of an estimated 14,000 gene complement. By analyzing automated Gene Ontology assignments, we provide a detailed view of important S. mansoni biological systems, including characterization of metazoa-specific and eukarya-conserved genes. Phylogenetic analysis suggests an early divergence from other metazoa. The data set provides insights into the molecular mechanisms of tissue organization, development, signaling, sexual dimorphism, host interactions and immune evasion and identifies novel proteins to be investigated as vaccine candidates and potential drug targets.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Ctr Biotecnol, BR-05503900 Sao Paulo, Brazil; Univ Sao Paulo, HCFM, Inst Psiquiatria, Lab Neurosci LIM27, BR-05403010 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, Lab Bioinformat, BR-05508900 Sao Paulo, Brazil; Univ Estadual Campinas, Inst Computacao, BR-13084971 Campinas, SP, Brazil; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508900 Sao Paulo, Brazil; Univ Vale Rio Doce, BR-35030390 Governador Valadares, MG, Brazil; Inst Butantan, Parasitol Lab, BR-05503900 Sao Paulo, Brazil; Univ Sao Paulo, Fac Med Vet & Zootecnia, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Orthopaed, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biophys, Iowa City, IA 52242 USA; Inst Adolfo Lutz Registro, Dept Parasitol, BR-01246902 Sao Paulo, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Estadual de Campinas; University of York - UK; University of Iowa; Universidade de Sao Paulo; University Vale Rio Doce; Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Instituto Adolfo Lutz	Verjovski-Almeida, S (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.	verjo@iq.usp.br	Setubal, Joao Carlos/C-7305-2012; Rodrigues, Vanderlei/I-4528-2012; Wilson, Alan/AAD-5050-2020; Nascimento, Ana L. T. O./E-8488-2012; Ojopi, Elida Benquique/A-6773-2012; Nishiyama, Milton/AAE-5736-2021; Ho, Paulo/P-8267-2015; Leite, Luciana/D-1353-2012; Farias, Leonardo P/C-4072-2012; Reis, Eduardo Moraes Rego/AAF-3553-2020; Reis, Eduardo M/H-2008-2011; Menck, Carlos FM/G-6321-2011; DeMarco, Ricardo/A-7773-2008; Dias-Neto, Emmanuel/A-5869-2008; Farias, Leonardo Paiva/GLV-4591-2022; Nishiyama, Milton Y/H-4002-2013; Madeira, AMBN/E-7971-2012; Malaquias, Luiz Cosme/K-7210-2013; Verjovski-Almeida, Sergio/E-4082-2012; Miyasato, Patricia A/P-8045-2018; Dias-Neto, Emmanuel/AAA-6701-2019; Martins, Elizabeth AL/B-7135-2015; Guimaraes, Pedro/A-9715-2008; GARGIONI, CYBELE/B-5213-2016	Setubal, Joao Carlos/0000-0001-9174-2816; Nascimento, Ana L. T. O./0000-0003-4851-0870; Ojopi, Elida Benquique/0000-0001-5824-5199; Nishiyama, Milton/0000-0002-2410-0562; Ho, Paulo/0000-0003-3652-241X; Leite, Luciana/0000-0003-0156-1312; Farias, Leonardo P/0000-0002-4909-5333; Reis, Eduardo M/0000-0002-9556-3070; Menck, Carlos FM/0000-0003-1941-0694; DeMarco, Ricardo/0000-0001-8944-1301; Dias-Neto, Emmanuel/0000-0001-5670-8559; Farias, Leonardo Paiva/0000-0002-4909-5333; Nishiyama, Milton Y/0000-0002-2410-0562; Madeira, AMBN/0000-0002-3917-1849; Malaquias, Luiz Cosme/0000-0002-4920-072X; Verjovski-Almeida, Sergio/0000-0002-6356-2401; Miyasato, Patricia A/0000-0003-4871-5972; Martins, Elizabeth AL/0000-0002-2333-9379; Guimaraes, Pedro/0000-0002-7530-600X; GARGIONI, CYBELE/0000-0002-9154-6839; Dillon, Gary/0000-0002-7743-5040; Wilson, Alan/0000-0002-7210-0321; Ashton, Peter/0000-0002-7446-5009				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BASCH PF, 1988, COMP BIOCHEM PHYS B, V90, P389, DOI 10.1016/0305-0491(88)90093-4; Boyle JP, 2003, MOL BIOCHEM PARASIT, V128, P205, DOI 10.1016/S0166-6851(03)00078-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Coulson PS, 1997, ADV PARASIT, V39, P271, DOI 10.1016/S0065-308X(08)60048-2; Cutts L, 1997, PARASITE IMMUNOL, V19, P91, DOI 10.1046/j.1365-3024.1997.d01-184.x; DAMONNEVILLE M, 1984, INT ARCH ALLER A IMM, V73, P248, DOI 10.1159/000233477; de Mendonca RL, 2000, PARASITOL TODAY, V16, P233, DOI 10.1016/S0169-4758(00)01641-0; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; DeMarco R, 2003, BIOCHEM BIOPH RES CO, V307, P831, DOI 10.1016/S0006-291X(03)01268-3; DISSOUS C, 1995, PARASITOL TODAY, V11, P45, DOI 10.1016/0169-4758(95)80111-1; Doenhoff MJ, 2002, T ROY SOC TROP MED H, V96, P465, DOI 10.1016/S0035-9203(02)90405-0; Dorsey CH, 2002, MICRON, V33, P279, DOI 10.1016/S0968-4328(01)00019-1; Dunne D., 2001, BOOKSGOOGLECOM, P133, DOI [10.1142/9781848161511_0005, DOI 10.1142/9781848161511_0005]; Fietto JLR, 2002, BIOTECHNIQUES, V32, P1404, DOI 10.2144/02326rr01; FULFORD AJC, 1995, PARASITOLOGY, V110, P307, DOI 10.1017/S0031182000080896; Halton DW, 1996, PARASITOLOGY, V113, pS47, DOI 10.1017/S0031182000077891; Hausdorf B, 2000, SYST BIOL, V49, P130, DOI 10.1080/10635150050207438; Hoffmann KF, 2001, MOL BIOCHEM PARASIT, V112, P113, DOI 10.1016/S0166-6851(00)00352-2; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; King CL, 2001, SCHISTOSOMIASIS, P218; Mair GR, 2000, PARASITOLOGY, V121, P163, DOI 10.1017/S0031182099006174; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mansour TE., 2002, CHEMOTHERAPEUTIC TAR, DOI 10.1017/CBO9780511546440; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Neto ED, 2000, P NATL ACAD SCI USA, V97, P3491; Neto ED, 1997, GENE, V186, P135, DOI 10.1016/S0378-1119(96)00699-3; Osman A, 2001, J BIOL CHEM, V276, P10072, DOI 10.1074/jbc.M005933200; PAPPAS PW, 1975, EXP PARASITOL, V37, P469, DOI 10.1016/0014-4894(75)90016-8; Paquola ACM, 2003, BIOINFORMATICS, V19, P1587, DOI 10.1093/bioinformatics/btg196; PAX RA, 1991, PARASITOLOGY, V102, pS31, DOI 10.1017/S0031182000073273; Pryon SC, 2000, ACTA BIOL HUNG, V51, P331; Racoosin EL, 1999, MOL BIOCHEM PARASIT, V104, P285, DOI 10.1016/S0166-6851(99)00156-5; Ramos CRR, 2003, J BIOL CHEM, V278, P12745, DOI 10.1074/jbc.M211268200; Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200; Santos TM, 1999, MOL BIOCHEM PARASIT, V103, P79, DOI 10.1016/S0166-6851(99)00100-0; Saule P, 2002, J PARASITOL, V88, P849, DOI 10.1645/0022-3395(2002)088[0849:EVOHTA]2.0.CO;2; SIMPSON AJG, 1982, MOL BIOCHEM PARASIT, V6, P125, DOI 10.1016/0166-6851(82)90070-6; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; SMART D, 1994, J COMP NEUROL, V347, P426, DOI 10.1002/cne.903470308; SNYDER SD, 2000, INTERRELATIONSHIPS P, P194; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Stekel DJ, 2000, GENOME RES, V10, P2055, DOI 10.1101/gr.GR-1325RR; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Williams SA, 1999, PARASITOLOGY, V118, pS19, DOI 10.1017/S0031182099004473; WILSON RA, 1977, PARASITOLOGY, V74, P61, DOI 10.1017/S0031182000047533; World Health Organization (WHO), 2002, TDR STRAT DIR RES SC; XU XF, 1992, EUR J CELL BIOL, V57, P229	50	392	414	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					148	157		10.1038/ng1237	http://dx.doi.org/10.1038/ng1237			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12973350				2022-12-25	WOS:000185625300011
J	Awatramani, R; Soriano, P; Rodriguez, C; Mai, JJ; Dymecki, SM				Awatramani, R; Soriano, P; Rodriguez, C; Mai, JJ; Dymecki, SM			Cryptic boundaries in roof plate and choroid plexus identified by intersectional gene activation	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASES; MOUSE EMBRYOS; NEURAL CREST; DEVELOPING HINDBRAIN; NERVOUS-SYSTEM; EPH FAMILY; EXPRESSION; RHOMBOMERES; FATE; RECOMBINATION	The hindbrain roof plate and choroid plexus are essential organizing centers for inducing dorsal neuron fates and sustaining neuron function. To map the formation of these structures, we developed a broadly applicable, high resolution, recombinase-based method for mapping the fate of cells originating from coordinates defined by intersecting combinations of expressed genes. Using this method, we show that distinct regions of hindbrain roof plate originate from discrete subdomains of rhombencephalic neuroectoderm expressing Wnt1; that choroid plexus, a secretory epithelium important for patterning later-formed hindbrain structures and maintaining neuron function(1), derives from the same embryonic primordium as the hindbrain roof plate; and that, unlike the floor plate(2,3), these dorsal organizing centers develop in a patterned, segmental manner, built from lineage-restricted compartments. Our data suggest that the roof plate and choroid plexus may be formed of functional units that are capable of differentially organizing the generation of distinct neuronal cell types at different axial levels.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Dymecki, SM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Rodriguez, Carolyn I/K-8479-2014; Soriano, Philippe M/E-5797-2015	Rodriguez, Carolyn I/0000-0001-6697-1692; Soriano, Philippe M/0000-0002-0427-926X	NHGRI NIH HHS [F31 HG000180] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [F31HG000180] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altman J, 1997, DEV CEREBELLAR SYSTE; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; Chai Y, 2000, DEVELOPMENT, V127, P1671; Dymecki SM, 1998, DEV BIOL, V201, P57, DOI 10.1006/dbio.1998.8971; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FRASCH M, 1995, DEVELOPMENT, V121, P957; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; Gale NW, 1996, ONCOGENE, V13, P1343; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Lee KJ, 2000, NATURE, V403, P734, DOI 10.1038/35001507; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Manzanares M, 2000, MECH DEVELOP, V94, P147, DOI 10.1016/S0925-4773(00)00288-4; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Millonig JH, 2000, NATURE, V403, P764, DOI 10.1038/35001573; PRINCE V, 1994, DEVELOPMENT, V120, P911; Rodriguez CI, 2000, NEURON, V27, P475, DOI 10.1016/S0896-6273(00)00059-3; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Voiculescu O, 2000, GENESIS, V26, P123, DOI 10.1002/(SICI)1526-968X(200002)26:2<123::AID-GENE7>3.0.CO;2-O; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; Wingate RJT, 1999, DEVELOPMENT, V126, P4395; Yamamoto M, 1996, DEV BRAIN RES, V93, P182, DOI 10.1016/0165-3806(96)00038-7; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	30	153	156	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					70	75		10.1038/ng1228	http://dx.doi.org/10.1038/ng1228			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12923530				2022-12-25	WOS:000185018500013
J	Boonrod, KJ; Galetzka, D; Nagy, PD; Conrad, U; Krczal, G				Boonrod, KJ; Galetzka, D; Nagy, PD; Conrad, U; Krczal, G			Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance	NATURE BIOTECHNOLOGY			English	Article							BUSHY-STUNT VIRUS; ESCHERICHIA-COLI; EXPRESSION; REPLICATION; PROTEINS; GENE; IMMUNOMODULATION; TOMBUSVIRUS; DNA; DOMAIN	Crop loss due to viral diseases is still a major problem for agriculture today. We present a strategy to achieve virus resistance based on the expression of single-chain Fv fragments (scFvs) against a conserved domain in a plant viral RNA-dependent RNA polymerase (RdRp), a key enzyme in virus replication. The selected scFvs inhibited complementary RNA synthesis of different plant virus RdRps in vitro and virus replication in planta. Moreover, the scFvs also bound to the RdRp of the distantly related hepatitis C virus. T-1 and T-2 progeny of transgenic lines of Nicotiana benthamiana expressing different scFvs either in the cytosol or in the endoplasmic reticulum showed varying degrees of resistance against four plant viruses from different genera, three of which belong to the Tombusviridae family. Virus resistance based on antibodies to RdRps adds another tool to the repertoire for combating plant viruses.	Dienstleistungszentrum Landlicher Raum Rheinpfalz, Ctr Grune Gentech, D-67435 Neustadt, Germany; Univ Mainz Klinikum, Inst Humangenet, D-55101 Mainz, Germany; Univ Kentucky, Dept Plant Pathol, Lexington, KY 40546 USA; Inst Plant Genet & Crop Res Gatersleben, Gatersleben, Germany	Johannes Gutenberg University of Mainz; University of Kentucky; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Krczal, G (corresponding author), Dienstleistungszentrum Landlicher Raum Rheinpfalz, Ctr Grune Gentech, Breitenweg 71, D-67435 Neustadt, Germany.	gabi.krczal@dlr.rlp.de	Galetzka, Danuta/D-2199-2012					Bartenschlager R, 2000, BEST PRACT RES CL GA, V14, P241, DOI 10.1053/bega.1999.0073; BATES HJ, 1995, J GEN VIROL, V76, P1483, DOI 10.1099/0022-1317-76-6-1483; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Burgyan J, 1996, J GEN VIROL, V77, P1967, DOI 10.1099/0022-1317-77-8-1967; CLARK MF, 1977, J GEN VIROL, V34, P475, DOI 10.1099/0022-1317-34-3-475; Conrad U, 2001, TRENDS PLANT SCI, V6, P399, DOI 10.1016/S1360-1385(01)02043-X; Conrad U, 1998, PLANT MOL BIOL, V38, P101, DOI 10.1023/A:1006029617949; CONRAD U, 1997, RECOMBINANT PROTEINS, P103; De Jaeger G, 2000, PLANT MOL BIOL, V43, P419, DOI 10.1023/A:1006471528756; Fischer R, 1999, BIOL CHEM, V380, P825, DOI 10.1515/BC.1999.102; Galetzka D., 2000, Journal of Plant Pathology, V82, P151; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; Hajukiewicz P., 1994, PLANT MOL BIOL, V25, P989; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HAYES RJ, 1994, J GEN VIROL, V75, P3177, DOI 10.1099/0022-1317-75-11-3177; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; HORSCH RB, 1985, COLD SPRING HARB SYM, V50, P433, DOI 10.1101/SQB.1985.050.01.054; *INT COMM TAX VIR, UN VIR DAT BAS INT C; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Luerssen K, 1998, PLANT J, V15, P755, DOI 10.1046/j.1365-313X.1998.00259.x; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MLYNAROVA L, 1995, PLANT CELL, V7, P599, DOI 10.1105/tpc.7.5.599; Nagy PD, 2000, VIROLOGY, V276, P279, DOI 10.1006/viro.2000.0577; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Oster SK, 1998, J VIROL, V72, P5845, DOI 10.1128/JVI.72.7.5845-5851.1998; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Qiut WP, 2001, J GEN VIROL, V82, P3107, DOI 10.1099/0022-1317-82-12-3107; Rajendran KS, 2002, J VIROL, V76, P1707, DOI 10.1128/JVI.76.4.1707-1717.2002; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; RUBINO L, 1995, ARCH VIROL, V140, P2027, DOI 10.1007/BF01322690; Rubino L, 2001, J GEN VIROL, V82, P29, DOI 10.1099/0022-1317-82-1-29; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scholthof HB, 1999, J VIROL, V73, P7823, DOI 10.1128/JVI.73.9.7823-7829.1999; SCHOLTHOF HB, 1993, MOL PLANT MICROBE IN, V6, P309, DOI 10.1094/MPMI-6-309; SCHOLTHOF KBG, 1995, VIROLOGY, V208, P365, DOI 10.1006/viro.1995.1162; Schouten A, 1997, FEBS LETT, V415, P235, DOI 10.1016/S0014-5793(97)01129-0; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Turner KA, 2004, VIROLOGY, V320, P276, DOI 10.1016/j.virol.2003.12.006; VOSS A, 1995, MOL BREEDING, V1, P39, DOI 10.1007/BF01682088; Yang YN, 2000, PLANT J, V22, P543, DOI 10.1046/j.1365-313x.2000.00760.x; Zimmermann S, 1998, MOL BREEDING, V4, P369, DOI 10.1023/A:1009638600492	45	79	83	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					856	862		10.1038/nbt983	http://dx.doi.org/10.1038/nbt983			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15195103				2022-12-25	WOS:000222533000026
J	Kamakura, S; Oishi, K; Yoshimatsu, T; Nakafuku, M; Masuyama, N; Gotoh, Y				Kamakura, S; Oishi, K; Yoshimatsu, T; Nakafuku, M; Masuyama, N; Gotoh, Y			Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE; NERVOUS-SYSTEM; DIFFERENTIATION; GENE; GROWTH; CELLS; GLIOGENESIS; ACTIVATION; FOREBRAIN; EFFICIENT	Although the Notch and JAK-STAT signalling pathways fulfill overlapping roles in growth and differentiation regulation, no coordination mechanism has been proposed to explain their relationship. Here we show that STAT3 is activated in the presence of active Notch, as well as the Notch effectors Hes1 and Hes5. Hes proteins associate with JAK2 and STAT3, and facilitate complex formation between JAK2 and STAT3, thus promoting STAT3 phosphorylation and activation. Furthermore, suppression of endogenous Hes1 expression reduces growth factor induction of STAT3 phosphorylation. STAT3 seems to be essential for maintenance of radial glial cells and differentiation of astrocytes by Notch in the developing central nervous system. These results suggest that direct protein-protein interactions coordinate cross-talk between the Notch-Hes and JAK-STAT pathways.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Cincinnati Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Japan Sci & Technol Corp, PRESTO Project, Tokyo, Japan; Japan Sci & Technol Corp, CREST Project, Tokyo, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	University of Tokyo; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ygotoh@iam.u-tokyo.ac.jp	Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005; Yoshimatsu, Takeshi/0000-0002-4939-2020				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Chambers CB, 2001, DEVELOPMENT, V128, P689; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rajan P, 1998, J NEUROSCI, V18, P3620; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Satow T, 2001, J NEUROSCI, V21, P1265; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	30	337	343	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					547	554		10.1038/ncb1138	http://dx.doi.org/10.1038/ncb1138			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15156153				2022-12-25	WOS:000221759400015
J	Topaz, O; Shurman, DI; Bergman, R; Indelman, M; Ratajczak, P; Mizrachi, M; Khamaysi, Z; Behar, D; Petronius, D; Friedman, V; Zelikovic, I; Raimer, S; Metzker, A; Richard, G; Sprecher, E				Topaz, O; Shurman, DI; Bergman, R; Indelman, M; Ratajczak, P; Mizrachi, M; Khamaysi, Z; Behar, D; Petronius, D; Friedman, V; Zelikovic, I; Raimer, S; Metzker, A; Richard, G; Sprecher, E			Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; PHOSPHATE; CLONING; FGF23	Familial tumoral calcinosis (FTC; OMIM 211900) is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Using linkage analysis, we mapped the gene underlying FTC to 2q24-q31. This region includes the gene GALNT3, which encodes a glycosyltransferase responsible for initiating mucin-type O-glycosylation. Sequence analysis of GALNT3 identified biallelic deleterious mutations in all individuals with FTC, suggesting that defective post-translational modification underlies the disease.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Dermatol, Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Lab Mol Dermatol, Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Rambam Med Ctr, Pediat Nephrol Unit, Haifa, Israel; Rambam Med Ctr, Lab Dev Nephrol, Haifa, Israel; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Jefferson University; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; University of Texas System; University of Texas Medical Branch Galveston	Sprecher, E (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Dermatol, Haifa, Israel.	e-sprecher@rambam.health.gov.il						Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Berndt T, 2003, J CLIN INVEST, V112, P785, DOI 10.1172/JC1200318563; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; de Beur SMJ, 2002, J CLIN ENDOCR METAB, V87, P2467, DOI 10.1210/jc.87.6.2467; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; PRINCE MJ, 1982, ANN INTERN MED, V96, P586, DOI 10.7326/0003-4819-96-5-586; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Rowe PSN, 2004, BONE, V34, P303, DOI 10.1016/j.bone.2003.10.005; Schiavi SC, 2004, KIDNEY INT, V65, P1, DOI 10.1111/j.1523-1755.2004.00355.x; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; SLAVIN RE, 1993, AM J SURG PATHOL, V17, P788, DOI 10.1097/00000478-199308000-00004; STEINHERZ R, 1985, AM J DIS CHILD, V139, P816, DOI 10.1001/archpedi.1985.02140100078036; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007	15	389	404	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					579	581		10.1038/ng1358	http://dx.doi.org/10.1038/ng1358			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15133511	Bronze			2022-12-25	WOS:000221763700013
J	Behnia, R; Panic, B; Whyte, JRC; Munro, S				Behnia, R; Panic, B; Whyte, JRC; Munro, S			Targeting of the arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BINDING PROTEINS; GRIP DOMAINS; YEAST; ACETYLTRANSFERASE; COMPLEX; FAMILY; TRANSPORT	The GTPase Arl3p is required to recruit a second GTPase, ArI1p, to the Golgi in Saccharomyces cerevisiae. ArI1p binds to the GRIP domain, which is present in a number of long coiled-coil proteins or 'golgins'. Here we show that Arl3p is not myristoylated like most members of the Arf family, but is instead amino-terminally acetylated by the NatC complex. Targeting of Arl3p also requires a Golgi membrane protein Sys1p. The human homologues of Arl3p (Arf-related protein 1 (ARFRP1)) and Sys1p (hSys1) can be isolated in a complex after chemical cross-linking. This suggests that the targeting of ARFRP1/Arl3p to the Golgi is mediated by a direct interaction between its acetylated N terminus and Sys1p/hSys1.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sean@mrc-lmb.cam.ac.uk		Munro, Sean/0000-0001-6160-5773				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gillingham AK, 2002, MOL BIOL CELL, V13, P3761, DOI 10.1091/mbc.E02-06-0349; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lu L, 2003, MOL BIOL CELL, V14, P3767, DOI 10.1091/mbc.E03-01-0864; Lu L, 2001, J CELL SCI, V114, P4543; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Mueller AG, 2002, MOL CELL BIOL, V22, P1488, DOI 10.1128/MCB.22.5.1488-1494.2002; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Peneff C, 2001, J BIOL CHEM, V276, P16328, DOI 10.1074/jbc.M009988200; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2001, J BIOL CHEM, V276, P20154, DOI 10.1074/jbc.M011440200; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; Tsukada M, 1999, MOL BIOL CELL, V10, P63, DOI 10.1091/mbc.10.1.63; Tsukada M, 1996, J CELL SCI, V109, P2471; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; VOGEL F, 1990, EUR J CELL BIOL, V53, P197; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	47	178	188	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					405	+		10.1038/ncb1120	http://dx.doi.org/10.1038/ncb1120			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15077113				2022-12-25	WOS:000221432600010
J	Marchini, J; Cardon, LR; Phillips, MS; Donnelly, P				Marchini, J; Cardon, LR; Phillips, MS; Donnelly, P			The effects of human population structure on large genetic association studies	NATURE GENETICS			English	Article							STRATIFICATION; DIFFERENTIATION; INFERENCE	Large-scale association studies hold substantial promise for unraveling the genetic basis of common human diseases. A well-known problem with such studies is the presence of undetected population structure, which can lead to both false positive results and failures to detect genuine associations. Here we examine similar to15,000 genome-wide single-nucleotide polymorphisms typed in three population groups to assess the consequences of population structure on the coming generation of association studies. The consequences of population structure on association outcomes increase markedly with sample size. For the size of study needed to detect typical genetic effects in common diseases, even the modest levels of population structure within population groups cannot safely be ignored. We also examine one method for correcting for population structure ( Genomic Control). Although it often performs well, it may not correct for structure if too few loci are used and may overcorrect in other settings, leading to substantial loss of power. The results of our analysis can guide the design of large-scale association studies.	Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; McGill Univ, Genome Ctr, Montreal, PQ H3A 1A4, Canada; Genome Quebec, Montreal, PQ H3A 1A4, Canada	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; McGill University	Donnelly, P (corresponding author), Univ Oxford, Dept Stat, 1 S Parks Rd, Oxford OX1 3TG, England.	donnelly@stats.ox.ac.uk	Peng, Bo/A-6920-2009; Marchini, Jonathan/ABE-9024-2020	Peng, Bo/0000-0001-8225-2284; Marchini, Jonathan/0000-0003-0610-8322; Donnelly, Peter/0000-0001-9495-3408				Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719; Bacanu SA, 2000, AM J HUM GENET, V66, P1933, DOI 10.1086/302929; Balding DJ, 2003, THEOR POPUL BIOL, V63, P221, DOI 10.1016/S0040-5809(03)00007-8; BALDING DJ, 1995, GENETICA, V96, P3, DOI 10.1007/BF01441146; CLAYTON D, 2001, HDB STAT GENETICS, P519; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Excoffier L, 2001, HDB STAT GENETICS, P271; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Moller T, 2003, ANN ONCOL, V14, P946, DOI 10.1093/annonc/mdg255; Nicholson G, 2002, J ROY STAT SOC B, V64, P695, DOI 10.1111/1467-9868.00357; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Pritchard JK, 2000, GENETICS, V155, P945; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Ripatti S, 2001, GENET EPIDEMIOL, V21, pS409, DOI 10.1002/gepi.2001.21.s1.s409; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Satten GA, 2001, AM J HUM GENET, V68, P466, DOI 10.1086/318195; Spence MA, 2003, AM J HUM GENET, V72, P1084, DOI 10.1086/374826; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; Ziv E, 2003, PHARMACOGENOMICS, V4, P431, DOI 10.1517/phgs.4.4.431.22758; [No title captured]	28	630	658	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					512	517		10.1038/ng1337	http://dx.doi.org/10.1038/ng1337			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15052271	Bronze			2022-12-25	WOS:000221183000026
J	Acevedo, L; Yu, J; Erdjument-Bromage, H; Miao, RQ; Kim, JE; Fulton, D; Tempst, P; Strittmatter, SM; Sessa, WC				Acevedo, L; Yu, J; Erdjument-Bromage, H; Miao, RQ; Kim, JE; Fulton, D; Tempst, P; Strittmatter, SM; Sessa, WC			A new role for Nogo as a regulator of vascular remodeling	NATURE MEDICINE			English	Article							AXONAL REGENERATION; NEURITE OUTGROWTH; INHIBITOR; MYELIN; PROTEIN; INJURY; IDENTIFICATION; RECOMBINANT; APOPTOSIS; IN-1	Although Nogo-A has been identified in the central nervous system as an inhibitor of axonal regeneration, the peripheral roles of Nogo isoforms remain virtually unknown. Here, using a proteomic analysis to identify proteins enriched in caveolae and/or lipid rafts (CEM/LR), we show that Nogo-B is highly expressed in cultured endothelial and smooth muscle cells, as well as in intact blood vessels. The N terminus of Nogo-B promotes the migration of endothelial cells but inhibits the migration of vascular smooth muscle (VSM) cells, processes necessary for vascular remodeling. Vascular injury in Nogo-A/B-deficient mice promotes exaggerated neointimal proliferation, and adenoviral-mediated gene transfer of Nogo-B rescues the abnormal vascular expansion in those knockout mice. Our discovery that Nogo-B is a regulator of vascular homeostasis and remodeling broadens the functional scope of this family of proteins.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Yale University; Yale University; Memorial Sloan Kettering Cancer Center	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Strittmatter, Stephen/F-5739-2011; Sessa, William C/B-6844-2011; Miao, Qing/K-3186-2019; Kim, Jean Jieun/G-5774-2018	Strittmatter, Stephen/0000-0001-8188-3092; Sessa, William C/0000-0001-5759-1938; Miao, Qing/0000-0002-3125-1238; Kim, Jean Jieun/0000-0003-4709-262X; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; Brosamle C, 2000, J NEUROSCI, V20, P8061; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Wang XX, 2002, J NEUROSCI, V22, P5505; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yu J, 2002, LAB INVEST, V82, P825, DOI 10.1097/01.LAB.0000018828.61722.BD; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	22	195	215	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					382	388		10.1038/nm1020	http://dx.doi.org/10.1038/nm1020			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034570				2022-12-25	WOS:000220587000029
J	Mitelman, F; Johansson, B; Mertens, F				Mitelman, F; Johansson, B; Mertens, F			Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer	NATURE GENETICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SOLID TUMORS; TRANSLOCATIONS; FIBROSARCOMA; INSTABILITY	Cytogenetic aberrations have been reported in 45,000 human neoplasms. Structural balanced rearrangements are associated with distinct tumor subtypes with remarkable specificity and have been essential for identifying genes involved in tumorigenesis(1,2). All balanced rearrangements that have been characterized molecularly act by deregulating a gene in one of the breakpoints or by creating a fusion gene(3-6). Because most recurrent aberrations and rearranged genes have been found in hematological disorders, whereas numerous genomic imbalances have been identified in solid tumors(7,8), it has become generally accepted that there are pathogenetic differences between these neoplasms. We here show that in every tumor type, the numbers of recurrent balanced chromosome abnormalities, fusion genes and genes rearranged as a consequence of balanced aberrations are simply a function of the number of cases with an abnormal karyotype. Hence, there may not be any fundamental tissue-specific differences in the genetic mechanisms by which neoplasia is initiated.	Univ Hosp, Dept Clin Genet, SE-22185 Lund, Sweden	Lund University; Skane University Hospital	Mitelman, F (corresponding author), Univ Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	felix.mitelman@klingen.lu.se		Mitelman, Felix/0000-0002-3757-7212; Mertens, Fredrik/0000-0002-6278-5232				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEIM S, 1988, CANCER RES, V48, P5911; Heim S, 1995, CANC CYTOGENETICS; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 2001, P NATL ACAD SCI USA, V98, P12331, DOI 10.1073/pnas.231485898; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mertens F, 1997, CANCER RES, V57, P2765; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Rabbitts TH, 2003, NAT MED, V9, P383, DOI 10.1038/nm0403-383; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0	26	237	256	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2004	36	4					331	334		10.1038/ng1335	http://dx.doi.org/10.1038/ng1335			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15054488	Green Published, Bronze			2022-12-25	WOS:000220647200013
J	Wang, D; King, SM; Quill, TA; Doolittle, LK; Garbers, DL				Wang, D; King, SM; Quill, TA; Doolittle, LK; Garbers, DL			A new sperm-specific Na+/H+ Exchanger required for sperm motility and fertility	NATURE CELL BIOLOGY			English	Letter							ENCODING SECRETED PROTEINS; SEA-URCHIN SPERM; INTRACELLULAR PH; MOLECULAR-CLONING; SPERMATOZOA; CAPACITATION; SELECTION; RECEPTORS; SEQUENCE; CALMEGIN	It has long been speculated that intracellular pH is a critical regulator of both invertebrate and vertebrate sperm motility(1-3), and sodium-hydrogen exchange has been suggested as a mediator of such pH(i) regulation in various instances(4,5). Two sodium-hydrogen exchangers (NHE1 and NHE5) are expressed in spermatozoa(6). However, elimination of the NHE1 gene fails to cause infertility(7), suggesting that normal sperm function is maintained in NHE1-null animals. Here, we used a functionally unbiased signal peptide trap screen to identify a novel sperm-specific NHE. The NHE contains 14 predicted transmembrane segments, including a potential voltage sensor and a consensus cyclic nucleotide-binding motif. Testis histology, sperm numbers and morphology were normal, but NHE-null males were completely infertile with severely diminished sperm motility. The addition of ammonium chloride, which elevates intracellular pH, partially rescued the motility and fertility defects. Surprisingly, cyclic AMP analogues almost completely rescued the motility and infertility phenotypes. The existence of this new sperm NHE provides an attractive contraceptive target, given its cell-specific expression and absolute requirement for fertility.	Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NICHD NIH HHS [HD 36022] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036022] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABCOCK DF, 1983, P NATL ACAD SCI-BIOL, V80, P1327, DOI 10.1073/pnas.80.5.1327; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; CARR DW, 1989, BIOL REPROD, V41, P907, DOI 10.1095/biolreprod41.5.907; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; FRASER LR, 1993, METHOD ENZYMOL, V225, P239; GARBERS DL, 1982, J BIOL CHEM, V257, P2734; GARBERS DL, 1992, CELL, V71, P1; Garcia MA, 1999, MOL REPROD DEV, V52, P189, DOI 10.1002/(SICI)1098-2795(199902)52:2<189::AID-MRD10>3.0.CO;2-D; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; LEE HC, 1985, J BIOL CHEM, V260, P794; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Moy G.W., 1979, Current Topics in Developmental Biology, V13, P31; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; Si YM, 2000, BIOL REPROD, V62, P1231, DOI 10.1095/biolreprod62.5.1231; WATANABE D, 1994, J BIOL CHEM, V269, P7744; Woo AL, 2002, MOL REPROD DEV, V62, P348, DOI 10.1002/mrd.90002	25	184	192	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1117	1122		10.1038/ncb1072	http://dx.doi.org/10.1038/ncb1072			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634667				2022-12-25	WOS:000186892900019
J	Allen, PG				Allen, PG			Actin filament uncapping localizes to ruffling lamellae and rocketing vesicles	NATURE CELL BIOLOGY			English	Letter							ARP2/3 COMPLEX; BARBED ENDS; PROTEIN INTERACTIONS; CAPPING PROTEIN; GELSOLIN; NUCLEATION; RAC; POLYMERIZATION; CYTOCHALASIN; CYTOSKELETON	Regulated actin filament assembly is critical for eukaryotic cell physiology. Actin filaments are polar structures(1), and those with free high affinity or barbed ends are crucial for actin dynamics and cell motility(2). Actin filament barbed-end-capping proteins inhibit filament elongation after binding(3), and their regulated disassociation is proposed to provide a source of free filament ends to drive processes dependent on actin polymerization(4). To examine whether dissociation of actin filament capping proteins occurs with the correct spatiotemporal constraints to contribute to regulated actin assembly in live cells, I measured the dissociation of an actin capping protein, gelsolin, from actin in cells using a variation of fluorescence resonance energy transfer ( FRET). Uncapping was found to occur in cells at sites of active actin assembly, including protruding lamellae and rocketing vesicles, with the correct spatio-temporal properties to provide sites of actin filament polymerization during protrusion. These observations are consistent with models where uncapping of existing filaments provides sites of actin filament elongation.	Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Allen, PG (corresponding author), Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.	pallen@rics.bwh.harvard.edu			NIGMS NIH HHS [R01GM57256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Bearer EL, 2000, CELL MOTIL CYTOSKEL, V47, P351, DOI 10.1002/1097-0169(200012)47:4<351::AID-CM8>3.0.CO;2-8; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carpenter CL, 2000, CRIT CARE MED, V28, pN94, DOI 10.1097/00003246-200004001-00011; Carpenter CL, 1999, ADV ENZYME REGUL, V39, P299, DOI 10.1016/S0065-2571(98)00009-0; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Falet H, 2002, P NATL ACAD SCI USA, V99, P16782, DOI 10.1073/pnas.222652499; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KOEPF EK, 1993, EUR J BIOCHEM, V212, P713, DOI 10.1111/j.1432-1033.1993.tb17709.x; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Oosawa F., 1975, THERMODYNAMICS POLYM; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; Stossel TP, 1999, BIOCHEM SOC SYMP, V65, P267; Suchy SF, 2002, AM J HUM GENET, V71, P1420, DOI 10.1086/344517; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; WEGNER A, 1977, BIOPHYS CHEM, V7, P51, DOI 10.1016/0301-4622(77)87014-2; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529	41	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					972	979		10.1038/ncb1059	http://dx.doi.org/10.1038/ncb1059			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14557819				2022-12-25	WOS:000186273100013
J	Dean, P				Dean, P			Cell of the month - An insect blood cell engulfing bacteria	NATURE CELL BIOLOGY			English	Article									Univ Bristol, Bristol BS8 1TH, Avon, England	University of Bristol	Dean, P (corresponding author), Univ Bristol, Bristol BS8 1TH, Avon, England.			Dean, Paul/0000-0002-2822-4677					0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					957	957		10.1038/ncb1103-957	http://dx.doi.org/10.1038/ncb1103-957			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14593420	Bronze			2022-12-25	WOS:000186273100010
J	Gaggar, A; Shayakhmetov, DM; Lieber, A				Gaggar, A; Shayakhmetov, DM; Lieber, A			CD46 is a cellular receptor for group B adenoviruses	NATURE MEDICINE			English	Article							HUMAN CD34(+) CELLS; EFFICIENT TRANSDUCTION; MEASLES-VIRUS; SUBGROUP-B; PROTEIN; VECTORS; BINDING; COMMON; HOST	Group B adenoviruses, a subgenus of human Adenoviridae, are associated with a variety of often-fatal illnesses in immunocompromised individuals, including bone marrow transplant recipients and cancer and AIDS patients(1-3). Recently, group B adenovirus derivatives have gained interest as attractive gene therapy vectors because they can transduce target tissues, such as hematopoietic stem cells, dendritic cells and malignant tumor cells, that are refractory to infection by commonly used adenoviral vectors(4-6). Whereas many adenoviruses infect cells through the coxsackievirus and adenovirus receptor (CAR), group B adenoviruses use an alternate, as-yet-unidentified cellular attachment receptor(7-10). Using mass spectrometric analysis of proteins interacting with a group B fiber, we identified human CD46 as a cellular attachment receptor for most group B adenoviruses. We show that ectopic expression of human CD46 rendered nonhuman cells susceptible to infection with group B viruses in vitro and in vivo. In addition, both siRNA-mediated knockdown of CD46 and a soluble form of CD46 blocked infection of human cell lines and primary human cells. The discovery that group B adenoviruses use CD46, a ubiquitously expressed complement regulatory protein, as a cellular attachment receptor elucidates the diverse clinical manifestation of group B virus infections, and bears directly on the application of these vectors for gene therapy.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lieber, A (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.			Lieber, Andre/0000-0001-6742-6266	NHLBI NIH HHS [HL-00-008] Funding Source: Medline; NIDDK NIH HHS [DK47754] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEJONG PJ, 1983, LANCET, V1, P1293, DOI 10.1016/S0140-6736(83)92411-X; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Havenga MJE, 2002, J VIROL, V76, P4612, DOI 10.1128/JVI.76.9.4612-4620.2002; HIERHOLZER JC, 1992, CLIN MICROBIOL REV, V5, P262, DOI 10.1128/CMR.5.3.262-274.1992; HSU KHL, 1988, J VIROL, V62, P1647, DOI 10.1128/JVI.62.5.1647-1652.1988; Kemper C, 2001, CLIN EXP IMMUNOL, V124, P180, DOI 10.1046/j.1365-2249.2001.01458.x; Luppi M, 1999, J VIROL, V73, P754, DOI 10.1128/JVI.73.1.754-759.1999; Manchester M, 2002, J VIROL, V76, P6636, DOI 10.1128/JVI.76.13.6636-6642.2002; OGLESBY TJ, 1991, T ASSOC AM PHYSICIAN, V104, P164; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Rea D, 2001, J IMMUNOL, V166, P5236, DOI 10.4049/jimmunol.166.8.5236; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Ruuskanen Olli, 2002, P515; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Seya T, 1999, INT J BIOCHEM CELL B, V31, P1255, DOI 10.1016/S1357-2725(99)00092-8; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Shayakhmetov DM, 2003, J VIROL, V77, P3712, DOI 10.1128/JVI.77.6.3712-3723.2003; Shayakhmetov DM, 2002, CANCER RES, V62, P1063; Shenk T, 2001, FIELDS VIROLOGY, V2, P2265; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wadell G, 1980, Ann N Y Acad Sci, V354, P16, DOI 10.1111/j.1749-6632.1980.tb27955.x; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703	28	584	617	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1408	1412		10.1038/nm952	http://dx.doi.org/10.1038/nm952			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566335				2022-12-25	WOS:000186319700032
J	Veigel, C; Molloy, JE; Schmitz, S; Kendrick-Jones, J				Veigel, C; Molloy, JE; Schmitz, S; Kendrick-Jones, J			Load-dependent kinetics of force production by smooth muscle myosin measured with optical tweezers	NATURE CELL BIOLOGY			English	Letter							CROSS-BRIDGE CYCLE; LIGHT-CHAIN; ADP RELEASE; MECHANISM; GENERATION; PHOSPHORYLATION; MOVEMENT; REGION; HEADS; MGADP	Muscle contraction is driven by the cyclical interaction of myosin with actin, coupled with ATP hydrolysis. Myosin attaches to actin, forming a crossbridge that produces force and movement as it tilts(1) or rocks into subsequent bound states(2) before finally detaching. It has been hypothesized that the kinetics of one or more of these mechanical transitions are dependent on load, allowing muscle to shorten quickly under low load, but to sustain tension economically, with slowly cycling crossbridges under high load conditions(2-6). The idea that muscle biochemistry depends on mechanical output is termed the 'Fenn effect'. However, the molecular details of how load affects the kinetics of a single crossbridge are unknown. Here, we describe a new technique based on optical tweezers to rapidly apply force to a single smooth muscle myosin crossbridge. The crossbridge produced movement in two phases that contribute 4 nm + 2 nm of displacement. Duration of the first phase depended in an exponential manner on the amplitude of applied load. Duration of the second phase was much less affected by load, but was significantly shorter at high ATP concentration. The effect of load on the lifetime of the bound crossbridge is to prolong binding when load is high, but to accelerate release when load is low or negative.	Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC National Institute for Medical Research; MRC Laboratory Molecular Biology	Veigel, C (corresponding author), Natl Inst Med Res, Div Phys Biochem, Ridgeway Mill Hill, London NW7 1AA, England.	cveigel@nimr.mrc.ac.uk		Molloy, Justin/0000-0002-8307-2450				Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dantzig JA, 1999, BIOPHYS J, V77, P386, DOI 10.1016/S0006-3495(99)76897-9; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; Fenn WO, 1923, J PHYSIOL-LONDON, V58, P0175; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Howard J., 2001, MECH MOTOR PROTEINS; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KENDRICKJONES J, 1983, J MOL BIOL, V165, P139, DOI 10.1016/S0022-2836(83)80247-2; Khromov AS, 2001, BIOPHYS J, V80, P1905, DOI 10.1016/S0006-3495(01)76160-7; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Piazzesi G, 2002, NATURE, V415, P659, DOI 10.1038/415659a; RALL JA, 1982, AM J PHYSIOL, V242, pH1, DOI 10.1152/ajpheart.1982.242.1.H1; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SMITH DA, 1995, BIOPHYS J, V69, P524, DOI 10.1016/S0006-3495(95)79926-X; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	31	259	262	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					980	986		10.1038/ncb1060	http://dx.doi.org/10.1038/ncb1060			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14578909				2022-12-25	WOS:000186273100014
J	Liu, D; Burton, S; Glancy, T; Li, ZS; Hampton, R; Meade, T; Merlo, DJ				Liu, D; Burton, S; Glancy, T; Li, ZS; Hampton, R; Meade, T; Merlo, DJ			Insect resistance conferred by 283-kDa Photorhabdus luminescens protein TcdA in Arabidopsis thaliana	NATURE BIOTECHNOLOGY			English	Article							AGROBACTERIUM; PLANTS; EXPRESSION; SEQUENCE; TOXINS; GENES; TOBACCO	The tcdA gene of Photorhabdus luminescens encodes a 283-kDa protein, toxin A, that is highly toxic to a variety of insects, including some agriculturally important pests. We tested the efficacy of transgenic toxin A in Arabidopsis thaliana for control of feeding insects. Plants with toxin A expression above about 700 ng/mg of extractable protein were highly toxic to tobacco hornworm (Manduca sexta). Toxin A isolated from transgenic plants also strongly inhibited growth of the southern corn rootworm (Diabrotica undecimpunctata howardi). Addition of 5 and 3 untranslated regions of a tobacco osmotin gene (osm) increased toxin A production 10-fold and recovery of insect-resistant lines 12-fold. In the best line, high toxin A expression and insect resistance were maintained for at least five generations in all progeny. The intact tcdA mRNA represents the largest effective transgenic transcript produced in plants to date. These results may open a new route to transgenic pest control in agriculture.	Dow Agrosci LLC, Indianapolis, IN 46268 USA	Dow Chemical Company	Liu, D (corresponding author), Dow Agrosci LLC, 9330 Zionsville Rd, Indianapolis, IN 46268 USA.	dliu@dow.com						BARKER RF, 1983, PLANT MOL BIOL, V2, P335, DOI 10.1007/BF01578595; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; Diehn S H, 1996, Genet Eng (N Y), V18, P83; Ensign J.C., 1998, World Intellectual Property Patent, Patent No. [WO 98 /08932 A1, 9808932]; ffrench-Constant R, 1999, CURR OPIN MICROBIOL, V2, P284, DOI 10.1016/S1369-5274(99)80049-6; ffrench-Constant RH, 2000, CELL MOL LIFE SCI, V57, P828, DOI 10.1007/s000180050044; Guo LN, 1999, J BIOL CHEM, V274, P9836, DOI 10.1074/jbc.274.14.9836; HEPBURN AG, 1985, J GEN MICROBIOL, V131, P2961; HOFTE H, 1989, MICROBIOL REV, V53, P242; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koziel MG, 1996, PLANT MOL BIOL, V32, P393, DOI 10.1007/BF00039392; MATTANOVICH D, 1989, NUCLEIC ACIDS RES, V17, P6747, DOI 10.1093/nar/17.16.6747; Morgan JAW, 2001, APPL ENVIRON MICROB, V67, P2062, DOI 10.1128/AEM.67.5.2062-2069.2001; NELSON DE, 1992, PLANT MOL BIOL, V19, P577, DOI 10.1007/BF00026784; PETELL JK, 2003, Patent No. 6590142; Poppy G, 2000, TRENDS PLANT SCI, V5, P4, DOI 10.1016/S1360-1385(99)01514-9; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; Silva CP, 2002, CELL MICROBIOL, V4, P329, DOI 10.1046/j.1462-5822.2002.00194.x; SINGH NK, 1985, PLANT PHYSIOL, V79, P126, DOI 10.1104/pp.79.1.126; Verdaguer B, 1996, PLANT MOL BIOL, V31, P1129, DOI 10.1007/BF00040830; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3	24	76	92	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1222	1228		10.1038/nbt866	http://dx.doi.org/10.1038/nbt866			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	12949536				2022-12-25	WOS:000185647200035
J	Mangi, AA; Noiseux, N; Kong, DL; He, HM; Rezvani, M; Ingwall, JS; Dzau, VJ				Mangi, AA; Noiseux, N; Kong, DL; He, HM; Rezvani, M; Ingwall, JS; Dzau, VJ			Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts	NATURE MEDICINE			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; SKELETAL MYOBLAST TRANSPLANTATION; IMPROVES CARDIAC-FUNCTION; MYOCARDIAL-INFARCTION; IN-VITRO; CELLULAR CARDIOMYOPLASTY; ISCHEMIC-MYOCARDIUM; PROGENITOR CELLS; ADHERENT CELLS	Transplantation of adult bone marrow-derived mesenchymal stem cells has been proposed as a strategy for cardiac repair following myocardial damage. However, poor cell viability associated with transplantation has limited the reparative capacity of these cells in vivo. In this study, we genetically engineered rat mesenchymal stem cells using ex vivo retroviral transduction to overexpress the prosurvival gene Akt1 (encoding the Akt protein). Transplantation of 5 x 10(6) cells overexpressing Akt into the ischemic rat myocardium inhibited the process of cardiac remodeling by reducing intramyocardial inflammation, collagen deposition and cardiac myocyte hypertrophy, regenerated 80-90% of lost myocardial volume, and completely normalized systolic and diastolic cardiac function. These observed effects were dose (cell number) dependent. Mesenchymal stem cells transduced with Akt1 restored fourfold greater myocardial volume than equal numbers of cells transduced with the reporter gene lacZ. Thus, mesenchymal stem cells genetically enhanced with Akt1 can repair infarcted myocardium, prevent remodeling and nearly normalize cardiac performance.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dzau, VJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL072010, R01HL035610, R01HL058516, F32HL010503, P50HL052320] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 F32 NHL 10503-01, HL058516, HL072010, HL35610, HL52320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkins BZ, 1999, J SURG RES, V85, P234, DOI 10.1006/jsre.1999.5681; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Hunnestad JA, 1999, STEM CELLS, V17, P31, DOI 10.1002/stem.170031; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li RK, 1997, CIRCULATION, V96, P179; LI RK, 1997, CIRCULATION, V96, P186; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2000, CARDIOVASC PATHOL, V9, P337, DOI 10.1016/S1054-8807(00)00055-7; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Williams RS, 2000, J CLIN INVEST, V106, P813, DOI 10.1172/JCI11205; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367	46	1202	1350	1	64	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1195	1201		10.1038/nm912	http://dx.doi.org/10.1038/nm912			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910262				2022-12-25	WOS:000185061600033
J	Nishimura, T; Fukata, Y; Kato, K; Yamaguchi, T; Matsuura, Y; Kamiguchi, H; Kaibuchi, K				Nishimura, T; Fukata, Y; Kato, K; Yamaguchi, T; Matsuura, Y; Kamiguchi, H; Kaibuchi, K			CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth	NATURE CELL BIOLOGY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; ADHESION MOLECULE L1; SIGNALING PATHWAYS; NERVOUS-SYSTEM; ALPHA-ADAPTIN; CONE COLLAPSE; PROTEIN; BINDING; DOMAIN; DIVISION	Axon growth during neural development is highly dependent on both cytoskeletal re-organization and polarized membrane trafficking. Previously, we demonstrated that collapsin response mediator protein-2 (CRMP-2) is critical for specifying axon/dendrite fate and axon growth in cultured hippocampal neurons, possibly by interacting with tubulin heterodimers and promoting microtubule assembly. Here, we identify Numb as a CRMP-2-interacting protein. Numb has been shown to interact with alpha-adaptin and to be involved in endocytosis. We found that Numb was associated with L1, a neuronal cell adhesion molecule that is endocytosed and recycled at the growth cone, where CRMP-2 and Numb were colocalized. Furthermore, expression of dominant-negative CRMP-2 mutants or knockdown of CRMP-2 message with small-interfering (si) RNA inhibited endocytosis of L1 at axonal growth cones and suppressed axon growth. These results suggest that in addition to regulating microtubule assembly, CRMP-2 is involved in polarized Numb-mediated endocytosis of proteins such as L1.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Osaka Univ, Res Ctr Emerging Infect Dis, Suita, Osaka 5650871, Japan; RIKEN, Brain Sci Inst, Dev Brain Sci Grp, Wako, Saitama 3510198, Japan	Nagoya University; Osaka University; RIKEN	Kaibuchi, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, 65 Tsurumai, Aichi 4668550, Japan.		Kato, Katsuhiro/AAV-8356-2020; Nishimura, Takashi/AAQ-9299-2020; Kamiguchi, Hiroyuki/N-5409-2015; Yamaguchi, Tomoya/AAN-7524-2020; Nishimura, Takashi/D-7672-2017	Nishimura, Takashi/0000-0002-6773-0302; Kamiguchi, Hiroyuki/0000-0003-1802-6324; Yamaguchi, Tomoya/0000-0001-6933-543X; Nishimura, Takashi/0000-0002-6773-0302; Fukata, Yuko/0000-0001-7724-8643				Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Castellani V, 2002, EMBO J, V21, P6348, DOI 10.1093/emboj/cdf645; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Inatome R, 2000, J BIOL CHEM, V275, P27291; James P, 1996, GENETICS, V144, P1425; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 2001, J NEUROSCI, V21, P9194, DOI 10.1523/JNEUROSCI.21-23-09194.2001; Kamiguchi H, 2000, J NEUROSCI, V20, P3676, DOI 10.1523/JNEUROSCI.20-10-03676.2000; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schaefer AW, 2002, J CELL BIOL, V157, P1223, DOI 10.1083/jcb.200203024; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Wang LH, 1996, J NEUROSCI, V16, P6197	35	203	208	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					819	826		10.1038/ncb1039	http://dx.doi.org/10.1038/ncb1039			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12942088				2022-12-25	WOS:000185059000015
J	Polack, FP; Hoffman, SJ; Crujeiras, G; Griffin, DE				Polack, FP; Hoffman, SJ; Crujeiras, G; Griffin, DE			A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles	NATURE MEDICINE			English	Article							HUMORAL IMMUNE-RESPONSE; AFFINITY MATURATION; GERMINAL-CENTERS; RHESUS MACAQUES; FC-GAMMA; DISEASE; VACCINE; IMMUNIZATION; RECEPTORS; CD46	In the 1960s, a formalin-inactivated measles vaccine (FIMV) predisposed recipients to atypical measles, an immune complex-mediated disease(1,2). To identify characteristics of the immune priming that leads to atypical measles, responses of monkeys to FIMV were compared with responses to live attenuated virus (LAV) and hemagglutinin (H-DNA) vaccines that do not prime for atypical measles. Antibodies induced by FIMV were transient and avidity did not mature. Antibodies induced by LAV and H-DNA vaccines were sustained and avidity matured over time. After challenge with measles virus, FIMV and H-DNA recipients developed high titers of complement-fixing antibodies. In FIMV recipients, the antibodies were of low avidity, whereas in H-DNA vaccine recipients, the antibodies were of high avidity. Neutralizing capacity in B958 cells correlated with avidity. Only FIMV recipients had immune complex deposition. Failure of FIMV to induce affinity maturation results in anamnestic production of nonprotective, complement-fixing antibodies, immune complex deposition and atypical measles.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Maryland Dept Hlth & Mental Hyg, Div Virol Immunol, Baltimore, MD 21203 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Maryland Department of Health & Mental Hygiene	Polack, FP (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.				NIAID NIH HHS [AI-35149] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035149] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso A, 1998, LAB INVEST, V78, P377; CARTER CH, 1962, JAMA-J AM MED ASSOC, V179, P848, DOI 10.1001/jama.1962.03050110016003; CARTER PM, 1973, ANN RHEUM DIS, V32, P265, DOI 10.1136/ard.32.3.265; CHARGELEGUE D, 1995, CLIN EXP IMMUNOL, V99, P175, DOI 10.1111/j.1365-2249.1995.tb05529.x; DEVEY ME, 1990, IMMUNOLOGY, V70, P168; DEVEY ME, 1984, IMMUNOLOGY, V52, P377; DEVEY ME, 1980, IMMUNOLOGY, V41, P303; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Erlenhofer C, 2002, J GEN VIROL, V83, P1431, DOI 10.1099/0022-1317-83-6-1431; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; GRADY LJ, 1985, J GEN VIROL, V66, P2773, DOI 10.1099/0022-1317-66-12-2773; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KJELLEN L, 1985, J GEN VIROL, V66, P2279, DOI 10.1099/0022-1317-66-10-2279; Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; NADER PR, 1968, J PEDIATR-US, V72, P22, DOI 10.1016/S0022-3476(68)80396-8; Olszewska W, 2000, VIROLOGY, V272, P98, DOI 10.1006/viro.2000.0285; Polack FP, 2000, NAT MED, V6, P776, DOI 10.1038/77506; Polack FP, 1999, NAT MED, V5, P629, DOI 10.1038/9473; Ruppach H, 2000, J VIROL, V74, P5403, DOI 10.1128/JVI.74.12.5403-5411.2000; Santiago C, 2002, J BIOL CHEM, V277, P32294, DOI 10.1074/jbc.M202973200; SOOTHILL JF, 1971, CLIN EXP IMMUNOL, V9, P193; STEWARD MW, 1991, IMMUNOLOGY, V72, P99; STEWARD MW, 1979, CLIN EXP IMMUNOL, V38, P414; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Voice JK, 1997, EUR J IMMUNOL, V27, P2514, DOI 10.1002/eji.1830271008; Walker LSK, 2000, IMMUNOL TODAY, V21, P333, DOI 10.1016/S0167-5699(00)01636-4; Walport MJ, 1997, ANN NY ACAD SCI, V815, P267, DOI 10.1111/j.1749-6632.1997.tb52069.x; ZIOLA B, 1983, INFECT IMMUN, V41, P578, DOI 10.1128/IAI.41.2.578-583.1983	30	110	116	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1209	1213		10.1038/nm918	http://dx.doi.org/10.1038/nm918			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925847				2022-12-25	WOS:000185061600035
J	Anderson, DG; Levenberg, S; Langer, R				Anderson, DG; Levenberg, S; Langer, R			Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							DIFFERENTIATION; MICROARRAYS; EXPRESSION; PATTERNS	Identification of biomaterials that support appropriate cellular attachment, proliferation and gene expression patterns is critical for tissue engineering and cell therapy. Here we describe an approach for rapid, nanoliter-scale synthesis of biomaterials and characterization of their interactions with cells. We simultaneously characterize over 1,700 human embryonic stem cell-material interactions and identify a host of unexpected materials effects that offer new levels of control over human embryonic stem cell behavior.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	rlanger@mit.edu		Levenberg, Shulamit/0000-0001-5471-7339	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham VC, 2004, TRENDS BIOTECHNOL, V22, P15, DOI 10.1016/j.tibtech.2003.10.012; Burkoth AK, 2000, J BIOMED MATER RES, V51, P352; Chen RR, 2003, PHARM RES-DORDR, V20, P1103, DOI 10.1023/A:1025034925152; Fisher JP, 2001, ANN REV MATER RES, V31, P171, DOI 10.1146/annurev.matsci.31.1.171; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; MacBeath G, 2000, SCIENCE, V289, P1760; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Sakiyama-Elbert SE, 2001, ANNU REV MATER RES, V31, P183, DOI 10.1146/annurev.matsci.31.1.183; SALTZMAN WM, 2000, PRINCIPLES TISSUE EN, P221; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	19	617	681	1	124	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					863	866		10.1038/nbt981	http://dx.doi.org/10.1038/nbt981			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15195101				2022-12-25	WOS:000222533000027
J	Koistinaho, M; Lin, SZ; Wu, X; Esterman, M; Koger, D; Hanson, J; Higgs, R; Liu, F; Malkani, S; Bales, KR; Paul, SM				Koistinaho, M; Lin, SZ; Wu, X; Esterman, M; Koger, D; Hanson, J; Higgs, R; Liu, F; Malkani, S; Bales, KR; Paul, SM			Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides	NATURE MEDICINE			English	Article							SPORADIC ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; MICROGLIAL CELLS; PLAQUE-FORMATION; DIFFUSE PLAQUES; TRANSGENIC MICE; RAT-BRAIN; IN-VITRO; PROTEIN	We have previously shown that apolipoprotein E (Apoe) promotes the formation of amyloid in brain and that astrocyte-specific expression of APOE markedly affects the deposition of amyloid-peptides (Abeta) in a mouse model of Alzheimer disease. Given the capacity of astrocytes to degrade Abeta, we investigated the potential role of Apoe in this astrocyte-mediated degradation. In contrast to cultured adult wild-type mouse astrocytes, adult Apoe(-/-) astrocytes do not degrade Abeta present in Abeta plaque-bearing brain sections in vitro. Coincubation with antibodies to either Apoe or Abeta, or with RAP, an antagonist of the low-density lipoprotein receptor family, effectively blocks Abeta degradation by astrocytes. Phase-contrast and confocal microscopy show that Apoe(-/-) astrocytes do not respond to or internalize Abeta deposits to the same extent as do wild-type astrocytes. Thus, Apoe seems to be important in the degradation and clearance of deposited Abeta species by astrocytes, a process that may be impaired in Alzheimer disease.	Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Discovery Informat Technol, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Genom Informat Stat, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Paul, SM (corresponding author), Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA.	Paul_Steven_M@Lilly.com	Paul, Steve/ABE-5400-2020					AlAli SY, 1996, J ANAT, V188, P257; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Funato H, 1998, AM J PATHOL, V152, P983; Giulian D, 1996, J NEUROSCI, V16, P6021; Guillaume D, 1996, J NEUROCHEM, V66, P2410; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Marr RA, 2003, J NEUROSCI, V23, P1992; Matsunaga W, 2003, NEUROSCI LETT, V342, P129, DOI 10.1016/S0304-3940(03)00240-4; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; NITTA T, 1992, NEUROSURGERY, V31, P83, DOI 10.1227/00006123-199207000-00012; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; REBECK GW, 1993, NEURON, V11, P575; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saura J, 2003, J NEUROCHEM, V85, P1455, DOI 10.1046/j.1471-4159.2003.01788.x; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHAO YP, 1994, GLIA, V11, P147, DOI 10.1002/glia.440110209; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Urmoneit B, 1997, LAB INVEST, V77, P157; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; Wegiel J, 2001, NEUROBIOL AGING, V22, P49, DOI 10.1016/S0197-4580(00)00181-0; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Wisniewski HM, 1996, NEUROPATH APPL NEURO, V22, P3, DOI 10.1046/j.1365-2990.1996.1698016.x; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790	38	445	459	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					719	726		10.1038/nm1058	http://dx.doi.org/10.1038/nm1058			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195085				2022-12-25	WOS:000222460400026
J	Wang, GD; Li, QJ; Luo, B; Chen, XY				Wang, GD; Li, QJ; Luo, B; Chen, XY			Ex planta phytoremediation of trichlorophenol and phenolic allelochemicals via an engineered secretory laccase	NATURE BIOTECHNOLOGY			English	Article							TRANSGENIC PLANTS; METABOLISM; GENES; OVEREXPRESSION; IDENTIFICATION; ALLELOPATHY; TOLERANCE; MODEL	Plant roots release a range of enzymes capable of degrading chemical compounds in their immediate vicinity(1-2). We present a system of phytoremediation ex planta based on the overexpression of one such enzyme, a secretory laccase. Laccases catalyze the oxidation of a broad range of phenolic compounds(3), including polychlorinated phenols such as 2,4,6-trichlorophenol (TCP), that are among the most hazardous and recalcitrant pollutants in the environment(4). We isolated a secretory laccase cDNA of LAC1, which is specifically expressed in the roots of Gossypium arboreum (cotton). Transgenic Arabidopsis thaliana plants overexpressing LAC1 exhibited enhanced resistance to several phenolic allelochemicals and TCP. The secretory laccase activity in these plants was responsible for the conversion of sinapic acid into a mono-lactone type dimer and for the transformation of TCP.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Natl Key Lab Plant Mol Genet, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Natl Key Lab Plant Mol Genet, 300 Fenglin Rd, Shanghai 200032, Peoples R China.	xychen@sibs.ac.cn	Wang, Guodong/AAW-5987-2020	Wang, Guodong/0000-0001-9917-0656; Chen, Xiaoya/0000-0002-2909-8414				Ahn MY, 2002, J ENVIRON QUAL, V31, P1509, DOI 10.2134/jeq2002.1509; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Boyajian GE, 1997, NAT BIOTECHNOL, V15, P127, DOI 10.1038/nbt0297-127; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; Chu W, 2003, CHEMOSPHERE, V51, P289, DOI 10.1016/S0045-6535(02)00318-1; Dhankher OP, 2002, NAT BIOTECHNOL, V20, P1140, DOI 10.1038/nbt747; Doty SL, 2000, P NATL ACAD SCI USA, V97, P6287, DOI 10.1073/pnas.97.12.6287; Duran N, 2002, ENZYME MICROB TECH, V31, P907, DOI 10.1016/S0141-0229(02)00214-4; Hannink N, 2001, NAT BIOTECHNOL, V19, P1168, DOI 10.1038/nbt1201-1168; Howles PA, 1996, PLANT PHYSIOL, V112, P1617, DOI 10.1104/pp.112.4.1617; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Leontievsky AA, 2001, APPL MICROBIOL BIOT, V57, P85; Li L, 2002, PLANTA, V215, P239, DOI 10.1007/s00425-002-0750-4; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Luo P, 2001, PLANT J, V28, P95, DOI 10.1046/j.1365-313X.2001.01133.x; Mayer AM, 2002, PHYTOCHEMISTRY, V60, P551, DOI 10.1016/S0031-9422(02)00171-1; Min KL, 2001, ARCH BIOCHEM BIOPHYS, V392, P279, DOI 10.1006/abbi.2001.2459; Nitta K, 2002, J INORG BIOCHEM, V91, P125, DOI 10.1016/S0162-0134(02)00440-3; Niwa T, 1999, FEBS LETT, V459, P43, DOI 10.1016/S0014-5793(99)01216-8; Ranocha P, 2002, PLANT PHYSIOL, V129, P145, DOI 10.1104/pp.010988; Sen Gupta S, 2002, SCIENCE, V296, P326, DOI 10.1126/science.1069297; Song WY, 2003, NAT BIOTECHNOL, V21, P914, DOI 10.1038/nbt850; STERJIADES R, 1993, PLANTA, V190, P75, DOI 10.1007/BF00195678; Tan XP, 2000, PLANTA, V210, P644, DOI 10.1007/s004250050055; Ullah MA, 2000, APPL MICROBIOL BIOT, V53, P230, DOI 10.1007/s002530050013; Wu HW, 2002, J AGR FOOD CHEM, V50, P4567, DOI 10.1021/jf025508v	28	104	124	1	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					893	897		10.1038/nbt982	http://dx.doi.org/10.1038/nbt982			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15195102				2022-12-25	WOS:000222533000033
J	Greenbaum, D; Douglas, SM; Smith, A; Lim, J; Fischer, M; Schultz, M; Gerstein, M				Greenbaum, D; Douglas, SM; Smith, A; Lim, J; Fischer, M; Schultz, M; Gerstein, M			Computer security in academia - a potential roadblock to distributed annotation of the human genome	NATURE BIOTECHNOLOGY			English	Editorial Material							DATABASE		Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Gerstein, M (corresponding author), Yale Univ, Dept Genet, POB 208114, New Haven, CT 06520 USA.	Mark.Gerstein@yale.edu	Greenbaum, Dov/ABG-8539-2021	Greenbaum, Dov/0000-0003-4440-3090				Butler D, 2003, NATURE, V425, P3, DOI 10.1038/425003a; Clamp M, 2003, NUCLEIC ACIDS RES, V31, P38, DOI 10.1093/nar/gkg083; *COMM I COOP, 2000, INC COST AN MOD PROJ; *COMM I COOP, 1998, INC COST AN MOD PROJ; Dowell RD, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-7; Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104; Foster I, 1997, INT J SUPERCOMPUT AP, V11, P115, DOI 10.1177/109434209701100205; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Gerstein M, 2000, SCIENCE, V288, P1590; Hubbard T, 2000, NATURE, V403, P825, DOI 10.1038/35002770; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; RICHARDSON R, 2003, 8 ANN CSI FBI COMP C; RICHMOND R, 2003, WALL STREET J   0929, pR4; Stein L, 2002, NATURE, V417, P119, DOI 10.1038/417119a	14	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					771	772		10.1038/nbt0604-771	http://dx.doi.org/10.1038/nbt0604-771			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15175700				2022-12-25	WOS:000221785300044
J	Garcia-Blanco, MA; Baraniak, AP; Lasda, EL				Garcia-Blanco, MA; Baraniak, AP; Lasda, EL			Alternative splicing in disease and therapy	NATURE BIOTECHNOLOGY			English	Review							PRE-MESSENGER-RNA; SPINAL MUSCULAR-ATROPHY; DOMINANT RETINITIS-PIGMENTOSA; GROWTH-FACTOR RECEPTOR; TRACT BINDING-PROTEIN; TRANSMEMBRANE REGULATOR EXON-9; GLYCOGEN-SYNTHASE KINASE-3; INHERITED DEMENTIA FTDP-17; NONSENSE-MEDIATED DECAY; NUCLEAR FACTOR TDP-43	Alternative splicing is the major source of proteome diversity in humans and thus is highly relevant to disease and therapy. For example, recent work suggests that the long-sought-after target of the analgesic acetaminophen is a neural-specific, alternatively spliced isoform of cyclooxygenase 1 (COX-1). Several important diseases, such as cystic fibrosis, have been linked with mutations or variations in either cis-acting elements or trans-acting factors that lead to aberrant splicing and abnormal protein production. Correction of erroneous splicing is thus an important goal of molecular therapies. Recent experiments have used modified oligonucleotides to inhibit cryptic exons or to activate exons weakened by mutations, suggesting that these reagents could eventually lead to effective therapies.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3053,Res Dr, Durham, NC 27710 USA.	garci001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R33CA097502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER; NCI NIH HHS [R33 CA97502] Funding Source: Medline; NIGMS NIH HHS [R01 GM63090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; ARNAREZ I, 2003, HUM MOL GENET, V12, P2031; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; Auboeuf D, 2004, P NATL ACAD SCI USA, V101, P2270, DOI 10.1073/pnas.0308133100; Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; Baron-Delage S, 2000, MOL MED, V6, P957, DOI 10.1007/BF03401830; Belfort R, 2002, AM J OPHTHALMOL, V133, P467; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bingham CO, 2002, CLEV CLIN J MED, V69, P5; BOUCHER RC, 2001, HARRISONS PRINCIPLES, P1487; Bracco L, 2003, TRENDS BIOTECHNOL, V21, P346, DOI 10.1016/S0167-7799(03)00146-X; Brichta L, 2003, HUM MOL GENET, V12, P2481, DOI 10.1093/hmg/ddg256; Buchner DA, 2003, SCIENCE, V301, P967, DOI 10.1126/science.1086187; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2003, TRENDS MOL MED, V9, P229, DOI 10.1016/S1471-4914(03)00072-8; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; Chao HJ, 2003, NAT MED, V9, P1015, DOI 10.1038/nm900; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Chiba-Falek O, 1998, GENOMICS, V53, P276, DOI 10.1006/geno.1998.5517; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; COSTES B, 1995, EUR J HUM GENET, V3, P285; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Daoud R, 2002, J NEUROSCI, V22, P5889; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; Deidda G, 2003, NAT BIOTECHNOL, V21, P1499, DOI 10.1038/nbt908; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eperon IC, 2003, TRENDS MOL MED, V9, P233, DOI 10.1016/S1471-4914(03)00068-6; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; Fomenkov A, 2003, J BIOL CHEM, V278, P23906, DOI 10.1074/jbc.M300746200; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; GARCIACLANCO MA, 2001, RNA, P109; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 2000, ANN NY ACAD SCI, V920, P74; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Grover A, 2002, NEUROSCI LETT, V323, P33, DOI 10.1016/S0304-3940(02)00124-6; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hefferon TW, 2002, AM J HUM GENET, V71, P294, DOI 10.1086/341664; HEIDER KH, 2004, CANC IMMUNOL IMMUNOT; Helmken C, 2003, HUM GENET, V114, P11, DOI 10.1007/s00439-003-1025-2; Hernandez F, 2004, J BIOL CHEM, V279, P3801, DOI 10.1074/jbc.M311512200; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; Isoherranen N, 2003, CURR OPIN NEUROL, V16, P203, DOI 10.1097/00019052-200304000-00014; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kalbfuss B, 2001, J BIOL CHEM, V276, P42986, DOI 10.1074/jbc.M105113200; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Karras JG, 2001, BIOCHEMISTRY-US, V40, P7853, DOI 10.1021/bi010263l; Kashima T, 2003, NAT GENET, V34, P460, DOI 10.1038/ng1207; Khoo B, 2003, TRENDS BIOTECHNOL, V21, P328, DOI 10.1016/S0167-7799(03)00168-9; Kowalska Anna, 2002, Journal of Applied Genetics, V43, P535; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Labrador M, 2003, GENOME RES, V13, P2220, DOI 10.1101/gr.1440703; Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Larriba S, 1998, HUM MOL GENET, V7, P1739, DOI 10.1093/hmg/7.11.1739; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mak V, 1997, HUM MOL GENET, V6, P2099, DOI 10.1093/hmg/6.12.2099; Manabe T, 2003, CELL DEATH DIFFER, V10, P698, DOI 10.1038/sj.cdd.4401221; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; MAQUAT LE, 1980, P NATL ACAD SCI-BIOL, V77, P4287, DOI 10.1073/pnas.77.7.4287; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555; Mercatante DR, 2001, CURR CANCER DRUG TAR, V1, P211, DOI 10.2174/1568009013334124; Millar DS, 2003, HUM MUTAT, V21, P424, DOI 10.1002/humu.10168; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Mine M, 2003, J BIOL CHEM, V278, P11768, DOI 10.1074/jbc.M211106200; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; MURAKI M, 2004, J BIOL CHEM     0308; Musunuru K, 2003, TRENDS CARDIOVAS MED, V13, P188, DOI 10.1016/S1050-1738(03)00075-6; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Nissim-Rafinia M, 2000, HUM MOL GENET, V9, P1771, DOI 10.1093/hmg/9.12.1771; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Noone PG, 2001, RESP RES, V2, P328, DOI 10.1186/rr82; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Pagani F, 2003, J BIOL CHEM, V278, P26580, DOI 10.1074/jbc.M212813200; Patel AA, 2003, NAT REV MOL CELL BIO, V4, P960, DOI 10.1038/nrm1259; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Rogers CS, 2002, J CLIN INVEST, V110, P1783, DOI 10.1172/JCI200216481; Rowntree RK, 2003, ANN HUM GENET, V67, P471, DOI 10.1046/j.1469-1809.2003.00028.x; Ryther RCC, 2003, HUM GENET, V113, P140, DOI 10.1007/s00439-003-0949-x; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Shaftel SS, 2003, MOL BRAIN RES, V119, P213, DOI 10.1016/j.molbrainres.2003.09.006; Simmons DL, 2003, THROMB RES, V110, P265, DOI 10.1016/S0049-3848(03)00380-3; Singh NN, 2004, BIOCHEM BIOPH RES CO, V315, P381, DOI 10.1016/j.bbrc.2004.01.067; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; Sorek R, 2004, TRENDS GENET, V20, P68, DOI 10.1016/j.tig.2003.12.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; Srivastava S, 2001, AM J MED GENET, V101, P198, DOI 10.1002/ajmg.1386; Stanford PM, 2003, BRAIN, V126, P814, DOI 10.1093/brain/awg090; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Sullenger BA, 2002, NATURE, V418, P252, DOI 10.1038/418252a; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Teng H, 1997, HUM MOL GENET, V6, P85, DOI 10.1093/hmg/6.1.85; Tolnay M, 2000, NEUROPATH APPL NEURO, V26, P368, DOI 10.1046/j.1365-2990.2000.00109.x; Vacek MM, 2003, BLOOD, V101, P104, DOI 10.1182/blood-2002-06-1869; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Van Deerlin VM, 2003, CLIN CHEM, V49, P1717, DOI 10.1373/49.10.1717; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Villemaire J, 2003, J BIOL CHEM, V278, P50031, DOI 10.1074/jbc.M308897200; Vithana EN, 2001, MOL CELL, V8, P375, DOI 10.1016/S1097-2765(01)00305-7; Wagner EJ, 2003, RNA, V9, P1552, DOI 10.1261/rna.5840803; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; Watanabe T, 2000, ADV DRUG DELIVER REV, V44, P109, DOI 10.1016/S0169-409X(00)00089-2; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zhang XHF, 2003, GENOME RES, V13, P2637, DOI 10.1101/gr.1679003; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZUCCATO E, 2004, J BIOL CHEM     0213	186	400	441	0	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					535	546		10.1038/nbt964	http://dx.doi.org/10.1038/nbt964			12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15122293				2022-12-25	WOS:000221159700021
J	Godi, A; Di Campli, A; Konstantakopoulos, A; Di Tullio, G; Alessi, DR; Kular, GS; Daniele, T; Marra, P; Lucocq, JM; De Matteis, MA				Godi, A; Di Campli, A; Konstantakopoulos, A; Di Tullio, G; Alessi, DR; Kular, GS; Daniele, T; Marra, P; Lucocq, JM; De Matteis, MA			FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P	NATURE CELL BIOLOGY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PLASMA-MEMBRANE; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; BREFELDIN-A; TRANSPORT; COMPLEX; SECRETION; 4-KINASE	The molecular mechanisms underlying the formation of carriers trafficking from the Golgi complex to the cell surface are still ill-defined; nevertheless, the involvement of a lipid-based machinery is well established. This includes phosphatidylinositol 4-phosphate (PtdIns(4)P), the precursor for phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). In yeast, PtdIns(4)P exerts a direct role, however, its mechanism of action and its targets in mammalian cells remain uncharacterized. We have identified two effectors of PtdIns(4)P, the four-phosphate-adaptor protein 1 and 2 (FAPP1 and FAPP2). Both proteins localize to the trans-Golgi network (TGN) on nascent carriers, and interact with PtdIns(4)P and the small GTPase ADP-ribosylation factor (ARF) through their plekstrin homology (PH) domain. Displacement or knockdown of FAPPs inhibits cargo transfer to the plasma membrane. Moreover, overexpression of FAPP-PH impairs carrier fission. Therefore, FAPPs are essential components of a PtdIns(4)P- and ARF-regulated machinery that controls generation of constitutive post-Golgi carriers.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, CH, Italy; Univ Dundee, Div Cell Signalling, Dundee DD1 5EH, Scotland	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Dundee	De Matteis, MA (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, CH, Italy.	dematteis@negrisud.it	Daniele, Tiziana/AAN-1916-2020; De Matteis, Maria Antonietta/AHE-5161-2022	De Matteis, Maria Antonietta/0000-0003-0053-3061; DI CAMPLI, ANTONELLA/0000-0003-4504-5942; lucocq, john/0000-0002-5191-0093; Daniele, Tiziana/0000-0002-6465-1078; Alessi, Dario/0000-0002-2140-9185	Telethon [GP0203Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Buccione R, 1996, J BIOL CHEM, V271, P3523; Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; De Matteis MA, 2002, CURR OPIN CELL BIOL, V14, P434, DOI 10.1016/S0955-0674(02)00357-5; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Jacques KM, 2002, J BIOL CHEM, V277, P47235, DOI 10.1074/jbc.M208875200; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; LUCOCQ JM, 1993, FINE STRUCTURE IMMUN, P279; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; RANDAZZO PA, 2000, SCI STKE, V59; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	46	413	428	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					393	+		10.1038/ncb1119	http://dx.doi.org/10.1038/ncb1119			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15107860				2022-12-25	WOS:000221432600009
J	Ko, SBH; Zeng, WZ; Dorwart, MR; Luo, X; Kim, KH; Millen, L; Goto, H; Naruse, S; Soyombo, A; Thomas, PJ; Muallem, S				Ko, SBH; Zeng, WZ; Dorwart, MR; Luo, X; Kim, KH; Millen, L; Goto, H; Naruse, S; Soyombo, A; Thomas, PJ; Muallem, S			Gating of CFTR by the STAS domain of SLC26 transporters	NATURE CELL BIOLOGY			English	Letter							DEPENDENT HCO3-TRANSPORT; CYSTIC-FIBROSIS; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-MECHANISM; CL-/HCO3-EXCHANGER; INTERLOBULAR DUCTS; ANION-EXCHANGER; ADENOMA DRA; CONDUCTANCE; MUTATIONS	Chloride absorption and bicarbonate secretion are vital functions of epithelia(1-6), as highlighted by cystic fibrosis and diseases associated with mutations in members of the SLC26 chloride-bicarbonate exchangers. Many SLC26 transporters (SLC26T) are expressed in the luminal membrane together with CFTR7, which activates electrogenic chloride-bicarbonate exchange by SLC26T(8). However, the ability of SLC26T to regulate CFTR and the molecular mechanism of their interaction are not known. We report here a reciprocal regulatory interaction between the SLC26T DRA, SLC26A6 and CFTR. DRA markedly activates CFTR by increasing its overall open probablity (NPo) sixfold. Activation of CFTR by DRA was facilitated by their PDZ ligands and binding of the SLC26T STAS domain to the CFTR R domain. Binding of the STAS and R domains is regulated by PKA-mediated phosphorylation of the R domain. Notably, CFTR and SLC26T co-localize in the luminal membrane and recombinant STAS domain activates CFTR in native duct cells. These findings provide a new understanding of epithelial chloride and bicarbonate transport and may have important implications for both cystic fibrosis and diseases associated with SLC26T.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Grad Program Mol Biophys, Dallas, TX 75390 USA; Nagoya Univ, Grad Sch Med, Dept Med, Div Gastroenterol, Nagoya, Aichi 4668550, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Nagoya University	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu	Ko, Shigeru/H-3450-2012; Thomas, Philip J/F-7115-2012	Ko, Shigeru/0000-0003-1913-6357; Soyombo, Abigail/0000-0003-0850-2593	NIDCR NIH HHS [DE12309, R01 DE012309] Funding Source: Medline; NIDDK NIH HHS [R01 DK049835, DK49835, R37 DK049835, R01 DK038938, DK38938] Funding Source: Medline; NIGMS NIH HHS [GM-08203, T32 GM008203] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], [No title captured]; Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Argent B. E., 1994, P1473; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; COOK DI, 1994, TXB PHYSL GASTROINTE, P1061; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; HADORN B, 1968, CAN MED ASSOC J, V98, P377; Haila S, 2000, HISTOCHEM CELL BIOL, V113, P279, DOI 10.1007/s004180000131; Hanrahan JW, 1998, METHOD ENZYMOL, V293, P169; Ishiguro H, 2002, J GEN PHYSIOL, V120, P617, DOI 10.1085/jgp.20028631; Ishiguro H, 2002, J PHYSIOL-LONDON, V539, P175, DOI 10.1113/jphysiol.2001.012490; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lamprecht G, 2002, BIOCHEMISTRY-US, V41, P12336, DOI 10.1021/bi0259103; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Lohi H, 2003, AM J PHYSIOL-CELL PH, V284, pC769, DOI 10.1152/ajpcell.00270.2002; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Makela S, 2002, HUM MUTAT, V20, P425, DOI 10.1002/humu.10139; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Ostedgaard LS, 2001, J BIOL CHEM, V276, P7689, DOI 10.1074/jbc.R100001200; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Sohma Y, 2000, J MEMBRANE BIOL, V176, P77, DOI 10.1007/s002320001077; Sokol R Z, 2001, Curr Opin Pulm Med, V7, P421, DOI 10.1097/00063198-200111000-00011; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Wilschanski M, 1998, J ROY SOC MED, V91, P40, DOI 10.1177/014107689809134S07; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	33	339	347	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					343	350		10.1038/ncb1115	http://dx.doi.org/10.1038/ncb1115			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048129	Green Accepted			2022-12-25	WOS:000220587600016
J	Moreira, MC; Klur, S; Watanabe, M; Nemeth, AH; Le Ber, I; Moniz, JC; Tranchant, C; Aubourg, P; Tazir, M; Schols, L; Pandolfo, M; Schulz, JB; Pouget, J; Calvas, P; Shizuka-Ikeda, M; Shoji, M; Tanaka, M; Izatt, L; Shaw, CE; M'Zahem, A; Dunne, E; Bomont, P; Benhassine, T; Bouslam, N; Stevanin, G; Brice, A; Guimaraes, J; Mendonca, P; Barbot, C; Coutinho, P; Sequeiros, J; Durr, A; Warter, JM; Koenig, M				Moreira, MC; Klur, S; Watanabe, M; Nemeth, AH; Le Ber, I; Moniz, JC; Tranchant, C; Aubourg, P; Tazir, M; Schols, L; Pandolfo, M; Schulz, JB; Pouget, J; Calvas, P; Shizuka-Ikeda, M; Shoji, M; Tanaka, M; Izatt, L; Shaw, CE; M'Zahem, A; Dunne, E; Bomont, P; Benhassine, T; Bouslam, N; Stevanin, G; Brice, A; Guimaraes, J; Mendonca, P; Barbot, C; Coutinho, P; Sequeiros, J; Durr, A; Warter, JM; Koenig, M			Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2	NATURE GENETICS			English	Article							SPINOCEREBELLAR ATAXIA; PERIPHERAL NEUROPATHY; CEREBELLAR ATROPHY; GENE; DNA; ENCODES; SEN1	Ataxia-ocular apraxia 2 (AOA2) was recently identified as a new autosomal recessive ataxia. We have now identified causative mutations in 15 families, which allows us to clinically define this entity by onset between 10 and 22 years, cerebellar atrophy, axonal sensorimotor neuropathy, oculomotor apraxia and elevated alpha-fetoprotein (AFP). Ten of the fifteen mutations cause premature termination of a large DEAxQ-box helicase, the human ortholog of yeast Sen1p, involved in RNA maturation and termination.	ULP, CNRS, INSERM, IGBMC, F-67404 Illkirch Graffenstaden, Cu Strasbourg, France; Gunma Univ, Sch Med, Maebashi, Gumma 3718511, Japan; Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Hop La Pitie Salpetriere, APHP, INSERM, U289, F-75651 Paris, France; Hop La Pitie Salpetriere, APHP, Dept Genet Cytogenet & Embryol, F-75651 Paris, France; Hosp Sto Antonio dos Capuchos, Lisbon, Portugal; Hop Univ Strasbourg, F-67091 Strasbourg, France; Hop St Vincent de Paul, INSERM, U342, F-75675 Paris, France; Ctr Hosp Univ Algier, Algiers, Algeria; Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany; Free Univ Brussels, Hop Erasme, B-1070 Brussels, Belgium; Univ Tubingen, Ctr Neurol, Dept Gen Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Hop Timone Adults, F-13385 Marseille, France; Hop Purpan, F-31059 Toulouse, France; Guys Hosp, Dept Clin Genet, London SE1 9RT, England; Univ London Kings Coll, Inst Psychiat, London SE5 8AF, England; Guys Kings & St Thomas Sch Med, London SE5 8AF, England; Ctr Hosp Univ Ben Badis, Constantine, Algeria; Inst Pasteur Alger, Algiers, Algeria; Hosp Egas Moniz, Lisbon, Portugal; Hosp Divino Espirito Santo, Dept Hematol, Azores, Portugal; Univ Porto, UnIGENe, IBMC, ICBAS, P-4150180 Oporto, Portugal; Hosp Maria Pia, Dept Neuropediat, P-4050 Oporto, Portugal; Hosp Sao Sebastiao, Dept Neurol, P-4520 Sta Maria Da Feira, Portugal	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Gunma University; University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruhr University Bochum; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU de Toulouse; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Egas Moniz Hospital; Universidade do Porto	Koenig, M (corresponding author), ULP, CNRS, INSERM, IGBMC, F-67404 Illkirch Graffenstaden, Cu Strasbourg, France.	mkoenig@igbmc.u-strasbg.fr	brice, alexis/AAE-8275-2019; Barbot, Clara/K-6378-2013; Brice, Alexis/A-2170-2009; Stevanin, Giovanni/E-5038-2016; Bomont, Pascale/GLS-8721-2022; Bomont, Pascale L/Y-5517-2018; Coutinho, Paula/K-6053-2013; Dunne, Eimear/C-6785-2012; Dunne, Eimear/AGX-1949-2022; Schöls, Ludger/ABB-2482-2021; Lima, Marta T/C-7042-2009; Pandolfo, Massimo/B-2853-2010; Schulz, Jörg B/D-9786-2012	brice, alexis/0000-0002-0941-3990; Barbot, Clara/0000-0002-5597-107X; Stevanin, Giovanni/0000-0001-9368-8657; Bomont, Pascale/0000-0001-7216-3261; Bomont, Pascale L/0000-0001-7216-3261; Dunne, Eimear/0000-0001-9862-1398; Dunne, Eimear/0000-0001-9862-1398; Schöls, Ludger/0000-0001-7774-5025; Schulz, Jörg B/0000-0002-8903-0593; Franco Mendonca, Pedro/0000-0002-3850-2909; Shoji, Mikio/0000-0003-1027-1712; Nemeth, Andrea/0000-0002-2941-7657; tranchant, christine/0000-0002-2895-1292; Sequeiros, Jorge/0000-0002-9846-1037; Coutinho, Paula/0000-0002-3461-230X				Bomont P, 2000, EUR J HUM GENET, V8, P986, DOI 10.1038/sj.ejhg.5200586; Cox GA, 1998, NEURON, V21, P1327, DOI 10.1016/S0896-6273(00)80652-2; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Grohmann K, 2001, NAT GENET, V29, P75, DOI 10.1038/ng703; Kim HD, 1999, BIOCHEMISTRY-US, V38, P14697, DOI 10.1021/bi991470c; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Nemeth AH, 2000, AM J HUM GENET, V67, P1320, DOI 10.1016/S0002-9297(07)62962-0; Rasmussen TP, 1998, MOL CELL BIOL, V18, P6885, DOI 10.1128/MCB.18.12.6885; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Ursic D, 1997, NUCLEIC ACIDS RES, V25, P4778, DOI 10.1093/nar/25.23.4778; Wang WR, 2001, EMBO J, V20, P880, DOI 10.1093/emboj/20.4.880; Watanabe M, 1998, ANN NEUROL, V44, P265, DOI 10.1002/ana.410440220	15	343	355	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					225	227		10.1038/ng1303	http://dx.doi.org/10.1038/ng1303			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14770181	Green Published, Bronze			2022-12-25	WOS:000189250400008
J	Noguchi, H; Matsushita, M; Okitsu, T; Moriwaki, A; Tomizawa, K; Kang, SY; Li, ST; Kobayashi, N; Matsumoto, S; Tanaka, K; Tanaka, N; Matsui, H				Noguchi, H; Matsushita, M; Okitsu, T; Moriwaki, A; Tomizawa, K; Kang, SY; Li, ST; Kobayashi, N; Matsumoto, S; Tanaka, K; Tanaka, N; Matsui, H			A new cell-permeable peptide allows successful allogeneic islet transplantation in mice	NATURE MEDICINE			English	Article							VIVO PROTEIN TRANSDUCTION; CYCLOSPORINE-A; DELIVERY; MECHANISM; FK506	Calcineurin inhibitors such as cyclosporine A and FK506 have been used for transplant therapy and treatment of autoimmune diseases. However, the inhibition of calcineurin outside the immune system has a number of side effects, including hyperglycemia. In the search for safer drugs, we developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system(1,2). This peptide provided immunosuppression for fully mismatched islet allografts in mice. In addition, it did not affect insulin secretion, whereas FK506 caused a dose-dependent decrease in insulin secretion. Cell-permeable peptides can thus provide a new strategy for drug development and may eventually be useful clinically.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg Transplant & Surg Oncol, Okayama 7008558, Japan; Kyoto Univ Hosp, Dept Transplantat & Immunol, Sakyo Ku, Kyoto 6068507, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Okayama Univ, Grad Sch Med & Dent, Japan Sci & Technol Corp, Off Technol,Preventure Program, Okayama 7008558, Japan	Okayama University; Okayama University; Kyoto University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Japan Science & Technology Agency (JST); Okayama University	Matsushita, M (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	masayuki@cc.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Kang, Sunghyun/0000-0003-1542-9750; Li, Sheng Tian/0000-0002-2836-3802; Noguchi, Hirofumi/0000-0002-0880-6805				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Matsui H, 2003, CURR PROTEIN PEPT SC, V4, P151, DOI 10.2174/1389203033487270; Matsushita M, 2001, J NEUROSCI, V21, P6000, DOI 10.1523/JNEUROSCI.21-16-06000.2001; ODOCHA O, 1993, TRANSPLANT P, V25, P2433; Okitsu T, 2001, AM J TRANSPLANT, V1, P138, DOI 10.1034/j.1600-6143.2001.10207.x; Pascual M, 1998, IMMUNOL TODAY, V19, P514, DOI 10.1016/S0167-5699(98)01324-3; PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Todt J, 2000, J IMMUNOL, V164, P4037, DOI 10.4049/jimmunol.164.8.4037; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	21	229	241	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					305	309		10.1038/nm994	http://dx.doi.org/10.1038/nm994			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770176				2022-12-25	WOS:000189297700044
J	Spiotto, MT; Rowley, DA; Schreiber, H				Spiotto, MT; Rowley, DA; Schreiber, H			Bystander elimination of antigen loss variants in established tumors	NATURE MEDICINE			English	Article							CLASS-I; T-CELLS; EXPRESSION; REJECTION; TARGET; IMMUNOSELECTION; ANGIOGENESIS; INHIBITOR; MELANOMA; PEPTIDE	Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs)(1,2). However, cancer cells are genetically unstable 3. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively(1,4-13). We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Spiotto, MT (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mspiotto@midway.uchicago.edu	Spiotto, Michael/AAC-8331-2021		NCI NIH HHS [P01-CA97296, R01-CA22677, R01-CA37516, CA-14599] Funding Source: Medline; NICHD NIH HHS [HD 07009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097296, R01CA022677, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DUTZ JP, 1994, MOL IMMUNOL, V31, P967, DOI 10.1016/0161-5890(94)90091-4; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; Jager E, 1997, INT J CANCER, V71, P142, DOI 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lee KH, 1998, J IMMUNOL, V161, P4183; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Markiewicz MA, 2003, EUR J IMMUNOL, V33, P2917, DOI 10.1002/eji.200324273; MULLEN CA, 1985, J EXP MED, V162, P1665, DOI 10.1084/jem.162.5.1665; Niederman TMJ, 2002, P NATL ACAD SCI USA, V99, P7009, DOI 10.1073/pnas.092562399; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Plautz GE, 2000, J IMMUNOL, V165, P3656, DOI 10.4049/jimmunol.165.7.3656; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; Schmollinger JC, 2003, P NATL ACAD SCI USA, V100, P3398, DOI 10.1073/pnas.0530311100; SINGH S, 1992, J EXP MED, V175, P139, DOI 10.1084/jem.175.1.139; Spiotto MT, 2002, IMMUNITY, V17, P737, DOI 10.1016/S1074-7613(02)00480-6; Udaka K, 1996, J IMMUNOL, V157, P670; URBAN JL, 1982, J EXP MED, V156, P1025, DOI 10.1084/jem.156.4.1025; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; Valujskikh A, 2002, NAT IMMUNOL, V3, P844, DOI 10.1038/ni831; VASMEL WLE, 1989, J EXP MED, V169, P1233, DOI 10.1084/jem.169.4.1233; WARD PL, 1990, CANCER RES, V50, P3851; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	30	209	216	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					294	298		10.1038/nm999	http://dx.doi.org/10.1038/nm999			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981514				2022-12-25	WOS:000189297700042
J	Liu, XQ; Zhao, Y; Gao, JG; Pawlyk, B; Starcher, B; Spencer, JA; Yanagisawa, H; Zuo, J; Li, TS				Liu, XQ; Zhao, Y; Gao, JG; Pawlyk, B; Starcher, B; Spencer, JA; Yanagisawa, H; Zuo, J; Li, TS			Elastic fiber homeostasis requires lysyl oxidase-like 1 protein	NATURE GENETICS			English	Article							BINDING PROTEIN; AORTIC-ANEURYSMS; PELVIC FLOOR; MICE; EMPHYSEMA; TROPOELASTIN; CELL	Elastic fibers are components of the extracellular matrix and confer resilience(1). Once laid down, they are thought to remain stable(2), except in the uterine tract where cycles of active remodeling occur(3). Loss of elastic fibers underlies connective tissue aging and important diseases including emphysema(4-7). Failure to maintain elastic fibers is explained by a theory of antielastase-elastase imbalance(8), but little is known about the role of renewal. Here we show that mice lacking the protein lysyl oxidase like 1 (LOXL1) do not deposit normal elastic fibers in the uterine tract post partum and develop pelvic organ prolapse, enlarged airspaces of the lung, loose skin and vascular abnormalities with concomitant tropoelastin accumulation. Distinct from the prototypic lysyl oxidase (LOX), LOXL1 localizes specifically to sites of elastogenesis and interacts with fibulin-5. Thus elastin polymer deposition is a crucial aspect of elastic fiber maintenance and is dependent on LOXL1, which serves both as a cross-linking enzyme and an element of the scaffold to ensure spatially defined deposition of elastin.	Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; St Jude Children's Research Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, TS (corresponding author), Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA.	tli@meei.harvard.edu	Yanagisawa, Hiromi/Y-2843-2019	Yanagisawa, Hiromi/0000-0002-7576-9186				BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; Chaudhry SS, 2001, HUM MOL GENET, V10, P835, DOI 10.1093/hmg/10.8.835; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; Hasham SN, 2002, CURR OPIN CARDIOL, V17, P677, DOI 10.1097/00001573-200211000-00015; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hong DH, 2001, J BIOL CHEM, V276, P12091, DOI 10.1074/jbc.M009351200; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1986, J CELL BIOL, V103, P1121, DOI 10.1083/jcb.103.3.1121; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kielty CM, 2002, J CELL SCI, V115, P2817; Koduri S, 2000, CURR OPIN OBSTET GYN, V12, P399, DOI 10.1097/00001703-200010000-00009; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Nakamoto T, 2002, PLANT PROD SCI, V5, P175, DOI 10.1626/pps.5.175; PasqualiRonchetti I, 1997, MICROSC RES TECHNIQ, V38, P428, DOI 10.1002/(SICI)1097-0029(19970815)38:4<428::AID-JEMT10>3.0.CO;2-L; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Shapiro SD, 1995, P ASSOC AM PHYSICIAN, V107, P346; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; STARCHER B, 1995, CONNECT TISSUE RES, V31, P133, DOI 10.3109/03008209509028401; STARCHER B, 1985, CONNECT TISSUE RES, V13, P207, DOI 10.3109/03008208509152400; Sultan AH, 1996, BRIT J HOSP MED, V55, P575; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Yamamoto M, 2002, CELL BIOL INT, V26, P441, DOI 10.1006/cbir.2002.0877; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a	30	501	539	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					178	182		10.1038/ng1297	http://dx.doi.org/10.1038/ng1297			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14745449	Bronze			2022-12-25	WOS:000188542700021
J	Searle, JS; Schollaert, KL; Wilkins, BJ; Sanchez, Y				Searle, JS; Schollaert, KL; Wilkins, BJ; Sanchez, Y			The DNA damage checkpoint and PKA pathways converge on APC substrates and Cdc20 to regulate mitotic progression	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; DEPENDENT PROTEIN-KINASE; YEAST SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PSEUDOHYPHAL DIFFERENTIATION; GAP COMPLEX; PROTEOLYSIS; EXIT; MITOSIS; PDS1	The conserved checkpoint kinases Chk1 and Rad53 - Dun1 block the metaphase to anaphase transition by the phosphorylation and stabilization of securin, and block the mitotic exit network regulated by the Bfa1 - Bub2 complex. However, both chk1 and rad53 mutants are able to exit from mitosis and initiate a new cell cycle, suggesting that both pathways have supporting functions in restraining anaphase and in blocking the inactivation of mitotic cyclin - Cdk1 complexes. Here we find that the cyclic-AMP-dependent protein kinase (PKA) pathway supports Chk1 in the regulation of mitosis by targeting the mitotic inducer Cdc20. Cdc20 is phosphorylated on PKA consensus sites after DNA damage, and this phosphorylation requires the Atr orthologue Mec1 and the PKA catalytic subunits Tpk1 and Tpk2. We show that the inactivation of PKA or expression of phosphorylation-defective Cdc20 proteins accelerates securin and Clb2 destruction in chk1 mutants and is sufficient to remove most of the DNA damage-induced delay. Mutation of the Cdc20 phosphorylation sites permitted the interaction of Cdc20 with Clb2 under conditions that should halt cell cycle progression. These data show that PKA pathways regulate mitotic progression through Cdc20 and support the DNA damage checkpoint pathways in regulating the destruction of Clb2 and securin.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Sanchez, Y (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	yolanda.sanchez@uc.edu		Schollaert-Fitch, Kaila/0000-0001-9062-1772	NATIONAL CANCER INSTITUTE [R01CA084463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84463] Funding Source: Medline; NIEHS NIH HHS [P30 ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531; Bolte M, 2003, MICROBIOL-SGM, V149, P1205, DOI 10.1099/mic.0.26062-0; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Goh PY, 2000, EUR J BIOCHEM, V267, P434, DOI 10.1046/j.1432-1327.2000.01014.x; Heo SJ, 1999, CURR GENET, V36, P329, DOI 10.1007/s002940050507; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Irniger S, 2000, GENETICS, V154, P1509; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Kishimoto N, 2000, YEAST, V16, P523, DOI 10.1002/(SICI)1097-0061(200004)16:6<523::AID-YEA546>3.3.CO;2-X; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; PALMER RE, 1989, J CELL BIOL, V109, P3355, DOI 10.1083/jcb.109.6.3355; Pan XW, 2000, CURR OPIN MICROBIOL, V3, P567, DOI 10.1016/S1369-5274(00)00142-9; Pan XW, 2002, MOL CELL BIOL, V22, P3981, DOI 10.1128/MCB.22.12.3981-3993.2002; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Portela P, 2001, MICROBIOL-SGM, V147, P1149, DOI 10.1099/00221287-147-5-1149; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sanchez Y, 1997, METHOD ENZYMOL, V283, P398; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang YC, 2000, CURR BIOL, V10, P1379, DOI 10.1016/S0960-9822(00)00779-X; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; WEINERT TA, 1993, GENETICS, V134, P63; Yamada H, 1997, J CELL SCI, V110, P1793; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0	35	77	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					138	+		10.1038/ncb1092	http://dx.doi.org/10.1038/ncb1092			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743219				2022-12-25	WOS:000188668300013
J	Aoki, K; Tamai, Y; Horiike, S; Oshima, M; Taketo, MM				Aoki, K; Tamai, Y; Horiike, S; Oshima, M; Taketo, MM			Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc(+/Delta 716) Cdx(2+/-) compound mutant mice	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR GENE; GENOMIC INSTABILITY; COLORECTAL ADENOMA; CDX2 EXPRESSION; KNOCKOUT MICE; MOUSE EMBRYO; CELL-LINES; CYCLIN D1; APC; PROTEIN	The mammalian homeobox transcription factor CDX2 has key roles in intestinal development and differentiation. Heterozygous Cdx2 mice develop one or two benign hamartomas in the proximal colon, whereas heterozygous Apc(Delta716) mice develop numerous adenomatous polyps, mostly in the small intestine. Here we show that the colonic polyp number is about six times higher in Apc(+/Delta716) Cdx2(+/-) compound mutant mice. Levels of both APC and CDX2 were significantly lower in the distal colon, which caused high anaphase bridge index (ABI) associated with a higher frequency of loss of heterozygosity (LOH) at Apc. In cultured rat intestinal epithelial and human colon cancer cell lines, suppression of CDX2 by antisense RNA caused marked increases in ABI and chromosomal aberrations. This was mediated by stimulation of the mTOR pathway, causing translational deregulation and G(1)-S acceleration, associated with low levels of p27 and activation of cyclin E-Cdk2. We obtained similar results in the colonic mucosa of Apc(+/Delta716) Cdx2(+/-) compound mutant mice. Forced activation of mTOR through upstream regulator Akt also increased ABI in colon cancer cells. High ABI in all cell lines was suppressed by mTOR inhibitors LY294002 and rapamycin. These results suggest that reduced expression of CDX2 is important in colon tumorigenesis through mTOR-mediated chromosomal instability.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Banyu Tsukuba Res Inst Merck, Ibaraki 3002611, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6028566, Japan	Kyoto University; Merck & Company; Kyoto Prefectural University of Medicine	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.		Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004				BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHEN TR, 1995, CANCER GENET CYTOGEN, V81, P103, DOI 10.1016/0165-4608(94)00225-Z; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; EE HC, 1995, AM J PATHOL, V147, P586; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Goel A, 2003, CANCER RES, V63, P1608; GRODEN J, 1995, CANCER RES, V55, P1531; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Seno H, 2002, INT J ONCOL, V21, P769; Shih IM, 2001, CANCER RES, V61, P818; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P16910, DOI 10.1073/pnas.012679099; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tamai Y, 1999, CANCER RES, V59, P2965; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Willenbucher RF, 1999, AM J PATHOL, V154, P1825, DOI 10.1016/S0002-9440(10)65438-7; Zhou P, 1996, CANCER RES, V56, P36	48	191	197	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2003	35	4					323	330		10.1038/ng1265	http://dx.doi.org/10.1038/ng1265			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14625550	Green Submitted			2022-12-25	WOS:000186791000013
J	Floyd, JA; Gold, DA; Concepcion, D; Poon, TH; Wang, XB; Keithley, E; Chen, D; Ward, EJ; Chinn, SB; Friedman, RA; Yu, HT; Moriwaki, K; Shiroishi, T; Hamilton, BA				Floyd, JA; Gold, DA; Concepcion, D; Poon, TH; Wang, XB; Keithley, E; Chen, D; Ward, EJ; Chinn, SB; Friedman, RA; Yu, HT; Moriwaki, K; Shiroishi, T; Hamilton, BA			A natural allele of Nxf1 suppresses retrovirus insertional mutations	NATURE GENETICS			English	Article							MESSENGER-RNA EXPORT; NUCLEAR EXPORT; BINDING DOMAIN; HAIRLESS GENE; MOUSE MODEL; MICE; EXPRESSION; COMPLEX; GENOME; AXIN	Endogenous retroviruses have shaped the evolution of mammalian genomes. Host genes that control the effects of retrovirus insertions are therefore of great interest. The modifier-of-vibrator-1 locus (Mvb1) controls levels of correctly processed mRNA from genes mutated by endogenous retrovirus insertions into introns, including the Pitpn(vb) tremor mutation and the Eya1(BOR) model of human branchiootorenal syndrome. Positional complementation cloning identifies Mvb1 as the nuclear export factor Nxf1, providing an unexpected link between the mRNA export receptor and pre-mRNA processing. Population structure of the suppressive allele in wild Mus musculus castaneus suggests selective advantage. A congenic Mvb1(CAST) allele is a useful tool for modifying gene expression from existing mutations and could be used to manipulate engineered mutations containing retroviral elements.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Div Otolaryngol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Mol Pathol Grad Program, La Jolla, CA 92093 USA; House Ear Res Inst, Los Angeles, CA 90057 USA; Natl Taiwan Univ, Dept Zool, Taipei 107, Taiwan; RIKEN, Bioresource Ctr, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Genet, Mammalian Genet Lab, Mishima, Shizuoka 4118540, Japan; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Rebecca & John Moores UCSD Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; House Research Institute; National Taiwan University; RIKEN; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of California System; University of California San Diego; University of California System; University of California San Diego	Hamilton, BA (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Chinn, Steven/0000-0003-4282-0640; Hamilton, Bruce/0000-0001-5599-9139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004796] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC004796-05, R01 DC004796] Funding Source: Medline; NIGMS NIH HHS [T32 GM008666, R01 GM086912] Funding Source: Medline; NIMH NIH HHS [R01 MH059207-04, R01 MH059207-06, R01 MH059207-01, R01 MH059207-02, R01 MH059207-05, R01 MH059207, R01 MH059207-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Boeke J. D., 1997, P343; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Grant RP, 2003, J MOL BIOL, V326, P849, DOI 10.1016/S0022-2836(02)01474-2; Grant RP, 2002, NAT STRUCT BIOL, V9, P247, DOI 10.1038/nsb773; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hamilton BA, 2001, CELL, V107, P13, DOI 10.1016/S0092-8674(01)00514-1; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Johnson KR, 1999, HUM MOL GENET, V8, P645, DOI 10.1093/hmg/8.4.645; Lindtner S, 2002, RNA, V8, P345, DOI 10.1017/S1355838202027759; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Tabernero C, 1997, J VIROL, V71, P95, DOI 10.1128/JVI.71.1.95-101.1997; Vasicek TJ, 1997, GENETICS, V147, P777; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEIMAR WR, 1982, BRAIN RES, V251, P357, DOI 10.1016/0006-8993(82)90754-5; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; YONEKAWA H, 1988, MOL BIOL EVOL, V5, P63; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	33	30	31	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					221	228		10.1038/ng1247	http://dx.doi.org/10.1038/ng1247			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14517553	Green Accepted, Green Published			2022-12-25	WOS:000186273300017
J	Kuberan, B; Lech, MZ; Beeler, DL; Wu, ZLL; Rosenberg, RD				Kuberan, B; Lech, MZ; Beeler, DL; Wu, ZLL; Rosenberg, RD			Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide	NATURE BIOTECHNOLOGY			English	Letter							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; K5 CAPSULAR POLYSACCHARIDE; EXPRESSION; PURIFICATION; CLONING; BIOSYNTHESIS; MECHANISM; SUBSTRATE; RESIDUES; ISOFORMS	Heparan sulfate (HS) proteoglycans are crucial to numerous biological processes and pathological conditions, but to date only a few HS structures have been synthesized and characterized with regard to structure-function relationships. Because HS proteoglycans are highly diverse in structure, there are substantial limitations on their synthesis by classical chemical means, and thus new methods to rapidly assemble bioactive HS structures are needed. Here we report the biosynthesis of bioactive HS oligosaccharides using an engineered set of cloned enzymes that mimics the Golgi apparatus in vitro. We rapidly and efficiently assembled the antithrombin III-binding pentasaccharide in just 6 steps, in contrast to the approximately 60 steps needed for its chemical synthesis, with an overall yield at least twofold greater and a completion time at least 100 times faster than for the chemical process.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Wu, Zhengliang/0000-0002-0700-0906; Balagurunathan, Kuberan/0000-0001-9203-8118				ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WARNICK CT, 1972, BIOCHEMISTRY-US, V11, P568, DOI 10.1021/bi00754a014; Weber B, 1996, HUM MOL GENET, V5, P771, DOI 10.1093/hmg/5.6.771; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com	22	120	128	0	32	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1343	1346		10.1038/nbt885	http://dx.doi.org/10.1038/nbt885			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14528313				2022-12-25	WOS:000186320000036
J	Martienssen, RA				Martienssen, RA			Maintenance of heterochromatin by RNA interference of tandem repeats	NATURE GENETICS			English	Article							FISSION YEAST; CENTROMERE; DOMAIN	Tandem repeats are prone to epigenetic silencing regulated by RNA interference. This may be because siRNAs from tandem array transcripts are regenerated by RNA-dependent RNA polymerase (RdRP) and Dicer, but siRNAs from single-copy sequences are exhausted by sequential use of downstream primers by RdRP. This could account for the formation of heterochromatin from tandem repeats.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Martienssen, RA (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.							Ayoub N, 2000, GENETICS, V156, P983; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Pontecorvo G, 1944, NATURE, V153, P365, DOI 10.1038/153365a0; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Selker EU, 2002, ADV GENET, V46, P439; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0	18	151	168	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					213	214		10.1038/ng1252	http://dx.doi.org/10.1038/ng1252			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14593407				2022-12-25	WOS:000186273300013
J	Borsello, T; Clarke, PGH; Hirt, L; Vercelli, A; Repici, M; Schorderet, DF; Bogousslavsky, J; Bonny, C				Borsello, T; Clarke, PGH; Hirt, L; Vercelli, A; Repici, M; Schorderet, DF; Bogousslavsky, J; Bonny, C			A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia	NATURE MEDICINE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; THERAPEUTIC WINDOW; INDUCED APOPTOSIS; INJURY; STROKE; BRAIN; JNK; NEURONS; NUCLEUS; DAMAGE	Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to activate the c-Jun N-terminal kinase (JNK) pathway. We have evaluated the neuroprotective power of a cell-penetrating, protease-resistant peptide that blocks the access of JNK to many of its targets. We obtained strong protection in two models of middle cerebral artery occlusion (MCAO): transient occlusion in adult mice and permanent occlusion in 14-d-old rat pups. In the first model, intraventricular administration as late as 6 h after occlusion reduced the lesion volume by more than 90% for at least 14 d and prevented behavioral consequences. In the second model, systemic delivery reduced the lesion by 78% and 49% at 6 and 12 h after ischemia, respectively. Protection correlated with prevention of an increase in c-Jun activation and c-Fos transcription. In view of its potency and long therapeutic window, this protease-resistant peptide is a promising neuroprotective agent for stroke.	Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland; Dept Anat Pharmacol & Forens Med, I-10126 Turin, Italy; CHU Vaudois, Univ Hosp, Div Med Genet, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Lab Rech Neurol, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Borsello, T (corresponding author), Univ Lausanne, Inst Biol Cellulaire & Morphol, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.		Vercelli, Alessandro E/A-1926-2012; Hirt, Lorenz/G-3553-2010; Borsello, Tiziana/ABG-7759-2020; Borsello, Tiziana/J-8232-2016	Vercelli, Alessandro E/0000-0002-5909-2128; Hirt, Lorenz/0000-0002-2921-5000; Borsello, Tiziana/0000-0002-9729-7642; Repici, Mariaelena/0000-0002-9420-528X				Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffey ET, 2000, J NEUROSCI, V20, P7602; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Dawson DA, 2001, BRAIN RES, V892, P344, DOI 10.1016/S0006-8993(00)03269-8; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Imai H, 2002, J CEREBR BLOOD F MET, V22, P1080, DOI 10.1097/00004647-200209000-00005; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Ko HW, 1998, J NEUROCHEM, V71, P1390; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Ma JY, 2001, BRIT J PHARMACOL, V133, P345, DOI 10.1038/sj.bjp.0704075; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Morris DC, 2001, STROKE, V32, P2635, DOI 10.1161/hs1101.097390; Namura S, 1998, J NEUROSCI, V18, P3659; Petty MA, 1999, BRAIN RES REV, V31, P58, DOI 10.1016/S0165-0173(99)00025-9; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Yam PS, 2000, J CEREBR BLOOD F MET, V20, P772, DOI 10.1097/00004647-200005000-00003; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; [No title captured]	41	569	618	0	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1180	1186		10.1038/nm911	http://dx.doi.org/10.1038/nm911			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937412				2022-12-25	WOS:000185061600031
J	Willenbring, H; Bailey, AS; Foster, M; Akkari, Y; Dorrell, C; Olson, S; Finegold, M; Fleming, WH; Grompe, M				Willenbring, H; Bailey, AS; Foster, M; Akkari, Y; Dorrell, C; Olson, S; Finegold, M; Fleming, WH; Grompe, M			Myelomonocytic cells are sufficient for therapeutic cell fusion in liver	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW; IN-VIVO; HEREDITARY TYROSINEMIA; MYELOID PROGENITORS; PURKINJE NEURONS; MURINE MODEL; HEPATOCYTES; MUSCLE; MICE	Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency(1). BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes(2). To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah(-/-) mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1(-/-) mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Oregon Stem Cell Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Div Hematol & Med Oncol, Portland, OR 97239 USA; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Baylor College of Medicine; Oregon Health & Science University	Willenbring, H (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	willenbr@ohsu.edu		Grompe, Markus/0000-0002-6616-4345	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067636] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL69133] Funding Source: Medline; NIDDK NIH HHS [R01-DK067636] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bailey AS, 2004, BLOOD, V103, P13, DOI 10.1182/blood-2003-05-1684; BitMansour A, 2002, BLOOD, V100, P4660, DOI 10.1182/blood-2002-05-1552; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Freeman BJ, 1999, BLOOD, V94, P2142, DOI 10.1182/blood.V94.6.2142.418k16_2142_2150; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; VanRooijen N, 1996, HEPATOLOGY, V23, P1239; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053	30	314	331	2	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2004	10	7					744	748		10.1038/nm1062	http://dx.doi.org/10.1038/nm1062			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195088				2022-12-25	WOS:000222460400030
J	Davila, S; Furu, L; Gharavi, AG; Tian, X; Onoe, T; Qian, Q; Li, AR; Cai, YQ; Kamath, PS; King, BF; Azurmendi, PJ; Tahvanainen, P; Kaariainen, H; Hockerstedt, K; Devuyst, O; Pirson, Y; Martin, RS; Lifton, RP; Tahvanainen, E; Torres, VE; Somlo, S				Davila, S; Furu, L; Gharavi, AG; Tian, X; Onoe, T; Qian, Q; Li, AR; Cai, YQ; Kamath, PS; King, BF; Azurmendi, PJ; Tahvanainen, P; Kaariainen, H; Hockerstedt, K; Devuyst, O; Pirson, Y; Martin, RS; Lifton, RP; Tahvanainen, E; Torres, VE; Somlo, S			Mutations in SEC63 cause autosomal dominant polycystic liver disease	NATURE GENETICS			English	Article							N-LINKED GLYCANS; KIDNEY-DISEASE; TRANSLOCATION; PATHWAY; PRKCSH	Mutations in PRKCSH, encoding the beta-subunit of glucosidase II, an N-linked glycan-processing enzyme in the endoplasmic reticulum (ER), cause autosomal dominant polycystic liver disease. We found that mutations in SEC63, encoding a component of the protein translocation machinery in the ER, also cause this disease. These findings are suggestive of a role for cotranslational protein-processing pathways in maintaining epithelial luminal structure and implicate noncilial ER proteins in human polycystic disease.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Mayo Clin, Dept Med, Rochester, MN USA; Mayo Clin, Dept Radiol, Rochester, MN USA; Univ Buenos Aires, Buenos Aires, DF, Argentina; Natl Inst Publ Hlth, Dept Human Mol Genet, Helsinki, Finland; Turku Univ, Dept Med Genet, Turku, Finland; Univ Helsinki Hosp, Transplantat & Liver Surg Unit, Helsinki, Finland; Clin Univ St, Brussels, Belgium; Univ Helsinki, Dept Med Genet, Helsinki, Finland	Yale University; Yale University; Mayo Clinic; Mayo Clinic; University of Buenos Aires; University of Turku; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Somlo, S (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208029,333 Cedar St, New Haven, CT 06520 USA.	stefan.somlo@yale.edu		Azurmendi, Pablo Javier/0000-0001-7787-5882; Devuyst, Olivier/0000-0003-3744-4767				Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; Furu L, 2003, J AM SOC NEPHROL, V14, P2004, DOI 10.1097/01.ASN.0000078805.87038.05; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Iglesias DM, 1999, DIGEST DIS SCI, V44, P385, DOI 10.1023/A:1026623005401; Li AR, 2003, AM J HUM GENET, V72, P691, DOI 10.1086/368295; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; Pirson Y, 1996, HEPATOLOGY, V23, P249, DOI 10.1002/hep.510230208; Qian Q, 2003, HEPATOLOGY, V37, P164, DOI 10.1053/jhep.2003.50006; Reynolds DM, 2000, AM J HUM GENET, V67, P1598, DOI 10.1086/316904; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Tahvanainen P, 2003, J HEPATOL, V38, P39, DOI 10.1016/S0168-8278(02)00348-3; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	15	182	190	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					575	577		10.1038/ng1357	http://dx.doi.org/10.1038/ng1357			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15133510	Bronze			2022-12-25	WOS:000221763700011
J	Joeng, KS; Song, EJ; Lee, KJ; Lee, J				Joeng, KS; Song, EJ; Lee, KJ; Lee, J			Long lifespan in worms with long telomeric DNA	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; IN-VITRO; HNRNP A1; GENE; LONGEVITY; PROTEIN; STRESS; DAF-16; THERMOTOLERANCE	Telomere length is a crucial factor in senescence(1-3), but it has not been determined whether animals with long telomeres live longer than those with normal-length telomeres in the isogenic background of a given species. Here we show the effect of long telomeres on lifespan in the nematode Caenorhabditis elegans. We examined the effect of telomere length on lifespan by overexpressing HRP-1, a telomere-binding protein, which gradually increased telomere length in worms. Worms with longer telomeres lived longer. We confirmed that the extension of lifespan was due to the increased telomere length, and not to the overexpression of HRP-1 per se, by examining the lifespans of nontransgenic progeny of the transgenic worms, who retained the longer telomeres. The lifespan-extending effect of long telomeres was dependent on daf-16. The number of germ stem cells was not affected in worms with long telomeres, indicating that the telomere effect on lifespan is independent of germ stem cell cycling. Worms with long telomeres were more resistant to heat stress. Taken together, our results suggest that signaling may be initiated in postmitotic somatic cells by telomere length to regulate organismal lifespan.	Yonsei Univ, Dept Biol, Natl Res Lab & Mol Aging Res Ctr, Seoul 120749, South Korea; Ewha Womans Univ, Div Mol Life Sci, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea	Yonsei University; Ewha Womans University; Ewha Womans University	Lee, J (corresponding author), Yonsei Univ, Dept Biol, Natl Res Lab & Mol Aging Res Ctr, 134 Shinchon, Seoul 120749, South Korea.	leej@yonsei.ac.kr		Lee, Kong-Joo/0000-0001-7972-6020; Song, Eun Joo/0000-0002-2420-6666	NICHD NIH HHS [P01 HD070394] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD070394] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Benard C, 2002, MECH AGEING DEV, V123, P869, DOI 10.1016/S0047-6374(02)00024-6; Benard C, 2001, DEVELOPMENT, V128, P4045; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Garigan D, 2002, GENETICS, V161, P1101; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Krupp G, 2000, CELL MOL LIFE SCI, V57, P464, DOI 10.1007/PL00000708; Kwon JY, 1999, P NATL ACAD SCI USA, V96, P14990, DOI 10.1073/pnas.96.26.14990; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lim CS, 2001, CURR BIOL, V11, P1706, DOI 10.1016/S0960-9822(01)00526-7; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morin GB, 1997, EXP GERONTOL, V32, P375, DOI 10.1016/S0531-5565(96)00164-7; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983	27	97	107	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					607	611		10.1038/ng1356	http://dx.doi.org/10.1038/ng1356			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15122256	Bronze			2022-12-25	WOS:000221763700018
J	Conery, AR; Cao, YN; Thompson, EA; Townsend, CM; Ko, TC; Luo, KX				Conery, AR; Cao, YN; Thompson, EA; Townsend, CM; Ko, TC; Luo, KX			Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta-induced apoptosis	NATURE CELL BIOLOGY			English	Letter							GROWTH-FACTOR-BETA; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; HEPATOMA-CELLS; EXPRESSION; ACTIVATION; PHOSPHORYLATION; RECEPTOR	Transforming growth factor beta (TGF-beta) induces both apoptosis and cell-cycle arrest in some cell lines, but only growth arrest in others(1). It is not clear how this differential response to TGF-beta is specified. Smad proteins are critical mediators of TGF-beta signalling. After stimulation by TGF-beta, Smad2 and Smad3 become phosphorylated by the activated TGF-beta receptor kinases, oligomerize with Smad4, translocate to the nucleus and regulate the expression of TGF-beta target genes(1-5). Here we report that the sensitivity to TGF-beta-induced apoptosis is regulated by crosstalk between the Akt/PKB serine/threonine kinase and Smad3 through a mechanism that is independent of Akt kinase activity. Akt interacts directly with unphosphorylated Smad3 to sequester it outside the nucleus, preventing its phosphorylation and nuclear translocation. This results in inhibition of Smad3-mediated transcription and apoptosis. Furthermore, the ratio of Smad3 to Akt correlates with the sensitivity of cells to TGF-beta-induced apoptosis. Alteration of this ratio changes the apoptotic, but not the growth-inhibitory, responses of cells to TGF-beta. These findings identify an important determinant of sensitivity to TGF-beta-induced apoptosis that involves crosstalk between the TGF-beta and phosphatidylinositol-3-OH kinase (PI(3)K) pathways.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Mayo Canc Ctr, Jacksonville, FL 32224 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Mayo Clinic	Luo, KX (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	tko@utmb.edu; kluo@uclink.berkeley.edu		CONERY, ANDREW/0000-0003-3638-7633				Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Buenemann CL, 2001, CARCINOGENESIS, V22, P447, DOI 10.1093/carcin/22.3.447; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Engel ME, 1998, J CELL BIOCHEM, P111; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Parsons MJ, 2001, J IMMUNOL, V167, P42, DOI 10.4049/jimmunol.167.1.42; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanaka S, 1996, CANCER RES, V56, P3391; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123	30	308	330	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					366	372		10.1038/ncb1117	http://dx.doi.org/10.1038/ncb1117			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15104092				2022-12-25	WOS:000220587600019
J	Craddock, N				Craddock, N			Flies in the soup - European GM labeling legislation	NATURE BIOTECHNOLOGY			English	Editorial Material									Neville Craddock Associates, Surrey RH1 4PA, England		Craddock, N (corresponding author), Neville Craddock Associates, Tun House,28 High St, Surrey RH1 4PA, England.	nevillecraddock@tunhouse28.fsnet.co.uk							0	4	4	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2004	22	4					383	384		10.1038/nbt0404-383	http://dx.doi.org/10.1038/nbt0404-383			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	809AR	15060547				2022-12-25	WOS:000220610100015
J	Desrosiers, RC				Desrosiers, RC			Prospects for an AIDS vaccine	NATURE MEDICINE			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL RESPONSES; DISEASE PROGRESSION; VIRAL REPLICATION; IMMUNE-RESPONSES; RHESUS MACAQUES; PROTECTION; CHALLENGE; PREVENTION; STRATEGIES		Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA	Harvard University	Desrosiers, RC (corresponding author), Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA.	ronald_desrosiers@hms.harvard.edu						Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; KUIKEN CL, 2002, HIV SEQUENCE COMPEND; Letvin NL, 2001, J VIROL, V75, P4165, DOI 10.1128/JVI.75.9.4165-4175.2001; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Nickle DC, 2003, SCIENCE, V299, P1515; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999	19	91	181	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					221	223		10.1038/nm0304-221	http://dx.doi.org/10.1038/nm0304-221			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14991035	Bronze			2022-12-25	WOS:000189297700018
J	Neves, G; Zucker, J; Daly, M; Chess, A				Neves, G; Zucker, J; Daly, M; Chess, A			Stochastic yet biased expression of multiple Dscam splice variants by individual cells	NATURE GENETICS			English	Article							DROSOPHILA DSCAM; RECEPTOR; GUIDANCE; GENOME; GENES	The Drosophila melanogaster gene Dscam is essential for axon guidance and has 38,016 possible alternative splice forms. This diversity can potentially be used to distinguish cells. We analyzed the Dscam mRNA isoforms expressed by different cell types and individual cells. The choice of splice variants expressed is regulated both spatially and temporally. Different subtypes of photoreceptors express broad yet distinctive spectra of Dscam isoforms. Single-cell RT-PCR documented that individual cells express several different Dscam isoforms and allowed an estimation of the diversity that is present. For example, we estimate that each R3/R4 photoreceptor cell expresses 14-50 distinct mRNAs chosen from the spectrum of thousands of splice variants distinctive of its cell type. Thus, the Dscam repertoire of each cell is different from those of its neighbors, providing a potential mechanism for generating unique cell identity in the nervous system and elsewhere.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Chess, A (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	chess@wi.mit.edu	Neves, Guilherme/G-8957-2011	Neves, Guilherme/0000-0001-6463-6997				ASBURNER M, 1989, DROSOPHILA LAB MANUA; Barlow GM, 2002, BIOCHEM BIOPH RES CO, V293, P881, DOI 10.1016/S0006-291X(02)00307-8; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Celotto AM, 2001, GENETICS, V159, P599; Cooper MTD, 2000, CURR BIOL, V10, P1507, DOI 10.1016/S0960-9822(00)00826-5; Echalier G., 1997, DROSOPHILA CELLS CUL; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Jasper H, 2002, DEV CELL, V3, P511, DOI 10.1016/S1534-5807(02)00297-6; KLICKSTEIN LB, 1995, CURRENT PROTOCOLS MO, V1; Lee CH, 2001, NEURON, V30, P437, DOI 10.1016/S0896-6273(01)00291-4; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Wang J, 2002, NEURON, V33, P559, DOI 10.1016/S0896-6273(02)00570-6; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061	25	191	193	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					240	246		10.1038/ng1299	http://dx.doi.org/10.1038/ng1299			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14758360	Bronze			2022-12-25	WOS:000189250400012
J	Stegmaier, K; Ross, KN; Colavito, SA; O'Malley, S; Stockwell, BR; Golub, TR				Stegmaier, K; Ross, KN; Colavito, SA; O'Malley, S; Stockwell, BR; Golub, TR			Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; SMALL-MOLECULE INHIBITORS; TRANS-RETINOIC ACID; GROWTH-INHIBITION; CELLS; HL-60; MECHANISM; IDENTIFICATION; METHOTREXATE; DISCOVERY	Chemical genomics involves generating large collections of small molecules and using them to modulate cellular states. Despite recent progress in the systematic synthesis of structurally diverse compounds, their use in screens of cellular circuitry is still an ad hoc process(1-4). Here, we outline a general, efficient approach called gene expression based high-throughput screening (GE-HTS) in which a gene expression signature is used as a surrogate for cellular states, and we describe its application in a particular setting: the identification of compounds that induce the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature and, furthermore, yielded functional evidence of bona fide differentiation. The results indicate that GE-HTS may be a powerful, general approach for chemical screening.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; Howard Hughes Med Inst, Chevy Chase, MD USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute	Golub, TR (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	golub@broad.mit.edu	Colavito, Sierra A/AAE-3957-2019; Stockwell, Brent R/AAE-7200-2019	Stockwell, Brent R/0000-0002-3532-3868; Colavito, Sierra/0000-0002-2814-4853				Baker K, 2002, P NATL ACAD SCI USA, V99, P16537, DOI 10.1073/pnas.262420099; Barrie SE, 2003, ANAL BIOCHEM, V320, P66, DOI 10.1016/S0003-2697(03)00349-X; BENBARUCH N, 1994, MOL PHARMACOL, V46, P73; BODNER AJ, 1981, J NATL CANCER I, V67, P1025; Clemons PA, 2001, CHEM BIOL, V8, P1183, DOI 10.1016/S1074-5521(01)00086-2; Dubey RK, 2000, HYPERTENSION, V35, P262, DOI 10.1161/01.HYP.35.1.262; DUNCAN GS, 1982, J IMMUNOPHARMACOL, V4, P79, DOI 10.3109/08923978209031077; Fici GJ, 1997, LIFE SCI, V60, P1597, DOI 10.1016/S0024-3205(97)00126-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129; Harvath L, 1999, Methods Mol Biol, V115, P281; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Johnson PH, 2002, MOL CANCER THER, V1, P1293; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KALINYAK KA, 1985, LIFE SCI, V36, P1909, DOI 10.1016/0024-3205(85)90439-4; MANTEL N, 1967, CANCER RES, V27, P209; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MCBURNEY MW, 1975, CANCER RES, V35, P586; Mountford JC, 1999, EXP HEMATOL, V27, P451, DOI 10.1016/S0301-472X(98)00078-2; Perachon S, 1999, EUR J PHARMACOL, V366, P293, DOI 10.1016/S0014-2999(98)00896-6; Peterson RT, 2000, P NATL ACAD SCI USA, V97, P12965, DOI 10.1073/pnas.97.24.12965; REYES P, 1965, MOL PHARMACOL, V1, P14; Root DE, 2003, CHEM BIOL, V10, P881, DOI 10.1016/j.chembiol.2003.08.009; Seiter K, 2000, BRIT J HAEMATOL, V108, P40, DOI 10.1046/j.1365-2141.2000.01804.x; Shim GJ, 2003, P NATL ACAD SCI USA, V100, P6694, DOI 10.1073/pnas.0731830100; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Yang L, 2001, GENOME RES, V11, P1888, DOI 10.1101/gr.190901; Yeakley JM, 2002, NAT BIOTECHNOL, V20, P353, DOI 10.1038/nbt0402-353	30	205	229	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					257	263		10.1038/ng1305	http://dx.doi.org/10.1038/ng1305			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14770183	Bronze			2022-12-25	WOS:000189250400014
J	Weidenmaier, C; Kokai-Kun, JF; Kristian, SA; Chanturiya, T; Kalbacher, H; Gross, M; Nicholson, G; Neumeister, B; Mond, JJ; Peschel, A				Weidenmaier, C; Kokai-Kun, JF; Kristian, SA; Chanturiya, T; Kalbacher, H; Gross, M; Nicholson, G; Neumeister, B; Mond, JJ; Peschel, A			Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections	NATURE MEDICINE			English	Article							DEFENSINS; CARRIAGE	Colonization of the anterior nares in 37% of the population is a major risk factor for severe Staphylococcus aureus infections. Here we show that wall teichoic acid (WTA), a surface-exposed staphylococcal polymer, is essential for nasal colonization and mediates interaction with human nasal epithelial cells. WTA-deficient mutants were impaired in their adherence to nasal cells, and were completely unable to colonize cotton rat nares. This study describes the first essential factor for S. aureus nasal colonization.	Univ Tubingen, Med Microbiol & Hyg Dept, D-72076 Tubingen, Germany; Biosynexus Inc, Gaithersburg, MD 20877 USA; Univ Tubingen, Dept Transfus Med, D-72076 Tubingen, Germany; Univ Tubingen, Med & Nat Sci Res Ctr, D-72074 Tubingen, Germany; Univ Tubingen, Dept Organ Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Peschel, A (corresponding author), Univ Tubingen, Med Microbiol & Hyg Dept, Elfriede Aulhorn Str 6, D-72076 Tubingen, Germany.	andreas.peschel@uni-tuebingen.de		Weidenmaier, Christopher/0000-0003-4107-739X				ALY R, 1980, J INFECT DIS, V141, P463, DOI 10.1093/infdis/141.4.463; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Cole AM, 2002, J IMMUNOL, V169, P6985, DOI 10.4049/jimmunol.169.12.6985; ENDL J, 1983, ARCH MICROBIOL, V135, P215, DOI 10.1007/BF00414483; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Kokai-Kun JF, 2003, ANTIMICROB AGENTS CH, V47, P1589, DOI 10.1128/AAC.47.5.1589-1597.2003; Niewiesk S, 2002, LAB ANIM-UK, V36, P357, DOI 10.1258/002367702320389026; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Peacock SJ, 2001, TRENDS MICROBIOL, V9, P605, DOI 10.1016/S0966-842X(01)02254-5; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; PRINCE GA, 1978, AM J PATHOL, V93, P771; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102	15	402	417	3	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					243	245		10.1038/nm991	http://dx.doi.org/10.1038/nm991			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14758355				2022-12-25	WOS:000189297700033
J	Smith, ST; Petruk, S; Sedkov, Y; Cho, E; Tillib, S; Canaani, E; Mazo, A				Smith, ST; Petruk, S; Sedkov, Y; Cho, E; Tillib, S; Canaani, E; Mazo, A			Modulation of heat shock gene expression by the TAC1 chromatin-modifying complex	NATURE CELL BIOLOGY			English	Article							HISTONE H3; DROSOPHILA TRITHORAX; SET DOMAIN; PROMOTER; DNA; TRANSCRIPTION; ASSOCIATION; RECRUITMENT; METHYLATION; REGULATOR	Rapid induction of the Drosophila melanogaster heat shock gene hsp70 is achieved through the binding of heat shock factor(1) (HSF) to heat shock elements (HSEs) located upstream of the transcription start site(2) ( reviewed in ref. 3). The subsequent recruitment of several other factors(4-8), including Spt5, Spt6 and FACT, is believed to facilitate Pol II elongation through nucleosomes downstream of the start site(9-11). Here, we report a novel mechanism of heat shock gene regulation that involves modifications of nucleosomes by the TAC1 histone modification complex(12). After heat stress, TAC1 is recruited to several heat shock gene loci, where its components are required for high levels of gene expression. Recruitment of TAC1 to the 5'-coding region of hsp70 seems to involve the elongating Pol II complex. TAC1 has both histone H3 Lys 4-specific (H3-K4) methyltransferase (HMTase) activity and histone acetyltransferase activity through Trithorax (Trx) and CREB-binding protein (CBP), respectively. Consistently, TAC1 is required for methylation and acetylation of nucleosomal histones in the 5'-coding region of hsp70 after induction, suggesting an unexpected role for TAC1 during transcriptional elongation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Jefferson University; Weizmann Institute of Science	Mazo, A (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	A_Mazo@mail.jci.tju.edu	Tillib, Sergei/AAT-2293-2020; Tillib, Sergei/I-4115-2013	Tillib, Sergei/0000-0002-7172-8731; Tillib, Sergei/0000-0002-7172-8731	NCI NIH HHS [CA009678, CA50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, T32CA009678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Breen TR, 1999, GENETICS, V152, P319; Brock HW, 2001, CURR OPIN GENET DEV, V11, P175, DOI 10.1016/S0959-437X(00)00176-3; Casso D, 2000, MECH DEVELOP, V91, P449; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Farkas G, 2000, GENE, V253, P117, DOI 10.1016/S0378-1119(00)00240-7; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Florence B, 1998, GENETICS, V150, P1497; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Katsani KR, 2001, GENE DEV, V15, P2197, DOI 10.1101/gad.201901; Lis JT, 2000, GENE DEV, V14, P792; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Park JM, 2001, MOL CELL, V8, P9, DOI 10.1016/S1097-2765(01)00296-9; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Sedkov Y, 2003, NATURE, V426, P78, DOI 10.1038/nature02080; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; UDVARDY A, 1991, MOL CELL BIOL, V11, P4973, DOI 10.1128/MCB.11.10.4973; Weber JA, 1997, MOL CELL BIOL, V17, P3799, DOI 10.1128/MCB.17.7.3799; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	30	147	152	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					162	167		10.1038/ncb1088	http://dx.doi.org/10.1038/ncb1088			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14730313				2022-12-25	WOS:000188668300016
J	Johnstone, TBC; Hogenkamp, DJ; Coyne, L; Su, JP; Halliwell, RF; Tran, MB; Yoshimura, RF; Li, WY; Wang, J; Gee, KW				Johnstone, TBC; Hogenkamp, DJ; Coyne, L; Su, JP; Halliwell, RF; Tran, MB; Yoshimura, RF; Li, WY; Wang, J; Gee, KW			Modifying quinolone antibiotics yields new anxiolytics	NATURE MEDICINE			English	Article							GABA(A) RECEPTORS; BENZODIAZEPINES; ANXIETY	Patients taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and anxiety. These side effects probably result from antagonism of the neurotransmitter gamma-aminobutyric acid (GABA) at the brain GABA(A) receptor complex (GRC). Modification of norfloxacin yields molecules such as compound 4 that potentiate GABA action with alpha(2) subunit selectivity. Compound 4 is anxiolytic but does not cause sedation, and may represent a new class of ligands that have anxiolytic activity without sedative liability.	Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92697 USA; Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Pacific, Thomas J Long Sch Pharm & Hlth Sci, Stockton, CA 95211 USA	University of California System; University of California Irvine; Durham University; University of the Pacific	Gee, KW (corresponding author), Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92697 USA.		Johnstone, Tom/C-5909-2011	Johnstone, Tom/0000-0001-8635-8158; Halliwell, Robert Francis/0000-0003-0397-3740; Coyne, Leanne/0000-0001-7741-9254	NIMH NIH HHS [MH60527] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R41MH060527] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Carboni E, 1996, PSYCHOPHARMACOLOGY, V126, P173, DOI 10.1007/BF02246353; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; De Sarro A, 1999, ANTIMICROB AGENTS CH, V43, P1729, DOI 10.1128/AAC.43.7.1729; HALLIWELL RF, 1993, J ANTIMICROB CHEMOTH, V31, P457, DOI 10.1093/jac/31.4.457; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N	9	41	41	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					31	32		10.1038/nm967	http://dx.doi.org/10.1038/nm967			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14647497				2022-12-25	WOS:000187743600035
J	Tseng, JC; Levin, B; Hurtado, A; Yee, H; Perez de Castro, I; Jimenez, M; Shamamian, P; Jin, RZ; Novick, RP; Pellicer, A; Meruelo, D				Tseng, JC; Levin, B; Hurtado, A; Yee, H; Perez de Castro, I; Jimenez, M; Shamamian, P; Jin, RZ; Novick, RP; Pellicer, A; Meruelo, D			Systemic tumor targeting and killing by Sindbis viral vectors	NATURE BIOTECHNOLOGY			English	Article							67-KD LAMININ RECEPTOR; HUMAN OVARIAN CARCINOMAS; DIFFERENTIAL EXPRESSION; ALPHA/BETA INTERFERONS; ADENOVIRAL VECTORS; VIRUS-INFECTION; CANCER-CELLS; GENE; REPLICATION; METASTASIS	Successful cancer gene therapy requires a vector that systemically and specifically targets tumor cells throughout the body. Although several vectors have been developed to express cytotoxic genes via tumor-specific promoters or to seclectively replicate in tumor cells, most are taken up and expressed by just a few targeted tumor cells. By contrast, we show here that blood-borne Sindbis viral vectors systemically and specifically infect tumor cells. A single intraperitoneal treatment allows the vectors to target most tumor cells, as demonstrated by immunohistochemistry, without infecting normal cells. Further, Sindbis infection is sufficient to induce complete tumor regression. We demonstrate systemic vector targeting of tumors growing subcutaneously, intrapancreatically, intraperitoneally and in the lungs. The vectors can also target syngeneic and spontaneous tumors in immune-competent mice. We document the anti-tumor specificity of a vector that systemically targets and eradicates tumor cells throughout the body without adverse effects.	NYU, Sch Med, NYU Gene therapy Ctr, NYU Canc Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Surg, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst,Dept Microbiol, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Meruelo, D (corresponding author), NYU, Sch Med, NYU Gene therapy Ctr, NYU Canc Inst, 550 1st Ave, New York, NY 10016 USA.	daniel.meruelo@med.nyu.edu	MARTINEZ, ANTONIO PELLICER/C-4832-2015; JIMENEZ, MARIA/H-7117-2015; de Castro, Ignacio Pérez/A-6260-2012	JIMENEZ, MARIA/0000-0003-2673-6369; de Castro, Ignacio Pérez/0000-0002-8822-8274; Novick, richard/0000-0003-4418-7893; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA022247, R01CA068498, R37CA022247] Funding Source: NIH RePORTER; NCI NIH HHS [CA22247, CA68498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; BARSKY SH, 1984, BREAST CANCER RES TR, V4, P181, DOI 10.1007/BF01806483; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Brynes AP, 1998, J VIROL, V72, P7349, DOI 10.1128/JVI.72.9.7349-7356.1998; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; CIOCE V, 1991, J NATL CANCER I, V83, P29, DOI 10.1093/jnci/83.1.29; Cook SH, 2003, J VIROL, V77, P5333, DOI 10.1128/JVI.77.9.5333-5338.2003; de Manzoni G, 1998, JPN J CLIN ONCOL, V28, P534, DOI 10.1093/jjco/28.9.534; FROLOV I, 1994, J VIROL, V68, P1721, DOI 10.1128/JVI.68.3.1721-1727.1994; Frolova EI, 2002, J VIROL, V76, P11254, DOI 10.1128/JVI.76.22.11254-11264.2002; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Green NK, 2002, CANCER GENE THER, V9, P1036, DOI 10.1038/sj.cgt.7700541; Jan JT, 1999, J VIROL, V73, P10296, DOI 10.1128/JVI.73.12.10296-10302.1999; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Leucht C, 2003, EMBO REP, V4, P290, DOI 10.1038/sj.embor.embor768; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LIEBMAN JM, 1993, INT J CANCER, V55, P102, DOI 10.1002/ijc.2910550119; LIOTTA LA, 1984, CIBA F SYMP, V108, P146; LIOTTA LA, 1985, EXP CELL RES, V156, P117, DOI 10.1016/0014-4827(85)90266-6; LIOTTA LA, 1986, CANCER RES, V46, P1; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; OLIVO PD, 1994, VIROLOGY, V198, P381, DOI 10.1006/viro.1994.1046; Ozaki I, 1998, GUT, V43, P837, DOI 10.1136/gut.43.6.837; Polo JM, 1999, P NATL ACAD SCI USA, V96, P4598, DOI 10.1073/pnas.96.8.4598; Putzer BM, 2002, MOL THER, V5, P405, DOI 10.1006/mthe.2002.0570; Ryman KD, 2000, J VIROL, V74, P3366, DOI 10.1128/JVI.74.7.3366-3378.2000; Sanjuan X, 1996, J PATHOL, V179, P376, DOI 10.1002/(SICI)1096-9896(199608)179:4<376::AID-PATH591>3.0.CO;2-V; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STRAUSS JH, 1994, ARCH VIROL, P473; TARABOLETTI G, 1993, J NATL CANCER I, V85, P235, DOI 10.1093/jnci/85.3.235; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; Tseng JC, 2002, JNCI-J NATL CANCER I, V94, P1790; vandenBrule FA, 1996, EUR J CANCER, V32A, P1598, DOI 10.1016/0959-8049(96)00119-0; VANDENBRULE FA, 1994, EUR J CANCER, V30A, P1096, DOI 10.1016/0959-8049(94)90464-2; Viacava P, 1997, J PATHOL, V182, P36, DOI 10.1002/(SICI)1096-9896(199705)182:1<36::AID-PATH802>3.0.CO;2-W; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Yaghoubi SS, 2001, GENE THER, V8, P1072, DOI 10.1038/sj.gt.3301490	42	118	150	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					70	77		10.1038/nbt917	http://dx.doi.org/10.1038/nbt917			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14647305				2022-12-25	WOS:000187745400029
J	Wu, ZH; Bensinger, SJ; Zhang, JD; Chen, CQ; Yuan, XL; Huang, XL; Markmann, JF; Kassaee, A; Rosengard, BR; Hancock, WW; Sayegh, MH; Turka, LA				Wu, ZH; Bensinger, SJ; Zhang, JD; Chen, CQ; Yuan, XL; Huang, XL; Markmann, JF; Kassaee, A; Rosengard, BR; Hancock, WW; Sayegh, MH; Turka, LA			Homeostatic proliferation is a barrier to transplantation tolerance	NATURE MEDICINE			English	Article							NAIVE T-CELLS; STAGE RENAL-DISEASE; ALLOGRAFT TOLERANCE; LYMPHOHEMATOPOIETIC CHIMERISM; COSTIMULATORY BLOCKADE; LYMPHOPENIC HOSTS; IMMUNE-RESPONSES; MULTIPLE-MYELOMA; MIXED CHIMERISM; IN-VIVO	Despite the ease of inhibiting immune responses by blockade of T-cell costimulation in naive rodent models, it is difficult to suppress those responses in animals with memory cells(1,2). Studies demonstrating the importance of alloreactive T-cell deletion during tolerance induction have promoted use of peritransplant T-cell-depleting therapies in clinical trials(3-6). But potentially complicating wide-scale, nonspecific T-cell depletion is the finding that extensive T-cell proliferation can occur under conditions of lymphopenia. This process, termed homeostatic proliferation(7,8), may induce acquisition of functional memory T cells(9-13). Here, using clinically relevant mouse models of peripheral T-cell depletion, we show that residual nondepleted T cells undergo substantial homeostatic expansion. In this setting, costimulatory blockade neither significantly suppresses homeostatic proliferation nor prevents allograft rejection. In addition, T cells that have completed homeostatic proliferation show dominant resistance to tolerance when adoptively transferred into wild-type recipients, consistent with known properties of memory cells in vivo. These findings establish the importance of homeostatic proliferation in clinically relevant settings, demonstrate the barrier that homeostatic proliferation can present to the induction of transplantation tolerance, and have important implications for transplantation protocols that use partial or complete peripheral T-cell depletion.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02131 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Pathol & Biesecker Pediat Liver Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Turka, LA (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.			Sayegh, Mohamed/0000-0002-2847-588X	NIAID NIH HHS [P01 AI041521, R21 AI043626, R01 AI062789-01A1, AI-41521, R01 AI043626, AI-43626, AI-37691, R01 AI037691, R01 AI037691-10, R01 AI062789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041521, R01AI062789, R01AI043626, R21AI043626, R01AI037691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; Chalasani G, 2002, P NATL ACAD SCI USA, V99, P6175, DOI 10.1073/pnas.092596999; Dummer W, 2002, J CLIN INVEST, V110, P185, DOI 10.1172/JCI200215175; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Goldrath AW, 2000, J EXP MED, V192, P557, DOI 10.1084/jem.192.4.557; Gudmundsdottir H, 2001, J IMMUNOL, V167, P3699, DOI 10.4049/jimmunol.167.7.3699; Hakim FT, 1997, BLOOD, V90, P3789, DOI 10.1182/blood.V90.9.3789; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; Hu HM, 2002, CANCER RES, V62, P3914; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kieper WC, 1999, P NATL ACAD SCI USA, V96, P13306, DOI 10.1073/pnas.96.23.13306; KIRK AD, 2002, AM J TRANSPL S3, V2, P379; KNECHTLE SJ, 2002, AM J TRANSPLANT S3, V2, P459; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733; Onodera K, 1997, J IMMUNOL, V159, P1711; Prlic M, 2001, J IMMUNOL, V167, P5664, DOI 10.4049/jimmunol.167.10.5664; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Valujskikh A, 2002, AM J TRANSPLANT, V2, P501, DOI 10.1034/j.1600-6143.2002.20603.x; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260	30	341	348	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					87	92		10.1038/nm965	http://dx.doi.org/10.1038/nm965			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14647496	Green Accepted			2022-12-25	WOS:000187743600043
J	Deyev, SM; Waibel, R; Lebedenko, EN; Schubiger, AP; Pluckthun, A				Deyev, SM; Waibel, R; Lebedenko, EN; Schubiger, AP; Pluckthun, A			Design of multivalent complexes using the barnase-barstar module	NATURE BIOTECHNOLOGY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HIGH AVIDITY; ANTIBODY; FRAGMENTS; PROTEINS; DIABODY; BIODISTRIBUTION; MINIANTIBODIES; CONSTRUCTION	The ribonuclease barnase (12 kDa) and its inhibitor barstar (10 kDa) form a very tight complex in which all N and C termini are accessible for fusion. Here we exploit this system to create modular targeting molecules based on antibody scFv fragment fusions to barnase, to two barnase molecules in series and to barstar. We describe the construction, production and purification of defined dimeric and trimeric complexes. Immobilized barnase fusions are used to capture barstar fusions from crude extracts to yield homogeneous, heterodimeric fusion proteins. These proteins are stable, soluble and resistant to proteolysis. Using fusions with anti- p185(HER2- ECD) 4D5 scFv, we show that the anticipated gain in avidity from monomer to dimer to trimer is obtained and that favorable tumor targeting properties are achieved. Many permutations of engineered multispecific fusion proteins become accessible with this technology of quasi- covalent heterodimers.	Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Inst Gene Biol, Moscow 117997, Russia; Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; University of Zurich	Deyev, SM (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya Str 16-10, Moscow 117997, Russia.	deyev@ibch.ru; plueckthun@bioc.unizh.ch	Deyev, Sergey M/F-8191-2014; Plückthun, Andreas/C-2746-2009; Lebedenko, Ekaterina/B-7139-2012	Deyev, Sergey M/0000-0002-3952-0631; Plückthun, Andreas/0000-0003-4191-5306; Lebedenko, Ekaterina/0000-0002-7031-5994				Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Casey JL, 1999, BRIT J CANCER, V81, P972, DOI 10.1038/sj.bjc.6690795; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; Deyev SM, 1998, MOL GEN GENET, V259, P379, DOI 10.1007/s004380050825; Dreier T, 2002, INT J CANCER, V100, P690, DOI 10.1002/ijc.10557; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; Ge L, 1995, ANTIBODY ENG, P229; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1993, BIOCHEMISTRY-US, V32, P5978, DOI 10.1021/bi00074a008; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; Hartley RW, 2001, METHOD ENZYMOL, V341, P599, DOI 10.1016/S0076-6879(01)41179-7; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KING DJ, 1994, CANCER RES, V54, P6176; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; Miller K, 2003, J IMMUNOL, V170, P4854, DOI 10.4049/jimmunol.170.9.4854; Nielsen UB, 2000, CANCER RES, V60, P6434; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; RODRIGUES ML, 1993, J IMMUNOL, V151, P6954; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Schreiber G, 2000, METH MOL B, V160, P213; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tahtis K, 2001, CLIN CANCER RES, V7, P1061; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Trejtnar F, 2002, Q J NUCL MED, V46, P181; Waibel R, 1999, NAT BIOTECHNOL, V17, P897, DOI 10.1038/12890; Willuda J, 2001, J BIOL CHEM, V276, P14385, DOI 10.1074/jbc.M011669200; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yazaki Paul J, 2003, Methods Mol Biol, V207, P351; Yazaki PJ, 2001, BIOCONJUGATE CHEM, V12, P220, DOI 10.1021/bc000092h	42	151	189	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1486	1492		10.1038/nbt916	http://dx.doi.org/10.1038/nbt916			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14634668				2022-12-25	WOS:000186845200027
J	Kakiuchi, C; Iwamoto, K; Ishiwata, M; Bundo, M; Kasahara, T; Kusumi, I; Tsujita, T; Okazaki, Y; Nanko, S; Kunugi, H; Sasaki, T; Kato, T				Kakiuchi, C; Iwamoto, K; Ishiwata, M; Bundo, M; Kasahara, T; Kusumi, I; Tsujita, T; Okazaki, Y; Nanko, S; Kunugi, H; Sasaki, T; Kato, T			Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder	NATURE GENETICS			English	Article							ENDOPLASMIC-RETICULUM; ER STRESS; SUSCEPTIBILITY LOCUS; CHROMOSOME-22; ATF6; EXPRESSION; PROTEINS; CORTEX; BINDS; SCAN	The pathophysiology of bipolar disorder is still unclear, although family, twin and linkage studies implicate genetic factors(1). Here we identified XBP1, a pivotal gene in the endoplasmic reticulum ( ER) stress response, as contributing to the genetic risk factor for bipolar disorder. Using DNA microarray analysis of lymphoblastoid cells derived from two pairs of twins discordant with respect to the illness, we found downregulated expression of genes related to ER stress response in both affected twins. A polymorphism (-116C-->G) in the promoter region of XBP1, affecting the putative binding site of XBP1, was significantly more common in Japanese patients ( odds ratio = 4.6) and overtransmitted to affected offspring in trio samples of the NIMH Bipolar Disorder Genetics Initiative. XBP1-dependent transcription activity of the -116G allele was lower than that of the -116C allele, and in the cells with the G allele, induction of XBP1 expression after ER stress was markedly reduced. Valproate, one of three mood stabilizers, rescued the impaired response by inducing ATF6, the gene upstream of XBP1. These results indicate that the -116C--> G polymorphism in XBP1 causes an impairment of its positive feedback system and increases the risk of bipolar disorder.	RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan; Hokkaido Univ, Dept Psychiat, Sapporo, Hokkaido 0608648, Japan; Nagasaki Univ, Dept Psychiat, Nagasaki 8528523, Japan; Mie Univ, Dept Psychiat, Tsu, Mie 5148507, Japan; Teikyo Univ, Sch Med, Dept Psychiat, Itabashi Ku, Tokyo 1738605, Japan; Natl Inst Neurosci, Dept Mental Disorder Res, Kodaira, Tokyo 1878502, Japan; Univ Tokyo, Hlth Serv Ctr, Dept Psychiat, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Hokkaido University; Nagasaki University; Mie University; Teikyo University; National Center for Neurology & Psychiatry - Japan; University of Tokyo	Kato, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.		Kasahara, Takaoki/AAJ-5367-2020; Kato, Tadafumi/J-3583-2014; Kusumi, Ichiro/A-4067-2012; Kakiuchi, Chihiro/AAO-1103-2020; Kunugi, Hiroshi/ABC-5260-2021	Kasahara, Takaoki/0000-0002-0953-5146; Kato, Tadafumi/0000-0001-7856-3952; Kunugi, Hiroshi/0000-0002-7209-3790				BANKS RE, 1990, J AFFECT DISORDERS, V19, P1, DOI 10.1016/0165-0327(90)90002-P; Bown C, 2000, NEUROPSYCHOPHARMACOL, V22, P327, DOI 10.1016/S0893-133X(99)00091-3; Chen B, 2000, BIOL PSYCHIAT, V48, P658, DOI 10.1016/S0006-3223(00)00878-7; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; Edenberg HJ, 1997, AM J MED GENET, V74, P238, DOI 10.1002/(SICI)1096-8628(19970531)74:3<238::AID-AJMG2>3.0.CO;2-M; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Goodwin F, 1990, MANIC DEPRESSIVE ILL; Gray NA, 2003, J CLIN PSYCHIAT, V64, P3; Ikeda A, 2003, PSYCHIAT CLIN NEUROS, V57, P243, DOI 10.1046/j.1440-1819.2003.01112.x; Kato T, 2002, LIFE SCI, V71, P581, DOI 10.1016/S0024-3205(02)01725-3; Kato T, 2001, NEUROSCI RES, V40, P105, DOI 10.1016/S0168-0102(01)00221-8; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kelsoe JR, 2001, P NATL ACAD SCI USA, V98, P585, DOI 10.1073/pnas.011358498; KUSUMI I, 1995, BIOL PSYCHIAT, V37, P553, DOI 10.1016/0006-3223(94)00364-9; Lachman HM, 1997, AM J MED GENET, V74, P121, DOI 10.1002/(SICI)1096-8628(19970418)74:2<121::AID-AJMG2>3.0.CO;2-X; PEREZ J, 1995, AM J PSYCHIAT, V152, P1204; Petronis A, 2001, TRENDS GENET, V17, P142, DOI 10.1016/S0168-9525(00)02213-7; Pritchard JK, 2000, GENETICS, V155, P945; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Wang JF, 2001, INT J NEUROPSYCHOPH, V4, P65, DOI 10.1017/S1461145701002231; Yoon IS, 2001, MOL PSYCHIATR, V6, P678, DOI 10.1038/sj.mp.4000901; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	25	223	234	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					171	175		10.1038/ng1235	http://dx.doi.org/10.1038/ng1235			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12949534				2022-12-25	WOS:000185625300014
J	Ossipova, O; Bardeesy, N; DePinho, RA; Green, JBA				Ossipova, O; Bardeesy, N; DePinho, RA; Green, JBA			LKB1 (XEEK1) regulates Wnt signalling in vertebrate development	NATURE CELL BIOLOGY			English	Article							PEUTZ-JEGHERS-SYNDROME; SERINE-THREONINE KINASE; TUMOR-SUPPRESSOR; CELL POLARITY; GENE; POLYPOSIS; PROTEIN; EMBRYOS; GROWTH; TRANSFORMATION	Germline LKB1/STK11 mutations are associated with the cancer-prone Peutz-Jeghers syndrome (PJS) in humans(1-3), and nullizygosity provokes a poorly understood constellation of developmental perturbations in the mid-gestational mouse(4). To gain a better understanding of the processes regulated by LKB1, we have exploited the experimental merits of the developing Xenopus embryo. Here, specific inhibition of XEEK1, the Xenopus orthologue of LKB1, engendered developmental anomalies - shortened body axis and defective dorsoanterior patterning - associated previously with aberrant Wnt signalling. In line with this, LKB1/XEEK1 cooperates with the Wnt - - catenin signalling in axis induction and modulates the expression of Wnt-responsive genes in both Xenopus embryos and mammalian cells. We establish that LKB1/XEEK1 acts upstream of - catenin in the Wnt - - catenin pathway in vivo. LKB1/XEEK1 regulates glycogen synthase kinase (GSK) 3beta phosphorylation and it is physically associated in vivo with GSK3beta and protein kinase C ( PKC)-zeta, a known GSK3 kinase. These studies show that LKB1/XEEK1 is required for Wnt-beta-catenin signalling in frogs and mammals and provides novel insights into its role in vertebrate developmental patterning and carcinogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Green, JBA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.		Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036345] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 36345] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; COOPER HS, 1998, PATHOLOGY GASTROINTE, P819; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Hung TJ, 1999, DEVELOPMENT, V126, P127; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; Niemann C, 2002, DEVELOPMENT, V129, P95; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Watts JL, 2000, DEVELOPMENT, V127, P1467; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	30	110	117	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					889	894		10.1038/ncb1048	http://dx.doi.org/10.1038/ncb1048			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	12973359				2022-12-25	WOS:000185647400014
J	Zhang, GJ; Safran, M; Wei, WY; Sorensen, E; Lassota, P; Zhelev, N; Neuberg, DS; Shapiro, G; Kaelin, WG				Zhang, GJ; Safran, M; Wei, WY; Sorensen, E; Lassota, P; Zhelev, N; Neuberg, DS; Shapiro, G; Kaelin, WG			Bioluminescent imaging of Cdk2 inhibition in vivo	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITORS; ANAPHASE-PROMOTING COMPLEX; PROTEIN-KINASE; CYCLIN-A; CELLS; PHOSPHORYLATION; ANTAGONISTS; REPORTERS; CANCER; MODEL	Many proteins and pathways of pharmaceutical interest impinge on ubiquitin ligases or their substrates. The cyclin-dependent kinase (Cdk) inhibitor p27, for example, is polyubiquitylated in a cell cycle-dependent manner by a ubiquitin ligase complex containing the F-box protein Skp2. Regulated turnover of p27 is due, at least partly, to its phosphorylation by Cdk2 on threonine 187, which generates a Skp2-binding site. We made a p27-luciferase (p27Luc) fusion protein and show here that its abundance, like that of p27, is regulated by Skp2 in a cell cycle-dependent manner. As predicted, p27Luc levels increased after blocking Cdk2 activity with inhibitory proteins, peptides or small interfering RNA (siRNA). Accumulation of p27Luc in response to Cdk2 inhibitory drugs (flavopiridol and R-roscovitine) was demonstrable in human tumor cells in vivo using noninvasive bioluminescent imaging. In theory, the approach described here could be used to develop bioluminescent reporters for any drug target that directly or indirectly affects the turnover of a ubiquitin ligase substrate.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Cyclacel Ltd James Lindsay Pl, Dundee DD1 5JJ, Scotland; Univ Abertay, Sch Contemporary Sci, SIMBIOS, CMCBR, Dundee DD1 1HG, Scotland; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Novartis; University of Abertay Dundee; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.	william_kaelin@dfci.harvard.edu	Zhelev, Nikolai Z/A-8589-2012; Zhang, Guo-Jun/H-3890-2015	Zhelev, Nikolai Z/0000-0002-5189-3975; Zhang, Guo-Jun/0000-0001-5182-5887				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOLLINGSHEAD MG, 1995, LIFE SCI, V57, P131, DOI 10.1016/0024-3205(95)00254-4; JENKINS TM, 1990, BIOCHEM SOC T, V18, P463, DOI 10.1042/bst0180463; KENDALL J M, 1992, Biochemical Society Transactions, V20, p144S; KREK W, 1995, METHOD ENZYMOL, V254, P114; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; McInnes Campbell, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P57, DOI 10.2174/1568011033353506; Mendoza N, 2003, CANCER RES, V63, P1020; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SALANEWBY GB, 1991, BIOCHEM J, V279, P727, DOI 10.1042/bj2790727; Senderowicz AM, 2002, HEMATOL ONCOL CLIN N, V16, P1229, DOI 10.1016/S0889-8588(02)00049-7; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Toogood PL, 2001, MED RES REV, V21, P487, DOI 10.1002/med.1021; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x	30	76	85	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					643	648		10.1038/nm1047	http://dx.doi.org/10.1038/nm1047			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15122251				2022-12-25	WOS:000221759600031
J	Su, RC; Brown, KE; Saaber, S; Fisher, AG; Merkenschlager, M; Smale, ST				Su, RC; Brown, KE; Saaber, S; Fisher, AG; Merkenschlager, M; Smale, ST			Dynamic assembly of silent chromatin during thymocyte maturation	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; NUCLEAR-ORGANIZATION; GENE-EXPRESSION; METHYLATION; HISTONE; HETEROCHROMATIN; PROTEINS; TRANSCRIPTION; ESTABLISHMENT; COMPETITION	Considerable knowledge has been gained from temporal analyses of molecular events culminating in gene activation(1), but technical hurdles have hindered comparable studies of gene silencing. Here we describe the temporal assembly of silent chromatin at the mouse terminal transferase gene (Dntt), which is silenced and repositioned to pericentromeric heterochromatin during thymocyte maturation(2). Silencing was nucleated at the Dntt promoter by the ordered deacetylation of histone H3 at Lys9 (H3-Lys9), loss of methylation at H3-Lys4 and acquisition of methylation at H3-Lys9, followed by bidirectional spreading of each event. Deacetylation at H3-Lys9 coincided with pericentromeric repositioning, and neither of these early events required de novo protein synthesis. CpG methylation increased primarily in mature T cells that had left the thymus. A transformed thymocyte line supported reversible inactivation of Dntt without repositioning. In these cells, histone modification changes were nucleated at the promoter but did not spread. These results provide a foundation for elucidating the mechanisms of silent chromatin assembly during development.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Imperial College London	Smale, ST (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	smale@mednet.ucla.edu		Merkenschlager, Matthias/0000-0003-2889-3288	Medical Research Council [MC_U120081295] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fisher AG, 2002, CURR OPIN GENET DEV, V12, P193, DOI 10.1016/S0959-437X(02)00286-1; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; GROVES T, 1995, J IMMUNOL, V154, P5011; GROVES T, 1997, J IMMUNOL, V158, P67; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	24	117	120	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					502	506		10.1038/ng1351	http://dx.doi.org/10.1038/ng1351			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15098035	Bronze			2022-12-25	WOS:000221183000024
J	Helgadottir, A; Manolescu, A; Thorleifsson, G; Gretarsdottir, S; Jonsdottir, H; Thorsteinsdottir, U; Samani, NJ; Gudmundsson, G; Grant, SFA; Thorgeirsson, G; Sveinbjornsdottir, S; Valdimarsson, EM; Matthiasson, SE; Johannsson, H; Gudmundsdottir, O; Gurney, ME; Sainz, J; Thorhallsdottir, M; Andresdottir, M; Frigge, ML; Topol, EJ; Kong, A; Gudnason, V; Hakonarson, H; Gulcher, JR; Stefansson, K				Helgadottir, A; Manolescu, A; Thorleifsson, G; Gretarsdottir, S; Jonsdottir, H; Thorsteinsdottir, U; Samani, NJ; Gudmundsson, G; Grant, SFA; Thorgeirsson, G; Sveinbjornsdottir, S; Valdimarsson, EM; Matthiasson, SE; Johannsson, H; Gudmundsdottir, O; Gurney, ME; Sainz, J; Thorhallsdottir, M; Andresdottir, M; Frigge, ML; Topol, EJ; Kong, A; Gudnason, V; Hakonarson, H; Gulcher, JR; Stefansson, K			The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; CORONARY; SUSCEPTIBILITY; LEUKOTRIENES; DISEASE; POLYMORPHISMS; LOCALIZATION; SUGGESTS; LOCUS; CELLS	We mapped a gene predisposing to myocardial infarction to a locus on chromosome 13q12-13. A four-marker single-nucleotide polymorphism (SNP) haplotype in this locus spanning the gene ALOX5AP encoding 5-lipoxygenase activating protein (FLAP) is associated with a two times greater risk of myocardial infarction in Iceland. This haplotype also confers almost two times greater risk of stroke. Another ALOX5AP haplotype is associated with myocardial infarction in individuals from the UK. Stimulated neutrophils from individuals with myocardial infarction produce more leukotriene B4, a key product in the 5-lipoxygenase pathway, than do neutrophils from controls, and this difference is largely attributed to cells from males who carry the at-risk haplotype. We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by increasing leukotriene production and inflammation in the arterial wall.	deCODE Genet, Reykjavik, Iceland; Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England; Natl Univ Hosp Reykjavik, Reykjavik, Iceland; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Iceland Heart Assoc, Reykjavik, Iceland	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Landspitali National University Hospital; Cleveland Clinic Foundation; Icelandic Heart Association	Stefansson, K (corresponding author), deCODE Genet, Sturlugata 8, Reykjavik, Iceland.	kstefans@decode.is	Gudnason, Vilmundur/K-6885-2015; Stefansson, Kari/AAE-7187-2019; Manolescu, Andrei/G-4565-2014; Gudnason, Vilmundur/AAE-7126-2019	Gudnason, Vilmundur/0000-0001-5696-0084; Manolescu, Andrei/0000-0002-0713-4664; Gudnason, Vilmundur/0000-0001-5696-0084; Topol, Eric/0000-0002-1478-4729; Grant, Struan/0000-0003-2025-5302				Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; *AM HEART ASS, 2002, HEART DIS STROK STAT; [Anonymous], 1979, Circulation, V59, P607; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827; Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32; BURKE JA, 1982, J PHARMACOL EXP THER, V221, P235; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; DAHINDEN CA, 1985, P NATL ACAD SCI USA, V82, P6632, DOI 10.1073/pnas.82.19.6632; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Francke S, 2001, HUM MOL GENET, V10, P2751, DOI 10.1093/hmg/10.24.2751; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Gudmundsson G, 2002, AM J HUM GENET, V70, P586, DOI 10.1086/339251; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Harrap SB, 2002, ARTERIOSCL THROM VAS, V22, P874, DOI 10.1161/01.ATV.0000016258.40568.F1; HILL WG, 1968, GENETICS, V60, P615; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Koshino T, 1999, Mol Cell Biol Res Commun, V2, P32, DOI 10.1006/mcbr.1999.0147; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LEWONTIN RC, 1964, GENETICS, V50, P757; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; NICOLAE D, 1999, ALLELE SHARING MODEL; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Pajukanta P, 2000, AM J HUM GENET, V67, P1481, DOI 10.1086/316902; POOLE JCF, 1958, J PATHOL BACTERIOL, V75, P245, DOI 10.1002/path.1700750202; ROTH DM, 1983, PROSTAGLANDINS, V26, P573, DOI 10.1016/0090-6980(83)90195-8; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Steeds R, 1998, THROMB HAEMOSTASIS, V79, P980; STRATFORD N, 1986, ATHEROSCLEROSIS, V59, P271, DOI 10.1016/0021-9150(86)90122-X; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; WARGOVICH T, 1985, J AM COLL CARDIOL, V6, P1047, DOI 10.1016/S0735-1097(85)80307-7; WHITTEMORE AS, 1994, BIOMETRICS, V50, P118, DOI 10.2307/2533202; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	50	745	821	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					233	239		10.1038/ng1311	http://dx.doi.org/10.1038/ng1311			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14770184	Bronze			2022-12-25	WOS:000189250400011
J	Goggel, R; Winoto-Morbach, S; Vielhaber, G; Imai, Y; Lindner, K; Brade, L; Brade, H; Ehlers, S; Slutsky, AS; Schutze, S; Gulbins, E; Uhlig, S				Goggel, R; Winoto-Morbach, S; Vielhaber, G; Imai, Y; Lindner, K; Brade, L; Brade, H; Ehlers, S; Slutsky, AS; Schutze, S; Gulbins, E; Uhlig, S			PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide	NATURE MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; RESPIRATORY-DISTRESS-SYNDROME; NECROSIS FACTOR-ALPHA; PHOSPHOLIPASE-C; LUNG INJURY; SECRETORY SPHINGOMYELINASE; FACTOR ACETYLHYDROLASE; ENDOTHELIAL APOPTOSIS; CELLS; METABOLISM	Platelet-activating factor (PAF) induces pulmonary edema and has a key role in acute lung injury (ALI). Here we show that PAF induces pulmonary edema through two mechanisms: acid sphingomyelinase (ASM)-dependent production of ceramide, and activation of the cyclooxygenase pathway. Agents that interfere with PAF-induced ceramide synthesis, such as steroids or the xanthogenate D609, attenuate pulmonary edema formation induced by PAF, endotoxin or acid instillation. Our results identify acid sphingomyelinase and ceramide as possible therapeutic targets in acute lung injury.	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Essen Gesamthsch, D-45122 Essen, Germany	Forschungszentrum Borstel; University of Kiel; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Duisburg Essen	Uhlig, S (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany.	suhlig@fz-borstel.de	Gulbins, Erich/L-6989-2014; Slutsky, Arthur/M-3325-2019; Imai, Yumiko/GXW-1144-2022; Uhlig, Stefan/A-7290-2014; Schütze, Stefan/C-8596-2011; Slutsky, Arthur S/A-6013-2008; Ehlers, Stefan/B-4075-2010	Gulbins, Erich/0000-0002-3117-1342; Uhlig, Stefan/0000-0003-2332-1280; Slutsky, Arthur S/0000-0002-6063-3876; 				ALBOUZ S, 1986, LIFE SCI, V38, P357, DOI 10.1016/0024-3205(86)90083-4; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BESSIN P, 1983, EUR J PHARMACOL, V86, P403, DOI 10.1016/0014-2999(83)90190-5; Bligh E.G., 1959, CAN J BIOCHEM PHYSIO, V37, P912; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; BRADE L, 1993, INFECT IMMUN, V61, P4514, DOI 10.1128/IAI.61.10.4514-4517.1993; Carter MB, 1996, J SURG RES, V60, P403, DOI 10.1006/jsre.1996.0066; Chae HJ, 2000, ENDOCRINOLOGY, V141, P2904, DOI 10.1210/en.141.8.2904; CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; DODAM JR, 1994, EXP LUNG RES, V20, P131, DOI 10.3109/01902149409064378; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; Falk S, 1999, AM J RESP CRIT CARE, V160, P1734, DOI 10.1164/ajrccm.160.5.9902033; Goggel R, 2002, AM J RESP CRIT CARE, V166, P657, DOI 10.1164/rccm.20011.0710C; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HAYTER H, 1999, LIPID 2 MESSENGERS, P17; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; RUSTENBECK I, 1990, J CHROMATOGR-BIOMED, V525, P85, DOI 10.1016/S0378-4347(00)83381-2; Schuster DP, 2003, CRIT CARE MED, V31, P1612, DOI 10.1097/01.CCM.0000063267.79824.DB; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Taylor A, 1997, LUNG SCI FDN, P1549; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TSCHUGGUEL W, 1995, PFLUG ARCH EUR J PHY, V430, P145, DOI 10.1007/BF00373850; UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7; UHLIG S, 1994, J APPL PHYSIOL, V77, P262, DOI 10.1152/jappl.1994.77.1.262; Uhlig S, 1998, METHODS PULMONARY RE, P29; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Vielhaber G, 2001, J INVEST DERMATOL, V117, P1126, DOI 10.1046/j.0022-202x.2001.01527.x; Vielhaber G, 2001, GLYCOBIOLOGY, V11, P451, DOI 10.1093/glycob/11.6.451; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5	45	233	245	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					155	160		10.1038/nm977	http://dx.doi.org/10.1038/nm977			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704790				2022-12-25	WOS:000188719600034
J	Jeffreys, AJ; May, CA				Jeffreys, AJ; May, CA			Intense and highly localized gene conversion activity in human meiotic crossover hot spots	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; HAPLOTYPE BLOCKS; HUMAN GENOME; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; RECOMBINATION; LOCUS; MUTATION; CHROMOSOMES; DIVERSITY	Meiotic gene conversion has an important role in allele diversification and in the homogenization of gene and other repeat DNA sequence families(1-5), sometimes with pathological consequences(6,7). But little is known about the dynamics of gene conversion in humans and its relationship to meiotic crossover. We therefore developed screening and selection methods to characterize sperm conversions in two meiotic crossover hot spots in the major histocompatibility complex (MHC)(8) and one in the sex chromosomal pseudoautosomal pairing region PAR1 (ref. 9). All three hot spots are active in gene conversion and crossover. Conversion tracts are short and define a steep bidirectional gradient centered at the peak of crossover activity, consistent with crossovers and conversions being produced by the same recombination-initiating events. These initiations seem to be spread over a narrow zone, rather than occurring at a single site, and seem preferentially to yield conversions rather than crossovers. Crossover breakpoints are more broadly diffused than conversion breakpoints, suggesting either differences between conversion and crossover processing after initiation or the existence of a quality control checkpoint at which short interactions between homologous chromosomes are preferentially aborted as conversions.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Leicester	Jeffreys, AJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	ajj@le.ac.uk		May, Celia/0000-0001-8541-2458				Ardlie K, 2001, AM J HUM GENET, V69, P582, DOI 10.1086/323251; BORTS RH, 1989, GENETICS, V123, P69; CLARKE SH, 1982, P NATL ACAD SCI-BIOL, V79, P3280, DOI 10.1073/pnas.79.10.3280; COLLIER S, 1993, NAT GENET, V3, P260, DOI 10.1038/ng0393-260; ERLICH HA, 1991, IMMUNOL TODAY, V12, P411, DOI 10.1016/0167-5699(91)90143-H; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Guillon H, 2002, NAT GENET, V32, P296, DOI 10.1038/ng990; HILLIKER AJ, 1994, GENETICS, V137, P1019; HUANG MM, 1995, HUM MUTAT, V6, P303, DOI 10.1002/humu.1380060404; Jaatinen T, 2002, J IMMUNOL, V168, P5652, DOI 10.4049/jimmunol.168.11.5652; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jeffreys AJ, 2002, NAT GENET, V31, P267, DOI 10.1038/ng910; Jeffreys AJ, 2003, GENOME RES, V13, P2316, DOI 10.1101/gr.1214603; JINKSROBERTSON S, 1985, P NATL ACAD SCI USA, V82, P3350, DOI 10.1073/pnas.82.10.3350; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Koppens PFJ, 2002, HUM MOL GENET, V11, P2581, DOI 10.1093/hmg/11.21.2581; Losekoot M, 1997, J MED GENET, V34, P924, DOI 10.1136/jmg.34.11.924; May CA, 2002, NAT GENET, V31, P272, DOI 10.1038/ng918; Ogasawara K, 2001, IMMUNOGENETICS, V53, P190, DOI 10.1007/s002510100315; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; POWERS PA, 1986, GENETICS, V112, P343; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; SCHULTES NP, 1990, GENETICS, V126, P813; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TUSIELUNA MT, 1995, P NATL ACAD SCI USA, V92, P10796, DOI 10.1073/pnas.92.23.10796; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398; Watnick TJ, 1998, HUM MOL GENET, V7, P1239, DOI 10.1093/hmg/7.8.1239; ZANGENBERG G, 1995, NAT GENET, V10, P407, DOI 10.1038/ng0895-407	30	224	231	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2004	36	2					151	156		10.1038/ng1287	http://dx.doi.org/10.1038/ng1287			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14704667	Bronze			2022-12-25	WOS:000188542700016
J	Hisaeda, H; Maekawa, Y; Iwakawa, D; Okada, H; Himeno, K; Kishihara, K; Tsukumo, S; Yasutomo, K				Hisaeda, H; Maekawa, Y; Iwakawa, D; Okada, H; Himeno, K; Kishihara, K; Tsukumo, S; Yasutomo, K			Escape of malaria parasites from host immunity requires CD4(+)CD25(+) regulatory T cells	NATURE MEDICINE			English	Article								Infection with malaria parasites frequently induces total immune suppression, which makes it difficult for the host to maintain long-lasting immunity. Here we show that depletion of CD4(+)CD25(+) regulatory T cells (T-reg) protects mice from death when infected with a lethal strain of Plasmodium yoelii, and that this protection is associated with an increased T-cell responsiveness against parasite-derived antigens. These results suggest that activation of T-reg cells contributes to immune suppression during malaria infection, and helps malaria parasites to escape from host immune responses.	Univ Tokushima, Sch Med, Dept Immunol & Parasitol, Tokushima 7708503, Japan; Kyushu Univ, Fac Med Sci, Dept Parasitol, Fukuoka 8128582, Japan	Tokushima University; Kyushu University	Yasutomo, K (corresponding author), Univ Tokushima, Sch Med, Dept Immunol & Parasitol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	yasutomo@basic.med.tokushima-u.ac.jp		Yasutomo, Koji/0000-0003-0411-2037; Maekawa, Yoichi/0000-0002-3879-5713				BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; HO M, 1988, J IMMUNOL, V141, P2755; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; VIENS P, 1974, AM J TROP MED HYG, V23, P846, DOI 10.4269/ajtmh.1974.23.846; WILLIAMSON WA, 1978, LANCET, V1, P1328; YOELI M, 1975, ANN TROP MED PARASIT, V69, P173, DOI 10.1080/00034983.1975.11686998	15	277	310	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					29	30		10.1038/nm975	http://dx.doi.org/10.1038/nm975			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702631				2022-12-25	WOS:000187743600034
J	Oshima, K; Kakizawa, S; Nishigawa, H; Jung, HY; Wei, W; Suzuki, S; Arashida, R; Nakata, D; Miyata, S; Ugaki, M; Namba, S				Oshima, K; Kakizawa, S; Nishigawa, H; Jung, HY; Wei, W; Suzuki, S; Arashida, R; Nakata, D; Miyata, S; Ugaki, M; Namba, S			Reductive evolution suggested from the complete genome sequence of a plant-pathogenic phytoplasma	NATURE GENETICS			English	Article							DIVERSITY	The minimal gene set essential for life has long been sought. We report the 860-kb genome of the obligate intracellular plant pathogen phytoplasma (Candidatus Phytoplasma asteris, OY strain). The phytoplasma genome encodes even fewer metabolic functions than do mycoplasma genomes. It lacks the pentose phosphate cycle and, more unexpectedly, ATP-synthase subunits, which are thought to be essential for life. This may be the result of reductive evolution as a consequence of life as an intracellular parasite in a nutrient-rich environment.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Namba, S (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, 202 Biosci Bldg,5-1-5 Kashiwanoha, Chiba 2778562, Japan.		kakizawa, shigeyuki/L-8901-2018; Suzuki, Shiho/Z-4458-2019	kakizawa, shigeyuki/0000-0003-3885-4434; Oshima, Kenro/0000-0001-7327-4481; Suzuki, Shiho/0000-0003-3168-1729; WEI, WEI/0000-0003-3561-913X				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; DOI Y., 1967, Annals of the Phytopathological Society of Japan, V33, P259; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Lee IM, 2000, ANNU REV MICROBIOL, V54, P221, DOI 10.1146/annurev.micro.54.1.221; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NAMBA S, 1993, INT J SYST BACTERIOL, V43, P461, DOI 10.1099/00207713-43-3-461; Nishigawa H, 2002, MICROBIOL-SGM, V148, P1389, DOI 10.1099/00221287-148-5-1389; Oshima K, 2001, PHYTOPATHOLOGY, V91, P1024, DOI 10.1094/PHYTO.2001.91.11.1024; Oshima Kenro, 2002, Journal of General Plant Pathology, V68, P225, DOI 10.1007/PL00013081; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; SANTANA M, 1994, J BACTERIOL, V176, P6802, DOI 10.1128/JB.176.22.6802-6811.1994; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Van Sluys MA, 2002, ANNU REV PHYTOPATHOL, V40, P169, DOI 10.1146/annurev.phyto.40.030402.090559; Wernegreen JJ, 2002, NAT REV GENET, V3, P850, DOI 10.1038/nrg931	15	321	486	0	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					27	29		10.1038/ng1277	http://dx.doi.org/10.1038/ng1277			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14661021	Bronze			2022-12-25	WOS:000187666800010
J	Sheen, VL; Ganesh, VS; Topcu, M; Sebire, G; Bodell, A; Hill, RS; Grant, PE; Shugart, YY; Imitola, J; Khoury, SJ; Guerrini, R; Walsh, CA				Sheen, VL; Ganesh, VS; Topcu, M; Sebire, G; Bodell, A; Hill, RS; Grant, PE; Shugart, YY; Imitola, J; Khoury, SJ; Guerrini, R; Walsh, CA			Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex	NATURE GENETICS			English	Article							NUCLEOTIDE-EXCHANGE PROTEINS; ADP-RIBOSYLATION FACTORS; TRANS-GOLGI NETWORK; BREFELDIN-A; PERIVENTRICULAR HETEROTOPIA; NEURONAL MIGRATION; CORTICAL SIZE; CELL-ADHESION; GROWTH; BIG2	Disruption of human neural precursor proliferation can give rise to a small brain ( microcephaly), and failure of neurons to migrate properly can lead to an abnormal arrest of cerebral cortical neurons in proliferative zones near the lateral ventricles (periventricular heterotopia). Here we show that an autosomal recessive condition characterized by microcephaly and periventricular heterotopia 1 maps to chromosome 20 and is caused by mutations in the gene ADP-ribosylation factor guanine nucleotide-exchange factor-2 (ARFGEF2). By northern-blot analysis, we found that mouse Arfgef2 mRNA levels are highest during embryonic periods of ongoing neuronal proliferation and migration, and by in situ hybridization, we found that the mRNA is widely distributed throughout the embryonic central nervous system (CNS). ARFGEF2 encodes the large (>200 kDa) brefeldin A (BFA)-inhibited GEF2 protein (BIG2), which is required for vesicle and membrane trafficking from the trans-Golgi network (TGN). Inhibition of BIG2 by BFA, or by a dominant negative ARFGEF2 cDNA, decreases cell proliferation in vitro, suggesting a cell-autonomous regulation of neural expansion. Inhibition of BIG2 also disturbed the intracellular localization of such molecules as E-cadherin and beta-catenin by preventing their transport from the Golgi apparatus to the cell surface. Our findings show that vesicle trafficking is an important regulator of proliferation and migration during human cerebral cortical development.	Harvard Univ, Sch Med, Div Neurogenet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurol,Beth Israel Diaconess Med Ctr, Boston, MA 02115 USA; Hacettepe Univ, Fac Med, Ihsan Dogramaci Childrens Hosp, Dept Pediat Neurol, TR-06100 Ankara, Turkey; Univ Sherbrooke, CHU Fleurimont, Dept Pediat Neurol, Sherbrooke, PQ J1H 5N4, Canada; Harvard Univ, Sch Med, Athinoula A Marinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Pediat Neuroradiol, Boston, MA 02114 USA; Johns Hopkins Med Sch, Dept Pediat Epidemiol, Baltimore, MD 21205 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Dept Neurol, Boston, MA 02115 USA; Univ Pisa, Div Child Neurol & Psychiat, Epilepsy Neurophysiol & Neurogenet Unit, I-56018 Pisa, Italy; IRCCS Fdn Stella Maris, I-56018 Pisa, Italy; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Hacettepe University; University of Sherbrooke; Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pisa; IRCCS Fondazione Stella Maris; Harvard University; Harvard Medical School	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Div Neurogenet, Boston, MA 02115 USA.			khoury, samia/0000-0003-3198-6063; Walsh, Christopher/0000-0002-0156-2238; Grant, Patricia/0000-0003-1005-4013; Guerrini, Renzo/0000-0002-7272-7079; YAO, YIN/0000-0003-3053-8429	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH063886] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH063886] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berger UV, 2001, J COMP NEUROL, V433, P101, DOI 10.1002/cne.1128; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Bonifacino JS, 2003, CELL, V112, P141, DOI 10.1016/S0092-8674(03)00038-2; Borghesani PR, 2002, DEVELOPMENT, V129, P1435; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Jareb M, 1997, J NEUROSCI, V17, P8955; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Pacheco-Rodriguez G, 2002, METHOD ENZYMOL, V345, P397; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Poon PP, 2001, J CELL BIOL, V155, P1239, DOI 10.1083/jcb.200108075; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roberts E, 2002, J MED GENET, V39, P718, DOI 10.1136/jmg.39.10.718; Ruthel G, 1999, J NEUROBIOL, V39, P97, DOI 10.1002/(SICI)1097-4695(199904)39:1<97::AID-NEU8>3.0.CO;2-Z; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHEEN VL, 1994, EXP NEUROL, V130, P67, DOI 10.1006/exnr.1994.1186; Sheen VL, 2003, NEUROLOGY, V60, P1108, DOI 10.1212/01.WNL.0000055898.00349.02; Sheen VL, 2002, HUM MOL GENET, V11, P2845, DOI 10.1093/hmg/11.23.2845; Sheen VL, 1999, EXP NEUROL, V158, P47, DOI 10.1006/exnr.1999.7104; Sheen Volney L, 2003, Curr Neurol Neurosci Rep, V3, P433, DOI 10.1007/s11910-003-0027-8; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Shinotsuka C, 2002, BIOCHEM BIOPH RES CO, V294, P254, DOI 10.1016/S0006-291X(02)00456-4; Shinotsuka C, 2002, J BIOL CHEM, V277, P9468, DOI 10.1074/jbc.M112427200; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	30	261	270	0	15	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					69	76		10.1038/ng1276	http://dx.doi.org/10.1038/ng1276			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14647276	Bronze			2022-12-25	WOS:000187666800016
J	Sato, M; Ueda, Y; Takagi, T; Umezawa, Y				Sato, M; Ueda, Y; Takagi, T; Umezawa, Y			Production of PtdInsP(3) at endomembranes is triggered by receptor endocytosis	NATURE CELL BIOLOGY			English	Letter							PLECKSTRIN HOMOLOGY DOMAIN; PLASMA-MEMBRANE; FLUORESCENT INDICATORS; PHOSPHOINOSITIDE 3-KINASE; STIMULATED TRANSLOCATION; SIGNAL-TRANSDUCTION; KINASE-B; PROTEIN; LOCALIZATION; DEPHOSPHORYLATION	Phosphatidylinositol-3,4,5-trisphosphate (PtdInsP(3)) regulates diverse cellular functions, including cell proliferation and apoptosis, and has roles in the progression of diabetes and cancer. However, little is known about its production. Here, we describe fluorescent indicators for PtdInsP(3) that allow a spatio-temporal examination of PtdInsP(3) production in single living cells. After ligand stimulation, PtdInsP(3) levels increased to a larger extent at the endomembranes (that is, the endoplasmic reticulum and the Golgi) than at the plasma membrane. This increase was found to originate from in situ production at the endomembranes, a process stimulated directly by receptor tyrosine kinases endocytosed from the plasma membrane to the endomembranes. The demonstration of PtdInsP(3) production through receptor endocytosis addresses a long-standing question about how signalling pathways downstream of PtdInsP(3) are activated at intracellular compartments remote from the plasma membrane.	Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Umezawa, Y (corresponding author), Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan.	umezawa@chem.s.u-tokyo.ac.jp	Sato, Moritoshi/O-2735-2018; Ueda, Yoshibumi/AHA-4956-2022	Sato, Moritoshi/0000-0002-3095-5831; Ueda, Yoshibumi/0000-0003-1500-3469				Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Sato M, 2000, ANAL CHEM, V72, P5918, DOI 10.1021/ac0006167; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	30	147	152	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					1016	1022		10.1038/ncb1054	http://dx.doi.org/10.1038/ncb1054			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14528311				2022-12-25	WOS:000186273100019
J	Sheehy, AM; Gaddis, NC; Malim, MH				Sheehy, AM; Gaddis, NC; Malim, MH			The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN; INFECTIVITY; PATHWAY; TSG101; DNA; CD4; TRANSCRIPTION; DEGRADATION; EXPRESSION	The human protein apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G), also known as CEM-15, mediates a newly described form of innate resistance to retroviral infection by catalyzing the deamination of deoxycytidine to deoxyuridine in viral cDNA replication intermediates. Because DNA deamination takes place after virus entry into target cells, APOBEC3G function is dependent on its association with the viral nucleoprotein complexes that synthesize cDNA and must therefore be incorporated into virions as they assemble in infected cells. Here we show that the HIV-1 virion infectivity factor (Vif) protein protects the virus from APOBEC3G-mediated inactivation by preventing its incorporation into progeny virions, thus allowing the ensuing infection to proceed without DNA deamination. In addition to helping exclude APOBEC3G from nascent virions, Vif also removes APOBEC3G from virus-producing cells by inducing its ubiquitination and subsequent degradation by the proteasome. Our findings indicate that pharmacologic strategies aimed at stabilizing APOBEC3G in HIV-1 infected cells should be explored as potential HIV/AIDS therapeutics.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Infect Dis, London SE1 9RT, England; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of London; King's College London; University of Pennsylvania	Malim, MH (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Infect Dis, London SE1 9RT, England.	michael.malim@kcl.ac.uk	Gaddis, Nathan/GXG-6447-2022; Gaddis, Nathan/GXG-6395-2022	Malim, Michael/0000-0002-7699-2064; Gaddis, Nathan/0000-0001-5205-7138				Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Levesque K, 2003, J BIOL CHEM, V278, P28346, DOI 10.1074/jbc.M300327200; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	25	768	789	0	26	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1404	1407		10.1038/nm945	http://dx.doi.org/10.1038/nm945			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528300				2022-12-25	WOS:000186319700031
J	Chaudhuri, SK; Lovley, DR				Chaudhuri, SK; Lovley, DR			Electricity generation by direct oxidation of glucose in mediatorless microbial fuel cells	NATURE BIOTECHNOLOGY			English	Article							BIOFUEL CELL; REDUCTION; BIOMASS; ENERGY; BIOTECHNOLOGY; PERFORMANCE; ELECTRODES; METABOLISM; BACTERIUM; SEDIMENTS	Abundant energy, stored primarily in the form of carbohydrates, can be found in waste biomass from agricultural, municipal and industrial sources as well as in dedicated energy crops, such as corn and other grains(1-4). Potential strategies for deriving useful forms of energy from carbohydrates include production of ethanol(4-6) and conversion to hydrogen(7-10), but these approaches face technical and economic hurdles. An alternative strategy is direct conversion of sugars to electrical power. Existing transition metal-catalyzed fuel cells cannot be used to generate electric power from carbohydrates(11). Alternatively, biofuel cells in which whole cells or isolated redox enzymes catalyze the oxidation of the sugar have been developed(12-19), but their applicability has been limited by several factors, including (i) the need to add electron-shuttling compounds that mediate electron transfer from the cell to the anode, (ii) incomplete oxidation of the sugars and (iii) lack of long-term stability of the fuel cells. Here we report on a novel microorganism, Rhodoferax ferrireducens, that can oxidize glucose to CO2 and quantitatively transfer electrons to graphite electrodes without the need for an electron-shuttling mediator. Growth is supported by energy derived from the electron transfer process itself and results in stable, long-term power production.	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							ALLEN RM, 1993, APPL BIOCHEM BIOTECH, V39, P27, DOI 10.1007/BF02918975; Aurbach D, 2002, J ELECTROCHEM SOC, V149, pA1267, DOI 10.1149/1.1502684; Bjerre AB, 1996, BIOTECHNOL BIOENG, V49, P568, DOI 10.1002/(SICI)1097-0290(19960305)49:5<568::AID-BIT10>3.3.CO;2-4; Bond DR, 2002, SCIENCE, V295, P483, DOI 10.1126/science.1066771; Bond DR, 2003, APPL ENVIRON MICROB, V69, P1548, DOI 10.1128/AEM.69.3.1548-1555.2003; Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009; Czernik S, 2002, IND ENG CHEM RES, V41, P4209, DOI 10.1021/ie020107q; DELANEY GM, 1984, J CHEM TECH BIOT B, V34, P13; DIPARDO J, 2003, EIA FORECASTS   0913; Finneran KT, 2003, INT J SYST EVOL MICR, V53, P669, DOI 10.1099/ijs.0.02298-0; Hao XH, 2003, INT J HYDROGEN ENERG, V28, P55, DOI 10.1016/S0360-3199(02)00056-3; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; KATZ E, 2003, HDB FUEL CELLS FUNDA, V1, P355; Kim KH, 2002, BIOTECHNOL PROGR, V18, P489, DOI 10.1021/bp025503i; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; Mano N, 2003, J AM CHEM SOC, V125, P6588, DOI 10.1021/ja0346328; Mano N, 2002, J AM CHEM SOC, V124, P12962, DOI 10.1021/ja028514g; Martin C, 2002, ENZYME MICROB TECH, V31, P274, DOI 10.1016/S0141-0229(02)00112-6; Park DH, 2003, BIOTECHNOL BIOENG, V81, P348, DOI 10.1002/bit.10501; Park DH, 2000, APPL ENVIRON MICROB, V66, P1292, DOI 10.1128/AEM.66.4.1292-1297.2000; Park HS, 2001, ANAEROBE, V7, P297, DOI 10.1006/anae.2001.0399; ROLLER SD, 1984, J CHEM TECH BIOT B, V34, P3; Sheehan J, 1999, BIOTECHNOL PROGR, V15, P817, DOI 10.1021/bp990110d; TAYHAS G, 1994, ENZYMATIC CONVERSION, P271; Tender LM, 2002, NAT BIOTECHNOL, V20, P821, DOI 10.1038/nbt716; THURSTON CF, 1985, J GEN MICROBIOL, V131, P1393; van Wyk JPH, 2001, TRENDS BIOTECHNOL, V19, P172, DOI 10.1016/S0167-7799(01)01601-8; Woodward J, 2000, NATURE, V405, P1014, DOI 10.1038/35016633; Yamane H, 2002, J ELECTROCHEM SOC, V149, pA1514, DOI 10.1149/1.1515278	30	1074	1203	18	810	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1229	1232		10.1038/nbt867	http://dx.doi.org/10.1038/nbt867			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	12960964				2022-12-25	WOS:000185647200036
J	Jazwinska, A; Ribeiro, C; Affolter, M				Jazwinska, A; Ribeiro, C; Affolter, M			Epithelial tube morphogenesis during Drosophila tracheal development requires Piopio, a luminal ZP protein	NATURE CELL BIOLOGY			English	Article							CELLS; GFP; GENE; ARCHITECTURE; EMBRYOS; DOMAIN	The formation of branched epithelial networks is fundamental to the development of many organs, such as the lung, the kidney or the vasculature. Little is known about the mechanisms that control cell rearrangements during tubulogenesis and regulate the size of individual tubes. Recent studies indicate that whereas the basal surface of tube cells interacts with the surrounding tissues and helps to shape the ramification pattern of tubular organs, the apical surface has an important role in the regulation of tube diameter and tube growth. Here we report that two proteins, Piopio (Pio) and Dumpy (Dp), containing a zona pellucida (ZP) domain are essential for the generation of the interconnected tracheal network in Drosophila melanogaster. Pio is secreted apically, accumulates in the tracheal lumen and possibly interacts with Dp through the ZP domains. In the absence of Pio and Dp, multicellular tubes do not rearrange through cell elongation and cell intercalation to form narrow tubes with autocellular junctions; instead they are transformed into multicellular cysts, which leads to a severe disruption of the branched pattern. We propose that an extracellular matrix containing Pio and Dp provides a structural network in the luminal space, around which cell rearrangements can take place in an ordered fashion without losing interconnections. Our results suggest that a similar structural role might be attributed to other ZP-domain proteins in the formation of different branched organs.	Univ Basel, Biozentrum, Abt Zellbiol, CH-4056 Basel, Switzerland	University of Basel	Affolter, M (corresponding author), Univ Basel, Biozentrum, Abt Zellbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Markus.Affolter@unibas.ch	Jazwinska, Anna/M-8705-2016	Jazwinska, Anna/0000-0003-3881-9284; Ribeiro, Carlos/0000-0002-9542-7335; Affolter, Markus/0000-0002-5171-0016				AFFOLTER M, 1994, DEVELOPMENT, V120, P743; Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BRAND A, 1995, TRENDS GENET, V11, P324, DOI 10.1016/S0168-9525(00)89091-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buechner M, 2002, TRENDS CELL BIOL, V12, P479, DOI 10.1016/S0962-8924(02)02364-4; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Lecuit T, 2003, NAT CELL BIOL, V5, P103, DOI 10.1038/ncb0203-103; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Myat MM, 2002, CELL, V111, P879, DOI 10.1016/S0092-8674(02)01140-6; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Oda H, 1999, DEV GENES EVOL, V209, P218, DOI 10.1007/s004270050246; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Prout M, 1997, GENETICS, V146, P275; Ribeiro C, 2002, DEV CELL, V2, P677, DOI 10.1016/S1534-5807(02)00171-5; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Uv A, 2003, TRENDS CELL BIOL, V13, P301, DOI 10.1016/S0962-8924(03)00083-7; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wilkin MB, 2000, CURR BIOL, V10, P559, DOI 10.1016/S0960-9822(00)00482-6	30	140	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					895	901		10.1038/ncb1049	http://dx.doi.org/10.1038/ncb1049			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	12973360				2022-12-25	WOS:000185647400015
J	Pfaller, K				Pfaller, K			Human Langerhans cell in a dermal lymphatic vessel	NATURE CELL BIOLOGY			English	Article									Univ Innsbruck, Dept Histol & Mol Cell Biol, A-6020 Innsbruck, Austria	University of Innsbruck	Pfaller, K (corresponding author), Univ Innsbruck, Dept Histol & Mol Cell Biol, A-6020 Innsbruck, Austria.	kristian.pfaller@uibk.ac.at							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					867	867		10.1038/ncb1003-867	http://dx.doi.org/10.1038/ncb1003-867			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14523401	Bronze			2022-12-25	WOS:000185647400011
J	Feng, B; Yao, PM; Li, YK; Devlin, CM; Zhang, DJ; Harding, HP; Sweeney, M; Rong, JX; Kuriakose, G; Fisher, EA; Marks, AR; Ron, D; Tabas, I				Feng, B; Yao, PM; Li, YK; Devlin, CM; Zhang, DJ; Harding, HP; Sweeney, M; Rong, JX; Kuriakose, G; Fisher, EA; Marks, AR; Ron, D; Tabas, I			The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages	NATURE CELL BIOLOGY			English	Article							UNFOLDED-PROTEIN RESPONSE; E-DEFICIENT MICE; CELL-DEATH; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PLASMA-MEMBRANE; MESSENGER-RNA; ER STRESS; ATHEROSCLEROSIS	Excess cellular cholesterol induces apoptosis in macrophages, an event likely to promote progression of atherosclerosis. The cellular mechanism of cholesterol-induced apoptosis is unknown but had previously been thought to involve the plasma membrane. Here we report that the unfolded protein response (UPR) in the endoplasmic reticulum is activated in cholesterol-loaded macrophages, resulting in expression of the cell death effector CHOP. Cholesterol loading depletes endoplasmic reticulum calcium stores, an event known to induce the UPR. Furthermore, endoplasmic reticulum calcium depletion, the UPR, caspase-3 activation and apoptosis are markedly inhibited by selective inhibition of cholesterol trafficking to the endoplasmic reticulum, and Chop(-/-) macrophages are protected from cholesterol-induced apoptosis. We propose that cholesterol trafficking to endoplasmic reticulum membranes, resulting in activation of the CHOP arm of the UPR, is the key signalling step in cholesterol-induced apoptosis in macrophages.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Cell Biol, New York, NY 10032 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; Columbia Univ, Ctr Mol Cardiol, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA	Columbia University; Columbia University; New York University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Tabas, I (corresponding author), Columbia Univ, Dept Med, New York, NY 10032 USA.		Fisher, Edward/ABE-7469-2020	Harding, Heather P/0000-0002-7359-7974; Fisher, Edward/0000-0001-9802-143X; Ron, David/0000-0002-3014-5636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, P50HL056984, R01HL057560, R01HL061814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047119, R37DK047119, R29DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL57560, HL54591, HL61814] Funding Source: Medline; NIDDK NIH HHS [DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIKAWA K, 1994, BBA-LIPID LIPID MET, V1213, P127; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Christian AE, 1997, J LIPID RES, V38, P2264; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; GRAHAM JM, 1970, EUR J BIOCHEM, V12, P58, DOI 10.1111/j.1432-1033.1970.tb00820.x; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Kellner-Weibel G, 1999, ATHEROSCLEROSIS, V146, P309, DOI 10.1016/S0021-9150(99)00155-0; Khan N, 2003, BIOCHEMISTRY-US, V42, P23, DOI 10.1021/bi026039t; KRUTH HS, 1984, EXP MOL PATHOL, V40, P288, DOI 10.1016/0014-4800(84)90046-7; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGE Y, 1992, J LIPID RES, V33, P315; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; TABAS I, 1988, ARTERIOSCLEROSIS, V8, pA559; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Treiman M, 2002, TRENDS CARDIOVAS MED, V12, P57, DOI 10.1016/S1050-1738(01)00147-5; Trogan E, 2002, P NATL ACAD SCI USA, V99, P2234, DOI 10.1073/pnas.042683999; Underwood KW, 1996, J LIPID RES, V37, P1556; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	51	679	702	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					781	792		10.1038/ncb1035	http://dx.doi.org/10.1038/ncb1035			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12907943				2022-12-25	WOS:000185059000011
J	Peschen, D; Li, HP; Fischer, R; Kreuzaler, F; Liao, YC				Peschen, D; Li, HP; Fischer, R; Kreuzaler, F; Liao, YC			Fusion proteins comprising a Fusarium-specific antibody linked to antifungal peptides protect plants against a fungal pathogen	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; SINGLE-CHAIN FV; TRANSGENIC PLANTS; RECOMBINANT ANTIBODIES; ASPERGILLUS-GIGANTEUS; CHITINASE GENE; HEAD BLIGHT; RESISTANCE; SURFACE; ARABIDOPSIS	In planta expression of recombinant antibodies recognizing pathogen-specific antigens has been proposed as a strategy for crop protection. We report the expression of fusion proteins comprising a Fusarium-specific recombinant antibody linked to one of three antifungal peptides (AFPs) as a method for protecting plants against fungal diseases. A chicken-derived single-chain antibody specific to antigens displayed on the Fusarium cell surface was isolated from a pooled immunocompetent phage display library. This recombinant antibody inhibited fungal growth in vitro when fused to any of the three AFPs. Expression of the fusion proteins in transgenic Arabidopsis thaliana plants conferred high levels of protection against Fusarium oxysporum f.sp. matthiolae, whereas plants expressing either the fungus-specific antibody or AFPs alone exhibited only moderate resistance. Our results demonstrate that antibody fusion proteins may be used as effective and versatile tools for the protection of crop plants against fungal infection.	Rhein Westfal TH Aachen, Inst Biol Mol Biotechnol 7, D-52074 Aachen, Germany; Fraunhofer Inst Mol Biol & Angew Oekol, D-52074 Aachen, Germany; Huazhong Agr Univ, Coll Plant Sci & Technol, Wuhan 430070, Peoples R China; Rhein Westfal TH Aachen, Inst Biol Mol Genet 1, D-52074 Aachen, Germany	RWTH Aachen University; Fraunhofer Gesellschaft; Huazhong Agricultural University; RWTH Aachen University	Liao, YC (corresponding author), Rhein Westfal TH Aachen, Inst Biol Mol Biotechnol 7, Worringerweg 1, D-52074 Aachen, Germany.	yucailiao@mail.hzau.edu.cn						AGRIOS GN, 1997, PLANT PATHOLOGY; Aguilera O, 1999, FEBS LETT, V462, P273, DOI 10.1016/S0014-5793(99)01545-8; BENHAMOU N, 1993, CAN J MICROBIOL, V39, P318, DOI 10.1139/m93-045; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; DUVICK JP, 1992, J BIOL CHEM, V267, P18814; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gough KC, 1999, J IMMUNOL METHODS, V228, P97, DOI 10.1016/S0022-1759(99)00080-0; Grison R, 1996, NAT BIOTECHNOL, V14, P643, DOI 10.1038/nbt0596-643; HAYES AW, 1980, CLIN TOXICOL, V17, P45; Hiatt EE, 2001, FUNGAL GENET BIOL, V33, P107, DOI 10.1006/fgbi.2001.1271; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kathuria S, 2002, HUM REPROD, V17, P2054, DOI 10.1093/humrep/17.8.2054; Lacadena J, 1995, ARCH BIOCHEM BIOPHYS, V324, P273, DOI 10.1006/abbi.1995.0040; Le Gall F, 1998, APPL ENVIRON MICROB, V64, P4566; LIAO YC, 1994, PLANT SCI, V103, P177, DOI 10.1016/0168-9452(94)90206-2; Little M, 2000, IMMUNOL TODAY, V21, P364, DOI 10.1016/S0167-5699(00)01668-6; Liu SX, 2003, CROP SCI, V43, P760, DOI 10.2135/cropsci2003.0760; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; PARRY DW, 1995, PLANT PATHOL, V44, P207, DOI 10.1111/j.1365-3059.1995.tb02773.x; Placinta CM, 1999, ANIM FEED SCI TECH, V78, P21, DOI 10.1016/S0377-8401(98)00278-8; Punja ZK, 2001, CAN J PLANT PATHOL, V23, P216; Rademacher T, 2002, PLANT J, V32, P25, DOI 10.1046/j.1365-313X.2002.01397.x; Reglinski T, 2001, PHYSIOL MOL PLANT P, V58, P111, DOI 10.1006/pmpp.2001.0321; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; Sambrook J., 1996, MOL CLONING LAB MANU; Schilder P, 1912, Z GESAMTE NEUROL PSY, V10, P1, DOI 10.1007/BF02901445; Schoffelmeer EAM, 1999, FUNGAL GENET BIOL, V27, P275, DOI 10.1006/fgbi.1999.1153; Shah DM, 1997, CURR OPIN BIOTECH, V8, P208, DOI 10.1016/S0958-1669(97)80104-8; Stewart CN, 2001, PLANT CELL REP, V20, P376, DOI 10.1007/s002990100346; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; Thevissen K, 1996, J BIOL CHEM, V271, P15018, DOI 10.1074/jbc.271.25.15018; Thornton CR, 1997, PHYTOPATHOLOGY, V87, P123, DOI 10.1094/PHYTO.1997.87.1.123; Tierens KFMJ, 2001, PLANT PHYSIOL, V125, P1688, DOI 10.1104/pp.125.4.1688; VOSS A, 1995, MOL BREEDING, V1, P39, DOI 10.1007/BF01682088; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; Windels CE, 2000, PHYTOPATHOLOGY, V90, P17, DOI 10.1094/PHYTO.2000.90.1.17; WNENDT S, 1990, NUCLEIC ACIDS RES, V18, P3987, DOI 10.1093/nar/18.13.3987; Zhang MY, 2001, J VIROL METHODS, V91, P139, DOI 10.1016/S0166-0934(00)00262-7	41	104	125	3	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					732	738		10.1038/nbt970	http://dx.doi.org/10.1038/nbt970			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15146196				2022-12-25	WOS:000221785300035
J	Kim, JC; Badano, JL; Sibold, S; Esmail, MA; Hill, J; Hoskins, BE; Leitch, CC; Venner, K; Ansley, SJ; Ross, AJ; Leroux, MR; Katsanis, N; Beales, PL				Kim, JC; Badano, JL; Sibold, S; Esmail, MA; Hill, J; Hoskins, BE; Leitch, CC; Venner, K; Ansley, SJ; Ross, AJ; Leroux, MR; Katsanis, N; Beales, PL			The Bardet-Biedl protein BBS4 targets cargo to the pericentriolar region and is required for microtubule anchoring and cell cycle progression	NATURE GENETICS			English	Article							GAMMA-TUBULIN; CENTROSOME; OBESITY; COMPLEX; GENE; IDENTIFICATION; MUTATIONS; DYNACTIN; BINDS	BBS4 is one of several proteins that cause Bardet-Biedl syndrome (BBS), a multisystemic disorder of genetic and clinical complexity. Here we show that BBS4 localizes to the centriolar satellites of centrosomes and basal bodies of primary cilia, where it functions as an adaptor of the p150(glued) subunit of the dynein transport machinery to recruit PCM1 (pericentriolar material 1 protein) and its associated cargo to the satellites. Silencing of BBS4 induces PCM1 mislocalization and concomitant deanchoring of centrosomal microtubules, arrest in cell division and apoptotic cell death. Expression of two truncated forms of BBS4 that are similar to those found in some individuals with BBS had a similar effect on PCM1 and microtubules. Our findings indicate that defective targeting or anchoring of pericentriolar proteins and microtubule disorganization contribute to the BBS phenotype and provide new insights into possible causes of familial obesity, diabetes and retinal degeneration.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21287 USA; UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Inst Neurol, Dept Electron Microscopy, London WC1N 3BG, England; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA	Simon Fraser University; Johns Hopkins University; University of London; University College London; University of London; University College London; Johns Hopkins University; Johns Hopkins Medicine	Leroux, MR (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	leroux@sfu.ca; katsanis@jhmi.edu	Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009	Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652				Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Badano JL, 2003, AM J HUM GENET, V72, P650, DOI 10.1086/368204; Balczon R, 1999, CELL MOTIL CYTOSKEL, V42, P60, DOI 10.1002/(SICI)1097-0169(1999)42:1<60::AID-CM6>3.0.CO;2-7; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Beales PL, 1999, J MED GENET, V36, P437; Beisson J, 2003, CURR OPIN CELL BIOL, V15, P96, DOI 10.1016/S0955-0674(02)00017-0; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; Kubo A, 1999, J CELL BIOL, V147, P969, DOI 10.1083/jcb.147.5.969; Moudjou M, 1996, J CELL SCI, V109, P875; Mykytyn K, 2002, NAT GENET, V31, P435, DOI 10.1038/ng935; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Ou YY, 2003, CELL MOTIL CYTOSKEL, V55, P125, DOI 10.1002/cm.10115; Rattner J. B., 1992, P45; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	29	323	331	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					462	470		10.1038/ng1352	http://dx.doi.org/10.1038/ng1352			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107855	Bronze			2022-12-25	WOS:000221183000017
J	An, J; Muoio, DM; Shiota, M; Fujimoto, Y; Cline, GW; Shulman, GI; Koves, TR; Stevens, R; Millington, D; Newgard, CB				An, J; Muoio, DM; Shiota, M; Fujimoto, Y; Cline, GW; Shulman, GI; Koves, TR; Stevens, R; Millington, D; Newgard, CB			Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance	NATURE MEDICINE			English	Article							FATTY-ACID OXIDATION; SKELETAL-MUSCLE; PPAR-ALPHA; GLUCOSE; METABOLISM; RECEPTOR; OBESITY; MICE; RATS; OVEREXPRESSION	Lipid infusion or ingestion of a high-fat diet results in insulin resistance, but the mechanism underlying this phenomenon remains unclear. Here we show that, in rats fed a high-fat diet, whole-animal, muscle and liver insulin resistance is ameliorated following hepatic overexpression of malonyl-coenzyme A (CoA) decarboxylase (MCD), an enzyme that affects lipid partitioning. MCD overexpression decreased circulating free fatty acid (FFA) and liver triglyceride content. In skeletal muscle, levels of triglyceride and long-chain acyl-CoA (LC-CoA)-two candidate mediators of insulin resistance-were either increased or unchanged. Metabolic profiling of 36 acylcarnitine species by tandem mass spectrometry revealed a unique decrease in the concentration of one lipid-derived metabolite, beta-OH-butyrate, in muscle of MCD-overexpressing animals. The best explanation for our findings is that hepatic expression of MCD lowered circulating FFA levels, which led to lowering of muscle beta-OH-butyrate levels and improvement of insulin sensitivity.	Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA	Duke University; Duke University; Duke University; Vanderbilt University; Yale University	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA.	newga002@mc.duke.edu	Koves, Tim/I-4806-2012; Shulman, Gerald I./P-7176-2019; Muoio, Debbie Marie/E-1147-2012	Koves, Tim/0000-0001-8763-5866; Shulman, Gerald I./0000-0003-1529-5668; Muoio, Deborah/0000-0003-3760-9277	NIDDK NIH HHS [R01 DK040936, P01DK58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398, R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; CHU AC, IN PRESS AM J PHYSL; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; HOLNESS MJ, 1991, BIOCHEM J, V277, P429, DOI 10.1042/bj2770429; HOPPELER H, 1985, J APPL PHYSIOL, V59, P320, DOI 10.1152/jappl.1985.59.2.320; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MASCARO C, 1995, ARCH BIOCHEM BIOPHYS, V317, P385, DOI 10.1006/abbi.1995.1178; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; MCGARRY JD, 1991, BIOCHIMIE, V73, P77, DOI 10.1016/0300-9084(91)90078-F; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; NEWGARD CB, 1984, J BIOL CHEM, V259, P6958; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; RUDERMAN NB, 1977, FED PROC, V36, P171; RUSSELL RR, 1991, J CLIN INVEST, V87, P384, DOI 10.1172/JCI115008; RUSSELL RR, 1992, J CLIN INVEST, V89, P968, DOI 10.1172/JCI115679; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SINGH BM, 1993, DIABETES RES CLIN PR, V20, P55, DOI 10.1016/0168-8227(93)90023-X; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Tardif A, 2001, AM J PHYSIOL-ENDOC M, V281, pE1205, DOI 10.1152/ajpendo.2001.281.6.E1205; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	46	355	363	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					268	274		10.1038/nm995	http://dx.doi.org/10.1038/nm995			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770177				2022-12-25	WOS:000189297700038
J	Heikenwalder, M; Polymenidou, M; Junt, T; Sigurdson, C; Wagner, H; Akira, S; Zinkernagel, R; Aguzzi, A				Heikenwalder, M; Polymenidou, M; Junt, T; Sigurdson, C; Wagner, H; Akira, S; Zinkernagel, R; Aguzzi, A			Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; CONTAINING OLIGONUCLEOTIDES; MICE LACKING; RESPONSES; DNA; PATHOGENESIS; ACTIVATION; DISEASE; INTERFERON	DNA containing unmethylated cytidyl guanosyl (CpG) sequences, which are underrepresented in mammalian genomes but prevalent in prokaryotes, is endocytosed by cells of the innate immune system, including macrophages, monocytes and dendritic cells 1, and activates a pathway involving Toll-like receptor-9 (TLR9) 2. CpG-containing oligodeoxynucleotides (CpG-ODN) are potent stimulators of innate immunity, and are currently being tested as adjuvants of antimicrobial, antiallergic, anticancer and antiprion immunotherapy. Little is known, however, about the consequences of repeated CpG-ODN administration, which is advocated for some of these applications. Here we report that daily injection of 60 mug CpG-ODN dramatically alters the morphology and functionality of mouse lymphoid organs. By day 7, lymphoid follicles were poorly defined; follicular dendritic cells (FDC) and germinal center B lymphocytes were suppressed. Accordingly, CpG-ODN treatment for greater than or equal to7 d strongly reduced primary humoral immune responses and immunoglobulin class switching. By day 20, mice developed multifocal liver necrosis and hemorrhagic ascites. All untoward effects were strictly dependent on CpG and TLR9, as neither the CpG-ODN treatment of Tlr9(-/-) mice nor the repetitive challenge of wild-type mice with nonstimulatory ODN (AT-ODN) or with the TLR3 agonist polyinosinic: cytidylic acid (polyl:C) were immunotoxic or hepatotoxic.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Munich; Osaka University	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008; Heikenwalder, Mathias/AAA-2269-2020; Junt, Tobias/AAE-4389-2021; Akira, Shizuo/C-3134-2009; Polymenidou, Magdalini/D-2254-2014	Aguzzi, Adriano/0000-0002-0344-6708	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001802] Funding Source: NIH RePORTER; NIAID NIH HHS [K08-AI01802] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aucouturier P, 2001, J CLIN INVEST, V108, P703, DOI 10.1172/JCI200113155; Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517; Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539; Davila E, 2002, BLOOD, V100, P2537, DOI 10.1182/blood-2002-02-0401; Fehr T, 2000, INT IMMUNOL, V12, P1275, DOI 10.1093/intimm/12.9.1275; Gilch S, 2003, J BIOL CHEM, V278, P18524, DOI 10.1074/jbc.M210723200; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Karrer U, 2000, J IMMUNOL, V164, P768, DOI 10.4049/jimmunol.164.2.768; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; ODERMATT B, 1991, P NATL ACAD SCI USA, V88, P8252, DOI 10.1073/pnas.88.18.8252; Oxenius A, 1999, J VIROL, V73, P4120, DOI 10.1128/JVI.73.5.4120-4126.1999; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prinz M, 2003, EMBO REP, V4, P195, DOI 10.1038/sj.embor.embor731; RIVIERE Y, 1977, P NATL ACAD SCI USA, V74, P2135, DOI 10.1073/pnas.74.5.2135; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schmidt U, 1999, CELL MICROBIOL, V1, P61, DOI 10.1046/j.1462-5822.1999.00007.x; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sparwasser T, 1999, J IMMUNOL, V162, P2368; Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880; Vabulas RM, 2000, J IMMUNOL, V164, P2372, DOI 10.4049/jimmunol.164.5.2372	30	369	395	2	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					187	192		10.1038/nm987	http://dx.doi.org/10.1038/nm987			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14745443				2022-12-25	WOS:000188719600039
J	Taylor, TE; Fu, WJJ; Carr, RA; Whitten, RO; Mueller, JG; Fosiko, NG; Lewallen, S; Liomba, NG; Molyneux, ME				Taylor, TE; Fu, WJJ; Carr, RA; Whitten, RO; Mueller, JG; Fosiko, NG; Lewallen, S; Liomba, NG; Molyneux, ME			Differentiating the pathologies of cerebral malaria by postmortem parasite counts	NATURE MEDICINE			English	Article							FALCIPARUM-MALARIA; AFRICAN CHILDREN	To study the pathogenesis of fatal cerebral malaria, we conducted autopsies in 31 children with this clinical diagnosis. We found that 23% of the children had actually died from other causes. The remaining patients had parasites sequestered in cerebral capillaries, and 75% of those had additional intra- and perivascular pathology. Retinopathy was the only clinical sign distinguishing malarial from nonmalarial coma. These data have implications for treating malaria patients, designing clinical trials and assessing malaria-specific disease associations.	Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA; Blantyre Malaria Project, Blantyre 3, Malawi; Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; S Warwickshire Gen Hosp NHS Trust, Pathol Lab, Warwick CV34 5BH, England; Black Hills Pathol, Olympia, WA 98506 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Tumaini Univ, KCMC, Kilimanjaro Ctr Community Ophthalmol, Moshi, Tanzania; Univ Malawi, Coll Med, Dept Histopathol, Blantyre 3, Malawi; Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 3, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Michigan State University; Michigan State University College of Osteopathic Medicine; Michigan State University; Vanderbilt University; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool	Taylor, TE (corresponding author), Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.	taylort@msu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034969] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90301] Funding Source: Medline; NIAID NIH HHS [R01 AI034969, R01 AO34969] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Breiman L, 1993, CLASSIFICATION REGRE; Lewallen S, 1999, T ROY SOC TROP MED H, V93, P619, DOI 10.1016/S0035-9203(99)90071-8; Marsh K, 1996, ANN TROP MED PARASIT, V90, P395, DOI 10.1080/00034983.1996.11813068; Newton CRJC, 1998, AM J TROP MED HYG, V58, P673, DOI 10.4269/ajtmh.1998.58.673; SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O	6	490	495	0	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2004	10	2					143	145		10.1038/nm986	http://dx.doi.org/10.1038/nm986			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14745442				2022-12-25	WOS:000188719600031
J	Chan, J; Calder, GM; Doonan, JH; Lloyd, CW				Chan, J; Calder, GM; Doonan, JH; Lloyd, CW			EB1 reveals mobile microtubule nucleation sites in Arabidopsis	NATURE CELL BIOLOGY			English	Letter							APC-BINDING-PROTEIN; DYNAMIC INSTABILITY; HIGHER-PLANTS; CELL-CYCLE; TUBULIN; ARRAYS; YEAST; STABILIZATION; ORIENTATION; INTERACTS	In plants, it is unclear how dispersed cortical microtubules are nucleated, polarized and organized in the absence of centrosomes. In Arabidopsis thaliana cells, expression of a fusion between the microtubule-end-binding protein AtEB1a and green fluorescent protein (GFP) results in labelling of spindle poles, where minus ends gather. During interphase, AtEB1a-GFP labels the microtubule plus end as a comet, but also marks the minus end as a site from which microtubules can grow and shrink. These minus-end nucleation sites are mobile, explaining how the cortical array can redistribute during the cell cycle and supporting the idea of a flexible centrosome in plants.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Lloyd, CW (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.			doonan, john/0000-0001-6027-1919	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000129] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Chan J, 1996, PLANT J, V10, P251, DOI 10.1046/j.1365-313X.1996.10020251.x; Dhonukshe P, 2003, PLANT CELL, V15, P597, DOI 10.1105/tpc.008961; Drykova D, 2003, PLANT CELL, V15, P465, DOI 10.1105/tpc.007005; EUTENEUER U, 1981, P NATL ACAD SCI-BIOL, V78, P372, DOI 10.1073/pnas.78.1.372; Granger CL, 2001, PROTOPLASMA, V216, P201, DOI 10.1007/BF02673872; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; LAMBERT AM, 1994, MICROTUBULES, P327; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Morrison EE, 2001, EUR J CELL BIOL, V80, P749, DOI 10.1078/0171-9335-00221; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Panteris E, 2000, PROTOPLASMA, V210, P179, DOI 10.1007/BF01276858; Rehberg M, 2002, MOL BIOL CELL, V13, P2301, DOI 10.1091/mbc.E02-01-0054; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Schmit AC, 2002, INT REV CYTOL, V220, P257; Shaw SL, 2003, SCIENCE, V300, P1715, DOI 10.1126/science.1083529; STRAUBE A, 2003, USTILAGO MAYDIS MOL, V14, P642; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; Wasteneys GO, 2002, J CELL SCI, V115, P1345; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; YUAN M, 1994, P NATL ACAD SCI USA, V91, P6050, DOI 10.1073/pnas.91.13.6050; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	32	187	192	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					967	971		10.1038/ncb1057	http://dx.doi.org/10.1038/ncb1057			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14557818				2022-12-25	WOS:000186273100012
J	Saez, E; Olson, P; Evans, RM				Saez, E; Olson, P; Evans, RM			Genetic deficiency in Pparg does not alter development of experimental prostate cancer	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; COLON-CANCER	The role of the nuclear peroxisome proliferator-activated receptor (PPAR)-gamma in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly tested this notion using a mouse model of prostate cancer. Neither hemizygous deletion of Pparg nor complete ablation of Ppara influenced the development of prostate cancer in our experimental context.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Collett GP, 2000, CLIN CANCER RES, V6, P3241; Huss WJ, 2001, SEMIN CANCER BIOL, V11, P245, DOI 10.1006/scbi.2001.0373; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; PATTOO D, 2003, CANC LETT, V191, P67; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5	8	26	28	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1265	1266		10.1038/nm928	http://dx.doi.org/10.1038/nm928			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960963				2022-12-25	WOS:000185669700035
J	Eichhorst, ST; Krueger, A; Muerkoster, S; Fas, SC; Golks, A; Gruetzner, U; Schubert, L; Opelz, C; Bilzer, M; Gerbes, AL; Krammer, PH				Eichhorst, ST; Krueger, A; Muerkoster, S; Fas, SC; Golks, A; Gruetzner, U; Schubert, L; Opelz, C; Bilzer, M; Gerbes, AL; Krammer, PH			Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice	NATURE MEDICINE			English	Article							SIGNALING COMPLEX; MEDIATED APOPTOSIS; PROSTATE-CANCER; GROWTH-FACTOR; T-CELLS; CASPASE-8; FLICE; ACTIVATION; DISORDERS; MECHANISM	Suramin is a polysulfonated derivative of urea and has been widely used both to treat infections and as a chemotherapeutic drug. Suramin has been shown to inhibit growth factor signaling pathways; however, its effect on apoptosis is unknown. Here we show that suramin inhibits apoptosis induced through death receptors in hepatoma and lymphoma cells. It also inhibits the proapoptotic effect of chemotherapeutic drugs. The antiapoptotic mechanism is specific to cell type and is caused by reduced activation, but not altered composition, of the death-inducing signaling complex (DISC), and by inhibition of the initiator caspases 8, 9 and 10. Suramin also shows similar effects in in vivo models: apoptotic liver damage induced by CD95 stimulation and endotoxic shock mediated by tumor-necrosis factor (TNF) are inhibited in mice, but necrotic liver damage is not inhibited in a rat model of liver transplantation. Thus, the antiapoptotic property of suramin in the liver may be therapeutically exploited.	German Canc Res Ctr, Tumorimmunol Program, Div Immunogenet, D-69120 Heidelberg, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 2, D-81377 Munich, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hosp Schleswig Holstein, Dept Internal Med 1, D-24105 Kiel, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Surg, D-81377 Munich, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Krammer, PH (corresponding author), German Canc Res Ctr, Tumorimmunol Program, Div Immunogenet, INF 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Sebens, Susanne/C-1222-2010; Krueger, Andreas/M-9769-2019; Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Krueger, Andreas/0000-0001-7873-7334				ALLOLIO B, 1989, DEUT MED WOCHENSCHR, V114, P381, DOI 10.1055/s-2008-1066605; Chen EY, 2001, CANCER RES, V61, P2429; CHESON BD, 1987, JAMA-J AM MED ASSOC, V258, P1347, DOI 10.1001/jama.258.10.1347; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; Eichhorst ST, 2001, CANCER RES, V61, P243; EISENBERGER MA, 1994, CANCER TREAT REV, V20, P259, DOI 10.1016/0305-7372(94)90003-5; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer P H, 1999, Adv Immunol, V71, P163; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuyu H, 1999, ANN ONCOL, V10, P891, DOI 10.1023/A:1008385607847; Lambrecht G, 2002, CURR PHARM DESIGN, V8, P2371, DOI 10.2174/1381612023392973; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; McNally WP, 2000, LIFE SCI, V67, P1847, DOI 10.1016/S0024-3205(00)00767-0; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Rokhlin OW, 1997, CANCER RES, V57, P1758; Scaffidi C, 1999, METHODS, V17, P287, DOI 10.1006/meth.1999.0742; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Small EJ, 2002, J CLIN ONCOL, V20, P3369, DOI 10.1200/JCO.2002.10.022; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHAO XM, 1995, J IMMUNOL, V155, P3904	39	64	67	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					602	609		10.1038/nm1049	http://dx.doi.org/10.1038/nm1049			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146177				2022-12-25	WOS:000221759600025
J	Kosco-Vilbois, MH				Kosco-Vilbois, MH			A mightier mouse with human adaptive immunity	NATURE BIOTECHNOLOGY			English	Editorial Material							RECEPTOR-GAMMA CHAIN; CELL ENGRAFTMENT; MICE; DEFICIENT; MODEL; IMMUNODEFICIENCY; SYSTEM; RAG2		NovImmune SA, CH-1205 Geneva, Switzerland	NovImmune SA	Kosco-Vilbois, MH (corresponding author), NovImmune SA, 64 Ave Roseraie, CH-1205 Geneva, Switzerland.	mkosco-vilbois@novimmune.com						Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Goldman JP, 1998, BRIT J HAEMATOL, V103, P335, DOI 10.1046/j.1365-2141.1998.00980.x; HESSELTON RM, 1995, J INFECT DIS, V172, P974, DOI 10.1093/infdis/172.4.974; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lowry P A, 1996, Biol Blood Marrow Transplant, V2, P15; Mazurier F, 1999, J INTERF CYTOK RES, V19, P533, DOI 10.1089/107999099313983; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933	12	3	9	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					684	685		10.1038/nbt0604-684	http://dx.doi.org/10.1038/nbt0604-684			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15175689				2022-12-25	WOS:000221785300022
J	Scanlan, TS; Suchland, KL; Hart, ME; Chiellini, G; Huang, Y; Kruzich, PJ; Frascarelli, S; Crossley, DA; Bunzow, JR; Ronca-Testoni, S; Lin, ET; Hatton, D; Zucchi, R; Grandy, DK				Scanlan, TS; Suchland, KL; Hart, ME; Chiellini, G; Huang, Y; Kruzich, PJ; Frascarelli, S; Crossley, DA; Bunzow, JR; Ronca-Testoni, S; Lin, ET; Hatton, D; Zucchi, R; Grandy, DK			3-iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone	NATURE MEDICINE			English	Article							BODY-TEMPERATURE; RECEPTOR; RAT; DOPAMINE; AGENTS; METABOLITES; THYROXINE; SUBTYPE	Thyroxine (T-4) is the predominant form of thyroid hormone (TH). Hyperthyroidism, a condition associated with excess TH, is characterized by increases in metabolic rate, core body temperature and cardiac performance. In target tissues, T-4 is enzymatically deiodinated to 3,5,3-triiodothyronine (T-3), a high-affinity ligand for the nuclear TH receptors TRalpha and TRbeta, whose activation controls normal vertebrate development and physiology(1). T-3-modulated transcription of target genes via activation of TRalpha and TRbeta is a slow process, the effects of which manifest over hours and days. Although rapidly occurring effects of TH have been documented, the molecules that mediate these non-genomic effects remain obscure(2,3). Here we report the discovery of 3-iodothyronamine (T(1)AM), a naturally occurring derivative of TH that in vitro is a potent agonist of the G protein-coupled trace amine receptor TAR1. Administering T(1)AM in vivo induces profound hypothermia and bradycardia within minutes. T(1)AM treatment also rapidly reduces cardiac output in an ex vivo working heart preparation. These results suggest the existence of a new signaling pathway, stimulation of which leads to rapid physiological and behavioral consequences that are opposite those associated with excess TH.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA; Univ Pisa, Sez Biochim, Dipartimento Sci Uomo & Ambiente, I-56100 Pisa, Italy; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University; University of Pisa; University of California System; University of California San Francisco; Oregon Health & Science University; Oregon Health & Science University	Grandy, DK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	grandyd@ohsu.edu	Zucchi, Riccardo/AAC-8963-2022; Crossley, Dane A/S-4997-2016	Crossley, Dane A/0000-0001-9683-7013; ZUCCHI, RICCARDO/0000-0002-6450-3788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, R01DK052798] Funding Source: NIH RePORTER; NIDA NIH HHS [DA107803, DA07262] Funding Source: Medline; NIDDK NIH HHS [DK-52798] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; Branchek TA, 2003, CURR OPIN PHARMACOL, V3, P90, DOI 10.1016/S1471-4892(02)00028-0; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; CLARK WG, 1985, NEUROSCI BIOBEHAV R, V9, P299, DOI 10.1016/0149-7634(85)90052-1; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P281, DOI 10.1016/0149-7634(80)90002-0; CLARK WG, 1980, NEUROSCI BIOBEHAV R, V4, P175, DOI 10.1016/0149-7634(80)90015-9; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; DRATMAN MB, 1974, J THEOR BIOL, V46, P255, DOI 10.1016/0022-5193(74)90151-9; Falkenstein E, 2000, PHARMACOL REV, V52, P513; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; NEELY JR, 1967, AM J PHYSIOL, V212, P804; Pinna G, 2002, ENDOCRINOLOGY, V143, P1789, DOI 10.1210/en.143.5.1789; Stohr R, 1931, H-S Z PHYSIOL CHEM, V201, P142, DOI 10.1515/bchm2.1931.201.3-4.142; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TOMITA K, 1956, J BIOL CHEM, V219, P595; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZHU MY, 1995, GEN PHARMACOL-VASC S, V26, P681, DOI 10.1016/0306-3623(94)00223-A; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271	23	349	372	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					638	642		10.1038/nm1051	http://dx.doi.org/10.1038/nm1051			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15146179				2022-12-25	WOS:000221759600030
J	Setty, SRG; Strochlic, TI; Tong, AHY; Boone, C; Burd, CG				Setty, SRG; Strochlic, TI; Tong, AHY; Boone, C; Burd, CG			Golgi targeting of ARF-like GTPase Arl3p requires its N-alpha-acetylation and the integral membrane protein Sys1p	NATURE CELL BIOLOGY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; COILED-COIL PROTEINS; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; BUDDING YEAST; GRIP DOMAINS; LOCALIZATION; APPARATUS; SEQUENCE; ACETYLTRANSFERASES	Myristoylation of ARF family GTPases is required for their association with Golgi and endosomal membranes, where they regulate protein sorting and the lipid composition of these organelles. The Golgi-localized ARF-like GTPase Ar13p/ARP lacks a myristoylation signal, indicating that its targeting mechanism is distinct from myristoylated ARFs. We demonstrate that acetylation of the N-terminal methionine of Arl3p requires the NatC N'-acetyltransferase and that this modification is required for its Golgi localization. Chemical crosslinking and fluorescence microscopy experiments demonstrate that localization of Arl3p also requires Sys1p, a Golgi-localized integral membrane protein, which may serve as a receptor for acetylated Arl3p.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Pennsylvania; University of Toronto	Burd, CG (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 421 Curie Blvd,BRB 2-3 Room 1010, Philadelphia, PA 19104 USA.	cburd@mail.med.upenn.edu		Burd, Christopher/0000-0003-1831-8706; Gangi Setty, Subba Rao/0000-0003-4035-2900	NIGMS NIH HHS [GM61221] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM061221, R01GM061221] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bensen ES, 2001, MOL BIOL CELL, V12, P13, DOI 10.1091/mbc.12.1.13; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lu L, 2003, MOL BIOL CELL, V14, P3767, DOI 10.1091/mbc.E03-01-0864; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; Pesaresi P, 2003, PLANT CELL, V15, P1817, DOI 10.1105/tpc.012377; Petracek ME, 2002, METHOD ENZYMOL, V350, P445, DOI 10.1016/S0076-6879(02)50978-2; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 2001, J BIOL CHEM, V276, P20154, DOI 10.1074/jbc.M011440200; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Seron K, 1998, MOL BIOL CELL, V9, P2873, DOI 10.1091/mbc.9.10.2873; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; Shin ME, 2001, J BIOL CHEM, V276, P41388, DOI 10.1074/jbc.M105665200; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tsukada M, 1996, J CELL SCI, V109, P2471; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Williams BC, 2003, CURR BIOL, V13, P2025, DOI 10.1016/j.cub.2003.11.018	32	135	139	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					414	+		10.1038/ncb1121	http://dx.doi.org/10.1038/ncb1121			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15077114				2022-12-25	WOS:000221432600011
J	Mnatzakanian, GN; Lohi, H; Munteanu, I; Alfred, SE; Yamada, T; MacLeod, PJM; Jones, JR; Scherer, SW; Schanen, NC; Friez, MJ; Vincent, JB; Minassian, BA				Mnatzakanian, GN; Lohi, H; Munteanu, I; Alfred, SE; Yamada, T; MacLeod, PJM; Jones, JR; Scherer, SW; Schanen, NC; Friez, MJ; Vincent, JB; Minassian, BA			A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome	NATURE GENETICS			English	Article							CPG-BINDING PROTEIN-2; MUTATIONS	Rett syndrome is caused by mutations in the gene MECP2 in 80% of affected individuals. We describe a previously unknown MeCP2 isoform. Mutations unique to this isoform and the absence, until now, of identified mutations specific to the previously recognized protein indicate an important role for the newly discovered molecule in the pathogenesis of Rett syndrome.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada; Victoria Gen Hosp, Div Med Genet, Victoria, BC V8R 6R5, Canada; Greenwood Genet Ctr, Greenwood, SC 29646 USA; Alfred I duPOnt Hosp Children, Nemours Res Program, Wilmington, DE 19803 USA; Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Victoria; Greenwood Genetic Center; Nemours Alfred I. duPont Hospital for Children; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Minassian, BA (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bminass@sickkids.ca	Lohi, Hannes/F-4596-2011; Scherer, Stephen W./B-3785-2013; Yamada, Takahiro/A-4001-2011	Lohi, Hannes/0000-0003-1087-5532; Scherer, Stephen W./0000-0002-8326-1999; Vincent, Kirby/0000-0001-9325-5747				Aber KM, 2003, NEUROSCIENCE, V116, P77, DOI 10.1016/S0306-4522(02)00586-9; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; DEsposito M, 1996, MAMM GENOME, V7, P533, DOI 10.1007/s003359900157; Hagberg B, 2002, MENT RETARD DEV D R, V8, P61, DOI 10.1002/mrdd.10020; Hammer S, 2002, MENT RETARD DEV D R, V8, P94, DOI 10.1002/mrdd.10023; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Miltenberger-Miltenyi G, 2003, HUM MUTAT, V22, P107, DOI 10.1002/humu.10243; Reichwald K, 2000, MAMM GENOME, V11, P182, DOI 10.1007/s003350010035; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Shahbazian MD, 2002, HUM MOL GENET, V11, P115, DOI 10.1093/hmg/11.2.115; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Utsch B, 2002, HUM GENET, V110, P488, DOI 10.1007/s00439-002-0712-8	13	243	257	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					339	341		10.1038/ng1327	http://dx.doi.org/10.1038/ng1327			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15034579				2022-12-25	WOS:000220647200016
J	Ramanathan, C; Ghanem, RN; Jia, P; Ryu, K; Rudy, Y				Ramanathan, C; Ghanem, RN; Jia, P; Ryu, K; Rudy, Y			Noninvasive electrocardiographic imaging for cardiac electrophysiology and arrhythmia	NATURE MEDICINE			English	Article							ATRIAL-FLUTTER; VENTRICULAR-TACHYCARDIA; EPICARDIAL POTENTIALS; CRISTA TERMINALIS; HUMAN HEART; ACTIVATION; SURFACE; RECONSTRUCTION; REPOLARIZATION; ELECTROGRAMS	Over 7 million people worldwide die annually from erratic heart rhythms (cardiac arrhythmias), and many more are disabled. Yet there is no imaging modality to identify patients at risk, provide accurate diagnosis and guide therapy. Standard diagnostic techniques such as the electrocardiogram (ECG) provide only low-resolution projections of cardiac electrical activity on the body surface. Here we demonstrate the successful application in humans of a new imaging modality called electrocardiographic imaging (ECGI), which noninvasively images cardiac electrical activity in the heart. In ECGI, a multielectrode vest records 224 body-surface electrocardiograms; electrical potentials, electrograms and isochrones are then reconstructed on the heart's surface using geometrical information from computed tomography (CT) and a mathematical algorithm. We provide examples of ECGI application during atrial and ventricular activation and ventricular repolarization in (i) normal heart (ii) heart with a conduction disorder (right bundle branch block) (iii) focal activation initiated by right or left ventricular pacing, and (iv) atrial flutter.	Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rudy, Y (corresponding author), Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA.	yxr@po.cwru.edu			NHLBI NIH HHS [R37-HL-33343, R37 HL033343-20, R37 HL033343, R01 HL049054, R01-HL-49054] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049054, R37HL033343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARISI G, 1983, CIRC RES, V52, P706, DOI 10.1161/01.RES.52.6.706; Biermann M, 2003, CARDIAC MAPPING, P15; Burnes JE, 2000, CIRCULATION, V102, P2152, DOI 10.1161/01.CIR.102.17.2152; Burnes JE, 2000, CIRCULATION, V101, P533, DOI 10.1161/01.CIR.101.5.533; Burnes JE, 2001, J AM COLL CARDIOL, V38, P2071, DOI 10.1016/S0735-1097(01)01653-9; Daoud EG, 1998, ANNU REV MED, V49, P77; DURRER D, 1970, CIRCULATION, V41, P899, DOI 10.1161/01.CIR.41.6.899; Ghanem RN, 2003, IEEE T MED IMAGING, V22, P1307, DOI 10.1109/TMI.2003.818263; Ghanem RN, 2001, CIRCULATION, V104, P1306, DOI 10.1161/hc3601.094277; Gima K, 2002, CIRC RES, V90, P889, DOI 10.1161/01.RES.0000016960.61087.86; HAWS CW, 1990, CIRCULATION, V81, P281, DOI 10.1161/01.CIR.81.1.281; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; JOUVE A, 1959, AM HEART J, V59, P856; KUPERSMITH J, 1976, PROG CARDIOVASC DIS, V19, P167, DOI 10.1016/0033-0620(76)90015-3; LIEBMAN J, 1984, J ELECTROCARDIOL, V17, P329, DOI 10.1016/S0022-0736(84)80070-9; LUX RL, 1994, J ELECTROCARDIOL, V27, P100, DOI 10.1016/S0022-0736(94)80065-0; Matsuo K, 2001, AM J PHYSIOL-HEART C, V280, pH1683, DOI 10.1152/ajpheart.2001.280.4.H1683; Oster HS, 1997, CIRCULATION, V96, P1012; Oster HS, 1998, CIRCULATION, V97, P1496; Ramanathan C, 2003, ANN BIOMED ENG, V31, P981, DOI 10.1114/1.1588655; Rodriguez LM, 2001, CIRCULATION, V104, P2545, DOI 10.1161/hc4601.097996; ROOS JP, 1968, BRIT HEART J, V30, P630; RUDY Y, 1992, CRIT REV BIOMED ENG, V20, P25; Rudy Y., 1999, ANN NONINVAS ELECTRO, V4, P340, DOI DOI 10.1111/J.1542-474X.1999.TB00220.X; Sosa E, 1998, J CARDIOVASC ELECTR, V9, P229, DOI 10.1111/j.1540-8167.1998.tb00907.x; SPACH MS, 1977, CIRCULATION, V55, P268, DOI 10.1161/01.CIR.55.2.268; Tikhonov A., 1977, SOLUTION ILL POSED P, P45; WYNDHAM CR, 1979, CIRCULATION, V59, P161, DOI 10.1161/01.CIR.59.1.161; Yamabe H, 2002, PACE, V25, P132, DOI 10.1046/j.1460-9592.2002.00132.x	29	438	482	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					422	428		10.1038/nm1011	http://dx.doi.org/10.1038/nm1011			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034569	Green Accepted			2022-12-25	WOS:000220587000036
J	Kim, DH; Longo, M; Han, Y; Lundberg, P; Cantin, E; Rossi, JJ				Kim, DH; Longo, M; Han, Y; Lundberg, P; Cantin, E; Rossi, JJ			Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase	NATURE BIOTECHNOLOGY			English	Article							RNA INTERFERENCE; MAMMALIAN-CELLS; VIRUS-RNA; REPLICATION; INFECTION	Small interfering RNAs (siRNA) are potent reagents for directed post-transcriptional gene silencing 1 and a major new genetic tool for investigating mammalian cells. When synthetic siRNAs are used for gene silencing, the costs can be substantial because of variations in siRNA efficacies. An alternative to chemically synthesized siRNAs are siRNAs produced by bacteriophage T7 RNA polymerase. We found that siRNAs synthesized from the T7 RNA polymerase system can trigger a potent induction of interferon and in a variety of cell lines. Surprisingly, we also found very potent induction of interferon and by short single-stranded RNAs (ssRNAs) transcribed with T3, T7 and Sp6 RNA polymerases. Analyses of the potential mediators of this response revealed that the initiating 5 triphosphate is required for interferon induction. We describe here an improved method for T7 siRNA synthesis that alleviates the interferon response while maintaining full efficacy of the siRNAs.	City Hope Natl Med Ctr, Div Mol Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Div Virol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Sch Biol Sci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Div Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jrossi@coh.org			NHLBI NIH HHS [HL074704] Funding Source: Medline; NIAID NIH HHS [AI42552, AI29329] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029329, R37AI029329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andino R, 2003, NAT BIOTECHNOL, V21, P629, DOI 10.1038/nbt0603-629; Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elliott G, 1999, J VIROL, V73, P4110, DOI 10.1128/JVI.73.5.4110-4119.1999; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Honda A, 1998, VIRUS RES, V55, P199, DOI 10.1016/S0168-1702(98)00048-3; Kapadia SB, 2003, P NATL ACAD SCI USA, V100, P2014, DOI 10.1073/pnas.252783999; Kim DH, 2003, ANTISENSE NUCLEIC A, V13, P151, DOI 10.1089/108729003768247619; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sohail M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng038; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; WANG LH, 1976, P NATL ACAD SCI USA, V73, P3952, DOI 10.1073/pnas.73.11.3952	14	321	375	2	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2004	22	3					321	325		10.1038/nbt940	http://dx.doi.org/10.1038/nbt940			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	779LE	14990954				2022-12-25	WOS:000189297200025
J	Lampson, MA; Renduchitala, K; Khodjakov, A; Kapoor, TM				Lampson, MA; Renduchitala, K; Khodjakov, A; Kapoor, TM			Correcting improper chromosome-spindle attachments during cell division	NATURE CELL BIOLOGY			English	Article							SMALL-MOLECULE INHIBITOR; NEWT LUNG-CELLS; AURORA-B KINASE; BUDDING YEAST; MICROTUBULE ATTACHMENT; KINETOCHORE; MITOSIS; CHECKPOINT; CENTROSOME; TENSION	For accurate segregation of chromosomes during cell division, microtubule fibres must attach sister kinetochores to opposite poles of the mitotic spindle (bi-orientation). Aurora kinases are linked to oncogenesis(1) and have been implicated in the regulation of chromosome-microtubule attachments(2). Although loss of Aurora kinase activity causes an accumulation of mal-orientated chromosomes in dividing cells(3,4), it is not known how the active kinase corrects improper chromosome attachments. The use of reversible small-molecule inhibitors allows activation of protein function in living vertebrate cells with temporal control. Here we show that by removal of small-molecule inhibitors, controlled activation of Aurora kinase during mitosis can correct chromosome attachment errors by selective disassembly of kinetochore-microtubule fibres, rather than by alternative mechanisms involving initial release of microtubules from either kinetochores or spindle poles(5-7). Observation of chromosomes and microtubule dynamics with real-time high-resolution microscopy showed that mal-orientated, but not bi-orientated, chromosomes move to the spindle pole as both kinetochore-microtubule fibres shorten, followed by alignment at the metaphase plate. Our results provide direct evidence for a mechanism required for the maintenance of genome integrity during cell division.	Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA	Rockefeller University; State University of New York (SUNY) System; Wadsworth Center	Kapoor, TM (corresponding author), Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	kapoor@rockefeller.edu			NIGMS NIH HHS [R01 GM059363, GM65933, GM59363] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065933, R01GM059363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULT JG, 1992, CELL MOTIL CYTOSKEL, V22, P155, DOI 10.1002/cm.970220302; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gandhi, 2002, United States Patent, Patent No. [112, 1(12)]; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; MORTLOCK AA, 2001, Patent No. 62; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Roghi C, 1998, J CELL SCI, V111, P557; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181	30	333	339	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					232	237		10.1038/ncb1102	http://dx.doi.org/10.1038/ncb1102			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	14767480				2022-12-25	WOS:000189363000014
J	Lidke, DS; Nagy, P; Heintzmann, R; Arndt-Jovin, DJ; Post, JN; Grecco, HE; Jares-Erijman, EA; Jovin, TM				Lidke, DS; Nagy, P; Heintzmann, R; Arndt-Jovin, DJ; Post, JN; Grecco, HE; Jares-Erijman, EA; Jovin, TM			Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction	NATURE BIOTECHNOLOGY			English	Article							EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; EXTRACELLULAR REGION; CRYSTAL-STRUCTURE; LIVE CELLS; ACTIVATION; ERBB2; HETERODIMERIZATION; DIMERIZATION; COEXPRESSION	The erbB/HER family of transmembrane receptor tyrosine kinases (RTKs) mediate cellular responses to epidermal growth factor (EGF) and related ligands. We have imaged the early stages of RTK-dependent signaling in living cells using: (i) stable expression of erbB1/2/3 fused with visible fluorescent proteins (VFPs), (ii) fluorescent quantum dots (QDs) bearing epidermal growth factor (EGF-QD) and (iii) continuous confocal laser scanning microscopy and flow cytometry. Here we demonstrate that EGF-QDs are highly specific and potent in the binding and activation of the EGF receptor (erbB1), being rapidly internalized into endosomes that exhibit active trafficking and extensive fusion. EGF-QDs bound to erbB1 expressed on filopodia revealed a previously unreported mechanism of retrograde transport to the cell body. When erbB2-monomeric yellow fluorescent protein (mYFP) or erbB3-monomeric Citrine (mCitrine) were coexpressed with erbB1, the rates and extent of endocytosis of EGF-QD and the RTK-VFP demonstrated that erbB2 but not erbB3 heterodimerizes with erbB1 after EGF stimulation, thereby modulating EGF-induced signaling. QD-ligands will find widespread use in basic research and biotechnological developments.	Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, Lab Elect Cuant, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, RA-1428 Buenos Aires, DF, Argentina	Max Planck Society; University of Buenos Aires; University of Buenos Aires	Lidke, DS (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Biol, Fassberg 11, D-37077 Gottingen, Germany.	dlidke@gwdg.de; tjovin@gwdg.de	Post, Janine N./E-9983-2011; Heintzmann, Rainer/I-5667-2012; Heintzmann, Rainer/AAY-4849-2020; Nagy, Peter/D-2188-2013	Post, Janine N./0000-0002-6645-6583; Heintzmann, Rainer/0000-0002-4950-1936; Nagy, Peter/0000-0002-7466-805X				Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; Hasson T, 2003, J CELL SCI, V116, P3453, DOI 10.1242/jcs.00669; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lidke DS, 2003, BIOCHEM SOC T, V31, P1020; Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Nagy P, 2003, EXP CELL RES, V285, P39, DOI 10.1016/S0014-4827(02)00050-2; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Wilkinson JC, 2002, BIOCHEMISTRY-US, V41, P8, DOI 10.1021/bi015839l; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	31	687	721	1	153	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					198	203		10.1038/nbt929	http://dx.doi.org/10.1038/nbt929			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14704683				2022-12-25	WOS:000188730500019
J	McCarroll, SA; Murphy, CT; Zou, SG; Pletcher, SD; Chin, CS; Jan, YN; Kenyon, C; Bargmann, CI; Li, H				McCarroll, SA; Murphy, CT; Zou, SG; Pletcher, SD; Chin, CS; Jan, YN; Kenyon, C; Bargmann, CI; Li, H			Comparing genomic expression patterns across species identifies shared transcriptional profile in aging	NATURE GENETICS			English	Article							MESSENGER-RNA DECAY; GENE-EXPRESSION; C-ELEGANS; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; LIFE-SPAN; CALORIC RESTRICTION; OXIDATIVE STRESS; INSULIN-RECEPTOR; WIDE ANALYSIS	We developed a method for systematically comparing gene expression patterns across organisms using genome-wide comparative analysis of DNA microarray experiments. We identified analogous gene expression programs comprising shared patterns of regulation across orthologous genes. Biological features of these patterns could be identified as highly conserved subpatterns that correspond to Gene Ontology categories. Here, we demonstrate these methods by analyzing a specific biological process, aging, and show that similar analysis can be applied to a range of biological processes. We found that two highly diverged animals, the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster, implement a shared adult-onset expression program of genes involved in mitochondrial metabolism, DNA repair, catabolism, peptidolysis and cellular transport. Most of these changes were implemented early in adulthood. Using this approach to search databases of gene expression data, we found conserved transcriptional signatures in larval development, embryogenesis, gametogenesis and mRNA degradation.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; UCL, Dept Biol, London, England; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Li, H (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	haoli@genome.ucsf.edu	McCarroll, Steven A/A-8433-2009	Kenyon, Cynthia/0000-0003-3446-2636; Bargmann, Cornelia/0000-0002-8484-0618; McCarroll, Steven/0000-0002-6954-8184; Murphy, Coleen/0000-0002-8257-984X; Jan, Yuh Nung/0000-0003-1367-6299				Alter O, 2003, P NATL ACAD SCI USA, V100, P3351, DOI 10.1073/pnas.0530258100; Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Cuadras MA, 2002, J VIROL, V76, P4467, DOI 10.1128/JVI.76.9.4467-4482.2002; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Detweiler CS, 2001, P NATL ACAD SCI USA, V98, P5850, DOI 10.1073/pnas.091110098; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lewis JA, 1995, METHOD CELL BIOL, V48, P4; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Lund J, 2002, CURR BIOL, V12, P1566, DOI 10.1016/S0960-9822(02)01146-6; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; SOMANI SM, 1992, INT J CLIN PHARM TH, V30, P1; Stoeckert CJ, 2002, NAT GENET, V32, P469, DOI 10.1038/ng1028; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Teichmann SA, 2002, TRENDS BIOTECHNOL, V20, P407, DOI 10.1016/S0167-7799(02)02032-2; van Noort V, 2003, TRENDS GENET, V19, P238, DOI 10.1016/S0168-9525(03)00056-8; Wang DYC, 1999, P ROY SOC B-BIOL SCI, V266, P163, DOI 10.1098/rspb.1999.0617; Wang W, 2002, P NATL ACAD SCI USA, V99, P16893, DOI 10.1073/pnas.252638199; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	50	320	336	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					197	204		10.1038/ng1291	http://dx.doi.org/10.1038/ng1291			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14730301	Bronze			2022-12-25	WOS:000188542700024
J	Kobielak, A; Pasolli, HA; Fuchs, E				Kobielak, A; Pasolli, HA; Fuchs, E			Mammalian formin-1 participates in adherens junctions and polymerization of linear actin cables	NATURE CELL BIOLOGY			English	Article							CELL-CELL ADHESION; ALPHA-CATENIN; SACCHAROMYCES-CEREVISIAE; ARP2/3 COMPLEX; YEAST CYTOKINESIS; CAPPING PROTEIN; BETA-CATENIN; LIMB-BUD; NUCLEATION; BINDING	During epithelial sheet formation, linear actin cables assemble at nascent adherens junctions. This process requires alpha-catenin and actin polymerization, although the underlying mechanism is poorly understood. Here, we show that formin-1 interacts with alpha-catenin, localizes to adherens junctions and nucleates unbranched actin filaments. Furthermore, disruption of the alpha-catenin-formin-1 interaction blocks assembly of radial actin cables and perturbs intercellular adhesion. A fusion protein of the beta-catenin-binding domain of alpha-catenin with the actin polymerization domains of formin-1 rescues formation of adherens junctions and associated actin cables in alpha-catenin-null keratinocytes. These findings provide new insight into how alpha-catenin orchestrates actin dynamics during intercellular junction formation.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, 1230 York Ave,Box 300, New York, NY 10021 USA.		Fuchs, Elaine/G-1565-2016	Kobielak, Agnieszka/0000-0002-9293-0787; Pasolli, Hilda Amalia/0000-0003-3899-3530	NIAMS NIH HHS [R01 AR027883, R01 AR027883-28, R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Heil-Chapdelaine RA, 1999, J CELL BIOL, V144, P809, DOI 10.1083/jcb.144.5.809; Huber O, 1997, J CELL SCI, V110, P1759; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; JACKSONGRUSBY L, 1992, GENE DEV, V6, P29, DOI 10.1101/gad.6.1.29; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Leader B, 2002, NAT CELL BIOL, V4, P921, DOI 10.1038/ncb880; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Lew DJ, 2002, NAT CELL BIOL, V4, pE29, DOI 10.1038/ncb0202-e29; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Tepass U, 2002, BIOESSAYS, V24, P690, DOI 10.1002/bies.10129; Tolliday N, 2002, CURR BIOL, V12, P1864, DOI 10.1016/S0960-9822(02)01238-1; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645; YONEMURA S, 1995, J CELL SCI, V108, P127; Zuniga A, 1999, DEVELOPMENT, V126, P13	50	293	296	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					21	U2		10.1038/ncb1075	http://dx.doi.org/10.1038/ncb1075			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14647292	Green Accepted			2022-12-25	WOS:000187802600009
J	Millar, DG; Garza, KM; Odermatt, B; Elford, AR; Ono, N; Li, Z; Ohashi, PS				Millar, DG; Garza, KM; Odermatt, B; Elford, AR; Ono, N; Li, Z; Ohashi, PS			Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo	NATURE MEDICINE			English	Article							HEAT-SHOCK-PROTEIN; IMMATURE DENDRITIC CELLS; GP96 INDUCES MATURATION; NF-KAPPA-B; CROSS-PRESENTATION; PEPTIDE COMPLEXES; CUTTING EDGE; RECEPTOR; ACTIVATION; INDUCTION	Pathogens or pathogen- associated molecular patterns can signal to cells of the innate immune system and trigger effective adaptive immunity. However, relatively little is known about how the innate immune system detects tissue injury or necrosis. Evidence suggests that the release of heat- shock proteins (HSPs) may provide adjuvant- like signals, but the ability of HSPs to promote activation or tolerance in vivo has not been addressed. In this study we show that Hsp70 promotes dendritic cell (DC) function and, together with antigen, triggers autoimmune disease in vivo.	Ontario Canc Inst, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Texas, Dept Biol Sci, El Paso, TX 79968 USA; Univ Zurich Hosp, Dept Expt Pathol, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Connecticut, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT 06030 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Texas System; University of Texas El Paso; University of Zurich; University Zurich Hospital; University of Connecticut	Ohashi, PS (corresponding author), Ontario Canc Inst, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2M9, Canada.	pohashi@uhnres.utoronto.ca		ONO, NOBUYUKI/0000-0003-0709-4858; Ohashi, Pamela S./0000-0003-2915-9317; Millar, Douglas/0000-0002-8640-7148	NATIONAL CANCER INSTITUTE [K08CA090337] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR008124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008012] Funding Source: NIH RePORTER; NCI NIH HHS [CA90337] Funding Source: Medline; NCRR NIH HHS [SG12RR08124] Funding Source: Medline; NIGMS NIH HHS [S06GM08012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bansal-Pakala P, 2001, NAT MED, V7, P907, DOI 10.1038/90942; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1999, J IMMUNOL, V162, P3141; Chan VSF, 2002, EUR J IMMUNOL, V32, P1223, DOI 10.1002/1521-4141(200205)32:5<1223::AID-IMMU1223>3.0.CO;2-5; Chen W, 1999, J IMMUNOL, V162, P3212; CHILLER JM, 1973, J EXP MED, V137, P740, DOI 10.1084/jem.137.3.740; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LIU B, IN PRESS P NATL ACAD; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nguyen LT, 2002, J EXP MED, V195, P423, DOI 10.1084/jem.20010032; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Schuurhuis DH, 2000, J EXP MED, V192, P145, DOI 10.1084/jem.192.1.145; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4	55	217	233	1	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1469	1476		10.1038/nm962	http://dx.doi.org/10.1038/nm962			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625545				2022-12-25	WOS:000186845400029
J	Allen, M; Heinzmann, A; Noguchi, E; Abecasis, G; Broxholme, J; Ponting, CP; Bhattacharyya, S; Tinsley, J; Zhang, YM; Holt, R; Jones, EY; Lench, N; Carey, A; Jones, H; Dickens, NJ; Dimon, C; Nicholls, R; Baker, C; Xue, LZ; Townsend, E; Kabesch, M; Weiland, SK; Carr, D; von Mutius, E; Adcock, IM; Barnes, PJ; Lathrop, GM; Edwards, M; Moffatt, MF; Cookson, WOCM				Allen, M; Heinzmann, A; Noguchi, E; Abecasis, G; Broxholme, J; Ponting, CP; Bhattacharyya, S; Tinsley, J; Zhang, YM; Holt, R; Jones, EY; Lench, N; Carey, A; Jones, H; Dickens, NJ; Dimon, C; Nicholls, R; Baker, C; Xue, LZ; Townsend, E; Kabesch, M; Weiland, SK; Carr, D; von Mutius, E; Adcock, IM; Barnes, PJ; Lathrop, GM; Edwards, M; Moffatt, MF; Cookson, WOCM			Positional cloning of a novel gene influencing asthma from Chromosome 2q14	NATURE GENETICS			English	Article							GENOME-WIDE SEARCH; AIRWAY HYPERRESPONSIVENESS; LINKAGE DISEQUILIBRIUM; POLYMORPHISM; ASSOCIATION; FAMILIES; LOCI; ATOPY; MICE; MAPS	Asthma is a common disease in children and young adults. Four separate reports have linked asthma and related phenotypes to an ill-defined interval between 2q14 and 2q32 (refs. 1 4), and two mouse genome screens have linked bronchial hyper-responsiveness to the region homologous to 2q14 ( refs. 5,6). We found and replicated association between asthma and the D2S308 microsatellite, 800 kb distal to the IL1 cluster on 2q14. We sequenced the surrounding region and constructed a comprehensive, high-density, single-nucleotide polymorphism (SNP) linkage disequilibrium (LD) map. SNP association was limited to the initial exons of a solitary gene of 3.6 kb (DPP10), which extends over 1 Mb of genomic DNA. DPP10 encodes a homolog of dipeptidyl peptidases (DPPs) that cleave terminal dipeptides from cytokines and chemokines, and it presents a potential new target for asthma therapy.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Oxagen, Milton Pk, Oxon, England; Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 2JD, England; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany; Natl Heart & Lung Inst, Dept Thorac Med, London, England; Ctr Natl Genotypage, Evry, France	University of Oxford; Wellcome Centre for Human Genetics; Oxagen Limited; University of Oxford; University of Munich; Ulm University; Imperial College London; CEA; UDICE-French Research Universities; Universite Paris Saclay	Cookson, WOCM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Abecasis, Goncalo R/B-7840-2010; Cookson, William/HHC-1790-2022; Lench, Nicholas/AAB-1791-2021; Jones, Yvonne/J-2293-2016; Kabesch, Michael/AAB-5701-2020; Ponting, Chris/AAV-2621-2021; Adcock, Ian/L-3217-2019; Kabesch, Michael/GZM-1583-2022; Jones, Yvonne/N-8111-2019; Dickens, Nicholas/G-1445-2013	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Abecasis, Goncalo/0000-0003-1509-1825; Ponting, Chris/0000-0003-0202-7816; Lench, Nicholas/0000-0002-6108-0759; Dickens, Nicholas/0000-0003-0492-5855; von Mutius, Erika/0000-0002-8893-4515; Zhang, Youming/0000-0001-5403-4044; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; BAILLY S, 1993, EUR J IMMUNOL, V23, P1240, DOI 10.1002/eji.1830230607; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Di Giovine F. S., 1992, Human Molecular Genetics, V1, P450; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; EPPLEN C, 1994, HUM MOL GENET, V3, P1710, DOI 10.1093/hmg/3.9.1710; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Qi SY, 2003, BIOCHEM J, V373, P179, DOI 10.1042/BJ20021914; Rao NV, 1997, J BIOL CHEM, V272, P10260; SHAM PC, 1995, ANN HUM GENET, V59, P323, DOI 10.1111/j.1469-1809.1995.tb00751.x; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; 1987, AM REV RESP DIS, V136, P225	30	242	257	1	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					258	263		10.1038/ng1256	http://dx.doi.org/10.1038/ng1256			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14566338				2022-12-25	WOS:000186273300022
J	Hagan, CR; Sheffield, RF; Rudin, CM				Hagan, CR; Sheffield, RF; Rudin, CM			Human Alu element retrotransposition induced by genotoxic stress	NATURE GENETICS			English	Article							TRANSCRIPTION; SEQUENCES; REPEATS; SINES	Alu elements are found exclusively in primate species and comprise over 10% of the human genome. To better define the mechanisms responsible for Alu replication, we introduced a human Alu element into mouse cells. We report that Alu retrotransposition can be induced in mouse cells by exposure to the topoisomerase II inhibitor etoposide and is mediated in trans by endogenous mouse long interspersed elements (LINEs).	Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Rudin, CM (corresponding author), Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465				Brosius J, 1999, GENETICA, V107, P209, DOI 10.1023/A:1004018519722; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Felix CA, 1998, LEUKEMIA, V12, P976, DOI 10.1038/sj.leu.2401026; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kajikawa M, 2002, CELL, V111, P433, DOI 10.1016/S0092-8674(02)01041-3; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Roy AM, 2000, J MOL BIOL, V302, P17, DOI 10.1006/jmbi.2000.4027; Rudin CM, 2001, GENE CHROMOSOME CANC, V30, P64, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1066>3.0.CO;2-F; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1	14	95	97	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					219	220		10.1038/ng1259	http://dx.doi.org/10.1038/ng1259			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14578886				2022-12-25	WOS:000186273300016
J	Phan, V; Errington, F; Cheong, SC; Kottke, T; Gough, M; Altmann, S; Brandenburger, A; Emery, S; Strome, S; Bateman, A; Bonnotte, B; Melcher, A; Vile, R				Phan, V; Errington, F; Cheong, SC; Kottke, T; Gough, M; Altmann, S; Brandenburger, A; Emery, S; Strome, S; Bateman, A; Bonnotte, B; Melcher, A; Vile, R			A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines	NATURE MEDICINE			English	Article							RETROVIRAL VECTORS; CLINICAL-TRIAL; VACCINATION; GLYCOPROTEIN; IMMUNITY; THERAPY	Fusion of tumor cells with antigen-presenting cells (APCs) has been proposed for the preparation of cancer vaccines. However, generation of these hybrids, using physical or chemical methods such as electrofusion or polyethylene glycol (PEG), has been difficult to standardize. Characterization of cell fusion has also been problematic because of difficulties in differentiating fusion from cell aggregation, leakage of cellular dyes and dendritic-cell (DC) phagocytosis of tumor material. In this report, we describe a new method to generate hybrid cell vaccines, based on gene transfer of a viral fusogenic membrane glycoprotein (FMG) into tumor cells, and incorporate a genetic method by which true hybrid formation can be unambiguously detected. We describe a new class of tumor cell-DC hybrid that can be rapidly isolated after cell fusion. These hybrids are highly potent in in vitro antigen presentation assays, target lymph nodes in vivo and are powerful immunogens against established metastatic disease.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; St James Hosp, CRUK Oncol Unit, Leeds LS9 7TF, W Yorkshire, England; Free Univ Brussels, B-6041 Gosselies, Belgium; AstraZeneca, Alderley Pk SK10, Cheshire, England; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Fac Med, INSERM, U517, F-21079 Dijon, France; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Saint James's University Hospital; AstraZeneca; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Mayo Clinic	Vile, R (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	vile.richard@mayo.edu	Errington-Mais, Fiona/AAK-7245-2020; Gough, Michael/AAY-3419-2020; Bonnotte, Bernard/ABA-2525-2021	Gough, Michael/0000-0002-5575-0074; Bonnotte, Bernard/0000-0002-1098-4598; Errington-Mais, Fiona/0000-0003-2155-534X	NATIONAL CANCER INSTITUTE [R01CA085931, P50CA091956, R01CA094180] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA91956, R01 CA094180, R01 CA85931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Bateman A, 2000, CANCER RES, V60, P1492; BATEMAN A, 2002, THESIS OPEN U; Diaz RM, 2000, GENE THER, V7, P1656, DOI 10.1038/sj.gt.3301277; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; Fielding AK, 2000, HUM GENE THER, V11, P817, DOI 10.1089/10430340050015437; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Kikuchi T, 2001, CANCER IMMUNOL IMMUN, V50, P337, DOI 10.1007/s002620100205; Koido S, 2002, J IMMUNOL, V168, P2111, DOI 10.4049/jimmunol.168.5.2111; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Linardakis E, 2002, CANCER RES, V62, P5495; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; Trefzer U, 2000, INT J CANCER, V85, P618; Trefzer U, 2000, METH MOLEC MED, V35, P469, DOI 10.1385/1-59259-086-1:469; Trefzer U, 2000, E SCHERING RES FDN W, V30, P155; Tsujimoto H, 2001, INT J ONCOL, V19, P89; VILE RG, 1995, VIROLOGY, V214, P307, DOI 10.1006/viro.1995.9923; Walden P, 2000, ADV EXP MED BIOL, V465, P347; Wang JL, 1998, J IMMUNOL, V161, P5516	20	60	65	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1215	1219		10.1038/nm923	http://dx.doi.org/10.1038/nm923			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925849				2022-12-25	WOS:000185061600036
J	Kuroiwa, Y; Kasinathan, P; Matsushita, H; Sathiyaselan, J; Sullivan, EJ; Kakitani, M; Tomizuka, K; Ishida, I; Robl, JM				Kuroiwa, Y; Kasinathan, P; Matsushita, H; Sathiyaselan, J; Sullivan, EJ; Kakitani, M; Tomizuka, K; Ishida, I; Robl, JM			Sequential targeting of the genes encoding immunoglobulin-mu and prion protein in cattle	NATURE GENETICS			English	Article							NUCLEAR TRANSFER; STEM-CELLS; CALVES; RECOMBINATION; EXPRESSION; GENOME; FETAL; PIGS	Gene targeting is accomplished using embryonic stem cells in the mouse but has been successful, only using primary somatic cells followed by embryonic cloning, in other species. Gene targeting in somatic cells versus embryonic stem cells is a challenge; consequently, there are few reported successes and none include the targeting of transcriptionally silent genes or double targeting to produce homozygotes. Here, we report a sequential gene targeting system for primary fibroblast cells that we used to knock out both alleles of a silent gene, the bovine gene encoding immunoglobulin-mu (IGHM), and produce both heterozygous and homozygous knockout calves. We also carried out sequential knockout targeting of both alleles of a gene that is active in fibroblasts, encoding the bovine prion protein ( PRNP), in the same genetic line to produce doubly homozygous knockout fetuses. The sequential gene targeting system we used alleviates the need for germline transmission for complex genetic modifications and should be broadly applicable to gene functional analysis and to biomedical and agricultural applications.	Hematech, Sioux Falls, SD 57106 USA; Gemini Sci, San Diego, CA 92109 USA; Kirin Brewery Co Ltd, Div Pharmaceut, Shibuya Ku, Tokyo, Japan	Kirin Brewery Company Limited	Robl, JM (corresponding author), Hematech, 4401 S Technol Dr, Sioux Falls, SD 57106 USA.	i-ishida@kirin.co.jp; jrobl@hematech.com		Sullivan, Eddie/0000-0001-7468-2006				Abuin A, 1996, MOL CELL BIOL, V16, P1851; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chesne P, 2002, NAT BIOTECHNOL, V20, P366, DOI 10.1038/nbt0402-366; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Denning C, 2003, REPRODUCTION, V126, P1, DOI 10.1530/rep.0.1260001; Denning C, 2001, NAT BIOTECHNOL, V19, P559, DOI 10.1038/89313; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Kuroiwa Y, 2002, NAT BIOTECHNOL, V20, P889, DOI 10.1038/nbt727; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Piedrahita JA, 2000, THERIOGENOLOGY, V53, P105, DOI 10.1016/S0093-691X(99)00244-7; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Sharma A, 2003, TRANSPLANTATION, V75, P430, DOI 10.1097/01.TP.0000053615.98201.77; Sullivan EJ, 2004, BIOL REPROD, V70, P146, DOI 10.1095/biolreprod.103.021220; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Thomson AJ, 2003, REPRODUCTION, P495; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Wang Bin, 2003, Reprod Biol Endocrinol, V1, P103, DOI 10.1186/1477-7827-1-103; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Zhou Q, 2003, SCIENCE, V302, P1179, DOI 10.1126/science.1088313	26	123	196	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					775	780		10.1038/ng1373	http://dx.doi.org/10.1038/ng1373			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15184897	Bronze			2022-12-25	WOS:000222354100031
J	Dewannieux, M; Dupressoir, A; Harper, F; Pierron, G; Heidmann, T				Dewannieux, M; Dupressoir, A; Harper, F; Pierron, G; Heidmann, T			Identification of autonomous IAP LTR retrotransposons mobile in mammalian cells	NATURE GENETICS			English	Article							TY1 RETROTRANSPOSITION; RNA INTERFERENCE; GENE; ACTIVATION; SEQUENCE; ELEMENTS; FAMILY	Mammalian genomes contain two main classes of retrotransposons, the well-characterized long and short interspersed nuclear elements, which account for similar to30% of the genome, and the long terminal repeat (LTR) retrotransposons, which resemble the proviral integrated form of retroviruses, except for the absence of an envelope gene in some cases. Genetic studies confirmed mobility of the latter class of elements in mice, with a high proportion of phenotypic mutations consequent to transposition of the intracisternal A particle (IAP) family of LTR retrotransposons(1). Using the mouse genome sequence and an efficient ex vivo retrotransposition assay, we identified functional, master IAP copies that encode all the enzymatic and structural proteins necessary for their autonomous transposition in heterologous cells. By introducing mutations, we found that the three genes gag, prt and pol are all required for retrotransposition and identified the IAP gene products by electron microscopy in the form of intracellular A-type particles in the transfected cells. These prototypic elements, devoid of an envelope gene, are the first LTR retrotransposons autonomous for transposition to be identified in mammals. Their high rates of retrotransposition indicate that they are potent insertional mutagens that could serve as safe ( noninfectious) genetic tools in a large panel of cells.	Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, F-94805 Villejuif, France; Inst Andre Lwoff, UPR 1983, Lab Replicat Adn & Ultrastruct Noyau, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, Rue Camille Desmoulins, F-94805 Villejuif, France.	heidmann@igr.fr	Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513; Dewannieux, Marie/0000-0003-3918-2414				BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; Bernstein E, 2001, RNA, V7, P1509; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Esnault C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.11.e49; Fehrmann F, 1997, VIROLOGY, V235, P352, DOI 10.1006/viro.1997.8708; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; KAWAKAMI K, 1993, GENETICS, V135, P309; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LUEDERS KK, 1993, MOL CELL BIOL, V13, P7439, DOI 10.1128/MCB.13.12.7439; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Welker R, 1997, J VIROL, V71, P5209, DOI 10.1128/JVI.71.7.5209-5217.1997; XU H, 1990, Proceedings of the National Academy of Sciences of the United States of America, V87, P8360, DOI 10.1073/pnas.87.21.8360	23	107	108	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					534	539		10.1038/ng1353	http://dx.doi.org/10.1038/ng1353			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107856	Bronze			2022-12-25	WOS:000221183000030
J	Nygren, JM; Jovinge, S; Breitbach, M; Sawen, P; Roll, W; Hescheler, J; Taneera, J; Fleischmann, BK; Jacobsen, SEW				Nygren, JM; Jovinge, S; Breitbach, M; Sawen, P; Roll, W; Hescheler, J; Taneera, J; Fleischmann, BK; Jacobsen, SEW			Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation	NATURE MEDICINE			English	Article							STEM-CELLS; PROGENITOR CELLS; MYOCARDIAL-INFARCTION; PURKINJE NEURONS; IN-VIVO; TRANSPLANTATION; EXPRESSION; MUSCLE; BLOOD; CARDIOMYOPLASTY	Recent studies have suggested that bone marrow cells might possess a much broader differentiation potential than previously appreciated. In most cases, the reported efficiency of such plasticity has been rather low and, at least in some instances, is a consequence of cell fusion. After myocardial infarction, however, bone marrow cells have been suggested to extensively regenerate cardiomyocytes through transdifferentiation. Although bone marrow-derived cells are already being used in clinical trials, the exact identity, longevity and fate of these cells in infarcted myocardium have yet to be investigated in detail. Here we use various approaches to induce acute myocardial injury and deliver transgenically marked bone marrow cells to the injured myocardium. We show that unfractionated bone marrow cells and a purified population of hematopoietic stem and progenitor cells efficiently engraft within the infarcted myocardium. Engraftment was transient, however, and hematopoietic in nature. In contrast, bone marrow-derived cardiomyocytes were observed outside the infarcted myocardium at a low frequency and were derived exclusively through cell fusion.	Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden; Lund Univ, Univ Hosp MAS, Dept Cardiol, S-20502 Malmo, Sweden; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Univ Bonn, Dept Cardiac Surg, D-53105 Bonn, Germany; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany	Lund University; Lund University; Skane University Hospital; University of Bonn; University of Bonn; University of Cologne	Jacobsen, SEW (corresponding author), Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, BMC B10,Klin Gatan 26, S-22184 Lund, Sweden.	Sten.Jacobsen@stemcell.lu.se	Jacobsen, Sten Eirik W/D-3974-2018	Jacobsen, Sten Eirik W/0000-0002-1362-3659; Taneera, Jalal/0000-0002-3341-1063; Roell, Wilhelm/0000-0002-2213-5024; Nygren, Jens M/0000-0002-3576-2393				Agbulut O, 2003, CARDIOVASC RES, V58, P451, DOI 10.1016/S0008-6363(03)00281-5; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bensinger W I, 2001, Rev Clin Exp Hematol, V5, P67, DOI 10.1046/j.1468-0734.2001.00033.x; Borge OJ, 1999, BLOOD, V94, P3781, DOI 10.1182/blood.V94.11.3781.423k04_3781_3790; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Geiger H, 2002, BLOOD, V100, P721, DOI 10.1182/blood.V100.2.721; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kronenwett R, 2000, STEM CELLS, V18, P320, DOI 10.1634/stemcells.18-5-320; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Matsubara H, 2004, LANCET, V363, P746, DOI 10.1016/S0140-6736(04)15713-9; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Roell W, 2002, TRANSPLANTATION, V73, P462, DOI 10.1097/00007890-200202150-00022; Roell W, 2002, CIRCULATION, V105, P2435, DOI 10.1161/01.CIR.0000016063.66513.BB; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	47	813	896	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					494	501		10.1038/nm1040	http://dx.doi.org/10.1038/nm1040			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107841	Green Published			2022-12-25	WOS:000221242400027
J	Yuan, YZ; Shen, HM; Franklin, DS; Scadden, DT; Cheng, T				Yuan, YZ; Shen, HM; Franklin, DS; Scadden, DT; Cheng, T			In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, P18(INK4C)	NATURE CELL BIOLOGY			English	Letter							DEPENDENT KINASE INHIBITORS; CDK INHIBITORS; TRANSPLANTATION; TUMORIGENESIS; REPOPULATION; REGULATORS; PROGENITOR; P27(KIP1); CAPACITY; KINETICS	Self-renewal of stem cells is critical for tissue repair and maintenance of organ integrity in most mammalian systems. The relative asymmetry between self-renewal and differentiation in balance with apoptosis determines the size and durability of a stem-cell pool. Regulation of the cell cycle is one of the fundamental mechanisms underlying determination of cell fate. Absence of p21(Cip1/Waf1), a late G1-phase cyclin-dependent kinase inhibitor (CKI), has previously been shown to enable cell-cycle entry of haematopoietic stem cells, but leads to premature exhaustion of the stem cells under conditions of stress. We show here that deletion of an early G1-phase CKI, p18(INK4C), results in strikingly improved long-term engraftment, largely by increasing self-renewing divisions of the primitive cells in murine transplant models. Therefore, different CKIs have highly distinct effects on the kinetics of stem cells, possibly because of their active position in the cell cycle, and p18(INK4C) appears to be a strong inhibitor limiting the potential of stem-cell self-renewal in vivo.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Boston, MA 02129 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School; Massachusetts General Hospital	Cheng, T (corresponding author), Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.	chengt@msx.upmc.edu		Cheng, Tao/0000-0002-5925-2769	NHLBI NIH HHS [HL70561] Funding Source: Medline; NIDDK NIH HHS [DK02761] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002761] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 2002, INT J HEMATOL, V75, P460, DOI 10.1007/BF02982107; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; HARRISON DE, 1980, BLOOD, V55, P77; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; MAUCH P, 1989, BLOOD, V74, P872; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Osawa M, 1996, J IMMUNOL, V156, P3207; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SPANGRUDE GJ, 1989, SCIENCE, V244, P1030; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SZILVASSY SJ, 2002, HAEMATOPOIETIC STEM, P167; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807	30	211	230	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					436	442		10.1038/ncb1126	http://dx.doi.org/10.1038/ncb1126			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15122268				2022-12-25	WOS:000221432600014
J	Bjorkbacka, H; Kunjathoor, VV; Moore, KJ; Koehn, S; Ordija, CM; Lee, MA; Means, T; Halmen, K; Luster, AD; Golenbock, DT; Freeman, MW				Bjorkbacka, H; Kunjathoor, VV; Moore, KJ; Koehn, S; Ordija, CM; Lee, MA; Means, T; Halmen, K; Luster, AD; Golenbock, DT; Freeman, MW			Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; MURINE MODELS; MACROPHAGES; DEFICIENT; LESIONS; EXPRESSION; AORTA	Atherosclerosis, the leading cause of death in developed countries, has been linked to hypercholesterolemia for decades. More recently, atherosclerotic lesion progression has been shown to depend on persistent, chronic inflammation in the artery wall(1). Although several studies have implicated infectious agents in this process, the role of infection in atherosclerosis remains controversial(2-4). Because the involvement of monocytes and macrophages in the pathogenesis of atherosclerosis is well established, we investigated the possibility that macrophage innate immunity signaling pathways normally activated by pathogens might also be activated in response to hyperlipidemia. We examined atherosclerotic lesion development in uninfected, hyperlipidemic mice lacking expression of either lipopolysaccharide (LPS) receptor CD14 or myeloid differentiation protein-88 (MyD88), which transduces cell signaling events downstream of the Toll-like receptors (TLRs), as well as receptors for interleukin-1 (IL-1) and IL-18. Whereas the MyD88-deficient mice evinced a marked reduction in early atherosclerosis, mice deficient in CD14 had no decrease in early lesion development. Inactivation of the MyD88 pathway led to a reduction in atherosclerosis through a decrease in macrophage recruitment to the artery wall that was associated with reduced chemokine levels. These findings link elevated serum lipid levels to a proinflammatory signaling cascade that is also engaged by microbial pathogens.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01655 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester	Freeman, MW (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.	freeman@molbio.mgh.harvard.edu	Luster, Andrew/ABE-6504-2020; Moore, Kathryn/ABE-6416-2020; Björkbacka, Harry/I-7157-2019	Luster, Andrew/0000-0001-9679-7912; Moore, Kathryn/0000-0003-2505-2547; Björkbacka, Harry/0000-0003-3918-0857	NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL66678, HL45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, U01HL066678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Burke-Gaffney A, 2002, VASC PHARMACOL, V38, P283, DOI 10.1016/S1537-1891(02)00253-7; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Epstein SE, 2000, ARTERIOSCL THROM VAS, V20, P1417, DOI 10.1161/01.ATV.20.6.1417; Frishman William H, 2002, Cardiol Rev, V10, P199, DOI 10.1097/00045415-200207000-00004; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Ismail A, 1999, Heart Dis, V1, P233; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3; Kunjathoor VV, 2002, ARTERIOSCL THROM VAS, V22, P462, DOI 10.1161/hq0302.105378; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mach F, 2001, Curr Atheroscler Rep, V3, P243, DOI 10.1007/s11883-001-0067-y; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Moore KJ, 1996, J IMMUNOL, V157, P433; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Raschi E, 2003, BLOOD, V101, P3495, DOI 10.1182/blood-2002-08-2349; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saal LH, 2002, GENOME BIOL, V3; Tanaka E, 2003, ARTERIOSCL THROM VAS, V23, P244, DOI 10.1161/01.ATV.0000051876.26766.FD; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Wright SD, 2000, J EXP MED, V191, P1437, DOI 10.1084/jem.191.8.1437; Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631	33	511	547	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					416	421		10.1038/nm1008	http://dx.doi.org/10.1038/nm1008			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034566				2022-12-25	WOS:000220587000035
J	Kim, HJ; Hyun, Y; Park, JY; Park, MJ; Park, MK; Kim, MD; Kim, HJ; Lee, MH; Moon, J; Lee, I; Kim, J				Kim, HJ; Hyun, Y; Park, JY; Park, MJ; Park, MK; Kim, MD; Kim, HJ; Lee, MH; Moon, J; Lee, I; Kim, J			A genetic link between cold responses and flowering time through FVE in Arabidopsis thaliana	NATURE GENETICS			English	Article							MADS DOMAIN PROTEIN; HISTONE DEACETYLASE; EXPRESSION; ELEMENT; DROUGHT; ENCODES; PATHWAY	Cold induces expression of a number of genes that encode proteins that enhance tolerance to freezing temperatures in plants(1,2). A cis-acting element responsive to cold and drought, the C-repeat/dehydration-responsive element (C/DRE), was identified in the Arabidopsis thaliana stress-inducible genes RD29A(3) and COR15a(4) and found in other cold-inducible genes in various plants(1,5). C/DRE-binding factor/DRE-binding protein (CBF/DREB) is an essential component of the cold-acclimation response(1,2), but the signaling pathways and networks are mostly unknown. Here we used targeted genetic approach to isolate A. thaliana mutants with altered cold-responsive gene expression (acg) and identify ACG1 as a negative regulator of the CBF/DREB pathway. acg1 flowered late and had elevated expression of FLOWERING LOCUS C (FLC)(6), a repressor of flowering encoding a MADS-box protein. We showed that acg1 is a null allele of the autonomous pathway gene FVE. FVE encodes a homolog of the mammalian retinoblastoma-associated protein, a component of a histone deacetylase (HDAC) complex involved in transcriptional repression(7,8). We also showed that plants sense intermittent cold stress through FVE and delay flowering with increasing expression of FLC. Dual roles of FVE in regulating the flowering time and the cold response may have an evolutionary advantage for plants by increasing their survival rates.	Kumho Life & Environm Sci Lab, Puk Gu 500712, Gwangju, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Chonnam Natl Univ, Agr Plant Stress Res Ctr, Solid State Phys Lab, Kwangju 500757, South Korea; Kyung Hee Univ, Plant Metab Res Ctr, Suwon 449701, South Korea	Seoul National University (SNU); Chonnam National University; Kyung Hee University	Kim, J (corresponding author), Kumho Life & Environm Sci Lab, 1 Oryong Dong, Puk Gu 500712, Gwangju, South Korea.	jungmookkim@hanmail.net		Hyun, Youbong/0000-0002-9421-7061; Kim, Jungmook/0000-0003-1735-5564				Ausin I, 2004, NAT GENET, V36, P162, DOI 10.1038/ng1295; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; Blazquez MA, 2003, NAT GENET, V33, P168, DOI 10.1038/ng1085; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; HE Y, 2003, SCIENCE         1030, DOI DOI 10.1126/SCIENCE.1091109; Ishitani M, 1998, PLANT CELL, V10, P1151, DOI 10.1105/tpc.10.7.1151; Jaglo KR, 2001, PLANT PHYSIOL, V127, P910, DOI 10.1104/pp.010548; Jefferson R. A., 1991, PLANT MOL BIOL MAN B, V14, P1; Kim HJ, 2002, PLANT J, V29, P693, DOI 10.1046/j.1365-313X.2002.01249.x; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Rossi V, 2003, PLANT MOL BIOL, V51, P401, DOI 10.1023/A:1022090916446; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sheldon CC, 2000, CURR OPIN PLANT BIOL, V3, P418, DOI 10.1016/S1369-5266(00)00106-0; Shinozaki K, 2000, CURR OPIN PLANT BIOL, V3, P217, DOI 10.1016/S1369-5266(00)00067-4; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Wu KQ, 2003, PLANT J, V34, P241, DOI 10.1046/j.1365-313X.2003.01714.x; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	25	213	235	5	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					167	171		10.1038/ng1298	http://dx.doi.org/10.1038/ng1298			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14745450	Bronze			2022-12-25	WOS:000188542700019
J	Smani, T; Zakharov, SI; Csutora, P; Leno, E; Trepakova, ES; Bolotina, VM				Smani, T; Zakharov, SI; Csutora, P; Leno, E; Trepakova, ES; Bolotina, VM			A novel mechanism for the store-operated calcium influx pathway	NATURE CELL BIOLOGY			English	Article							INDEPENDENT PHOSPHOLIPASE A(2); INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; XENOPUS OOCYTES; BINDING DOMAIN; CA2+ STORES; ENTRY; CALMODULIN; CELLS; DEPLETION; RELEASE	Activation of store-operated channels (SOCs) and capacitative calcium influx are triggered by depletion of intracellular calcium stores. However, the exact molecular mechanism of such communication remains unclear. Recently, we demonstrated(1) that native SOC channels(2) can be activated by calcium influx factor (CIF)(3) that is produced upon depletion of calcium stores(4,5), and showed that Ca2+-independent phospholipase A(2) (iPLA(2)) has an important role in the store-operated calcium influx pathway(6). Here, we identify the key plasma-membrane-delimited events that result in activation of SOC channels. We also propose a novel molecular mechanism in which CIF displaces inhibitory calmodulin (CaM) from iPLA(2), resulting in activation of iPLA(2) and generation of lysophospholipids that in turn activate SOC channels and capacitative calcium influx. Upon refilling of the stores and termination of CIF production, CaM rebinds to iPLA(2), inhibits it, and the activity of SOC channels and capacitative calcium influx is terminated.	Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Pecs, H-7624 Pecs, Hungary	Boston University; University of Pecs	Bolotina, VM (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.	vbolotina@medicine.bu.edu	IBIS, CARDIOVASCULAR/P-3910-2015; Hajami, Tarik Smani/D-5372-2016	Hajami, Tarik Smani/0000-0002-1877-7438; Bolotina, Victoria/0000-0001-5862-181X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert AP, 2002, J PHYSIOL-LONDON, V538, P717, DOI 10.1113/jphysiol.2001.013101; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Hamilton JA, 1998, J LIPID RES, V39, P467; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Lan L, 1998, BIOCHEM J, V330, P1149, DOI 10.1042/bj3301149; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Su ZC, 2003, AM J PHYSIOL-CELL PH, V284, pC497, DOI 10.1152/ajpcell.00183.2002; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	29	226	233	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					113	+		10.1038/ncb1089	http://dx.doi.org/10.1038/ncb1089			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14730314				2022-12-25	WOS:000188668300010
J	Alivisatos, P				Alivisatos, P			The use of nanocrystals in biological detection	NATURE BIOTECHNOLOGY			English	Editorial Material							SEMICONDUCTOR QUANTUM DOTS; ENHANCED RAMAN-SCATTERING; PHOTONIC CRYSTAL; OPTICAL-PROPERTIES; PLASMON RESONANCE; CARBON NANOTUBES; NANOPARTICLES; SILVER; DNA; SHAPE	In the coming decade, the ability to sense and detect the state of biological systems and living organisms optically, electrically and magnetically will be radically transformed by developments in materials physics and chemistry. The emerging ability to control the patterns of matter on the nanometer length scale can be expected to lead to entirely new types of biological sensors. These new systems will be capable of sensing at the single-molecule level in living cells, and capable of parallel integration for detection of multiple signals, enabling a diversity of simultaneous experiments, as well as better crosschecks and controls.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Alivisatos, P (corresponding author), Univ Calif Berkeley, Dept Chem, B60 Hildebrand Hall, Berkeley, CA 94720 USA.	alivis@uclink4.berkeley.edu	Alivisatos, Paul/N-8863-2015	Alivisatos, Paul/0000-0001-6895-9048				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Argyros A, 2002, MICRON, V33, P483, DOI 10.1016/S0968-4328(01)00044-0; Artemyev MV, 2001, NANO LETT, V1, P309, DOI 10.1021/nl015545l; Asher SA, 2003, J AM CHEM SOC, V125, P3322, DOI 10.1021/ja021037h; Asher SA, 2002, ANAL BIOANAL CHEM, V373, P632, DOI 10.1007/s00216-002-1366-z; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Bayley H, 2000, ADV MATER, V12, P139, DOI 10.1002/(SICI)1521-4095(200001)12:2<139::AID-ADMA139>3.3.CO;2-H; Besse PA, 2002, APPL PHYS LETT, V80, P4199, DOI 10.1063/1.1483909; Bosnick KA, 2002, J PHYS CHEM B, V106, P8096, DOI 10.1021/jp0256241; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chapon C, 2003, INVEST RADIOL, V38, P141; Chemla YR, 2000, P NATL ACAD SCI USA, V97, P14268, DOI 10.1073/pnas.97.26.14268; Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100; Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b; Clausen-Schaumann H, 2000, CURR OPIN CHEM BIOL, V4, P524, DOI 10.1016/S1367-5931(00)00126-5; Coffey WT, 1998, PHYS REV LETT, V80, P5655, DOI 10.1103/PhysRevLett.80.5655; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Dahan M, 2001, OPT LETT, V26, P825, DOI 10.1364/OL.26.000825; Deamer DW, 2002, ACCOUNTS CHEM RES, V35, P817, DOI 10.1021/ar000138m; DiVincenzo DP, 1999, J MAGN MAGN MATER, V200, P202, DOI 10.1016/S0304-8853(99)00315-7; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Dunin-Borkowski RE, 1998, SCIENCE, V282, P1868, DOI 10.1126/science.282.5395.1868; EBBESEN TW, 1994, ANNU REV MATER SCI, V24, P235, DOI 10.1146/annurev.ms.24.080194.001315; Efros AL, 1997, PHYS REV LETT, V78, P1110, DOI 10.1103/PhysRevLett.78.1110; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; ESAKI L, 1995, CURR SCI INDIA, V69, P240; ESAKI L, 1992, NANOSTRUCT MATER, V12, P1; Fan X, 1998, APPL PHYS LETT, V73, P3190, DOI 10.1063/1.122714; GAPONENKO SV, 2000, J LUMIN, V9, P152; Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488; Guo WZ, 2003, CHEM MATER, V15, P3125, DOI 10.1021/cm034341y; Haes AJ, 2002, J AM CHEM SOC, V124, P10596, DOI 10.1021/ja020393x; Hammel PC, 2003, P IEEE, V91, P789, DOI 10.1109/JPROC.2003.811797; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; Hirsch LR, 2003, ANAL CHEM, V75, P2377, DOI 10.1021/ac0262210; Hogemann D, 2000, BIOCONJUGATE CHEM, V11, P941, DOI 10.1021/bc000079x; Horber JKH, 2003, SCIENCE, V302, P1002, DOI 10.1126/science.1067410; Hu JT, 2001, SCIENCE, V292, P2060, DOI 10.1126/science.1060810; Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365; Jackson JB, 2003, APPL PHYS LETT, V82, P257, DOI 10.1063/1.1534916; Jiang P, 2001, SCIENCE, V291, P453, DOI 10.1126/science.291.5503.453; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y; Kiraz A, 2003, J OPT B-QUANTUM S O, V5, P129, DOI 10.1088/1464-4266/5/2/303; Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667; Kneipp K, 2002, J PHYS-CONDENS MAT, V14, pR597, DOI 10.1088/0953-8984/14/18/202; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Kreibig U., 1995, OPTICAL PROPERTIES M, P1, DOI [10.1007/978-3-662-09109-8_1, DOI 10.1007/978-3-662-09109-8_1]; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Leatherdale CA, 2002, J PHYS CHEM B, V106, P7619, DOI 10.1021/jp025698c; Li LS, 2001, NANO LETT, V1, P349, DOI 10.1021/nl015559r; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Link S, 1999, J PHYS CHEM B, V103, P3073, DOI 10.1021/jp990183f; Loweth CJ, 1999, ANGEW CHEM INT EDIT, V38, P1808, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1808::AID-ANIE1808>3.0.CO;2-C; McFarland AD, 2003, NANO LETT, V3, P1057, DOI 10.1021/nl034372s; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079; Mock JJ, 2002, J CHEM PHYS, V116, P6755, DOI 10.1063/1.1462610; Murthy SN, 1999, PHARMAZIE, V54, P377; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Norris DJ, 2001, ADV MATER, V13, P371, DOI 10.1002/1521-4095(200103)13:6<371::AID-ADMA371>3.0.CO;2-K; Novak JP, 2000, J AM CHEM SOC, V122, P3979, DOI 10.1021/ja000477a; Paegel BM, 2003, CURR OPIN BIOTECH, V14, P42, DOI 10.1016/S0958-1669(02)00004-6; Parak WJ, 2002, ADV MATER, V14, P882, DOI 10.1002/1521-4095(20020618)14:12<882::AID-ADMA882>3.0.CO;2-Y; Parak WJ, 2002, CHEM MATER, V14, P2113, DOI 10.1021/cm0107878; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Reese CE, 2003, ANAL CHEM, V75, P3915, DOI 10.1021/ac034276b; Regelman DV, 2002, PHYS STATUS SOLIDI A, V190, P491, DOI 10.1002/1521-396X(200204)190:2<491::AID-PSSA491>3.0.CO;2-G; Saleh OA, 2003, NANO LETT, V3, P37, DOI 10.1021/nl0255202; Shi J, 1996, SCIENCE, V271, P937, DOI 10.1126/science.271.5251.937; Shimizu KT, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.117401; Siwy Z, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.198103; Solovyev VG, 2003, J APPL PHYS, V94, P1205, DOI 10.1063/1.1587007; Stiriba SE, 2002, ANGEW CHEM INT EDIT, V41, P1329, DOI 10.1002/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P; Taylor JR, 2000, ANAL CHEM, V72, P1979, DOI 10.1021/ac9913311; Tchikov V, 1999, J MAGN MAGN MATER, V194, P242, DOI 10.1016/S0304-8853(98)00567-8; TIEFENAUER LX, 1993, BIOCONJUGATE CHEM, V4, P347, DOI 10.1021/bc00023a007; Tran PT, 2002, PHYS STATUS SOLIDI B, V229, P427, DOI 10.1002/1521-3951(200201)229:1<427::AID-PSSB427>3.0.CO;2-K; Velev OD, 2000, CURR OPIN COLLOID IN, V5, P56, DOI 10.1016/S1359-0294(00)00039-X; Vos WL, 2001, MRS BULL, V26, P642, DOI 10.1557/mrs2001.160; Wang SP, 2002, NANO LETT, V2, P817, DOI 10.1021/n10255193; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; Wilhelm C, 2002, EUR BIOPHYS J BIOPHY, V31, P118, DOI 10.1007/s00249-001-0200-4; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Wu YY, 2002, CHEM-EUR J, V8, P1261, DOI 10.1002/1521-3765(20020315)8:6<1260::AID-CHEM1260>3.0.CO;2-Q; Xu HX, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng043; Yablonovitch E, 2001, SCI AM, V285, P46, DOI 10.1038/scientificamerican1201-46; Yoffe AD, 2001, ADV PHYS, V50, P1, DOI 10.1080/00018730010006608; Zanchet D, 2001, NANO LETT, V1, P32, DOI 10.1021/nl005508e	97	2615	2724	13	824	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					47	52		10.1038/nbt927	http://dx.doi.org/10.1038/nbt927			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704706				2022-12-25	WOS:000187745400025
J	Gil, J; Bernard, D; Martinez, D; Beach, D				Gil, J; Bernard, D; Martinez, D; Beach, D			Polycomb CBX7 has a unifying role in cellular lifespan	NATURE CELL BIOLOGY			English	Article							GROUP PROTEIN COMPLEXES; TUMOR SUPPRESSION; MAMMALIAN-CELLS; INK4A LOCUS; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; SENESCENCE; EXPRESSION; ONCOGENE; CANCER	In contrast to cancer cells and embryonic stem cells, the lifespan of primary human cells is finite. After a defined number of population doublings, cells enter in an irreversible growth-arrested state termed replicative senescence(1). Mutations of genes involved in immortalization can contribute to cancer(2,3). In a genetic screen for cDNAs bypassing replicative senescence of normal human prostate epithelial cells (HPrEC), we identified CBX7, a gene that encodes a Polycomb protein, as shown by sequence homology, its interaction with Ring1 and its localization to nuclear Polycomb bodies. CBX7 extends the lifespan of a wide range of normal human cells and immortalizes mouse fibroblasts by downregulating expression of the Ink4a/Arf locus. CBX7 does not inter-function or colocalize with Bmi1, and both can exert their actions independently of each other as shown by reverse genetics. CBX7 expression is downregulated during replicative senescence and its ablation by short-hairpin RNA (shRNA) treatment inhibited growth of normal cells though induction of the Ink4a/Arf locus. Taken together, these data show that CBX7 controls cellular lifespan through regulation of both the p16(Ink4a)/Rb and the Arf/p53 pathways.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Gil, J (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	jesus.gil@cancer.org.uk	Martinez, Lola/L-2308-2014; Martinez, Lola/ABG-2474-2020; Gil, Jesus/C-7739-2012; Bernard, David/D-6265-2018	Martinez, Lola/0000-0001-6273-6724; Gil, Jesus/0000-0002-4303-6260; Bernard, David/0000-0002-1557-2074				Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Dimri GP, 2002, CANCER RES, V62, P4736; Gunster MJ, 2001, J CELL BIOCHEM, P129, DOI 10.1002/jcb.1093; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; QUELLE DE, 1995, CELL, V83, P993; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	30	251	264	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					67	U19		10.1038/ncb1077	http://dx.doi.org/10.1038/ncb1077			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14647293				2022-12-25	WOS:000187802600015
J	Nishiwaki, K; Kubota, Y; Chigira, Y; Roy, SK; Suzuki, M; Schvarzstein, M; Jigami, Y; Hisamoto, N; Matsumoto, K				Nishiwaki, K; Kubota, Y; Chigira, Y; Roy, SK; Suzuki, M; Schvarzstein, M; Jigami, Y; Hisamoto, N; Matsumoto, K			An NDPase links ADAM protease glycosylation with organ morphogenesis in C-elegans	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS; CELL; EXPRESSION; METALLOPROTEASE; REQUIREMENTS; MIGRATION; MUTATIONS; GENETICS; COLLAGEN; HOMOLOG	In the nematode Caenorhabditis elegans, the gonad acquires two U-shaped arms through the directed migration of its distal tip cells (DTCs), which are located at the tip of the growing gonad arms(1). A member of the ADAM (a disintegrin and metalloprotease) family, MIG-17, regulates directional migration of DTCs: MIG-17 is synthesized and secreted from the muscle cells of the body wall, and diffuses to the gonad where it is required for DTC migration(2). The mig-23 mutation causes defective migration of DTCs and interacts genetically with mig-17. Here, we report that mig-23 encodes a membrane-bound nucleoside diphosphatase (NDPase) required for glycosylation and proper localization of MIG-17. Our findings indicate that an NDPase affects organ morphogenesis through glycosylation of the MIG-17 ADAM protease.	RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; Japan Sci & Technol Corp, PRESTO, Chuo Ku, Kobe, Hyogo 6500047, Japan; Natl Inst Adv Ind Sci & Technol, AIST Cent 6, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Nagoya Univ, Inst Adv Res, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	RIKEN; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Nagoya University; Japan Science & Technology Agency (JST); University of Toronto	Nishiwaki, K (corresponding author), RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan.	nishiwak@cdb.riken.go.jp	Schvarzstein, Mara/AAD-7676-2022	Schvarzstein, Mara/0000-0003-4913-2402; Kubota, Yukihiko/0000-0002-8151-9888				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BRENNER S, 1974, GENETICS, V77, P71; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gilleard JS, 1997, MOL CELL BIOL, V17, P2301, DOI 10.1128/MCB.17.4.2301; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HIRSCHBERG CB, 1996, TRANSPORTER NUCLEOTI, P105; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Iino M, 1998, ARCH BIOCHEM BIOPHYS, V352, P182, DOI 10.1006/abbi.1998.0595; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Komoszynski M, 1996, BBA-MOL CELL RES, V1310, P233, DOI 10.1016/0167-4889(95)00135-2; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; Nishiwaki K, 1999, GENETICS, V152, P985; OKKEMA PG, 1993, GENETICS, V135, P385; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Yochem J, 1998, GENETICS, V149, P1323	21	45	53	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					31	U4		10.1038/ncb1079	http://dx.doi.org/10.1038/ncb1079			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14688791				2022-12-25	WOS:000187802600010
J	Kahle, KT; Wilson, FH; Leng, Q; Lalioti, MD; O'Connell, AD; Dong, K; Rapson, AK; MacGregor, GG; Giebisch, G; Hebert, SC; Lifton, RP				Kahle, KT; Wilson, FH; Leng, Q; Lalioti, MD; O'Connell, AD; Dong, K; Rapson, AK; MacGregor, GG; Giebisch, G; Hebert, SC; Lifton, RP			WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion	NATURE GENETICS			English	Article							INHERITED HYPERTENSION; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; HYPERKALEMIA; MUTATIONS; COTRANSPORTER; ENDOCYTOSIS; CLATHRIN; PROTEIN; CL	A key question in systems biology is how diverse physiologic processes are integrated to produce global homeostasis(1). Genetic analysis can contribute by identifying genes that perturb this integration. One system orchestrates renal NaCl and K+ flux to achieve homeostasis of blood pressure and serum K+ concentration (refs. 2,3). Positional cloning implicated the serine-threonine kinase WNK4 in this process(4); clustered mutations in PRKWNK4, encoding WNK4, cause hypertension and hyperkalemia (pseudohypoaldosteronism type II, PHAII(5)) by altering renal NaCl and K+ handling. Wild-type WNK4 inhibits the renal Na-Cl cotransporter (NCCT); mutations that cause PHAII relieve this inhibition(6). This explains the hypertension of PHAII but does not account for the hyperkalemia. By expression in Xenopus laevis oocytes, we show that WNK4 also inhibits the renal K+ channel ROMK. This inhibition is independent of WNK4 kinase activity and is mediated by clathrin-dependent endocytosis of ROMK, mechanisms distinct from those that characterize WNK4 inhibition of NCCT. Most notably, the same mutations in PRKWNK4 that relieve NCCT inhibition markedly increase inhibition of ROMK. These findings establish WNK4 as a multifunctional regulator of diverse ion transporters; moreover, they explain the pathophysiology of PHAII. They also identify WNK4 as a molecular switch that can vary the balance between NaCl reabsorption and K+ secretion to maintain integrated homeostasis.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yale University	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 300 Cedar St,TAC S-341D, New Haven, CT 06510 USA.	richard.lifton@yale.edu	Leng, John/A-9359-2011; Leng, John/GRO-2256-2022	Wilson, Frederick/0000-0002-5019-0186				BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Choate KA, 2003, P NATL ACAD SCI USA, V100, P663, DOI 10.1073/pnas.242728499; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; GORDON RD, 1986, HYPERTENSION, V8, P93, DOI 10.1161/01.HYP.8.2.93; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Leipziger J, 2000, AM J PHYSIOL-RENAL, V279, pF919, DOI 10.1152/ajprenal.2000.279.5.F919; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Ortega B, 2000, J PHYSIOL-LONDON, V528, P5, DOI 10.1111/j.1469-7793.2000.00005.x; REEVES WB, 2000, KIDNEY PHYSL PATHOPH, P1333; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001	21	296	311	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2003	35	4					372	376		10.1038/ng1271	http://dx.doi.org/10.1038/ng1271			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14608358				2022-12-25	WOS:000186791000020
J	Brander, C; Walker, BD				Brander, C; Walker, BD			Gradual adaptation of HIV to human host populations: good or bad news?	NATURE MEDICINE			English	Article							T-CELL RESPONSES; SIMIAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE RESPONSES; PRIMARY INFECTION; ESCAPE MUTATIONS; VIRAL LOAD; HLA; SELECTION; IMMUNODOMINANT; EVOLUTION	The continuous evolution and adaptation of HIV to its host has produced extensive global viral diversity. Understanding the kinetics and directions of this continuing adaptation and its impact on viral fitness, immunogenicity and pathogenicity will be crucial to the successful design of effective HIV vaccines. Here we discuss some potential scenarios of viral and host coevolution.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Div AIDS, Boston, MA 02114 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Brander, C (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.			Brander, Christian/0000-0002-0548-5778				Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Brander C, 1999, J IMMUNOL, V162, P4796; BRANDER C, 2001, HIV MOL IMMUNOLOGY D; BROWNING MJ, 1990, J IMMUNOL, V145, P985; CALEF C, 2000, HIV MOL IMMUNOLOGY D; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Courgnaud V, 1998, VIROLOGY, V247, P41, DOI 10.1006/viro.1998.9217; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0; FRAHM N, 2002, HIV MOL IMMUNOLOGY D; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Goulder PJR, 2000, J VIROL, V74, P5679, DOI 10.1128/JVI.74.12.5679-5690.2000; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Goulder PJR, 2000, J EXP MED, V192, P1819, DOI 10.1084/jem.192.12.1819; Holmes EC, 2001, BIOL REV, V76, P239, DOI 10.1017/S1464793101005668; Kaur A, 2001, EUR J IMMUNOL, V31, P3207, DOI 10.1002/1521-4141(200111)31:11<3207::AID-IMMU3207>3.0.CO;2-H; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; KORBER B, 2001, HIV MOL IMMUNOLOGY D; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Norley S, 1999, IMMUNOL LETT, V66, P47, DOI 10.1016/S0165-2478(98)00184-9; OCONNOR DJ, 2001, WHERE HAVE ALL MONKE; PELLETIER E, 1996, J NIH RES, V8, P45; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	38	54	55	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1359	1362		10.1038/nm941	http://dx.doi.org/10.1038/nm941			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14595431	Bronze			2022-12-25	WOS:000186319700024
J	Herbert, M; Levasseur, M; Homer, H; Yallop, K; Murdoch, A; McDougall, A				Herbert, M; Levasseur, M; Homer, H; Yallop, K; Murdoch, A; McDougall, A			Homologue disjunction in mouse oocytes requires proteolysis of securin and cyclin B1	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS; MEIOSIS-I; XENOPUS-OOCYTES; ANAPHASE; DEGRADATION; ACTIVATION; METAPHASE; CDC20; CDH1	Disjunction of pairs of homologous chromosomes during the first meiotic division (MI) requires anaphase-promoting complex (APC)-mediated activation of separase in budding yeast(1,2) and Caenorhabditis elegans(3,4,5), but not Xenopus laevis(6,7). It is not clear which model best fits the mammalian system. Here we show that homologue disjunction in mouse oocytes is dependent on proteolysis of the separase inhibitor securin and the Cdk1 regulatory sub-unit cyclin B1. Proteolysis of both proteins was entirely dependent on their conserved destruction box (D-box) motifs, through which they are targeted to the APC(8). These data indicate that the mechanisms regulating homologue disjunction in mammalian oocytes are similar to those of budding yeast and C. elegans.	Int Ctr Life, Biosci Ctr, Sch Surg & Reprod Sci, Cell & Dev Physiol Res Grp, Newcastle Upon Tyne NE1 4EP, Tyne & Wear, England; Med Sch Newcastle Upon Tyne, Sch Cell & Mol Biosci, Cell & Dev Physiol Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Int Ctr Life, Biosci Ctr, Newcastle Fertil Ctr, Newcastle Upon Tyne NE1 4EP, Tyne & Wear, England	Newcastle University - UK	Herbert, M (corresponding author), Int Ctr Life, Biosci Ctr, Sch Surg & Reprod Sci, Cell & Dev Physiol Res Grp, Times Sq, Newcastle Upon Tyne NE1 4EP, Tyne & Wear, England.		McDougall, Alex/J-1930-2014; Homer, Hayden/K-1517-2014	McDougall, Alex/0000-0003-0324-3836; Homer, Hayden/0000-0002-3104-0449; Herbert, Mary/0000-0002-8488-2770				Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Clouston HJ, 1997, HUM GENET, V101, P30, DOI 10.1007/s004390050581; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; Golden A, 2000, J CELL BIOL, V151, P1469, DOI 10.1083/jcb.151.7.1469; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Kanatsu-Shinohara M, 2000, BIOL REPROD, V63, P1610, DOI 10.1095/biolreprod63.6.1610; Ledan E, 2001, DEV BIOL, V232, P400, DOI 10.1006/dbio.2001.0188; Levasseur M, 2000, DEVELOPMENT, V127, P631; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Siomos MF, 2001, CURR BIOL, V11, P1825, DOI 10.1016/S0960-9822(01)00588-7; STEMMANN, 2000, CELL, V107, P715; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	17	158	161	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					1023	1025		10.1038/ncb1062	http://dx.doi.org/10.1038/ncb1062			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14593421	Green Published			2022-12-25	WOS:000186273100020
J	Chan, EM; Young, EJ; Ianzano, L; Munteanu, I; Zhao, XC; Christopoulos, CC; Avanzini, G; Elia, M; Ackerley, CA; Jovic, NJ; Bohlega, S; Andermann, E; Rouleau, GA; Delgado-Escueta, AV; Minassian, BA; Scherer, SW				Chan, EM; Young, EJ; Ianzano, L; Munteanu, I; Zhao, XC; Christopoulos, CC; Avanzini, G; Elia, M; Ackerley, CA; Jovic, NJ; Bohlega, S; Andermann, E; Rouleau, GA; Delgado-Escueta, AV; Minassian, BA; Scherer, SW			Mutations in NHLRC1 cause progressive myoclonus epilepsy	NATURE GENETICS			English	Article							LAFORIN; BODIES; FAMILY	Lafora progressive myoclonus epilepsy is characterized by pathognomonic endoplasmic reticulum (ER)-associated polyglucosan accumulations. We previously discovered that mutations in EPM2A cause Lafora disease. Here, we identify a second gene associated with this disease, NHLRC1 ( also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Inst Nazl Neurol, I-20133 Milan, Italy; Oasi Inst Res Mental Retardat & Brain Aging, Dept Neurol, I-94018 Troina, Italy; Hosp Sick Children, Dept Pathol & Lab Med, Toronto, ON M5G 1X8, Canada; Clin Neurol & Psychiat Children & Youth, YU-11000 Belgrade, Serbia Monteneg, Serbia; King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Riyadh 11211, Saudi Arabia; McGill Univ, Montreal Neurol Inst, Neurogenet Unit, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Gen Hosp, Ctr Hlth, Res Inst Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Univ Calif Los Angeles, Sch Med, W Los Angeles DVA Med Ctr, Dept Neurol,Comprehens Epilepsy Program, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, W Los Angeles DVA Med Ctr, Brain Res Inst, Los Angeles, CA 90073 USA; Hosp Sick Children, Dept Pediat, Div Neurol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; IRCCS Istituto Neurologico Besta; IRCCS Oasi Maria SS; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); King Faisal Specialist Hospital & Research Center; McGill University; McGill University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Minassian, BA (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bminass@sickkids.ca; steve@genet.sickkids.on.ca	Elia, Maurizio/K-3285-2016; Scherer, Stephen W./B-3785-2013	Elia, Maurizio/0000-0002-0414-1359; Scherer, Stephen W./0000-0002-8326-1999; Delgado-Escueta, Antonio V./0000-0002-1581-6999; Young, Ted (Edwin)/0000-0003-4882-6752	Telethon [GFP01003] Funding Source: Medline	Telethon(Fondazione Telethon)		Cavanagh JB, 1999, BRAIN RES REV, V29, P265, DOI 10.1016/S0165-0173(99)00003-X; Chan EM, 2003, J MED GENET, V40, P671, DOI 10.1136/jmg.40.9.671; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Ganesh S, 2000, HUM MOL GENET, V9, P2251, DOI 10.1093/oxfordjournals.hmg.a018916; Ganesh S, 2003, HUM MOL GENET, V12, P2359, DOI 10.1093/hmg/ddg253; Ganesh S, 2002, HUM MOL GENET, V11, P1251, DOI 10.1093/hmg/11.11.1251; Ganesh S, 2002, BIOCHEM BIOPH RES CO, V291, P1134, DOI 10.1006/bbrc.2002.6590; Hatakeyama S, 2003, BIOCHEM BIOPH RES CO, V302, P635, DOI 10.1016/S0006-291X(03)00245-6; Ianzano L, 2003, GENOMICS, V81, P579, DOI 10.1016/S0888-7543(03)00094-6; Lafora GR, 1911, Z GESAMTE NEUROL PSY, V6, P1, DOI 10.1007/BF02863929; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Minassian BA, 2002, ADV NEUROL, V89, P199; Minassian BA, 1999, ANN NEUROL, V45, P262, DOI 10.1002/1531-8249(199902)45:2<262::AID-ANA20>3.0.CO;2-9; Minassian BA, 2001, ANN NEUROL, V49, P271, DOI 10.1002/1531-8249(20010201)49:2<271::AID-ANA52>3.3.CO;2-4; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7	15	211	218	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					125	127		10.1038/ng1238	http://dx.doi.org/10.1038/ng1238			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12958597				2022-12-25	WOS:000185625300007
J	Lahner, B; Gong, JM; Mahmoudian, M; Smith, EL; Abid, KB; Rogers, EE; Guerinot, ML; Harper, JF; Ward, JM; McIntyre, L; Schroeder, JI; Salt, DE				Lahner, B; Gong, JM; Mahmoudian, M; Smith, EL; Abid, KB; Rogers, EE; Guerinot, ML; Harper, JF; Ward, JM; McIntyre, L; Schroeder, JI; Salt, DE			Genomic scale profiling of nutrient and trace elements in Arabidopsis thaliana	NATURE BIOTECHNOLOGY			English	Article							FUNCTIONAL GENOMICS; PLANT; PROJECT; MUTANT; OILS	Understanding the functional connections between genes, proteins, metabolites and mineral ions is one of biology's greatest challenges in the postgenomic era. We describe here the use of mineral nutrient and trace element profiling as a tool to determine the biological significance of connections between a plant's genome and its elemental profile. Using inductively coupled plasma spectroscopy, we quantified 18 elements, including essential macro- and micronutrients and various nonessential elements, in shoots of 6,000 mutagenized M2 Arabidopsis thaliana plants. We isolated 51 mutants with altered elemental profiles. One mutant contains a deletion in FRD3, a gene known to control iron-deficiency responses in A. thaliana. Based on the frequency of elemental profile mutations, we estimate 2-4% of the A. thaliana genome is involved in regulating the plant's nutrient and trace element content. These results demonstrate the utility of elemental profiling as a useful functional genomics tool.	Purdue Univ, Ctr Plant Environm Stress Physiol, W Lafayette, IN 47907 USA; Univ Calif San Diego, Div Biol Sci, Cell & Dev Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 250, St Paul, MN 55108 USA; Purdue Univ, Dept Agron, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California San Diego; University of California System; University of California San Diego; Dartmouth College; University of Missouri System; University of Missouri Columbia; Scripps Research Institute; University of Minnesota System; University of Minnesota Twin Cities; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Salt, DE (corresponding author), Purdue Univ, Ctr Plant Environm Stress Physiol, Hort Bldg,625 Agr Mall Dr, W Lafayette, IN 47907 USA.		Rogers, Elizabeth/AAB-3643-2021; Salt, David E/B-3864-2009; Rogers, Elizabeth E/D-2087-2009	Rogers, Elizabeth/0000-0002-0545-4744; Rogers, Elizabeth E/0000-0002-0545-4744; Ward, John/0000-0001-8185-0434; Schroeder, Julian/0000-0002-3283-5972; McIntyre, Lauren/0000-0002-0077-3359				Aharoni A, 2002, PLANT MOL BIOL, V48, P99, DOI 10.1023/A:1013734019946; Chory J, 2000, PLANT PHYSIOL, V123, P423, DOI 10.1104/pp.123.2.423; Daar AS, 2002, NAT GENET, V32, P229, DOI 10.1038/ng1002-229; DANGL J, 2002, PLANT PHYSIOL, V130, P1741; Delhaize E, 1996, PLANT PHYSIOL, V111, P849, DOI 10.1104/pp.111.3.849; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Finkelstein D, 2002, PLANT MOL BIOL, V48, P119, DOI 10.1023/A:1013765922672; Guerinot ML, 2001, PLANT PHYSIOL, V125, P164, DOI 10.1104/pp.125.1.164; Jakab A, 2002, RAPID COMMUN MASS SP, V16, P2291, DOI 10.1002/rcm.862; Johnson R. A., 2007, APPL MULTIVARIATE ST, V6th; KERTEN B, 2002, PLANT MOL BIOL, V48, P133; Koller A, 2002, P NATL ACAD SCI USA, V99, P11969, DOI 10.1073/pnas.172183199; Leone M, 2002, J SPORT SCI, V20, P443, DOI 10.1080/02640410252925116; LEVITSKY VG, 2003, IN SILICO BIOL, V3, P8; Li X, 2001, PLANT J, V27, P235, DOI 10.1046/j.1365-313x.2001.01084.x; Li Xin, 2002, Funct Integr Genomics, V2, P254, DOI 10.1007/s10142-002-0076-0; Mannina L, 2003, J AGR FOOD CHEM, V51, P120, DOI 10.1021/jf025656l; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Montgomery D. C., 2012, INTRO STAT QUALITY C; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11; Rogers EE, 2002, PLANT CELL, V14, P1787, DOI 10.1105/tpc.001495; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Vermerris W, 2001, J AGR FOOD CHEM, V49, P721, DOI 10.1021/jf000740r; Williams RJP, 2001, COORDIN CHEM REV, V216, P583, DOI 10.1016/S0010-8545(00)00398-2	25	302	326	6	96	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1215	1221		10.1038/nbt865	http://dx.doi.org/10.1038/nbt865			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	12949535				2022-12-25	WOS:000185647200034
J	Johnston, LA; Sanders, AL				Johnston, LA; Sanders, AL			Wingless promotes cell survival but constrains growth during Drosophila wing development	NATURE CELL BIOLOGY			English	Article							LONG-RANGE ACTION; MORPHOGEN GRADIENT; IMAGINAL DISC; CYCLE; DEATH; GENE; MELANOGASTER; EXPRESSION; PARAMETERS; HOMOTHORAX	During animal development, organs grow to a fixed size and shape. Organ development typically begins with a rapid growth phase followed by a gradual decline in growth rate as the organ matures(1), but the regulation of either stage of growth remains unclear. The Wnt/Wingless (Wg) proteins are critical for patterning most animal organs, have diverse effects on development and have been proposed to promote organ growth(2). Here we report that contrary to this view, Wg activity actually constrains wing growth during Drosophila melanogaster wing development. In addition, we demonstrate that Wg is required for wing cell survival, particularly during the rapid growth phase of wing development. We propose that the cell-survival- and growth-constraining activities of Wg function to sculpt and delimit final wing size as part of its overall patterning programme.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Johnston, LA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NICHD NIH HHS [R01 HD042770-05, HD42770, R01 HD042770-04, R01 HD042770-03, R01 HD042770-02, R01 HD042770, R01 HD042770-01A1] Funding Source: Medline; NIGMS NIH HHS [GM51186] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042770] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Azpiazu N, 2000, DEVELOPMENT, V127, P2685; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1985, DEV BIOL, V107, P355, DOI 10.1016/0012-1606(85)90317-3; Casares F, 2000, DEVELOPMENT, V127, P1499; Chen CM, 1999, DEVELOPMENT, V126, P5441; Cifuentes FJ, 1997, P NATL ACAD SCI USA, V94, P11405, DOI 10.1073/pnas.94.21.11405; Cox RT, 2000, GENETICS, V155, P1725; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HAY BA, 1994, DEVELOPMENT, V120, P2121; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nolo R, 2001, GENETICS, V157, P307; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; SERRANO N, 1997, CURR BIOL, V7, P186; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	29	102	103	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					827	833		10.1038/ncb1041	http://dx.doi.org/10.1038/ncb1041			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12942089				2022-12-25	WOS:000185059000016
J	Barresi, R; Michele, DE; Kanagawa, M; Harper, HA; Dovico, SA; Satz, JS; Moore, SA; Zhang, WL; Schachter, H; Dumanski, JP; Cohn, RD; Nishino, I; Campbell, KP				Barresi, R; Michele, DE; Kanagawa, M; Harper, HA; Dovico, SA; Satz, JS; Moore, SA; Zhang, WL; Schachter, H; Dumanski, JP; Cohn, RD; Nishino, I; Campbell, KP			LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies	NATURE MEDICINE			English	Article							WALKER-WARBURG-SYNDROME; EYE-BRAIN DISEASE; HUMAN LARGE GENE; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; EXTRACELLULAR-MATRIX; GALNAC TRANSFERASE; LAMININ; MUTATIONS; GLYCOSYLTRANSFERASE	Several congenital muscular dystrophies caused by defects in known or putative glycosyltransferases are commonly associated with hypoglycosylation of alpha-dystroglycan (alpha-DG) and a marked reduction of its receptor function. We have investigated changes in the processing and function of alpha-DG resulting from genetic manipulation of LARGE, the putative glycosyltransferase mutated both in Large(myd) mice and in humans with congenital muscular dystrophy 1D (MDC1D). Here we show that overexpression of LARGE ameliorates the dystrophic phenotype of Large(myd) mice and induces the synthesis of glycan-enriched alpha-DG with high affinity for extracellular ligands. Notably, LARGE circumvents the alpha-DG glycosylation defect in cells from individuals with genetically distinct types of congenital muscular dystrophy. Gene transfer of LARGE into the cells of individuals with congenital muscular dystrophies restores alpha-DG receptor function, whereby glycan-enriched alpha-DG coordinates the organization of laminin on the cell surface. Our findings indicate that modulation of LARGE expression or activity is a viable therapeutic strategy for glycosyltransferase-deficient congenital muscular dystrophies.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Roy J & Luclle A Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Toronto, Hosp Sick Children, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Uppsala University; National Center for Neurology & Psychiatry - Japan	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022; Nishino, Ichizo/G-2676-2010; Cohn, Ronald/AAC-5835-2021	Barresi, Rita/0000-0001-7351-959X; Nishino, Ichizo/0000-0001-9452-112X; Campbell, Kevin/0000-0003-2066-5889; Dumanski, Jan Piotr/0000-0002-1489-1452; Moore, Steven/0000-0002-6353-7900; Kanagawa, Motoi/0000-0003-0984-6398	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD083284] Funding Source: NIH RePORTER; NICHD NIH HHS [HD83284] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213; Dubowitz T, 2000, ANN NEUROL, V47, P143, DOI 10.1002/1531-8249(200002)47:2<143::AID-ANA2>3.0.CO;2-Y; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2003, P NATL ACAD SCI USA, V100, P8910, DOI 10.1073/pnas.1537554100; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hayashi YK, 2001, NEUROLOGY, V57, P115, DOI 10.1212/WNL.57.1.115; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; Jimenez-Mallebrera C, 2003, EUR J PAEDIATR NEURO, V7, P129, DOI 10.1016/S1090-3798(03)00042-4; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kano H, 2002, BIOCHEM BIOPH RES CO, V291, P1283, DOI 10.1006/bbrc.2002.6608; Kanoff RJ, 1998, PEDIATR NEUROL, V18, P76, DOI 10.1016/S0887-8994(97)00137-9; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kondo-Iida E, 1999, HUM MOL GENET, V8, P2303, DOI 10.1093/hmg/8.12.2303; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; Longman C, 2003, NEUROMUSCULAR DISORD, V13, P645; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Nguyen HH, 2002, P NATL ACAD SCI USA, V99, P5616, DOI 10.1073/pnas.082613599; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Sabatelli P, 2003, BBA-MOL BASIS DIS, V1638, P57, DOI 10.1016/S0925-4439(03)00040-1; Saito Y, 2000, ANN NEUROL, V47, P756, DOI 10.1002/1531-8249(200006)47:6<756::AID-ANA8>3.3.CO;2-0; Takeda S, 2003, HUM MOL GENET, V12, P1449, DOI 10.1093/hmg/ddg153; Taniguchi K, 2003, HUM MOL GENET, V12, P527, DOI 10.1093/hmg/ddg043; Toda T, 2000, NEUROMUSCULAR DISORD, V10, P153, DOI 10.1016/S0960-8966(99)00109-1; Xia B, 2002, DEV BIOL, V242, P58, DOI 10.1006/dbio.2001.0530; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zhang WL, 2003, CLIN BIOCHEM, V36, P339, DOI 10.1016/S0009-9120(03)00036-5; Zhang WL, 2002, BIOCHEM J, V361, P153, DOI 10.1042/0264-6021:3610153	39	197	203	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					696	703		10.1038/nm1059	http://dx.doi.org/10.1038/nm1059			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15184894				2022-12-25	WOS:000222460400023
J	Mathur, RK; Awasthi, A; Wadhone, P; Ramanamurthy, B; Saha, B				Mathur, RK; Awasthi, A; Wadhone, P; Ramanamurthy, B; Saha, B			Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses	NATURE MEDICINE			English	Article							LEISHMANIA-MAJOR INFECTION; IL-12 PRODUCTION; CYTOKINE PRODUCTION; T-CELLS; INTERLEUKIN-12 INDUCTION; KINASE; MACROPHAGES; TH1; DIFFERENTIATION; ALPHA	Macrophages play host to Leishmania major, a parasite that causes leishmaniasis in 500,000 people annually. Macrophage-expressed CD40, a costimulatory molecule 1, induces interleukin-12 (IL-12)-dependent and interferon-gamma (IFN-gamma)-dependent host-protective immune responses to Leishmania and other intracellular pathogens(2-6). Paradoxically, IL-10, another CD40-induced cytokine in macrophages(7), promotes Leishmania infection(8). How CD40 signaling regulates the secretion of these two counteractive cytokines remains unknown. Here we show that weak CD40 signals induce extracellular stress-related kinase-1/2 (ERK-1/ 2)-dependent IL-10 expression, whereas stronger signals induce p38 mitogen-activated protein kinase (p38MAPK) dependent IL-12 production. p38MAPK and ERK-1/ 2 therefore have counter-regulatory actions. Leishmania skews CD40 signaling toward ERK-1/ 2, inducing IL-10, which inhibits activation of CD40-induced p38MAPK and expression of inducible nitric oxide synthase-2 (iNOS-2) and IL-12. ERK-1/ 2 inhibition or IL-10 neutralization restores CD40-induced p38MAPK activation and parasite killing in macrophages and the BALB/c mouse, a susceptible host. These data uncover a new immune evasion strategy, whereby Leishmania differentially modulates CD40-engaged, reciprocally functioning signaling modules, and provide a new conceptual framework for immune homeostasis.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Saha, B (corresponding author), Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.	sahab@nccs.res.in	Gangalum, Pallavi/H-1354-2013	Gangalum, Pallavi/0000-0002-3258-6523; mathur, Ramkumar/0000-0002-9317-2631				Awasthi A, 2003, J EXP MED, V197, P1037, DOI 10.1084/jem.20022033; Belkaid Y, 1998, EUR J IMMUNOL, V28, P1389, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1389::AID-IMMU1389&gt;3.0.CO;2-1; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Dong C, 2001, CURR OPIN HEMATOL, V8, P47, DOI 10.1097/00062752-200101000-00009; Feng GJ, 1999, J IMMUNOL, V163, P6403; Foey AD, 2000, CYTOKINE, V12, P1496, DOI 10.1006/cyto.2000.0750; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Groux H, 1999, J IMMUNOL, V162, P1723; Heinzel FP, 1998, CELL IMMUNOL, V184, P129, DOI 10.1006/cimm.1998.1267; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MOSMANN TR, 1991, IMMUNOL TODAY, V12, P49; Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705; Park SJ, 2001, BIOCHEM BIOPH RES CO, V287, P1140, DOI 10.1006/bbrc.2001.5713; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Samten B, 2003, J IMMUNOL, V170, P3180, DOI 10.4049/jimmunol.170.6.3180; Scott P, 1998, IMMUNOL RES, V17, P229, DOI 10.1007/BF02786447; Speirs K, 2002, J IMMUNOL, V168, P4406, DOI 10.4049/jimmunol.168.9.4406; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Tachimoto H, 2000, J ALLERGY CLIN IMMUN, V106, P141, DOI 10.1067/mai.2000.107043; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; Xu DM, 1998, J IMMUNOL, V160, P1285; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	30	195	200	1	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					540	544		10.1038/nm1045	http://dx.doi.org/10.1038/nm1045			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107845				2022-12-25	WOS:000221242400034
J	Wang, W; Yu, HJ; Long, MY				Wang, W; Yu, HJ; Long, MY			Duplication-degeneration as a mechanism of gene fission and the origin of new genes in Drosophila species	NATURE GENETICS			English	Article							EVOLUTION; MELANOGASTER; FUSION; RETROPOSONS; SELECTION; MUTATIONS; PROTEINS; JINGWEI; EXONS; LOCUS	Gene fission and fusion, the processes by which a single gene is split into two separate genes and two adjacent genes are fused into a single gene, respectively, are among the primary processes that generate new genes(1-4). Despite their seeming reversibility(4,5), nothing is known about the mechanism of gene fission. Because the nucleotide sequences of fission genes record little about their origination process, conventional analysis of duplicate genes may not be powerful enough to unravel the underlying mechanism. In a survey for young genes in species of the Drosophila melanogaster subgroup using fluorescence in situ hybridization, we identified a young gene family, monkey king, whose genesis sheds light on the evolutionary process of gene fission. Its members originated 1-2 million years ago as retroposed duplicates and evolved into fission genes that separately encode protein domains from a multidomain ancestor. The mechanism underlying this process is gene duplication with subsequent partial degeneration.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Chinese Acad Sci, Kunming Inst Zool, CAS Max Planck Jr Sci Grp, Key Lab Cellular & Mol Evolut, Kunming 650223, Yunnan, Peoples R China; Yunnan Univ, Sch Life Sci, Kunming 650091, Yunnan, Peoples R China	University of Chicago; Chinese Academy of Sciences; Kunming Institute of Zoology; Yunnan University	Long, MY (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	mlong@midway.uchicago.edu	Wang, Wen/AAP-9873-2020	Wang, Wen/0000-0002-7801-2066				ABRINK M, 1995, DNA CELL BIOL, V14, P125, DOI 10.1089/dna.1995.14.125; Altschmied J, 2002, GENETICS, V161, P259; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; Brosius J, 1999, TRENDS GENET, V15, P304, DOI 10.1016/S0168-9525(99)01783-7; Comeron JM, 1999, BIOINFORMATICS, V15, P763, DOI 10.1093/bioinformatics/15.9.763; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Fay JC, 2000, GENETICS, V155, P1405; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Force A, 1999, GENETICS, V151, P1531; FU YH, 1993, GENETICS, V133, P6934; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; KUMAR S, 2001, MEGA2 MOL EVOLUTIONA; Lachaise D, 2000, P ROY SOC B-BIOL SCI, V267, P1487, DOI 10.1098/rspb.2000.1169; Li W. H, 1997, MOL EVOLUTION; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Nekrutenko A, 2002, GENOME RES, V12, P198, DOI 10.1101/gr.200901; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; Powell J. R., 1997, PROGR PROSPECTS EVOL; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Snel B, 2000, TRENDS GENET, V16, P9, DOI 10.1016/S0168-9525(99)01924-1; Sokal R. R., 2000, BIOMETRY; Stone JR, 2001, MOL BIOL EVOL, V18, P1764, DOI 10.1093/oxfordjournals.molbev.a003964; TAJIMA F, 1989, GENETICS, V123, P585; Thomson TM, 2000, GENOME RES, V10, P1743, DOI 10.1101/gr.GR-1405R; Wang W, 2000, MOL BIOL EVOL, V17, P1294, DOI 10.1093/oxfordjournals.molbev.a026413; Wang W, 2002, P NATL ACAD SCI USA, V99, P4448, DOI 10.1073/pnas.072066399	30	75	79	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					523	527		10.1038/ng1338	http://dx.doi.org/10.1038/ng1338			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15064762	Bronze			2022-12-25	WOS:000221183000028
J	Bulavin, DV; Phillips, C; Nannenga, B; Timofeev, O; Donehower, LA; Anderson, CW; Appella, E; Fornace, AJ				Bulavin, DV; Phillips, C; Nannenga, B; Timofeev, O; Donehower, LA; Anderson, CW; Appella, E; Fornace, AJ			Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway	NATURE GENETICS			English	Article							CYCLIN D1; TRANSGENIC MICE; GENE PROMOTER; AMPLIFICATION; EXPRESSION; PPM1D; PHOSPHORYLATION; METHYLATION; APOPTOSIS; P53	Modulation of tumor suppressor activities may provide new opportunities for cancer therapy. Here we show that disruption of the gene Ppm1d encoding Wip1 phosphatase activated the p53 and p16 ( also called Ink4a) p19 ( also called ARF) pathways through p38 MAPK signaling and suppressed in vitro transformation of mouse embryo fibroblasts ( MEFs) by oncogenes. Disruption of the gene Cdkn2a ( encoding p16 and p19), but not of Trp53 ( encoding p53), reconstituted cell transformation in Ppm1d - null MEFs. In vivo, deletion of Ppm1d in mice bearing mouse mammary tumor virus ( MMTV) promoter driven oncogenes Erbb2 ( also called c - neu) or Hras1 impaired mammary carcinogenesis, whereas reduced expression of p16 and p19 by methylation-induced silencing or inactivation of p38 MAPK correlated with tumor appearance. We conclude that inactivation or depletion of the Wip1 phosphatase with resultant p38 MAPK activation suppresses tumor appearance by modulating the Cdkn2a tumor-suppressor locus.	NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; Baylor College of Medicine; United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bulavin, DV (corresponding author), NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	bulavin@nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Timofeev, Oleg/0000-0002-3114-6403; Dudgeon, Crissy/0000-0001-9010-2569	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC005599, Z01BC005599] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bowe DB, 2002, ONCOGENE, V21, P291, DOI 10.1038/sj/onc/1205025; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Choi J, 2000, GENOMICS, V64, P298, DOI 10.1006/geno.2000.6134; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; DICKINSON AJ, 1990, OPHTHALMIC PAED GEN, V11, P1, DOI 10.3109/13816819009012942; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; GILLETT C, 1994, CANCER RES, V54, P1812; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Koch-Paiz CA, 2000, BIOTECHNIQUES, V29, P706, DOI 10.2144/00294bm07; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257	38	344	361	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					343	350		10.1038/ng1317	http://dx.doi.org/10.1038/ng1317			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	14991053	Bronze			2022-12-25	WOS:000220647200017
J	Torres, VE; Wang, XF; Qian, Q; Somlo, S; Harris, PC; Gattone, VH				Torres, VE; Wang, XF; Qian, Q; Somlo, S; Harris, PC; Gattone, VH			Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease	NATURE MEDICINE			English	Article							RENAL CYSTS; CELLS; CAMP; INHIBITION; SECRETION; FLUID; CA2+	Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.	Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA; Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06536 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Mayo Clinic; Yale University; Indiana University System; Indiana University-Purdue University Indianapolis	Torres, VE (corresponding author), Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA.	torres.vicente@mayo.edu		Torres, Vicente/0000-0003-2008-1576	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; GABOW PA, 1989, KIDNEY INT, V35, P675, DOI 10.1038/ki.1989.38; Gattone VH, 2003, NAT MED, V9, P1323, DOI 10.1038/nm935; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Sweeney WE, 2001, AM J PHYSIOL-CELL PH, V281, pC1695, DOI 10.1152/ajpcell.2001.281.5.C1695; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; VERANI RR, 1988, MODERN PATHOL, V1, P457; Wallace DP, 2001, AM J PHYSIOL-RENAL, V280, pF1019, DOI 10.1152/ajprenal.2001.280.6.F1019; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamaguchi T, 2002, J AM SOC NEPHROL, V13, p105A; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; YE M, 1993, NEW ENGL J MED, V329, P310, DOI 10.1056/NEJM199307293290503	14	352	365	2	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					363	364		10.1038/nm1004	http://dx.doi.org/10.1038/nm1004			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	14991049				2022-12-25	WOS:000220587000025
J	Khanna, C; Wan, XL; Bose, S; Cassaday, R; Olomu, O; Mendoza, A; Yeung, C; Gorlick, R; Hewitt, SM; Helman, LJ				Khanna, C; Wan, XL; Bose, S; Cassaday, R; Olomu, O; Mendoza, A; Yeung, C; Gorlick, R; Hewitt, SM; Helman, LJ			The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis	NATURE MEDICINE			English	Article							CELL; APOPTOSIS; SURVIVAL; BINDING; KINASE; MERLIN; MODEL	Metastatic cancers, once established, are the primary cause of mortality associated with cancer. Previously, we used a genomic approach to identify metastasis-associated genes in cancer 1. From this genomic data, we selected ezrin for further study based on its role in physically and functionally connecting the actin cytoskeleton to the cell membrane 2. In a mouse model of osteosarcoma, a highly metastatic pediatric cancer, we found ezrin to be necessary for metastasis. By imaging metastatic cells in the lungs of mice, we showed that ezrin expression provided an early survival advantage for cancer cells that reached the lung. AKT and MAPK phosphorylation and activity were reduced when ezrin protein was suppressed. Ezrin-mediated early metastatic survival was partially dependent on activation of MAPK, but not AKT. To define the relevance of ezrin in the biology of metastasis, beyond the founding mouse model, we examined ezrin expression in dogs that naturally developed osteosarcoma. High ezrin expression in dog tumors was associated with early development of metastases. Consistent with this data, we found a significant association between high ezrin expression and poor outcome in pediatric osteosarcoma patients.	NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Tissue Array Project Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Khanna, C (corresponding author), NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.	khannac@mail.nih.gov	Cassaday, Ryan/AAF-4290-2021	GORLICK, RICHARD/0000-0001-8995-2929; Hewitt, Stephen/0000-0001-8283-1788	NATIONAL CANCER INSTITUTE [Z01BC010566, ZIABC010566, ZIASC006892, Z01SC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chambers A F, 2001, Surg Oncol Clin N Am, V10, P243; Chambers AF, 2000, BREAST CANCER RES, V2, P400, DOI 10.1186/bcr86; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Hiscox S, 1999, J CELL SCI, V112, P3081; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2002, CLIN CANCER RES, V8, P2406; Khanna C, 2001, CANCER RES, V61, P3750; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Ohtani K, 2002, CANCER LETT, V179, P79, DOI 10.1016/S0304-3835(01)00857-6; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159; Wong CW, 2002, AM J PATHOL, V161, P749, DOI 10.1016/S0002-9440(10)64233-2; Wong CW, 2001, CANCER RES, V61, P333; YU Y, 2004, NAT MED, V10, P48	27	548	653	1	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					182	186		10.1038/nm982	http://dx.doi.org/10.1038/nm982			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704791				2022-12-25	WOS:000188719600038
J	Dominguez, M; Ferres-Marco, D; Gutierrez-Avino, FJ; Speicher, SA; Beneyto, M				Dominguez, M; Ferres-Marco, D; Gutierrez-Avino, FJ; Speicher, SA; Beneyto, M			Growth and specification of the eye are controlled independently by Eyegone and Eyeless in Drosophila melanogaster	NATURE GENETICS			English	Article							PAIRED DOMAIN; PAX PROTEINS; GENE; EXPRESSION; UPSTREAM; PATTERN; HOMEODOMAIN; BOUNDARIES; ANIRIDIA; POLARITY	Control of growth determines the size and shape of organs. Localized signals known as organizers and members of the Pax family of proto-oncogenes are both elements in this control. Pax proteins have a conserved DNA-binding paired domain, which is presumed to be essential for their oncogenic activity. We present evidence that the organizing signal Notch does not promote growth in eyes of D. melanogaster through either Eyeless (Ey) or Twin of eyeless (Toy), the two Pax6 transcription factors. Instead, it acts through Eyegone (Eyg), which has a truncated paired domain, consisting of only the C-terminal subregion. In humans and mice, the sole PAX6 gene produces the isoform PAX6(5a) by alternative splicing; like Eyegone, this isoform binds DNA though the C terminus of the paired domain. Overexpression of human PAX6(5a) induces strong overgrowth in vivo, whereas the canonical PAX6 variant hardly effects growth. These results show that growth and eye specification are subject to independent control and explain hyperplasia in a new way.	CSIC, Inst Neurciencias, E-03550 Sant Joan dAlacant, Spain; Univ Miguel Hernandez, E-03550 Sant Joan dAlacant, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche	Dominguez, M (corresponding author), CSIC, Inst Neurciencias, Apartado 18, E-03550 Sant Joan dAlacant, Spain.	m.dominguez@umh.es	Dominguez, Maria/G-2171-2014; Ferres-Marco, Maria/G-8364-2015	Dominguez, Maria/0000-0002-3329-7862; Ferres-Marco, Maria/0000-0002-0596-4891; Gutierrez Avino, Francisco Jose/0000-0002-9428-0765				Aldaz S, 2003, DEVELOPMENT, V130, P4473, DOI 10.1242/dev.00643; Azuma N, 1999, AM J HUM GENET, V65, P656, DOI 10.1086/302529; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; Callaerts P, 2001, J NEUROBIOL, V46, P73, DOI 10.1002/1097-4695(20010205)46:2<73::AID-NEU10>3.0.CO;2-N; Cavodeassi F, 1999, DEVELOPMENT, V126, P4933; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Das P, 2002, HUM GENET, V110, P371, DOI 10.1007/s00439-002-0699-1; Day SJ, 2000, DEVELOPMENT, V127, P2977; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GNARRA JR, 1995, CANCER RES, V55, P4092; Go MJ, 1998, DEVELOPMENT, V125, P2031; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; HEBERLEIN U, 2000, FINI, P37; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; Jang CC, 2003, DEVELOPMENT, V130, P2939, DOI 10.1242/dev.00522; Jun S, 1998, P NATL ACAD SCI USA, V95, P13720, DOI 10.1073/pnas.95.23.13720; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kronhamn J, 2002, DEVELOPMENT, V129, P1015; Kumar JP, 2001, CELL, V104, P687, DOI 10.1016/S0092-8674(01)00265-3; Kurata S, 2000, P NATL ACAD SCI USA, V97, P2117, DOI 10.1073/pnas.040556497; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Martinez S, 2001, INT J DEV BIOL, V45, P367; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Newsome TP, 2000, DEVELOPMENT, V127, P851; OHUCHI H, 1999, CELL TISSUE RES, V199, P247; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Scholl FA, 2001, CANCER RES, V61, P823; Sepp KJ, 1999, GENETICS, V151, P1093; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; Steinbach JP, 2001, INT J CANCER, V93, P459, DOI 10.1002/ijc.1371; TON CT, 1991, CELL, V68, P491; van Heyningen V, 2002, HUM MOL GENET, V11, P1161, DOI 10.1093/hmg/11.10.1161; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811; XU T, 1993, DEVELOPMENT, V117, P1223; Yang CH, 1999, DEVELOPMENT, V126, P5857	50	120	123	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2004	36	1					31	39		10.1038/ng1281	http://dx.doi.org/10.1038/ng1281			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702038	Bronze			2022-12-25	WOS:000187666800011
J	Larimer, FW; Chain, P; Hauser, L; Lamerdin, J; Malfatti, S; Do, L; Land, ML; Pelletier, DA; Beatty, JT; Lang, AS; Tabita, FR; Gibson, JL; Hanson, TE; Bobst, C; Torres, JLTY; Peres, C; Harrison, FH; Gibson, J; Harwood, CS				Larimer, FW; Chain, P; Hauser, L; Lamerdin, J; Malfatti, S; Do, L; Land, ML; Pelletier, DA; Beatty, JT; Lang, AS; Tabita, FR; Gibson, JL; Hanson, TE; Bobst, C; Torres, JLTY; Peres, C; Harrison, FH; Gibson, J; Harwood, CS			Complete genome sequence of the metabolically versatile photosynthetic bacterium Rhodopseudomonas palustris	NATURE BIOTECHNOLOGY			English	Article							GENE-TRANSFER AGENT; RHODOBACTER-CAPSULATUS; CHLOROBIUM-TEPIDUM; SULFUR METABOLISM; STEM NODULATION; TRANSPORT; CARBOXYLASE/OXYGENASE; IDENTIFICATION; TRANSDUCTION; DIVERSITY	Rhodopseudomonas palustris is among the most metabolically versatile bacteria known. It uses light, inorganic compounds, or organic compounds, for energy. It acquires carbon from many types of green plant-derived compounds or by carbon dioxide fixation, and it fixes nitrogen. Here we describe the genome sequence of R. palustris, which consists of a 5,459,213-base-pair (bp) circular chromosome with 4,836 predicted genes and a plasmid of 8,427 bp. The sequence reveals genes that confer a remarkably large number of options within a given type of metabolism, including three nitrogenases, five benzene ring cleavage pathways and four light harvesting 2 systems. R. palustris encodes 63 signal transduction histidine kinases and 79 response regulator receiver domains. Almost 15% of the genome is devoted to transport. This genome sequence is a starting point to use R. palustris as a model to explore how organisms integrate metabolic modules in response to environmental perturbations.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Joint Genome Inst, Walnut Creek, CA 94598 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA	University of Iowa; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of British Columbia; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Harwood, CS (corresponding author), Univ Iowa, Dept Microbiol, 3-432 Bowen Sci Bldg, Iowa City, IA 52242 USA.	caroline-harwood@uiowa.edu	Land, Miriam L/A-6200-2011; Rechsteiner, Cindyr/C-2144-2011; Pelletier, Dale/F-4154-2011; chain, patrick/B-9777-2013; Hanson, Thomas/G-9386-2016; Hauser, Loren J/H-3881-2012; Chain, Patrick/O-4140-2019	Land, Miriam L/0000-0001-7102-0031; Hanson, Thomas/0000-0002-1967-5986; Chain, Patrick/0000-0003-3949-3634; Lang, Andrew/0000-0002-4510-7683; Malfatti, Stephanie/0000-0003-4225-9857; Pelletier, Dale/0000-0002-4321-7918; Do, Long/0000-0003-0911-1463				Badger JH, 1999, MOL BIOL EVOL, V16, P512, DOI 10.1093/oxfordjournals.molbev.a026133; Barbosa MJ, 2001, J BIOTECHNOL, V85, P25, DOI 10.1016/S0168-1656(00)00368-0; Boivin C, 1997, CRIT REV PLANT SCI, V16, P1, DOI 10.1080/713608143; Cao TB, 2001, MICROBIOL-SGM, V147, P3201, DOI 10.1099/00221287-147-12-3201; Chain P, 2003, J BACTERIOL, V185, P2759, DOI 10.1128/JB.185.9.2759-2773.2003; Cogdell RJ, 1999, J BACTERIOL, V181, P3869, DOI 10.1128/JB.181.13.3869-3879.1999; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Do YS, 2003, APPL ENVIRON MICROB, V69, P1710, DOI 10.1128/AEM.69.3.1710-1720.2003; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; Egland PG, 2001, APPL ENVIRON MICROB, V67, P1396, DOI 10.1128/AEM.67.3.1396-1399.2001; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; Gall A, 1999, BIOCHEMISTRY-US, V38, P5185, DOI 10.1021/bi982486q; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Giraud E, 2000, P NATL ACAD SCI USA, V97, P14795, DOI 10.1073/pnas.250484097; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hanson TE, 2003, PHOTOSYNTH RES, V78, P231, DOI 10.1023/B:PRES.0000006829.41444.3d; Hanson TE, 2001, P NATL ACAD SCI USA, V98, P4397, DOI 10.1073/pnas.081610398; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; Hu XC, 2002, Q REV BIOPHYS, V35, P1, DOI 10.1017/S0033583501003754; Johnson CH, 1999, ANNU REV MICROBIOL, V53, P389, DOI 10.1146/annurev.micro.53.1.389; Kelly DJ, 2001, FEMS MICROBIOL REV, V25, P405, DOI 10.1111/j.1574-6976.2001.tb00584.x; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; Kobayashi M., 1995, Anoxygenic photosynthetic bacteria., P1269; Lang AS, 2001, ARCH MICROBIOL, V175, P241, DOI 10.1007/s002030100260; Lynch D, 2001, J BACTERIOL, V183, P2576, DOI 10.1128/JB.183.8.2576-2585.2001; Marketon MM, 2003, J BACTERIOL, V185, P325, DOI 10.1128/JB.185.1.325-331.2003; Masai E, 2003, J BACTERIOL, V185, P1768, DOI 10.1128/JB.185.6.1768-1775.2003; McGrath JE, 1997, APPL ENVIRON MICROB, V63, P3333, DOI 10.1128/AEM.63.8.3333-3335.1997; Newman JD, 2001, J MOL BIOL, V313, P485, DOI 10.1006/jmbi.2001.5069; Noh U, 2002, APPL MICROBIOL BIOT, V58, P830, DOI 10.1007/s00253-002-0954-3; Oda Y, 2002, APPL ENVIRON MICROB, V68, P3467, DOI 10.1128/AEM.68.7.3467-3477.2002; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Philippot L, 2002, BBA-GENE STRUCT EXPR, V1577, P355, DOI 10.1016/S0167-4781(02)00420-7; ROLLS JP, 1967, J BACTERIOL, V94, P860, DOI 10.1128/JB.94.4.860-866.1967; Rosen BP, 2002, COMP BIOCHEM PHYS A, V133, P689, DOI 10.1016/S1095-6433(02)00201-5; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Sasikala C, 1995, ADV APPL MICROBIOL, V41, P227, DOI 10.1016/S0065-2164(08)70311-3; Sasikala C, 1998, ADV MICROB PHYSIOL, V39, P339; Schaefer AL, 2002, J BACTERIOL, V184, P6515, DOI 10.1128/JB.184.23.6515-6521.2002; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; van Berkum P, 2003, J BACTERIOL, V185, P2988, DOI 10.1128/JB.185.10.2988-2998.2003; Visca P, 2002, MOL MICROBIOL, V45, P1177, DOI 10.1046/j.1365-2958.2002.03088.x	48	539	1045	17	117	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					55	61		10.1038/nbt923	http://dx.doi.org/10.1038/nbt923			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704707	hybrid			2022-12-25	WOS:000187745400027
J	Aicher, A; Heeschen, C; Mildner-Rihm, C; Urbich, C; Ihling, C; Technau-Ihling, K; Zeiher, AM; Dimmeler, S				Aicher, A; Heeschen, C; Mildner-Rihm, C; Urbich, C; Ihling, C; Technau-Ihling, K; Zeiher, AM; Dimmeler, S			Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM; POSTNATAL NEOVASCULARIZATION; MATRIX METALLOPROTEINASES; ADHESION MOLECULES; TUMOR ANGIOGENESIS; IN-VITRO; GROWTH; RECRUITMENT; MECHANISMS; VEGF	Endothelial nitric oxide synthase (eNOS) is essential for neovascularization. Here we show that the impaired neovascularization in mice lacking eNOS is related to a defect in progenitor cell mobilization. Mice deficient in eNOS <LF>(Nos3(-/-)) show reduced vascular endothelial growth factor (VEGF)-induced mobilization of endothelial progenitor cells (EPCs) and increased mortality after myelosuppression. Intravenous infusion of wild-type progenitor cells, but not bone marrow transplantation, rescued the defective neovascularization of Nos3(-/-) mice in a model of hind-limb ischemia, suggesting that progenitor mobilization from the bone marrow is impaired in Nos3(-/-) mice. Mechanistically, matrix metalloproteinase-9 (MMP-9), which is required for stem cell mobilization, was reduced in the bone marrow of Nos3(-/-) mice. These findings indicate that eNOS expressed by bone marrow stromal cells influences recruitment of stem and progenitor cells. This may contribute to impaired regeneration processes in ischemic heart disease patients, who are characterized by a reduced systemic NO bioactivity.	Goethe Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Freiburg, Dept Pathol, D-79104 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Guba, Markus/M-4309-2019; Aicher, Alexandra/GZK-8031-2022	Heeschen, Christopher/0000-0002-1158-8554; Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Eriksson U, 2002, NAT MED, V8, P775, DOI 10.1038/nm0802-775; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Shami PJ, 1996, BLOOD, V87, P977, DOI 10.1182/blood.V87.3.977.bloodjournal873977; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taylor DA, 2002, CIRCULATION, V106, P2, DOI 10.1161/01.CIR.0000024386.99599.4A; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900; Zeiher AM, 1996, LANCET, V348, pS10, DOI 10.1016/S0140-6736(96)98004-6; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	40	1105	1209	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1370	1376		10.1038/nm948	http://dx.doi.org/10.1038/nm948			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14556003				2022-12-25	WOS:000186319700026
J	Balbin, M; Fueyo, A; Tester, AM; Pendas, AM; Pitiot, AS; Astudillo, A; Overall, CM; Shapiro, SD; Lopez-Otin, C				Balbin, M; Fueyo, A; Tester, AM; Pendas, AM; Pitiot, AS; Astudillo, A; Overall, CM; Shapiro, SD; Lopez-Otin, C			Loss of collagenase-2 confers increased skin tumor susceptibility to male mice	NATURE GENETICS			English	Article							EXPRESSION; MMP-8; INHIBITION; CHEMOKINES; INFLAMMATION; CANCER; CELLS; GAMMA	Matrix metalloproteinases (MMPs) have fundamental roles in tumor progression(1,2), but most clinical trials with MMP inhibitors have not shown improvements in individuals with cancer(3). This may be partly because broad-range inhibitors also reduce host-protective antitumor properties of individual MMPs. We generated mice deficient in collagenase-2 (Mmp8), an MMP mainly produced by neutrophils in inflammatory reactions and detected in some malignant tumors(1,4). Loss of Mmp8 did not cause abnormalities during embryonic development or in adult mice. Contrary to previous studies with MMP-deficient mice, however, the absence of Mmp8 strongly increased the incidence of skin tumors in male Mmp8 / mice. Female Mmp8 / mice whose ovaries were removed or were treated with tamoxifen were also more susceptible to tumors compared with wild-type mice. Bone marrow transplantation experiments confirmed that Mmp8 supplied by neutrophils was sufficient to restore the natural protection against tumor development mediated by this protease in male mice. Histopathological analysis showed that mutant mice had abnormalities in the inflammatory response induced by carcinogens. Our study identifies a paradoxical protective role for Mmp8 in cancer and provides a genetic model to evaluate the molecular basis of gender differences in cancer susceptibility.	Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Biol Func, E-33006 Oviedo, Spain; Univ British Columbia, CIHR Grp Matrix Dynam, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, CIHR Grp Matrix Dynam, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Hosp Cent Asturias, Serv Anat Patol, Oviedo, Spain; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pulm & Crit Care Med, Boston, MA 02115 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of British Columbia; University of British Columbia; Central University Hospital Asturias; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	López-Otín, Carlos/AAB-2106-2020; Pendas, Alberto M/L-1017-2014; Balbín, Milagros/I-4206-2015; Pitiot, Ana S/AAA-9161-2020; Fueyo, Antonio/ABH-3243-2020	López-Otín, Carlos/0000-0001-6964-1904; Balbín, Milagros/0000-0001-5325-0407; Pitiot, Ana S/0000-0002-5318-3168; Fueyo, Antonio/0000-0002-7121-9398; Pendas, Alberto M/0000-0001-9264-3721; Astudillo Gonzalez, Maria Aurora/0000-0001-8947-8809				Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 2000, METH MOL B, V151, P149, DOI 10.1385/1-59259-046-2:149; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DEVARAJAN P, 1991, BLOOD, V77, P2731; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Kiili M, 2002, J CLIN PERIODONTOL, V29, P224, DOI 10.1034/j.1600-051x.2002.290308.x; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Moilanen M, 2002, J PATHOL, V197, P72, DOI 10.1002/path.1078; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pirila E, 2003, DIGEST DIS SCI, V48, P93, DOI 10.1023/A:1021790532723; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Qin ZH, 2002, J EXP MED, V195, P1479, DOI 10.1084/jem.20011887; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ridger VC, 2001, J IMMUNOL, V166, P3484, DOI 10.4049/jimmunol.166.5.3484; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494; Wuyts A, 1999, J IMMUNOL, V163, P6155; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x	25	366	386	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2003	35	3					252	257		10.1038/ng1249	http://dx.doi.org/10.1038/ng1249			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14517555				2022-12-25	WOS:000186273300021
J	Bomar, JM; Benke, PJ; Slattery, EL; Puttagunta, R; Taylor, LP; Seong, E; Nystuen, A; Chen, WD; Albin, RL; Patel, PD; Kittles, RA; Sheffield, VC; Burmeister, M				Bomar, JM; Benke, PJ; Slattery, EL; Puttagunta, R; Taylor, LP; Seong, E; Nystuen, A; Chen, WD; Albin, RL; Patel, PD; Kittles, RA; Sheffield, VC; Burmeister, M			Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse	NATURE GENETICS			English	Article							CRYSTAL-STRUCTURE; TRANSFER PROTEIN; EXPRESSION; 19P13.3; GENOME; MAP; DNA	Cayman ataxia is a recessive congenital ataxia restricted to one area of Grand Cayman Island(1,2). Comparative mapping suggested that the locus on 19p13.3 associated with Cayman ataxia might be homologous to the locus on mouse chromosome 10 associated with the recessive ataxic mouse mutant jittery. Screening genes in the region of overlap identified mutations in a novel predicted gene in three mouse jittery alleles, including the first mouse mutation caused by an Alu-related (B1 element) insertion. We found two mutations exclusively in all individuals with Cayman ataxia. The gene ATCAY or Atcay encodes a neuron-restricted protein called caytaxin. Caytaxin contains a CRAL- TRIO motif common to proteins that bind small lipophilic molecules. Mutations in another protein containing a CRAL-TRIO domain, alpha-tocopherol transfer protein ( TTPA), cause a vitamin E responsive ataxia. Three-dimensional protein structural modeling predicts that the caytaxin ligand is more polar than vitamin E. Identification of the caytaxin ligand may help develop a therapy for Cayman ataxia.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Miami, Dept Pediat, Miami, FL 33152 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Human Genet, Iowa City, IA 52242 USA; Howard Univ, Natl Human Genome Ctr, Washington, DC 20059 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Vet Assoc Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Miami; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; Howard University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Burmeister, M (corresponding author), Univ Michigan, Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.		Burmeister, Margit/A-3157-2013; Seong, Eunju/ABH-2705-2020; Puttagunta, Radhika/B-8664-2015; Puttagunta, Radhika/AAC-3217-2020	Burmeister, Margit/0000-0002-1914-2434; Puttagunta, Radhika/0000-0001-7674-8064; Sheffield, Val/0000-0002-6282-0835; Patel, Paresh/0000-0002-9145-4475				BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BROWN L M, 1984, Neurology, V34, P273; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; DIETRICH W, 1992, GENETICS, V131, P423; Drewett PL, 2000, PREHISTORIC SETTLEME, P5; HERMAN JP, 1990, ENDOCRINOLOGY, V127, P2408, DOI 10.1210/endo-127-5-2408; JOHNSON WG, 1978, NEUROLOGY, V28, P352; Kapfhamer D, 1996, GENOMICS, V35, P533, DOI 10.1006/geno.1996.0394; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Nystuen A, 1996, HUM MOL GENET, V5, P525, DOI 10.1093/hmg/5.4.525; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Puttagunta R, 2000, GENOME RES, V10, P1369, DOI 10.1101/gr.145200; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stocker A, 2002, STRUCTURE, V10, P1533, DOI 10.1016/S0969-2126(02)00884-5; Zhang HM, 2002, CIRC RES, V90, P1251, DOI 10.1161/01.RES.0000024690.69379.5C	20	102	108	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					264	269		10.1038/ng1255	http://dx.doi.org/10.1038/ng1255			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14556008				2022-12-25	WOS:000186273300023
J	Krosl, J; Austin, P; Beslu, N; Kroon, E; Humphries, RK; Sauvageau, G				Krosl, J; Austin, P; Beslu, N; Kroon, E; Humphries, RK; Sauvageau, G			In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein	NATURE MEDICINE			English	Article							BONE-MARROW-CELLS; MAMMALIAN-CELLS; EX-VIVO; TAT; PROLIFERATION; GENERATION; DELIVERY	Hematopoietic stem cells (HSCs) can self-renew extensively after transplantation. The conditions supporting their in vitro expansion are still being defined. Retroviral overexpression of the human homeobox B4 (HOXB4) gene in mouse bone marrow cells enables over 40-fold expansion of HSCs in vitro. To circumvent the requirement for retroviral infection, we used recombinant human TAT-HOXB4 protein carrying the protein transduction domain of the HIV transactivating protein (TAT) as a potential growth factor for stem cells. HSCs exposed to TAT-HOXB4 for 4 d expanded by about four- to sixfold and were 8-20 times more numerous than HSCs in control cultures, indicating that HSC expansion induced by TAT-HOXB4 was comparable to that induced by the human HOXB4 retrovirus during a similar period of observation. Our results also show that TAT-HOXB4-expanded HSC populations retain their normal in vivo potential for differentiation and long-term repopulation. It is thus feasible to exploit recombinant HOXB4 protein for rapid and significant ex vivo expansion of normal HSCs.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; British Columbia Cancer Agency; Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Downtown Stn, CP 6128, Montreal, PQ H3C 3J7, Canada.			KROON, EVERT/0000-0002-4069-3644; Humphries, Richard/0000-0003-0540-7005; Sauvageau, Guy/0000-0002-4333-7266				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lewis ID, 2001, BLOOD, V97, P3441, DOI 10.1182/blood.V97.11.3441; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	22	238	279	0	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1428	1432		10.1038/nm951	http://dx.doi.org/10.1038/nm951			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14578881				2022-12-25	WOS:000186319700036
J	Varon, R; Gooding, R; Steglich, C; Marns, L; Tang, H; Angelicheva, D; Yong, KK; Ambrugger, P; Reinhold, A; Morar, B; Baas, F; Kwa, M; Tournev, I; Guerguelcheva, V; Kremensky, I; Lochmuller, H; Mullner-Eidenbock, A; Merlini, L; Neumann, L; Burger, J; Walter, M; Swoboda, K; Thomas, PK; von Moers, A; Risch, N; Kalaydjieva, L				Varon, R; Gooding, R; Steglich, C; Marns, L; Tang, H; Angelicheva, D; Yong, KK; Ambrugger, P; Reinhold, A; Morar, B; Baas, F; Kwa, M; Tournev, I; Guerguelcheva, V; Kremensky, I; Lochmuller, H; Mullner-Eidenbock, A; Merlini, L; Neumann, L; Burger, J; Walter, M; Swoboda, K; Thomas, PK; von Moers, A; Risch, N; Kalaydjieva, L			Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome	NATURE GENETICS			English	Article							CCFDN SYNDROME; MUTATION; DEPHOSPHORYLATES; FCP1; ROMA; GYPSIES; DISEASE; SITE	Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome ( OMIM 604168) is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies; refs. 1-3). We previously localized the gene associated with CCFDN to 18qter, where a conserved haplotype suggested a single founder mutation(4). In this study, we used recombination mapping to refine the gene position to a 155-kb critical interval. During haplotype analysis, we found that the non-transmitted chromosomes of some unaffected parents carried the conserved haplotype associated with the disease. Assuming such parents to be completely homozygous across the critical interval except with respect to the disease-causing mutation, we developed a new not quite identical by descent (NQIBD) approach, which allowed us to identify the mutation causing the disease by sequencing DNA from a single unaffected homozygous parent. We show that CCFDN is caused by a single-nucleotide substitution in an antisense Alu element in intron 6 of CTDP1 ( encoding the protein phosphatase FCP1, an essential component of the eukaryotic transcription machinery(5,6)), resulting in a rare mechanism of aberrant splicing and an Alu insertion in the processed mRNA. CCFDN thus joins the group of transcription syndromes(7) and is the first purely transcriptional defect identified that affects polymerase II mediated gene expression.	Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Mol Genet Lab, Perth, WA 6009, Australia; Humboldt Univ, Charite, Inst Human Genet, Berlin, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Humboldt Univ, Charite, Dept Neuropediat, Berlin, Germany; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1012 WX Amsterdam, Netherlands; Med Univ Sofia, Dept Neurol, Sofia, Bulgaria; Med Univ Sofia, Lab Mol Pathol, Sofia, Bulgaria; Univ Munich, Friedrich Baur Inst, Munich, Germany; Univ Hosp Vienna, Dept Ophthalmol, Vienna, Austria; Ist Ortoped Rizzoli, Bologna, Italy; Munich Re, Ctr Competence Biosci, Munich, Germany; Univ Utah, Sch Med, Salt Lake City, UT USA; Inst Neurol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Kaiser Permanente, Div Res, Oakland, CA USA	University of Western Australia; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Fred Hutchinson Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Amsterdam; Academic Medical Center Amsterdam; Medical University Sofia; Medical University Sofia; University of Munich; University Hospital Vienna; IRCCS Istituto Ortopedico Rizzoli; Munich RE Group; Utah System of Higher Education; University of Utah; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Stanford University; Kaiser Permanente	Kalaydjieva, L (corresponding author), Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Mol Genet Lab, Perth, WA 6009, Australia.	luba@cyllene.uwa.edu.au	Morar, Bharti/O-8697-2014; Baas, Frank/F-9574-2010; Merlini, Luciano/N-6478-2019	Morar, Bharti/0000-0003-3897-1403; Baas, Frank/0000-0003-3912-5428; Merlini, Luciano/0000-0002-1108-1198; Lochmuller, Hanns/0000-0003-2324-8001; Swoboda, Kathryn/0000-0002-4593-6342				Angelicheva D, 1999, EUR J HUM GENET, V7, P560, DOI 10.1038/sj.ejhg.5200319; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Gresham D, 2001, AM J HUM GENET, V69, P1314, DOI 10.1086/324681; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hunter M, 2002, PEDIATR RES, V51, P602, DOI 10.1203/00006450-200205000-00010; Kalaydjieva L, 2001, BMC Med Genet, V2, P5, DOI 10.1186/1471-2350-2-5; Kalaydjieva L, 2001, EUR J HUM GENET, V9, P97, DOI 10.1038/sj.ejhg.5200597; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; LAGIERTOURENNE C, IN PRESS EUR J HUM G; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588; Licciardo P, 2001, NUCLEIC ACIDS RES, V29, P3539, DOI 10.1093/nar/29.17.3539; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Merlini L, 2002, NEUROLOGY, V58, P231, DOI 10.1212/WNL.58.2.231; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; Muller-Felber W, 1998, NEUROPEDIATRICS, V29, P97, DOI 10.1055/s-2007-973542; Nachman MW, 2000, GENETICS, V156, P297; Reeve JP, 2002, BIOINFORMATICS, V18, P894, DOI 10.1093/bioinformatics/18.6.894; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; Tournev I, 1999, ANN NEUROL, V45, P742; Tournev I, 1999, ACTA NEUROPATHOL, V98, P165, DOI 10.1007/s004010051065; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200	30	110	113	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2003	35	2					185	189		10.1038/ng1243	http://dx.doi.org/10.1038/ng1243			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	14517542				2022-12-25	WOS:000185625300017
J	Mori, H; Hanada, R; Hanada, T; Aki, D; Mashima, R; Nishinakamura, H; Torisu, T; Chien, KR; Yasukawa, H; Yoshimura, A				Mori, H; Hanada, R; Hanada, T; Aki, D; Mashima, R; Nishinakamura, H; Torisu, T; Chien, KR; Yasukawa, H; Yoshimura, A			Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity	NATURE MEDICINE			English	Article							BODY-WEIGHT; SIGNAL TRANSDUCER; MICE LACKING; RECEPTOR; GENE; TRANSCRIPTION-3; IDENTIFICATION; DISRUPTION; ACTIVATOR	Leptin is an adipocyte-derived hormone that plays a key role in energy homeostasis, yet resistance to leptin is a feature of most cases of obesity in humans and rodents. In vitro analysis suggested that the suppressor of cytokine signaling-3 (Socs3) is a negative-feedback regulator of leptin signaling involved in leptin resistance. To determine the functional significance of Socs3 in vivo, we generated neural cell specific SOCS3 conditional knockout mice using the Cre-loxP system. Compared to their wild-type littermates, Socs3-deficient mice showed enhanced leptin-induced hypothalamic Stat3 tyrosine phosphorylation as well as pro-opiomelanocortin (POMC) induction, and this resulted in a greater body weight loss and suppression of food intake. Moreover, the Socs3-deficient mice were resistant to high fat diet induced weight gain and hyperleptinemia, and insulin-sensitivity was retained. These data indicate that Socs3 is a key regulator of diet-induced leptin as well as insulin resistance. Our study demonstrates the negative regulatory role of Socs3 in leptin signaling in vivo, and thus suppression of Socs3 in the brain is a potential therapy for leptin-resistance in obesity.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Dept Mol Genet, Kurume, Fukuoka 8390861, Japan; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kurume Univ, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Inst Cardiovasc Res, Kurume, Fukuoka 8300011, Japan	Kyushu University; Kurume University; University of California System; University of California San Diego; University of California System; University of California San Diego; Kurume University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	MORI, HIROYUKI/D-3343-2013; Yoshimura, Akihiko/K-5515-2013					Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	29	477	502	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					739	743		10.1038/nm1071	http://dx.doi.org/10.1038/nm1071			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15208705				2022-12-25	WOS:000222460400029
J	Costoya, JA; Hobbs, RM; Barna, M; Cattoretti, G; Manova, K; Sukhwani, M; Orwig, KE; Wolgemuth, DJ; Pandolfi, PP				Costoya, JA; Hobbs, RM; Barna, M; Cattoretti, G; Manova, K; Sukhwani, M; Orwig, KE; Wolgemuth, DJ; Pandolfi, PP			Essential role of Plzf in maintenance of spermatogonial stem cells	NATURE GENETICS			English	Article							LEUKEMIA ZINC-FINGER; PROMYELOCYTIC LEUKEMIA; MALE-INFERTILITY; PROTEIN PLZF; MOUSE; EXPRESSION; TESTIS; GERM; GENE; DIFFERENTIATION	Little is known of the molecular mechanisms whereby spermatogonia, mitotic germ cells of the testis, self-renew and differentiate into sperm(1,2). Here we show that Zfp145, encoding the transcriptional repressor Plzf, has a crucial role in spermatogenesis. Zfp145 expression was restricted to gonocytes and undifferentiated spermatogonia and was absent in tubules of W/W-v mutants that lack these cells. Mice lacking Zfp145 underwent a progressive loss of spermatogonia with age, associated with increases in apoptosis and subsequent loss of tubule structure but without overt differentiation defects or loss of the supporting Sertoli cells. Spermatogonial transplantation experiments revealed a depletion of spermatogonial stem cells in the adult. Microarray analysis of isolated spermatogonia from Zfp145-null mice before testis degeneration showed alterations in the expression profile of genes associated with spermatogenesis. These results identify Plzf as a spermatogonia-specific transcription factor in the testis that is required to regulate self-renewal and maintenance of the stem cell pool.	Mem Sloan Kettering Canc Ctr, Dept Pathol, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Dev Biol Program, Mol Cytol Core Facil, New York, NY 10021 USA; Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Columbia University; Memorial Sloan Kettering Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Costoya, Jose A./B-2718-2009; Cattoretti, Giorgio/H-2340-2011; Hobbs, Robin/I-2577-2014	Costoya, Jose A./0000-0003-3691-6419; Orwig, Kyle/0000-0002-7952-8419; Cattoretti, Giorgio/0000-0003-3799-3221; Hobbs, Robin/0000-0002-3853-2614				Andersson S, 1995, J STEROID BIOCHEM, V55, P533, DOI 10.1016/0960-0760(95)00202-2; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Beumer TL, 2000, BIOL REPROD, V63, P1893, DOI 10.1095/biolreprod63.6.1893; Beumer TL, 1999, ENDOCRINOLOGY, V140, P1834, DOI 10.1210/en.140.4.1834; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; BUAAS FW, 2004, NAT GENET       0523; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Cooke HJ, 2002, NAT REV GENET, V3, P790, DOI 10.1038/nrg911; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; COULOMBRE JL, 1954, J EXP ZOOL, V126, P277, DOI 10.1002/jez.1401260207; Cunningham DB, 1998, DEV BIOL, V204, P345, DOI 10.1006/dbio.1998.9004; de Rooij DG, 2001, REPRODUCTION, V121, P347, DOI 10.1530/rep.0.1210347; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; Handel MA, 1999, J EXP ZOOL, V285, P243, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;243::AID-JEZ7&gt;3.0.CO;2-#; Inoue N, 1999, HUM MOL GENET, V8, P1201, DOI 10.1093/hmg/8.7.1201; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; MANOVA K, 1990, DEVELOPMENT, V110, P1057; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; McLaren A, 2000, MOL CELL ENDOCRINOL, V163, P3, DOI 10.1016/S0303-7207(99)00234-8; Narula A, 2002, AM J PATHOL, V161, P1723, DOI 10.1016/S0002-9440(10)64449-5; Orwig KE, 2002, BIOL REPROD, V66, P944, DOI 10.1095/biolreprod66.4.944; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Scott KL, 2003, MOL CELL BIOL, V23, P4522, DOI 10.1128/MCB.23.13.4522-4531.2003; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; Venables JP, 1999, CURR OPIN GENET DEV, V9, P346, DOI 10.1016/S0959-437X(99)80052-5; Wrobel KH, 1996, CELL TISSUE RES, V283, P191, DOI 10.1007/s004410050529; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	30	717	759	1	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					653	659		10.1038/ng1367	http://dx.doi.org/10.1038/ng1367			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15156143	Bronze			2022-12-25	WOS:000221763700026
J	Marone, R; Hess, D; Dankort, D; Muller, WJ; Hynes, NE; Badache, A				Marone, R; Hess, D; Dankort, D; Muller, WJ; Hynes, NE; Badache, A			Memo mediates ErbB2-driven cell motility	NATURE CELL BIOLOGY			English	Article							RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; AUTOPHOSPHORYLATION SITES; ACTIN CYTOSKELETON; ERBB-2 KINASE; TRANSFORMATION; MICROTUBULE; INVASION; PHOSPHORYLATION	Clinical studies have revealed that cancer patients whose tumours have increased ErbB2 expression tend to have more aggressive, metastatic disease, which is associated with parameters predicting a poor outcome(1,2). The molecular basis underlying ErbB2-dependent cell motility and metastases formation, however, still remains poorly understood. In this study, we show that activation of a set of signalling molecules, including MAPK, phosphatidylinositol-3-OH kinase (PI(3) K) and Src, is required for Neu/ErbB2-dependent lamellipodia formation and for motility of breast carcinoma cells. Stimulation of these molecules, however, failed to induce efficient cell migration in the absence of Neu/ErbB2 phosphorylation at Tyr 1201 or Tyr 1227. We describe a novel molecule, Memo (mediator of ErbB2-driven cell motility), that interacts with a phospho-Tyr 1227-containing peptide, most probably through the Shc adaptor protein. After Neu/ErbB2 activation, Memo-defective cells form actin fibres and grow lamellipodia, but fail to extend microtubules towards the cell cortex. Our data suggest that Memo controls cell migration by relaying extracellular chemotactic signals to the microtubule cytoskeleton.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; McGill University	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	hynes@fmi.ch	Badache, Ali/Q-6098-2017	Badache, Ali/0000-0001-7710-2505; Dankort, David/0000-0002-5862-6829; Marone, Romina/0000-0003-1474-1689				BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kisielow M, 2002, BIOCHEM J, V363, P1, DOI 10.1042/0264-6021:3630001; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; RICCI A, 1995, ONCOGENE, V11, P1519; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	30	100	104	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					515	522		10.1038/ncb1134	http://dx.doi.org/10.1038/ncb1134			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15156151				2022-12-25	WOS:000221759400011
J	Revenkova, E; Eijpe, M; Heyting, C; Hodges, CA; Hunt, PA; Liebe, B; Scherthan, H; Jessberger, R				Revenkova, E; Eijpe, M; Heyting, C; Hodges, CA; Hunt, PA; Liebe, B; Scherthan, H; Jessberger, R			Cohesin SMC1 beta is required for meiotic chromosome dynamics, sister chromatid cohesion and DNA recombination	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEXES; SMC PROTEINS; MOUSE; CONDENSATION; ASSOCIATION; SEGREGATION; PROPHASE; MITOSIS	Sister chromatid cohesion ensures the faithful segregation of chromosomes in mitosis and in both meiotic divisions(1-4). Meiosis-specific components of the cohesin complex, including the recently described SMC1 isoform SMC1beta(5), were suggested to be required for meiotic sister chromatid cohesion and DNA recombination. Here we show that SMC1beta-deficient mice of both sexes are sterile. Male meiosis is blocked in pachytene; female meiosis is highly error-prone but continues until metaphase II. Prophase axial elements (AEs) are markedly shortened, chromatin extends further from the AEs, chromosome synapsis is incomplete, and sister chromatid cohesion in chromosome arms and at centromeres is lost prematurely. In addition, crossover-associated recombination foci are absent or reduced, and meiosis-specific perinuclear telomere arrangements are impaired. Thus, SMC1beta has a key role in meiotic cohesion, the assembly of AEs, synapsis, recombination, and chromosome movements.	CUNY Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, New York, NY 10029 USA; Univ Wageningen & Res Ctr, Mol Genet Grp, NL-6703 BD Wageningen, Netherlands; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Wageningen University & Research; Case Western Reserve University; Max Planck Society	Jessberger, R (corresponding author), CUNY Mt Sinai Sch Med, Ctr Gene Therapy & Mol Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.	rolf.jessberger@mssm.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062517] Funding Source: NIH RePORTER; NICHD NIH HHS [HD37502] Funding Source: Medline; NIGMS NIH HHS [GM62517] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1999, GENETICS, V151, P1569; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; DEVEAUX LC, 1992, GENETICS, V130, P251; Drabent B, 1996, HISTOCHEM CELL BIOL, V106, P247; Eijpe M, 2000, J CELL SCI, V113, P673; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hamer G, 2003, BIOL REPROD, V68, P628, DOI 10.1095/biolreprod.102.008672; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kleckner N, 2003, TRENDS GENET, V19, P623, DOI 10.1016/j.tig.2003.09.004; Koehler KE, 2002, GENETICS, V162, P297; Krawchuk MD, 1999, GENETICS, V153, P57; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; Moens PB, 1999, CHROMOSOMA, V108, P95, DOI 10.1007/s004120050356; Moens PB, 2002, J CELL SCI, V115, P1611; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; Page SL, 2003, SCIENCE, V301, P785, DOI 10.1126/science.1086605; Pelttari J, 2001, MOL CELL BIOL, V21, P5667, DOI 10.1128/MCB.21.16.5667-5677.2001; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Prieto I, 2002, EMBO REP, V3, P543, DOI 10.1093/embo-reports/kvf108; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Rieder CL, 1999, J CELL SCI, V112, P2607; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Scherthan H, 2000, MOL BIOL CELL, V11, P4189, DOI 10.1091/mbc.11.12.4189; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; van Heemst D, 2000, CHROMOSOMA, V109, P10, DOI 10.1007/s004120050408; WILTSHIRE T, 1995, DEV BIOL, V169, P557, DOI 10.1006/dbio.1995.1169; Xu HL, 2004, EMBO REP, V5, P378, DOI 10.1038/sj.embor.7400121	37	280	295	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					555	562		10.1038/ncb1135	http://dx.doi.org/10.1038/ncb1135			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15146193				2022-12-25	WOS:000221759400016
J	Suter, CM; Martin, DIK; Ward, RL				Suter, CM; Martin, DIK; Ward, RL			Germline epimutation of MLH1 in individuals with multiple cancers	NATURE GENETICS			English	Article							MICROSATELLITE INSTABILITY; EPIGENETIC INHERITANCE; METHYLATION; GENETICS; CPG; HYPERMETHYLATION; ALLELE	Epigenetic silencing can mimic genetic mutation by abolishing expression of a gene. We hypothesized that an epimutation could occur in any gene as a germline event that predisposes to disease and looked for examples in tumor suppressor genes in individuals with cancer. Here we report two individuals with soma-wide, allele-specific and mosaic hypermethylation of the DNA mismatch repair gene MLH1. Both individuals lack evidence of genetic mutation in any mismatch repair gene but have had multiple primary tumors that show mismatch repair deficiency, and both meet clinical criteria for hereditary nonpolyposis colorectal cancer. The epimutation was also present in spermatozoa of one of the individuals, indicating a germline defect and the potential for transmission to offspring. Germline epimutation provides a mechanism for phenocopying of genetic disease. The mosaicism and nonmendelian inheritance that are characteristic of epigenetic states could produce patterns of disease risk that resemble those of polygenic or complex traits.	Victor Chang Cardiac Res Inst, Sydney, NSW, Australia; St Vincents Hosp, Dept Med Oncol, Sydney, NSW 2010, Australia; Univ New S Wales, Sch Med, Sydney, NSW, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia	Victor Chang Cardiac Research Institute; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Martin, DIK (corresponding author), Victor Chang Cardiac Res Inst, Sydney, NSW, Australia.	d.martin@victorchang.unsw.edu.au	Ward, Robyn L/I-2313-2013	Ward, Robyn L/0000-0002-6877-8906				Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Chandler VL, 2000, PLANT MOL BIOL, V43, P121, DOI 10.1023/A:1006499808317; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; DAS OP, 1994, GENETICS, V136, P1121; Deng GR, 1999, CANCER RES, V59, P2029; Gazzoli I, 2002, CANCER RES, V62, P3925; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jass JR, 2000, ANN NY ACAD SCI, V910, P62; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Lynch HT, 1998, DIGESTION, V59, P481, DOI 10.1159/000007525; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Nakagawa H, 2001, CANCER RES, V61, P6991; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; Schoell WMJ, 1999, OBSTET GYNECOL, V94, P623, DOI 10.1016/S0029-7844(99)00373-7; Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; Suter CM, 2003, BRIT J CANCER, V88, P413, DOI 10.1038/sj.bjc.6600699; van Overveld PGM, 2003, NAT GENET, V35, P315, DOI 10.1038/ng1262; Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	30	348	367	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					497	501		10.1038/ng1342	http://dx.doi.org/10.1038/ng1342			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15064764	Bronze			2022-12-25	WOS:000221183000023
J	Zhang, H; Smolen, GA; Palmer, R; Christoforou, A; van den Heuvel, S; Haber, DA				Zhang, H; Smolen, GA; Palmer, R; Christoforou, A; van den Heuvel, S; Haber, DA			SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2	NATURE GENETICS			English	Article							SAM DOMAIN; HOMOLOG; TEL	Post-translational modification of proteins by the ubiquitin-like molecule SUMO (sumoylation) regulates their subcellular localization and affects their functional properties in vitro 1,2, but the physiological function of sumoylation in multicellular organisms is largely unknown. Here, we show that the C. elegans Polycomb group (PcG) protein SOP-2 interacts with the SUMO-conjugating enzyme UBC-9 through its evolutionarily conserved SAM domain. Sumoylation of SOP-2 is required for its localization to nuclear bodies in vivo and for its physiological repression of Hox genes. Global disruption of sumoylation phenocopies a sop-2 mutation by causing ectopic Hox gene expression and homeotic transformations. Chimeric constructs in which the SOP-2 SAM domain is replaced with that derived from fruit fly or mammalian PcG proteins, but not those in which the SOP-2 SAM domain is replaced with the SAM domains of non-PcG proteins, confer appropriate in vivo nuclear localization and Hox gene repression. These observations indicate that sumoylation of PcG proteins, modulated by their evolutionarily conserved SAM domain, is essential to their physiological repression of Hox genes.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.	haber@helix.mgh.harvard.edu	van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Apionishev S, 2001, GENES CELLS, V6, P215, DOI 10.1046/j.1365-2443.2001.00413.x; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; BRENNER S, 1974, GENETICS, V77, P71; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; EMMONS SW, 1999, CELL LINEAGE FATE DE, P139; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Ferreira HB, 1999, DEV BIOL, V207, P215, DOI 10.1006/dbio.1998.9124; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Jones D, 2002, GENOME BIOL, V3; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Netter S, 2001, DNA CELL BIOL, V20, P483, DOI 10.1089/104454901316976118; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Zhang H, 2003, DEV CELL, V4, P903, DOI 10.1016/S1534-5807(03)00136-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	20	68	81	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					507	511		10.1038/ng1336	http://dx.doi.org/10.1038/ng1336			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107848	Bronze			2022-12-25	WOS:000221183000025
J	Bienengraeber, M; Olson, TM; Selivanov, VA; Kathmann, EC; O'Cochlain, F; Gao, F; Karger, AB; Ballew, JD; Hodgson, DM; Zingman, LV; Pang, YP; Alekseev, AE; Terzic, A				Bienengraeber, M; Olson, TM; Selivanov, VA; Kathmann, EC; O'Cochlain, F; Gao, F; Karger, AB; Ballew, JD; Hodgson, DM; Zingman, LV; Pang, YP; Alekseev, AE; Terzic, A			ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic K-ATP channel gating	NATURE GENETICS			English	Article							SULFONYLUREA RECEPTOR; HEART-FAILURE; KIR6.2; TRAFFICKING; GENE; SUR1	Stress tolerance of the heart requires high-fidelity metabolic sensing by ATP-sensitive potassium (K-ATP) channels that adjust membrane potential dependent functions to match cellular energetic demand. Scanning of genomic DNA from individuals with heart failure and rhythm disturbances due to idiopathic dilated cardiomyopathy identified two mutations in ABCC9, which encodes the regulatory SUR2A subunit of the cardiac K-ATP channel. These missense and frameshift mutations mapped to evolutionarily conserved domains adjacent to the catalytic ATPase pocket within SUR2A. Mutant SUR2A proteins showed aberrant redistribution of conformations in the intrinsic ATP hydrolytic cycle, translating into abnormal K-ATP channel phenotypes with compromised metabolic signal decoding. Defective catalysis-mediated pore regulation is thus a mechanism for channel dysfunction and susceptibility to dilated cardiomyopathy.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Med, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Pediat Cardiol, Dept Pediat & Adolescent Med, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Alekseev, Alexey/I-5346-2013; Zingman, Leonid V/GXG-0136-2022	Zingman, Leonid V/0000-0002-7566-4616; Pang, Yuan-Ping/0000-0003-0838-2560; Selivanov, Vitaly/0000-0002-7937-9249; Karger, Amy/0000-0002-2781-3824; Olson, Timothy/0000-0003-2716-9423	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071225] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071225, R01 HL071225-01, R01 HL071225-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 2002, J BIOL CHEM, V277, P24427, DOI 10.1074/jbc.M201777200; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chien KR, 2003, NAT MED, V9, P508, DOI 10.1038/nm0503-508; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsushita K, 2002, CIRC RES, V90, P554, DOI 10.1161/01.RES.0000012666.42782.30; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Pang YP, 2001, PROTEINS, V45, P183, DOI 10.1002/prot.1138; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	29	263	273	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					382	387		10.1038/ng1329	http://dx.doi.org/10.1038/ng1329			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15034580	Green Accepted, Bronze			2022-12-25	WOS:000220647200022
J	Gissen, P; Johnson, CA; Morgan, NV; Stapelbroek, JM; Forshew, T; Cooper, WN; McKiernan, PJ; Klomp, LWJ; Morris, AAM; Wraith, JE; McClean, P; Lynch, SA; Thompson, RJ; Lo, B; Quarrell, OW; Di Rocco, M; Trembath, RC; Mandel, H; Wali, S; Karet, FE; Knisely, AS; Houwen, RHJ; Kelly, DA; Maher, ER				Gissen, P; Johnson, CA; Morgan, NV; Stapelbroek, JM; Forshew, T; Cooper, WN; McKiernan, PJ; Klomp, LWJ; Morris, AAM; Wraith, JE; McClean, P; Lynch, SA; Thompson, RJ; Lo, B; Quarrell, OW; Di Rocco, M; Trembath, RC; Mandel, H; Wali, S; Karet, FE; Knisely, AS; Houwen, RHJ; Kelly, DA; Maher, ER			Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; PROTEINS; HOMOLOG	ARC syndrome ( OMIM 208085) is an autosomal recessive multisystem disorder characterized by neurogenic arthrogryposis multiplex congenita, renal tubular dysfunction and neonatal cholestasis with bile duct hypoplasia and low gamma glutamyl transpeptidase (gGT) activity. Platelet dysfunction is common. Affected infants do not thrive and usually die in the first year of life(1-5). To elucidate the molecular basis of ARC, we mapped the disease to a 7-cM interval on 15q26.1 and then identified germline mutations in the gene VPS33B in 14 kindreds with ARC. VPS33B encodes a homolog of the class C yeast vacuolar protein sorting gene, Vps33, that contains a Sec1-like domain important in the regulation of vesicle-to-target SNARE complex formation and subsequent membrane fusion(6-9).	Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England; Univ Med Ctr, Dept Pediat Gastroenterol, Utrecht, Netherlands; Univ Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands; Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England; Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England; Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada; Sheffield Childrens Hosp, Dept Clin Genet, Sheffield S10 2TH, S Yorkshire, England; Gaslini Inst, Pediat Unit 2, I-16147 Genoa, Italy; Univ Leicester, Dept Genet & Cardiovasc Dis, Div Med Genet, Leicester LE1 7RH, Leics, England; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Pediat,Metab Dis Unit, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Pediat,Pediat Gastroenterol & Nutr Unit, IL-31096 Haifa, Israel; Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; Univ Cambridge, Addenbrookes Hosp, Dept Med Genet & Neprhol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; St James Hosp, Dept Paediat, Leeds LS9 7TF, W Yorkshire, England; Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	University of Birmingham; University of Birmingham; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Royal Manchester Children's Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Leicester; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Prince Sultan Military Medical City; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Saint James's University Hospital; Newcastle University - UK	Maher, ER (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Gissen, Paul/A-4352-2010; MAHER, EAMONN R/A-9507-2008; Lo, Bruce/AAV-1510-2021; Thompson, Richard J/B-7954-2009; Morgan, Neil V/A-5475-2009	Gissen, Paul/0000-0002-9712-6122; MAHER, EAMONN R/0000-0002-6226-6918; Lo, Bruce/0000-0001-6210-9667; Thompson, Richard J/0000-0001-5652-0150; Morgan, Neil V/0000-0001-6433-5692; Johnson, Colin/0000-0002-2979-8234; Karet, Fiona/0000-0002-2457-2869; Trembath, Richard/0000-0003-0550-3400; Lynch, Sally Ann/0000-0003-3540-1333; Forshew, Tim/0000-0003-2093-7020				Abdullah MA, 2000, SAUDI MED J, V21, P297; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Caplan S, 2001, J CELL BIOL, V154, P109, DOI 10.1083/jcb.200102142; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Denecke J, 2000, KLIN PADIATR, V212, P77, DOI 10.1055/s-2000-9656; Devonald MAJ, 2003, NAT GENET, V33, P125, DOI 10.1038/ng1082; DIROCCO M, 1995, EUR J PEDIATR, V154, P835, DOI 10.1007/BF01959793; Eastham KM, 2001, ARCH DIS CHILD, V85, P415, DOI 10.1136/adc.85.5.415; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GISSEN P, 2003, EUR J HUM GENET, V11, P827; Halachmi N, 1996, J NEUROCHEM, V66, P889; Hanigan MH, 2003, LAB INVEST, V83, p301A; HORSLEN SP, 1994, J MED GENET, V31, P62, DOI 10.1136/jmg.31.1.62; Huizing M, 2001, GENE, V264, P241, DOI 10.1016/S0378-1119(01)00333-X; Iwasaki H, 2002, DNA RES, V9, P59, DOI 10.1093/dnares/9.2.59; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Johnson CA, 2001, J BIOL CHEM, V276, P4539, DOI 10.1074/jbc.C000824200; Kim BY, 2001, J BIOL CHEM, V276, P29393, DOI 10.1074/jbc.M101778200; Morgan NV, 2002, HUM GENET, V111, P456, DOI 10.1007/s00439-002-0817-0; MUELLER RF, 1993, J MED GENET, V30, P798, DOI 10.1136/jmg.30.9.798; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Poupon V, 2003, MOL BIOL CELL, V14, P4015, DOI 10.1091/mbc.E03-01-0040; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	30	231	241	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					400	404		10.1038/ng1325	http://dx.doi.org/10.1038/ng1325			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15052268	Bronze			2022-12-25	WOS:000220647200025
J	Guo, ZM; Linn, JF; Wu, GJ; Anzick, SL; Eisenberger, CF; Halachmi, S; Cohen, Y; Fomenkov, A; Hoque, MO; Okami, K; Steiner, G; Engles, JM; Osada, M; Moon, C; Ratovitski, E; Trent, JM; Meltzer, PS; Westra, WH; Kiemeney, LA; Schoenberg, MP; Sidransky, D; Trink, B				Guo, ZM; Linn, JF; Wu, GJ; Anzick, SL; Eisenberger, CF; Halachmi, S; Cohen, Y; Fomenkov, A; Hoque, MO; Okami, K; Steiner, G; Engles, JM; Osada, M; Moon, C; Ratovitski, E; Trent, JM; Meltzer, PS; Westra, WH; Kiemeney, LA; Schoenberg, MP; Sidransky, D; Trink, B			CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer	NATURE MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; B-CELL LYMPHOMAS; BREAST-CANCER; COPY NUMBER; DNA AMPLIFICATION; LONG ARM; MYC; SEQUENCES; RECEPTOR	Genomic amplification at 20q11-13 is a common event in human cancers. We isolated a germline translocation breakpoint at 20q11 from a bladder cancer patient. We identified CDC91L1, the gene encoding CDC91L1 (also called phosphatidylinositol glycan class U (PIG-U), a transamidase complex unit in the glycosylphosphatidylinositol (GPI) anchoring pathway), as the only gene whose expression was affected by the translocation. CDC91L1 was amplified and overexpressed in about one-third of bladder cancer cell lines and primary tumors, as well as in oncogenic uroepithelial cells transformed with human papillomavirus (HPV) E7. Forced overexpression of CDC91L1 malignantly transformed NIH3T3 cells in vitro and in vivo. Overexpression of CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and in turn increased STAT-3 phosphorylation in bladder cancer cells. Our findings suggest that CDC91L1 is an oncogene in bladder cancer, and implicate the GPI anchoring system as a potential oncogenic pathway and therapeutic target in human cancers.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Univ Med Ctr, Dept Urol, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands; Johns Hopkins Univ Hosp, Inst Med, Dept Urol, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins University; Radboud University Nijmegen; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu; btrink@jhmi.edu	Kiemeney, Lambertus A./D-3357-2009	Kiemeney, Lambertus A./0000-0002-2368-1326; Hoque, Mohammad Obaidul/0000-0001-6701-9978	NCI NIH HHS [5P01CA77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bringuier PP, 1996, ONCOGENE, V12, P1747; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Forozan F, 2000, CANCER RES, V60, P4519; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO;2-W; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Guan XY, 1996, CANCER RES, V56, P3446; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Hovey RM, 1998, CANCER RES, V58, P3555; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; MAGUIRE RT, 1983, P NATL ACAD SCI-BIOL, V80, P1947, DOI 10.1073/pnas.80.7.1947; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; Schoenberg M, 1996, J UROLOGY, V155, P1035, DOI 10.1016/S0022-5347(01)66380-8; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287; Wu GJ, 2000, CANCER RES, V60, P5371; Wu GJ, 2001, CANCER RES, V61, P4951; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	34	62	62	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					374	381		10.1038/nm1010	http://dx.doi.org/10.1038/nm1010			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034568				2022-12-25	WOS:000220587000028
J	Li, WQ; Li, MY; Zhang, WH; Welti, R; Wang, XM				Li, WQ; Li, MY; Zhang, WH; Welti, R; Wang, XM			The plasma membrane-bound phospholipase D delta enhances freezing tolerance in Arabidopsis thaliana	NATURE BIOTECHNOLOGY			English	Article							PLANT COLD-ACCLIMATION; D-ALPHA; STRESS; CALCIUM; GENES; ACID; DROUGHT; TRANSCRIPTOME; EXPRESSION; ACTIVATION	Freezing injury is a major environmental limitation on the productivity and geographical distribution of plants. Here we show that freezing tolerance can be manipulated in Arabidopsis thaliana by genetic alteration of the gene encoding phospholipase Ddelta (PLDdelta), which is involved in membrane lipid hydrolysis and cell signaling. Genetic knockout of the plasma membrane-associated PLDdelta rendered A. thaliana plants more sensitive to freezing, whereas overexpression of PLDdelta increased freezing tolerance. Lipid profiling revealed that PLDdelta contributed approximately 20% of the phosphatidic acid produced in wild-type plants during freezing, and overexpression of PLDdelta increased the production of phosphatidic acid species. The PLDdelta alterations did not affect the expression of the cold-regulated genes COR47 or COR78 or alter cold-induced increases in proline or soluble sugars, suggesting that the PLD pathway is a unique determinant of the response to freezing and may present opportunities for improving plant freezing tolerance.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University; Kansas State University	Wang, XM (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	wangs@ksu.edu	Wang, Xuemin/M-2853-2013	Li, Maoyin/0000-0002-9976-1349; wang, xuemin/0000-0002-6251-6745; Welti, Ruth/0000-0003-4373-2538				Bravo LA, 1998, PHYSIOL PLANTARUM, V103, P17, DOI 10.1034/j.1399-3054.1998.1030103.x; Chinnusamy V, 2003, GENE DEV, V17, P1043, DOI 10.1101/gad.1077503; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Dubouzet JG, 2003, PLANT J, V33, P751, DOI 10.1046/j.1365-313X.2003.01661.x; Fan L, 1997, PLANT CELL, V9, P2183, DOI 10.1105/tpc.9.12.2183; Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; Gong ZZ, 2002, P NATL ACAD SCI USA, V99, P11507, DOI 10.1073/pnas.172399299; Hardy S, 2000, CANCER RES, V60, P6353; Iba K, 2002, ANNU REV PLANT BIOL, V53, P225, DOI 10.1146/annurev.arplant.53.100201.160729; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Kachroo P, 2001, P NATL ACAD SCI USA, V98, P9448, DOI 10.1073/pnas.151258398; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; Katagiri T, 2001, PLANT J, V26, P595, DOI 10.1046/j.1365-313x.2001.01060.x; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; MAGNE C, 1992, ANAL BIOCHEM, V200, P115, DOI 10.1016/0003-2697(92)90285-F; McKersie BD, 1999, PLANT PHYSIOL, V119, P839, DOI 10.1104/pp.119.3.839; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Plieth C, 1999, PLANT J, V18, P491, DOI 10.1046/j.1365-313X.1999.00471.x; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; Sakamoto A, 2000, PLANT J, V22, P449, DOI 10.1046/j.1365-313X.2000.00749.x; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Thomashow MF, 2001, PLANT PHYSIOL, V125, P89, DOI 10.1104/pp.125.1.89; VERLEIJ AJ, 1982, BIOCHIM BIOPHYS ACTA, V684, P255; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Xin ZG, 1998, P NATL ACAD SCI USA, V95, P7799, DOI 10.1073/pnas.95.13.7799	31	253	293	3	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2004	22	4					427	433		10.1038/nbt949	http://dx.doi.org/10.1038/nbt949			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	809AR	15004566				2022-12-25	WOS:000220610100031
J	Passage, E; Norreel, JC; Noack-Fraissignes, P; Sanguedolce, V; Pizant, J; Thirion, X; Robaglia-Schlupp, A; Pellissier, JF; Fontes, M				Passage, E; Norreel, JC; Noack-Fraissignes, P; Sanguedolce, V; Pizant, J; Thirion, X; Robaglia-Schlupp, A; Pellissier, JF; Fontes, M			Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease	NATURE MEDICINE			English	Article							SCHWANN-CELLS; PMP22 GENE; TYPE-1A; MYELIN; MUTATION; DUPLICATION; NEUROPATHY; MICE; DIFFERENTIATION; EXPRESSION	Charcot-Marie-Tooth disease (CMT) is the most common hereditary peripheral neuropathy, affecting 1 in 2,500 people. The only treatment currently available is rehabilitation or corrective surgery. The most frequent form of the disease, CMT-1A, involves abnormal myelination of the peripheral nerves. Here we used a mouse model of CMT-1A to test the ability of ascorbic acid, a known promoter of myelination, to correct the CMT-1A phenotype. Ascorbic acid treatment resulted in substantial amelioration of the CMT-1A phenotype, and reduced the expression of PMP22 to a level below what is necessary to induce the disease phenotype. As ascorbic acid has already been approved by the FDA for other clinical indications, it offers an immediate therapeutic possibility for patients with the disease.	Fac Med Timone, IPHM, INSERM, UMR491, F-13385 Marseille 5, France; CNRS, UPR 9011, F-13402 Marseille 20, France; Fac Med Timone, Lab Sante Publ, EA 3279, F-13385 Marseille 5, France; CHU Timone Adulte, Serv Anat Pathol, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Fontes, M (corresponding author), Fac Med Timone, IPHM, INSERM, UMR491, 27 Bd J Moulin, F-13385 Marseille 5, France.	Michel.Fontes@medecine.univ-mrs.fr						Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; Arrigoni O, 2002, BBA-GEN SUBJECTS, V1569, P1, DOI 10.1016/S0304-4165(01)00235-5; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; CAREY DJ, 1987, DEV BRAIN RES, V32, P95, DOI 10.1016/0165-3806(87)90142-8; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chapillon P, 1998, BEHAV BRAIN RES, V93, P77, DOI 10.1016/S0166-4328(97)00137-X; Coschigano KT, 2003, ENDOCRINOLOGY, V144, P3799, DOI 10.1210/en.2003-0374; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; FENTON CF, 1984, J AM POD ASSOC, V74, P490, DOI 10.7547/87507315-74-10-490; Garcia CA, 1999, ANN NY ACAD SCI, V883, P69, DOI 10.1111/j.1749-6632.1999.tb08570.x; GOULD N, 1984, FOOT ANKLE, V4, P267, DOI 10.1177/107110078400400508; HOOD J, 1969, NEW ENGL J MED, V281, P1292, DOI 10.1056/NEJM196912042812309; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Huxley C, 1998, HUM MOL GENET, V7, P449, DOI 10.1093/hmg/7.3.449; Lopez-Lluch G, 1998, BIOCHEM J, V331, P21, DOI 10.1042/bj3310021; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; Melendez RR, 2002, REV INVEST CLIN, V54, P77; Nelis E, 1996, EUR J HUM GENET, V4, P25; Nishikawa Y, 2003, METABOLISM, V52, P760, DOI 10.1016/S0026-0495(03)00069-6; Njegovan M E, 1997, Clin Podiatr Med Surg, V14, P99; Norreel JC, 2001, EUR J NEUROSCI, V13, P1625, DOI 10.1046/j.0953-816x.2001.01535.x; Ouvrier RA, 1995, BRAIN DEV-JPN, V17, P31, DOI 10.1016/0387-7604(94)00127-8; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Plant GW, 2002, J NEUROSCI, V22, P6083; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; Saberan-Djoneidi D, 2000, GENE, V248, P223, DOI 10.1016/S0378-1119(00)00116-5; Sancho S, 1999, BRAIN, V122, P1563, DOI 10.1093/brain/122.8.1563; SKRE H, 1974, CLIN GENET, V6, P98; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; Yang ZY, 1996, BRAIN RES, V706, P243, DOI 10.1016/0006-8993(95)01135-8	35	247	267	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					396	401		10.1038/nm1023	http://dx.doi.org/10.1038/nm1023			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034573				2022-12-25	WOS:000220587000031
J	Zhang, JK; Gray, J; Wu, LZ; Leone, G; Rowan, S; Cepko, CL; Zhu, XM; Craft, CM; Dyer, MA				Zhang, JK; Gray, J; Wu, LZ; Leone, G; Rowan, S; Cepko, CL; Zhu, XM; Craft, CM; Dyer, MA			Rb regulates proliferation and rod photoreceptor development in the mouse retina	NATURE GENETICS			English	Article							BETA-GLOBIN LOCUS; RAT RETINA; CELL-DIFFERENTIATION; HISTONE ACETYLATION; RETINOBLASTOMA GENE; CHIMERIC MICE; LOCALIZATION; NEUROGENESIS; EXPRESSION; DEFICIENT	The retinoblastoma protein (Rb) regulates proliferation, cell fate specification and differentiation in the developing central nervous system (CNS), but the role of Rb in the developing mouse retina has not been studied, because Rb-deficient embryos die before the retinas are fully formed. We combined several genetic approaches to explore the role of Rb in the mouse retina. During postnatal development, Rb is expressed in proliferating retinal progenitor cells and differentiating rod photoreceptors. In the absence of Rb, progenitor cells continue to divide, and rods do not mature. To determine whether Rb functions in these processes in a cell-autonomous manner, we used a replication-incompetent retrovirus encoding Cre recombinase to inactivate the Rb1(lox) allele in individual retinal progenitor cells in vivo. Combined with data from studies of conditional inactivation of Rb1 using a combination of Cre transgenic mouse lines, these results show that Rb is required in a cell-autonomous manner for appropriate exit from the cell cycle of retinal progenitor cells and for rod development.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA	St Jude Children's Research Hospital; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Southern California	Dyer, MA (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	michael.dyer@stjude.org	Rowan, Sheldon/AAA-3271-2019; Dyer, Michael/N-8134-2018	Rowan, Sheldon/0000-0002-1123-6743; 				Alexiades MR, 1996, DEV DYNAM, V205, P293, DOI 10.1002/(SICI)1097-0177(199603)205:3<293::AID-AJA9>3.0.CO;2-D; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774; Dyer MA, 2001, J COMP NEUROL, V429, P601; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; Dyer MA, 2003, CELL CYCLE, V2, P350, DOI 10.4161/cc.2.4.429; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Greenlee MHW, 2002, SEMIN CELL DEV BIOL, V13, P99, DOI 10.1016/S1084-9521(02)00015-0; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Koulen P, 1999, EUR J NEUROSCI, V11, P2007, DOI 10.1046/j.1460-9568.1999.00622.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Schubeler D, 2000, GENE DEV, V14, P940; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Vooijs M, 2002, ONCOGENE, V21, P4635, DOI 10.1038/sj.onc.1205575; Whitehead JL, 1999, EXP EYE RES, V69, P491, DOI 10.1006/exer.1999.0724; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	41	148	153	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2004	36	4					351	360		10.1038/ng1318	http://dx.doi.org/10.1038/ng1318			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	14991054	Bronze			2022-12-25	WOS:000220647200018
J	Lahav, G; Rosenfeld, N; Sigal, A; Geva-Zatorsky, N; Levine, AJ; Elowitz, MB; Alon, U				Lahav, G; Rosenfeld, N; Sigal, A; Geva-Zatorsky, N; Levine, AJ; Elowitz, MB; Alon, U			Dynamics of the p53-Mdm2 feedback loop in individual cells	NATURE GENETICS			English	Article							P53; GENE; MDM2; PROTEIN; PHOSPHORYLATION; EXPRESSION; MODULE	The tumor suppressor p53, one of the most intensely investigated proteins(1-5), is usually studied by experiments that are averaged over cell populations, potentially masking the dynamic behavior in individual cells. We present a system for following, in individual living cells, the dynamics of p53 and its negative regulator Mdm2 (refs.1, 4-7) : this system uses functional p53-CFP and Mdm2-YFP fusion proteins and time-lapse fluorescence microscopy. We found that p53 was expressed in a series of discrete pulses after DNA damage. Genetically identical cells had different numbers of pulses: zero, one, two or more. The mean height and duration of each pulse were fixed and did not depend on the amount of DNA damage. The mean number of pulses, however, increased with DNA damage. This approach can be used to study other signaling systems and suggests that the p53-Mdm2 feedback loop generates a digital clock that releases well-timed quanta of p53 until damage is repaired or the cell dies.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Inst Adv Studies, Sch Nat Sci, Princeton, NJ 08540 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Weizmann Institute of Science; Weizmann Institute of Science; Institute for Advanced Study - USA; California Institute of Technology	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il	Sigal, Alex/GWC-7488-2022; Geva-Zatorsky, Naama/AAP-9176-2021	Sigal, Alex/0000-0001-8571-2004; Geva-Zatorsky, Naama/0000-0002-7303-854X				Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Bonner WM, 2003, P NATL ACAD SCI USA, V100, P4973, DOI 10.1073/pnas.1031538100; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; Guttmann-Raviv N, 2002, MOL CELL BIOL, V22, P2047, DOI 10.1128/MCB.22.7.2047-2056.2002; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; LARKIN ND, 1999, ONCOGENE, V18, P7644; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mihalas GI, 2000, J BIOL SYST, V8, P21, DOI 10.1142/S0218339000000031; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Offer H, 2001, CANCER RES, V61, P88; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1993, J CELL SCI, V105, P607; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	30	757	789	3	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					147	150		10.1038/ng1293	http://dx.doi.org/10.1038/ng1293			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14730303	Bronze			2022-12-25	WOS:000188542700015
J	Webb, DJ; Donais, K; Whitmore, LA; Thomas, SM; Turner, CE; Parsons, JT; Horwitz, AF				Webb, DJ; Donais, K; Whitmore, LA; Thomas, SM; Turner, CE; Parsons, JT; Horwitz, AF			FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION; CELL-MIGRATION; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; ADAPTER PROTEIN; FAMILY KINASES; ALPHA-ACTININ; BINDING; INTEGRIN; FIBROBLASTS	Cell migration is a complex, highly regulated process that involves the continuous formation and disassembly of adhesions ( adhesion turnover). Adhesion formation takes place at the leading edge of protrusions, whereas disassembly occurs both at the cell rear and at the base of protrusions. Despite the importance of these processes in migration, the mechanisms that regulate adhesion formation and disassembly remain largely unknown. Here we develop quantitative assays to measure the rate of incorporation of molecules into adhesions and the departure of these proteins from adhesions. Using these assays, we show that kinases and adaptor molecules, including focal adhesion kinase (FAK), Src, p130CAS, paxillin, extracellular signal-regulated kinase (ERK) and myosin light-chain kinase (MLCK) are critical for adhesion turnover at the cell front, a process central to migration.	UVA Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Canc Biol Program, Boston, MA 02215 USA; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	University of Virginia; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Webb, DJ (corresponding author), UVA Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	djw2p@virginia.edu			NCI NIH HHS [CA40042] Funding Source: Medline; NICHD NIH HHS [HD07528-01] Funding Source: Medline; NIGMS NIH HHS [GM23244, R01 GM047607, GM47607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R37GM023244, R29GM047607, R01GM023244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; ILLC D, 1995, NATURE, V377, P539; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Palecek SP, 1996, J CELL SCI, V109, P941; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Ren XD, 2000, J CELL SCI, V113, P3673; Ridley AJ, 2001, J CELL SCI, V114, P2713; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zamir E, 2001, J CELL SCI, V114, P3583	41	1051	1069	4	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					154	+		10.1038/ncb1094	http://dx.doi.org/10.1038/ncb1094			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743221				2022-12-25	WOS:000188668300015
J	Camera, P; Da Silva, JS; Griffiths, G; Giuffrida, MG; Ferrara, L; Schubert, V; Imarisio, S; Silengo, L; Dotti, CG; Di Cunto, F				Camera, P; Da Silva, JS; Griffiths, G; Giuffrida, MG; Ferrara, L; Schubert, V; Imarisio, S; Silengo, L; Dotti, CG; Di Cunto, F			Citron-N is a neuronal Rho-associated protein involved in Golgi organization through actin cytoskeleton regulation	NATURE CELL BIOLOGY			English	Letter							GLUTAMATERGIC SYNAPSES; BREFELDIN-A; KINASE; COMPLEX; IDENTIFICATION; MORPHOLOGY; MEMBRANES; PATHWAY; GTPASES; MOTORS	The actin cytoskeleton is best known for its role during cellular morphogenesis. However, other evidence suggests that actin is also crucial for the organization and dynamics of membrane organelles such as endosomes and the Golgi complex(1-3). As in morphogenesis, the Rho family of small GTPases are key mediators of organelle actin-driven events(4,5), although it is unclear how these ubiquitously distributed proteins are activated to regulate actin dynamics in an organelle-specific manner. Here we show that the brain-specific Rho-binding protein Citron-N-6 is enriched at, and associates with, the Golgi apparatus of hippocampal neurons in culture. Suppression of the whole protein or expression of a mutant form lacking the Rho-binding activity results in dispersion of the Golgi apparatus. In contrast, high intracellular levels induce localized accumulation of RhoA and filamentous actin, protecting the Golgi from the rupture normally produced by actin depolymerization. Biochemical and functional analyses indicate that Citron-N controls actin locally by assembling together the Rho effector ROCK-II and the actin-binding, neuron-specific, protein Profilin-IIa (PIIa). Together with recent data on endosomal dynamics(5), our results highlight the importance of organelle-specific Rho modulators for actin-dependent organelle organization and dynamics.	Univ Turin, Dipartimento Genet Biol & Biochim, Turin, Italy; Univ Turin, Cavalieri Ottolenghi Sci Inst, I-10024 Turin, Italy; European Mol Biol Lab, Dept Cell Biol, D-69012 Heidelberg, Germany; CNR, Ist Sci Prod Alimentari, I-10126 Turin, Italy	University of Turin; University of Turin; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto Scienze delle Produzioni Alimentari (ISPA-CNR)	Dotti, CG (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Via Santena,5 Bis, Turin, Italy.		Dotti, Carlos G/I-5533-2015; Giuffrida, Maria Gabriella/AAY-6314-2020; Di Cunto, Ferdinando/K-5575-2016	Dotti, Carlos G/0000-0003-4052-1719; Giuffrida, Maria Gabriella/0000-0002-1297-2558; di cunto, ferdinando/0000-0001-9367-6357	Telethon [GGP02245] Funding Source: Medline	Telethon(Fondazione Telethon)		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Allan VJ, 1999, CURR OPIN CELL BIOL, V11, P476, DOI 10.1016/S0955-0674(99)80068-4; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Furuyashiki T, 1999, J NEUROSCI, V19, P109, DOI 10.1523/JNEUROSCI.19-01-00109.1999; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Goslin K., 1991, CULTURING NERVE CELL, P251; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; Krebs A, 2001, J CELL SCI, V114, P3663; KRIJNSELOCKER J, 1995, MOL BIOL CELL, V6, P1315, DOI 10.1091/mbc.6.10.1315; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999; Zmuda JF, 2000, J NEUROBIOL, V43, P313, DOI 10.1002/1097-4695(20000615)43:4<313::AID-NEU1>3.0.CO;2-2	34	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1071	1078		10.1038/ncb1064	http://dx.doi.org/10.1038/ncb1064			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14595335				2022-12-25	WOS:000186892900012
J	Yamada, K; Andrews, C; Chan, WM; McKeown, CA; Magli, A; de Berardinis, T; Loewenstein, A; Lazar, M; O'Keefe, M; Letson, R; London, A; Ruttum, M; Matsumoto, N; Saito, N; Morris, L; Del Monte, M; Johnson, RH; Uyama, E; Houtman, WA; de Vries, B; Carlow, TJ; Hart, BL; Krawiecki, N; Shoffner, J; Vogel, MC; Katowitz, J; Goldstein, SM; Levin, AV; Sener, EC; Ozturk, BT; Akarsu, AN; Brodsky, MC; Hanisch, F; Cruse, RP; Zubcov, AA; Robb, RM; Roggenkaemper, P; Gottlob, I; Kowal, L; Battu, R; Traboulsi, EI; Franceschini, P; Newlin, A; Demer, JL; Engle, EC				Yamada, K; Andrews, C; Chan, WM; McKeown, CA; Magli, A; de Berardinis, T; Loewenstein, A; Lazar, M; O'Keefe, M; Letson, R; London, A; Ruttum, M; Matsumoto, N; Saito, N; Morris, L; Del Monte, M; Johnson, RH; Uyama, E; Houtman, WA; de Vries, B; Carlow, TJ; Hart, BL; Krawiecki, N; Shoffner, J; Vogel, MC; Katowitz, J; Goldstein, SM; Levin, AV; Sener, EC; Ozturk, BT; Akarsu, AN; Brodsky, MC; Hanisch, F; Cruse, RP; Zubcov, AA; Robb, RM; Roggenkaemper, P; Gottlob, I; Kowal, L; Battu, R; Traboulsi, EI; Franceschini, P; Newlin, A; Demer, JL; Engle, EC			Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1)	NATURE GENETICS			English	Article							EXTERNAL OPHTHALMOPLEGIA; CHROMOSOME-12; REFINEMENT; REGION; MAPS	Congenital fibrosis of the extraocular muscles type 1 (CFEOM1; OMIM #135700) is an autosomal dominant strabismus disorder associated with defects of the oculomotor nerve. We show that individuals with CFEOM1 harbor heterozygous missense mutations in a kinesin motor protein encoded by KIF21A. We identified six different mutations in 44 of 45 probands. The primary mutational hotspots are in the stalk domain, highlighting an important new role for KIF21A and its stalk in the formation of the oculomotor axis.	Childrens Hosp Boston, Dept Med Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA; Univ Naples, Dipartimento Sci Oftalmol, Naples, Italy; Tel Aviv Univ, Sackler Fac Med, Dept Ophthalmol, IL-69978 Tel Aviv, Israel; Our Ladys Hosp Sick Children, Dept Ophthalmol, Dublin, Ireland; Univ Minnesota, Dept Ophthalmol, St Paul, MN 55108 USA; Aspen Med Grp, Dept Pediat, St Paul, MN USA; Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA; Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 852, Japan; Shin Koga Hosp, Dept Gynecol, Kurume, Fukuoka, Japan; Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA; Univ Washington, Childrens Hosp, Dept Ophthalmol, Seattle, WA 98195 USA; Kumamoto Univ, Sch Med, Dept Neurol, Kumamoto 860, Japan; Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, Groningen, Netherlands; Univ New Mexico, Dept Radiol & Ophthalmol, Albuquerque, NM 87131 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; Horizon Mol Med, Atlanta, GA USA; Hosp Ninos Dr Roberto Del Rio, Dept Ophthalmol, Santiago, Chile; Childrens Hosp Philadelphia, Dept Ophthalmol, Philadelphia, PA 19104 USA; Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada; Hacettepe Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Pediat, TR-06100 Ankara, Turkey; Univ Arkansas, Dept Ophthalmol, Little Rock, AR 72204 USA; Univ Arkansas, Dept Pediat, Little Rock, AR 72204 USA; Univ Halle Wittenberg, Dept Neurol, Halle An Der Saale, Germany; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Eye Hosp, Frankfurt, Germany; Childrens Hosp Boston, Dept Ophthalmol, Boston, MA USA; Univ Eye Clin, Bonn, Germany; Univ Leicester, Dept Ophthalmol, Leicester, Leics, England; Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia; St Johns Med Coll, Dept Ophthalmol, Bangalore, Karnataka, India; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Univ Turin, Ctr Univ Dismorfol Clin, Turin, Italy; Univ Illinois, Dept Ophthalmol, Chicago, IL 60680 USA; Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; Childrens Hosp Boston, Dept Neurol, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Bascom Palmer Eye Institute; University of Naples Federico II; Tel Aviv University; Sackler Faculty of Medicine; Our Ladys Children Hospital Crumlin; University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin; Nagasaki University; University of Michigan System; University of Michigan; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Kumamoto University; University of Groningen; University of New Mexico; Emory University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Hacettepe University; Hacettepe University; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Martin Luther University Halle Wittenberg; Baylor College of Medicine; Harvard University; Boston Children's Hospital; University of Bonn; University of Leicester; University of Melbourne; St. John's National Academy of Health Sciences; St. John's Medical College; Cleveland Clinic Foundation; University of Turin; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital	Engle, EC (corresponding author), Childrens Hosp Boston, Dept Med Genet, Enders 5,300 Longwood Ave, Boston, MA 02115 USA.	engle@enders.tch.harvard.edu	Akarsu, Nurten/E-9758-2013; Magli, Adriano/AAU-7380-2020; Traboulsi, Elias/AAY-7443-2020	Akarsu, Nurten/0000-0001-5432-0032; Magli, Adriano/0000-0002-6490-2068; DE BERARDINIS, Teresa/0000-0001-6872-0432; Del Monte, Monte/0000-0002-3153-959X	NEI NIH HHS [R01 EY008313] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008313] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Brodsky MC, 1998, OPHTHALMOLOGY, V105, P717, DOI 10.1016/S0161-6420(98)94029-5; Doherty EJ, 1999, INVEST OPHTH VIS SCI, V40, P1687; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; ENGLE EC, 1995, AM J HUM GENET, V57, P1086; Engle EC, 1997, ANN NEUROL, V41, P314, DOI 10.1002/ana.410410306; Engle EC, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-3; HARLEY RD, 1978, J PEDIAT OPHTH STRAB, V15, P346; Mackey DA, 2002, HUM GENET, V110, P510, DOI 10.1007/s00439-002-0707-5; Magli Adriano, 2003, BMC Ophthalmol, V3, P6, DOI 10.1186/1471-2415-3-6; Marszalek JR, 1999, J CELL BIOL, V145, P469, DOI 10.1083/jcb.145.3.469; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Peretti D, 2000, J CELL BIOL, V149, P141, DOI 10.1083/jcb.149.1.141; Reid E, 2002, AM J HUM GENET, V71, P1189, DOI 10.1086/344210; Uyama E, 2003, NEUROMUSCULAR DISORD, V13, P472, DOI 10.1016/S0960-8966(03)00065-8; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	15	172	191	1	15	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2003	35	4					318	321		10.1038/ng1261	http://dx.doi.org/10.1038/ng1261			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14595441				2022-12-25	WOS:000186791000012
J	Barberi, T; Klivenyi, P; Calingasan, NY; Lee, H; Kawamata, H; Loonam, K; Perrier, AL; Bruses, J; Rubio, ME; Topf, N; Tabar, V; Harrison, NL; Beal, MF; Moore, MAS; Studer, L				Barberi, T; Klivenyi, P; Calingasan, NY; Lee, H; Kawamata, H; Loonam, K; Perrier, AL; Bruses, J; Rubio, ME; Topf, N; Tabar, V; Harrison, NL; Beal, MF; Moore, MAS; Studer, L			Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice	NATURE BIOTECHNOLOGY			English	Article							EXPANDED MESENCEPHALIC PRECURSORS; DOPAMINERGIC-NEURONS; IN-VITRO; BONE-MARROW; ES CELLS; DIFFERENTIATION; TRANSPLANTATION; INDUCTION; RAT; GENERATION	Existing protocols for the neural differentiation of mouse embryonic stem (ES) cells require extended in vitro culture, yield variable differentiation results or are limited to the generation of selected neural subtypes. Here we provide a set of coculture conditions that allows rapid and efficient derivation of most central nervous system phenotypes. The fate of both fertilization- and nuclear transfer-derived ES (ntES) cells was directed selectively into neural stem cells, astrocytes, oligodendrocytes or neurons. Specific differentiation into gamma-aminobutyric acid (GABA), dopamine, serotonin or motor neurons was achieved by defining conditions to induce forebrain, midbrain, hindbrain and spinal cord identity. Neuronal function of ES cell-derived dopaminergic neurons was shown in vitro by electron microscopy, measurement of neurotransmitter release and intracellular recording. Furthermore, transplantation of ES and ntES cell-derived dopaminergic neurons corrected the phenotype of a mouse model of Parkinson disease, demonstrating an in vivo application of therapeutic cloning in neural disease.	Cornell Univ, Weill Med Coll, Div Neurosurg, Lab Stem Cell & Tumor Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dev Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Sloan Kettering Inst,Cell Biol Program, James Ewing Lab Dev Hematopoiesis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Sloan Kettering Inst, Lab Neural Dev, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; University of Connecticut; Cornell University; Cornell University	Studer, L (corresponding author), Cornell Univ, Weill Med Coll, Div Neurosurg, Lab Stem Cell & Tumor Biol, New York, NY 10021 USA.		Perrier, Anselme L/B-2272-2019; Perrier, Anselme/E-3764-2010; Studer, Lorenz/ABH-1491-2021	Perrier, Anselme L/0000-0001-7915-1968; Studer, Lorenz/0000-0003-0741-7987; Klivenyi, Peter/0000-0002-5389-3266	NINDS NIH HHS [1R21NS44231-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044231] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEOUD P, 1995, NEUROSCIENCE, V67, P837, DOI 10.1016/0306-4522(95)00112-V; Battisti JJ, 1999, PSYCHOPHARMACOLOGY, V146, P42, DOI 10.1007/s002130051086; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Cibelli JB, 2002, SCIENCE, V295, P819, DOI 10.1126/science.1065637; COLLINS LS, 1987, J IMMUNOL, V138, P1082; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; ITOH K, 1989, EXP HEMATOL, V17, P145; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Studer L, 1996, BRAIN RES BULL, V41, P143, DOI 10.1016/0361-9230(96)00114-1; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wilson SW, 2000, NEURON, V28, P641, DOI 10.1016/S0896-6273(00)00171-9; WINKLER JD, 1986, J PHARMACOL EXP THER, V238, P242; Xu MJ, 1998, BLOOD, V92, P2032, DOI 10.1182/blood.V92.6.2032.418k29_2032_2040; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yan J, 2001, J NEUROCHEM, V76, P307, DOI 10.1046/j.1471-4159.2001.00073.x; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zawada WM, 1998, NAT MED, V4, P569, DOI 10.1038/nm0598-569	35	496	550	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2003	21	10					1200	1207		10.1038/nbt870	http://dx.doi.org/10.1038/nbt870			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	727FL	14502203				2022-12-25	WOS:000185647200032
J	Udan, RS; Kango-Singh, M; Nolo, R; Tao, CY; Halder, G				Udan, RS; Kango-Singh, M; Nolo, R; Tao, CY; Halder, G			Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway	NATURE CELL BIOLOGY			English	Article							CELL-SURVIVAL; DEATH GENE; DROSOPHILA; GRIM; HID; ENCODES; KINASE; REAPER; GROWTH; SICKLE	Proliferation and apoptosis must be precisely regulated to form organs with appropriate cell numbers and to avoid tumour growth(1,2). Here we show that Hippo (Hpo), the Drosophila homologue of the mammalian Ste20-like kinases(3), MST1/ 2, promotes proper termination of cell proliferation and stimulates apoptosis during development. hpo mutant tissues are larger than normal because mutant cells continue to proliferate beyond normal tissue size and are resistant to apoptotic stimuli that usually eliminate extra cells. Hpo negatively regulates expression of Cyclin E to restrict cell proliferation, downregulates the Drosophila inhibitor of apoptosis protein DIAP1, and induces the proapoptotic gene head involution defective ( hid) to promote apoptosis. The mutant phenotypes of hpo are similar to those of warts (wts), which encodes a serine/threonine kinase of the myotonic dystrophy protein kinase family(4,5), and salvador (sav), which encodes a WW domain protein that binds to Wts(6,7). We find that Sav binds to a regulatory domain of Hpo that is essential for its function, indicating that Hpo acts together with Sav and Wts in a signalling module that coordinately regulates cell proliferation and apoptosis.	Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Sch Biomed Sci, Genes & Dev Grad Program, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Halder, G (corresponding author), Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.	ghalder@mdanderson.org	Halder, Georg/F-2966-2015; Kango-Singh, Madhuri/F-3647-2011	Halder, Georg/0000-0001-7580-3236; 	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067997] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NICHD NIH HHS [HD07325] Funding Source: Medline; NIEHS NIH HHS [T32 ES07332] Funding Source: Medline; NIGMS NIH HHS [GM067997] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NE, 2001, SEMIN CELL DEV BIOL, V12, P499, DOI 10.1006/scdb.2001.0274; Berger J, 2001, NAT GENET, V29, P475, DOI 10.1038/ng773; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lisi S, 2000, GENETICS, V154, P669; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Turenchalk GS, 1999, BBA-REV CANCER, V1424, pM9, DOI 10.1016/S0304-419X(99)00021-9; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang LH, 2003, DEV CELL, V4, P359, DOI 10.1016/S1534-5807(03)00059-5; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	34	564	593	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					914	920		10.1038/ncb1050	http://dx.doi.org/10.1038/ncb1050			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	14502294				2022-12-25	WOS:000185647400018
J	Zimmer, M; Palmer, A; Kohler, J; Klein, R				Zimmer, M; Palmer, A; Kohler, J; Klein, R			EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion	NATURE CELL BIOLOGY			English	Article							GROWTH CONE COLLAPSE; RECEPTORS; LIGAND; PROTEINS; INTERACT; DYNAMICS	Eph receptors and their membrane-associated ephrin ligands mediate cell - cell repulsion to guide migrating cells and axons. Repulsion requires that the ligand - receptor complex be removed from the cell surface, for example by proteolytic processing of the ephrin ectodomain. Here we show that cell contact-induced EphB - ephrinB complexes are rapidly endocytosed during the retraction of cells and neuronal growth cones. Endocytosis occurs in a bi-directional manner that comprises of full-length receptor and ligand complexes. Endocytosis is sufficient to promote cell detachment and seems necessary for axon withdrawal during growth cone collapse. Here, we show a mechanism for the termination of adhesion and the promotion of cell repulsion after intercellular ( trans) interaction between two transmembrane proteins.	Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	Max Planck Society	Klein, R (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Zimmer, Manuel/C-5275-2015; Klein, Ruediger/C-6147-2008	Zimmer, Manuel/0000-0002-8072-787X; Klein, Ruediger/0000-0002-3109-0163				Barker PA, 2002, TRENDS NEUROSCI, V25, P379, DOI 10.1016/S0166-2236(02)02199-9; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Gao PP, 1998, P NATL ACAD SCI USA, V95, P5329, DOI 10.1073/pnas.95.9.5329; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Jurney WM, 2002, J NEUROSCI, V22, P6019; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; MANN F, IN PRESS J NEUROBIOL; MARSTON DJ, 2003, NATURE CELL BIOL, V5; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Parks AL, 2000, DEVELOPMENT, V127, P1373; Qualmann B, 2002, INT REV CYTOL, V220, P93; Sambrook J., 2002, MOL CLONING LAB MANU; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883	27	274	277	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					869	878		10.1038/ncb1045	http://dx.doi.org/10.1038/ncb1045			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	12973358				2022-12-25	WOS:000185647400012
J	Zhou, ZH; Toh, SY; Chen, ZM; Guo, K; Ng, CP; Ponniah, S; Lin, SC; Hong, WJ; Li, P				Zhou, ZH; Toh, SY; Chen, ZM; Guo, K; Ng, CP; Ponniah, S; Lin, SC; Hong, WJ; Li, P			Cidea-deficient mice have lean phenotype and are resistant to obesity	NATURE GENETICS			English	Article							BROWN ADIPOSE-TISSUE; MITOCHONDRIAL UNCOUPLING PROTEIN; TRANSGENIC MICE; ENERGY-BALANCE; THERMOGENESIS; APOPTOSIS; LACKING; MUSCLE; DOMAIN	The thermogenic activity of brown adipose tissue (BAT), important for adaptive thermogenesis and energy expenditure, is mediated by the mitochondrial uncoupling protein1 (Ucp1) that uncouples ATP generation and dissipates the energy as heat. We show here that Cidea, a protein of unknown function sharing sequence similarity with the N-terminal region of DNA fragmentation factors Dffb and Dffa, is expressed at high levels in BAT. Cidea-null mice had higher metabolic rate, lipolysis in BAT and core body temperature when subjected to cold treatment. Notably, Cidea-null mice are lean and resistant to diet-induced obesity and diabetes. Furthermore, we provide evidence that the role of Cidea in regulating thermogenesis, lipolysis and obesity may be mediated in part through its direct suppression of Ucp1 activity. Our data thus indicate a role for Cidea in regulating energy balance and adiposity.	Inst Cell & Mol Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore; Inst Cell & Mol Biol, Lab Regulatory Biol, Singapore 117609, Singapore; Inst Cell & Mol Biol, Lab Membrane Biol, Singapore 117609, Singapore; Inst Cell & Mol Biol, In Vivo Model Unit, Singapore 117609, Singapore; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Hong Kong University of Science & Technology	Li, P (corresponding author), Inst Cell & Mol Biol, Lab Apoptosis Regulat, 30 Med Dr, Singapore 117609, Singapore.	bolipeng@ust.hk	Zhou, Z Hong/HDN-0747-2022; Lin, SC/G-4666-2010; HONG, Wanjin/E-9927-2010	Toh, Shen Yon/0000-0002-6421-0862				Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; Carson F. L., 1997, HISTOTECHNOLOGY SELF; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; DULLOO AG, 1984, CAN J PHYSIOL PHARM, V62, P235, DOI 10.1139/y84-035; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Lowell BB, 1997, ANNU REV MED, V48, P307; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Zhou P, 2001, P NATL ACAD SCI USA, V98, P6051, DOI 10.1073/pnas.111145098	26	359	384	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2003	35	1					49	56		10.1038/ng1225	http://dx.doi.org/10.1038/ng1225			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12910269				2022-12-25	WOS:000185018500010
J	Miller, DG; Petek, LM; Russell, DW				Miller, DG; Petek, LM; Russell, DW			Adeno-associated virus vectors integrate at chromosome breakage sites	NATURE GENETICS			English	Article							DOUBLE-STRAND BREAKS; CELLS; RECOMBINATION; REPAIR; PURIFICATION; TRANSDUCTION; SEQUENCES; JUNCTIONS; TITER	Adeno-associated virus (AAV) vectors transduce cells by multiple pathways, including integration at nonhomologous chromosomal locations by an unknown mechanism(1-5). We reasoned that spontaneous chromosome breaks may facilitate vector integration and investigated this in cells containing a specific chromosomal double-strand break created by the endonuclease I-Scel or multiple breaks created by treatment with etoposide or gamma-irradiation. Vector proviruses were found at I-Scel cleavage sites, and sequencing of vector-chromosome junctions detected microhomologies, deletions and insertions that were similar when integration occurred spontaneously at random locations or at induced double-strand breaks. Infection with AAV vectors did not increase mutation rates in normal human cells. Our results establish a mechanism for integration and suggest that AAV vectors can integrate at existing chromosome breaks rather than causing breaks themselves, which has implications for their clinical use.	Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Russell, DW (corresponding author), Univ Washington, Dept Med, Div Hematol, 1705 NE Pacific St, Seattle, WA 98195 USA.	drussell@u.washington.edu		Miller, Daniel/0000-0002-5700-3048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062100] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK062100] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Gonzalez-Barrera S, 2002, GENETICS, V162, P603; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Inoue N, 1999, J VIROL, V73, P7376, DOI 10.1128/JVI.73.9.7376-7380.1999; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8241, DOI 10.1073/pnas.131009198; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lin YF, 2001, GENETICS, V158, P1665; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Miller DG, 2003, MOL CELL BIOL, V23, P3550, DOI 10.1128/MCB.23.10.3550-3557.2003; Miller DG, 2002, NAT GENET, V30, P147, DOI 10.1038/ng824; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; Russell DW, 2003, NAT GENET, V34, P241, DOI 10.1038/ng0703-241; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Trobridge G, 2004, J VIROL, V78, P2327, DOI 10.1128/JVI.78.5.2327-2335.2004; Trobridge G, 2002, MOL THER, V6, P321, DOI 10.1006/mthe.2002.0672; Yang CC, 1997, J VIROL, V71, P9231, DOI 10.1128/JVI.71.12.9231-9247.1997; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	30	170	178	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					767	773		10.1038/ng1380	http://dx.doi.org/10.1038/ng1380			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15208627	Bronze			2022-12-25	WOS:000222354100030
J	Khil, PP; Smirnova, NA; Romanienko, PJ; Camerini-Otero, RD				Khil, PP; Smirnova, NA; Romanienko, PJ; Camerini-Otero, RD			The mouse X chromosome is enriched for sex-biased genes not subject to selection by meiotic sex chromosome inactivation	NATURE GENETICS			English	Article							SPERMATOGENIC CELLS; C-ELEGANS; EXPRESSION; EVOLUTION; TRANSCRIPTOME; MICROARRAYS; GERMLINE; SYNAPSIS; SPO11	Sex chromosomes are subject to sex-specific selective evolutionary forcest(1,2). One model predicts that genes with sex-biased expression should be enriched on the X chromosome(2-5). In agreement with Rice's hypothesis(3), spermatogonial genes are over-represented on the X chromosome of mice(6) and sex- and reproduction-related genes are over-represented on the human X chromosome(7,8). Male-biased genes are under-represented on the X chromosome in worms and flies(9-11), however. Here we show that mouse spermatogenesis genes are relatively underrepresented on the X chromosome and female-biased genes are enriched on it. We used Spo11(-/-) mice blocked in spermatogenesis early in meiosis(12) to evaluate the temporal pattern of gene expression in sperm development. Genes expressed before the Spo11 block are enriched on the X chromosome, whereas those expressed later in spermatogenesis are depleted. Inactivation of the X chromosome in male meiosis may be a universal driving force for X-chromosome demasculinization.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Camerini-Otero, RD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, 5 Mem Dr, Bethesda, MD 20892 USA.	camerini@ncifcrf.gov		Khil, Pavel/0000-0002-4903-8777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Bono H, 2003, GENOME RES, V13, P1318, DOI 10.1101/gr.1075103; Charlesworth B, 2002, NOVART FDN SYMP, V244, P207; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; Fraser LR, 1999, BIOESSAYS, V21, P304, DOI 10.1002/(SICI)1521-1878(199904)21:4<304::AID-BIES6>3.0.CO;2-H; GOLDSTEIN P, 1982, CHROMOSOMA, V86, P577, DOI 10.1007/BF00330128; Huminiecki L, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-31; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; Kelly WG, 2002, DEVELOPMENT, V129, P479; Lercher MJ, 2003, MOL BIOL EVOL, V20, P1113, DOI 10.1093/molbev/msg131; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Ranz JM, 2003, SCIENCE, V300, P1742, DOI 10.1126/science.1085881; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Saifi GM, 1999, P ROY SOC B-BIOL SCI, V266, P203, DOI 10.1098/rspb.1999.0623; Schlecht U, 2004, MOL BIOL CELL, V15, P1031, DOI 10.1091/mbc.E03-10-0762; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; Stekel DJ, 2000, GENOME RES, V10, P2055, DOI 10.1101/gr.GR-1325RR; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallender EJ, 2004, BIOESSAYS, V26, P159, DOI 10.1002/bies.10393; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927	30	244	252	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					642	646		10.1038/ng1368	http://dx.doi.org/10.1038/ng1368			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15156144	Bronze			2022-12-25	WOS:000221763700024
J	Cowan, CM; Shi, YY; Aalami, OO; Chou, YF; Mari, C; Thomas, R; Quarto, N; Contag, CH; Wu, B; Longaker, MT				Cowan, CM; Shi, YY; Aalami, OO; Chou, YF; Mari, C; Thomas, R; Quarto, N; Contag, CH; Wu, B; Longaker, MT			Adipose-derived adult stromal cells heal critical-size mouse calvarial defects	NATURE BIOTECHNOLOGY			English	Article							MESENCHYMAL STEM-CELLS; IN-VITRO; DURA-MATER; BONE-FORMATION; GROWTH-FACTOR; DIFFERENTIATION; TISSUE; REPAIR; VIVO; HYDROXYAPATITE	In adults and children over two years of age, large cranial defects do not reossify successfully, posing a substantial biomedical burden. The osteogenic potential of bone marrow stromal (BMS) cells has been documented. This study investigates the in vivo osteogenic capability of adipose-derived adult stromal (ADAS) cells, BMS cells, calvarial-derived osteoblasts and dura mater cells to heal critical-size mouse calvarial defects. Implanted, apatite-coated, PLGA scaffolds seeded with ADAS or BMS cells produced significant intramembranous bone formation by 2 weeks and areas of complete bony bridging by 12 weeks as shown by X-ray analysis, histology and live micromolecular imaging. The contribution of implanted cells to new bone formation was 84-99% by chromosomal detection. These data show that ADAS cells heal critical-size skeletal defects without genetic manipulation or the addition of exogenous growth factors.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA; Stanford Univ, Sch Med, Dept Radiol, Div Nucl Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; Stanford University; Stanford University	Longaker, MT (corresponding author), Stanford Univ, Sch Med, Dept Surg, 257 Campus Dr, Stanford, CA 94305 USA.	longaker@Stanford.edu		Contag, Christopher/0000-0002-1011-8278	NIDCR NIH HHS [R01DE-14526] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014526] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashjian PH, 2003, PLAST RECONSTR SURG, V111, P1922, DOI 10.1097/01.PRS.0000055043.62589.05; BOSTROM R, 1997, TISSUE ENG BONE, V1; Bourgeois B, 2003, J BIOMED MATER RES A, V65A, P402, DOI 10.1002/jbm.a.10518; Bradley JP, 1997, PLAST RECONSTR SURG, V100, P1091, DOI 10.1097/00006534-199710000-00001; Bradley JP, 1996, CLEFT PALATE-CRAN J, V33, P150, DOI 10.1597/1545-1569(1996)033<0150:SICSBV>2.3.CO;2; Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323; Cowan CM, 2003, J BIOL CHEM, V278, P32005, DOI 10.1074/jbc.M304698200; Dong J, 2001, J BIOMED MATER RES, V57, P208, DOI 10.1002/1097-4636(200111)57:2<208::AID-JBM1160>3.0.CO;2-N; Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736-0266(02)00238-3; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270; Fong KD, 2003, J CRANIOFAC SURG, V14, P333, DOI 10.1097/00001665-200305000-00011; FRAZZA E J, 1971, Journal of Biomedical Materials Research Biomedical Materials Symposium, V1, P43; Greenwald JA, 2000, J BONE MINER RES, V15, P2413, DOI 10.1359/jbmr.2000.15.12.2413; GUNDLE R, 1995, BONE, V16, P597, DOI 10.1016/8756-3282(95)00112-Q; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; Halvorsen YDC, 2001, METABOLISM, V50, P407, DOI 10.1053/meta.2001.21690; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; Hench LL, 1998, J AM CERAM SOC, V81, P1705; Hong L, 2000, J NEUROSURG, V92, P315, DOI 10.3171/jns.2000.92.2.0315; Im GI, 2001, J BONE JOINT SURG BR, V83B, P289, DOI 10.1302/0301-620X.83B2.10495; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Krebsbach PH, 1998, TRANSPLANTATION, V66, P1272, DOI 10.1097/00007890-199811270-00002; Lee JA, 2003, ANN PLAS SURG, V50, P610, DOI 10.1097/01.SAP.0000069069.23266.35; Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623-200107000-00008; LEHUEC JC, 1995, BIOMATERIALS, V16, P113, DOI 10.1016/0142-9612(95)98272-G; Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022; Marler JJ, 1998, ADV DRUG DELIVER REV, V33, P165, DOI 10.1016/S0169-409X(98)00025-8; Medvinsky A, 2003, NATURE, V422, P823, DOI 10.1038/422823a; Mehrara BJ, 1999, PLAST RECONSTR SURG, V104, P435, DOI 10.1097/00006534-199908000-00017; Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010; Mizuno H, 2002, PLAST RECONSTR SURG, V109, P199, DOI 10.1097/00006534-200201000-00030; MULLERMAI CM, 1995, J BIOMED MATER RES, V29, P9, DOI 10.1002/jbm.820290103; MULLIKEN JB, 1980, PLAST RECONSTR SURG, V65, P553, DOI 10.1097/00006534-198005000-00001; NEO M, 1992, J BIOMED MATER RES, V26, P1419, DOI 10.1002/jbm.820261103; Okumura A, 2001, BIOMATERIALS, V22, P2263, DOI 10.1016/S0142-9612(00)00415-4; OPPERMAN LA, 1995, J BONE MINER RES, V10, P1978; OPPERMAN LA, 1996, IN VITRO CELL DEV, V32, P150; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; REDDI AH, 1998, BIOCERAMICS, V11, P9; Rosa Adalberto Luiz, 2002, Pesqui Odontol Bras, V16, P209, DOI 10.1590/S1517-74912002000300005; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Sarkar BK, 1995, B MATER SCI, V18, P755, DOI 10.1007/BF02744809; Shea LD, 2000, TISSUE ENG, V6, P605, DOI 10.1089/10763270050199550; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Tholpady SS, 2003, ANAT REC PART A, V272A, P398, DOI 10.1002/ar.a.10039; Toquet J, 1999, J BIOMED MATER RES, V44, P98, DOI 10.1002/(SICI)1097-4636(199901)44:1<98::AID-JBM11>3.3.CO;2-G; VANBLITTERSWIJK CA, 1990, J BIOMED MATER RES, V24, P433, DOI 10.1002/jbm.820240403; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wickham MQ, 2003, CLIN ORTHOP RELAT R, P196, DOI 10.1097/01.blo.0000072467.53786.ca; Wiedmann-Al-Ahmad M, 2002, BIOMATERIALS, V23, P3319, DOI 10.1016/S0142-9612(02)00019-4; Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654; Zhao Feng, 2002, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V16, P130; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	61	746	820	2	128	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					560	567		10.1038/nbt958	http://dx.doi.org/10.1038/nbt958			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15077117				2022-12-25	WOS:000221159700024
J	Harman, FS; Nicol, CJ; Marin, HE; Ward, JM; Gonzalez, FJ; Peters, JM				Harman, FS; Nicol, CJ; Marin, HE; Ward, JM; Gonzalez, FJ; Peters, JM			Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis	NATURE MEDICINE			English	Article							PPAR-GAMMA; COLORECTAL-CANCER; POLYP FORMATION; PHASE-II; MICE; TROGLITAZONE; SUPPRESSION; DISRUPTION; LIGANDS; GROWTH	Peroxisome proliferator-activated receptor-delta (PPAR-delta; also known as PPAR-beta) is expressed at high levels in colon tumors, but its contribution to colon cancer is unclear. We examined the role of PPAR-delta in colon carcinogenesis using PPAR-delta-deficient (Ppard(-/-)) mice. In both the Min mutant and chemically induced mouse models, colon polyp formation was significantly greater in mice nullizygous for PPAR-delta. In contrast to previous reports suggesting that activation of PPAR-delta potentiates colon polyp formation, here we show that PPAR-delta attenuates colon carcinogenesis.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA; NCI, Lab Metab, Bethesda, MD 20892 USA; NCI, Vet & Tumor Pathol Sect, Off Lab Anim Resources, Frederick, MD 21702 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA.	jmp21@psu.edu	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [R01CA097999, ZIABC005708, R01CA089607, Z01BC005708] Funding Source: NIH RePORTER; NCI NIH HHS [CA97999, CA89607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Niho N, 2003, CANCER RES, V63, P6090; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108	15	183	188	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					481	483		10.1038/nm1026	http://dx.doi.org/10.1038/nm1026			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15048110				2022-12-25	WOS:000221242400024
J	Henne, A; Bruggemann, H; Raasch, C; Wiezer, A; Hartsch, T; Liesegang, H; Johann, A; Lienard, T; Gohl, O; Martinez-Arias, R; Jacobi, C; Starkuviene, V; Schlenczeck, S; Dencker, S; Huber, R; Klenk, HP; Kramer, W; Merkl, R; Gottschalk, G; Fritz, HJ				Henne, A; Bruggemann, H; Raasch, C; Wiezer, A; Hartsch, T; Liesegang, H; Johann, A; Lienard, T; Gohl, O; Martinez-Arias, R; Jacobi, C; Starkuviene, V; Schlenczeck, S; Dencker, S; Huber, R; Klenk, HP; Kramer, W; Merkl, R; Gottschalk, G; Fritz, HJ			The genome sequence of the extreme thermophile Thermus thermophilus	NATURE BIOTECHNOLOGY			English	Article							NATURAL TRANSFORMATION; BACTERIUM; DEINOCOCCUS; GENES; HB27; BIOSYNTHESIS; ENZYMES; SUBUNIT; HB8; THERMOSTABILITY	Thermus thermophilus HB27 is an extremely thermophilic, halotolerant bacterium, which was originally isolated from a natural thermal environment in Japan. This organism has considerable biotechnological potential; many thermostable proteins isolated from members of the genus Thermus are indispensable in research and in industrial applications. We present here the complete genome sequence of T. thermophilus HB27, the first for the genus Thermus. The genome consists of a 1,894,877 base pair chromosome and a 232,605 base pair megaplasmid, designated pTT27. The 2,218 identified putative genes were compared to those of the closest relative sequenced so far, the mesophilic bacterium Deinococcus radiodurans. Both organisms share a similar set of proteins, although their genomes lack extensive synteny. Many new genes of potential interest for biotechnological applications were found in T. thermophilus HB27. Candidates include various proteases and key enzymes of other fundamental biological processes such as DNA replication, DNA repair and RNA maturation.	Univ Gottingen, Inst Microbiol & Genet, Gottingen Genom Lab, D-37077 Gottingen, Germany; Univ Gottingen, Inst Microbiol & Genet, Dept Mol Genet & Preparat Mol Biol, D-37077 Gottingen, Germany; Univ Gottingen, Inst Microbiol & Genet, Dept Gen & Appl Microbiol, D-37077 Gottingen, Germany; Univ Regensburg, D-93053 Regensburg, Germany	University of Gottingen; University of Gottingen; University of Gottingen; University of Regensburg	Henne, A (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Gottingen Genom Lab, Grisebachstr 8, D-37077 Gottingen, Germany.	ahenne@g2l.bio.uni-goettingen.de	Merkl, Rainer/A-4534-2008; Starkuviene, Vytaute/AAG-9378-2021	Merkl, Rainer/0000-0002-3521-2957; Liesegang, Heiko/0000-0003-1792-2047; Bruggemann, Holger/0000-0001-7433-0190				Adachi O, 2003, APPL MICROBIOL BIOT, V60, P643, DOI 10.1007/s00253-002-1155-9; Besemer J, 2001, NUCLEIC ACIDS RES, V29, P2607, DOI 10.1093/nar/29.12.2607; BROCK TD, 1969, J BACTERIOL, V98, P289, DOI 10.1128/JB.98.1.289-297.1969; Bullard JM, 2002, J BIOL CHEM, V277, P13401, DOI 10.1074/jbc.M110833200; CHAMBERLAIN NR, 1991, INFECT IMMUN, V59, P4332, DOI 10.1128/IAI.59.12.4332-4337.1991; Daniel RM, 1996, BIOTECHNOL GENET ENG, V13, P51, DOI 10.1080/02648725.1996.10647924; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; Friedrich A, 2003, APPL ENVIRON MICROB, V69, P3695, DOI 10.1128/AEM.69.7.3695-3700.2003; Friedrich A, 2002, APPL ENVIRON MICROB, V68, P745, DOI 10.1128/AEM.68.2.745-755.2002; Fryxell KJ, 2000, MOL BIOL EVOL, V17, P1371, DOI 10.1093/oxfordjournals.molbev.a026420; HENSEL R, 1986, INT J SYST BACTERIOL, V36, P444, DOI 10.1099/00207713-36-3-444; HOSHINO T, 1993, APPL ENVIRON MICROB, V59, P3150, DOI 10.1128/AEM.59.9.3150-3153.1993; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; KRAFFT T, 1995, EUR J BIOCHEM, V230, P601; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; MATHER MW, 1993, J BIOL CHEM, V268, P5395; Niehaus F, 1999, APPL MICROBIOL BIOT, V51, P711, DOI 10.1007/s002530051456; Nishino H, 2002, CANCER METAST REV, V21, P257, DOI 10.1023/A:1021206826750; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Pantazaki AA, 2002, APPL MICROBIOL BIOT, V58, P1, DOI 10.1007/s00253-001-0843-1; Pantazaki AA, 1998, APPL BIOCHEM BIOTECH, V75, P249, DOI 10.1007/BF02787778; QUINTELA JC, 1995, J BACTERIOL, V177, P4947, DOI 10.1128/jb.177.17.4947-4962.1995; Ramirez-Arcos S, 1998, BBA-GENE STRUCT EXPR, V1396, P215, DOI 10.1016/S0167-4781(97)00183-8; Roessner CA, 2002, MICROBIOL-SGM, V148, P1845, DOI 10.1099/00221287-148-6-1845; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; RUTTIMANN C, 1985, EUR J BIOCHEM, V149, P41, DOI 10.1111/j.1432-1033.1985.tb08890.x; Sandmann G, 2001, ARCH BIOCHEM BIOPHYS, V385, P4, DOI 10.1006/abbi.2000.2170; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Staden R, 2000, Methods Mol Biol, V132, P115; Starkuviene V, 2002, NUCLEIC ACIDS RES, V30, P2097, DOI 10.1093/nar/30.10.2097; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; SUZUKI Y, 1991, APPL MICROBIOL BIOT, V34, P707; TABATA K, 1994, FEBS LETT, V341, P251, DOI 10.1016/0014-5793(94)80466-4; Tabata K, 1996, MICROBIOL-UK, V142, P401, DOI 10.1099/13500872-142-2-401; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; WILLIAMS RAD, 1995, INT J SYST BACTERIOL, V45, P495, DOI 10.1099/00207713-45-3-495; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yamaguchi M, 2002, J BIOL CHEM, V277, P33670, DOI 10.1074/jbc.M204170200; Yokoyama A, 1996, ARCH MICROBIOL, V165, P342, DOI 10.1007/s002030050336; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955	47	300	700	2	49	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					547	553		10.1038/nbt956	http://dx.doi.org/10.1038/nbt956			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15064768				2022-12-25	WOS:000221159700022
J	Navarro, C; Puthalakath, H; Adams, JM; Strasser, A; Lehmann, R				Navarro, C; Puthalakath, H; Adams, JM; Strasser, A; Lehmann, R			Egalitarian binds dynein light chain to establish oocyte polarity and maintain oocyte fate	NATURE CELL BIOLOGY			English	Letter							POSTERIOR DETERMINANT NANOS; MATERNAL-EFFECT MUTATIONS; DROSOPHILA-MELANOGASTER; BICAUDAL-D; CYTOPLASMIC DYNEIN; CELLULAR PROTEINS; MESSENGER-RNA; LOCALIZATION; OOGENESIS; MICROTUBULES	In many cell types polarized transport directs the movement of mRNAs and proteins from their site of synthesis to their site of action, thus conferring cell polarity(1). The cytoplasmic dynein microtubule motor complex is involved in this process. In Drosophila melanogaster, the Egalitarian (Egl) and Bicaudal-D (BicD) proteins are also essential for the transport of macromolecules to the oocyte and to the apical surface of the blastoderm embryo(2-5). Hence, EgI and BicD, which have been shown to associate(4), may be part of a conserved core localization machinery in Drosophila, although a direct association between these molecules and the dynein motor complex has not been shown. Here we report that EgI interacts directly with Drosophila dynein light chain (DIc), a microtubule motor component, through an EgI domain distinct from that which binds BicD(4). We propose that the Egl-BicD complex is loaded through Dic onto the dynein motor complex thereby facilitating transport of cargo. Consistent with this model, point mutations that specifically disrupt EgI-DIc association also disrupt microtubule-dependant trafficking both to and within the oocyte, resulting in a loss of oocyte fate maintenance and polarity. Our data provide a direct link between a molecule necessary for oocyte specification and the microtubule motor complex, and supports the hypothesis that microtubule-mediated transport is important for preserving oocyte fate.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; Walter & Eliza Hall Inst Med Res, Royal Parade, Vic 3050, Australia	New York University; New York University; Howard Hughes Medical Institute; New York University; Walter & Eliza Hall Institute	Lehmann, R (corresponding author), NYU, Sch Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	lehmann@saturn.med.nyu.edu	Puthalakath, Hamsa/B-8541-2011; Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013	Strasser, Andreas/0000-0002-5020-4891; Navarro, Caryn/0000-0002-9701-477X; Lehmann, Ruth/0000-0002-8454-5651; Adams, Jerry/0000-0002-4360-8628				BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; Bolivar J, 2001, DEVELOPMENT, V128, P1889; Bullock SL, 2001, NATURE, V414, P611, DOI 10.1038/414611a; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; Dick T, 1996, MOL CELL BIOL, V16, P1966; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huynh JR, 2000, DEVELOPMENT, V127, P2785; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LINDSLEY DL, 1992, GENOME DROSOPHILA ME, P851; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; MOHLER J, 1986, GENETICS, V112, P803; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Navarro C, 2001, CURR BIOL, V11, pR162, DOI 10.1016/S0960-9822(01)00083-5; PELEGRI FP, 1994, THESIS MIT, P285; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; SCHUPBACH T, 1989, GENETICS, V121, P101; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; Swan A, 1996, DEVELOPMENT, V122, P3577; Tekotte H, 2002, TRENDS GENET, V18, P636, DOI 10.1016/S0168-9525(02)02819-6; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; XU T, 1993, DEVELOPMENT, V117, P1223	32	139	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					427	+		10.1038/ncb1122	http://dx.doi.org/10.1038/ncb1122			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15077115				2022-12-25	WOS:000221432600013
J	Zaslaver, A; Mayo, AE; Rosenberg, R; Bashkin, P; Sberro, H; Tsalyuk, M; Surette, MG; Alon, U				Zaslaver, A; Mayo, AE; Rosenberg, R; Bashkin, P; Sberro, H; Tsalyuk, M; Surette, MG; Alon, U			Just-in-time transcription program in metabolic pathways	NATURE GENETICS			English	Article							RESPONSIVE REGULATORY PROTEIN; BACTERIAL-CELL-CYCLE; ESCHERICHIA-COLI; GENE-EXPRESSION; REGULATION NETWORK; OPTIMIZATION; KINETICS; SYSTEMS; ENZYMES	A primary goal of systems biology is to understand the design principles of the transcription networks that govern the timing of gene expression(1-5). Here we measured promoter activity for similar to100 genes in parallel from living cells at a resolution of minutes and accuracy of 10%, based on GFP and Lux reporter libraries(3). Focusing on the amino-acid biosynthesis systems of Escherichia coli 4, we identified a previously unknown temporal expression program and expression hierarchy that matches the enzyme order in unbranched pathways. We identified two design principles: the closer the enzyme is to the beginning of the pathway, the shorter the response time of the activation of its promoter and the higher its maximal promoter activity. Mathematical analysis suggests that this 'just-in-time' (ref. 5) transcription program is optimal under constraints of rapidly reaching a production goal with minimal total enzyme production(6,7). Our findings suggest that metabolic regulation networks are designed to generate precision promoter timing and activity programs that can be understood using the engineering principles of production pipelines.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Weizmann Institute of Science; Weizmann Institute of Science; University of Calgary	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	uri.alon@weizmann.ac.il	Surette, Michael G/AAE-8825-2020; mayo, avi/N-3756-2019; MAYO, AVI E/K-1736-2012	mayo, avi/0000-0002-4479-3423; 				Aizawa S, 1998, GENES CELLS, V3, P625, DOI 10.1046/j.1365-2443.1998.00219.x; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHARLIER D, 1992, J MOL BIOL, V226, P367, DOI 10.1016/0022-2836(92)90953-H; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Covert MW, 2002, J BIOL CHEM, V277, P28058, DOI 10.1074/jbc.M201691200; GILMAN A, 1995, BIOPHYS J, V69, P1321, DOI 10.1016/S0006-3495(95)79999-4; Goh EB, 2002, P NATL ACAD SCI USA, V99, P17025, DOI 10.1073/pnas.252607699; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HEINRICH R, 1991, EUR J BIOCHEM, V201, P1, DOI 10.1111/j.1432-1033.1991.tb16251.x; Heinrich R, 1996, J THEOR BIOL, V182, P243, DOI 10.1006/jtbi.1996.0161; Heinrich R., 1996, REGULATION CELLULAR; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; Hung SP, 2002, J BIOL CHEM, V277, P40309, DOI 10.1074/jbc.M204044200; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; Kalir S, 2001, SCIENCE, V292, P2080, DOI 10.1126/science.1058758; Klipp E, 2002, EUR J BIOCHEM, V269, P5406, DOI 10.1046/j.1432-1033.2002.03223.x; Laub MT, 2000, SCIENCE, V290, P2144, DOI 10.1126/science.290.5499.2144; LEGRAIN C, 1972, EUR J BIOCHEM, V27, P93, DOI 10.1111/j.1432-1033.1972.tb01814.x; McAdams HH, 2003, SCIENCE, V301, P1874, DOI 10.1126/science.1087694; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; PETTERSSON G, 1993, BIOCHIM BIOPHYS ACTA, V1164, P1, DOI 10.1016/0167-4838(93)90104-Y; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Rosenfeld N, 2003, J MOL BIOL, V329, P645, DOI 10.1016/S0022-2836(03)00506-0; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1974, NATURE, V252, P546, DOI 10.1038/252546a0; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881	30	354	358	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					486	491		10.1038/ng1348	http://dx.doi.org/10.1038/ng1348			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107854	Bronze			2022-12-25	WOS:000221183000021
J	Remy, I; Montmarquette, A; Michnick, SW				Remy, I; Montmarquette, A; Michnick, SW			PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3	NATURE CELL BIOLOGY			English	Letter							APOPTOSIS; PROTEIN; EXPRESSION; INDUCTION; DIFFERENTIATION; VISUALIZATION; ELEMENTS; COMPLEX; GENE; AKT	Transforming growth factor beta (TGF-beta) has a major role in cell proliferation, differentiation and apoptosis in many cell types. Integration of the TGF-beta pathway with other signalling cascades that control the same cellular processes may modulate TGF-beta responses. Here we report the discovery of a new functional link between TGF-beta and growth factor signalling pathways, mediated by a physical interaction between the serine-threonine kinase PKB (protein kinase B)/Akt and the transcriptional activator Smad3. Formation of the complex is induced by insulin, but inhibited by TGF-beta stimulation, placing PKB-Smad3 at a point of convergence between these two pathways. PKB inhibits Smad3 by preventing its phosphorylation, binding to Smad4 and nuclear translocation. In contrast, Smad3 does not inhibit PKB. Inhibition of Smad3 by PKB occurs through a kinase-activity-independent mechanism, resulting in a decrease in Smad3-mediated transcription and protection of cells against TGF-beta-induced apoptosis. Consistently, knockdown of the endogenous PKB gene with small-interfering RNA (siRNA) has the opposite effect. Our results suggest a very simple mechanism for the integration of signals arising from growth-factor- and TGF-beta-mediated pathways.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	stephen.michnick@umontreal.ca						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buenemann CL, 2001, CARCINOGENESIS, V22, P447, DOI 10.1093/carcin/22.3.447; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Ghosh I, 2000, J AM CHEM SOC, V122, P5658, DOI 10.1021/ja994421w; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim WH, 2003, AM J PHYSIOL-GASTR L, V285, pG761, DOI 10.1152/ajpgi.00224.2003; Li XF, 2003, ENDOCRINOLOGY, V144, P2514, DOI 10.1210/en.2002-220969; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 2001, J CELL SCI, V114, P4359; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; REMY I, 2001, PROTEIN PROTEIN INTE, P449; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Tanaka S, 1996, CANCER RES, V56, P3391; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123	30	309	336	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					358	365		10.1038/ncb1113	http://dx.doi.org/10.1038/ncb1113			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048128				2022-12-25	WOS:000220587600018
J	Braz, JC; Gregory, K; Pathak, A; Zhao, W; Sahin, B; Klevitsky, R; Kimball, TF; Lorenz, JN; Nairn, AC; Liggett, SB; Bodi, I; Wang, S; Schwartz, A; Lakatta, EG; DePaoli-Roach, AA; Robbins, J; Hewett, TE; Bibb, JA; Westfall, MV; Kranias, EG; Molkentin, JD				Braz, JC; Gregory, K; Pathak, A; Zhao, W; Sahin, B; Klevitsky, R; Kimball, TF; Lorenz, JN; Nairn, AC; Liggett, SB; Bodi, I; Wang, S; Schwartz, A; Lakatta, EG; DePaoli-Roach, AA; Robbins, J; Hewett, TE; Bibb, JA; Westfall, MV; Kranias, EG; Molkentin, JD			PKC-alpha regulates cardiac contractility and propensity toward heart failure	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; SARCOPLASMIC-RETICULUM; PHOSPHATASE INHIBITOR-1; CROSS-TALK; PHOSPHOLAMBAN; EXPRESSION; ISOFORMS; PHOSPHORYLATION; TRANSLOCATION; PROGRESSION	The protein kinase C (PKC) family of serine/threonine kinases functions downstream of nearly all membrane- associated signal transduction pathways. Here we identify PKC-alpha as a fundamental regulator of cardiac contractility and Ca2+ handling in myocytes. Hearts of Prkca-deficient mice are hypercontractile, whereas those of transgenic mice overexpressing Prkca are hypocontractile. Adenoviral gene transfer of dominant-negative or wild-type PKC-alpha into cardiac myocytes enhances or reduces contractility, respectively. Mechanistically, modulation of PKC-activity affects dephosphorylation of the sarcoplasmic reticulum Ca2+ ATPase-2 (SERCA-2) pump inhibitory protein phospholamban (PLB), and alters sarcoplasmic reticulum Ca2+ loading and the Ca2+ transient. PKC-directly phosphorylates protein phosphatase inhibitor-1 (I-1), altering the activity of protein phosphatase-1 (PP-1), which may account for the effects of PKC-alpha on PLB phosphorylation. Hypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3). Deletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1. Thus, PKC-alpha functions as a nodal integrator of cardiac contractility by sensing intracellular Ca2+ and signal transduction events, which can profoundly affect propensity toward heart failure.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Texas SW, Dept Psychiat, Dallas, TX 75390 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Univ Cincinnati, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Michigan, Sect Cardiac Surg, Ann Arbor, MI 48109 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Southwestern Medical Center Dallas; University System of Ohio; University of Cincinnati; Yale University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Indiana University System; Indiana University-Purdue University Indianapolis; University of Michigan System; University of Michigan	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy/G-1023-2011; Lakatta, Edward G/AAL-1447-2020; Hewett, Timothy E/E-3241-2011; liggett, stephen b/E-7453-2012	Molkentin, Jeffery/0000-0002-3558-6529; Nairn, Angus/0000-0002-7075-0195; Lakatta, Edward/0000-0002-4772-0035; Westfall, Margaret/0000-0001-9491-0125; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bayer AL, 2003, MOL CELL BIOCHEM, V242, P145, DOI 10.1023/A:1021106232511; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Champion HC, 2003, CIRCULATION, V108, P2790, DOI 10.1161/01.CIR.0000096487.88897.9B; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; Hahn HS, 2003, CIRC RES, V93, P1111, DOI 10.1161/01.RES.0000105087.79373.17; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; Klein L, 2003, AM J CARDIOL, V91, p18F, DOI 10.1016/S0002-9149(02)03336-2; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Neumann J, 2002, BASIC RES CARDIOL, V97, P1; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; STEENAART NAE, 1992, ARCH BIOCHEM BIOPHYS, V293, P17, DOI 10.1016/0003-9861(92)90359-5; Wang JW, 2003, AM J PHYSIOL-HEART C, V284, pH2277, DOI 10.1152/ajpheart.00142.2002; WARNERSTEVENSON L, 2003, CIRCULATION, V108, P492; Westfall MV, 2003, J BIOL CHEM, V278, P33694, DOI 10.1074/jbc.M305404200	30	457	485	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					248	254		10.1038/nm1000	http://dx.doi.org/10.1038/nm1000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966518				2022-12-25	WOS:000189297700035
J	Niwa, N; Hiromi, Y; Okabe, M				Niwa, N; Hiromi, Y; Okabe, M			A conserved developmental program for sensory organ formation in Drosophila melanogaster	NATURE GENETICS			English	Article							RETINAL GANGLION-CELL; EYE DEVELOPMENT; ECTOPIC EYES; EYELESS GENE; EXPRESSION; MORPHOGENESIS; MUTATION; HOMOLOG; ABSENT; PAX-6	Different sensory organs, such the eye and ear, are widely thought to have separate origins, guided by distinct organ-specific factors that direct all aspects of their development. Previous studies of the D. melanogaster gene eyeless (ey) and its vertebrate homolog Pax6 suggested that this gene acts in such a manner and specifically drives eye development(1,2). But diverse sensory organs might instead arise by segment-specific modification of a developmental program that is involved more generally in sensory organ formation. In D. melanogaster, a common proneural gene called atonal (ato) functions in the initial process of development of a number of segment-specific organs, including the compound eye, the auditory organ and the stretch receptor(3,4), suggesting that these organs share an evolutionary origin. Here we show that D. melanogaster segment-specific sensory organs form through the integration of decapentaplegic (dpp), wingless (wg) and ecdysone signals into a single cis-regulatory element of ato. The induction of ectopic eyes by ey also depends on these signals for ato expression, and the ey mutant eye imaginal disc allows ato expression if cell death is blocked. These results imply that ey does not induce the entire eye morphogenetic program but rather modifies ato dependent neuronal development. Our findings strongly suggest that various sensory organs evolved from an ato dependent protosensory organ through segment specification by ey and Hox genes.	SOKENDAI, Dept Genet, Shizuoka 4118540, Japan; Japan Sci & Technol Agcy, CREST, Tokyo, Japan; Natl Inst Genet, Div Dev Genet, Shizuoka 4118540, Japan	Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Hiromi, Y (corresponding author), Univ London Kings Coll, MRC, Ctr Dev Neurobiol, New Hunts House,4th Floor,Guys Hosp Campus, London SE1 1UL, England.	yhiromi@lab.nig.ac.jp; maokabe@lab.nig.ac.jp						Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Brennan CA, 1998, DEVELOPMENT, V125, P2653; Brown NL, 2001, DEVELOPMENT, V128, P2497; Caldwell JC, 2002, J NEUROBIOL, V53, P172, DOI 10.1002/neu.10126; Champlin DT, 1998, DEVELOPMENT, V125, P2009; Chen R, 1999, DEVELOPMENT, V126, P935; Chow RL, 1999, DEVELOPMENT, V126, P4213; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; Hallberg E, 1999, MICROSC RES TECHNIQ, V47, P428, DOI 10.1002/(SICI)1097-0029(19991215)47:6<428::AID-JEMT6>3.0.CO;2-P; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; HENRICH VC, 1987, DEV BIOL, V120, P50, DOI 10.1016/0012-1606(87)90102-3; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kronhamn J, 2002, DEVELOPMENT, V129, P1015; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Rogers BT, 1997, INT REV CYTOL, V174, P1, DOI 10.1016/S0074-7696(08)62115-4; Snodgrass RE, 1935, PRINCIPLES INSECT MO; Sun Y, 1998, DEVELOPMENT, V125, P3731; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wawersik S, 1999, DEV BIOL, V207, P176, DOI 10.1006/dbio.1998.9153	30	65	67	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					293	297		10.1038/ng1308	http://dx.doi.org/10.1038/ng1308			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981517	Bronze			2022-12-25	WOS:000189250400020
J	Sedelnikova, OA; Horikawa, I; Zimonjic, DB; Popescu, NC; Bonner, WM; Barrett, JC				Sedelnikova, OA; Horikawa, I; Zimonjic, DB; Popescu, NC; Bonner, WM; Barrett, JC			Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks	NATURE CELL BIOLOGY			English	Article							IN-VIVO; CELLULAR SENESCENCE; HISTONE H2AX; DAMAGE; GAMMA-H2AX; TELOMERASE; MOUSE; FOCI	Humans and animals undergo ageing, and although their primary cells undergo cellular senescence in culture, the relationship between these two processes is unclear(1,2). Here we show that gamma-H2AX foci (gamma-foci), which reveal DNA double-strand breaks (DSBs)(3,4), accumulate in senescing human cell cultures and in ageing mice. They colocalize with DSB repair factors, but not significantly with telomeres. These cryptogenic gamma-foci remain after repair of radiation-induced gamma-foci, suggesting that they may represent DNA lesions with unrepairable DSBs. Thus, we conclude that accumulation of unrepairable DSBs may have a causal role in mammalian ageing.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Lab Biosyst & Canc, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonner, WM (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	bonnerw@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020	Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	DIVISION OF BASIC SCIENCES - NCI [Z01BC010417] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC006140, Z01BC010038, Z01BC006140, ZIABC010038] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 2000, J ANTI-AGING MED, V3, P373, DOI 10.1089/rej.1.2000.3.373; Hornsby PJ, 2002, J GERONTOL A-BIOL, V57, pB251, DOI 10.1093/gerona/57.7.B251; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6	15	570	589	4	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					168	+		10.1038/ncb1095	http://dx.doi.org/10.1038/ncb1095			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14755273				2022-12-25	WOS:000188668300017
J	Almeida, A; Moncada, S; Bolanos, JP				Almeida, A; Moncada, S; Bolanos, JP			Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway	NATURE CELL BIOLOGY			English	Article							6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE GENE PFKFB3; MITOCHONDRIAL RESPIRATORY-CHAIN; FRUCTOSE 2,6-BISPHOSPHATE; RIBOSE 1,5-BISPHOSPHATE; EXPRESSION; CELL; PHOSPHOFRUCTOKINASE; INHIBITION; ASTROCYTES; ACTIVATION	After inhibition of cytochrome c oxidase by nitric oxide(1-3), astrocytes maintain energy production by upregulating glycolysis(4,5) - a response which does not seem to be available to neurons. Here, we show that in astrocytes, after inhibition of respiration by nitric oxide, there is a rapid, cyclic GMP-independent increase in the activity of 6-phosphofructo-1-kinase (PFK1), a master regulator of glycolysis(6), and an increase in the concentration of its most powerful positive allosteric activator(7), fructose-2,6-bisphosphate (F2,6P(2)). In neurons, nitric oxide failed to alter F2,6P(2) concentration or PFK1 activity. This failure could be accounted for by the much lower amount of 6-phosphofructo-2-kinase (PFK2, the enzyme responsible for F2,6P(2) biosynthesis(8)) in neurons. Indeed, full activation of neuronal PFK1 was achieved by adding cytosol from nitric oxide-treated astrocytes. Furthermore, using the small interfering RNA (siRNA) strategy(9), we demonstrated that the rapid activation of glycolysis by nitric oxide is dependent on phosphorylation of the energy charge-sensitive AMP-activated protein kinase, resulting in activation of PFK2 and protection of cells from apoptosis. Thus the virtual absence of PFK2 in neurons may explain their extreme sensitivity to energy depletion and degeneration(4,5,10).	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Hosp Univ Salamanca, Unidad Invest, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	University of London; University College London; University of Salamanca; University of Salamanca	Moncada, S (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	s.moncada@ucl.ac.uk	ALMEIDA, ANGELES/B-4727-2017; Bolaños, Juan Pedro/M-9518-2019	ALMEIDA, ANGELES/0000-0003-0485-8904; Bolaños, Juan Pedro/0000-0002-3949-6862				Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; AMBROSIO S, 1991, J NEUROCHEM, V57, P200, DOI 10.1111/j.1471-4159.1991.tb02116.x; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Gutmann I, 1974, METHOD ENZYMAT AN, P1464; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HERS HG, 1982, BIOCHEM J, V206, P1; Hirata T, 1998, BIOCHEM BIOPH RES CO, V242, P680, DOI 10.1006/bbrc.1997.8024; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; ISHIKAWA E, 1990, J BIOL CHEM, V265, P18875; Kawaguchi T, 2001, J BIOL CHEM, V276, P28554, DOI 10.1074/jbc.M101396200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Perez JX, 2000, AM J PHYSIOL-CELL PH, V279, pC1359, DOI 10.1152/ajpcell.2000.279.5.C1359; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sanchez-Martinez C, 2000, BIOCHEM BIOPH RES CO, V271, P635, DOI 10.1006/bbrc.2000.2681; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191	27	351	360	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					45	U9		10.1038/ncb1080	http://dx.doi.org/10.1038/ncb1080			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14688792	Green Published			2022-12-25	WOS:000187802600012
J	Kaykas, A; Yang-Snyder, J; Heroux, M; Shah, KV; Bouvier, M; Moon, RT				Kaykas, A; Yang-Snyder, J; Heroux, M; Shah, KV; Bouvier, M; Moon, RT			Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization	NATURE CELL BIOLOGY			English	Article							BETA-GALACTOSIDASE COMPLEMENTATION; COUPLED RECEPTOR DIMERIZATION; PROTEIN-PROTEIN INTERACTIONS; WNT; XENOPUS; GASTRULATION; MOVEMENTS; HOMOLOGS; PATHWAY; CELLS	nt signalling pathways regulate cell proliferation, cell fate and morphogenetic movements. Here, we demonstrate that the Frizzled (Fz) family of Wnt receptors(1-4), similarly to G-protein-coupled receptors (GPCRs)(5-7), form specific homo- and hetero-oligomers. Two lines of evidence suggest that oligomerization occurs in the endoplasmic reticulum: first, a mutant allele of Fz4, encoding a truncated protein that is retained in the endoplasmic reticulum, is linked to the autosomal-dominant retinal degenerative disease, familial exudative vitreoretinopathy (FEVR)(8). We show that this mutant form of Fz4 oligomerizes with wild-type Fz4, retains it in the endoplasmic reticulum and inhibits its signalling. Second, a derivative of Fz1 targeted to the endoplasmic reticulum traps wild-type Fz1 in the endoplasmic reticulum and blocks its signalling. These data support the hypothesis that oligomerization of mutant and wild-type Fz proteins occurs in the endoplasmic reticulum and may explain the genetic dominance of this FEVR allele.	Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universite de Montreal	Moon, RT (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA.		Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019; Bouvier, Michel/H-2758-2014	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Bouvier, Michel/0000-0003-1128-0100				Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Carron C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Ou W, 2003, VIROLOGY, V308, P101, DOI 10.1016/S0042-6822(02)00086-7; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Rossi FMV, 2000, METHOD ENZYMOL, V328, P231, DOI 10.1016/S0076-6879(00)28400-0; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Sumanas S, 2001, GENESIS, V30, P119, DOI 10.1002/gene.1044; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	23	145	149	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2004	6	1					52	U13		10.1038/ncb1081	http://dx.doi.org/10.1038/ncb1081			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	760GE	14688793				2022-12-25	WOS:000187802600013
J	Marston, DJ; Dickinson, S; Nobes, CD				Marston, DJ; Dickinson, S; Nobes, CD			Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion	NATURE CELL BIOLOGY			English	Article							GROWTH-CONE COLLAPSE; ACTIN POLYMERIZATION; TRANSMEMBRANE LIGAND; MEDIATED ENDOCYTOSIS; RHO GTPASES; RECEPTORS; PROTEIN; KINASE; ACTIVATION; MECHANISMS	Eph receptor-ephrin signals are important for controlling repulsive and attractive cell movements during tissue patterning in embryonic development. However, the dynamic cellular responses to these signals at cell - cell contact sites are poorly understood. To examine these events we have used cell microinjection to express EphB4 and ephrinB2 in adjacent Swiss 3T3 fibroblasts and have studied the interaction of the injected cells using time-lapse microscopy. We show that Eph receptors are locally activated wherever neighbouring cells make contact. This triggers dynamic, Rac-regulated membrane ruffles at the Eph - ephrin contact sites. Subsequently, the receptor and ligand cells retract from one another, concomitantly with the endocytosis of the activated Eph receptors and their bound, full-length ephrinB ligands. Both the internalization of the receptor - ligand complexes and the subsequent cell retraction events are dependent on actin polymerization, which in turn is dependent on Rac signalling within the receptor- expressing cells. Similar events occur in primary human endothelial cells. Our findings suggest a novel mechanism for cell repulsion, in which the contact between Eph- expressing and ephrin- expressing cells is destabilized by the localized phagocytosis of the ligand-expressing cell plasma membrane by the receptor- expressing cell.	UCL, Dept Anat & Dev Biol, Ctr Cell & Mol Dynam, London WC1E 6BT, England	University of London; University College London	Nobes, CD (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol & Biochem, Bristol BS8 1TD, Avon, England.	Catherine.Nobes@bristol.ac.uk			MRC [G117/410] Funding Source: UKRI; Medical Research Council [G117/410] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Jin Z, 1997, J NEUROSCI, V17, P6256; Jurney WM, 2002, J NEUROSCI, V22, P6019; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; Klueg KM, 1999, J CELL SCI, V112, P3289; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Litman Pninit, 2000, BMC Cell Biology, V1, P1, DOI 10.1186/1471-2121-1-1; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Pyenta PS, 2001, BIOPHYS J, V80, P2120, DOI 10.1016/S0006-3495(01)76185-1; Ridley AJ, 2001, J CELL SCI, V114, P2713; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Weinl C, 2003, DEVELOPMENT, V130, P1635, DOI 10.1242/dev.00386; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	37	229	231	2	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2003	5	10					879	888		10.1038/ncb1044	http://dx.doi.org/10.1038/ncb1044			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	727FM	12973357				2022-12-25	WOS:000185647400013
J	Belghith, M; Bluestone, JA; Barriot, S; Megret, J; Bach, JF; Chatenoud, L				Belghith, M; Bluestone, JA; Barriot, S; Megret, J; Bach, JF; Chatenoud, L			TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; REGULATORY T-CELLS; ANTI-CD3 MONOCLONAL-ANTIBODY; CYTOKINE-RELATED SYNDROME; NOD MICE; ANTIGEN 4; TRANSPLANTATION RESPONSES; L-SELECTIN; PHASE-I; CD4(+)CD25(+)	CD3-specific antibodies have the unique capacity to restore self-tolerance in established autoimmunity. They induce long-term remission of overt diabetes in nonobese diabetic (NOD) mice and in human type I diabetes. The underlying mechanisms had been unclear until now. Here we report that treatment with CD3epsilon-specific antibodies induces transferable T-cell-mediated tolerance involving CD4(+)CD25(+) cells. However, these CD4(+)CD25(+) T cells are distinct from naturally occurring regulatory T cells that control physiological autoreactivity. CD3-specific antibody treatment induced remission in NOD Cd28(-/-) mice that were devoid of such regulatory cells. Remission of diabetes was abrogated by coadministration of a neutralizing transforming growth factor (TGF)-beta-specific antibody. The central role of TGF-beta was further suggested by its increased, long-lasting production by CD4(+) T cells from tolerant mice. These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4(+) T cells.	Hop Necker Enfants Malad, IRNEM, INSERM, U580, F-75015 Paris, France; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Hop Necker Enfants Malad, Fac Necker Enfants Malad, IRNEM, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Chatenoud, L (corresponding author), Hop Necker Enfants Malad, IRNEM, INSERM, U580, 161 Rue Sevres, F-75015 Paris, France.							ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ALEGRE ML, 1995, J IMMUNOL, V155, P1544; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; BOITARD C, 1989, J EXP MED, V169, P1669, DOI 10.1084/jem.169.5.1669; Bridoux F, 1997, J EXP MED, V185, P1769, DOI 10.1084/jem.185.10.1769; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; CHATENOUD L, 1991, TRANSPLANTATION, V51, P334, DOI 10.1097/00007890-199102000-00012; CHATENOUD L, 1984, IMMUNOL TODAY, V5, P20, DOI 10.1016/0167-5699(84)90061-6; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; FERRAN C, 1990, EUR J IMMUNOL, V20, P509, DOI 10.1002/eji.1830200308; Friend PJ, 1999, TRANSPLANTATION, V68, P1632, DOI 10.1097/00007890-199912150-00005; Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HIRSCH R, 1990, TRANSPLANTATION, V49, P1117, DOI 10.1097/00007890-199006000-00018; HIRSCH R, 1988, J IMMUNOL, V140, P3766; HIRSCH R, 1989, J IMMUNOL, V142, P737; Itoh M, 1999, J IMMUNOL, V162, P5317; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; LEPAULT F, 1995, EUR J IMMUNOL, V25, P1502, DOI 10.1002/eji.1830250605; Levings MK, 2002, J EXP MED, V196, P1335, DOI 10.1084/jem.20021139; LUCAS C, 1990, J IMMUNOL, V145, P1415; Ludviksson BR, 1997, J IMMUNOL, V159, P3622; Luhder F, 1998, J EXP MED, V187, P427, DOI 10.1084/jem.187.3.427; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Papiernik M, 1998, INT IMMUNOL, V10, P371, DOI 10.1093/intimm/10.4.371; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Seddon B, 1999, J EXP MED, V189, P279, DOI 10.1084/jem.189.2.279; Simone EA, 1999, DIABETES CARE, V22, pB7; Stephens LA, 2000, J IMMUNOL, V165, P3105, DOI 10.4049/jimmunol.165.6.3105; SuriPayer E, 1996, J IMMUNOL, V157, P1799; Szanya V, 2002, J IMMUNOL, V169, P2461, DOI 10.4049/jimmunol.169.5.2461; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang B, 1998, DIABETES, V47, P1207, DOI 10.2337/diabetes.47.8.1207; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	46	481	513	1	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1202	1208		10.1038/nm924	http://dx.doi.org/10.1038/nm924			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937416				2022-12-25	WOS:000185061600034
J	Eustace, BK; Sakurai, T; Stewart, JK; Yimlamai, D; Unger, C; Zehetmeier, C; Lain, B; Torella, C; Henning, SW; Beste, G; Scroggins, BT; Neckers, L; Ilag, LL; Jay, DG				Eustace, BK; Sakurai, T; Stewart, JK; Yimlamai, D; Unger, C; Zehetmeier, C; Lain, B; Torella, C; Henning, SW; Beste, G; Scroggins, BT; Neckers, L; Ilag, LL; Jay, DG			Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness	NATURE CELL BIOLOGY			English	Article							HEAT-SHOCK PROTEINS; HSP90; EXPRESSION; RECEPTOR; COMPLEX; IDENTIFICATION; TRAFFICKING; METASTASIS; INHIBITION; EXOSOMES	Tumour cell invasiveness is crucial for cancer metastasis and is not yet understood. Here we describe two functional screens for proteins required for the invasion of fibrosarcoma cells that identified the molecular chaperone heat shock protein 90 (hsp90). The hsp90alpha isoform, but not hsp90beta, is expressed extracellularly where it interacts with the matrix metalloproteinase 2 (MMP2). Inhibition of extracellular hsp90alpha decreases both MMP2 activity and invasiveness. This role for extracellular hsp90alpha in MMP2 activation indicates that cell-impermeant anti-hsp90 drugs might decrease invasiveness without the concerns inherent in inhibiting intracellular hsp90.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Xerion Pharmaceut AG, D-81377 Munich, Germany; NCI, Cell & Canc Biol Branch, Rockville, MD 20850 USA	Tufts University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jay, DG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	daniel.jay@tufts.edu	Yimlamai, Dean/AAA-6607-2020	Yimlamai, Dean/0000-0002-7936-7168				ALBERTINI S, 1995, MUTAGENESIS, V10, P343, DOI 10.1093/mutage/10.4.343; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; FERRARINI M, 1992, INT J CANCER, V51, P613, DOI 10.1002/ijc.2910510418; GRESS TM, 1994, CANCER RES, V54, P547; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Harlow E., 1999, USING ANTIBODIES LAB; Harlow E., 1988, ANTIBODIES LAB MANUA; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; LEBEAU J, 1991, ONCOGENE, V6, P1125; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rust William L., 2002, Journal of Biomedicine & Biotechnology, V2, P124, DOI 10.1155/S1110724302204015; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; YUFU Y, 1992, LEUKEMIA RES, V16, P597, DOI 10.1016/0145-2126(92)90008-U	45	451	499	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					507	514		10.1038/ncb1131	http://dx.doi.org/10.1038/ncb1131			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15146192				2022-12-25	WOS:000221759400010
J	Melkko, S; Scheuermann, J; Dumelin, CE; Neri, D				Melkko, S; Scheuermann, J; Dumelin, CE; Neri, D			Encoded self-assembling chemical libraries	NATURE BIOTECHNOLOGY			English	Article							HIGH-AFFINITY LIGANDS; CARBONIC-ANHYDRASE; DRUG DISCOVERY; COMBINATORIAL CHEMISTRY; PHAGE ANTIBODIES; BINDING-AFFINITY; SPECIFICITY; INHIBITORS; PROTEINS; NMR	The isolation of molecules capable of high-affinity and specific binding to biological targets is a central problem in chemistry, biology and pharmaceutical sciences. Here we describe the use of encoded self-assembling chemical (ESAC) libraries for the facile identification of molecules that bind macromolecular targets. ESAC technology uses libraries of organic molecules linked to individual oligonucleotides that mediate the self-assembly of the library and provide a code associated with each organic molecule. After panning ESAC libraries on the biomolecular target of interest, the 'binding code' of the selected compounds can be 'decoded' by a number of experimental techniques (e. g., hybridization on oligonucleotide microarrays). The potential of this technology was demonstrated by the affinity maturation (>40-fold) of binding molecules to human serum albumin and bovine carbonic anhydrase, leading to binders with dissociation constants in the nanomolar range.	Swiss Fed Inst Technol, Dept Chem & Appl Chem, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Neri, D (corresponding author), Swiss Fed Inst Technol, Dept Chem & Appl Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	neri@pharma.ethz.ch	Neri, Dario/P-4368-2016; Melkko, Samu/AAG-7815-2019; Scheuermann, Joerg/N-8693-2016	Neri, Dario/0000-0001-5234-7370; Scheuermann, Joerg/0000-0001-7746-4717				BRENNER S, 1992, P NATL ACAD SCI USA, V89, P5381, DOI 10.1073/pnas.89.12.5381; CAROTTI A, 1989, QUANT STRUCT-ACT REL, V8, P1, DOI 10.1002/qsar.19890080102; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; Doyon JB, 2003, J AM CHEM SOC, V125, P12372, DOI 10.1021/ja036065u; EPPS DE, 1995, ANAL BIOCHEM, V227, P342, DOI 10.1006/abio.1995.1290; Erlanson DA, 2003, NAT BIOTECHNOL, V21, P308, DOI 10.1038/nbt786; Fattorusso R, 1999, STRUCTURE, V7, P381, DOI 10.1016/S0969-2126(99)80051-3; FERSHT A, 1990, ENZYME STRUCTURE MEC; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOSEPHSON S, 1984, ACTA CHEM SCAND B, V38, P539, DOI 10.3891/acta.chem.scand.38b-0539; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Maly DJ, 2000, P NATL ACAD SCI USA, V97, P2419, DOI 10.1073/pnas.97.6.2419; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MORGAN GT, 1920, J CHEM SOC, V117, P1639; NERI D, 1995, J MOL BIOL, V246, P367, DOI 10.1006/jmbi.1994.0091; Otto S, 2002, DRUG DISCOV TODAY, V7, P117, DOI 10.1016/S1359-6446(01)02086-4; Pellecchia M, 2002, NAT REV DRUG DISCOV, V1, P211, DOI 10.1038/nrd748; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; Ramstrom O, 2002, NAT REV DRUG DISCOV, V1, P26, DOI 10.1038/nrd704; RYE HS, 1992, NUCLEIC ACIDS RES, V20, P2803, DOI 10.1093/nar/20.11.2803; Scheuermann J, 2003, DRUG DEVELOP RES, V58, P268, DOI 10.1002/ddr.10161; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Scozzafava A, 1999, J MED CHEM, V42, P2641, DOI 10.1021/jm9900523; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	34	253	275	1	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					568	574		10.1038/nbt961	http://dx.doi.org/10.1038/nbt961			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15097996				2022-12-25	WOS:000221159700025
J	Demjen, D; Klussmann, S; Kleber, S; Zuliani, C; Stieltjes, B; Metzger, C; Hirt, UA; Walczak, H; Falk, W; Essig, M; Edler, L; Krammer, PH; Martin-Villalba, A				Demjen, D; Klussmann, S; Kleber, S; Zuliani, C; Stieltjes, B; Metzger, C; Hirt, UA; Walczak, H; Falk, W; Essig, M; Edler, L; Krammer, PH; Martin-Villalba, A			Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury	NATURE MEDICINE			English	Article							SIGNALING COMPLEX DISC; KAPPA-B ACTIVATION; DEFICIENT MICE; CELL-DEATH; TNF-ALPHA; AXONAL REGENERATION; NEURITE GROWTH; FAS; RATS; EXPRESSION	The clinical outcome of spinal cord injury (SCI) depends in part on the extent of secondary damage, to which apoptosis contributes. The CD95 and tumor necrosis factor (TNF) ligand/receptor systems play an essential role in various apoptotic mechanisms. To determine the involvement of these ligands in SCI-induced damage, we neutralized the activity of CD95 ligand (CD95L) and/or TNF in spinal cord-injured mice. Therapeutic neutralization of CD95L, but not of TNF, significantly decreased apoptotic cell death after SCI. Mice treated with CD95L-specific antibodies were capable of initiating active hind-limb movements several weeks after injury. The improvement in locomotor performance was mirrored by an increase in regenerating fibers and upregulation of growth-associated protein-43 (GAP-43). Thus, neutralization of CD95L promoted axonal regeneration and functional improvement in injured adult animals. This therapeutic strategy may constitute a potent future treatment for human spinal injury.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Radiol, D-69120 Heidelberg, Germany; Apogenix Biotechnol AG, D-69120 Heidelberg, Germany; Dept Internal Med 1, D-93053 Regensburg, Germany; German Canc Res Ctr, Biostat Unit, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Martin-Villalba, A (corresponding author), German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany.	a.martin-villalba@dkfz.de	Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; essig, marco/0000-0002-7964-2297; Martin-Villalba, Ana/0000-0002-9405-8910				BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brosamle C, 2000, J NEUROSCI, V20, P8061; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dong HX, 2003, J NEUROSCI, V23, P8682; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Fernandes KJL, 1999, J COMP NEUROL, V414, P495, DOI 10.1002/(SICI)1096-9861(19991129)414:4<495::AID-CNE6>3.0.CO;2-S; Fournier AE, 1997, J NEUROSCI, V17, P4623; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li WP, 2002, J NEUROSCI RES, V69, P189, DOI 10.1002/jnr.10285; Lindenlaub T, 2000, BRAIN RES, V866, P15, DOI 10.1016/S0006-8993(00)02190-9; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Ozawa H, 2002, EXP NEUROL, V177, P306, DOI 10.1006/exnr.2002.7998; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shackelford DA, 1996, J NEUROCHEM, V66, P286; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Ugolini G, 2003, J NEUROSCI, V23, P8526; Woolf C J, 1994, Drugs, V47 Suppl 5, P1, DOI 10.2165/00003495-199400475-00003; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	49	162	176	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					389	395		10.1038/nm1007	http://dx.doi.org/10.1038/nm1007			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15004554				2022-12-25	WOS:000220587000030
J	Zhang, SG				Zhang, SG			Beyond the Petri dish	NATURE BIOTECHNOLOGY			English	Editorial Material									MIT, Ctr Biomed Engn NE47 379, Cambridge, MA 02139 USA; MIT, Ctr Bits & Atoms, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Zhang, SG (corresponding author), MIT, Ctr Biomed Engn NE47 379, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	Shuguang@mit.edu		Zhang, Shuguang/0000-0002-3856-3752				Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Palsson B, 2003, TISSUE ENG PRINCIPLE; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874	5	170	185	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					151	152		10.1038/nbt0204-151	http://dx.doi.org/10.1038/nbt0204-151			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14755282				2022-12-25	WOS:000188730500008
J	Avecilla, ST; Hattori, K; Heissig, B; Tejada, R; Liao, F; Shido, K; Jin, DK; Dias, S; Zhang, F; Hartman, TE; Hackett, NR; Crystal, RG; Witte, L; Hicklin, DJ; Bohlen, P; Eaton, D; Lyden, D; de Sauvage, F; Rafii, S				Avecilla, ST; Hattori, K; Heissig, B; Tejada, R; Liao, F; Shido, K; Jin, DK; Dias, S; Zhang, F; Hartman, TE; Hackett, NR; Crystal, RG; Witte, L; Hicklin, DJ; Bohlen, P; Eaton, D; Lyden, D; de Sauvage, F; Rafii, S			Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN THROMBOPOIETIN; MPL-DEFICIENT MICE; MICROVASCULAR ENDOTHELIAL-CELLS; PLATELET PRODUCTION; GROWTH-FACTOR; IN-VIVO; MEGAKARYOCYTIC PROGENITORS; RESIDUAL MEGAKARYOCYTE; RECEPTOR CXCR4; KIT-LIGAND	The molecular pathways involved in the differentiation of hematopoietic progenitors are unknown. Here we report that chemokine-mediated interactions of megakaryocyte progenitors with sinusoidal bone marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production. Megakaryocyte-active cytokines, including interleukin-6 (IL-6) and IL-11, did not induce platelet production in thrombocytopenic, TPO-deficient (Thpo(-/-)) or TPO receptor-deficient (Mpl(-/-)) mice. In contrast, megakaryocyte-active chemokines, including stromal-derived factor-1 (SDF-1) and fibroblast growth factor-4 (FGF-4), restored thrombopoiesis in Thpo(-/-) and Mpl(-/-) mice. FGF-4 and SDF-1 enhanced vascular cell adhesion molecule- 1 (VCAM-1)- and very late antigen-4 (VLA-4)-mediated localization of CXCR4(+) megakaryocyte progenitors to the vascular niche, promoting survival, maturation and platelet release. Disruption of the vascular niche or interference with megakaryocyte motility inhibited thrombopoiesis under physiological conditions and after myelosuppression. SDF-1 and FGF-4 diminished thrombocytopenia after myelosuppression. These data suggest that TPO supports progenitor cell expansion, whereas chemokine-mediated interaction of progenitors with the bone marrow vascular niche allows the progenitors to relocate to a microenvironment that is permissive and instructive for megakaryocyte maturation and thrombopoiesis. Progenitor-active chemokines offer a new strategy to restore hematopoiesis in a clinical setting.	Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; ImClone Syst, New York, NY 10014 USA; Genentech Inc, San Francisco, CA 94404 USA; Cornell Univ, Coll Med, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Coll Med, Childrens Blood Fdn Labs, New York, NY 10021 USA	Cornell University; Eli Lilly; Roche Holding; Genentech; Cornell University; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.		Avecilla, Scott/AAR-5873-2021; Heissig, Beate/AAF-6771-2021; Dias, Sergio/L-1250-2014	Avecilla, Scott/0000-0003-0661-9704; Heissig, Beate/0000-0002-0348-5934; Dias, Sergio/0000-0002-7603-4616; Hartman, Travis/0000-0002-3926-6928	NCI NIH HHS [R01-CA-98234] Funding Source: Medline; NHLBI NIH HHS [HL67839, HL66592, R01 HL61849, HL59312] Funding Source: Medline; NIGMS NIH HHS [T32 GM007739, GM07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098234] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067839, P50HL059312, P01HL059312, R01HL061849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlmeidaPorada G, 1996, J LAB CLIN MED, V128, P399, DOI 10.1016/S0022-2143(96)80012-6; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM H, 1994, BLOOD, V83, P2126; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; Casella I, 2003, BLOOD, V101, P1316, DOI 10.1182/blood-2002-07-2184; Chen Q, 1998, Stem Cells, V16 Suppl 2, P31; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Delehanty LL, 2003, BLOOD, V101, P1744, DOI 10.1182/blood-2002-04-1278; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; Forster R, 1998, J IMMUNOL, V160, P1522; Gainsford T, 1998, BLOOD, V91, P2745, DOI 10.1182/blood.V91.8.2745.2745_2745_2752; Gainsford T, 2000, BLOOD, V95, P528, DOI 10.1182/blood.V95.2.528; GUMEY AL, 1996, STEM CELLS S1, V14, P116; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Kuter DJ, 2002, BLOOD, V100, P3457, DOI 10.1182/blood.V100.10.3457; Kuter DJ, 2002, TRANSFUSION, V42, P279, DOI 10.1046/j.1537-2995.2002.00056.x; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; Lane WJ, 2000, BLOOD, V96, P4152; Levin J, 2001, BLOOD, V98, P1019, DOI 10.1182/blood.V98.4.1019; Liao F, 2002, CANCER RES, V62, P2567; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; MASEK LC, 1994, EXP HEMATOL, V22, P1203; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rafii S, 1997, LEUKEMIA LYMPHOMA, V27, P375, DOI 10.3109/10428199709058305; RAFII S, 1994, BLOOD, V84, P10; RAFII S, 1995, BLOOD, V86, P3353, DOI 10.1182/blood.V86.9.3353.bloodjournal8693353; Riviere C, 1999, BLOOD, V93, P1511, DOI 10.1182/blood.V93.5.1511.405k02_1511_1523; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Schabath R, 1999, J LEUKOCYTE BIOL, V66, P996, DOI 10.1002/jlb.66.6.996; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; TAVASSOLI M, 1989, BLOOD CELLS, V15, P3; Vadhan-Raj S, 2003, J CLIN ONCOL, V21, P3158, DOI 10.1200/JCO.2003.08.003; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; Wang JF, 1998, BLOOD, V92, P756, DOI 10.1182/blood.V92.3.756.415k36_756_764; Zucker-Franklin D, 2000, AM J PATHOL, V157, P69, DOI 10.1016/S0002-9440(10)64518-X; Zweegman S, 2000, EXP HEMATOL, V28, P401, DOI 10.1016/S0301-472X(00)00128-4	50	568	601	0	28	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					64	71		10.1038/nm973	http://dx.doi.org/10.1038/nm973			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702636				2022-12-25	WOS:000187743600040
J	Bean, CJ; Schaner, CE; Kelly, WG				Bean, CJ; Schaner, CE; Kelly, WG			Meiotic pairing and imprinted X chromatin assembly in Caenorhabditis elegans	NATURE GENETICS			English	Article							HISTONE H3 LYSINE-9; C-ELEGANS; SEX DETERMINATION; METHYLATION; CHROMOSOME; GERMLINE; INACTIVATION; PATTERNS; GENES; DNA	The genetic imprinting of individual loci or whole chromosomes, as in imprinted X-chromosome inactivation in mammals(1,2), is established and reset during gametogenesis; defects in this process in the parent can result in disease in the offspring(3). We describe a sperm-specific chromatin-based imprinting of the X chromosome in the nematode Caenorhabditis elegans that is restricted to histone H3 modifications. The epigenetic imprint is established during spermatogenesis and its stability in the offspring is affected by the presence of a pairing partner during meiosis in the parental germ line. We observed that DNA lacking a pairing partner during meiosis, the normal situation for the X chromosome in males, is targeted for methylation of histone H3 at Lys9 (H3-Lys9) and can be silenced. Targeting unpaired DNA for silencing during meiosis, a potential hallmark of genome defense, could therefore have a conserved role in imprinted X-chromosome inactivation and, ultimately, in sex chromosome evolution.	Emory Univ, Rollins Res Ctr, Dept Biol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Kelly, WG (corresponding author), Emory Univ, Rollins Res Ctr, Dept Biol, 1510 Clifton Rd, Atlanta, GA 30322 USA.			Bean, Christopher/0000-0001-7433-9769	NIGMS NIH HHS [T32 GM008490, R01 GM077600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077600, T32GM008490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adenot PG, 1997, DEVELOPMENT, V124, P4615; Baugh LR, 2003, DEVELOPMENT, V130, P889, DOI 10.1242/dev.00302; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BRENNER S, 1974, GENETICS, V77, P71; BROVERMAN SA, 1994, GENETICS, V136, P119; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; HANDEL MA, 1992, BIOESSAYS, V14, P817, DOI 10.1002/bies.950141205; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Higashimoto K, 2003, AM J HUM GENET, V73, P948, DOI 10.1086/378595; HODGKIN J, 1979, GENETICS, V91, P67; Huynh KD, 2001, CURR OPIN CELL BIOL, V13, P690, DOI 10.1016/S0955-0674(00)00272-6; Hynes MJ, 2003, BIOESSAYS, V25, P99, DOI 10.1002/bies.10241; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly WG, 2002, DEVELOPMENT, V129, P479; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuwabara PE, 2001, BIOESSAYS, V23, P596, DOI 10.1002/bies.1085; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Prahlad V, 2003, SCIENCE, V302, P1046, DOI 10.1126/science.1087946; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Reuben M, 2002, DEV BIOL, V245, P71, DOI 10.1006/dbio.2002.0634; SCHEDL T, 1997, C ELEGANS, V2, P241; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Wu CI, 2003, TRENDS GENET, V19, P243, DOI 10.1016/S0168-9525(03)00058-1; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469	30	149	158	0	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					100	105		10.1038/ng1283	http://dx.doi.org/10.1038/ng1283			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702046	Green Accepted, Bronze			2022-12-25	WOS:000187666800021
J	Yasoda, A; Komatsu, Y; Chusho, H; Miyazawa, T; Ozasa, A; Miura, M; Kurihara, T; Rogi, T; Tanaka, S; Suda, M; Tamura, N; Ogawa, Y; Nakao, K				Yasoda, A; Komatsu, Y; Chusho, H; Miyazawa, T; Ozasa, A; Miura, M; Kurihara, T; Rogi, T; Tanaka, S; Suda, M; Tamura, N; Ogawa, Y; Nakao, K			Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway	NATURE MEDICINE			English	Article							NATRIURETIC PEPTIDE SYSTEM; GROWTH-FACTOR RECEPTOR-3; PROTEIN-KINASE; SKELETAL OVERGROWTH; BONE-GROWTH; DISTRACTION OSTEOGENESIS; MOLECULAR-BIOLOGY; TRANSGENIC MICE; MESSENGER-RNA; FACTOR-I	Achondroplasia is the most common genetic form of human dwarfism, for which there is presently no effective therapy. C-type natriuretic peptide (CNP) is a newly identified molecule that regulates endochondral bone growth through GC-B, a subtype of particulate guanylyl cyclase. Here we show that targeted overexpression of CNP in chondrocytes counteracts dwarfism in a mouse model of achondroplasia with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage. CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling. CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes. These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human achondroplasia.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Daiichi Suntory Inst Biomed Res, Shimamoto, Osaka 6188503, Japan	Kyoto University	Nakao, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.			Ogawa, Yoshihiro/0000-0002-0834-2836				Aldegheri R, 1999, J BONE JOINT SURG AM, V81A, P624, DOI 10.2106/00004623-199905000-00004; BELLUS GA, 1995, AM J HUM GENET, V56, P368; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Chusho H, 2000, ENDOCRINOLOGY, V141, P3807, DOI 10.1210/en.141.10.3807; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Cohen MM, 1997, PEDIATR RADIOL, V27, P442, DOI 10.1007/s002470050165; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Coxam V, 1995, BIOL NEONATE, V68, P368; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIEUDONNE SC, 1994, J BONE MINER RES, V9, P771; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Garbers D L, 1990, Recent Prog Horm Res, V46, P85; Jaubert J, 1999, P NATL ACAD SCI USA, V96, P10278, DOI 10.1073/pnas.96.18.10278; Kanaka-Gantenbein C, 2001, J PEDIATR ENDOCR MET, V14, P17; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Mericq V, 2000, PEDIATR RES, V47, P189, DOI 10.1203/00006450-200002000-00007; METSARANTA M, 1995, DEV DYNAM, V204, P202, DOI 10.1002/aja.1002040211; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1992, J HYPERTENS, V10, P1111, DOI 10.1097/00004872-199210000-00002; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Naski MC, 1998, DEVELOPMENT, V125, P4977; Noonan KJ, 1998, J BONE JOINT SURG AM, V80A, P793, DOI 10.2106/00004623-199806000-00003; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; OGAWA Y, 1994, GENOMICS, V24, P383, DOI 10.1006/geno.1994.1633; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; SCHEVEN BAA, 1991, ACTA ENDOCRINOL-COP, V124, P602, DOI 10.1530/acta.0.1240602; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; Suganami T, 2001, J AM SOC NEPHROL, V12, P2652, DOI 10.1681/ASN.V12122652; Tanaka H, 1998, EUR J ENDOCRINOL, V138, P275, DOI 10.1530/eje.0.1380275; Toyokuni S, 1997, LAB INVEST, V76, P365; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	44	283	317	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					80	86		10.1038/nm971	http://dx.doi.org/10.1038/nm971			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702637				2022-12-25	WOS:000187743600042
J	van Overveld, PGM; Lemmers, RJFL; Sandkuijl, LA; Enthoven, L; Winokur, ST; Bakels, F; Padberg, GW; van Ommen, GJB; Frants, RR; van der Maarel, SM				van Overveld, PGM; Lemmers, RJFL; Sandkuijl, LA; Enthoven, L; Winokur, ST; Bakels, F; Padberg, GW; van Ommen, GJB; Frants, RR; van der Maarel, SM			Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy	NATURE GENETICS			English	Article							DNA REARRANGEMENTS; METHYLATION; MUTATIONS; FSHD	The autosomal dominant myopathy facioscapulohumeral muscular dystrophy (FSHD1, OMIM 158900) is caused by contraction of the D4Z4 repeat array on 4qter. We show that this contraction causes marked hypomethylation of the contracted D4Z4 allele in individuals with FSHD1. Individuals with phenotypic FSHD1, who are clinically identical to FSHD1 but have an unaltered D4Z4, also have hypomethylation of D4Z4. These results strongly suggest that hypomethylation of D4Z4 is a key event in the cascade of epigenetic events causing FSHD1.	Leiden Univ, Med Ctr, Dept Human Genet, Ctr Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, NL-2300 RA Leiden, Netherlands; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92717 USA; Radboud Univ Nijmegen Med Ctr, Dept Neurol, Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of California System; University of California Irvine; Radboud University Nijmegen	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, Ctr Human & Clin Genet, POB 9502, NL-2300 RA Leiden, Netherlands.	maarel@lumc.nl	van der Maarel, Silvere/X-3631-2018; Padberg, G.W.A.M./H-8079-2014	van der Maarel, Silvere/0000-0001-8103-711X; van Overveld, Petra GM/0000-0003-0216-5004				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Jiang GC, 2003, HUM MOL GENET, V12, P2909, DOI 10.1093/hmg/ddg323; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Lemmers RJLF, 2002, NAT GENET, V32, P235, DOI 10.1038/ng999; Lunt P W, 1998, Neuromuscul Disord, V8, P126, DOI 10.1016/S0960-8966(98)00012-1; Padberg GW, 1982, FACIOSCAPULOHUMERAL; Rand E, 2003, J CELL BIOCHEM, V88, P400, DOI 10.1002/jcb.10352; Randolph-Anderson BL, 2002, AM J HUM GENET, V71, P530; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; VANDEUTEKOM JCT, 1993, HUM MOL GENET, V2, P2037; vanDeutekom JCT, 1996, HUM MOL GENET, V5, P1997, DOI 10.1093/hmg/5.12.1997; WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	15	275	288	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2003	35	4					315	317		10.1038/ng1262	http://dx.doi.org/10.1038/ng1262			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14634647				2022-12-25	WOS:000186791000011
J	Gross, S; Gilead, A; Scherz, A; Neeman, M; Salomon, Y				Gross, S; Gilead, A; Scherz, A; Neeman, M; Salomon, Y			Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI	NATURE MEDICINE			English	Article							IN-VIVO; MELANOMA TUMORS; OXYGENATION; ANGIOGENESIS; XENOGRAFTS; VESSELS	Antivascular photodynamic therapy (PDT) of tumors with palladium-bacteriopheophorbide (TOOKAD) relies on in situ photosensitization of the circulating drug by local generation of cytotoxic reactive oxygen species, which leads to rapid vascular occlusion, stasis, necrosis and tumor eradication. Intravascular production of reactive oxygen species is associated with photoconsumption of O-2 and consequent evolution of paramagnetic deoxyhemoglobin. In this study we evaluate the use of blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for real-time monitoring of PDT efficacy. Using a solid tumor model, we show that TOOKAD-PDT generates appreciable attenuation (25-40%) of the magnetic resonance signal, solely at the illuminated tumor site. This phenomenon is independent of, though augmented by, ensuing changes in blood flow. These results were validated by immunohistochemistry and intravital microscopy. The concept of photosensitized BOLD-contrast MRI may have intraoperative applications in interactive guidance and monitoring of antivascular cancer therapy, PDT treatment of macular degeneration, interventional cardiology and possibly other biomedical disciplines.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Salomon, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yoram.salomon@weizmann.ac.il	Neeman, Michal/A-8264-2008; Neeman, Michal/AAH-9602-2019	Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X				Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444; CHEN Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P88; Detre JA, 2001, NEUROSCIENTIST, V7, P64, DOI 10.1177/107385840100700110; Dolmans DEJGJ, 2002, CANCER RES, V62, P2151; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Gilead Assaf, 1999, Neoplasia (New York), V1, P226, DOI 10.1038/sj.neo.7900032; Hopper C, 2000, Lancet Oncol, V1, P212; Howe FA, 2001, NMR BIOMED, V14, P497, DOI 10.1002/nbm.716; Jolesz FA, 1998, JMRI-J MAGN RESON IM, V8, P3, DOI 10.1002/jmri.1880080104; Kelleher DK, 1999, INT J HYPERTHER, V15, P467, DOI 10.1080/026567399285468; Koudinova NV, 2003, INT J CANCER, V104, P782, DOI 10.1002/ijc.11002; Neeman M, 2001, MAGNET RESON MED, V45, P887, DOI 10.1002/mrm.1118; OGAWA S, 1990, MAGNET RESON MED, V16, P9, DOI 10.1002/mrm.1910160103; PREISE D, IN PRESS NEOPLASIA; Scherz A., 2003, U.S. Patent, Patent No. [6569846, 6,569,846]; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Sitnik TM, 1998, BRIT J CANCER, V77, P1386, DOI 10.1038/bjc.1998.231; Taylor NJ, 2001, J MAGN RESON IMAGING, V14, P156, DOI 10.1002/jmri.1166; Turner R, 1997, ADV EXP MED BIOL, V413, P19; Turner R, 2002, NEUROIMAGE, V16, P1062, DOI 10.1006/nimg.2002.1082; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; Yang M, 2002, P NATL ACAD SCI USA, V99, P3824, DOI 10.1073/pnas.052029099; Zilberstein J, 1997, PHOTOCHEM PHOTOBIOL, V65, P1012, DOI 10.1111/j.1751-1097.1997.tb07962.x; Zilberstein J, 2001, PHOTOCHEM PHOTOBIOL, V73, P257, DOI 10.1562/0031-8655(2001)073<0257:ATOSMT>2.0.CO;2	25	176	187	1	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1327	1331		10.1038/nm940	http://dx.doi.org/10.1038/nm940			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502284				2022-12-25	WOS:000185669700047
J	Hammarlund, E; Lewis, MW; Hansen, SG; Strelow, LI; Nelson, JA; Sexton, GJ; Hanifin, JM; Slifka, MK				Hammarlund, E; Lewis, MW; Hansen, SG; Strelow, LI; Nelson, JA; Sexton, GJ; Hanifin, JM; Slifka, MK			Duration of antiviral immunity after smallpox vaccination	NATURE MEDICINE			English	Article							CYTOTOXIC T-CELLS; VACCINIA VIRUS; GAMMA-GLOBULIN; NEUTRALIZING ANTIBODIES; LYMPHOCYTES; RESPONSES; PROTECTION; PROPHYLAXIS; GENERATION; INFECTION	Although naturally occurring smallpox was eliminated through the efforts of the World Health Organization Global Eradication Program, it remains possible that smallpox could be intentionally released. Here we examine the magnitude and duration of antiviral immunity induced by one or more smallpox vaccinations. We found that more than 90% of volunteers vaccinated 25-75 years ago still maintain substantial humoral or cellular immunity (or both) against vaccinia, the virus used to vaccinate against smallpox. Antiviral antibody responses remained stable between 1-75 years after vaccination, whereas antiviral T-cell responses declined slowly, with a half-life of 8-15 years. If these levels of immunity are considered to be at least partially protective, then the morbidity and mortality associated with an intentional smallpox outbreak would be substantially reduced because of preexisting immunity in a large number of previously vaccinated individuals.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Dermatol, Clin Res Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu		Lewis, Matthew/0000-0002-6241-3690	NCRR NIH HHS [P51 RR000163, RR00163] Funding Source: Medline; NHLBI NIH HHS [T32HL07781, T32 HL007781] Funding Source: Medline; NIAID NIH HHS [R01 AI051346, AI051346, AI21640] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640, R01AI051346] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SG, 1970, B WORLD HEALTH ORGAN, V42, P515; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Appay V, 2002, J IMMUNOL, V168, P5954, DOI 10.4049/jimmunol.168.11.5954; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P236; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P188; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P174; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P183; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P172; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P220; *CDC, 1963, MMWR-MORBID MORTAL W, V12, P191; CUTCHINS E, 1960, J IMMUNOL, V85, P275; CZERNY CP, 1990, J GEN VIROL, V71, P2341, DOI 10.1099/0022-1317-71-10-2341; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; DOWNIE A. W., 1958, JOUR HYGIENE, V56, P479; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; ERICKSON AL, 1993, J GEN VIROL, V74, P751, DOI 10.1099/0022-1317-74-4-751; FENNER F, 1988, PATHOGENESIS IMMUNOL; Frelinger JA, 2002, NEW ENGL J MED, V347, P689; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a; Gayton W., 1885, VALUE VACCINATION SH; Hanna W, 2002, Rev Med Virol, V12, P201; HANNA W, 1913, STUDIES SMALLPOX VAC; HEINER GG, 1971, AM J EPIDEMIOL, V94, P252, DOI 10.1093/oxfordjournals.aje.a121319; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; KEMPE CH, 1960, PEDIATRICS, V26, P176; KEMPE CH, 1961, B WORLD HEALTH ORGAN, V25, P41; KEMPE CH, 1956, PEDIATRICS, V18, P177; LITTAURA RA, 1992, J VIROL, V66, P2274, DOI 10.1128/JVI.66.4.2274-2280.1992; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; MCCARTHY K., 1958, JOUR HYGIENE, V56, P466; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; NYERGES G, 1972, ACTA MICROBIOL HUNG, V19, P63; O'Toole T, 2002, CLIN INFECT DIS, V34, P972, DOI 10.1086/339909; PEIRCE ER, 1958, LANCET, V2, P635; PERRIN LH, 1978, MED MICROBIOL IMMUN, V166, P71, DOI 10.1007/BF02121136; PERRIN LH, 1977, J EXP MED, V146, P949, DOI 10.1084/jem.146.4.949; Ramirez JC, 2002, J GEN VIROL, V83, P1059, DOI 10.1099/0022-1317-83-5-1059; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Slifka MK, 2000, J IMMUNOL, V164, P208, DOI 10.4049/jimmunol.164.1.208; Slifka MK, 1996, TRENDS MICROBIOL, V4, P394, DOI 10.1016/0966-842X(96)10059-7; Slifka MK, 1996, J IMMUNOL METHODS, V199, P37, DOI 10.1016/S0022-1759(96)00146-9; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; Speller SA, 2002, J IMMUNOL METHODS, V262, P167, DOI 10.1016/S0022-1759(02)00025-X; Stienlauf S, 1999, VACCINE, V17, P201, DOI 10.1016/S0264-410X(98)00197-2; Terajima M, 2003, J EXP MED, V197, P927, DOI 10.1084/jem.20022222; Yanai F, 2003, J IMMUNOL, V170, P2205, DOI 10.4049/jimmunol.170.4.2205; ZARLING JM, 1987, J IMMUNOL, V139, P988; ZINKERNAGEL RM, 1977, J EXP MED, V145, P644, DOI 10.1084/jem.145.3.644	56	622	641	3	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2003	9	9					1131	1137		10.1038/nm917	http://dx.doi.org/10.1038/nm917			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12925846				2022-12-25	WOS:000185061600024
J	Bernardi, R; Scaglioni, PP; Bergmann, S; Horn, HF; Vousden, KH; Pandolfi, PP				Bernardi, R; Scaglioni, PP; Bergmann, S; Horn, HF; Vousden, KH; Pandolfi, PP			PML regulates p53 stability by sequestering Mdm2 to the nucleolus	NATURE CELL BIOLOGY			English	Article							RIBOSOMAL-PROTEIN L11; DNA-DAMAGE; PREMATURE SENESCENCE; NUCLEAR-BODIES; ONCOGENIC RAS; INHIBITION; STRESS; ATM; SENSITIVITY; APOPTOSIS	The promyelocytic leukaemia (PML) tumour-suppressor protein potentiates p53 function by regulating post-translational modifications, such as CBP-dependent acetylation(1,2) and Chk2-dependent phosphorylation, in the PML-Nuclear Body (NB)(3). PML was recently shown to interact with the p53 ubiquitin-ligase Mdm2 (refs 4-6); however, the mechanism by which PML regulates Mdm2 remains unclear. Here, we show that PML enhances p53 stability by sequestering Mdm2 to the nucleolus. We found that after DNA damage, PML and Mdm2 accumulate in the nucleolus in an Arf-independent manner. In addition, we found that the nucleolar localization of PML is dependent on ATR activation and phosphorylation of PML by ATR. Notably, in Pml(-/-) cells, sequestration of Mdm2 to the nucleolus was impaired, as well as p53 stabilization and the induction of apoptosis. Furthermore, we demonstrate that PML physically associates with the nucleolar protein L11, and that L11 knockdown impairs the ability of PML to localize to nucleoli after DNA damage. These findings demonstrate an unexpected role of PML in the nucleolar network for tumour suppression.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol & Med, Canc Biol & Genet Program, New York, NY 10021 USA; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Memorial Sloan Kettering Cancer Center; Beatson Institute	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol & Med, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336; Horn, Henning/0000-0002-5885-8996; Scaglioni, Pier Paolo/0000-0002-6036-5138	NCI NIH HHS [R01 CA-71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gage BM, 2001, ONCOGENE, V20, P4291, DOI 10.1038/sj.onc.1204509; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sarkaria JN, 1999, CANCER RES, V59, P4375; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200	28	268	286	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					665	672		10.1038/ncb1147	http://dx.doi.org/10.1038/ncb1147			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15195100				2022-12-25	WOS:000222434900022
J	Inoue, M; Rashid, MH; Fujita, R; Contos, JJA; Chun, J; Ueda, H				Inoue, M; Rashid, MH; Fujita, R; Contos, JJA; Chun, J; Ueda, H			Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; SCIATIC-NERVE INJURY; UP-REGULATION; SPINAL-CORD; DORSAL-HORN; MICE; MONONEUROPATHY; SENSITIZATION; GAMMA; HYPERSENSITIVITY	Lysophosphatidic acid (LPA) is a bioactive lipid with activity in the nervous system mediated by G-protein-coupled receptors. Here, we examined the role of LPA signaling in the development of neuropathic pain by pharmacological and genetic approaches, including the use of mice lacking the LPA(1) receptor. Wild-type animals with nerve injury develop behavioral allodynia and hyperalgesia paralleled by demyelination in the dorsal root and increased expression of both the protein kinase C gamma-isoform within the spinal cord dorsal horn and the alpha(2)delta(1) calcium channel subunit in dorsal root ganglia. Intrathecal injection of LPA induced behavioral, morphological and biochemical changes similar to those observed after nerve ligation. In contrast, mice lacking a single LPA receptor (LPA(1), also known as EDG2) that activates the Rho-Rho kinase pathway do not develop signs of neuropathic pain after peripheral nerve injury. Inhibitors of Rho and Rho kinase also prevented these signs of neuropathic pain. These results imply that receptor-mediated LPA signaling is crucial in the initiation of neuropathic pain.	Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, Nagasaki 8528521, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Scripps Res Inst, Helen L Dorris Inst Neurol & Psychiat Disorders, Dept Mol Biol, La Jolla, CA 92037 USA	Nagasaki University; Fred Hutchinson Cancer Center; Scripps Research Institute	Ueda, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	ueda@net.nagasaki-u.ac.jp	Chun, Jerold/Y-4670-2019	Ueda, Hiroshi/0000-0002-8002-0137				Adlkofer K, 1997, J NEUROSCI, V17, P4662; Bennett GJ, 1999, P NATL ACAD SCI USA, V96, P7737, DOI 10.1073/pnas.96.14.7737; Brancolini C, 1999, MOL BIOL CELL, V10, P2441, DOI 10.1091/mbc.10.7.2441; Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12; Carter GT, 1998, ARCH PHYS MED REHAB, V79, P1560, DOI 10.1016/S0003-9993(98)90421-X; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Cui JG, 2000, PAIN, V88, P239, DOI 10.1016/S0304-3959(00)00331-6; Dickinson T, 1999, TRENDS PHARMACOL SCI, V20, P324, DOI 10.1016/S0165-6147(99)01340-1; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fukushima N, 2002, NEUROSCIENTIST, V8, P540, DOI 10.1177/1073858402238513; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gillespie CS, 2000, NEURON, V26, P523, DOI 10.1016/S0896-6273(00)81184-8; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Inoue M, 2003, J PHARMACOL EXP THER, V305, P495, DOI 10.1124/jpet.102.046326; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; ISHII I, IN PRESS ANN REV BIO; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kusaka S, 1998, J PHYSIOL-LONDON, V506, P445, DOI 10.1111/j.1469-7793.1998.445bw.x; Lin Q, 1996, J NEUROSCI, V16, P3026; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Ma WY, 2002, EUR J NEUROSCI, V15, P1037, DOI 10.1046/j.1460-9568.2002.01940.x; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; Miletic V, 2000, NEUROSCI LETT, V288, P199, DOI 10.1016/S0304-3940(00)01237-4; PENTLAND B, 1994, PAIN, V59, P159, DOI 10.1016/0304-3959(94)90068-X; Pezet S, 2002, BRAIN RES REV, V40, P240, DOI 10.1016/S0165-0173(02)00206-0; Ramer MS, 1999, PAIN, pS111, DOI 10.1016/S0304-3959(99)00144-X; Rashid MH, 2003, J PHARMACOL EXP THER, V304, P940, DOI 10.1124/jpet.102.046250; Renback K, 1999, NEUROSCI LETT, V270, P59, DOI 10.1016/S0304-3940(99)00464-4; Renback K, 2000, MOL BRAIN RES, V75, P350, DOI 10.1016/S0169-328X(99)00333-2; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; Sommer C, 1998, BRAIN RES, V784, P154, DOI 10.1016/S0006-8993(97)01327-9; Ueda H, 1999, JPN J PHARMACOL, V79, P263, DOI 10.1254/jjp.79.263; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Ye X, 2000, JPN J PHARMACOL, V83, P161, DOI 10.1254/jjp.83.161; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	46	418	483	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					712	718		10.1038/nm1060	http://dx.doi.org/10.1038/nm1060			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195086				2022-12-25	WOS:000222460400025
J	Koo, SH; Satoh, H; Herzig, S; Lee, CH; Hedrick, S; Kulkarni, R; Evans, RM; Olefsky, J; Montminy, M				Koo, SH; Satoh, H; Herzig, S; Lee, CH; Hedrick, S; Kulkarni, R; Evans, RM; Olefsky, J; Montminy, M			PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3	NATURE MEDICINE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; COACTIVATOR PGC-1; HEPATIC GLUCONEOGENESIS; FASTING RESPONSE; GENE-EXPRESSION; NULL MICE; MOUSE; PROTEIN; GLUCOSE; HEPATOCYTES	Insulin resistance is a major hallmark in the development of type 2 diabetes, which is characterized by an impaired ability of insulin to inhibit glucose output from the liver and to promote glucose uptake in muscle(1,2). The nuclear hormone receptor coactivator PGC-1 (peroxisome proliferator-activated (PPAR)-gamma coactivator-1) has been implicated in the onset of type 2 diabetes. Hepatic PGC-1 expression is elevated in mouse models of this disease, where it promotes constitutive activation of gluconeogenesis and fatty acid oxidation through its association with the nuclear hormone receptors HNF-4 and PPAR-alpha, respectively(3-5). Here we show that PGC-1-deficient mice, generated by adenoviral delivery of PGC-1 RNA interference (RNAi) to the liver, experience fasting hypoglycemia. Hepatic insulin sensitivity was enhanced in PGC-1-deficient mice, reflecting in part the reduced expression of the mammalian tribbles homolog TRB-3, a fasting-inducible inhibitor of the serine-threonine kinase Akt/PKB (ref. 6). We show here that, in the liver, TRB-3 is a target for PPAR-alpha. Knockdown of hepatic TRB-3 expression improved glucose tolerance, whereas hepatic overexpression of TRB-3 reversed the insulin-sensitive phenotype of PGC-1-deficient mice. These results indicate a link between nuclear hormone receptor and insulin signaling pathways, and suggest a potential role for TRB-3 inhibitors in the treatment of type 2 diabetes.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Labs, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Salk Institute; University of California System; University of California San Diego; Salk Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Evans, Ronald/AAF-4001-2019; Satoh, Hiroaki/E-9096-2017; Koo, Seung-Hoi/E-2763-2015	Evans, Ronald/0000-0002-9986-5965; Satoh, Hiroaki/0000-0002-0353-5807; Koo, Seung-Hoi/0000-0001-8769-2879; Herzig, Stephan/0000-0003-3950-3652	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM R01 37828] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hevener AL, 2001, DIABETES, V50, P2316, DOI 10.2337/diabetes.50.10.2316; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hribal ML, 2002, AM J PHYSIOL-ENDOC M, V282, pE977, DOI 10.1152/ajpendo.00561.2001; IMAI E, 1993, J BIOL CHEM, V268, P5353; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Klingenspor M, 1999, J BIOL CHEM, V274, P23078, DOI 10.1074/jbc.274.33.23078; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Kruszynska YT, 2002, J CLIN ENDOCR METAB, V87, P226, DOI 10.1210/jc.87.1.226; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	28	458	487	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					530	534		10.1038/nm1044	http://dx.doi.org/10.1038/nm1044			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107844				2022-12-25	WOS:000221242400032
J	Kieran, D; Kalmar, B; Dick, JRT; Riddoch-Contreras, J; Burnstock, G; Greensmith, L				Kieran, D; Kalmar, B; Dick, JRT; Riddoch-Contreras, J; Burnstock, G; Greensmith, L			Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; UP-REGULATION; FACTOR-I; STRESS; TRANSCRIPTION; DEGENERATION; MOTONEURONS; BIMOCLOMOL; ACTIVATION	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis(1,2). This condition has no cure(3) and results in eventual death, usually within 1-5 years of diagnosis(1,2). Although the specific etiology of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1)(4). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathology that are very similar to that seen in human ALS patients(5,6). Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1(G93A)). Arimoclomol-treated SOD1(G93A) mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacological activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.	UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol,Graham Watts Lab, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England; Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, London NW2 3PF, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Greensmith, L (corresponding author), UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol,Graham Watts Lab, Sobell Dept Motor Neurosci & Movement Disorders, Queen Sq, London WC1N 3BG, England.	l.greensmith@ion.ucl.ac.uk		Kalmar, Bernadett/0000-0003-3747-4843				Batulan Z, 2003, J NEUROSCI, V23, P5789; DICK J, 1995, NEUROMUSCULAR DISORD, V5, P371, DOI 10.1016/0960-8966(94)00088-Q; GAROFALO O, 1991, NEUROPATH APPL NEURO, V17, P39, DOI 10.1111/j.1365-2990.1991.tb00692.x; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hargitai J, 2003, BIOCHEM BIOPH RES CO, V307, P689, DOI 10.1016/S0006-291X(03)01254-3; Kalmar B, 2002, EXP NEUROL, V176, P87, DOI 10.1006/exnr.2002.7945; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Miller RG, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001447; Morrison AJ, 2000, J NEUROCHEM, V75, P363, DOI 10.1046/j.1471-4159.2000.0750363.x; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Shaw PJ, 1999, BMJ-BRIT MED J, V318, P1118, DOI 10.1136/bmj.318.7191.1118; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Vigh L, 1997, NAT MED, V3, P1150, DOI 10.1038/nm1097-1150; Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968; White CM, 2000, NEUROSCIENCE, V95, P1101; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	20	384	426	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2004	10	4					402	405		10.1038/nm1021	http://dx.doi.org/10.1038/nm1021			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034571				2022-12-25	WOS:000220587000032
J	Reece, WHH; Pinder, M; Gothard, PK; Milligan, P; Bojang, K; Doherty, T; Plebanski, M; Akinwunmi, P; Everaere, S; Watkins, KR; Voss, G; Tornieporth, N; Alloueche, A; Greenwood, BM; Kester, KE; McAdam, KPWJ; Cohen, J; Hill, AVS				Reece, WHH; Pinder, M; Gothard, PK; Milligan, P; Bojang, K; Doherty, T; Plebanski, M; Akinwunmi, P; Everaere, S; Watkins, KR; Voss, G; Tornieporth, N; Alloueche, A; Greenwood, BM; Kester, KE; McAdam, KPWJ; Cohen, J; Hill, AVS			A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease	NATURE MEDICINE			English	Article							MALARIA VACCINE; EFFICACY; SURFACE; LYMPHOCYTES; ANTIBODIES; RTS,S/AS02; INDUCTION; SUBSETS; TARGETS	Many human T-cell responses specific for epitopes in Plasmodium falciparum have been described, but none has yet been shown to be predictive of protection against natural malaria infection(1). Here we report a peptide-specific T-cell assay that is strongly associated with protection of humans in The Gambia, West Africa, from both malaria infection and disease. The assay detects interferon-gamma-secreting CD4(+) T cells specific for a conserved sequence from the circumsporozoite protein, which binds to many human leukocyte antigen (HLA)-DR types(2). The correlation was observed using a cultured, rather than an ex vivo, ELISPOT assay that measures central memory-type T cells rather than activated effector T cells(3,4). These findings provide direct evidence for a protective role for CD4(+) T cells in humans, and a precise target for the design of improved vaccines against P. falciparum.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; MRC Labs, Fajara, Gambia; GlaxoSmithKline Biol, B-1330 Rixensart, Belgium; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Walter Reed Army Inst Res, Silver Spring, MD 20910 USA	University of Oxford; MRC Laboratory Molecular Biology; GlaxoSmithKline; University of London; London School of Hygiene & Tropical Medicine; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Hill, AVS (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.	Adrian.Hill@ndm.ox.ac.uk	Kester, Kent/A-2114-2011; HILL, Adrian V>S>/C-1306-2008; Kester, Kent/AAF-8235-2020; Milligan, Paul/D-8985-2017; Plebanski, Magdalena/AAU-3144-2021	Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395; Bojang, Kalifa/0000-0001-7506-0938; , Magdalena/0000-0001-6889-3667				Aidoo M, 2000, PARASITOL TODAY, V16, P50, DOI 10.1016/S0169-4758(99)01592-6; Alloueche A, 2003, AM J TROP MED HYG, V68, P97, DOI 10.4269/ajtmh.2003.68.97; Baron V, 2003, IMMUNITY, V18, P193, DOI 10.1016/S1074-7613(03)00020-7; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Flanagan KL, 2003, AM J TROP MED HYG, V68, P421, DOI 10.4269/ajtmh.2003.68.421; Flanagan KL, 2001, J IMMUNOL, V167, P4729, DOI 10.4049/jimmunol.167.8.4729; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HOFFMAN SL, 1989, J IMMUNOL, V142, P1299; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x; Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003; RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schwenk R, 2003, PARASITE IMMUNOL, V25, P17, DOI 10.1046/j.1365-3024.2003.00495.x; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SINIGAGLIA F, 1988, EUR J IMMUNOL, V18, P633, DOI 10.1002/eji.1830180422; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961; Wang RB, 1996, J IMMUNOL, V157, P4061; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591	29	218	227	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					406	410		10.1038/nm1009	http://dx.doi.org/10.1038/nm1009			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15034567				2022-12-25	WOS:000220587000033
J	Suzuki, H; Watkins, DN; Jair, KW; Schuebel, KE; Markowitz, SD; Chen, WD; Pretlow, TP; Bin Yang,; Akiyama, Y; van Engeland, M; Toyota, M; Tokino, T; Hinoda, Y; Imai, K; Herman, JG; Baylin, SB				Suzuki, H; Watkins, DN; Jair, KW; Schuebel, KE; Markowitz, SD; Chen, WD; Pretlow, TP; Bin Yang,; Akiyama, Y; van Engeland, M; Toyota, M; Tokino, T; Hinoda, Y; Imai, K; Herman, JG; Baylin, SB			Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer	NATURE GENETICS			English	Article							FRIZZLED-RELATED PROTEIN; BETA-CATENIN; COLON-CARCINOMA; APC; EXPRESSION; IDENTIFICATION; INHIBITION; ANTAGONIST; ACTIVATION; MUTATIONS	Aberrant WNT pathway signaling is an early progression event in 90% of colorectal cancers(1). It occurs through mutations mainly of APC and less often of CTNNB1 (encoding beta-catenin)(1-3) or AXIN2 (encoding axin-2, also known as conductin)(4). These mutations allow ligand-independent WNT signaling that culminates in abnormal accumulation of free beta-catenin in the nucleus(1-3). We previously identified frequent promoter hypermethylation and gene silencing of the genes encoding secreted frizzled-related proteins (SFRPs) in colorectal cancer(5). SFRPs possess a domain similar to one in the WNT-receptor frizzled proteins and can inhibit WNT receptor binding to downregulate pathway signaling during development(6-10). Here we show that restoration of SFRP function in colorectal cancer cells attenuates WNT signaling even in the presence of downstream mutations. We also show that the epigenetic loss of SFRP function occurs early in colorectal cancer progression and may thus provide constitutive WNT signaling that is required to complement downstream mutations in the evolution of colorectal cancer.	Johns Hopkins Med Inst, Div Tumor Biol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Maastricht, Dept Pathol, NL-6200 MC Maastricht, Netherlands; Sapporo Med Univ, Dept Mol Biol, Inst Canc Res, Sapporo, Hokkaido, Japan; JST, PRESTO, Kawaguchi, Japan; Yamaguchi Univ, Dept Clin Lab Sci, Sch Med, Yamaguchi, Japan; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Johns Hopkins University; Johns Hopkins Medicine; Sapporo Medical University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Maastricht University; Sapporo Medical University; Japan Science & Technology Agency (JST); Yamaguchi University; Howard Hughes Medical Institute	Baylin, SB (corresponding author), Johns Hopkins Med Inst, Div Tumor Biol, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu	van Engeland, Manon/A-7479-2009; CHEN, WEI-DONG/F-4521-2014; Watkins, David N/I-6113-2013; Tokino, Takashi/AAI-9887-2021	van Engeland, Manon/0000-0002-7952-6843; CHEN, WEI-DONG/0000-0003-2264-5515; 				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Cong F, 2003, MOL CELL BIOL, V23, P8462, DOI 10.1128/MCB.23.23.8462-8470.2003; Dennis S, 1999, J CELL SCI, V112, P3815; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; JEN J, 1994, CANCER RES, V54, P5523; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Siu IM, 1999, CANCER RES, V59, P63; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Xu QH, 1998, DEVELOPMENT, V125, P4767	30	862	919	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					417	422		10.1038/ng1330	http://dx.doi.org/10.1038/ng1330			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15034581	Bronze			2022-12-25	WOS:000220647200028
J	Watts, GDJ; Wymer, J; Kovach, MJ; Mehta, SG; Mumm, S; Darvish, D; Pestronk, A; Whyte, MP; Kimonis, VE				Watts, GDJ; Wymer, J; Kovach, MJ; Mehta, SG; Mumm, S; Darvish, D; Pestronk, A; Whyte, MP; Kimonis, VE			Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein	NATURE GENETICS			English	Article							AAA-ATPASE P97; ENDOPLASMIC-RETICULUM; UBIQUITIN; GENE; CHAPERONE; DISORDERS; MUTATIONS; PATHWAYS; FAMILY; DOMAIN	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD) is a dominant progressive disorder that maps to chromosome 9p21.1-p12. We investigated 13 families with IBMPFD linked to chromosome 9 using a candidate-gene approach. We found six missense mutations in the gene encoding valosin-containing protein (VCP, a member of the AAA-ATPase superfamily) exclusively in all 61 affected individuals. Haplotype analysis indicated that descent from two founders in two separate North American kindreds accounted for IBMPFD in similar to 50% of affected families. VCP is associated with a variety of cellular activities, including cell cycle control, membrane fusion and the ubiquitin-proteasome degradation pathway. Identification of VCP as causing IBMPFD has important implications for other inclusion-body diseases, including myopathies, dementias and Paget disease of bone (PDB), as it may define a new common pathological ubiquitin-based pathway.	Harvard Univ, Childrens Hosp Boston, Div Genet, Sch Med, Boston, MA 02115 USA; Univ Tennessee, Dept Biol & Environm Sci, Chattanooga, TN USA; Univ Washington, Barnes Jewish Hosp, Div Bone & Mineral Dis, Sch Med, St Louis, MO USA; Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO USA; HIBM, Res Grp, Encino, CA USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Tennessee System; University of Tennessee at Chattanooga; Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	Kimonis, VE (corresponding author), Harvard Univ, Childrens Hosp Boston, Div Genet, Sch Med, 300 Longwood Ave, Boston, MA 02115 USA.	virginia.kimonis@childrens.harvard.edu						Beyer A, 1997, PROTEIN SCI, V6, P2043; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; Kimonis VE, 2000, GENET MED, V2, P232, DOI 10.1097/00125817-200007000-00006; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kovach MJ, 2001, MOL GENET METAB, V74, P458, DOI 10.1006/mgme.2001.3256; Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; WANG Q, 2003, J STRUCT BIOL   1219; Watts GDJ, 2003, NEUROMUSCULAR DISORD, V13, P559, DOI 10.1016/S0960-8966(03)00070-1; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x; YABE H, 1986, 8 ANN M AM SOC BON M, pA221; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	29	992	1025	3	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					377	381		10.1038/ng1332	http://dx.doi.org/10.1038/ng1332			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	15034582	Green Published, Bronze			2022-12-25	WOS:000220647200021
J	van den Brink, GR; Bleuming, SA; Hardwick, JCH; Schepman, BL; Offerhaus, GJ; Keller, JJ; Nielsen, C; Gaffield, W; van Deventer, SJH; Roberts, DJ; Peppelenbosch, MP				van den Brink, GR; Bleuming, SA; Hardwick, JCH; Schepman, BL; Offerhaus, GJ; Keller, JJ; Nielsen, C; Gaffield, W; van Deventer, SJH; Roberts, DJ; Peppelenbosch, MP			Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation	NATURE GENETICS			English	Article							INTESTINAL TREFOIL FACTOR; COLORECTAL-CANCER; EXPRESSION; INHIBITION; CARCINOMA; BUTYRATE; COMPLEX; CULTURE; GROWTH; VILLIN	Wnt signaling defines the colonic epithelial progenitor cell phenotype(1), and mutations in the gene adenomatous polyposis coli (APC) that activate the Wnt pathway cause the familial adenomatous polyposis coli (FAP) syndrome and most sporadic colon cancers(2). The mechanisms that regulate the transition of epithelial precursor cells into their differentiated derivatives are poorly characterized. We report that Indian hedgehog (Ihh) is expressed by mature colonocytes and regulates their differentiation in vitro and in vivo. Hedgehog (Hh) signaling restricts the expression of Wnt targets to the base of the colonic crypt in vivo, and transfection of Ihh into colon cancer cells leads to a downregulation of both components of the nuclear TCF4-beta-catenin complex and abrogates endogenous Wnt signaling in vitro. In turn, expression of Ihh is downregulated in polyps of individuals with FAP and expression of doxycycline-inducible dominant negative TCF4 (dnTCF4) restores Ihh expression in APC mutant DLD-1 colon cancer cells. These data identify a new Wnt-Hh axis in colonic epithelial renewal.	Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; ARS, Western Reg Res Ctr, USDA, Albany, CA USA; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Harvard University; Massachusetts General Hospital; United States Department of Agriculture (USDA); University of Amsterdam; Academic Medical Center Amsterdam	van den Brink, GR (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	g.r.vandenbrink@amc.uva.nl	Roberts, Drucilla/AAB-6379-2022; Hardwick, James/J-4862-2013	Peppelenbosch, Maikel/0000-0001-9112-6028; Hardwick, James/0000-0002-9575-5099				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; AUGERON C, 1984, CANCER RES, V44, P3961; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Boon EMJ, 2002, CANCER RES, V62, P5126; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Hao XP, 2001, CANCER RES, V61, P8085; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lengyel JA, 2002, DEV BIOL, V243, P1, DOI 10.1006/dbio.2002.0577; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; PRINGAULT E, 1986, EMBO J, V5, P3119, DOI 10.1002/j.1460-2075.1986.tb04618.x; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Taupin D, 1996, LAB INVEST, V75, P25; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; van den Brink GR, 2002, GUT, V51, P628, DOI 10.1136/gut.51.5.628; WEST AB, 1988, GASTROENTEROLOGY, V94, P343, DOI 10.1016/0016-5085(88)90421-0	21	295	302	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2004	36	3					277	282		10.1038/ng1304	http://dx.doi.org/10.1038/ng1304			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14770182	Bronze			2022-12-25	WOS:000189250400017
J	Yu, H; Ito, T; Wellmer, F; Meyerowitz, EM				Yu, H; Ito, T; Wellmer, F; Meyerowitz, EM			Repression of AGAMOUS-LIKE 24 is a crucial step in promoting flower development	NATURE GENETICS			English	Article							FLORAL MERISTEM IDENTITY; HOMEOTIC GENES; INFLORESCENCE DEVELOPMENT; ARABIDOPSIS-THALIANA; LEAFY; APETALA1; ARCHITECTURE; ACTIVATION; REGULATOR	Flower development begins as floral meristems arise in succession on the flank of the inflorescence meristem. Floral meristem identity genes LEAFY (LFY) and APETALA1 (AP1) promote establishment and maintenance of floral identity in newly formed floral primordia(1-9). Without their activity, the floral primordia develop with inflorescence characteristics. The underlying molecular-genetic mechanism is unknown. Here we show that these phenotypes are due in large part to the ectopic expression of AGAMOUS-LIKE 24 (AGL24), a central regulator of floral meristem identity. We present evidence that AGL24 is an early target of transcriptional repression by LFY and AP1. Without such repression, continued AGL24 expression in floral meristems is sufficient to cause floral reversion regardless of the activation of floral organ identity genes. This indicates that LFY and AP1 promote floral development not only by positively regulating genes activated in flower development, but also by repressing AGL24, a promoter of inflorescence fate.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore	California Institute of Technology; National University of Singapore	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	meyerow@its.caltech.edu	Yu, Hao/A-3867-2010; Meyerowitz, Elliot M/A-7118-2009	Yu, Hao/0000-0002-9778-8855; Wellmer, Frank/0000-0002-2095-0981; Ito, Toshiro/0000-0002-8206-2787				Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; CLARK SE, 1993, DEVELOPMENT, V119, P397; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; Long JA, 1998, DEVELOPMENT, V125, P3027; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Michaels SD, 2003, PLANT J, V33, P867, DOI 10.1046/j.1365-313X.2003.01671.x; Mizukami Y, 1997, PLANT CELL, V9, P393, DOI 10.1105/tpc.9.3.393; Ng M, 2001, PLANT CELL, V13, P739, DOI 10.1105/tpc.13.4.739; OKAMURO JK, 1993, PLANT CELL, V5, P1183, DOI 10.1105/tpc.5.10.1183; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Parcy F, 2002, DEVELOPMENT, V129, P2519; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; Wagner D, 1999, SCIENCE, V285, P582, DOI 10.1126/science.285.5427.582; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Yu Hao, 2002, Proceedings of the National Academy of Sciences of the United States of America, V99, P16336, DOI 10.1073/pnas.212624599	30	195	216	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					157	161		10.1038/ng1286	http://dx.doi.org/10.1038/ng1286			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14716314	Bronze			2022-12-25	WOS:000188542700017
J	Wang, TH; Niu, GL; Kortylewski, M; Burdelya, L; Shain, K; Zhang, SM; Bhattacharya, R; Gabrilovich, D; Heller, R; Coppola, D; Dalton, W; Jove, R; Pardoll, D; Yu, H				Wang, TH; Niu, GL; Kortylewski, M; Burdelya, L; Shain, K; Zhang, SM; Bhattacharya, R; Gabrilovich, D; Heller, R; Coppola, D; Dalton, W; Jove, R; Pardoll, D; Yu, H			Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells	NATURE MEDICINE			English	Article							DENDRITIC CELLS; GENE-REGULATION; ANTIGEN; DIFFERENTIATION; TRANSFORMATION; ACTIVATION; REJECTION; INTERLEUKIN-10; LYMPHOCYTES; EXPRESSION	Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Clin Invest Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	Johns Hopkins University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Pardoll, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.		Heller, Richard/I-6605-2012; Kortylewski, Marcin/H-8052-2019; Gabrilovich, Dmitry/ABE-7122-2020; Heller, Richard/ABF-1445-2020	Kortylewski, Marcin/0000-0002-6003-1816; Heller, Richard/0000-0003-1899-3859; YU, Hua/0000-0003-0931-1000				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brossart P, 2000, CANCER RES, V60, P4485; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sombroek CC, 2002, J IMMUNOL, V168, P4333, DOI 10.4049/jimmunol.168.9.4333; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; URBAN JL, 1982, J EXP MED, V155, P557, DOI 10.1084/jem.155.2.557; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WORTZEL RD, 1983, NATURE, V304, P165, DOI 10.1038/304165a0	38	828	889	1	61	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					48	54		10.1038/nm976	http://dx.doi.org/10.1038/nm976			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702634				2022-12-25	WOS:000187743600038
J	Bailis, JM; Bernard, P; Antonelli, R; Allshire, RC; Forsburg, SL				Bailis, JM; Bernard, P; Antonelli, R; Allshire, RC; Forsburg, SL			Hsk1-Dfp1 is required for heterochromatin-mediated cohesion at centromeres	NATURE CELL BIOLOGY			English	Letter							FISSION YEAST CENTROMERES; DISRUPT CHROMOSOME SEGREGATION; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SISTER CHROMATIDS; DNA-REPLICATION; PROTEIN-KINASE; HSK1 KINASE; INITIATION; CHECKPOINT	Heterochromatin performs a central role in chromosome segregation and stability by promoting cohesion at centromeres(1,2). Establishment of both heterochromatin-mediated silencing and cohesion requires passage through S phase, although the mechanism is unknown(3,4). Here we demonstrate that Schizosaccharomyces pombe Hsk1 (CDC7), a conserved Dbf4-dependent protein kinase (DDK) that regulates replication initiation(5), interacts with and phosphorylates the heterochromatin protein 1 (HP1) equivalent Swi6 (ref. 6). Hsk1 and its regulatory subunit Dfp1 function downstream of Swi6 localization to promote heterochromatin function and cohesion specifically at centromeres. This role for Hsk1-Dfp1 is separable from its replication initiation activity, providing a temporal link between S phase and centromere cohesion that is mediated by heterochromatin.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; CNRS, Unite Mixte Rech 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Salk Institute; University of Edinburgh; Centre National de la Recherche Scientifique (CNRS); University of Edinburgh	Forsburg, SL (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	forsburg@salk.edu	Bernard, Pascal/I-1859-2015	Bernard, Pascal/0000-0003-2732-9685; Allshire, Robin/0000-0002-8005-3625; Forsburg, Susan L/0000-0002-4895-8598				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Edwards RJ, 1997, METHOD ENZYMOL, V283, P471; Ekwall K, 1999, GENETICS, V153, P1153; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ekwall K, 1996, J CELL SCI, V109, P2637; Fung AD, 2002, MOL CELL BIOL, V22, P4477, DOI 10.1128/MCB.22.13.4477-4490.2002; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Partridge JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2000, J CELL SCI, V113, P4177; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Zhao T, 2001, J BIOL CHEM, V276, P9512, DOI 10.1074/jbc.M010098200	30	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1111	1116		10.1038/ncb1069	http://dx.doi.org/10.1038/ncb1069			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14625560				2022-12-25	WOS:000186892900018
J	Camargo, FD; Green, R; Capetenaki, Y; Jackson, KA; Goodell, MA				Camargo, FD; Green, R; Capetenaki, Y; Jackson, KA; Goodell, MA			Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates	NATURE MEDICINE			English	Article							BONE-MARROW CELLS; MDX MOUSE MUSCLE; IN-VIVO; MUSCULAR-DYSTROPHY; TRANSGENIC MICE; REGENERATION; EXPRESSION; TRANSPLANTATION; MACROPHAGES; FUSION	Recent studies have shown that cells from the bone marrow can give rise to differentiated skeletal muscle fibers. However, the mechanisms and identities of the cell types involved have remained unknown, and the validity of the observation has been questioned. Here, we use transplantation of single CD45(+) hematopoietic stem cells (HSCs) to demonstrate that the entire circulating myogenic activity in bone marrow is derived from HSCs and their hematopoietic progeny. We also show that ongoing muscle regeneration and inflammatory cell infiltration are required for HSC- derived contribution, which does not occur through a myogenic stem cell intermediate. Using a lineage tracing strategy, we show that myofibers are derived from mature myeloid cells in response to injury. Our results indicate that circulating myeloid cells, in response to inflammatory cues, migrate to regenerating skeletal muscle and stochastically incorporate into mature myofibers.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Baylor Coll Med, Mol Cell Biol Dept, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Goodell, MA (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza,BCM505, Houston, TX 77030 USA.			Goodell, Margaret A./0000-0003-1111-2932				ALVAREZDOLADO M, 2003, NATURE; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; De Luca A, 2002, NEUROMUSCULAR DISORD, V12, pS142, DOI 10.1016/S0960-8966(02)00100-1; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukada S, 2002, J CELL SCI, V115, P1285; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodell MA, 2001, CURR OPIN CELL BIOL, V13, P662, DOI 10.1016/S0955-0674(00)00268-4; GOODELL MA, 2002, CURRENT PROTOCOLS CY, V2; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jorgensen C, 2003, GENE THER, V10, P928, DOI 10.1038/sj.gt.3302019; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Lu QL, 1998, J HISTOCHEM CYTOCHEM, V46, P977, DOI 10.1177/002215549804600813; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; McKinney-Freeman SL, 2003, EXP HEMATOL, V31, P806, DOI 10.1016/S0301-472X(03)00186-3; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; ORIMO S, 1991, MUSCLE NERVE, V14, P515, DOI 10.1002/mus.880140605; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Parrish EP, 1996, GENE THER, V3, P13; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; QUINLAN JG, 1995, MUSCLE NERVE, V18, P201, DOI 10.1002/mus.880180209; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365-2613.2000.00164.x; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; WAKEFORD S, 1991, MUSCLE NERVE, V14, P42, DOI 10.1002/mus.880140108; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	53	311	337	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1520	1527		10.1038/nm963	http://dx.doi.org/10.1038/nm963			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625546				2022-12-25	WOS:000186845400036
J	Zhao, JZ; Cao, J; Li, YX; Collins, HL; Roush, RT; Earle, ED; Shelton, AM				Zhao, JZ; Cao, J; Li, YX; Collins, HL; Roush, RT; Earle, ED; Shelton, AM			Transgenic plants expressing two Bacillus thuringiensis toxins delay insect resistance evolution	NATURE BIOTECHNOLOGY			English	Article							DIAMONDBACK MOTH LEPIDOPTERA; PINK-BOLLWORM; MANAGEMENT; BROCCOLI; STRATEGIES; CRY1C; CROPS; FIELD; PLUTELLIDAE; PROTEIN	Preventing insect pests from developing resistance to Bacillus thuringiensis (Bt) toxins produced by transgenic crops is a major challenge for agriculture. Theoretical models suggest that plants containing two dissimilar Bt toxin genes ( pyramided' plants) have the potential to delay resistance more effectively than single- toxin plants used sequentially or in mosaics. To test these predictions, we developed a unique model system consisting of Bt transgenic broccoli plants and the diamondback moth, Plutella xylostella. We conducted a greenhouse study using an artificial population of diamondback moths carrying genes for resistance to the Bt toxins Cry1Ac and Cry1C at frequencies of about 0.10 and 0.20, respectively. After 24 generations of selection, resistance to pyramided two- gene plants was significantly delayed as compared with resistance to single- gene plants deployed in mosaics, and to Cry1Ac toxin when it was the first used in a sequence. These results have important implications for the development and regulation of transgenic insecticidal plants.	Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA; Univ Adelaide, Dept Appl & Mol Ecol, Waite Inst, Glen Osmond, SA 5064, Australia	Cornell University; Cornell University; University of Adelaide	Shelton, AM (corresponding author), Cornell Univ, New York State Agr Expt Stn, Dept Entomol, 630 W North St, Geneva, NY 14456 USA.			Zhao, Jianzhou/0000-0001-9136-2442				BAXTER S, 2002, J INSECT SCI, V2, P3; Cao J, 1999, MOL BREEDING, V5, P131, DOI 10.1023/A:1009619924620; Cao J, 2002, THEOR APPL GENET, V105, P258, DOI 10.1007/s00122-002-0942-0; Carriere Y, 2003, P NATL ACAD SCI USA, V100, P1519, DOI 10.1073/pnas.0436708100; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; Heckel DG, 1999, P NATL ACAD SCI USA, V96, P8373, DOI 10.1073/pnas.96.15.8373; JAMES C, 2002, 27 INT SERV ACQ AGR; METZ TD, 1995, MOL BREEDING, V1, P309, DOI 10.1007/BF01248408; Roush RT, 1998, PHILOS T R SOC B, V353, P1777, DOI 10.1098/rstb.1998.0330; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; Roush RT, 1997, PESTIC SCI, V51, P328, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;328::AID-PS650&gt;3.0.CO;2-B; Roush RT., 1990, PESTICIDE RESISTANCE, P97, DOI DOI 10.1007/978-1-4684-6429-0_5; SAS, 2003, US GUID STAT; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; SHELTON AM, 1991, J ENTOMOL SCI, V26, P17, DOI 10.18474/0749-8004-26.1.17; Shelton AM, 2002, ANNU REV ENTOMOL, V47, P845, DOI 10.1146/annurev.ento.47.091201.145309; Tabashnik BE, 2003, J ECON ENTOMOL, V96, P1031, DOI 10.1603/0022-0493-96.4.1031; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P1640, DOI 10.1073/pnas.94.5.1640; Tabashnik BE, 2002, APPL ENVIRON MICROB, V68, P3790, DOI 10.1128/AEM.68.8.3790-3794.2002; Tabashnik BE, 2002, J ECON ENTOMOL, V95, P1018, DOI 10.1603/0022-0493-95.5.1018; Tang JD, 2001, J ECON ENTOMOL, V94, P240, DOI 10.1603/0022-0493-94.1.240; USEPA, 2001, BIOP REG ACT DOC BAC; *USEPA, 2002, BIOP ACT INGR FACT S; Zhao JZ, 2000, APPL ENVIRON MICROB, V66, P3784, DOI 10.1128/AEM.66.9.3784-3789.2000; Zhao JZ, 2002, J ECON ENTOMOL, V95, P14, DOI 10.1603/0022-0493-95.1.14; Zhao JZ, 2001, J ECON ENTOMOL, V94, P1547, DOI 10.1603/0022-0493-94.6.1547	26	293	353	2	87	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1493	1497		10.1038/nbt907	http://dx.doi.org/10.1038/nbt907			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14608363				2022-12-25	WOS:000186845200028
J	Furukawa, M; He, YZJ; Borchers, C; Xiong, Y				Furukawa, M; He, YZJ; Borchers, C; Xiong, Y			Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases	NATURE CELL BIOLOGY			English	Letter							TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE; CAENORHABDITIS-ELEGANS; GENE-PRODUCT; C-ELEGANS; F-BOX; COMPLEX; FAMILY; DOMAIN; SCF	The concentrations and functions of many cellular proteins are regulated by the ubiquitin pathway. Cullin family proteins bind with the RING-finger protein Roc1 to recruit the ubiquitin-conjugating enzyme (E2) to the ubiquitin ligase complex (E3). Cul1 and Cul7, but not other cullins, bind to an adaptor protein, Skp1. Cul1 associates with one of many F-box proteins through Skp1 to assemble various SCF-Roc1 E3 ligases that each selectively ubiquitinate one or more specific substrates. Here, we show that Cul3, but not other cullins, binds directly to multiple BTB domains through a conserved amino-terminal domain. In vitro, Cul3 promoted ubiquitination of Caenorhabditis elegans MEI-1, a katanin-like protein whose degradation requires the function of both Cul3 and BTB protein MEL-26. We suggest that in vivo there exists a potentially large number of BCR3 (BTB-Cul3-Roc1) E3 ubiquitin ligases.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		BORCHERS, Christoph/U-5964-2019; , Proteomics Core UNC/AFQ-7201-2022	He, Yizhou/0000-0002-1396-7275				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CLARKMAGUIRE S, 1994, J CELL BIOL, V126, P199, DOI 10.1083/jcb.126.1.199; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; GODT D, 1993, DEVELOPMENT, V119, P799; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michel JJ, 2003, J BIOL CHEM, V278, P22828, DOI 10.1074/jbc.M210358200; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Srayko M, 2000, GENE DEV, V14, P1072; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	31	339	366	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					1001	1007		10.1038/ncb1056	http://dx.doi.org/10.1038/ncb1056			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14528312				2022-12-25	WOS:000186273100017
J	Konig, A				Konig, A			A framework for designing transgenic crops - science, safety and citizen's concerns	NATURE BIOTECHNOLOGY			English	Editorial Material							SELECTABLE MARKER GENES; PLANT-CELL; T-DNAS; INTRACHROMOSOMAL RECOMBINATION; HOMOLOGOUS RECOMBINATION; FLP RECOMBINASE; SELECTION; TOBACCO; TRANSFORMATION; SEGREGATION		Harvard Univ, Harvard Ctr Risk Anal, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Konig, A (corresponding author), Harvard Univ, Harvard Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.	ariane_koenig@harvard.edu	Konig, Ariane/L-3025-2015	Konig, Ariane/0000-0002-5212-4668				ARMSTRONG CL, 1995, CROP SCI, V35, P550, DOI 10.2135/cropsci1995.0011183X003500020045x; DALE EC, 1991, P NATL ACAD SCI USA, V88, P10558, DOI 10.1073/pnas.88.23.10558; DEFRAMOND AJ, 1986, MOL GEN GENET, V202, P125, DOI 10.1007/BF00330528; DEPICKER A, 1985, MOL GEN GENET, V201, P477, DOI 10.1007/BF00331342; Ebinuma H, 2001, PLANT CELL REP, V20, P383, DOI 10.1007/s002990100344; *EUR COMM, 2003, GUID DOC RISK ASS GE; FAO/WHO, 2000, SAF ASP GEN MOD FOOD; FUCHS RL, 1993, BIO-TECHNOL, V11, P1543, DOI 10.1038/nbt1293-1543; GASSER CS, 1989, SCIENCE, V244, P1293, DOI 10.1126/science.244.4910.1293; Gleave AP, 1999, PLANT MOL BIOL, V40, P223, DOI 10.1023/A:1006184221051; Haldrup A, 1998, PLANT MOL BIOL, V37, P287, DOI 10.1023/A:1005910417789; Hare PD, 2002, NAT BIOTECHNOL, V20, P575, DOI 10.1038/nbt0602-575; Hohn B, 2001, CURR OPIN BIOTECH, V12, P139, DOI 10.1016/S0958-1669(00)00188-9; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Joersbo M, 1996, PLANT CELL REP, V16, P219, DOI 10.1007/BF01890871; Joersbo M, 1998, MOL BREEDING, V4, P111, DOI 10.1023/A:1009633809610; KILBY NJ, 1995, PLANT J, V8, P637, DOI 10.1046/j.1365-313X.1995.08050637.x; Knoblauch M, 1999, NAT BIOTECHNOL, V17, P906, DOI 10.1038/12902; Komari T, 1996, PLANT J, V10, P165, DOI 10.1046/j.1365-313X.1996.10010165.x; KONIG A, 2000, P 6 INT S BIOS GEN M, P171; Kuiper HA, 2001, PLANT J, V27, P503, DOI 10.1046/j.1365-313X.2001.01119.x; LYZNIK LA, 1993, NUCLEIC ACIDS RES, V21, P969, DOI 10.1093/nar/21.4.969; MCKNIGHT TD, 1987, PLANT MOL BIOL, V8, P439, DOI 10.1007/BF00017989; Moore JA, 2001, ISSUES SCI TECHNOL, V17, P31; Nap Jan-Peter, 1992, Transgenic Research, V1, P239, DOI 10.1007/BF02525165; Negrotto D, 2000, PLANT CELL REP, V19, P798, DOI 10.1007/s002999900187; Nielsen KM, 1998, FEMS MICROBIOL REV, V22, P79, DOI 10.1111/j.1574-6976.1998.tb00362.x; ONOUCHI H, 1991, NUCLEIC ACIDS RES, V19, P6373, DOI 10.1093/nar/19.23.6373; Ow DW, 1996, CURR OPIN BIOTECH, V7, P181, DOI 10.1016/S0958-1669(96)80010-3; PETERHANS A, 1990, EMBO J, V9, P3437, DOI 10.1002/j.1460-2075.1990.tb07551.x; Puchta H, 1996, TRENDS PLANT SCI, V1, P340; Puchta H, 2000, TRENDS PLANT SCI, V5, P273, DOI 10.1016/S1360-1385(00)01684-8; Reiss B, 1996, P NATL ACAD SCI USA, V93, P3094, DOI 10.1073/pnas.93.7.3094; Rice MC, 2001, NAT BIOTECHNOL, V19, P321, DOI 10.1038/86701; RUSSELL SH, 1992, MOL GEN GENET, V234, P49, DOI 10.1007/BF00272344; SIEGENTHALER WE, 1986, AM J MED, V80, P2, DOI 10.1016/0002-9343(86)90473-0; *UK ADV COMM REL E, 2001, GUID PRINC BEST PRAC; Webler, 1995, FAIRNESS COMPETENCE, DOI 10.1007/978-94-011-0131-8; YODER JI, 1994, BIO-TECHNOL, V12, P263, DOI 10.1038/nbt0394-263; Zubko E, 2000, NAT BIOTECHNOL, V18, P442, DOI 10.1038/74515; Zuo JR, 2001, NAT BIOTECHNOL, V19, P157, DOI 10.1038/84428; 1999, DAILY MAIL      0426, P10; 1994, FED REG, V59, P26700	43	26	32	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1274	1279		10.1038/nbt1103-1274	http://dx.doi.org/10.1038/nbt1103-1274			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14595351				2022-12-25	WOS:000186320000015
J	Monk, NJ; Hargreaves, REG; Marsh, JE; Farrar, CA; Sacks, SH; Millrain, M; Simpson, E; Dyson, J; Jurcevic, S				Monk, NJ; Hargreaves, REG; Marsh, JE; Farrar, CA; Sacks, SH; Millrain, M; Simpson, E; Dyson, J; Jurcevic, S			Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade	NATURE MEDICINE			English	Article							RENAL-ALLOGRAFT REJECTION; ANIMAL TRANSPLANT MODEL; NONOBESE DIABETIC MICE; CD40 LIGAND; MONOCLONAL-ANTIBODY; DIABETOGENIC AUTOIMMUNITY; DEFICIENT MICE; FUSION PROTEIN; CUTTING EDGE; TOLERANCE	Although the underlying mechanisms are not well understood, it is generally believed that antigen recognition by T cells in the absence of costimulation may alter the immune response, leading to anergy or tolerance. Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific antibodies, have been highly effective. We investigated the mechanisms of action of an antibody to CD40L and provide evidence that its effects are dependent on the constant (Fc) region. Prolongation of graft survival is dependent on both complement- and Fc receptor-mediated mechanisms in a major histocompatibility complex (MHC)-mismatched skin transplant model. These data suggest that antibodies to CD40L act through selective depletion of activated T cells, rather than exerting immune modulation by costimulation blockade as currently postulated. This finding opens new avenues for treatment of immune disorders based on selective targeting of activated T cells.	Imperial Coll Sch Med, Hammersmith Hosp, MRC, Ctr Clin Sci,Transplantat Biol Grp, London W12 0NN, England; Univ London Kings Coll, Guys Kings & St Thomas Med Sch, Guys Hosp, Dept Nephrol & Transplantat, London SE1 9RT, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Simpson, E (corresponding author), Imperial Coll Sch Med, Hammersmith Hosp, MRC, Ctr Clin Sci,Transplantat Biol Grp, London W12 0NN, England.			Simpson, Elizabeth/0000-0002-2118-3139; Sacks, Steven/0000-0001-6361-9095				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dharnidharka VR, 2000, NAT MED, V6, P115, DOI 10.1038/72166; Durham MM, 2000, J IMMUNOL, V165, P1, DOI 10.4049/jimmunol.165.1.1; Ferguson TA, 1999, NAT MED, V5, P1231, DOI 10.1038/15180; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; Graca L, 2000, J IMMUNOL, V165, P4783, DOI 10.4049/jimmunol.165.9.4783; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; Gudmundsdottir H, 1999, J AM SOC NEPHROL, V10, P1356; Hancock WW, 1999, CURR OPIN NEPHROL HY, V8, P317, DOI 10.1097/00041552-199905000-00007; Houghton AN, 2000, NAT MED, V6, P373, DOI 10.1038/74621; Illei GG, 2000, CURR OPIN IMMUNOL, V12, P712, DOI 10.1016/S0952-7915(00)00167-9; Iwakoshi NN, 2000, J IMMUNOL, V164, P512, DOI 10.4049/jimmunol.164.1.512; JENKINS MK, 1987, IMMUNOL REV, V95, P113, DOI 10.1111/j.1600-065X.1987.tb00502.x; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LANE P, 1995, EUR J IMMUNOL, V25, P1788, DOI 10.1002/eji.1830250646; LANE P, 1993, IMMUNOLOGY, V80, P56; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li XC, 2000, CURR OPIN IMMUNOL, V12, P522, DOI 10.1016/S0952-7915(00)00133-3; Li YS, 2000, NAT MED, V6, P115, DOI 10.1038/72168; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Marsh JE, 2001, TRANSPLANTATION, V72, P1310, DOI 10.1097/00007890-200110150-00022; Matzinger P, 1999, NAT MED, V5, P616, DOI 10.1038/9458; Millrain M, 2001, J IMMUNOL, V167, P3756, DOI 10.4049/jimmunol.167.7.3756; PACHECOSILVA A, 1992, EUR J IMMUNOL, V22, P697, DOI 10.1002/eji.1830220312; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Simpson E, 1997, ANNU REV IMMUNOL, V15, P39, DOI 10.1146/annurev.immunol.15.1.39; Smiley ST, 2000, TRANSPLANTATION, V70, P415, DOI 10.1097/00007890-200008150-00005; STROM TB, 1993, ANNU REV MED, V44, P343, DOI 10.1146/annurev.med.44.1.343; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; Waldmann H, 1999, NAT MED, V5, P1245, DOI 10.1038/15197; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Wells AD, 2001, PHILOS T R SOC B, V356, P617, DOI 10.1098/rstb.2001.0845; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Zheng XX, 1999, J IMMUNOL, V163, P4041; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	43	120	124	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1275	1280		10.1038/nm931	http://dx.doi.org/10.1038/nm931			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502279				2022-12-25	WOS:000185669700038
J	Li, W; Zhang, Q; Oiso, N; Novak, EK; Gautam, R; O'Brien, EP; Tinsley, CL; Blake, DJ; Spritz, RA; Copeland, NG; Jenkins, NA; Amato, D; Roe, BA; Starcevic, M; Dell'Angelica, EC; Elliott, RW; Mishra, V; Kingsmore, SF; Paylor, RE; Swank, RT				Li, W; Zhang, Q; Oiso, N; Novak, EK; Gautam, R; O'Brien, EP; Tinsley, CL; Blake, DJ; Spritz, RA; Copeland, NG; Jenkins, NA; Amato, D; Roe, BA; Starcevic, M; Dell'Angelica, EC; Elliott, RW; Mishra, V; Kingsmore, SF; Paylor, RE; Swank, RT			Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1)	NATURE GENETICS			English	Article							HERMANSKY-PUDLAK-SYNDROME; STORAGE POOL DEFICIENCY; PLATELET-DENSE GRANULES; GENETIC-VARIATION; MOUSE MODEL; 6P22.3 GENE; MUTATION; PROTEIN; HOMOLOG; TRAFFICKING	Hermansky-Pudlak syndrome (HPS; MIM 203300) is a genetically heterogeneous disorder characterized by oculocutaneous albinism, prolonged bleeding and pulmonary fibrosis due to abnormal vesicle trafficking to lysosomes and related organelles, such as melanosomes and platelet dense granules(1-3). In mice, at least 16 loci are associated with HPS4-6, including sandy (sdy; ref. 7). Here we show that the sdy mutant mouse expresses no dysbindin protein owing to a deletion in the gene Dtnbp1 (encoding dysbindin) and that mutation of the human ortholog DTNBP1 causes a novel form of HPS called HPS-7. Dysbindin is a ubiquitously expressed protein that binds to alpha- and beta-dystrobrevins, components of the dystrophin-associated protein complex (DPC) in both muscle and nonmuscle cells(8). We also show that dysbindin is a component of the biogenesis of lysosome-related organelles complex 1 (BLOC-1; refs. 9-11), which regulates trafficking to lysosome-related organelles and includes the proteins pallidin, muted and cappuccino, which are associated with HPS in mice. These findings show that BLOC-1 is important in producing the HPS phenotype in humans, indicate that dysbindin has a role in the biogenesis of lysosome-related organelles and identify unexpected interactions between components of DPC and BLOC-1.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA; Univ Toronto, Dept Med, Div Hematol & Med Oncol, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA; Mol Staging, New Haven, CT 06511 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Roswell Park Cancer Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; State University System of Florida; University of Florida; Baylor College of Medicine	Swank, RT (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.		Oiso, Naoki/H-6540-2019	Oiso, Naoki/0000-0001-5593-6496; Kingsmore, Stephen/0000-0001-7180-2527; kingsmore, stephen/0000-0002-3758-4631	NHLBI NIH HHS [R01 HL068117] Funding Source: Medline; NIAID NIH HHS [P01 AI039824-050002, P01 AI039824] Funding Source: Medline; NICHD NIH HHS [U19 HD077693] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039824] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Lee ST, 1995, MOL CELLS, V5, P668; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nguyen T, 2002, J INVEST DERMATOL, V119, P1156, DOI 10.1046/j.1523-1747.2002.19535.x; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; REDDINGTON M, 1987, BLOOD, V69, P1300; Schwab SG, 2003, AM J HUM GENET, V72, P185, DOI 10.1086/345463; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; SWANK RT, 1991, GENET RES, V58, P51, DOI 10.1017/S0016672300029608; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; [No title captured]	30	337	351	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					84	89		10.1038/ng1229	http://dx.doi.org/10.1038/ng1229			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12923531	Green Accepted			2022-12-25	WOS:000185018500015
J	Joseph, B; Berishvili, E; Benten, D; Kumaran, V; Liponava, E; Bhargava, K; Palestro, C; Kakabadze, Z; Gupta, S				Joseph, B; Berishvili, E; Benten, D; Kumaran, V; Liponava, E; Bhargava, K; Palestro, C; Kakabadze, Z; Gupta, S			Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions	NATURE MEDICINE			English	Article							HEPATOCYTE TRANSPLANTATION; GENE-EXPRESSION; RAT; REGENERATION; MODEL; RECEPTORS; SURVIVAL; ISOFORMS; PATIENT; FLOW	We determine here the functional integrity of auxiliary livers in containers fashioned from the small intestine. Liver microfragments from dipeptidyl peptidase 4 (DPP4)-deficient rats were transplanted into syngeneic normal animals with isolated intestinal segments characterized by mucosal denudation but intact vascular supply. Transplanted liver fragments were restored to confluent tissue with normal hepatic architecture and development of DPP4-positive vessels, indicating angiogenesis and revascularization. Auxiliary liver units expressed multiple hepatotrophic and angiogenic genes, and transplanted tissues remained intact for up to the 6-week duration of the studies with neither ischemic injury nor significant hepatocellular proliferation. Hepatic metabolic, transport and synthetic functions were preserved in auxiliary livers, including uptake and biliary excretion of Tc-99m-mebrofenin in syngeneic recipients of liver from F344 rats, as well as secretion of albumin in allografted Nagase analbuminemic rats. This ability to produce functionally competent auxiliary livers in vascularized intestinal segments offers therapeutic potential for liver disease and genetic deficiency.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Georgian State Med Acad, Dept Clin Anat & Operat Surg, GE-380079 Tbilisi, Georgia; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Long Isl Jewish Med Ctr, Dept Radiol, Div Nucl Med, New York, NY 11040 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwell Health	Gupta, S (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA.	sanjvgupta@pol.net	Kumaran, Vinay/AAF-1889-2019; Berishvili, Ekaterine/AAL-9758-2020; Kakabadze, Zurab/L-6695-2019	Berishvili, Ekaterine/0000-0002-7969-1937; Kakabadze, Zurab/0000-0001-9038-5220; Kumaran, Vinay/0000-0003-0800-6290	NIDDK NIH HHS [R01 DK46952, P30-DK-41296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angelis M, 2001, J PEDIATR-US, V138, P120, DOI 10.1067/mpd.2001.109199; Azoulay D, 2001, ANN SURG, V234, P723, DOI 10.1097/00000658-200112000-00003; Berishvili E, 2003, TRANSPLANTATION, V75, P1827, DOI 10.1097/01.TP.0000065297.56712.C1; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; de Jonge J, 1999, J PEDIATR SURG, V34, P1265, DOI 10.1016/S0022-3468(99)90165-3; Durand F, 2002, LIVER TRANSPLANT, V8, P701, DOI 10.1053/jlts.2002.33745; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gaglio PJ, 2002, J HEPATOL, V37, P625, DOI 10.1016/S0168-8278(02)00262-3; GUPTA S, 1992, HEPATOLOGY, V15, P156, DOI 10.1002/hep.1840150126; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Haberal M, 2001, J PEDIATR SURG, V36, P667, DOI 10.1053/jpsu.2001.22317; Ishii H, 2002, ARCH ORAL BIOL, V47, P505, DOI 10.1016/S0003-9969(02)00033-X; Kaibori M, 1998, TRANSPLANTATION, V66, P935, DOI 10.1097/00007890-199810150-00022; Kalyani AJ, 1999, J NEUROBIOL, V38, P207, DOI 10.1002/(SICI)1097-4695(19990205)38:2<207::AID-NEU4>3.0.CO;2-G; Kayler LK, 2002, PEDIATR TRANSPLANT, V6, P295, DOI 10.1034/j.1399-3046.2002.02009.x; Kiuchi T, 1999, TRANSPLANT P, V31, P528, DOI 10.1016/S0041-1345(98)01539-5; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Malhi H, 2002, J NUCL MED, V43, P246; Oh SH, 2000, BIOCHEM BIOPH RES CO, V279, P500, DOI 10.1006/bbrc.2000.3985; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Rajvanshi P, 1996, HEPATOLOGY, V23, P482; Rela M, 1999, ANN SURG, V229, P565, DOI 10.1097/00000658-199904000-00017; Robotin-Johnson MC, 1998, J THORAC CARDIOV SUR, V116, P805, DOI 10.1016/S0022-5223(98)00436-X; Rudolfsson SH, 2003, BIOL REPROD, V69, P1231, DOI 10.1095/biolreprod.102.013375; Scotte M, 1997, CYTOKINE, V9, P859, DOI 10.1006/cyto.1997.0273; SELDEN C, 1995, HEPATOLOGY, V21, P1405, DOI 10.1016/0270-9139(95)90063-2; Sundback CA, 2000, GASTROENTEROLOGY, V118, P438; Suzuki S, 2002, BIOCHEM BIOPH RES CO, V292, P709, DOI 10.1006/bbrc.2002.6706; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9	30	25	26	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					749	753		10.1038/nm1057	http://dx.doi.org/10.1038/nm1057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15170210				2022-12-25	WOS:000222460400031
J	Cvejic, S; Zhu, Z; Felice, SJ; Berman, Y; Huang, XY				Cvejic, S; Zhu, Z; Felice, SJ; Berman, Y; Huang, XY			The endogenous ligand stunted of the GPCR methuselah extends lifespan in Drosophila	NATURE CELL BIOLOGY			English	Article							ATP SYNTHASE; G-PROTEINS; RECEPTOR; SURFACE; IDENTIFICATION; MITOCHONDRIA; ANGIOSTATIN; SUBUNIT; STRESS	Many extracellular signals are transmitted to the interior of the cell by receptors with seven membrane-spanning helices that trigger their effects by means of heterotrimeric guanine-nucleotide-binding regulatory proteins (G proteins)(1-4). These G-protein-coupled receptors (GPCRs) control various physiological functions in evolution from pheromone-induced mating in yeast to cognition in humans(5,6). The potential role of the G-protein signalling system in the control of animal ageing has been highlighted by the genetic revelation that mutation of a GPCR encoded by methuselah extends the lifespan of adult Drosophila flies(7). How methuselah functions in controlling ageing is not clear. A first essential step towards the understanding of methuselah function is to determine the ligands of Methuselah. Here we report the identification and characterization of two endogenous peptide ligands of Methuselah, designated Stunted A and B. Flies with mutations in the gene encoding these ligands show an increase in lifespan and resistance to oxidative stress. We conclude that the Stunted-Methuselah system is involved in the control of animal ageing.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Cornell University; New York University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.	xyhuang@med.cornell.edu	Gimenez, Luis E Diaz/D-9291-2011					Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Katzen AL, 1996, P NATL ACAD SCI USA, V93, P13955, DOI 10.1073/pnas.93.24.13955; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Simon AF, 2003, SCIENCE, V299, P1407, DOI 10.1126/science.1080539; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Song W, 2002, NEURON, V36, P105, DOI 10.1016/S0896-6273(02)00932-7; Tu Q, 2000, BIOCHEM J, V347, P17, DOI 10.1042/0264-6021:3470017; Wang XD, 2001, GENE DEV, V15, P2922	26	69	77	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					540	546		10.1038/ncb1133	http://dx.doi.org/10.1038/ncb1133			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15133470				2022-12-25	WOS:000221759400014
J	Schmitt-Ulms, G; Hansen, K; Liu, JL; Cowdrey, C; Yang, J; DeArmond, SJ; Cohen, FE; Prusiner, SB; Baldwin, MA				Schmitt-Ulms, G; Hansen, K; Liu, JL; Cowdrey, C; Yang, J; DeArmond, SJ; Cohen, FE; Prusiner, SB; Baldwin, MA			Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues	NATURE BIOTECHNOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; CELLULAR PRION PROTEIN; ENRICHED MEMBRANE SUBDOMAINS; FAMILIAL ALZHEIMERS-DISEASE; LIPID RAFTS; GAMMA-SECRETASE; SCRAPIE ISOFORM; IN-VIVO; MISSENSE MUTATIONS; ANCHORED PROTEINS	Because of their sensitivity to solubilizing detergents, membrane protein assemblies are difficult to study. We describe a protocol that covalently conserves protein interactions through time-controlled transcardiac perfusion cross-linking (tcTPC) before disruption of tissue integrity. To validate tcTPC for identifying protein-protein interactions, we established that tcTPC allowed stringent immunoaffinity purification of the gamma-secretase complex in high salt concentrations and detergents and was compatible with mass spectrometric identification of cross-linked aph-1, presenilin-1 and nicastrin. We then applied tcTPC to identify more than 20 proteins residing in the vicinity of the cellular prion protein (PrPC), suggesting that PrP is embedded in specialized membrane regions with a subset of molecules that, like PrP, use a glycosylphosphatidylinositol anchor for membrane attachment. Many of these proteins have been implicated in cell adhesion/neuritic outgrowth, and harbor immunoglobulin C2 and fibronectin type III-like motifs.	Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Schmitt-Ulms, G (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada.	g.schmittulms@utoronto.ca; mikeab@itsa.ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	NCRR NIH HHS [NCRR RR01614] Funding Source: Medline; NIA NIH HHS [AG02132, AG010770] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010770, P01AG002132] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Auerbach D, 2002, PROTEOMICS, V2, P611, DOI 10.1002/1615-9861(200206)2:6<611::AID-PROT611>3.0.CO;2-Y; Bini L, 2003, BIOCHEM J, V369, P301, DOI 10.1042/BJ20020503; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hannah MJ, 1998, METHODS, V16, P170, DOI 10.1006/meth.1998.0664; Holst BD, 1998, P NATL ACAD SCI USA, V95, P2597, DOI 10.1073/pnas.95.5.2597; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Jackson V, 1999, METHODS, V17, P125, DOI 10.1006/meth.1998.0724; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Reiss T, 2001, TRENDS BIOTECHNOL, V19, P496, DOI 10.1016/S0167-7799(01)01811-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vincent B, 2001, J BIOL CHEM, V276, P37743; Vinson M, 2003, MOL CELL NEUROSCI, V22, P344, DOI 10.1016/S1044-7431(02)00031-3; von Haller PD, 2001, PROTEOMICS, V1, P1010; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	48	135	140	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					724	731		10.1038/nbt969	http://dx.doi.org/10.1038/nbt969			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15146195				2022-12-25	WOS:000221785300034
J	Leu, JIJ; Dumont, P; Hafey, M; Murphy, ME; George, DL				Leu, JIJ; Dumont, P; Hafey, M; Murphy, ME; George, DL			Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex	NATURE CELL BIOLOGY			English	Letter							BCL-2 FAMILY; TRANSCRIPTIONAL REPRESSION; CELL-PROLIFERATION; BH3 DOMAIN; APOPTOSIS; PROTEIN; DEATH; MCL-1; DIFFERENTIATION; REGULATORS	The tumour suppressor activity of the p53 protein has been explained by its ability to induce apoptosis in response to a variety of cellular stresses(1,2). Thus, understanding the mechanism by which p53 functions in the execution of cell death pathways is of considerable importance in cancer biology Recent studies have indicated that p53 has a direct signalling role at mitochondria in the induction of apoptosis(3-6), although the mechanisms involved are not completely understood. Here we show that, after cell stress, p53 interacts with the proapoptotic mitochondrial membrane protein Bak. Interaction of p53 with Bak causes oligomerization of Bak and release of cytochrome c from mitochondria. Notably, we show that formation of the p53-Bak complex coincides with loss of an interaction between Bak and the anti-apoptotic Bc12-family member Mcl 1. These results are consistent with a model in which p53 and McI1 have opposing effects on mitochondrial apoptosis by interacting with, and modulating the activity of, the death effector Bak.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	University of Pennsylvania; Fox Chase Cancer Center	George, DL (corresponding author), Univ Penn, Sch Med, Dept Genet, 422 Curie Blvd, Philadelphia, PA 19104 USA.	georged@mail.med.upenn.edu		Murphy, Maureen/0000-0001-7644-7296	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007516] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA089240, R01CA080854] Funding Source: NIH RePORTER; NCI NIH HHS [CA080854, CA089240] Funding Source: Medline; NICHD NIH HHS [5-T32-HD07516] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bessette PH, 1999, P NATL ACAD SCI USA, V96, P13703, DOI 10.1073/pnas.96.24.13703; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NIJHAWAN D, 2003, GENE DEV, V17, P1; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vrana JA, 2002, CANCER RES, V62, P892; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R	30	623	648	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					443	450		10.1038/ncb1123	http://dx.doi.org/10.1038/ncb1123			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15077116				2022-12-25	WOS:000221432600015
J	Nakamura, T; Yao, R; Ogawa, T; Suzuki, T; Ito, C; Tsunekawa, N; Inoue, K; Ajima, R; Miyasaka, T; Yoshida, Y; Ogura, A; Toshimori, K; Noce, T; Yamamoto, T; Noda, T				Nakamura, T; Yao, R; Ogawa, T; Suzuki, T; Ito, C; Tsunekawa, N; Inoue, K; Ajima, R; Miyasaka, T; Yoshida, Y; Ogura, A; Toshimori, K; Noce, T; Yamamoto, T; Noda, T			Oligo-astheno-teratozoospermia in mice lacking Cnot7, a regulator of retinoid X receptor beta	NATURE GENETICS			English	Article							ALPHA MUTANT MICE; CCR4-NOT COMPLEX; MESSENGER-RNA; STEM-CELLS; VITAMIN-A; RXR-ALPHA; COMPONENT; TRANSPLANTATION; SPERMATOGENESIS; YEAST	Spermatogenesis is a complex process that involves cooperation of germ cells and testicular somatic cells. Various genetic disorders lead to impaired spermatogenesis, defective sperm function and male infertility(1). Here we show that Cnot7(-/-) males are sterile owing to oligo-astheno-teratozoospermia, suggesting that Cnot7, a CCR4-associated transcriptional cofactor(2), is essential for spermatogenesis. Maturation of spermatids is unsynchronized and impaired in seminiferous tubules of Cnot7(-/-) mice. Transplantation of spermatogonial stem cells from male Cnot7(-/-) mice to seminiferous tubules of Kit mutant mice (Kit(W/W-v)) restores spermatogenesis, suggesting that the function of testicular somatic cells is damaged in the Cnot7(-/-) condition. The testicular phenotypes of Cnot7(-/-) mice are similar to those of mice deficient in retinoid X receptor beta (Rxrb)(3). We further show that Cnot7 binds the AF-1 domain of Rxrb and that Rxrb malfunctions in the absence of Cnot7. Therefore, Cnot7 seems to function as a coregulator of Rxrb in testicular somatic cells and is thus involved in spermatogenesis.	Univ Tokyo, Inst Med Sci, Inst Med Sci, Tokyo 1088639, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanagawa 2360004, Japan; Chiba Univ, Grad Sch Med, Dept Anat & Dev Biol, Chiba 2608670, Japan; Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; RIKEN, Bioresource Ctr, Tsukuba 3050074, Japan; Tohoku Univ, Sch Med, Ctr Translat & Adv Anim Res Human Dis, Sendai, Miyagi 9808575, Japan; RIKEN, Genom Sci Ctr, Mouse Funct Genom Res Grp, Kanagawa 2440804, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Yokohama City University; Chiba University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); RIKEN; Tohoku University; RIKEN	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Inst Med Sci, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp; tnoda@ims.u-tokyo.ac.jp	noce, toshiaki/L-1739-2013; Noda, Tetsuo/B-1667-2016; Ogura, Atsuo/J-3916-2014	Ogura, Atsuo/0000-0003-0447-1988; Ito, Chizuru/0000-0003-2697-0382				Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; Creemers LB, 2002, BIOL REPROD, V66, P1579, DOI 10.1095/biolreprod66.6.1579; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Livera G, 2002, REPRODUCTION, V124, P173, DOI 10.1530/rep.0.1240173; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Maleszewski M, 1996, MOL REPROD DEV, V44, P256, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;256::AID-MRD16&gt;3.0.CO;2-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; Ogawa T, 2003, BIOL REPROD, V68, P316, DOI 10.1095/biolreprod.102.004549; Ogonuki N, 2003, BIOL REPROD, V68, P1821, DOI 10.1095/biolreprod.102.011726; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Prevot D, 2001, J BIOL CHEM, V276, P9640, DOI 10.1074/jbc.M008201200; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Tabuchi Y, 2002, J UROLOGY, V167, P1538, DOI 10.1016/S0022-5347(05)65359-1; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Yoshida Y, 2001, JPN J CANCER RES, V92, P592, DOI 10.1111/j.1349-7006.2001.tb01135.x	30	93	97	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2004	36	5					528	533		10.1038/ng1344	http://dx.doi.org/10.1038/ng1344			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	817NA	15107851	Bronze			2022-12-25	WOS:000221183000029
J	Zhou, CX; Zhang, YL; Xiao, LQ; Zheng, M; Leung, KM; Chan, MY; Lo, PS; Tsang, LL; Wong, HY; Ho, LS; Chung, YW; Chan, HC				Zhou, CX; Zhang, YL; Xiao, LQ; Zheng, M; Leung, KM; Chan, MY; Lo, PS; Tsang, LL; Wong, HY; Ho, LS; Chung, YW; Chan, HC			An epididymis-specific beta-defensin is important for the initiation of sperm maturation	NATURE CELL BIOLOGY			English	Article							RAT SPERMATOZOA; ANTIMICROBIAL PEPTIDE; CALCIUM-UPTAKE; MOTILITY; PROTEINS; CAPACITATION; INVOLVEMENT; SECRETION; HAMSTER; HUMANS	Although the role of the epididymis, a male accessory sex organ, in sperm maturation has been established for nearly four decades(1), the maturation process itself has not been linked to a specific molecule of epididymal origin. Here we show that Bin1b, a rat epididymis-specific beta-defensin with antimicrobial activity(2), can bind to the sperm head in different regions of the epididymis with varied binding patterns. In addition, Bin1b-expressing cells, either of epididymal origin or from a Bin1b-transfected cell line, can induce progressive sperm motility in immotile immature sperm. This induction of motility is mediated by the Bin1b-induced uptake of Ca2+, a mechanism that has a less prominent role in maintaining motility in mature sperm. In vivo antisense experiments show that suppressed expression of Bin1b results in reduced binding of Bin1b to caput sperm and in considerable attenuation of sperm motility and progressive movement. Thus, beta-defensin is important for the acquisition of sperm motility and the initiation of sperm maturation.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Hong Kong, Hong Kong, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese University of Hong Kong; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chan, HC (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Hong Kong, Hong Kong, Peoples R China.	hsiaocchan@cuhk.edu.hk	Chan, Hsiao Chang/E-1507-2016					Bateman A, 1996, J BIOL CHEM, V271, P10654, DOI 10.1074/jbc.271.18.10654; BEDFORD JM, 1967, NATURE, V213, P1097, DOI 10.1038/2131097a0; Breitbart H, 2002, MOL CELL ENDOCRINOL, V187, P139, DOI 10.1016/S0303-7207(01)00704-3; Chan HC, 1996, EXP PHYSIOL, V81, P515, DOI 10.1113/expphysiol.1996.sp003954; Com E, 2003, BIOL REPROD, V68, P95, DOI 10.1095/biolreprod.102.005389; CORONEL CE, 1992, J BIOL CHEM, V267, P20909; Dacheux JL, 2003, MICROSC RES TECHNIQ, V61, P7, DOI 10.1002/jemt.10312; Fouchecourt S, 2000, BIOL REPROD, V62, P1790, DOI 10.1095/biolreprod62.6.1790; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guraya SS, 2000, INT REV CYTOL, V199, P1, DOI 10.1016/S0074-7696(00)99001-6; HAMMERSTEDT RH, 1982, BIOL REPROD, V27, P745, DOI 10.1095/biolreprod27.3.745; HOSKINS DD, 1983, J SUBMICR CYTOL PATH, V15, P21; Hu YX, 2002, CELL RES, V12, P157, DOI 10.1038/sj.cr.7290122; Jeulin C, 1996, CELL MOTIL CYTOSKEL, V35, P147, DOI 10.1002/(SICI)1097-0169(1996)35:2<147::AID-CM7>3.3.CO;2-#; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Li P, 2001, SCIENCE, V291, P1783, DOI 10.1126/science.1056545; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; ORGEBINCRIST MC, 1967, NATURE, V216, P816, DOI 10.1038/216816a0; PETERSON RN, 1976, FERTIL STERIL, V27, P1301; SERRES C, 1984, REPROD NUTR DEV, V24, P81, DOI 10.1051/rnd:19840109; VIJAYARAGHAVAN S, 1989, BIOL REPROD, V40, P744, DOI 10.1095/biolreprod40.4.744; VIJAYARAGHAVAN S, 1988, GAMETE RES, V20, P343, DOI 10.1002/mrd.1120200309; von Horsten HH, 2002, BIOL REPROD, V67, P804, DOI 10.1095/biolreprod.102.004564; Welch JE, 2000, J ANDROL, V21, P328; Yamaguchi Y, 2002, J IMMUNOL, V169, P2516, DOI 10.4049/jimmunol.169.5.2516; YEUNG CH, 1992, J REPROD FERTIL, V96, P427, DOI 10.1530/jrf.0.0960427; YEUNG CH, 1994, MOL REPROD DEV, V38, P347, DOI 10.1002/mrd.1080380317; YEUNG CH, 2002, MOL CLIN PRACTICE, P417; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185	30	203	223	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					458	464		10.1038/ncb1127	http://dx.doi.org/10.1038/ncb1127			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15122269				2022-12-25	WOS:000221432600018
J	Polishchuk, R; Di Pentima, A; Lippincott-Schwartz, J				Polishchuk, R; Di Pentima, A; Lippincott-Schwartz, J			Delivery of raft-associated, GPI-anchored proteins to the apical surface of polarized MDCK cells by a transcytotic pathway	NATURE CELL BIOLOGY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; TRANS-GOLGI NETWORK; EPITHELIAL-CELLS; PLASMA-MEMBRANE; BASOLATERAL MEMBRANE; RECYCLING ENDOSOMES; CYTOPLASMIC DOMAIN; EXOCYTIC PATHWAY; LIVING CELLS; N-GLYCANS	Epithelial cell polarity depends on mechanisms for targeting proteins to different plasma membrane domains. Here, we dissect the pathway for apical delivery of several raft-associated, glycosyl phosphatidylinositol (GPI)-anchored proteins in polarized MDCK cells using live-cell imaging and selective inhibition of apical or basolateral exocytosis. Rather than trafficking directly from the trans-Golgi network (TGN) to the apical plasma membrane as previously thought, the GPI-anchored proteins followed an indirect, transcytotic route. They first exited the TGN in membrane-bound carriers that also contained basolateral cargo, although the two cargoes were laterally segregated. The carriers were then targeted to and fused with a zone of lateral plasma membrane adjacent to tight junctions that is known to contain the exocyst. Thereafter, the GPI-anchored proteins, but not basolateral cargo, were rapidly internalized, together with endocytic tracer, into clathrin-free transport intermediates that transcytosed to the apical plasma membrane. Thus, apical sorting of these GPI-anchored proteins occurs at the plasma membrane, rather than at the TGN.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	jlippin@helix.nih.gov		Polishchuk, Roman/0000-0002-7698-1955	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001609] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001609] Funding Source: NIH RePORTER; Telethon [GTF03006] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon)		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Ihrke G, 1995, Prog Liver Dis, V13, P63; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1997, J CELL SCI, V110, P3001; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Maier O, 2001, SEMIN CELL DEV BIOL, V12, P149, DOI 10.1006/scdb.2000.0232; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Newman TM, 1996, EUR J CELL BIOL, V70, P209; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; PANG S, IN RPESS J CELL SCI; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Traub LM, 2003, NAT CELL BIOL, V5, P1045, DOI 10.1038/ncb1203-1045; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	50	167	175	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					297	307		10.1038/ncb1109	http://dx.doi.org/10.1038/ncb1109			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048124				2022-12-25	WOS:000220587600011
J	Harrington, EA; Bebbington, D; Moore, J; Rasmussen, RK; Ajose-Adeogun, AO; Nakayama, T; Graham, JA; Demur, C; Hercend, T; Diu-Hercend, A; Su, M; Golec, JMC; Miller, KM				Harrington, EA; Bebbington, D; Moore, J; Rasmussen, RK; Ajose-Adeogun, AO; Nakayama, T; Graham, JA; Demur, C; Hercend, T; Diu-Hercend, A; Su, M; Golec, JMC; Miller, KM			VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo	NATURE MEDICINE			English	Article							PROTEIN-KINASE; A KINASE; MITOTIC PHOSPHORYLATION; COLORECTAL CANCERS; MAMMALIAN-CELLS; CLEAVAGE FURROW; BUDDING YEAST; HISTONE H3; B KINASE; M-PHASE	The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis. Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis. Here we report the discovery of a highly potent and selective small-molecule inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types. This compound causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.	Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; INSERM, Inst Claudis Regaud, F-31052 Toulouse, France	Vertex Pharmaceuticals; Vertex Pharmaceuticals; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Miller, KM (corresponding author), Vertex Pharmaceut Europe Ltd, 88 Milton Pk, Abingdon OX14 4RY, Oxon, England.	karen_miller@vrtx.com						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; MIHOSHIMA Y, 2003, DEV CELL, V4, P549; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pitt A.M., 1996, J BIOMOL SCREEN, V1, P47, DOI [10.1177/108705719600100115, DOI 10.1177/108705719600100115]; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sawyers CL, 2002, CANCER CELL, V1, P413, DOI 10.1016/S1535-6108(02)00080-6; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; WHEATLEY SP, IN PRESS J BIOL CHEM; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	46	845	962	2	41	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					262	267		10.1038/nm1003	http://dx.doi.org/10.1038/nm1003			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981513				2022-12-25	WOS:000189297700037
J	Ichikawa, M; Asai, T; Saito, T; Yamamoto, G; Seo, S; Yamazaki, I; Yamagata, T; Mitani, K; Chiba, S; Hirai, H; Ogawa, S; Kurokawa, M				Ichikawa, M; Asai, T; Saito, T; Yamamoto, G; Seo, S; Yamazaki, I; Yamagata, T; Mitani, K; Chiba, S; Hirai, H; Ogawa, S; Kurokawa, M			AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis	NATURE MEDICINE			English	Article							ACUTE-LEUKEMIA; MURINE MODEL; GENE; IDENTIFICATION; AML1-ETO; GATA-1; LEUKEMOGENESIS; ESTABLISHES; EXPRESSION; DEVELOP	Embryonic development of multilineage hematopoiesis requires the precisely regulated expression of lineage-specific transcription factors, including AML-1 (encoded by Runx1; also known as CBFA-2 or PEBP-2alphaB)(1-5). In vitro studies and findings in human diseases, including leukemias(6,7), myelodysplastic syndromes 8 and familial platelet disorder with predisposition to acute myeloid leukemia (AML)(9), suggest that AML-1 has a pivotal role in adult hematopoiesis. However, this role has not been fully uncovered in vivo because of the embryonic lethality of Runx1 knockout in mice. Here we assess the requirement of AML-1/Runx1 in adult hematopoiesis using an inducible gene-targeting method 10. In the absence of AML-1, hematopoietic progenitors were fully maintained with normal myeloid cell development. However, AML-1-deficient bone marrow showed inhibition of megakaryocytic maturation, increased hematopoietic progenitor cells and defective T- and B-lymphocyte development. AML-1 is thus required for maturation of megakaryocytes and differentiation of T and B cells, but not for maintenance of hematopoietic stem cells (HSCs) in adult hematopoiesis.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Regenerat Med Hematopoiesis, Bunkyo Ku, Tokyo 1138655, Japan; Inoue Mem Hosp, Dept Clin Lab & Pathol, Chuo Ku, Chiba 2600027, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; University of Tokyo; Dokkyo Medical University	Ogawa, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	sogawa-tky@umin.ac.jp	Ogawa, Seishi/AAE-7088-2019	Ichikawa, Motoshi/0000-0001-6497-0848				BRETONGORIUS J, 1978, BLOOD, V51, P45; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; Kaushansky K, 1999, BIOESSAYS, V21, P353, DOI 10.1002/(SICI)1521-1878(199904)21:4<353::AID-BIES12>3.0.CO;2-P; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Rhoades KL, 2000, BLOOD, V96, P2108; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x	29	467	475	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					299	304		10.1038/nm997	http://dx.doi.org/10.1038/nm997			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14966519				2022-12-25	WOS:000189297700043
J	Leslie, AJ; Pfafferott, KJ; Chetty, P; Draenert, R; Addo, MM; Feeney, M; Tang, Y; Holmes, EC; Allen, T; Prado, JG; Altfeld, M; Brander, C; Dixon, C; Ramduth, D; Jeena, P; Thomas, SA; St John, A; Roach, TA; Kupfer, B; Luzzi, G; Edwards, A; Taylor, G; Lyall, H; Tudor-Williams, G; Novelli, V; Martinez-Picado, J; Kiepiela, P; Walker, BD; Goulder, PJR				Leslie, AJ; Pfafferott, KJ; Chetty, P; Draenert, R; Addo, MM; Feeney, M; Tang, Y; Holmes, EC; Allen, T; Prado, JG; Altfeld, M; Brander, C; Dixon, C; Ramduth, D; Jeena, P; Thomas, SA; St John, A; Roach, TA; Kupfer, B; Luzzi, G; Edwards, A; Taylor, G; Lyall, H; Tudor-Williams, G; Novelli, V; Martinez-Picado, J; Kiepiela, P; Walker, BD; Goulder, PJR			HIV evolution: CTL escape mutation and reversion after transmission	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOTOXIC T-LYMPHOCYTES; PHYLOGENETIC ANALYSIS; GENETIC-VARIATION; HLA-B; RESPONSES; CELL; REPLICATION; AIDS; GAG	Within-patient HIV evolution reflects the strong selection pressure driving viral escape from cytotoxic T-lymphocyte (CTL) recognition. Whether this intrapatient accumulation of escape mutations translates into HIV evolution at the population level has not been evaluated. We studied over 300 patients drawn from the B- and C-clade epidemics, focusing on human leukocyte antigen (HLA) alleles HLA-B57 and HLA-B5801, which are associated with long-term HIV control and are therefore likely to exert strong selection pressure on the virus. The CTL response dominating acute infection in HLAB57/5801-positive subjects drove positive selection of an escape mutation that reverted to wild-type after transmission to HLA-B57/5801-negative individuals. A second escape mutation within the epitope, by contrast, was maintained after transmission. These data show that the process of accumulation of escape mutations within HIV is not inevitable. Complex epitope- and residue-specific selection forces, including CTL-mediated positive selection pressure and virus-mediated purifying selection, operate in tandem to shape HIV evolution at the population level.	Univ Oxford, Fuffield Dept Med, Dept Pediat, Oxford OX1 3SY, England; Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa; Partners AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Univ Oxford, Dept Zool, Oxford OX1 3SY, England; Hosp Badalona Germans Trias & Pujol, irsiCaixa Fdn, Barcelona 08916, Spain; Queen Elizabeth II Hosp, Bridgetown, Barbados; Univ Bonn, D-53105 Bonn, Germany; High Wycombe Gen Hosp, Dept Genitourinary Med, High Wycombe HP11 2TT, Bucks, England; Radcliffe Infirm Hosp, Harrison Clin, Oxford OX2 6HE, England; St Marys Hosp, Imperial Coll Sch Med, London W2 1NY, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of Oxford; University of Kwazulu Natal; Harvard University; Harvard Medical School; University of Oxford; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; University of Bonn; Radcliffe Infirmary; Imperial College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Goulder, PJR (corresponding author), Univ Oxford, Fuffield Dept Med, Dept Pediat, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England.	philip.goulder@ndm.ox.ac.uk	Altfeld, Marcus/AAE-7306-2019; Addo, Marylyn M./GNP-2548-2022; Holmes, Edward/GVR-9499-2022; Allen, Todd/F-5473-2011; Holmes, Edward/Y-2789-2019; Prado, Julia Garcia/R-7177-2019; Martinez-Picado, Javier/G-5507-2012	Altfeld, Marcus/0000-0001-5972-2997; Allen, Todd/0000-0002-6609-1318; Holmes, Edward/0000-0001-9596-3552; Prado, Julia Garcia/0000-0002-5439-4645; Martinez-Picado, Javier/0000-0002-4916-2129; leslie, alasdair/0000-0003-2538-6467; Addo, Marylyn/0000-0003-2836-9224; Brander, Christian/0000-0002-0548-5778	NIAID NIH HHS [AI46995-01A1, N01-AI-15442] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015442, R01AI046995] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Barber LD, 1997, J IMMUNOL, V158, P1660; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen J, 2003, SCIENCE, V299, P1505, DOI 10.1126/science.299.5612.1505; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; FRAHM N, IN PRESS J VIROL; Furuta RA, 1997, FEBS LETT, V415, P231, DOI 10.1016/S0014-5793(97)01132-0; Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Hayman A, 2001, AIDS RES HUM RETROV, V17, P689, DOI 10.1089/088922201750236960; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASPER P, 1995, AIDS RES HUM RETROV, V11, P1197, DOI 10.1089/aid.1995.11.1197; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Klenerman P, 2002, CURR OPIN MICROBIOL, V5, P408, DOI 10.1016/S1369-5274(02)00339-9; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; Krogstad P, 2002, VIROLOGY, V294, P282, DOI 10.1006/viro.2001.1319; McMichael A, 2002, SCIENCE, V296, P1410, DOI 10.1126/science.1072492; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002; Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002; O'Brien SJ, 2001, TRENDS MOL MED, V7, P379, DOI 10.1016/S1471-4914(01)02131-1; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Ross HA, 2002, J VIROL, V76, P11715, DOI 10.1128/JVI.76.22.11715-11720.2002; Singh AR, 2001, VIROLOGY, V279, P257, DOI 10.1006/viro.2000.0706; Swofford DL, 2002, PAUL PHYLOGENETIC AN; Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002; Yang ZH, 2000, J MOL EVOL, V51, P423, DOI 10.1007/s002390010105; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002	45	667	696	0	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					282	289		10.1038/nm992	http://dx.doi.org/10.1038/nm992			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14770175				2022-12-25	WOS:000189297700040
J	Dufresne, G; Duval, M				Dufresne, G; Duval, M			Genetic sequences: how are they patented?	NATURE BIOTECHNOLOGY			English	Editorial Material								A survey reveals that the way in which genetic sequences are claimed in granted patents are heterogeneous and imprecise, which may lead to questions regarding their validity.	IPSEN, Corp Intellectual Property Dept, F-75016 Paris, France; Pfizer Global Res & Dev, Gen & Prote Sci Dept, Groton, CT 06340 USA	Ipsen; Pfizer	Dufresne, G (corresponding author), IPSEN, Corp Intellectual Property Dept, 24 Rue Erlanger, F-75016 Paris, France.	manuel.duval@pfizer.com	Duval, Manuel X/D-6892-2013; Duval, Manuel/AAQ-6431-2020	Duval, Manuel X/0000-0001-5395-4543; Duval, Manuel/0000-0001-5395-4543				CACCONE A, 1988, J MOL EVOL, V27, P212, DOI 10.1007/BF02100076; Doyle JJ, 2000, PLANT MOL BIOL, V42, P1, DOI 10.1023/A:1006349518932; Dufresne G, 2002, NAT BIOTECHNOL, V20, P1269, DOI 10.1038/nbt1202-1269; Durbin R., 1998, BIOL SEQUENCE ANAL P; Grisham J, 2000, NAT BIOTECHNOL, V18, P921, DOI 10.1038/79381; Walker BW, 2003, NAT BIOTECHNOL, V21, P943, DOI 10.1038/nbt0803-943; 6319675; 6589767; 6586202; 6590077; 668351	11	6	11	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					231	232		10.1038/nbt0204-231	http://dx.doi.org/10.1038/nbt0204-231			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14755293				2022-12-25	WOS:000188730500025
J	Gardell, LR; Wang, RZ; Ehrenfels, C; Ossipov, MH; Rossomando, AJ; Miller, S; Buckley, C; Cai, AK; Tse, A; Foley, SF; Gong, BJ; Walus, L; Carmillo, P; Worley, D; Huang, C; Engber, T; Pepinsky, B; Cate, RL; Vanderah, TW; Lai, J; Sah, DWY; Porreca, F				Gardell, LR; Wang, RZ; Ehrenfels, C; Ossipov, MH; Rossomando, AJ; Miller, S; Buckley, C; Cai, AK; Tse, A; Foley, SF; Gong, BJ; Walus, L; Carmillo, P; Worley, D; Huang, C; Engber, T; Pepinsky, B; Cate, RL; Vanderah, TW; Lai, J; Sah, DWY; Porreca, F			Multiple actions of systemic artemin in experimental neuropathy	NATURE MEDICINE			English	Article							EXCITATORY TRANSMITTER RELEASE; NEUROTROPHIC FACTOR; RECEPTOR COMPONENTS; SPINAL DYNORPHIN; SENSORY NEURONS; TYROSINE KINASE; NERVE INJURY; CHRONIC PAIN; GDNF-FAMILY; SUBSTANCE-P	The clinical management of neuropathic pain is particularly challenging. Current therapies for neuropathic pain modulate nerve impulse propagation or synaptic transmission; these therapies are of limited benefit and have undesirable side effects. Injuries to peripheral nerves result in a host of pathophysiological changes associated with the sustained expression of abnormal pain. Here we show that systemic, intermittent administration of artemin produces dose- and time-related reversal of nerve injury-induced pain behavior, together with partial to complete normalization of multiple morphological and neurochemical features of the injury state. These effects of artemin were sustained for at least 28 days. Higher doses of artemin than those completely reversing experimental neuropathic pain did not elicit sensory or motor abnormalities. Our results indicate that the behavioral symptoms of neuropathic pain states can be treated successfully, and that partial to complete reversal of associated morphological and neurochemical changes is achievable with artemin.	Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA; Biogen Inc, Cambridge, MA 02142 USA	University of Arizona; University of Arizona Health Sciences; Biogen	Porreca, F (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA.	frankp@u.arizona.edu						Acheson A, 1996, PHILOS T ROY SOC B, V351, P417, DOI 10.1098/rstb.1996.0037; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bennett DLH, 2000, J NEUROSCI, V20, P427, DOI 10.1523/JNEUROSCI.20-01-00427.2000; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Burgess SE, 2002, J NEUROSCI, V22, P5129, DOI 10.1523/JNEUROSCI.22-12-05129.2002; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen JJ, 1996, PEPTIDES, V17, P31, DOI 10.1016/0196-9781(95)02091-8; DEVOR M, 1999, TXB PAIN, P129; Ehrenfels CW, 1999, DEV GENET, V24, P263, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<263::AID-DVG9>3.0.CO;2-D; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Gardell LR, 2003, J NEUROSCI, V23, P8370; Gardell LR, 2002, J NEUROSCI, V22, P6747; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Lai J, 2002, PAIN, V95, P143, DOI 10.1016/S0304-3959(01)00391-8; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu XG, 2000, PAIN, V84, P309, DOI 10.1016/S0304-3959(99)00211-0; Malan TP, 2000, PAIN, V86, P185, DOI 10.1016/S0304-3959(00)00243-8; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; MCQUAY HJ, 1992, ANAESTHESIA, V47, P757, DOI 10.1111/j.1365-2044.1992.tb03253.x; Merskey H., 1994, CLASSIFICATION CHRON, P40; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MOLLIVER DC, 1995, J COMP NEUROL, V361, P404, DOI 10.1002/cne.903610305; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Nichols ML, 1999, SCIENCE, V286, P1558, DOI 10.1126/science.286.5444.1558; Orozco OE, 2001, EUR J NEUROSCI, V13, P2177, DOI 10.1046/j.0953-816x.2001.01596.x; Ossipov MH, 2001, PROG PAIN RES MANAG, V21, P107; Ossipov MH, 2002, J NEUROSCI, V22, P9858; Payne R., 1986, CLIN J PAIN, V2, P59; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Rose MA, 2002, ANAESTHESIA, V57, P451, DOI 10.1046/j.0003-2409.2001.02399.x; Rosenblad C, 2000, MOL CELL NEUROSCI, V15, P199, DOI 10.1006/mcne.1999.0817; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21-05-01779.2001; Widenfalk J, 1998, EUR J NEUROSCI, V10, P1508, DOI 10.1046/j.1460-9568.1998.00192.x; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502; Wu G, 2001, J NEUROSCI, V21	50	122	140	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2003	9	11					1383	1389		10.1038/nm944	http://dx.doi.org/10.1038/nm944			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528299				2022-12-25	WOS:000186319700028
J	Rubio, V; Stuge, TB; Singh, N; Betts, MR; Weber, JS; Roederer, M; Lee, PP				Rubio, V; Stuge, TB; Singh, N; Betts, MR; Weber, JS; Roederer, M; Lee, PP			Ex vivo identification, isolation and analysis of tumor-cytolytic T cells	NATURE MEDICINE			English	Article							FUNCTIONAL AVIDITY; MULTIPEPTIDE VACCINE; METASTATIC MELANOMA; CYTOKINE PRODUCTION; TCR; LYMPHOCYTES; TETRAMERS; ESCAPE; CTL; SELECTION	We isolated pure, viable populations of tumor-cytolytic T cells directly from patient blood samples using flow cytometric quantification of the surface mobilization of CD107a-an integral membrane protein in cytolytic granules-as a marker for degranulation after tumor stimulation. We show that tumor-cytolytic T cells are indeed elicited in patients after cancer vaccination, and that tumor reactivity is strongly correlated with efficient T-cell recognition of peptide-bearing targets. We combined CD107a mobilization with peptide-major histocompatibility complex (P-MHC) tetramer staining to directly correlate antigen specificity and cytolytic ability on a single-cell level. This showed that tumor-cytolytic T cells with high recognition efficiency represent only a minority of peptide-specific T cells elicited in patients after heteroclitic peptide vaccination. We were also able to expand these cells to high numbers ex vivo while maintaining their cytolytic potential. These techniques will be useful not only for immune monitoring of cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion. The ability to rapidly identify and isolate tumor-cytolytic T cells would be very useful in cancer immunotherapy.	Stanford Univ, Dept Med, Stanford, CA 94305 USA; NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033 USA; NIAID, Immunotechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lee, PP (corresponding author), Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.		Roederer, Mario/G-1887-2011	Stuge, Tor B/0000-0002-6933-8419; Lee, Peter P./0000-0002-2660-4377	NCI NIH HHS [R01CA 090809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005020, Z01AI005020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; BETTS M, IN PRESS J IMMUNOL M; Cawthon AG, 2002, J IMMUNOL, V169, P3492, DOI 10.4049/jimmunol.169.7.3492; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Derby MA, 2001, INT IMMUNOL, V13, P817, DOI 10.1093/intimm/13.6.817; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dutoit V, 2002, J IMMUNOL, V168, P1167, DOI 10.4049/jimmunol.168.3.1167; Dutoit V, 2002, EUR J IMMUNOL, V32, P3285, DOI 10.1002/1521-4141(200211)32:11<3285::AID-IMMU3285>3.0.CO;2-9; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lee P, 2001, J CLIN ONCOL, V19, P3836, DOI 10.1200/JCO.2001.19.18.3836; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214; Margulies DH, 2001, NAT IMMUNOL, V2, P669, DOI 10.1038/90601; Molldrem JJ, 2003, J CLIN INVEST, V111, P639, DOI 10.1172/JCI200316398; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Oh S, 2003, J IMMUNOL, V170, P2523, DOI 10.4049/jimmunol.170.5.2523; Slifka MK, 2001, NAT IMMUNOL, V2, P711, DOI 10.1038/90650; Snyder JE, 2003, NAT MED, V9, P231, DOI 10.1038/nm821; Tomaru U, 2003, NAT MED, V9, P469, DOI 10.1038/nm845; Weber J, 2003, CANCER-AM CANCER SOC, V97, P186, DOI 10.1002/cncr.11045; Whiteside TL, 2003, CLIN CANCER RES, V9, P641; Yee C, 1999, J IMMUNOL, V162, P2227; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	26	329	352	1	21	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1377	1382		10.1038/nm942	http://dx.doi.org/10.1038/nm942			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528297				2022-12-25	WOS:000186319700027
J	Brewer, JA; Khor, B; Vogt, SK; Muglia, LM; Fujiwara, H; Haegele, KE; Sleckman, BP; Muglia, LJ				Brewer, JA; Khor, B; Vogt, SK; Muglia, LM; Fujiwara, H; Haegele, KE; Sleckman, BP; Muglia, LJ			T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR MONOCLONAL-ANTIBODY; CYCLOOXYGENASE-2 INHIBITORS; THYMOCYTE DEVELOPMENT; LYMPHOCYTES; EXPRESSION; RELEASE; MOUSE; INTERLEUKIN-6; SELECTION	Glucocorticoids, acting through the glucocorticoid receptor, potently modulate immune function and are a mainstay of therapy for treatment of inflammatory conditions, autoimmune diseases, leukemias and lymphomas(1). Moreover, removal of systemic glucocorticoids, by adrenalectomy in animal models or adrenal insufficiency in humans, has shown that endogenous glucocorticoid production is required for regulation of physiologic immune responses(2). These effects have been attributed to suppression of cytokines, although the crucial cellular and molecular targets remain unknown(3). In addition, considerable controversy remains as to whether glucocorticoids are required for thymocyte development(4-7). To assess the role of the glucocorticoid receptor in immune system development and function, we generated T-cell-specific glucocorticoid receptor knockout mice. Here we show that the T-cell is a critical cellular target of glucocorticoid receptor signaling, as immune activation in these mice resulted in significant mortality. This lethal activation is rescued by cyclooxygenase-2 (COX-2) inhibition but not steroid administration or cytokine neutralization. These studies indicate that glucocorticoid receptor suppression of COX-2 is crucial for curtailing lethal immune activation, and suggest new therapeutic approaches for regulation of T-cell-mediated inflammatory diseases.	Washington Univ, Sch Med, St Louis, MO 63110 USA; Pfizer Inc, Chesterfield, MO 63017 USA	Washington University (WUSTL); Pfizer	Muglia, LJ (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.		Brewer, Judson/K-2283-2019	Khor, Bernard/0000-0003-4689-5092				Ashwell JD, 2000, IMMUNOL TODAY, V21, P644, DOI 10.1016/S0167-5699(00)01758-8; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; CHARPENTIER B, 1992, TRANSPLANTATION, V54, P997, DOI 10.1097/00007890-199212000-00011; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Da Silva JAP, 1999, ANN NY ACAD SCI, V876, P102; FERRAN C, 1991, EUR J IMMUNOL, V21, P2349, DOI 10.1002/eji.1830211009; FERRAN C, 1990, TRANSPLANTATION, V50, P642, DOI 10.1097/00007890-199010000-00023; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Gross G, 2000, AM J PHYSIOL-REG I, V278, pR1415, DOI 10.1152/ajpregu.2000.278.6.R1415; Iniguez MA, 1999, J IMMUNOL, V163, P111; Jondal M, 2001, TRENDS IMMUNOL, V22, P185, DOI 10.1016/S1471-4906(01)01871-3; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Merger M, 2002, GUT, V51, P155, DOI 10.1136/gut.51.2.155; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; Muglia LJ, 2000, J CLIN INVEST, V105, P1269, DOI 10.1172/JCI5250; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2; SCOTT DE, 1990, J IMMUNOL, V145, P2183; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Vacchio MS, 1999, J IMMUNOL, V163, P1327; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9	25	105	110	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1318	1322		10.1038/nm895	http://dx.doi.org/10.1038/nm895			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12949501				2022-12-25	WOS:000185669700045
J	Gattone, VH; Wang, XF; Harris, PC; Torres, VE				Gattone, VH; Wang, XF; Harris, PC; Torres, VE			Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist	NATURE MEDICINE			English	Article							POLYCYSTIC KIDNEY-DISEASE; MEDULLARY COLLECTING DUCTS; M-1 CELLS; IN-VITRO; CAMP; PROTEIN; PROLIFERATION; NEPHRONOPHTHISIS; EXPRESSION; CA2+	The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct cysts(1,2). We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3',5'-cyclic monophosphate (cAMP) has a major role in cystogenesis(3,4), and the VPV2R is the major cAMP agonist in the collecting duct(5,6). OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.	Mayo Clin & Mayo Fdn, Div Nephrol, Rochester, MN 55905 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA	Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis	Gattone, VH (corresponding author), Mayo Clin & Mayo Fdn, Div Nephrol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; GABOW PA, 1989, KIDNEY INT, V35, P675, DOI 10.1038/ki.1989.38; Gattone VH, 1999, DEV GENET, V24, P309, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<309::AID-DVG14>3.0.CO;2-5; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; OHNISHI A, 1995, J PHARMACOL EXP THER, V272, P546; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF370, DOI 10.1152/ajprenal.2000.279.2.F370; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; VERANI RR, 1988, MODERN PATHOL, V1, P457; Wallace DP, 2001, AM J PHYSIOL-RENAL, V280, pF1019, DOI 10.1152/ajprenal.2001.280.6.F1019; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; WARD CJ, 2003, HUM MOL GENET   0812; Wong LL, 2001, CARDIOVASC RES, V51, P391, DOI 10.1016/S0008-6363(01)00315-7; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamaguchi T, 2002, J AM SOC NEPHROL, V13, p105A; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Yamaguchi T, 1997, AM J KIDNEY DIS, V30, P703, DOI 10.1016/S0272-6386(97)90496-0; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; Yasuda G, 1998, KIDNEY INT, V54, P80, DOI 10.1046/j.1523-1755.1998.00990.x; Zerres K, 1998, J MOL MED, V76, P303, DOI 10.1007/s001090050221	28	464	483	1	25	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1323	1326		10.1038/nm935	http://dx.doi.org/10.1038/nm935			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502283				2022-12-25	WOS:000185669700046
J	Lee, SH; Prince, JE; Rais, M; Kheradmand, F; Shardonofsky, F; Lu, HF; Beaudet, AL; Smith, CW; Soong, L; Corry, DB				Lee, SH; Prince, JE; Rais, M; Kheradmand, F; Shardonofsky, F; Lu, HF; Beaudet, AL; Smith, CW; Soong, L; Corry, DB			Differential requirement for CD 18 in T-helper effector homing	NATURE MEDICINE			English	Article							AIRWAY HYPERREACTIVITY; EXPERIMENTAL LEISHMANIASIS; INTERFERON-GAMMA; TH2 DEVELOPMENT; DEFICIENT MICE; MURINE MODEL; CELLS; ADHESION; EXPRESSION; INFLAMMATION	To understand the integrin requirements of T-helper (T-H) effector subsets, we investigated the contribution of CD18 (beta(2) integrin) to T(H)1 and T(H)2 function in vitro and in relevant disease models. CD18-deficient (Itgb2(-/-)) T cells showed largely normal in vitro function. Compared with wild-type mice, Itgb2(-/-) mice were better able to resolve Leishmania major infection and generated a superior T(H)1 immune response, as assessed from draining lymph nodes. In contrast, T(H)2-dependent allergic lung disease was markedly impaired in mutant mice. In both models, development of T(H)1 and T(H)2 cells in spleens was normal, but accumulation of T(H)2 (not T(H)1) cells at inflammatory sites was reduced. Thus, CD18 is selectively required for T(H)2, but not T(H)1, homing and has a minimal influence on T-effector development. These findings suggest a new integrin-based therapeutic approach in which the outcomes of diverse diseases may be favorably influenced by altering the homing of T(H)2 cells.	Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Corry, DB (corresponding author), Baylor Coll Med, Biol Inflammat Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.		Lee, Seung-Hyo/B-9922-2015	Lee, Seung-Hyo/0000-0003-0010-4072	NHLBI NIH HHS [F32-HL09657-02, HL64061-01, HL69585-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009657, R01HL069585, R01HL064061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abitorabi MA, 1996, J IMMUNOL, V156, P3111; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Brockdorff J, 1998, P NATL ACAD SCI USA, V95, P6959, DOI 10.1073/pnas.95.12.6959; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; CORRY DB, 1994, J IMMUNOL, V153, P4142; FISCHER H, 1992, J IMMUNOL, V148, P1993; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; GREEN JM, 1994, EUR J IMMUNOL, V24, P265, DOI 10.1002/eji.1830240141; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; KANEKO M, 1995, J IMMUNOL, V155, P2631; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PALLER AS, 1994, J AM ACAD DERMATOL, V31, P316, DOI 10.1016/S0190-9622(94)70162-8; SANDERS VM, 1986, J IMMUNOL, V137, P2395; Sasaki K, 2003, INT IMMUNOL, V15, P701, DOI 10.1093/intimm/dxg066; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schonlau F, 2000, EUR J IMMUNOL, V30, P2729, DOI 10.1002/1521-4141(200009)30:9&lt;2729::AID-IMMU2729&gt;3.0.CO;2-3; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Syrbe U, 1999, SPRINGER SEMIN IMMUN, V21, P263, DOI 10.1007/BF00812257; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Xu BH, 2003, J EXP MED, V197, P1255, DOI 10.1084/jem.20010685	37	25	26	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1281	1286		10.1038/nm932	http://dx.doi.org/10.1038/nm932			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502280				2022-12-25	WOS:000185669700039
J	Wang, L; McDonnell, SK; Cunningham, JM; Hebbring, S; Jacobsen, SJ; Cerhan, JR; Slager, SL; Blute, ML; Schaid, DJ; Thibodeau, SN				Wang, L; McDonnell, SK; Cunningham, JM; Hebbring, S; Jacobsen, SJ; Cerhan, JR; Slager, SL; Blute, ML; Schaid, DJ; Thibodeau, SN			No association of germline alteration of MSR1 with prostate cancer risk	NATURE GENETICS			English	Article							SCAVENGER RECEPTOR-1 GENE; SEQUENCE VARIANTS	The macrophage scavenger receptor 1 gene (MSR1) was recently identified as a candidate susceptibility gene for hereditary prostate cancer and as a risk factor for sporadic prostate cancer. To confirm these findings, we screened MSR1 for germline mutations among individuals with familial prostate cancer and tested gene variants for associations in both sporadic and familial prostate cancer. Our results do not support MSR1 as a risk factor for prostate cancer.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Thibodeau, SN (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 920 Hilton Bldg,200 1st St SW, Rochester, MN 55905 USA.		Slager, Susan L./B-6756-2009	Jacobsen, Steven/0000-0002-8174-8533; Cerhan, James/0000-0002-7482-178X; McDonnell, Shannon/0000-0001-6201-369X				Ronaghi M, 2001, GENOME RES, V11, P3, DOI 10.1101/gr.11.1.3; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Wang L, 2002, AM J HUM GENET, V71, P116, DOI 10.1086/341281; Xu JF, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu JF, 2003, AM J HUM GENET, V72, P208, DOI 10.1086/345802	6	44	48	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					128	129		10.1038/ng1239	http://dx.doi.org/10.1038/ng1239			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12958598				2022-12-25	WOS:000185625300008
J	Anes, E; Kuhnel, MP; Bos, E; Moniz-Pereira, J; Habermann, A; Griffiths, G				Anes, E; Kuhnel, MP; Bos, E; Moniz-Pereira, J; Habermann, A; Griffiths, G			Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria	NATURE CELL BIOLOGY			English	Article							SIGNAL-TRANSDUCTION; REACTIVE OXYGEN; FATTY-ACIDS; TUBERCULOSIS; MACROPHAGES; RESISTANCE; SPHINGOSINE-1-PHOSPHATE; ACIDIFICATION; MODULATION; MEMBRANES	Pathogenic mycobacteria such as Mycobacterium tuberculosis and Mycobacterium avium facilitate disease by surviving intracellularly within a potentially hostile environment: the macrophage phagosome. They inhibit phagosome maturation processes, including fusion with lysosomes, acidification and, as shown here, membrane actin assembly. An in vitro assay developed for latex bead phagosomes (LBPs) provided insights into membrane signalling events that regulate phagosome actin assembly, a process linked to membrane fusion. Different lipids were found to stimulate or inhibit actin assembly by LBPs and mycobacterial phagosomes in vitro. In addition, selected lipids activated actin assembly and phagosome maturation in infected macrophages, resulting in a significant killing of M. tuberculosis and M. avium. In contrast, the polyunsaturated sigma-3 lipids behaved differently and stimulated pathogen growth. Thus, lipids can be involved in both stimulatory and inhibitory signalling networks in the phagosomal membrane.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Lisbon, Fac Pharm, Mol Pathogenesis Ctr, P-1600085 Lisbon, Portugal	European Molecular Biology Laboratory (EMBL); Universidade de Lisboa	Griffiths, G (corresponding author), European Mol Biol Lab, Postfach 102209, D-69117 Heidelberg, Germany.		iMed.ULisboa, M2B/B-5277-2014; iMed.ULisboa, HPI/B-4239-2014; Anes, Elsa/K-3124-2013	iMed.ULisboa, M2B/0000-0002-1245-3715; iMed.ULisboa, HPI/0000-0001-5934-0198; Anes, Elsa/0000-0001-5934-0198; Habermann, Anja/0000-0003-3686-9050; /0000-0002-8779-2017				Akaki T, 2000, CLIN EXP IMMUNOL, V121, P302, DOI 10.1046/j.1365-2249.2000.01298.x; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; Barry CE, 2001, TRENDS MICROBIOL, V9, P237, DOI 10.1016/S0966-842X(01)02018-2; Blackwell JM, 2001, CELL MICROBIOL, V3, P773, DOI 10.1046/j.1462-5822.2001.00150.x; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; CHANG HR, 1992, METABOLISM, V41, P1, DOI 10.1016/0026-0495(92)90181-9; Clemens DL, 1996, TRENDS MICROBIOL, V4, P113, DOI 10.1016/0966-842X(96)81528-9; Defacque H, 2000, CYTOMETRY, V41, P46, DOI 10.1002/1097-0320(20000901)41:1<46::AID-CYTO7>3.0.CO;2-F; Defacque H, 2002, MOL BIOL CELL, V13, P1190, DOI 10.1091/mbc.01-06-0314; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Emans N, 1996, FEBS LETT, V398, P37, DOI 10.1016/S0014-5793(96)01213-6; Fischer K, 2001, J IMMUNOL, V167, P2187, DOI 10.4049/jimmunol.167.4.2187; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Guerin I, 2000, INFECT IMMUN, V68, P2655, DOI 10.1128/IAI.68.5.2655-2662.2000; Haas A, 1998, MOL MEMBR BIOL, V15, P103, DOI 10.3109/09687689809074522; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Kaplan GJ, 1970, AM REV RESPIR DIS, V105, P920; Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631; Kuehnel MP, 2001, CELL MICROBIOL, V3, P551, DOI 10.1046/j.1462-5822.2001.00139.x; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Paul KP, 1997, METABOLISM, V46, P619, DOI 10.1016/S0026-0495(97)90003-2; Pieters J, 2001, MICROBES INFECT, V3, P249, DOI 10.1016/S1286-4579(01)01376-4; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Sturgill-Koszycki S, 1997, ELECTROPHORESIS, V18, P2558, DOI 10.1002/elps.1150181411; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Tjelle TE, 2000, BIOESSAYS, V22, P255, DOI 10.1002/(SICI)1521-1878(200003)22:3<255::AID-BIES7>3.0.CO;2-R; Via LE, 1998, J CELL SCI, V111, P897; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691	41	207	213	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2003	5	9					793	802		10.1038/ncb1036	http://dx.doi.org/10.1038/ncb1036			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	716YZ	12942085				2022-12-25	WOS:000185059000012
J	Flick, K; Ouni, I; Wohlschlegel, JA; Capati, C; McDonald, WH; Yates, JR; Kaiser, P				Flick, K; Ouni, I; Wohlschlegel, JA; Capati, C; McDonald, WH; Yates, JR; Kaiser, P			Proteolysis-independent regulation of the transcription factor Met4 by a single Lys 48-linked ubiquitin chain	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; MULTIUBIQUITIN CHAIN; PROTEIN-DEGRADATION; SULFUR METABOLISM; ACTIVATOR MET4; SIGNAL; IDENTIFICATION; COMPLEXES; SYSTEM	The ubiquitin ligase SCFMet30 is required for cell cycle progression in budding yeast. The critical function of SCFMet30 is inactivation of the transcriptional activator Met4. Here we show that a single ubiquitin chain is attached to Met4 through lysine at position 163. Inhibition of Met4 ubiquitination by mutating lysine to arginine at this position constitutively activates, but does not stabilize, Met4. This supports a proteolysis-independent role of Cdc34-SCFMet30-catalysed Met4 ubiquitination. Surprisingly, the ubiquitin chain attached to Met4 is linked through Lys 48 in ubiquitin, a ubiquitin chain structure that is usually required for substrate targeting to the 26S proteasome. These results suggest that Lys 48-linked ubiquitin chains can have a regulatory role independent of proteolysis.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute	Kaiser, P (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	pkaiser@uci.edu	McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X				CHEREST H, 1992, GENETICS, V130, P51; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Guthrie C, 1991, GUIDE YEAST GENETICS; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597	32	125	136	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					634	641		10.1038/ncb1143	http://dx.doi.org/10.1038/ncb1143			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15208638				2022-12-25	WOS:000222434900018
J	Woodley, DT; Keene, DR; Atha, T; Huang, Y; Lipman, K; Li, W; Chen, M				Woodley, DT; Keene, DR; Atha, T; Huang, Y; Lipman, K; Li, W; Chen, M			Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa	NATURE MEDICINE			English	Article							EXPRESSION; FORMS	Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechano-bullous disorders that are caused by mutations in the type VII collagen gene and for which ex vivo gene therapy has been considered. To develop a simpler approach for treating DEB, we evaluated the feasibility of protein-based therapy by intradermally injecting human recombinant type VII collagen into mouse skin and a DEB human skin equivalent transplanted onto mice. The injected collagen localized to the basement membrane zone of both types of tissues, was organized into human anchoring fibril structures and reversed the features of DEB disease in the DEB skin equivalent.	Univ So Calif, Div Dermatol, Dept Med, Los Angeles, CA 90033 USA; Shriners Hosp Children, Portland, OR 97201 USA	University of Southern California	Chen, M (corresponding author), Univ So Calif, Div Dermatol, Dept Med, CRL 204,1303 Mission Rd, Los Angeles, CA 90033 USA.	chenm@usc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625, R01AR047981] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR33625, R01 AR47981] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRIGGAMAN RA, 1975, J INVEST DERMATOL, V65, P71, DOI 10.1111/1523-1747.ep12598050; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen M, 2002, NAT GENET, V32, P670, DOI 10.1038/ng1041; Chen M, 1997, J INVEST DERMATOL, V108, P68, DOI 10.1111/1523-1747.ep12285634; Chen M, 2002, J BIOL CHEM, V277, P2118, DOI 10.1074/jbc.M108779200; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KIM YH, 1992, J INVEST DERMATOL, V98, P191, DOI 10.1111/1523-1747.ep12555849; Lin AN, 1992, EPIDERMOLYSIS BULLOS; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Ortiz-Urda S, 2002, NAT MED, V8, P1166, DOI 10.1038/nm766; Ortiz-Urda S, 2003, J CLIN INVEST, V111, P251, DOI 10.1172/JCI200317193; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; UITTO J, 1994, ARCH DERMATOL RES, V287, P16, DOI 10.1007/BF00370713; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; Woodley DT, 2003, J INVEST DERMATOL, V121, P1021, DOI 10.1046/j.1523-1747.2003.12571.x	15	97	108	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2004	10	7					693	695		10.1038/nm1063	http://dx.doi.org/10.1038/nm1063			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835DM	15195089				2022-12-25	WOS:000222460400022
J	Jang, YY; Collector, MI; Baylin, SB; Diehl, AM; Sharkis, SJ				Jang, YY; Collector, MI; Baylin, SB; Diehl, AM; Sharkis, SJ			Hematopoietic stem cells convert into liver cells within days without fusion	NATURE CELL BIOLOGY			English	Article							BONE-MARROW-CELLS; HEREDITARY TYROSINEMIA; IN-VIVO; HEPATOCYTES; DIFFERENTIATE; ORIGIN; PLASTICITY; DERIVATION; MICE	Both plasticity and cell fusion have been suggested to have a role in germ-layer switching(1-7). To understand the mechanisms underlying cell fate changes, we have examined a highly enriched population of hematopoietic stem cells (HSCs)(8-10) in vitro or in vivo in response to injury for liver-specific phenotypic and functional changes. Here we show that HSCs become liver cells when cocultured with injured liver separated by a barrier. Chromosomal analyses and tissue-specific gene and/or protein expression show that microenvironmental cues rather than fusion are responsible for conversion in vitro. We transplanted HSCs into liver-injured mice and observed that HSCs convert into viable hepatocytes with increasing injury. Notably, liver function was restored 2-7 d after transplantation. We conclude that HSCs contribute to the regeneration of injured liver by converting into functional hepatocytes without fusion.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Sharkis, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	ssharkis@jhmi.edu						ALISON MR, 2001, NATURE, V414, P10; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; JAMES M, 2003, NATURE CELL BIOL, V5, P959; Jang YY, 2002, BLOOD, V100, p514A; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lanzkron SM, 1999, BLOOD, V93, P1916, DOI 10.1182/blood.V93.6.1916.406k15_1916_1921; Masuya M, 2003, BLOOD, V101, P2215, DOI 10.1182/blood-2002-04-1076; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Moore BE, 2003, LEUKEMIA, V17, P1205, DOI 10.1038/sj.leu.2402956; Newsome PN, 2003, GASTROENTEROLOGY, V124, P1891, DOI 10.1016/S0016-5085(03)00401-3; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Rajagopal J, 2003, SCIENCE, V299, P363; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Srivatsa B, 2001, LANCET, V358, P2034, DOI 10.1016/S0140-6736(01)07099-4; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Theise ND, 2003, SCIENCE, V299, p1317A, DOI 10.1126/science.1078412; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; WILSON KS, 1994, PEDIATR PATHOL, V14, P1055, DOI 10.3109/15513819409037702; Yan F, 2003, EXP HEMATOL, V31, P56, DOI 10.1016/S0301-472X(02)01012-3; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	34	447	503	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					532	539		10.1038/ncb1132	http://dx.doi.org/10.1038/ncb1132			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15133469				2022-12-25	WOS:000221759400013
J	Kolonin, MG; Saha, PK; Chan, L; Pasqualini, R; Arap, W				Kolonin, MG; Saha, PK; Chan, L; Pasqualini, R; Arap, W			Reversal of obesity by targeted ablation of adipose tissue	NATURE MEDICINE			English	Article							PHAGE DISPLAY; IN-VIVO; DIABETES-MELLITUS; INDUCED APOPTOSIS; BLOOD-VESSELS; ANGIOGENESIS; PROHIBITIN; PROTEINS; RECEPTOR; VASCULATURE	Obesity is an increasingly prevalent human condition in developed societies. Despite major progress in the understanding of the molecular mechanisms leading to obesity, no safe and effective treatment has yet been found. Here, we report an antiobesity therapy based on targeted induction of apoptosis in the vasculature of adipose tissue. We used in vivo phage display to isolate a peptide motif (sequence CKGGRAKDC) that homes to white fat vasculature. We show that the CKGGRAKDC peptide associates with prohibitin, a multifunctional membrane protein, and establish prohibitin as a vascular marker of adipose tissue. Targeting a proapoptotic peptide to prohibitin in the adipose vasculature caused ablation of white fat. Resorption of established white adipose tissue and normalization of metabolism resulted in rapid obesity reversal without detectable adverse effects. Because prohibitin is also expressed in blood vessels of human white fat, this work may lead to the development of targeted drugs for treatment of obese patients.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org; warap@mdanderson.org		Kolonin, Mikhail/0000-0002-3743-7869	NCI NIH HHS [CA078512, CA90810, CA88106, CA90270, CA103042, CA82976] Funding Source: Medline; NHLBI NIH HHS [HL51586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA090810, R01CA088106, P50CA090270, R01CA078512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cinti S, 2000, Eat Weight Disord, V5, P132; Clapham JC, 2001, PHARMACOL THERAPEUT, V89, P81, DOI 10.1016/S0163-7258(00)00105-4; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Greene AK, 2003, ANN SURG, V237, P530, DOI 10.1097/00000658-200304000-00015; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Kolonin MG, 2002, P NATL ACAD SCI USA, V99, P13055, DOI 10.1073/pnas.162468499; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lamers MC, 1997, INT ARCH ALLERGY IMM, V113, P146, DOI 10.1159/000237530; LEIBEL RL, 1989, ANNU REV NUTR, V9, P417, DOI 10.1146/annurev.nu.09.070189.002221; LEIBOWITZ SF, 1995, OBES RES, V3, P573; Licinio J, 2004, P NATL ACAD SCI USA, V101, P4531, DOI 10.1073/pnas.0308767101; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; McConkey DJ, 1996, ONCOGENE, V13, P1693; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sumi T, 2001, INT J MOL MED, V8, P533; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87; Woods SC, 2000, NUTRITION, V16, P894, DOI 10.1016/S0899-9007(00)00454-8; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	43	431	496	1	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					625	632		10.1038/nm1048	http://dx.doi.org/10.1038/nm1048			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15133506				2022-12-25	WOS:000221759600028
J	Zhang, L; Wu, CL; Carta, R; Baggerly, K; Coombes, KR				Zhang, L; Wu, CL; Carta, R; Baggerly, K; Coombes, KR			Preprocessing of oligonucleotide array data - Response	NATURE BIOTECHNOLOGY			English	Letter									Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Zhang, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, 1515 Holcombe Blvd,Box 447, Houston, TX 77030 USA.	lzhang@mdanderson.org		Zhang, Li/0000-0003-0517-7860				Cope LM, 2004, BIOINFORMATICS, V20, P323, DOI 10.1093/bioinformatics/btg410	1	4	6	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					658	658		10.1038/nbt0604-658	http://dx.doi.org/10.1038/nbt0604-658			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15175679	Bronze			2022-12-25	WOS:000221785300013
J	Emamian, ES; Hall, D; Birnbaum, MJ; Karayiorgou, M; Gogos, JA				Emamian, ES; Hall, D; Birnbaum, MJ; Karayiorgou, M; Gogos, JA			Convergent evidence for impaired AKT1-GSK3 beta signaling in schizophrenia	NATURE GENETICS			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; NEUROPATHOLOGY-CONSORTIUM; BIPOLAR-DISORDER; AKT; DISEQUILIBRIUM; ASSOCIATION; INHIBITION; PATHWAY; LITHIUM	AKT-GSK3beta signaling is a target of lithium and as such has been implicated in the pathogenesis of mood disorders. Here, we provide evidence that this signaling pathway also has a role in schizophrenia. Specifically, we present convergent evidence for a decrease in AKT1 protein levels and levels of phosphorylation of GSK3beta at Ser9 in the peripheral lymphocytes and brains of individuals with schizophrenia; a significant association between schizophrenia and an AKT1 haplotype associated with lower AKT1 protein levels; and a greater sensitivity to the sensorimotor gating disruptive effect of amphetamine, conferred by AKT1 deficiency. Our findings support the proposal that alterations in AKT1-GSK3beta signaling contribute to schizophrenia pathogenesis and identify AKT1 as a potential schizophrenia susceptibility gene. Consistent with this proposal, we also show that haloperidol induces a stepwise increase in regulatory phosphorylation of AKT1 in the brains of treated mice that could compensate for an impaired function of this signaling pathway in schizophrenia.	Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Ctr Neurobiol & Behav, New York, NY 10032 USA; Rockefeller Univ, Lab Human Neurogenet, New York, NY 10021 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Columbia University; Rockefeller University; Howard Hughes Medical Institute; University of Pennsylvania	Gogos, JA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Ctr Neurobiol & Behav, 630 W 168th St,P&S 11-519, New York, NY 10032 USA.	karayim@rockefeller.edu; jag90@columbia.edu		Birnbaum, Morris/0000-0001-9972-8680				Akama KT, 2003, J NEUROSCI, V23, P2333; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Berrettini WH, 2000, BIOL PSYCHIAT, V48, P531, DOI 10.1016/S0006-3223(00)00883-0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Gerber DJ, 2003, P NATL ACAD SCI USA, V100, P8993, DOI 10.1073/pnas.1432927100; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Knable MB, 2001, BRAIN RES BULL, V55, P651, DOI 10.1016/S0361-9230(01)00521-4; LEWONTIN RC, 1988, GENETICS, V120, P849; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Miyakawa T, 2003, P NATL ACAD SCI USA, V100, P8987, DOI 10.1073/pnas.1432926100; Mizuno M, 2003, MOL PSYCHIATR, V8, P217, DOI 10.1038/sj.mp.4001215; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Segurado R, 2003, AM J HUM GENET, V73, P49, DOI 10.1086/376547; Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326; Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9; Toyota T, 2003, NEUROSCI LETT, V339, P5, DOI 10.1016/S0304-3940(02)01428-3; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1	30	734	790	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					131	137		10.1038/ng1296	http://dx.doi.org/10.1038/ng1296			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14745448	Bronze			2022-12-25	WOS:000188542700013
J	Iwawaki, T; Akai, R; Kohno, K; Miura, M				Iwawaki, T; Akai, R; Kohno, K; Miura, M			A transgenic mouse model for monitoring endoplasmic reticulum stress	NATURE MEDICINE			English	Article							UNFOLDED-PROTEIN RESPONSE; ER STRESS; MESSENGER-RNA; CELL-DEATH; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; GENE-EXPRESSION; IRE1; HOMOCYSTEINE; ACTIVATION	Endoplasmic reticulum (ER) stress is caused by the accumulation of unfolded proteins in the ER lumen, and is associated with vascular and neurodegenerative diseases. Although the connection between ER stress and some disease-related proteins has been studied using animal models of these diseases, no in vivo data concerning ER stress are available. Here we report a new method for monitoring ER stress in vivo, based on XBP-1 mRNA splicing by inositol requiring-1 (IRE-1) during ER stress. The stress indicator was constructed by fusing XBP-1 and venus, a variant of green fluorescent protein. During stress, the spliced indicator mRNA is translated into an XBP-1-venus fusion protein, which can be detected by its fluorescence. We used transgenic animals expressing the ER stress indicator to show that it can be used to monitor physiological and pathological ER stress in vivo.	RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, Wako, Saitama 3510198, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Genet, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); University of Tokyo	Miura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551; Iwawaki, Takao/0000-0001-8753-1979				Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mudd S., 2001, METABOLIC MOL BASES, P2007; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reimold AM, 2000, GENE DEV, V14, P152; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	26	313	321	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2004	10	1					98	102		10.1038/nm970	http://dx.doi.org/10.1038/nm970			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14702639				2022-12-25	WOS:000187743600045
J	Papanikolaou, G; Samuels, ME; Ludwig, EH; MacDonald, MLE; Franchini, PL; Dube, MP; Andres, L; MacFarlane, J; Sakellaropoulos, N; Politou, M; Nemeth, E; Thompson, J; Risler, JK; Zaborowska, C; Babakaiff, R; Radomski, CC; Pape, TD; Davidas, O; Christakis, J; Brissot, P; Lockitch, G; Ganz, T; Hayden, MR; Goldberg, YP				Papanikolaou, G; Samuels, ME; Ludwig, EH; MacDonald, MLE; Franchini, PL; Dube, MP; Andres, L; MacFarlane, J; Sakellaropoulos, N; Politou, M; Nemeth, E; Thompson, J; Risler, JK; Zaborowska, C; Babakaiff, R; Radomski, CC; Pape, TD; Davidas, O; Christakis, J; Brissot, P; Lockitch, G; Ganz, T; Hayden, MR; Goldberg, YP			Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis	NATURE GENETICS			English	Article							ANTIMICROBIAL PEPTIDE HEPCIDIN; CHRONIC DISEASE; HEREDITARY HEMOCHROMATOSIS; GENETIC-HETEROGENEITY; LIVER HEPCIDIN; LOCUS MAPS; ANEMIA; EXPRESSION; PROTEIN; MOUSE	Juvenile hemochromatosis is an early-onset autosomal recessive disorder of iron overload resulting in cardiomyopathy, diabetes and hypogonadism that presents in the teens and early 20s (refs. 1,2). Juvenile hemochromatosis has previously been linked to the centromeric region of chromosome 1q (refs. 3 6), a region that is incomplete in the human genome assembly. Here we report the positional cloning of the locus associated with juvenile hemochromatosis and the identification of a new gene crucial to iron metabolism. We finely mapped the recombinant interval in families of Greek descent and identified multiple deleterious mutations in a transcription unit of previously unknown function (LOC148738), now called HFE2, whose protein product we call hemojuvelin. Analysis of Greek, Canadian and French families indicated that one mutation, the amino acid substitution G320V, was observed in all three populations and accounted for two-thirds of the mutations found. HFE2 transcript expression was restricted to liver, heart and skeletal muscle, similar to that of hepcidin, a key protein implicated in iron metabolism(7-9). Urinary hepcidin levels were depressed in individuals with juvenile hemochromatosis, suggesting that hemojuvelin is probably not the hepcidin receptor. Rather, HFE2 seems to modulate hepcidin expression.	Xenon Genet, Burnaby, BC V5G 4W8, Canada; Univ Athens, Dept Internal Med 1, Sch Med, Laikon Gen Hosp, Athens 11527, Greece; Xenon Genet Res, Montreal, PQ H3A 1L2, Canada; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Theagenio Canc Ctr, Dept Hematol, Thessaloniki 54007, Greece; Univ Rennes, Serv Malad Foie, F-35033 Rennes, France; Univ Rennes, INSERM, U522, F-35033 Rennes, France; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6H 3V4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada	Athens Medical School; Laiko General Hospital; National & Kapodistrian University of Athens; University of California System; University of California Los Angeles; Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; University of British Columbia; University of British Columbia	Hayden, MR (corresponding author), Xenon Genet, Burnaby, BC V5G 4W8, Canada.	mrh@cmmt.ubc.ca	Ganz, Tomas/AAN-3308-2020; Girelli, Domenico/B-1183-2008; Dubé, Marie-Pierre/B-9364-2008; PAPANIKOLAOU, GEORGE/AAL-9017-2021; Hayden, Michael R/D-8581-2011; Ganz, Tomas/D-4567-2009	Girelli, Domenico/0000-0001-9684-1899; Dubé, Marie-Pierre/0000-0001-8442-4393; PAPANIKOLAOU, GEORGE/0000-0002-6755-3633; Hayden, Michael R/0000-0001-5159-1419; Nemeth, Elizabeta/0000-0002-3477-2397; MacDonald, Marcia/0000-0001-7946-0023; Ganz, Tomas/0000-0002-2830-5469				Ahmad KA, 2002, BLOOD CELL MOL DIS, V29, P361, DOI 10.1006/bcmd.2002.0575; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Means RT, 2000, BEST PRACT RES CL HA, V13, P151, DOI 10.1053/beha.1999.0065; Merryweather-Clarke AT, 2003, HUM MOL GENET, V12, P2241, DOI 10.1093/hmg/ddg225; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Nicolas G, 2002, BLOOD CELL MOL DIS, V29, P327, DOI 10.1006/bcmd.2002.0573; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Papanikolaou G, 2000, BLOOD CELL MOL DIS, V26, P163, DOI 10.1006/bcmd.2000.0292; Papanikolaou G, 2002, BLOOD CELL MOL DIS, V29, P168, DOI 10.1006/bcmd.2002.0553; Papanikolaou G, 2001, BLOOD CELL MOL DIS, V27, P744, DOI 10.1006/bcmd.2001.0444; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Rivard SR, 2003, EUR J HUM GENET, V11, P585, DOI 10.1038/sj.ejhg.5201009; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Roy CN, 2003, PEDIATR RES, V53, P507, DOI 10.1203/01.PDR.0000049513.67410.2D; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260; Weiss G, 2002, BLOOD REV, V16, P87, DOI 10.1054/blre.2002.0193	29	732	777	2	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					77	82		10.1038/ng1274	http://dx.doi.org/10.1038/ng1274			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14647275	Bronze			2022-12-25	WOS:000187666800017
J	Kalscheuer, VM; Freude, K; Musante, L; Jensen, LR; Yntema, HG; Gecz, J; Sefiani, A; Hoffmann, K; Moser, B; Haas, S; Gurok, U; Haesler, S; Aranda, B; Nshedjan, A; Tzschach, A; Hartmann, N; Roloff, TC; Shoichet, S; Hagens, O; Tao, J; van Bokhoven, H; Turner, G; Chelly, J; Moraine, C; Fryns, JP; Nuber, U; Hoeltzenbein, M; Scharff, C; Scherthan, H; Lenzner, S; Hamel, BCJ; Schweiger, S; Ropers, HH				Kalscheuer, VM; Freude, K; Musante, L; Jensen, LR; Yntema, HG; Gecz, J; Sefiani, A; Hoffmann, K; Moser, B; Haas, S; Gurok, U; Haesler, S; Aranda, B; Nshedjan, A; Tzschach, A; Hartmann, N; Roloff, TC; Shoichet, S; Hagens, O; Tao, J; van Bokhoven, H; Turner, G; Chelly, J; Moraine, C; Fryns, JP; Nuber, U; Hoeltzenbein, M; Scharff, C; Scherthan, H; Lenzner, S; Hamel, BCJ; Schweiger, S; Ropers, HH			Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation	NATURE GENETICS			English	Article							BINDING PROTEIN; TRACT-BINDING; WW DOMAIN; TRANSCRIPTION; PQBP-1; NPW38	We found mutations in the gene PQBP1 in 5 of 29 families with nonsyndromic (MRX) and syndromic (MRXS) forms of X-linked mental retardation (XLMR). Clinical features in affected males include mental retardation, microcephaly, short stature, spastic paraplegia and midline defects. PQBP1 has previously been implicated in the pathogenesis of polyglutamine expansion diseases. Our findings link this gene to XLMR and shed more light on the pathogenesis of this common disorder.	Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Womens & Childrens Hosp, Adelaide, SA, Australia; Univ Adelaide, Adelaide, SA, Australia; Dept Genet & Biol Mol INH, Rabat, Morocco; Hunter Genet, Waratah, NSW 2298, Australia; Univ Newcastle, Waratah, NSW 2298, Australia; CHU Cochin Port Royal, INSERM, CNRS, Inst Cochin Genet Mol, F-75014 Paris, France; CHU Bretonneau, INSERM, U316, Serv Genet, F-37044 Tours, France; Catholic Univ Louvain, Ctr Human Genet, Clin Genet Unit, B-3000 Louvain, Belgium	Max Planck Society; Radboud University Nijmegen; Womens & Childrens Hospital Australia; University of Adelaide; University of Newcastle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Catholique Louvain	Kalscheuer, VM (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.		Haesler, Sebastian/A-8755-2012; Scharff, Constance/HHN-0673-2022; van Bokhoven, Hans/D-8764-2012; Tzschach, Andreas/I-2648-2019; Musante, Luciana/AAA-5726-2021; Hoeltzenbein, Maria/AAP-4145-2020; Chelly, Jamel/J-7528-2015; Bokhoven, J.H.L.M. van van/H-8015-2014; Yntema, H.G./L-4771-2015; Gecz, Jozef/X-3469-2019	Tzschach, Andreas/0000-0002-6840-965X; Musante, Luciana/0000-0002-2742-1484; Hoeltzenbein, Maria/0000-0002-2451-4247; Chelly, Jamel/0000-0002-0939-8719; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Gecz, Jozef/0000-0002-7884-6861; Haesler, Sebastian/0000-0003-4924-7381; Freude, Kristine/0000-0001-9480-2386; Kalscheuer, Vera/0000-0001-6898-3259; Haas, Stefan/0000-0003-3418-3688				Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Craggs G, 2001, J BIOL CHEM, V276, P30552, DOI 10.1074/jbc.M103142200; Deqaqi SC, 1998, ANN GENET-PARIS, V41, P11; HAMEL BCJ, 1994, AM J MED GENET, V51, P591, DOI 10.1002/ajmg.1320510459; Iwamoto K, 2000, GENE, V259, P69, DOI 10.1016/S0378-1119(00)00437-6; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Okazawa H, 2001, BRAIN RES BULL, V56, P273, DOI 10.1016/S0361-9230(01)00579-2; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; Reuter K, 1999, J MOL BIOL, V294, P515, DOI 10.1006/jmbi.1999.3258; Ropers HH, 2003, TRENDS GENET, V19, P316, DOI 10.1016/S0168-9525(03)00113-6; SHOICHET S, IN PRESS AM J HUM GE; SUTHERLAND GR, 1988, AM J MED GENET, V30, P493, DOI 10.1002/ajmg.1320300152; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Waragai M, 2000, BIOCHEM BIOPH RES CO, V273, P592, DOI 10.1006/bbrc.2000.2992	15	122	123	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2003	35	4					313	315		10.1038/ng1264	http://dx.doi.org/10.1038/ng1264			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	747DY	14634649	Green Published			2022-12-25	WOS:000186791000010
J	Wild, MA; Xin, H; Maruyama, T; Nolan, MJ; Calveley, PM; Malone, JD; Wallace, MR; Bowdish, KS				Wild, MA; Xin, H; Maruyama, T; Nolan, MJ; Calveley, PM; Malone, JD; Wallace, MR; Bowdish, KS			Human antibodies from immunized donors are protective against anthrax toxin in vivo	NATURE BIOTECHNOLOGY			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN; COMPONENT	A panel of Fabs that neutralize anthrax toxin in vitro was selected from libraries generated from human donors vaccinated against anthrax. At least two of these antibodies protect rats from anthrax intoxication in vivo. Fabs 83K7C and 63L1D bind with subnanomolar affinity to protective antigen (PA) 63, and Fab 63L1D neutralizes toxin substoichiometrically, inhibits lethal factor (LF) interaction with PA63 and binds to a conformational epitope formed by PA63.	Alex Antibody Technol Inc, San Diego, CA 92121 USA; Natl Naval Med Res Inst, San Diego, CA 92134 USA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Naval Medical Center San Diego	Bowdish, KS (corresponding author), Alex Antibody Technol Inc, 3985 Sorrento Valley Blvd, San Diego, CA 92121 USA.	kbowdish@alxnsd.com						KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; LITTLE SF, 1990, INFECT IMMUN, V58, P1606, DOI 10.1128/IAI.58.6.1606-1613.1990; Little SF, 1997, INFECT IMMUN, V65, P5171, DOI 10.1128/IAI.65.12.5171-5175.1997; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9	7	79	86	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2003	21	11					1305	1306		10.1038/nbt891	http://dx.doi.org/10.1038/nbt891			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	739AL	14555959				2022-12-25	WOS:000186320000030
J	Thiel, K				Thiel, K			Oligo oligarchy - the surprisingly small world of aptamers	NATURE BIOTECHNOLOGY			English	Article							RNA											Gold L., 1997, U.S. Patent, Patent No. [5,670,637, 5670637]; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	4	42	50	0	15	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					649	651		10.1038/nbt0604-649	http://dx.doi.org/10.1038/nbt0604-649			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15175673				2022-12-25	WOS:000221785300007
J	Heidelberg, JF; Seshadri, R; Haveman, SA; Hemme, CL; Paulsen, IT; Kolonay, JF; Eisen, JA; Ward, N; Methe, B; Brinkac, LM; Daugherty, SC; Deboy, RT; Dodson, RJ; Durkin, AS; Madupu, R; Nelson, WC; Sullivan, SA; Fouts, D; Haft, DH; Selengut, J; Peterson, JD; Davidsen, TM; Zafar, N; Zhou, LW; Radune, D; Dimitrov, G; Hance, M; Tran, K; Khouri, H; Gill, J; Utterback, TR; Feldblyum, TV; Wall, JD; Voordouw, G; Fraser, CM				Heidelberg, JF; Seshadri, R; Haveman, SA; Hemme, CL; Paulsen, IT; Kolonay, JF; Eisen, JA; Ward, N; Methe, B; Brinkac, LM; Daugherty, SC; Deboy, RT; Dodson, RJ; Durkin, AS; Madupu, R; Nelson, WC; Sullivan, SA; Fouts, D; Haft, DH; Selengut, J; Peterson, JD; Davidsen, TM; Zafar, N; Zhou, LW; Radune, D; Dimitrov, G; Hance, M; Tran, K; Khouri, H; Gill, J; Utterback, TR; Feldblyum, TV; Wall, JD; Voordouw, G; Fraser, CM			The genome sequence of the anaerobic, sulfate-reducing bacterium Desulfovibrio vulgaris Hildenborough	NATURE BIOTECHNOLOGY			English	Article							ELECTRON-TRANSFER; SUPEROXIDE-DISMUTASE; CARBON RESERVES; CYTOCHROMES-C; HMC OPERON; PROTEIN; HYDROGENASES; METABOLISM; SYSTEM; GIGAS	Desulfovibrio vulgaris Hildenborough is a model organism for studying the energy metabolism of sulfate-reducing bacteria (SRB) and for understanding the economic impacts of SRB, including biocorrosion of metal infrastructure and bioremediation of toxic metal ions. The 3,570,858 base pair (bp) genome sequence reveals a network of novel c-type cytochromes, connecting multiple periplasmic hydrogenases and formate dehydrogenases, as a key feature of its energy metabolism. The relative arrangement of genes encoding enzymes for energy transduction, together with inferred cellular location of the enzymes, provides a basis for proposing an expansion to the 'hydrogen-cycling' model for increasing energy efficiency in this bacterium. Plasmid-encoded functions include modification of cell surface components, nitrogen fixation and a type-III protein secretion system. This genome sequence represents a substantial step toward the elucidation of pathways for reduction (and bioremediation) of pollutants such as uranium and chromium and offers a new starting point for defining this organism's complex anaerobic respiration.	Inst Genom Res, Rockville, MD 20850 USA; Univ Maryland, Ctr Marine Biotechnol, Baltimore, MD 21202 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA	J. Craig Venter Institute; University System of Maryland; University of Maryland Baltimore; University of Calgary; University of Missouri System; University of Missouri Columbia; Johns Hopkins University; George Washington University	Heidelberg, JF (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	dvu@tigr.org	Nelson, William C/E-9263-2016; Paulsen, Ian T/K-3832-2012; Eisen, Jonathan A./H-2706-2019; Voordouw, Gerrit/F-5327-2013	Nelson, William C/0000-0002-1873-3929; Paulsen, Ian T/0000-0001-9015-9418; Eisen, Jonathan A./0000-0002-0159-2197; Heidelberg, John/0000-0003-0673-3224; Fraser, Claire/0000-0003-1462-2428				Aubert C, 1998, BIOCHEM BIOPH RES CO, V242, P213, DOI 10.1006/bbrc.1997.7852; Aubert C, 2000, BBA-PROTEIN STRUCT M, V1476, P85, DOI 10.1016/S0167-4838(99)00221-6; BADZIONG W, 1978, ARCH MICROBIOL, V117, P209, DOI 10.1007/BF00402310; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BOCK A, 1996, ESCHERICHIA COLI SAL, P262; BUCHANAN BB, 1990, PHOTOSYNTH RES, V24, P47, DOI 10.1007/BF00032643; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cypionka H, 2000, ANNU REV MICROBIOL, V54, P827, DOI 10.1146/annurev.micro.54.1.827; Dolla A, 2000, ARCH MICROBIOL, V174, P143, DOI 10.1007/s002030000183; Dos Santos WG, 2000, J BACTERIOL, V182, P796, DOI 10.1128/JB.182.3.796-804.2000; Fareleira P, 1997, J BACTERIOL, V179, P3972, DOI 10.1128/jb.179.12.3972-3980.1997; Fournier M, 2003, J BACTERIOL, V185, P71, DOI 10.1128/JB.185.1.71-79.2003; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; GOTTSCHALK G, 1967, BIOCHEMISTRY-US, V6, P1027, DOI 10.1021/bi00856a011; Greene EA, 2003, ENVIRON MICROBIOL, V5, P607, DOI 10.1046/j.1462-2920.2003.00446.x; Haft DH, 2001, NUCLEIC ACIDS RES, V29, P41, DOI 10.1093/nar/29.1.41; Hamilton WA, 2003, BIOFOULING, V19, P65, DOI 10.1080/0892701021000041078; HANSEN TA, 1994, ANTON LEEUW INT J G, V66, P165, DOI 10.1007/BF00871638; Haveman SA, 2003, J BACTERIOL, V185, P4345, DOI 10.1128/JB.185.15.4345-4353.2003; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; LISSOLO T, 1986, BIOCHEM BIOPH RES CO, V139, P701, DOI 10.1016/S0006-291X(86)80047-X; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Meuer J, 1999, EUR J BIOCHEM, V265, P325, DOI 10.1046/j.1432-1327.1999.00738.x; Michel C, 2001, APPL MICROBIOL BIOT, V55, P95, DOI 10.1007/s002530000467; ODOM JM, 1981, FEMS MICROBIOL LETT, V12, P47; PANKHANIA IP, 1988, ARCH MICROBIOL, V150, P26, DOI 10.1007/BF00409713; Payne RB, 2002, APPL ENVIRON MICROB, V68, P3129, DOI 10.1128/AEM.68.6.3129-3132.2002; Pereira IAC, 1998, J BIOL INORG CHEM, V3, P494, DOI 10.1007/s007750050259; Petnicki-Ocwieja T, 2002, P NATL ACAD SCI USA, V99, P7652, DOI 10.1073/pnas.112183899; Pieulle L, 1997, J BACTERIOL, V179, P5684, DOI 10.1128/jb.179.18.5684-5692.1997; POSTGATE J, 1986, FEMS MICROBIOL LETT, V33, P159; Postgate J. R., 1984, SULPHATE REDUCING BA, V130; PRICE SB, 1989, J BACTERIOL, V171, P5646, DOI 10.1128/jb.171.10.5646-5653.1989; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; ROSSI M, 1993, J BACTERIOL, V175, P4699, DOI 10.1128/JB.175.15.4699-4711.1993; SANTOS H, 1993, BIOCHEM BIOPH RES CO, V195, P551, DOI 10.1006/bbrc.1993.2081; SINGLETON R, 1993, SULFATE REDUCING BAC, P189; Tettelin H, 1999, GENOMICS, V62, P500, DOI 10.1006/geno.1999.6048; TRUPER HG, 1984, STUDIES INORGANIC CH, V5, P351; Voordouw G, 2002, J BACTERIOL, V184, P5903, DOI 10.1128/JB.184.21.5903-5911.2002; VOORDOUW G, 1990, APPL ENVIRON MICROB, V56, P3748, DOI 10.1128/AEM.56.12.3748-3754.1990; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; Wall JD, 2003, BIOCHEMISTRY AND PHYSIOLOGY OF ANAEROBIC BACTERIA, P85, DOI 10.1007/0-387-22731-8_7; Widdel F., 1992, PROKARYOTES, DOI 10.1007/978-1-4757-2191-1_2; Widdel F., 1988, BIOL ANAEROBIC MICRO, P469; Xiong JJ, 2000, BIOCHEMISTRY-US, V39, P5117, DOI 10.1021/bi992796o	50	460	863	3	131	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					554	559		10.1038/nbt959	http://dx.doi.org/10.1038/nbt959			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15077118	hybrid			2022-12-25	WOS:000221159700023
J	Thompson, HM; Cao, H; Chen, J; Euteneuer, U; McNiven, MA				Thompson, HM; Cao, H; Chen, J; Euteneuer, U; McNiven, MA			Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion	NATURE CELL BIOLOGY			English	Letter							C-TERMINAL DOMAIN; MAMMALIAN-CELLS; GOLGI-APPARATUS; CYTOKINESIS; PROTEIN; MIDBODY; GTPASE; CYCLE; LOCALIZATION; MICROTUBULES	Dynamin 2 (Dyn2) is a large GTPase involved in vesicle formation and actin reorganization(1-3). In this study, we report a novel role for Dyn2 as a component of the centrosome that is involved in centrosome cohesion. By light microscopy, Dyn2 localized aside centrin and colocalized with gamma-tubulin at the centrosome; by immunoelectron microscopy, however, Dyn2 was detected in the pericentriolar material as well as on centrioles. Exogenously expressed green fluorescent protein (GFP)-tagged Dyn2 also localized to the centrosome, whereas glutathione S-transferase (GST)-tagged Dyn2 pulled down a protein complex(es) containing actin, alpha-tubulin and gamma-tubulin from liver homogenate. Furthermore, gel overlay and immunoprecipitation indicated a direct interaction between gamma-tubulin and a 219-amino-acid middle domain of Dyn2. Reduction of Dyn2 protein levels with small-interfering RNA (siRNA) resulted in centrosome splitting, whereas microtubule nucleation from centrosomes was not affected, suggesting a role for Dyn2 in centrosome cohesion. Finally, fluorescence recovery after photobleaching (FRAP) analysis of a GFP-tagged Dyn2 middle domain indicated that Dyn2 is a dynamic exchangeable component of the centrosome. These findings suggest a novel function for Dyn2 as a participant in centrosome cohesion.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	Mayo Clinic; University of Munich	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	mmcniven@mayo.edu						Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Euteneuer U, 1998, J CELL SCI, V111, P405; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Herrmann L, 2003, MOL BIOL CELL, V14, P230, DOI 10.1091/mbc.E02-04-0191; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; JULIAN M, 1993, J CELL SCI, V105, P145; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; MARKS DL, 1994, J CELL SCI, V107, P2417; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Moudjou M, 1996, J CELL SCI, V109, P875; MOUDJOU M, 1994, CELL BIOL LAB HDB, V1, P595; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553	30	129	137	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2004	6	4					335	342		10.1038/ncb1112	http://dx.doi.org/10.1038/ncb1112			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	808SA	15048127				2022-12-25	WOS:000220587600015
J	Knoch, KP; Bergert, H; Borgonovo, B; Saeger, HD; Altkruger, A; Verkade, P; Solimena, M				Knoch, KP; Bergert, H; Borgonovo, B; Saeger, HD; Altkruger, A; Verkade, P; Solimena, M			Polypyrimidine tract-binding protein promotes insulin secretory granule biogenesis	NATURE CELL BIOLOGY			English	Article							PANCREATIC BETA-CELLS; MESSENGER-RNA STABILITY; GENE-EXPRESSION; TRANSLATIONAL CONTROL; CHROMOGRANIN-A; ON/OFF SWITCH; RIN-5F CELLS; CYCLIC-AMP; HNRNP-I; GLUCOSE	Pancreatic beta-cells store insulin in secretory granules that undergo exocytosis upon glucose stimulation. Sustained stimulation depletes beta-cells of their granule pool, which must be quickly restored. However, the factors promoting rapid granule biogenesis are unknown. Here we show that beta-cell stimulation induces the nucleocytoplasmic translocation of polypyrimidine tract-binding protein (PTB). Activated cytosolic PTB binds and stabilizes mRNAs encoding proteins of secretory granules, thus increasing their translation, whereas knockdown of PTB expression by RNA interference (RNAi) results in the depletion of secretory granules. These findings may provide insight for the understanding and treatment of diabetes, in which insulin secretion is typically impaired.	Tech Univ Dresden, Carl Gustav Carus Med Sch, Dept Surg, D-01307 Dresden, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Technische Universitat Dresden; Max Planck Society	Solimena, M (corresponding author), Tech Univ Dresden, Carl Gustav Carus Med Sch, Dept Surg, D-01307 Dresden, Germany.	michele.solimena@mailbox.tu-dresden.de	Solimena, Michele/E-1275-2011; Verkade, Paul/N-7240-2014; Solimena, Michele/GVS-5990-2022	Verkade, Paul/0000-0002-2497-1026; 	Telethon [GFP02003] Funding Source: Medline	Telethon(Fondazione Telethon)		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Borgonovo B, 1998, J BIOL CHEM, V273, P34683, DOI 10.1074/jbc.273.52.34683; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Lee MS, 1998, ENDOCRINOLOGY, V139, P2727, DOI 10.1210/en.139.6.2727; Malosio ML, 2004, J CELL SCI, V117, P743, DOI 10.1242/jcs.00934; MARTIN SK, 1994, FEBS LETT, V356, P279, DOI 10.1016/0014-5793(94)01284-9; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; SARASTE J, 1991, J CELL SCI, V100, P415; SCHATZ H, 1975, EUR J CLIN INVEST, V5, P477, DOI 10.1111/j.1365-2362.1975.tb02312.x; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Steinbrenner H, 2002, ENDOCRINOLOGY, V143, P3839, DOI 10.1210/en.2002-220583; Tillmar L, 2002, MOL MED, V8, P263, DOI 10.1007/BF03402152; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485	41	141	145	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2004	6	3					207	214		10.1038/ncb1099	http://dx.doi.org/10.1038/ncb1099			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	780GB	15039777				2022-12-25	WOS:000189363000011
J	Svendsen, CN; Langston, JW				Svendsen, CN; Langston, JW			Stem cells for Parkinson disease and ALS: replacement or protection?	NATURE MEDICINE			English	Editorial Material							MOTOR-NEURONS; TRANSPLANTATION; MODEL; BRAIN		Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Parkinsons Inst, Sunnyvale, CA 94089 USA	University of Wisconsin System; University of Wisconsin Madison	Svendsen, CN (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.	svenden@waisman.wisc.edu						Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Imura T, 2003, J NEUROSCI, V23, P2824; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Tai YT, 2004, CURR OPIN PHARMACOL, V4, P98, DOI 10.1016/j.coph.2003.09.006; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8	12	60	63	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2004	10	3					224	225		10.1038/nm0304-224	http://dx.doi.org/10.1038/nm0304-224			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14991036				2022-12-25	WOS:000189297700019
J	Windpassinger, C; Auer-Grumbach, M; Irobi, J; Patel, H; Petek, E; Horl, G; Malli, R; Reed, JA; Dierick, I; Verpoorten, N; Warner, TT; Proukakis, C; Van den Bergh, P; Verellen, C; Van Maldergem, L; Merlini, L; De Jonghe, P; Timmerman, V; Crosby, AH; Wagner, K				Windpassinger, C; Auer-Grumbach, M; Irobi, J; Patel, H; Petek, E; Horl, G; Malli, R; Reed, JA; Dierick, I; Verpoorten, N; Warner, TT; Proukakis, C; Van den Bergh, P; Verellen, C; Van Maldergem, L; Merlini, L; De Jonghe, P; Timmerman, V; Crosby, AH; Wagner, K			Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome	NATURE GENETICS			English	Article							SPINAL MUSCULAR-ATROPHY; CHROMOSOME 11Q12-Q14; AGGRESOME FORMATION; SPASTIC PARAPLEGIA; HETEROGENEITY	Distal hereditary motor neuropathy (dHMN) or distal spinal muscular atrophy (OMIM #182960) is a heterogeneous group of disorders characterized by an almost exclusive degeneration of motor nerve fibers, predominantly in the distal part of the limbs(1). Silver syndrome (OMIM #270685) is a rare form of hereditary spastic paraparesis mapped to chromosome 11q12q14 (SPG17) in which spasticity of the legs is accompanied by amyotrophy of the hands and occasionally also the lower limbs(2,3). Silver syndrome and most forms of dHMN are autosomal dominantly inherited with incomplete penetrance and a broad variability in clinical expression. A genome-wide scan in an Austrian family with dHMN-V (ref. 4) showed linkage to the locus SPG17, which was confirmed in 16 additional families with a phenotype characteristic of dHMN or Silver syndrome. After refining the critical region to 1 Mb, we sequenced the gene Berardinelli-Seip congenital lipodystrophy (BSCL2) and identified two heterozygous missense mutations resulting in the amino acid substitutions N88S and S90L. Null mutations in BSCL2, which encodes the protein seipin, were previously shown to be associated with autosomal recessive Berardinelli-Seip congenital lipodystrophy 5 (OMIM #269700). We show that seipin is an integral membrane protein of the endoplasmic reticulum (ER). The amino acid substitutions N88S and S90L affect glycosylation of seipin and result in aggregate formation leading to neurodegeneration.	Med Univ Graz, Inst Med Biol & Human Genet, A-8010 Graz, Austria; Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium; Univ London St Georges Hosp, Sch Med, Div Med Genet, London SW17 0RE, England; Med Univ Graz, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; UCL Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, London NW3 2PF, England; Univ Louvain, St Luc Univ Hosp, Dept Neurol, Brussels, Belgium; Univ Louvain, St Luc Univ Hosp, Med Genet Unit, Brussels, Belgium; Ctr Human Genet, Inst Pathol & Genet, Loverval, Belgium; Ist Ortoped Rizzoli, Neuromuscular Lab, Bologna, Italy	Medical University of Graz; Flanders Institute for Biotechnology (VIB); University of Antwerp; St Georges University London; Medical University of Graz; University of London; University College London; UCL Medical School; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Istituto Ortopedico Rizzoli	Wagner, K (corresponding author), Med Univ Graz, Inst Med Biol & Human Genet, Harrachgasse 21-8, A-8010 Graz, Austria.	klaus.wagner@meduni-graz.at	Merlini, Luciano/N-6478-2019; Warner, Thomas T/A-1454-2013; Malli, Roland/B-7369-2008; Timmerman, Vincent/O-7283-2019; Van Maldergem, Lionel/G-9849-2017; Proukakis, Christos/G-4548-2013; Crosby, Andrew H/E-2218-2015; proukakis, christos/ABE-3447-2020; Van Maldergem, Lionel/O-3242-2019	Merlini, Luciano/0000-0002-1108-1198; Warner, Thomas T/0000-0001-6195-6995; Timmerman, Vincent/0000-0002-2162-0933; Van Maldergem, Lionel/0000-0001-8880-5214; Crosby, Andrew H/0000-0003-3667-9054; proukakis, christos/0000-0001-6423-6539; Van Maldergem, Lionel/0000-0001-8880-5214; Hoerl, Gerd/0000-0002-0884-0851; Malli, Roland/0000-0001-6327-8729				Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; Auer-Grumbach M, 2000, BRAIN, V123, P1612, DOI 10.1093/brain/123.8.1612; CHRISTODOULOU K, 1995, HUM MOL GENET, V4, P1629, DOI 10.1093/hmg/4.9.1629; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; HARDING AE, 1993, SEMIN NEUROL, V13, P333, DOI 10.1055/s-2008-1041143; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee MJ, 2003, HUM MOL GENET, V12, P1917, DOI 10.1093/hmg/ddg198; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Patel H, 2001, AM J HUM GENET, V69, P209, DOI 10.1086/321267; Ryan MC, 2002, NEUROBIOL DIS, V10, P109, DOI 10.1006/nbdi.2002.0500; Saliba RS, 2002, J CELL SCI, V115, P2907; SILVER JR, 1966, J NEUROL NEUROSUR PS, V29, P135, DOI 10.1136/jnnp.29.2.135; Van Maldergem L, 2002, J MED GENET, V39, P722, DOI 10.1136/jmg.39.10.722; Windpassinger C, 2003, HUM GENET, V114, P99, DOI 10.1007/s00439-003-1021-6	17	273	296	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2004	36	3					271	276		10.1038/ng1313	http://dx.doi.org/10.1038/ng1313			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981520	Bronze			2022-12-25	WOS:000189250400016
J	Papa, S; Zazzeroni, F; Bubici, C; Jayawardena, S; Alvarez, K; Matsuda, S; Nguyen, DU; Pham, CG; Nelsbach, AH; Melis, T; De Smaele, E; Tang, WJ; D'Adamio, L; Franzoso, G				Papa, S; Zazzeroni, F; Bubici, C; Jayawardena, S; Alvarez, K; Matsuda, S; Nguyen, DU; Pham, CG; Nelsbach, AH; Melis, T; De Smaele, E; Tang, WJ; D'Adamio, L; Franzoso, G			Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2	NATURE CELL BIOLOGY			English	Article							TNF-ALPHA; INDUCED APOPTOSIS; KINASE; ACTIVATION; PROTEIN; PATHWAY; P38; TRANSDUCTION; INHIBITOR; HOMOLOG	NF-kappaB/Rel transcription factors control apoptosis, also known as programmed cell death. This control is crucial for oncogenesis, cancer chemo-resistance and for antagonizing tumour necrosis factor alpha (TNFalpha)- induced killing(1,2). With regard to TNFalpha, the anti-apoptotic activity of NF-kappaB involves suppression of the c-Jun N-terminal kinase (JNK) cascade(3-5). Using an unbiased screen, we have previously identified Gadd45beta/Myd118, a member of the Gadd45 family of inducible factors(6), as a pivotal mediator of this suppressive activity of NF-kappaB(3). However, the mechanisms by which Gadd45 inhibits JNK signalling are not understood. Here, we identify MKK7/JNKK2 - a specific and essential activator of JNK(7,8) - as a target of Gadd45beta, and in fact, of NF-kappaB itself. Gadd45beta binds to MKK7 directly and blocks its catalytic activity, thereby providing a molecular link between the NF-kappaB and JNK pathways. Importantly, Gadd45 is required to antagonize TNFalpha-induced cytotoxicity, and peptides disrupting the Gadd45beta/MKK7 interaction hinder the ability of Gadd45beta, as well as of NF-kappaB, to suppress this cytotoxicity. These findings establish a basis for the NF-kappaB control of JNK activation and identify MKK7 as a potential target for antiinflammatory and anti-cancer therapy.	Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Cell Signalling Technol Inc, Beverly, MA 01915 USA; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy; Univ Naples Federico II, CEINGE, Naples, Italy	University of Chicago; University of Chicago; Yeshiva University; Albert Einstein College of Medicine; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Franzoso, G (corresponding author), Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, 924 E 57th St, Chicago, IL 60637 USA.	gfranzos@midway.uchicago.edu	Franzoso, Guido/GRR-8628-2022; Papa, Salvatore/J-9413-2012; De Smaele, Enrico/C-1124-2013	Papa, Salvatore/0000-0002-8369-6538; De Smaele, Enrico/0000-0003-4524-4423; Zazzeroni, Francesca/0000-0002-4474-3274; Franzoso, Guido/0000-0002-0778-988X; D'Adamio, Luciano/0000-0002-9820-4882; Tang, Wei-Jen/0000-0002-8267-8995; Bubici, Concetta/0000-0002-8074-4661; D'Adamio, Luciano/0000-0002-2204-9441	NATIONAL CANCER INSTITUTE [R01CA084040, R01CA098583] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA84040, R01-CA098583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; Franzoso G, 2003, CELL DEATH DIFFER, V10, P13, DOI 10.1038/sj.cdd.4401154; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Matsuda S, 2001, J NEUROSCI, V21, P6597; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689	30	278	299	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					146	+		10.1038/ncb1093	http://dx.doi.org/10.1038/ncb1093			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743220				2022-12-25	WOS:000188668300014
J	Shirane, D; Sugao, K; Namiki, S; Tanabe, M; Iino, M; Hirose, K				Shirane, D; Sugao, K; Namiki, S; Tanabe, M; Iino, M; Hirose, K			Enzymatic production of RNAi libraries from cDNAs	NATURE GENETICS			English	Article							SHORT-INTERFERING RNAS; MAMMALIAN-CELLS; GENE-EXPRESSION; INOSITOL 1,4,5-TRISPHOSPHATE; CAENORHABDITIS-ELEGANS; STEM-CELLS; GENOME; MESSENGER; SEQUENCE; RECEPTOR	RNA interference (RNAi) induced by small interfering (siRNA) or short hairpin RNA (shRNA) is an important research approach in mammalian genetics. Here we describe a technology called enzymatic production of RNAi library (EPRIL) by which cDNAs are converted by a sequence of enzymatic treatments into an RNAi library consisting of a vast array of different shRNA expression constructs. We applied EPRIL to a single cDNA source and prepared an RNAi library consisting of shRNA constructs with various RNAi efficiencies. High-throughput screening allowed us to rapidly identify the best shRNA constructs from the library. We also describe a new selection scheme using the thymidine kinase gene for obtaining efficient shRNA constructs. Furthermore, we show that EPRIL can be applied to constructing an RNAi library from a cDNA library, providing a basis for future whole-genome phenotypic screening of genes.	Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hirose, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kenzo@m.u-tokyo.ac.jp	Namiki, Shigeyuki/AAF-6157-2019	Namiki, Shigeyuki/0000-0003-1520-8261; Hirose, Kenzo/0000-0002-8944-6513				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; BOYD AC, 1986, NUCLEIC ACIDS RES, V14, P5255, DOI 10.1093/nar/14.13.5255; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; Chen YT, 2000, GENESIS, V28, P31, DOI 10.1002/1526-968X(200009)28:1<31::AID-GENE40>3.0.CO;2-K; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kile BT, 2003, NATURE, V425, P81, DOI 10.1038/nature01865; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	28	127	153	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					190	196		10.1038/ng1290	http://dx.doi.org/10.1038/ng1290			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14704669	Bronze			2022-12-25	WOS:000188542700023
J	Yu, YL; Khan, J; Khanna, C; Helman, L; Meltzer, PS; Merlino, G				Yu, YL; Khan, J; Khanna, C; Helman, L; Meltzer, PS; Merlino, G			Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators	NATURE MEDICINE			English	Article							GENE-EXPRESSION; ERM PROTEINS; CELL-ADHESION; VERTEBRATE MUSCLE; CDNA MICROARRAYS; TUMOR-SUPPRESSOR; RHO-GTPASES; MODEL; RHABDOMYOSARCOMA; PHOSPHORYLATION	Patients presenting with metastatic rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, have a very poor clinical prognosis. This is due, in large part, to our rudimentary knowledge of the molecular events that dictate metastatic potential. We used cDNA microarray analysis of RMS cell lines, derived from Ink4a/Arf-deficient mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF), to identify a set of genes whose expression was significantly different between highly and poorly metastatic cells. Subsequent in vivo functional studies revealed that the actin filament-plasma membrane linker ezrin (encoded by Vil2) and the homeodomain-containing transcription factor Six-1 (sine oculis-related homeobox-1 homolog) had essential roles in determining the metastatic fate of RMS cells. VIL2 and SIX1 expression was enhanced in human RMS tissue, significantly correlating with clinical stage. The identification of ezrin and Six-1 as critical regulators of metastasis in RMS provides new mechanistic and therapeutic insights into this pediatric cancer.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Merlino, G (corresponding author), NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov	Khan, Javed/P-9157-2014		NATIONAL CANCER INSTITUTE [ZIABC010566, Z01SC010366, Z01BC010566, Z01SC006892, ZIASC006892, ZIASC010366] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen Y., 1997, BIOMED OPTICS, V2, P364; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Dagher R, 1999, Oncologist, V4, P34; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Kardon G, 2002, DEV DYNAM, V224, P350, DOI 10.1002/dvdy.10107; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2001, CANCER RES, V61, P3750; KHANNA C, IN PRESS NAT MED; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nestl A, 2001, CANCER RES, V61, P1569; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Relaix F, 1999, GENE DEV, V13, P3171, DOI 10.1101/gad.13.24.3171; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ringner M, 2002, PHARMACOGENOMICS, V3, P403, DOI 10.1517/14622416.3.3.403; Ruymann FB, 2000, CANCER INVEST, V18, P223, DOI 10.3109/07357900009031827; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schafer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu YL, 2002, CANCER RES, V62, P2951; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	45	377	475	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					175	181		10.1038/nm966	http://dx.doi.org/10.1038/nm966			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14704789				2022-12-25	WOS:000188719600037
J	Moers, A; Nieswandt, B; Massberg, S; Wettschureck, N; Gruner, S; Konrad, I; Schulte, V; Aktas, B; Gratacap, MP; Simon, MI; Gawaz, M; Offermanns, S				Moers, A; Nieswandt, B; Massberg, S; Wettschureck, N; Gruner, S; Konrad, I; Schulte, V; Aktas, B; Gratacap, MP; Simon, MI; Gawaz, M; Offermanns, S			G(13) is an essential mediator of platelet activation in hemostasis and thrombosis	NATURE MEDICINE			English	Article							SIGNALING PATHWAYS; SHAPE CHANGE; G-PROTEIN; RHO-KINASE; IN-VIVO; PHOSPHORYLATION; AGGREGATION; MYOSIN; G-ALPHA(13); RECEPTORS	Platelet activation at sites of vascular injury is essential for primary hemostasis, but also underlies arterial thrombosis leading to myocardial infarction or stroke(1,2). Platelet activators such as adenosine diphosphate, thrombin or thromboxane A(2) (TXA(2)) activate receptors that are coupled to heterotrimeric G proteins(1,3). Activation of platelets through these receptors involves signaling through G(q), G(i) and G(z) (refs. 4- 6). However, the role and relative importance of G(12) and G(13), which are activated by various platelet stimuli(7-9), are unclear. Here we show that lack of Galpha(13), but not Galpha(12), severely reduced the potency of thrombin, TXA(2) and collagen to induce platelet shape changes and aggregation in vitro. These defects were accompanied by reduced activation of RhoA and inability to form stable platelet thrombi under high shear stress ex vivo. Galpha(13) deficiency in platelets resulted in a severe defect in primary hemostasis and complete protection against arterial thrombosis in vivo. We conclude that G(13)-mediated signaling processes are required for normal hemostasis and thrombosis and may serve as a new target for antiplatelet drugs.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Tech Univ Munich, Med Klin 1, D-80636 Munich, Germany; Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA	Ruprecht Karls University Heidelberg; University of Wurzburg; Technical University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; California Institute of Technology	Offermanns, S (corresponding author), Univ Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Massberg, Steffen/AAN-6054-2021; Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805; Gratacap, Marie-Pierre/0000-0003-4362-6401				ABRAMS CS, 2001, HEMOSTASIS THROMBOSI, P541; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Missy K, 2001, THROMB HAEMOSTASIS, V85, P514, DOI 10.1055/s-0037-1615614; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Savage B, 2001, CURR OPIN HEMATOL, V8, P270, DOI 10.1097/00062752-200109000-00002; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; Yang J, 2002, J BIOL CHEM, V277, P46035, DOI 10.1074/jbc.M208519200	28	191	198	0	11	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1418	1422		10.1038/nm943	http://dx.doi.org/10.1038/nm943			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14528298				2022-12-25	WOS:000186319700034
J	Meetei, AR; de Winter, JP; Medhurst, AL; Wallisch, M; Waisfisz, Q; van de Vrugt, HJ; Oostra, AB; Yan, ZJ; Ling, C; Bishop, CE; Hoatlin, ME; Joenje, H; Wang, WD				Meetei, AR; de Winter, JP; Medhurst, AL; Wallisch, M; Waisfisz, Q; van de Vrugt, HJ; Oostra, AB; Yan, ZJ; Ling, C; Bishop, CE; Hoatlin, ME; Joenje, H; Wang, WD			A novel ubiquitin ligase is deficient in Fanconi anemia	NATURE GENETICS			English	Article							TARGETED DISRUPTION; NUCLEAR-COMPLEX; REDUCED FERTILITY; GROUP-C; PROTEINS; GENE; FANCG/XRCC9; PATHWAY; MICE; HYPERSENSITIVITY	Fanconi anemia is a recessively inherited disease characterized by congenital defects, bone marrow failure and cancer susceptibility(1,2). Cells from individuals with Fanconi anemia are highly sensitive to DNA-crosslinking drugs, such as mitomycin C (MMC). Fanconi anemia proteins function in a DNA damage response pathway involving breast cancer susceptibility gene products, BRCA1 and BRCA2 (refs. 1,2). A key step in this pathway is monoubiquitination of FANCD2, resulting in the redistribution of FANCD2 to nuclear foci containing BRCA1 (ref. 3). The underlying mechanism is unclear because the five Fanconi anemia proteins known to be required for this ubiquitination have no recognizable ubiquitin ligase motifs. Here we report a new component of a Fanconi anemia protein complex, called PHF9, which possesses E3 ubiquitin ligase activity in vitro and is essential for FANCD2 monoubiquitination in vivo. Because PHF9 is defective in a cell line derived from an individual with Fanconi anemia, we conclude that PHF9 ( also called FANCL) represents a novel Fanconi anemia complementation group (FA-L). Our data suggest that PHF9 has a crucial role in the Fanconi anemia pathway as the likely catalytic subunit required for monoubiquitination of FANCD2.	NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; Free Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97239 USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Vrije Universiteit Amsterdam; Oregon Health & Science University; Baylor College of Medicine	Wang, WD (corresponding author), NIA, Genet Lab, NIH, 333 Cassell Dr,TRIAD Ctr Room 3000, Baltimore, MD 21224 USA.		Wang, Weidong/AAV-2446-2021; 高, 雨莉/HGU-8187-2022	Wallisch, Michael/0000-0002-7133-795X; Wang, Weidong/0000-0002-0658-7928; Waisfisz, Quinten/0000-0002-7384-9182	NATIONAL INSTITUTE ON AGING [ZIAAG000688, Z01AG000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agoulnik AI, 2002, HUM MOL GENET, V11, P3047, DOI 10.1093/hmg/11.24.3047; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; BRUNN D, 2003, DNA REPAIR; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Cheng NC, 2000, HUM MOL GENET, V9, P1805, DOI 10.1093/hmg/9.12.1805; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hoatlin ME, 1998, BLOOD, V91, P1418, DOI 10.1182/blood.V91.4.1418; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; Koomen M, 2002, HUM MOL GENET, V11, P273, DOI 10.1093/hmg/11.3.273; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Nadler JJ, 2000, GENESIS, V27, P117, DOI 10.1002/1526-968X(200007)27:3<117::AID-GENE40>3.0.CO;2-7; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Whitney MA, 1996, BLOOD, V88, P49; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435	30	446	464	0	22	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2003	35	2					165	170		10.1038/ng1241	http://dx.doi.org/10.1038/ng1241			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	726WV	12973351				2022-12-25	WOS:000185625300013
J	Uyttenhove, C; Pilotte, L; Theate, I; Stroobant, V; Colau, D; Parmentier, N; Boon, T; Van den Eynde, BJ				Uyttenhove, C; Pilotte, L; Theate, I; Stroobant, V; Colau, D; Parmentier, N; Boon, T; Van den Eynde, BJ			Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase	NATURE MEDICINE			English	Article							T-CELL PROLIFERATION; TRANSFER-RNA SYNTHETASE; DENDRITIC CELLS; METASTATIC MELANOMA; FETAL REJECTION; PEPTIDE; CATABOLISM; GENE; INHIBITION; EXPRESSION	T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degradation. Here we show that most human tumors constitutively express IDO. We also observed that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice. This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity. These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium; Univ Catholique Louvain, Dept Pathol, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Van den Eynde, BJ (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.			Pilotte, Luc/0000-0001-6761-6836				Bilsborough J, 2002, J IMMUNOL, V169, P3053, DOI 10.4049/jimmunol.169.6.3053; Boon T, 2003, CURR OPIN IMMUNOL, V15, P129, DOI 10.1016/S0952-7915(03)00010-4; Brandle D, 1998, EUR J IMMUNOL, V28, P4010, DOI 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; Fallarino F, 2002, INT IMMUNOL, V14, P65, DOI 10.1093/intimm/14.1.65; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Frumento G, 2001, TRANSPLANT P, V33, P428, DOI 10.1016/S0041-1345(00)02078-9; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; HABARAOHKUBO A, 1991, GENE, V105, P221, DOI 10.1016/0378-1119(91)90154-4; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kudo Y, 2000, BBA-MOL BASIS DIS, V1500, P119, DOI 10.1016/S0925-4439(99)00096-4; Kudo Y, 2001, J PHYSIOL-LONDON, V535, P207, DOI 10.1111/j.1469-7793.2001.00207.x; Kudo Y, 2001, J PHYSIOL-LONDON, V531, P405, DOI 10.1111/j.1469-7793.2001.0405i.x; LETHE B, 1992, EUR J IMMUNOL, V22, P2283, DOI 10.1002/eji.1830220916; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pawelec G, 2000, CRIT REV ONCOGENESIS, V11, P97; Praetorius-Ibba M, 2000, BIOCHEMISTRY-US, V39, P13136; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Suzuki S, 2001, BIOCHEM J, V355, P425, DOI 10.1042/0264-6021:3550425; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Uno T, 1997, INVEST OPHTH VIS SCI, V38, P2531; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202	38	1705	1886	3	178	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1269	1274		10.1038/nm934	http://dx.doi.org/10.1038/nm934			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502282				2022-12-25	WOS:000185669700037
J	Hirata, H; Bessho, Y; Kokubu, H; Masamizu, Y; Yamada, S; Lewis, J; Kageyama, R				Hirata, H; Bessho, Y; Kokubu, H; Masamizu, Y; Yamada, S; Lewis, J; Kageyama, R			Instability of Hes7 protein is crucial for the somite segmentation clock	NATURE GENETICS			English	Article							LUNATIC-FRINGE EXPRESSION; OSCILLATORY EXPRESSION; PRESOMITIC MESODERM; DYNAMIC EXPRESSION; MECHANISM; GENES; SUGGESTS; PATHWAY; HER1; TIME	During somitogenesis, a pair of somites buds off from the presomitic mesoderm every 2 hours in mouse embryos, suggesting that somite segmentation is controlled by a biological clock with a 2-hour cycle(1-3). Expression of the basic helix-loop-helix factor Hes7, an effector of Notch signaling, follows a 2-hour oscillatory cycle controlled by negative feedback; this is proposed to be the molecular basis for the somite segmentation clock(4-6). If the proposal is correct, this clock should depend crucially on the short lifetime of Hes7. To address the biological importance of Hes7 instability, we generated mice expressing mutant Hes7 with a longer half-life (similar to30 min compared with similar to22 min for wild-type Hes7) but normal repressor activity. In these mice, somite segmentation and oscillatory expression became severely disorganized after a few normal cycles of segmentation. We simulated this effect mathematically using a direct autorepression model. Thus, instability of Hes7 is essential for sustained oscillation and for its function as a segmentation clock.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Canc Res UK London Res Inst, Vertebrate Dev Lab, London WC2A 3PX, England	Kyoto University; Cancer Research UK	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	rkageyam@virus.kyoto-u.ac.jp	Lewis, Julian H/E-8733-2010	Hirata, Hiromi/0000-0002-3769-7441; Masamizu, Yoshito/0000-0002-6929-4882				Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Bessho Y, 2003, GENE DEV, V17, P1451, DOI 10.1101/gad.1092303; Bessho Y, 2003, CURR OPIN GENET DEV, V13, P379, DOI 10.1016/S0959-437X(03)00083-2; Bessho Y, 2001, GENE DEV, V15, P2642, DOI 10.1101/gad.930601; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Henry CA, 2002, DEVELOPMENT, V129, P3693; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Holley SA, 2002, DEVELOPMENT, V129, P1175; Jensen MH, 2003, FEBS LETT, V541, P176, DOI 10.1016/S0014-5793(03)00279-5; Jouve C, 2000, DEVELOPMENT, V127, P1421; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Lewis J, 2003, CURR BIOL, V13, P1398, DOI 10.1016/S0960-9822(03)00534-7; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Monk NAM, 2003, CURR BIOL, V13, P1409, DOI 10.1016/S0960-9822(03)00494-9; Morales AV, 2002, DEV CELL, V3, P63, DOI 10.1016/S1534-5807(02)00211-3; Oates AC, 2002, DEVELOPMENT, V129, P2929; Pourquie O, 2003, SCIENCE, V301, P328, DOI 10.1126/science.1085887; Pourquie O, 2001, ANNU REV CELL DEV BI, V17, P311, DOI 10.1146/annurev.cellbio.17.1.311; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; Sawada A, 2000, DEVELOPMENT, V127, P1691; Serth K, 2003, GENE DEV, V17, P912, DOI 10.1101/gad.250603; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460	25	182	190	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					750	754		10.1038/ng1372	http://dx.doi.org/10.1038/ng1372			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15170214	Bronze			2022-12-25	WOS:000222354100027
J	Qi, BX; Fraser, T; Mugford, S; Dobson, G; Sayanova, O; Butler, J; Napier, JA; Stobart, AK; Lazarus, CM				Qi, BX; Fraser, T; Mugford, S; Dobson, G; Sayanova, O; Butler, J; Napier, JA; Stobart, AK; Lazarus, CM			Production of very long chain polyunsaturated omega-3 and omega-6 fatty acids in plants	NATURE BIOTECHNOLOGY			English	Article							HETEROLOGOUS EXPRESSION; MORTIERELLA-ALPINA; MASS-SPECTROMETRY; DESATURASE GENE; LINOLENIC ACID; IDENTIFICATION; CLONING; CDNA; BIOSYNTHESIS; ACCUMULATION	We report the production of two very long chain polyunsaturated fatty acids, arachidonic acid (AA) and eicosapentaenoic acid (EPA), in substantial quantities in a higher plant. This was achieved using genes encoding enzymes participating in the omega3/6 Delta(8)-desaturation biosynthetic pathways for the formation of C20 polyunsaturated fatty acids. Arabidopsis thaliana was transformed sequentially with genes encoding a Delta(9)-specific elongating activity from Isochrysis galbana, a Delta(8)-desaturase from Euglena gracilis and a Delta(5)-desaturase from Mortierella alpina. Instrumental in the successful reconstitution of these C20 polyunsaturated fatty acid biosynthetic pathways was the I. galbana C18-Delta(9)-elongating activity, which may bypass rate-limiting steps present in the conventional Delta(6)-desaturase/elongase pathways. The accumulation of EPA and AA in transgenic plants is a breakthrough in the search for alternative sustainable sources of fish oils.	Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England; Long Ashton Res Stn, Bristol BS41 9AF, Avon, England; Scottish Crop Res Inst, Dundee DD2 5DA, Scotland	University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; James Hutton Institute	Qi, BX (corresponding author), Univ Bath, Dept Biol & Biochem, 4 South,Claverton Down, Bath BA2 7AY, Avon, England.	bssbq@bath.ac.uk	Lazarus, Colin M/B-9474-2011	Napier, Johnathan/0000-0003-3580-3607; Qi, Baoxiu/0000-0002-9425-935X; Mugford, Sam/0000-0002-8537-5578	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004156] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Berdeaux O, 1996, J AM OIL CHEM SOC, V73, P1323, DOI 10.1007/BF02525463; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Crawford MA, 2000, AM J CLIN NUTR, V71, p275S, DOI 10.1093/ajcn/71.1.275S; Domergue F, 2003, J BIOL CHEM, V278, P35115, DOI 10.1074/jbc.M305990200; Drexler H, 2003, J PLANT PHYSIOL, V160, P779, DOI 10.1078/0176-1617-01025; Fievez V, 2003, ANIM FEED SCI TECH, V104, P41, DOI 10.1016/S0377-8401(02)00330-9; Gill I, 1997, TRENDS BIOTECHNOL, V15, P401, DOI 10.1016/S0167-7799(97)01076-7; Girke T, 1998, PLANT J, V15, P39, DOI 10.1046/j.1365-313X.1998.00178.x; Hites RA, 2004, SCIENCE, V303, P226, DOI 10.1126/science.1091447; Huang YS, 1999, LIPIDS, V34, P649, DOI 10.1007/s11745-999-0410-8; KINSELLA JE, 1990, NUTRITION, V6, P24; Knutzon DS, 1998, J BIOL CHEM, V273, P29360, DOI 10.1074/jbc.273.45.29360; Larson TR, 2000, BIOCHEM SOC T, V28, P575, DOI 10.1042/BST0280575; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Leonard AE, 2000, BIOCHEM J, V347, P719, DOI 10.1042/0264-6021:3470719; McCormac AC, 1997, MOL BIOTECHNOL, V8, P199, DOI 10.1007/BF02760773; Michaelson LV, 1998, FEBS LETT, V439, P215, DOI 10.1016/S0014-5793(98)01385-4; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; Millar AA, 1998, PLANT CELL, V10, P1889, DOI 10.1105/tpc.10.11.1889; Napier JA, 1998, BIOCHEM J, V330, P611; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; QI B, 2004, IN PRESS PLANT PHYSL; Qi BX, 2003, FEBS LETT, V547, P137, DOI 10.1016/S0014-5793(03)00676-8; Qi BX, 2002, FEBS LETT, V510, P159, DOI 10.1016/S0014-5793(01)03247-1; Sakuradani E, 1999, GENE, V238, P445, DOI 10.1016/S0378-1119(99)00359-5; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; STYMNE S, 1984, BIOCHEM J, V223, P305, DOI 10.1042/bj2230305; STYMNE S, 1988, BIOCH PLANTS COMPREH, P175; Thies F, 2003, LANCET, V361, P477, DOI 10.1016/S0140-6736(03)12468-3; Wallis JG, 1999, ARCH BIOCHEM BIOPHYS, V365, P307, DOI 10.1006/abbi.1999.1167; Watts JL, 1999, ARCH BIOCHEM BIOPHYS, V362, P175, DOI 10.1006/abbi.1998.1024; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; YAMAZAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1123, P18, DOI 10.1016/0005-2760(92)90166-S; Yokoo Edna M, 2003, Environ Health, V2, P8, DOI 10.1186/1476-069X-2-8; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x; ZHANG JY, 1988, BIOMED ENVIRON MASS, V15, P33, DOI 10.1002/bms.1200150106	42	317	390	4	100	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					739	745		10.1038/nbt972	http://dx.doi.org/10.1038/nbt972			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15146198	Green Published			2022-12-25	WOS:000221785300036
J	Smith-Jones, PM; Solit, DB; Akhurst, T; Afroze, F; Rosen, N; Larson, SM				Smith-Jones, PM; Solit, DB; Akhurst, T; Afroze, F; Rosen, N; Larson, SM			Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; PROSTATE-CANCER; TYROSINE-KINASE; MONOCLONAL-ANTIBODIES; EXPRESSION; THERAPY; TUMORS; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN	The development of therapeutic inhibitors of key signaling pathways has been hampered by the inability to assess the effect of a drug on its target in the patient. 17-allylaminogeldanamycin (17-AAG) is the first Hsp90 inhibitor to be tested in a clinical trial. It causes the degradation of HER2 and other Hsp90 targets, and has antitumor activity in preclinical models. We have developed a method for imaging the inhibition of Hsp90 by 17-AAG. We labeled an F( ab) 2 fragment of the anti-HER2 antibody Herceptin with Ga-68, a positron emitter, which allows the sequential positron-emission tomographic imaging of HER2 expression. We have used this method to quantify as a function of time the loss and recovery of HER2 induced by 17-AAG in animal tumors. This approach allows noninvasive imaging of the pharmacodynamics of a targeted drug and will facilitate the rational design of combination therapy based on target inhibition.	Mem Sloan Kettering Canc Ctr, Dept Radiol, Nucl Med Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Smith-Jones, PM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiol, Nucl Med Serv, Box 77,1275 York Ave, New York, NY 10021 USA.	smith-jp@mskcc.org	Rosen, Neal/ABF-2677-2020; Solit, David B./AAC-5309-2019		NATIONAL CANCER INSTITUTE [R24CA086307, P50CA086438] Funding Source: NIH RePORTER; NCI NIH HHS [CA86307, P50 CA86438] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anido J, 2003, CLIN CANCER RES, V9, P1274; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; Baselga J, 2002, ONCOLOGY-BASEL, V63, P6, DOI 10.1159/000066198; Cohen SJ, 2003, J CLIN ONCOL, V21, P1301, DOI 10.1200/JCO.2003.08.040; Ebert AD, 2000, J RECEPT SIGNAL TR R, V20, P1, DOI 10.3109/10799890009150035; Harris LN, 2001, J CLIN ONCOL, V19, P1698, DOI 10.1200/JCO.2001.19.6.1698; Herbst RS, 2002, ONCOLOGIST, V7, P9; Hidalgo M, 2003, SEMIN ONCOL, V30, P25, DOI 10.1016/S0093-7754(03)00186-6; Khalil Mazen Y, 2003, Expert Rev Anticancer Ther, V3, P367, DOI 10.1586/14737140.3.3.367; Mandelli Franco, 2002, Rev Clin Exp Hematol, V6, P60, DOI 10.1046/j.1468-0734.2002.00061.x; Maulik G, 2002, CLIN CANCER RES, V8, P620; Nahta R, 2003, ONCOLOGIST, V8, P5, DOI 10.1634/theoncologist.8-1-5; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neckers L, 2002, CLIN CANCER RES, V8, P962; Paterson SC, 2003, BRIT J CANCER, V88, P983, DOI 10.1038/sj.bjc.6600828; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Rasey JS, 1996, INT J RADIAT ONCOL, V36, P417, DOI 10.1016/S0360-3016(96)00325-2; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; ROCKOFF SD, 1980, CANCER RES, V40, P3054; Scher HI, 1995, CLIN CANCER RES, V1, P545; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Sledge GW, 2003, SEMIN ONCOL, V30, P19, DOI 10.1053/sonc.2003.37271; Smith-Jones PM, 2000, CANCER RES, V60, P5237; Solit DB, 2003, CANCER RES, V63, P2139; Solit DB, 2002, CLIN CANCER RES, V8, P986; Vogel Charles L, 2003, Breast J, V9, P452, DOI 10.1046/j.1524-4741.2003.09602.x; Yee Karen W L, 2003, Expert Rev Anticancer Ther, V3, P295, DOI 10.1586/14737140.3.3.295; Zheng FF, 2000, CANCER RES, V60, P2090	30	255	261	1	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					701	706		10.1038/nbt968	http://dx.doi.org/10.1038/nbt968			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15133471				2022-12-25	WOS:000221785300031
J	Spillane, C; Curtis, MD; Grossniklaus, U				Spillane, C; Curtis, MD; Grossniklaus, U			Apomixis technology development - virgin births in farmers' fields?	NATURE BIOTECHNOLOGY			English	Editorial Material							TRANSGENIC CROPS; PLANTS; EVOLUTION; SEX	Apomixis is the process of asexual reproduction through seed, in the absence of meiosis and fertilization, generating clonal progeny of maternal origin. Major benefits to agriculture could result from harnessing apomixis in crop plants. Although >400 apomictic plant species are known, apomixis is rare among crop plants, and the transfer of apomixis to crop varieties by conventional breeding has been largely unsuccessful. Because apomictic and sexual pathways are closely related, de novo engineering of apomixis might be achieved in sexually reproducing crops. Early consideration of issues relating to biosafety and intellectual property (IP) management can facilitate the acceptance and deployment of apomixis technology in agriculture.	Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; Univ Zurich, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland	University of Zurich; University of Zurich	Grossniklaus, U (corresponding author), Univ Zurich, Inst Plant Biol, Zollikerstr 107, CH-8008 Zurich, Switzerland.	grossnik@boinst.unizh.ch	Grossniklaus, Ueli/A-2736-2012; Grossniklaus, Ueli/E-9995-2016; Spillane, Charles/H-3786-2013	Grossniklaus, Ueli/0000-0002-0522-8974; Spillane, Charles/0000-0003-3318-323X				Alleman M, 2000, PLANT MOL BIOL, V43, P147, DOI 10.1023/A:1006419025155; Baroux C, 2002, ADV GENET, V46, P165; Berthaud J, 2001, FLOWERING OF APOMIXIS: FROM MECHANISMS TO GENETIC ENGINEERING, P8; BIERZYCHUDEK P, 1985, EXPERIENTIA, V41, P1255, DOI 10.1007/BF01952068; Chapman HM, 2000, HEREDITY, V84, P401, DOI 10.1046/j.1365-2540.2000.00657.x; Dale PJ, 2002, NAT BIOTECHNOL, V20, P567, DOI 10.1038/nbt0602-567; Daniell H, 2002, NAT BIOTECHNOL, V20, P581, DOI 10.1038/nbt0602-581; Daniell H, 2000, BIOTECHNOL GENET ENG, V17, P327, DOI 10.1080/02648725.2000.10647997; Ellstrand NC, 2000, P NATL ACAD SCI USA, V97, P7043, DOI 10.1073/pnas.97.13.7043; Grossniklaus U, 2001, FLOWERING OF APOMIXIS: FROM MECHANISMS TO GENETIC ENGINEERING, P168; Grossniklaus U, 2001, PLANT CELL, V13, P1491, DOI 10.1105/tpc.13.7.1491; Holsinger KE, 2000, P NATL ACAD SCI USA, V97, P7037, DOI 10.1073/pnas.97.13.7037; Hurst LD, 1996, TRENDS ECOL EVOL, V11, pA46; Jaenisch R, 2001, SCIENCE, V291, P2552, DOI 10.1126/science.1060463; JEFFERSON RA, 1994, MONITOR, V19, P14; Koltunow AM, 2003, ANNU REV PLANT BIOL, V54, P547, DOI 10.1146/annurev.arplant.54.110901.160842; KONDRASHOV AS, 1985, GENETICS, V111, P635; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; Manganaris GA, 2003, PLANT CELL REP, V22, P195, DOI 10.1007/s00299-003-0681-y; MCMENIMAN S, 1997, WP28 ACIAR; Quarin CL, 2001, SEX PLANT REPROD, V13, P243, DOI 10.1007/s004970100070; Redenbaugh K., 1993, SYNSEEDS APPL SYNTHE; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rose-Fricker CA, 2002, CROP SCI, V42, P307, DOI 10.2135/cropsci2002.0307; Scheid OM, 1996, P NATL ACAD SCI USA, V93, P7114, DOI 10.1073/pnas.93.14.7114; Smale M, 1997, WORLD DEV, V25, P1257, DOI 10.1016/S0305-750X(97)00038-7; Spielman M, 2003, PHILOS T ROY SOC B, V358, P1095, DOI 10.1098/rstb.2003.1298; Spillane C, 2002, BIOTECHNOLOGY, AGRICULTURE AND THE DEVELOPING WORLD: THE DISTRIBUTIONAL IMPLICATIONS OF TECHNOLOGICAL CHANGE, P67; Spillane C, 2001, SEX PLANT REPROD, V14, P179, DOI 10.1007/s00497-001-0117-1; van Dijk P, 2000, TRENDS PLANT SCI, V5, P81, DOI 10.1016/S1360-1385(99)01545-9; Wood D, 1998, FOOD POLICY, V23, P371, DOI 10.1016/S0306-9192(98)00043-8; 2001, SEEDLING, V18	32	119	131	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					687	691		10.1038/nbt976	http://dx.doi.org/10.1038/nbt976			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15175691				2022-12-25	WOS:000221785300028
J	Zhang, HQ; Berg, JS; Li, ZL; Wang, YL; Lang, P; Sousa, AD; Bhaskar, A; Cheney, RE; Stromblad, S				Zhang, HQ; Berg, JS; Li, ZL; Wang, YL; Lang, P; Sousa, AD; Bhaskar, A; Cheney, RE; Stromblad, S			Myosin-X provides a motor-based link between integrins and the cytoskeleton	NATURE CELL BIOLOGY			English	Article							CELL-MIGRATION; UNCONVENTIONAL MYOSIN; SIGNAL-TRANSDUCTION; DOMAIN; TALIN; ACTIVATION; ADHESION; RECOGNITION; FILOPODIA; MUTATIONS	Unconventional myosins are actin-based motors with a growing number of attributed functions(1). Interestingly, it has been proposed that integrins are transported by unidentified myosins to facilitate cellular remodelling(2). Here we present an interaction between the unconventional myosin-X (Myo10) FERM (band 4.1/ezrin/radixin/moesin) domain and an NPXY motif within beta-integrin cytoplasmic domains. Importantly, knock-down of Myo10 by short interfering RNA impaired integrin function in cell adhesion, whereas overexpression of Myo10 stimulated the formation and elongation of filopodia in an integrin-dependent manner and relocalized integrins together with Myo10 to the tips of filopodia. This integrin relocalization and filopodia elongation did not occur with Myo10 mutants deficient in integrin binding or with a beta(1)-integrin point mutant deficient in Myo10 binding. Taken together, these results indicate that Myo10-mediated relocalization of integrins might serve to form adhesive structures and thereby promote filopodial extension.	Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Pathol, Karolinska Inst, SE-14186 Huddinge, Sweden; First Mil Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Peoples R China; First Mil Med Univ, Nanfang Hosp, Inst Gastroenterol, Guangzhou 510515, Peoples R China; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Karolinska Institutet; Karolinska University Hospital; Southern Medical University - China; Southern Medical University - China; University of North Carolina; University of North Carolina Chapel Hill	Stromblad, S (corresponding author), Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Pathol, Karolinska Inst, SE-14186 Huddinge, Sweden.	hongquan.zhang@labmed.ki.se; staffan.stromblad@labmed.ki.se	Lång, Pernilla/AAA-6660-2019	Lång, Pernilla/0000-0002-3605-4014; Berg, Jonathan/0000-0003-2360-2664; Sousa, Aurea/0000-0002-9153-7414; Stromblad, Staffan/0000-0002-1236-6339; Cheney, Richard/0000-0001-6565-7888	NIDCD NIH HHS [DC03299, R01 DC003299] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003299, R29DC003299] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Evans AL, 2000, NAT GENET, V24, P424, DOI 10.1038/74286; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Grabham PW, 2000, J CELL SCI, V113, P3003; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Steketee M, 2001, MOL BIOL CELL, V12, P2378, DOI 10.1091/mbc.12.8.2378; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Vuori K, 1999, NAT CELL BIOL, V1, pE85, DOI 10.1038/12081; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; YLANNE J, 1998, FRONT BIOSCI, V3, P877; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	30	268	276	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2004	6	6					523	531		10.1038/ncb1136	http://dx.doi.org/10.1038/ncb1136			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	825LH	15156152				2022-12-25	WOS:000221759400012
J	Miklos, GLG; Maleszka, R				Miklos, GLG; Maleszka, R			Microarray reality checks in the context of a complex disease	NATURE BIOTECHNOLOGY			English	Article							DIFFERENTIAL GENE-EXPRESSION; MESSENGER-RNA EXPRESSION; OLIGONUCLEOTIDE ARRAYS; SACCHAROMYCES-CEREVISIAE; CDNA MICROARRAYS; SCHIZOPHRENIA; BRAINS; MODEL; LONG; ADENOCARCINOMA	A problem in analyzing microarray-based gene expression data is the separation of genes causally involved in a disease from innocent bystander genes, whose expression levels have been secondarily altered by primary changes elsewhere. To investigate this issue systematically in the context of a class of complex human diseases, we have compared microarray-based gene expression data with non-microarray-based clinical and biological data about the schizophrenias to ask whether these two approaches prioritize the same genes. We find that genes whose expression changes are deemed to be of importance from microarrays are rarely those classified as of importance from clinical, in situ, molecular, single-nucleotide polymorphism (SNP) association, knockout and drug perturbation data. This disparity is not limited to the schizophrenias but characterizes other human disease data sets. It also extends to biological validation of microarray data in model organisms, in which genome-wide phenotypic data have been systematically compared with microarray data. In addition, different bioinformatic protocols applied to the same microarray data yield quite different gene sets and thus make clinical decisions less straightforward. We discuss how progress may be improved in the clinical area by the assignment of high-quality phenotypic values to each member of a microarray-assigned gene set.	Secure Genet, Sydney, NSW 2108, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 0200, Australia	Australian National University	Miklos, GLG (corresponding author), Secure Genet, 81 Bynya Rd, Sydney, NSW 2108, Australia.	gmiklos@securegenetics.com	Blow, joe/C-8616-2009; Maleszka, Ryszard/A-6078-2008	Maleszka, Ryszard/0000-0003-1855-555X				Andreasen NC, 2000, BRAIN RES REV, V31, P106, DOI 10.1016/S0165-0173(99)00027-2; ANDREASEN NC, 1995, ARCH GEN PSYCHIAT, V52, P341; Andreasen NC, 1999, ARCH GEN PSYCHIAT, V56, P781, DOI 10.1001/archpsyc.56.9.781; Arkin A, 1997, SCIENCE, V277, P1275, DOI 10.1126/science.277.5330.1275; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Barczak A, 2003, GENOME RES, V13, P1775, DOI 10.1101/gr.1048803; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; Bernstein HG, 2002, NEUROREPORT, V13, P393, DOI 10.1097/00001756-200203250-00006; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birrell GW, 2002, P NATL ACAD SCI USA, V99, P8778, DOI 10.1073/pnas.132275199; BROWNING MD, 1993, BIOL PSYCHIAT, V34, P529, DOI 10.1016/0006-3223(93)90195-J; Carney SL, 2003, DRUG DISCOV TODAY, V8, P436, DOI 10.1016/S1359-6446(03)02710-7; *CHIPP FOR II, 2002, NATURE GENET S, V32, P465; Chudin E, 2002, GENOME BIOL, V3; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Davidson EH, 2003, P NATL ACAD SCI USA, V100, P1475, DOI 10.1073/pnas.0437746100; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dewey TG, 2002, DRUG DISCOV TODAY, V7, pS170, DOI 10.1016/S1359-6446(02)02440-6; Erickson HP, 1997, NAT GENET, V17, P5, DOI 10.1038/ng0997-5; Famili I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/pnas.2235812100; Fan JQ, 2004, P NATL ACAD SCI USA, V101, P1135, DOI 10.1073/pnas.0307557100; Freedman R, 2003, NEW ENGL J MED, V349, P1738, DOI 10.1056/NEJMra035458; Garber K, 2004, SCIENCE, V303, P1754, DOI 10.1126/science.303.5665.1754; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Guidotti A, 2000, ARCH GEN PSYCHIAT, V57, P1061, DOI 10.1001/archpsyc.57.11.1061; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Herrgard MJ, 2003, GENOME RES, V13, P2423, DOI 10.1101/gr.1330003; Holzman T, 2004, CURR OPIN BIOTECH, V15, P52, DOI 10.1016/j.copbio.2003.12.004; Honey GD, 2003, PSYCHOL MED, V33, P1007, DOI 10.1017/S0033291703007864; Huntsman MM, 1998, P NATL ACAD SCI USA, V95, P15066, DOI 10.1073/pnas.95.25.15066; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; JONES L, 2004, IN PRESS METHODS MIC, V3; JUNG SH, 2004, IN PRESS METHODS MIC, V3; KACSER H, 1981, GENETICS, V97, P639; Karlsson H, 2001, P NATL ACAD SCI USA, V98, P4634, DOI 10.1073/pnas.061021998; KIIVERI HT, 2003, LECT NOTES MONOGRAPH, V40, P127; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Kothapalli R, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-22; Kuo WP, 2002, BIOINFORMATICS, V18, P405, DOI 10.1093/bioinformatics/18.3.405; Lemon WJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r67; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 2002, TOXICOL SCI, V69, P383, DOI 10.1093/toxsci/69.2.383; Li JZ, 2004, HUM MOL GENET, V13, P609, DOI 10.1093/hmg/ddh065; Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; McGinnis RE, 2001, NAT GENET, V28, P128, DOI 10.1038/88839; Middleton FA, 2002, J NEUROSCI, V22, P2718, DOI 10.1523/JNEUROSCI.22-07-02718.2002; MIKLOS GLG, 1993, J NEUROBIOL, V24, P842, DOI 10.1002/neu.480240610; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Miklos GLG, 2001, PROTEOMICS, V1, P30; Miklos GLG, 2001, PROTEOMICS, V1, P169, DOI 10.1002/1615-9861(200102)1:2<169::AID-PROT169>3.0.CO;2-C; Mills MA, 2001, HUM MOL GENET, V10, P1335, DOI 10.1093/hmg/10.13.1335; Mimmack ML, 2002, P NATL ACAD SCI USA, V99, P4680, DOI 10.1073/pnas.032069099; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Moler EJ, 2000, PHYSIOL GENOMICS, V4, P109, DOI 10.1152/physiolgenomics.2000.4.2.109; MORRIS JS, 2004, IN PRESS METHODS MIC, V3, P1; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Palsson BO, 2004, CURR OPIN BIOTECH, V15, P50, DOI 10.1016/j.copbio.2004.01.006; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Pongrac J, 2002, NEUROCHEM RES, V27, P1049, DOI 10.1023/A:1020904821237; Popken GJ, 2000, P NATL ACAD SCI USA, V97, P9276, DOI 10.1073/pnas.150243397; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P323, DOI 10.1093/cercor/5.4.323; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; ROBB L, 2004, IN PRESS METHODS MIC, V3; Rothermundt M, 2001, BRAIN BEHAV IMMUN, V15, P319, DOI 10.1006/brbi.2001.0648; SEDVALL G, 1995, LANCET, V346, P743, DOI 10.1016/S0140-6736(95)91508-7; Shedden K, 2002, P NATL ACAD SCI USA, V99, P4379, DOI 10.1073/pnas.062569899; Somorjai RL, 2003, BIOINFORMATICS, V19, P1484, DOI 10.1093/bioinformatics/btg182; Staudt LM, 2000, ANNU REV IMMUNOL, V18, P829, DOI 10.1146/annurev.immunol.18.1.829; Stock RP, 2003, NAT BIOTECHNOL, V21, P13, DOI 10.1038/nbt0103-13; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; TAUSSIG MJ, 2003, TARGETS, V2, P169, DOI DOI 10.1007/S00216-010-3661-4; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Tkachev D, 2003, LANCET, V362, P798, DOI 10.1016/S0140-6736(03)14289-4; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; WATKINS S, 1994, P NATL ACAD SCI USA, V91, P9417, DOI 10.1073/pnas.91.20.9417; Wigle DA, 2002, CANCER RES, V62, P3005; Wigle Dennis A, 2004, Genome Biol, V5, P309, DOI 10.1186/gb-2004-5-2-309; WUENSCHE A, 2004, MODULARITY DEV EVOLU, P1; Yolken RH, 2000, BRAIN RES REV, V31, P193, DOI 10.1016/S0165-0173(99)00037-5; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	94	131	145	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					615	621		10.1038/nbt965	http://dx.doi.org/10.1038/nbt965			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15122300				2022-12-25	WOS:000221159700033
J	Roy, NS; Nakano, T; Keyoung, HM; Windrem, M; Rashbaum, WK; Alonso, ML; Kang, J; Peng, WG; Carpenter, MK; Lin, J; Nedergaard, M; Goldman, SA				Roy, NS; Nakano, T; Keyoung, HM; Windrem, M; Rashbaum, WK; Alonso, ML; Kang, J; Peng, WG; Carpenter, MK; Lin, J; Nedergaard, M; Goldman, SA			Telomerase immortalization of neuronally restricted progenitor cells derived from the human fetal spinal cord	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO; NEURAL STEM; BRAIN; DIFFERENTIATION; PROTEIN; GENE; IDENTIFICATION; MULTIPOTENT; PRECURSORS; EXPRESSION	Lineage-restricted progenitors of the central nervous system (CNS) are not readily expandable because their mitotic competence is limited. Here we used retroviral overexpression of human telomerase reverse transcriptase (hTERT) to immortalize progenitors from human fetal spinal cord. The hTERT-immortalized cells divided in basic fibroblast growth factor (bFGF) expressed high telomerase activity, and gave rise to phenotypically restricted subpopulations of either glia or neurons. The latter included a prototypic line, hSC11V-TERT, that gave rise only to neurons. These included both chx10(+) interneurons and Islet1(+)/Hb9(+)/ChAT(+) motor neurons; the latter were recognized by green fluorescent protein (GFP) driven by the Hb9 enhancer. The neurons were postmitotic and achieved electrophysiologic competence. Upon xenograft to both fetal rat brain and injured adult spinal cord, they matured as neurons and survived for 6 months, with no evident tumorigenesis. The cells have survived >168 doublings in vitro, with karyotypic normalcy and without replicative senescence. hTERT overexpression thus permits the generation of progenitor lines able to give rise to phenotypically restricted neurons.	Cornell Univ, Med Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY 10021 USA; Cornell Univ, Med Ctr, Dept Pathol, New York, NY 10021 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA; Geron Corp, Menlo Pk, CA 94025 USA; Univ Rochester, Med Ctr, Rochester, NY 14642 USA	Cornell University; Cornell University; Cornell University; New York Medical College; Geron Corporation; University of Rochester	Goldman, SA (corresponding author), Cornell Univ, Med Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA.	steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; BARBER RP, 1982, BRAIN RES, V238, P305, DOI 10.1016/0006-8993(82)90107-X; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; Fu WM, 2002, J NEUROSCI, V22, P10710; Gorbunova V, 2003, CELL CYCLE, V2, P534, DOI 10.4161/cc.2.6.515; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Rao MS, 1999, ANAT RECORD, V257, P137; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; TODARO GJ, 1965, VIROLOGY, V27, P179, DOI 10.1016/0042-6822(65)90157-1; TSE FW, 1992, J NEUROSCI, V12, P1781; Ulaner GA, 1997, MOL HUM REPROD, V3, P769, DOI 10.1093/molehr/3.9.769; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; WINDREM M, 2004, NAT MED, V9, P439; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; YOUNG W, 1980, J NEUROSURG, V52, P64, DOI 10.3171/jns.1980.52.1.0064; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	44	108	119	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2004	22	3					297	305		10.1038/nbt944	http://dx.doi.org/10.1038/nbt944			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	779LE	14990951				2022-12-25	WOS:000189297200022
J	Satchi-Fainaro, R; Puder, M; Davies, JW; Tran, HT; Sampson, DA; Greene, AK; Corfas, G; Folkman, J				Satchi-Fainaro, R; Puder, M; Davies, JW; Tran, HT; Sampson, DA; Greene, AK; Corfas, G; Folkman, J			Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470	NATURE MEDICINE			English	Article							ENZYME PRODRUG THERAPY; CATHEPSIN-B; PHASE-I; INHIBITOR TNP-470; ENDOTHELIAL-CELLS; AGENT TNP-470; SOLID TUMORS; BRAIN-TUMORS; HUMAN PLASMA; CANCER	Angiogenesis is crucial for tumor growth. Angiogenesis inhibitors, such as O-(chloracetyl-carbamoyl) fumagillol (TNP-470), are thus emerging as a new class of anticancer drugs. In clinical trials, TNP-470 slowed tumor growth in patients with metastatic cancer. However, at higher doses necessary for tumor regression, many patients experienced neurotoxicity. We therefore synthesized and characterized a water-soluble conjugate of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer, Gly-Phe-Leu-Gly linker and TNP-470. This conjugate accumulated selectively in tumor vessels because of the enhanced permeability and retention (EPR) effect. HPMA copolymer-TNP-470 substantially enhanced and prolonged the activity of TNP-470 in vivo in tumor and hepatectomy models. Polymer conjugation prevented TNP-470 from crossing the blood-brain barrier (BBB) and decreased its accumulation in normal organs, thereby avoiding drug-related toxicities. Treatment with TNP-470 caused weight loss and neurotoxic effects in mice, whereas treatment with the conjugate did not. This new approach for targeting angiogenesis inhibitors specifically to the tumor vasculature may provide a new strategy for the rational design of cancer therapies.	Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Polymer Labs, Church Stretton SY6 6EA, Shrops, England; Univ Texas, MD Anderson Canc Ctr, Div Canc Med & Pharm, Houston, TX 77030 USA; Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Boston Children's Hospital	Folkman, J (corresponding author), Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.	judah.folkman@childrens.harvard.edu	Satchi-Fainaro, Ronit/F-9137-2011; Corfas, Gabriel/AAH-2378-2020	Satchi-Fainaro, Ronit/0000-0002-7360-7837; Corfas, Gabriel/0000-0001-5412-9473; Tran, Hai/0000-0003-4065-9355				ANTOINE N, 1994, CANCER RES, V54, P2073; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; DUNCAN R, 1983, MAKROMOL CHEM, V184, P1997; DUNCAN R, 1986, BIOSCIENCE REP, V6, P869, DOI 10.1007/BF01116240; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Duncan R, 2001, J CONTROL RELEASE, V74, P135, DOI 10.1016/S0168-3659(01)00328-5; Duncan R, 1998, HUM EXP TOXICOL, V17, P93, DOI 10.1191/096032798678908378; DVORAK HF, 1988, AM J PATHOL, V133, P95; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1998, ACCOMPLISHMENTS CANC, P32; Folkman J, 2003, CANC MED, P161; Francis G. E., 1992, STABILITY PROTEIN PH, P235; Gianasi E, 1999, EUR J CANCER, V35, P994, DOI 10.1016/S0959-8049(99)00030-1; Greene AK, 2003, ANN SURG, V237, P530, DOI 10.1097/00000658-200304000-00015; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Herbst RS, 2002, J CLIN ONCOL, V20, P4440, DOI 10.1200/JCO.2002.04.006; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kim Edward S, 2002, Curr Oncol Rep, V4, P325, DOI 10.1007/s11912-002-0008-0; Kudelka AP, 1997, CLIN CANCER RES, V3, P1501; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Lah TT, 2000, HUM PATHOL, V31, P149, DOI 10.1016/S0046-8177(00)80214-2; Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; Ong VS, 1998, J CHROMATOGR B, V710, P173, DOI 10.1016/S0378-4347(98)00111-X; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Paxinos G., 2001, MOUSE BRAIN STEREOTA; RIHOVA B, 1989, BIOMATERIALS, V10, P335, DOI 10.1016/0142-9612(89)90075-6; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Satchi R, 2001, BRIT J CANCER, V85, P1070, DOI 10.1054/bjoc.2001.2026; Satchi-Fainaro R, 2003, BIOCONJUGATE CHEM, V14, P797, DOI 10.1021/bc020091k; Satchi-Fainaro R, 2002, J DRUG TARGET, V10, P529, DOI 10.1080/1061186021000051062; SCHOOF DD, 1993, INT J CANCER, V55, P630, DOI 10.1002/ijc.2910550419; SEYMOUR LW, 1994, BRIT J CANCER, V70, P636, DOI 10.1038/bjc.1994.363; SEYMOUR LW, 1991, BRIT J CANCER, V63, P859, DOI 10.1038/bjc.1991.190; SEYMOUR LW, 1990, BIOCHEM PHARMACOL, V39, P1125, DOI 10.1016/0006-2952(90)90293-T; Stadler WM, 1999, J CLIN ONCOL, V17, P2541, DOI 10.1200/JCO.1999.17.8.2541; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Strojnik T, 2000, PFLUG ARCH EUR J PHY, V439, pR122, DOI 10.1007/s004240000114; Vasey PA, 1999, CLIN CANCER RES, V5, P83; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; WAYNFORTH HB, 1980, EXPT SURG TECHNIQUE, V2, P34; Whalen CT, 2002, J CHROMATOGR SCI, V40, P214, DOI 10.1093/chromsci/40.4.214; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	49	292	325	2	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					255	261		10.1038/nm1002	http://dx.doi.org/10.1038/nm1002			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14981512				2022-12-25	WOS:000189297700036
J	Thibault, ST; Singer, MA; Miyazaki, WY; Milash, B; Dompe, NA; Singh, CM; Buchholz, R; Demsky, M; Fawcett, R; Francis-Lang, HL; Ryner, L; Cheung, LM; Chong, A; Erickson, C; Fisher, WW; Greer, K; Hartouni, SR; Howie, E; Jakkula, L; Joo, D; Killpack, K; Laufer, A; Mazzotta, J; Smith, RD; Stevens, LM; Stuber, C; Tan, LR; Ventura, R; Woo, A; Zakrajsek, I; Zhao, L; Chen, F; Swimmer, C; Kopczynski, C; Duyk, G; Winberg, ML; Margolis, J				Thibault, ST; Singer, MA; Miyazaki, WY; Milash, B; Dompe, NA; Singh, CM; Buchholz, R; Demsky, M; Fawcett, R; Francis-Lang, HL; Ryner, L; Cheung, LM; Chong, A; Erickson, C; Fisher, WW; Greer, K; Hartouni, SR; Howie, E; Jakkula, L; Joo, D; Killpack, K; Laufer, A; Mazzotta, J; Smith, RD; Stevens, LM; Stuber, C; Tan, LR; Ventura, R; Woo, A; Zakrajsek, I; Zhao, L; Chen, F; Swimmer, C; Kopczynski, C; Duyk, G; Winberg, ML; Margolis, J			A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac	NATURE GENETICS			English	Article							INSERTIONAL MUTAGENESIS; FLP RECOMBINASE; GENOME PROJECT; ELEMENT; GENE; TRANSFORMATION; SEQUENCE; PROTEIN; RNA	With the availability of complete genome sequence for Drosophila melanogaster, one of the next strategic goals for fly researchers is a complete gene knockout collection. The P element transposon(1), the workhorse of D. melanogaster molecular genetics, has a pronounced nonrandom insertion spectrum(2). It has been estimated that 87% saturation of the 13,500-gene complement of D. melanogaster(3) might require generating and analyzing up to 150,000 insertions(2). We describe specific improvements to the lepidopteran transposon piggyBac(4) and the P element that enabled us to tag and disrupt genes in D. melanogaster more efficiently. We generated over 29,000 inserts resulting in 53% gene saturation and a more diverse collection of phenotypically stronger insertional alleles. We found that piggyBac has distinct global and local gene-tagging behavior from that of P elements. Notably, piggyBac excisions from the germ line are nearly always precise, piggyBac does not share chromosomal hotspots associated with P and piggyBac is more effective at gene disruption because it lacks the P bias for insertion in 5' regulatory sequences.	Exelixis, San Francisco, CA 94083 USA	Exelixis, Inc.	Thibault, ST (corresponding author), Exelixis, 170 Harbor Way, San Francisco, CA 94083 USA.	thibault@exelixis.com	Wilson, Matthew H/K-3193-2013					Adams MD, 2002, NAT REV GENET, V3, P189, DOI 10.1038/nrg752; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashburner M., 1989, DROSOPHILA LAB HDB; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Goodwin SF, 2000, GENETICS, V154, P725; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hacker U, 2003, P NATL ACAD SCI USA, V100, P7720, DOI 10.1073/pnas.1230526100; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Handler AM, 2001, INSECT BIOCHEM MOLEC, V31, P111, DOI 10.1016/S0965-1748(00)00159-4; Horn C, 2003, GENETICS, V163, P647; HOROWITZ H, 1995, GENETICS, V139, P327; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; PARKS AL, 2004, NAT GENET       0222; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; ROSEMAN RR, 1995, GENETICS, V141, P1061; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SERANO T, 1995, DEVELOPMENT, V121, P3809; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Spradling AC, 1999, GENETICS, V153, P135; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; ZHANG P, 1993, GENETICS, V133, P361	26	630	643	0	37	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2004	36	3					283	287		10.1038/ng1314	http://dx.doi.org/10.1038/ng1314			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	778PR	14981521	Bronze			2022-12-25	WOS:000189250400018
J	Alexandrakis, G; Brown, EB; Tong, RT; McKee, TD; Campbell, RB; Boucher, Y; Jain, RK				Alexandrakis, G; Brown, EB; Tong, RT; McKee, TD; Campbell, RB; Boucher, Y; Jain, RK			Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors	NATURE MEDICINE			English	Article							IN-VIVO MEASUREMENT; CORRELATION SPECTROSCOPY; PHOTOBLEACHING RECOVERY; HYALURONIC-ACID; DIFFUSION; MACROMOLECULES; INTERSTITIUM; COLLAGEN; ANGIOGENESIS; CONVECTION	Transport parameters determine the access of drugs to tumors. However, technical difficulties preclude the measurement of these parameters deep inside living tissues. To this end, we adapted and further optimized two-photon fluorescence correlation microscopy (TPFCM) for in vivo measurement of transport parameters in tumors. TPFCM extends the detectable range of diffusion coefficients in tumors by one order of magnitude, and reveals both a fast and a slow component of diffusion. The ratio of these two components depends on molecular size and can be altered in vivo with hyaluronidase and collagenase. These studies indicate that TPFCM is a promising tool to dissect the barriers to drug delivery in tumors.	Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Northeastern University	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017; McKee, Trevor David/N-4308-2019	Jain, Rakesh K/0000-0001-7571-3548; McKee, Trevor David/0000-0002-2195-6146	NCI NIH HHS [F32 CA097818, T32CA73479, F32CA97818, P01CA80124, R24CA85140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA073479, P01CA080124, R24CA085140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; BECKENLEHNER K, 1992, J CANCER RES CLIN, V118, P591, DOI 10.1007/BF01211802; Berk DA, 1997, P NATL ACAD SCI USA, V94, P1785, DOI 10.1073/pnas.94.5.1785; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; DE SMEDT SC, 1994, MACROMOLECULES, V27, P141, DOI 10.1021/ma00079a021; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; FLAMION B, 1991, BIOPHYS J, V60, P1229, DOI 10.1016/S0006-3495(91)82157-9; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JAIN RK, 1987, CANCER RES, V47, P3039; LEUNIG M, 1992, CANCER RES, V52, P6553; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Masuda A, 2001, J AM CHEM SOC, V123, P11468, DOI 10.1021/ja016401b; Netti PA, 2000, CANCER RES, V60, P2497; Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; Qiu XL, 1999, LUNG, V177, P273, DOI 10.1007/PL00007647; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Shenoy V, 1995, MACROMOLECULES, V28, P8751, DOI 10.1021/ma00130a007; Smith KJ, 1997, J AM ACAD DERMATOL, V36, P239, DOI 10.1016/S0190-9622(97)70288-3; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9	30	139	141	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					203	207		10.1038/nm981	http://dx.doi.org/10.1038/nm981			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716306				2022-12-25	WOS:000188719600042
J	Ausin, I; Alonso-Blanco, C; Jarillo, JA; Ruiz-Garcia, L; Martinez-Zapater, JM				Ausin, I; Alonso-Blanco, C; Jarillo, JA; Ruiz-Garcia, L; Martinez-Zapater, JM			Regulation of flowering time by FVE, a retinoblastoma-associated protein	NATURE GENETICS			English	Article							ARABIDOPSIS-THALIANA; REPRODUCTIVE DEVELOPMENT; REPEAT PROTEINS; GENE; VERNALIZATION; MUTATIONS; ENCODES; MUTANTS; FRIGIDA; LUMINIDEPENDENS	The initiation of flowering in plants is controlled by environmental and endogenous signals(1,2). Molecular analysis of this process in Arabidopsis thaliana indicates that environmental control is exerted through the photoperiod and vernalization pathways, whereas endogenous signals regulate the autonomous and gibberellin pathways. The vernalization and autonomous pathways converge on the negative regulation of FLC3,4, a gene encoding a MADS-box protein that inhibits flowering(3,4). We cloned FVE, a component of the autonomous pathway that encodes AtMSI4, a putative retinoblastoma-associated protein. FVE interacted with retinoblastoma protein in immunoprecipitation assays, and FLC chromatin was enriched in acetylated histones in fve mutants. We conclude that FVE participates in a protein complex repressing FLC transcription through a histone deacetylation mechanism. Our data provide genetic evidence of a new developmental function of these conserved proteins and identify a new genetic mechanism in the regulation of flowering.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Genet Mol Plantas, E-28049 Madrid, Spain; Inst Nacl Invest & Tecnol Agr & Alimentaria, Dept Biotecnol, Madrid 28040, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Martinez-Zapater, JM (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Genet Mol Plantas, Campus Univ, E-28049 Madrid, Spain.	zapater@cnb.uam.es	Martinez Zapater, Jose/I-4892-2012; Alonso-Blanco, Carlos/F-8864-2016; Ausin, Israel/A-7065-2011	Martinez Zapater, Jose/0000-0001-7217-4454; Alonso-Blanco, Carlos/0000-0002-4738-5556; Ausin, Israel/0000-0002-3707-1780; Ruiz-Garcia, Leonor/0000-0002-3182-4438; Jarillo, Jose Antonio/0000-0002-2963-7641				Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; Boniotti MB, 2001, PLANT J, V28, P341, DOI 10.1046/j.1365-313X.2001.01160.x; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; He YH, 2003, SCIENCE, V302, P1751, DOI 10.1126/science.1091109; Hennig L, 2003, DEVELOPMENT, V130, P2555, DOI 10.1242/dev.00470; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Kenzior AL, 1998, FEBS LETT, V440, P425, DOI 10.1016/S0014-5793(98)01500-2; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LEE I, 1994, PLANT J, V6, P903, DOI 10.1046/j.1365-313X.1994.6060903.x; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; MACKNIGHT R, 1997, CELL, V89, P1; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; MARTINEZZAPATER JM, 1995, PLANT J, V7, P543, DOI 10.1046/j.1365-313X.1995.7040543.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; Rossi V, 2003, PLANT MOL BIOL, V51, P401, DOI 10.1023/A:1022090916446; Rossi V, 2001, MOL GENET GENOMICS, V265, P576, DOI 10.1007/s004380100461; Sanda SL, 1996, MOL GEN GENET, V251, P69; Schomburg FM, 2001, PLANT CELL, V13, P1427, DOI 10.1105/tpc.13.6.1427; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; Williams L, 2000, TRENDS PLANT SCI, V5, P239, DOI 10.1016/S1360-1385(00)01653-8	30	290	309	5	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					162	166		10.1038/ng1295	http://dx.doi.org/10.1038/ng1295			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14745447	Bronze			2022-12-25	WOS:000188542700018
J	Ohtsuka, T; Ryu, H; Minamishima, YA; Macip, S; Sagara, J; Nakayama, KI; Aaronson, SA; Lee, SW				Ohtsuka, T; Ryu, H; Minamishima, YA; Macip, S; Sagara, J; Nakayama, KI; Aaronson, SA; Lee, SW			ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway	NATURE CELL BIOLOGY			English	Article							BCL-2 FAMILY-MEMBERS; RECRUITMENT DOMAIN PROTEIN; KAPPA-B; ACTIVATION; P53; SUPPRESSES; PYRIN; LIFE	The apoptosis-associated speck-like protein (ASC) is an unusual adaptor protein that contains the Pyrin/PAAD death domain in addition to the CARD protein-protein interaction domain(1-5). Here, we present evidence that ASC can function as an adaptor molecule for Bax and regulate a p53-Bax mitochondrial pathway of apoptosis. When ectopically expressed, ASC interacted directly with Bax, colocalized with Bax to the mitochondria, induced cytochrome c release with a significant reduction of mitochondrial membrane potential and resulted in the activation of caspase-9, -2 and -3. The rapid induction of apoptosis by ASC was not observed in Bax-deficient cells. We also show that induction of ASC after exposure to genotoxic stress is dependent on p53. Blocking of endogenous ASC expression by small-interfering RNA ( siRNA) reduced the apoptotic response and inhibited translocation of Bax to mitochondria in response to p53 or genotoxic insult, suggesting that ASC is required to translocate Bax to the mitochondria. Our findings demonstrate that ASC has an essential role in the intrinsic mitochondrial pathway of apoptosis through a p53-Bax network.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Neurol, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Shinshu Univ, Sch Med, Dept Mol Oncol & Angiol, Nagano 3908621, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University; Geriatric Research Education & Clinical Center; Icahn School of Medicine at Mount Sinai; Shinshu University; Kyushu University; Kyushu University	Lee, SW (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu	Macip, Salvador/P-4233-2019; Minamishima, Yoji Andrew/E-5380-2010; Macip, Salvador/K-5985-2014; Macip, Salvador/S-6358-2019	Macip, Salvador/0000-0003-1963-8840; Minamishima, Yoji Andrew/0000-0001-7995-9318; Ryu, Hoon/0000-0001-6544-3732	NCI NIH HHS [CA82211, CA78356, CA80058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356, R01CA082211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Conway KE, 2000, CANCER RES, V60, P6236; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Masumoto J, 2001, BIOCHEM BIOPH RES CO, V280, P652, DOI 10.1006/bbrc.2000.4190; McConnell BB, 2000, CANCER RES, V60, P6243; MIYASHITA T, 1995, CELL, V80, P293; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	30	197	208	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					121	+		10.1038/ncb1087	http://dx.doi.org/10.1038/ncb1087			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14730312				2022-12-25	WOS:000188668300011
J	Yeaman, C; Ayala, MI; Wright, JR; Bard, F; Bossard, C; Ang, A; Maeda, Y; Seufferlein, T; Mellman, I; Nelson, WJ; Malhotra, V				Yeaman, C; Ayala, MI; Wright, JR; Bard, F; Bossard, C; Ang, A; Maeda, Y; Seufferlein, T; Mellman, I; Nelson, WJ; Malhotra, V			Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network	NATURE CELL BIOLOGY			English	Article							POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE; MDCK CELLS; REQUIRES; RECRUITMENT; SECRETION; COMPLEXES; SURFACE; FAMILY; DOMAIN	Protein kinase D (PKD) binds to diacylglycerol (DAG) in the trans-Golgi network (TGN) and is activated by trimeric G-protein subunits.. This complex then regulates the formation of transport carriers in the TGN that traffic to the plasma membrane in non-polarized cells. Here we report specificity of different PKD isoforms in regulating protein trafficking from the TGN. Kinase-inactive forms of PKD1, PKD2 and PKD3 localize to the TGN in polarized and non-polarized cells. PKD activity is required only for the transport of proteins containing basolateral sorting information, and seems to be cargo specific.	Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Osaka 5650871, Japan; Univ Ulm, Dept Internal Med 1, D-89071 Ulm, Germany	University of California System; University of California San Diego; University of Iowa; Stanford University; Yale University; Osaka University; Ulm University	Malhotra, V (corresponding author), Univ Calif San Diego, La Jolla, CA 92093 USA.	malhotra@biomail.ucsd.edu	Ayala, Inmaculada/U-4565-2018; Malhotra, Vivek/O-9811-2014; Yeaman, Charles A/A-1624-2009; BARD, Frederic/G-9914-2011; Seufferlein, Thomas TW/P-7147-2018; Mellman, Ira/ABG-5896-2020	Ayala, Inmaculada/0000-0002-3329-1428; Malhotra, Vivek/0000-0001-6198-7943; BARD, Frederic/0000-0002-3783-4805; Yeaman, Charles/0000-0001-6149-628X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R01GM053747, R01GM046224] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53747, GM 46224, R01 GM053747, GM35227, R01 GM035527, R01 GM046224] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOSTOV KE, 1989, METHOD CELL BIOL, V32, P85; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toomre D, 1999, J CELL SCI, V112, P21; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	28	200	204	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2004	6	2					106	112		10.1038/ncb1090	http://dx.doi.org/10.1038/ncb1090			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	769UN	14743217	Green Accepted			2022-12-25	WOS:000188668300009
J	Pendergraft, WF; Preston, GA; Shah, RR; Tropsha, A; Carter, CW; Jennette, JC; Falk, RJ				Pendergraft, WF; Preston, GA; Shah, RR; Tropsha, A; Carter, CW; Jennette, JC; Falk, RJ			Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3	NATURE MEDICINE			English	Article							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SMALL-VESSEL VASCULITIS; MYASTHENIA-GRAVIS; SYSTEMIC VASCULITIS; PEPTIDE VACCINE; MOLECULAR CHARACTERIZATION; ANTIIDIOTYPIC ANTIBODIES; ACETYLCHOLINE-RECEPTOR; THYROID-DISEASE	It remains unclear how and why autoimmunity occurs. Here we show evidence for a previously unrecognized and possibly general mechanism of autoimmunity. This new finding was discovered serendipitously using material from patients with inflammatory vascular disease caused by antineutrophil cytoplasmic autoantibodies (ANCA) with specificity for proteinase-3 (PR-3). Such patients harbor not only antibodies to the autoantigen (PR-3), but also antibodies to a peptide translated from the antisense DNA strand of PR-3 (complementary PR-3, cPR-3) or to a mimic of this peptide. Immunization of mice with the middle region of cPR-3 resulted in production of antibodies not only to cPR-3, but also to the immunogen's sense peptide counterpart, PR-3. Both human and mouse antibodies to PR-3 and cPR-3 bound to each other, indicating idiotypic relationships. These findings indicate that autoimmunity can be initiated through an immune response against a peptide that is antisense or complementary to the autoantigen, which then induces anti-idiotypic antibodies (autoantibodies) that cross-react with the autoantigen.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Falk, RJ (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.	ronald_falk@med.unc.edu	Tropsha, Alexander/G-6245-2014; Tropsha, Alexander/AAB-8324-2020	Jennette, John Charles/0000-0002-8081-6565	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIDDK NIH HHS [DK-58335-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araga S, 1999, J IMMUNOL, V163, P476; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; Araga S, 1994, Immunomethods, V5, P130, DOI 10.1006/immu.1994.1047; Araga S, 2000, FASEB J, V14, P185, DOI 10.1096/fasebj.14.1.185; Araga S, 1996, J IMMUNOL, V157, P386; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; Benoist C, 1998, NATURE, V394, P227, DOI 10.1038/28282; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Carter CW, 2002, MOL CELL, V10, P705, DOI 10.1016/S1097-2765(02)00688-3; CHARLES LA, 1991, J LEUKOCYTE BIOL, V50, P539, DOI 10.1002/jlb.50.6.539; DAU PC, 1977, NEW ENGL J MED, V297, P1134, DOI 10.1056/NEJM197711242972102; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DWYER DS, 1983, NATURE, V301, P611, DOI 10.1038/301611a0; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FALK RJ, 1990, ANN INTERN MED, V113, P656, DOI 10.7326/0003-4819-113-9-656; Falk RJ, 1997, J AM SOC NEPHROL, V8, P314; Heal JR, 2002, CHEMBIOCHEM, V3, P137, DOI 10.1002/1439-7633(20020301)3:2/3<136::AID-CBIC136>3.0.CO;2-7; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmich B, 2001, CLIN RHEUMATOL, V20, P441, DOI 10.1007/PL00011214; Hemmer B, 1999, NAT MED, V5, P1375; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1990, BLOOD, V75, P2263; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Jethwa HS, 2000, J IMMUNOL, V165, P3890, DOI 10.4049/jimmunol.165.7.3890; Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; MEKLER LB, 1973, ONCOLOGY-BASEL, V27, P286; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; MEZZANO S, 1993, ADV EXP MED BIOL, V336, P449; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; Ohlsson S, 2003, CLIN EXP IMMUNOL, V131, P528, DOI 10.1046/j.1365-2249.2003.02083.x; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PASCUAL D W, 1989, Peptide Research, V2, P207; PUDIFIN DJ, 1994, CLIN EXP IMMUNOL, V97, P48, DOI 10.1111/j.1365-2249.1994.tb06578.x; Routsias JG, 2003, J AUTOIMMUN, V21, P17, DOI 10.1016/S0896-8411(03)00063-5; Routsias JG, 2002, MOL MED, V8, pA3, DOI 10.1007/BF03402155; Ruiz-Opazo N, 1998, MOL MED, V4, P96, DOI 10.1007/BF03401733; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; Selo I, 2002, IMMUNOL LETT, V80, P133, DOI 10.1016/S0165-2478(01)00319-4; SHOENFELD Y, 1994, FASEB J, V8, P1296, DOI 10.1096/fasebj.8.15.8001742; SMITH LR, 1987, J IMMUNOL, V138, P7; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stassi G, 2002, NAT REV IMMUNOL, V2, P195, DOI 10.1038/nri750; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Tropsha Alexander, 1992, Journal of Molecular Recognition, V5, P43, DOI 10.1002/jmr.300050202; Tzioufas AG, 2002, CLIN EXP RHEUMATOL, V20, P289; van der Geld YM, 2001, KIDNEY INT, V59, P147, DOI 10.1046/j.1523-1755.2001.00475.x; Weathington Nathaniel M, 2003, Expert Rev Vaccines, V2, P61, DOI 10.1586/14760584.2.1.61; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yang JJ, 2002, KIDNEY INT, V62, P1638, DOI 10.1046/j.1523-1755.2002.00619.x; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yu M, 1995, Adv Exp Med Biol, V380, P165; ZHOU SR, 1993, J IMMUNOL, V150, P1629; Zhou SR, 1996, J NEUROSCI RES, V45, P439, DOI 10.1002/(SICI)1097-4547(19960815)45:4<439::AID-JNR13>3.0.CO;2-W	59	255	270	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2004	10	1					72	79		10.1038/nm968	http://dx.doi.org/10.1038/nm968			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	759NK	14661018				2022-12-25	WOS:000187743600041
J	Corbel, SY; Lee, A; Yi, L; Duenas, J; Brazelton, TR; Blau, HM; Rossi, FMV				Corbel, SY; Lee, A; Yi, L; Duenas, J; Brazelton, TR; Blau, HM; Rossi, FMV			Contribution of hematopoietic stem cells to skeletal muscle	NATURE MEDICINE			English	Letter							BONE-MARROW; MYOGENIC SPECIFICATION; IN-VIVO; FUSION; REGENERATION; TRANSPLANTATION; PLASTICITY; EXPRESSION; MOUSE	Cells from adult bone marrow participate in the regeneration of damaged skeletal myofibers. However, the relationship of these cells with the various hematopoietic and nonhematopoietic cell types found in bone marrow is still unclear. Here we show that the progeny of a single cell can both reconstitute the hematopoietic system and contribute to muscle regeneration. Integration of bone marrow cells into myofibers occurs spontaneously at low frequency and increases with muscle damage. Thus, classically defined single hematopoietic stem cells can give rise to both blood and muscle.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Stanford Univ, Dept Mol Pharmacol, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	University of British Columbia; Stanford University; Stanford University	Rossi, FMV (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Rossi, Fabio MV/B-5587-2013	Rossi, Fabio MV/0000-0002-0368-2620	NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG2096L, AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; NIGMS NIH HHS [GM07149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; Dixon RW, 1996, J NEUROPATH EXP NEUR, V55, P1230, DOI 10.1097/00005072-199612000-00006; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEIMANN JM, IN PRESS NAT CELL BI; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	25	197	209	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1528	1532		10.1038/nm959	http://dx.doi.org/10.1038/nm959			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625543				2022-12-25	WOS:000186845400037
J	Eriksson, U; Ricci, R; Hunziker, L; Kurrer, MO; Oudit, GY; Watts, TH; Sonderegger, I; Bachmaier, K; Kopf, M; Penninger, JM				Eriksson, U; Ricci, R; Hunziker, L; Kurrer, MO; Oudit, GY; Watts, TH; Sonderegger, I; Bachmaier, K; Kopf, M; Penninger, JM			Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity	NATURE MEDICINE			English	Article							DILATED CARDIOMYOPATHY; MYOCARDITIS; MICE; CD40; ACTIVATION; PROTECTION; INFECTION; DISEASE; EPITOPE; IL-12	Genetic susceptibility and autoimmunity triggered by microbial infections are factors implicated in the pathogenesis of dilated cardiomyopathy, the most common cause of heart failure in young patients. Here we show that dendritic cells (DCs) loaded with a heart- specific self peptide induce CD4+ T- cell- mediated myocarditis in nontransgenic mice. Toll- like receptor (TLR) stimulation, in concert with CD40 triggering of self peptide- loaded dendritic cells, was shown to be required for disease induction. After resolution of acute myocarditis, DC- immunized mice developed heart failure, and TLR stimulation of these mice resulted in relapse of inflammatory infiltrates. Injection of damaged, syngeneic cardiomyocytes also induced myocarditis in mice if TLRs were activated in vivo. DC- induced myocarditis provides a unifying theory as to how tissue damage and activation of TLRs during infection can induce autoimmunity, relapses and cardiomyopathy.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Basel Hosp, Dept Res & Med A, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Swiss Fed Inst Technol, CH-8952 Zurich, Switzerland; Univ Toronto, Princess Margaret Hosp, Dept Med Biophys, Univ Hlth Network, Toronto, ON M5G 2C1, Canada	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Basel; University of Zurich; University Zurich Hospital; University of Toronto; University of Toronto; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Eriksson, U (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	ueriksson@uhbs.ch; josef.penninger@oeaw.ac.at	Kopf, Manfred/B-6907-2009; Ricci, Romeo/K-3009-2013; Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/B-6331-2014; Bachmaier, Kurt/AHC-5491-2022	Kopf, Manfred/0000-0002-0628-7140; Ricci, Romeo/0000-0002-9766-4369; Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Hunziker, Lukas/0000-0003-0081-8518; Eriksson, Urs/0000-0003-1217-9696				Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Caforio ALP, 2002, EUR J HEART FAIL, V4, P411, DOI 10.1016/S1388-9842(02)00010-7; Calabrese F, 2002, DIAGN MOL PATHOL, V11, P212, DOI 10.1097/00019606-200212000-00004; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dittel BN, 1999, J IMMUNOL, V163, P32; DONERMEYER DL, 1995, J EXP MED, V182, P1291, DOI 10.1084/jem.182.5.1291; Eriksson U, 2003, J EXP MED, V197, P323, DOI 10.1084/jem.20021788; Eriksson U, 2003, CIRCULATION, V107, P320, DOI 10.1161/01.CIR.0000043802.38699.66; Eriksson U, 2001, J IMMUNOL, V167, P5464, DOI 10.4049/jimmunol.167.9.5464; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Howard LM, 2001, J IMMUNOL, V166, P1547, DOI 10.4049/jimmunol.166.3.1547; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Labow M, 1997, J IMMUNOL, V159, P2452; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; NEU N, 1987, J IMMUNOL, V139, P3630; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; Roig E, 1998, AM J CARDIOL, V82, P688, DOI 10.1016/S0002-9149(98)00388-9; ROSE NR, 1988, IMMUNOL TODAY, V9, P117, DOI 10.1016/0167-5699(88)91282-0; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Turley SJ, 2002, CURR OPIN IMMUNOL, V14, P765, DOI 10.1016/S0952-7915(02)00399-0	39	310	331	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1484	1490		10.1038/nm960	http://dx.doi.org/10.1038/nm960			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14625544				2022-12-25	WOS:000186845400031
J	Di Pasquale, G; Davidson, BL; Stein, CS; Martins, IS; Scudiero, D; Monks, A; Chiorini, JA				Di Pasquale, G; Davidson, BL; Stein, CS; Martins, IS; Scudiero, D; Monks, A; Chiorini, JA			Identification of PDGFR as a receptor for AAV-5 transduction	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS TYPE-2; GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TUMOR-CELL-LINES; GENE-TRANSFER; SIALIC-ACID; VECTORS; EXPRESSION; INTERNALIZATION; BINDING	Understanding the process of vector transduction has important implications for the application and optimal use of a vector system for human gene therapy. Recent studies with vectors based on adeno-associated virus type 5 (AAV-5) have shown utility, of this vector system in the lung, central nervous system, muscle and eye. To understand the natural tropism of this virus and to identify proteins necessary for AAV-5 transduction, we characterized 43 cell lines as permissive or nonpermissive for AAV-5 transduction and compared the gene expression profiles derived from cDNA microarray analyses of those cell lines. A statistically significant correlation was observed between expression of the platelet-derived growth factor receptor (PDGFR-alpha-polypeptide) and AAV-5 transduction. Subsequent experiments confirmed the role of PDGFR-alpha and PDGFR-beta as receptors for AAV-5. The tropism of AAV-5 in vivo also correlated with the expression pattern of PDGFR-alpha.	Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; SAIC Frederick, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Iowa; University of Iowa; University of Iowa; Science Applications International Corporation (SAIC); SAIC-Frederick	Chiorini, JA (corresponding author), Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA.							Alisky JM, 2000, NEUROREPORT, V11, P2669, DOI 10.1097/00001756-200008210-00013; Bantel-Schaal U, 2002, J VIROL, V76, P2340, DOI 10.1128/JVI.76.5.2340-2349.2002; Bantel-Schaal U, 1999, J VIROL, V73, P939, DOI 10.1128/JVI.73.2.939-947.1999; Chiorini JA, 1997, J VIROL, V71, P6823, DOI 10.1128/JVI.71.9.6823-6833.1997; Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; GEORGFRIES B, 1984, VIROLOGY, V134, P64, DOI 10.1016/0042-6822(84)90272-1; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; HOSANG M, 1988, J RECEPTOR RES, V8, P455, DOI 10.3109/10799898809049004; Kaludov N, 2001, J VIROL, V75, P6884, DOI 10.1128/JVI.75.15.6884-6893.2001; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Koo HM, 1996, CANCER RES, V56, P5211; LEE JS, 1994, MOL PHARMACOL, V46, P627; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; Muramatsu S, 1996, VIROLOGY, V221, P208, DOI 10.1006/viro.1996.0367; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Oumesmar BN, 1997, J NEUROSCI, V17, P125, DOI 10.1523/JNEUROSCI.17-01-00125.1997; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rutledge EA, 1998, J VIROL, V72, P309, DOI 10.1128/JVI.72.1.309-319.1998; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Walters RW, 2001, J BIOL CHEM, V276, P20610, DOI 10.1074/jbc.M101559200; Wang YZ, 2000, J BIOL CHEM, V275, P22550, DOI 10.1074/jbc.M909785199; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILLIAMS LT, 1989, CLIN RES, V37, P564; Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000; Zaharevitz DW, 2002, J MOL GRAPH MODEL, V20, P297, DOI 10.1016/S1093-3263(01)00126-7	40	263	279	0	7	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2003	9	10					1306	1312		10.1038/nm929	http://dx.doi.org/10.1038/nm929			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	14502277	Green Published			2022-12-25	WOS:000185669700043
J	Mekhail, K; Gunaratnam, L; Bonicalzi, ME; Lee, S				Mekhail, K; Gunaratnam, L; Bonicalzi, ME; Lee, S			HIF activation by pH-dependent nucleolar sequestration of VHL	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NUCLEAR-CYTOPLASMIC TRAFFICKING; LINDAU GENE-PRODUCT; CANCER-CELLS; HYPOXIA; COMPLEX; GROWTH; UBIQUITYLATION; ANGIOGENESIS; DEPRIVATION	Hypoxia and acidosis occur in a wide variety of physiological and pathological settings that include muscle stress, tumour development and ischaemic disorders. A central element in the adaptive response to cellular hypoxia is HIF (hypoxia-inducible factor), a transcription factor that activates an array of genes implicated in oxygen homeostasis, tumour vascularization and ischaemic preconditioning(1). HIF is activated by hypoxia, but undergoes degradation by the VHL (von Hippel-Lindau) tumour suppressor protein in the presence of oxygen(2,3). Here, we demonstrate that hypoxia induction or normoxic acidosis can neutralize the function of VHL by triggering its nucleolar sequestration, a regulatory mechanism of protein function that is observed rarely(4-7). VHL is confined to nucleoli until neutral pH conditions are re-instated. Nucleolar sequestration of VHL enables HIF to evade destruction in the presence of oxygen and activate its target genes. Our findings suggest that an increase in hydrogen ions elicits a transient and reversible loss of VHL function by promoting its nucleolar sequestration.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Lee, S (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	slee@uottawa.ca	Gunaratnam, Lakshman/G-3299-2011	Gunaratnam, Lakshman/0000-0002-8845-1126; Mekhail, Karim/0000-0002-6084-020X				Bachant JB, 1999, NATURE, V398, P757, DOI 10.1038/19641; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Chavez JC, 2002, J NEUROSCI, V22, P8922; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Gunaratnam L, 2003, J BIOL CHEM, V278, P44966, DOI 10.1074/jbc.M305502200; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lee S, 1999, MOL CELL BIOL, V19, P1486; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morimoto Y, 1997, CRIT CARE MED, V25, P841, DOI 10.1097/00003246-199705000-00021; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Semenza GL, 2000, GENE DEV, V14, P1983; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Wagner PD, 2001, ADV EXP MED BIOL, V502, P21; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O., 1931, METABOLISM TUMORS; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	30	189	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2004	6	7					642	647		10.1038/ncb1144	http://dx.doi.org/10.1038/ncb1144			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	834TX	15181450				2022-12-25	WOS:000222434900019
J	Simone, C; Forcales, SV; Hill, DA; Imbalzano, AN; Latella, L; Puri, PL				Simone, C; Forcales, SV; Hill, DA; Imbalzano, AN; Latella, L; Puri, PL			p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci	NATURE GENETICS			English	Article							TRANSCRIPTIONAL ACTIVATION; MAP KINASE; MYOD; DIFFERENTIATION; BINDING; FAMILY; ACETYLATION; ROLES; MEF2C; PCAF	During skeletal myogenesis, genomic reprogramming toward terminal differentiation is achieved by recruiting chromatin-modifying enzymes to muscle-specific loci(1,2). The relative contribution of extracellular signaling cascades in targeting these enzymes to individual genes is unknown. Here we show that the differentiation-activated p38 pathway(3-5) targets the SWI-SNF chromatin-remodeling complex to myogenic loci. Upon differentiation, p38 kinases were recruited to the chromatin of muscle-regulatory elements. Blockade of p38alpha/beta repressed the transcription of muscle genes by preventing recruitment of the SWI-SNF complex at these elements without affecting chromatin binding of muscle-regulatory factors and acetyltransferases. The SWI-SNF subunit BAF60 could be phosphorylated by p38alpha-beta in vitro, and forced activation of p38alpha/beta in myoblasts by expression of a constitutively active MKK6 (refs. 5-7) promoted unscheduled SWI-SNF recruitment to the myogenin promoter. Conversely, inactivation of SWI-SNF enzymatic subunits abrogated MKK6-dependent induction of muscle gene expression. These results identify an unexpected function of differentiation-activated p38 in converting external cues into chromatin modifications at discrete loci, by selectively targeting SWI-SNF to muscle-regulatory elements.	Fdn A Cesalpino, Inst Cell Biol & Tissue Engn, Dulbecco Telethon Inst, Gene Express Lab, I-00128 Rome, Italy; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92093 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Salk Institute; University of Massachusetts System; University of Massachusetts Worcester	Puri, PL (corresponding author), Fdn A Cesalpino, Inst Cell Biol & Tissue Engn, Dulbecco Telethon Inst, Gene Express Lab, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy.	plpuri@dti.telethon.it	Latella, Lucia/K-7834-2016; Forcales, Sonia/AAU-8996-2020; Forcales, Sonia-V./B-2157-2013; Simone, Cristiano/K-3452-2018	Forcales, Sonia/0000-0002-7111-4959; Forcales, Sonia-V./0000-0002-7111-4959; Simone, Cristiano/0000-0002-2628-7658; Puri, Pier Lorenzo/0000-0003-4964-0095; LATELLA, LUCIA/0000-0003-1317-9233	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056244] Funding Source: Medline; Telethon [TCP00081, GFP01009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DEBRIL MB, 2003, J BIOL CHEM, V16, P16677; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 2001, FRONT BIOSCI-LANDMRK, V6, pD1024, DOI 10.2741/Sartorel; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21	29	308	319	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2004	36	7					738	743		10.1038/ng1378	http://dx.doi.org/10.1038/ng1378			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	833QT	15208625	Bronze			2022-12-25	WOS:000222354100025
J	Andreoletti, O; Simon, S; Lacroux, C; Morel, N; Tabouret, G; Chabert, A; Lugan, S; Corbiere, F; Ferre, P; Foucras, G; Laude, H; Eychenne, F; Grassi, J; Schelcher, F				Andreoletti, O; Simon, S; Lacroux, C; Morel, N; Tabouret, G; Chabert, A; Lugan, S; Corbiere, F; Ferre, P; Foucras, G; Laude, H; Eychenne, F; Grassi, J; Schelcher, F			PrPSc accumulation in myocytes from sheep incubating natural scrapie	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; BRITISH SHEEP; PRION PROTEIN; TISSUES; RISK	Because variant Creutzfeldt-Jakob disease (vCJD) in humans probably results from consumption of products contaminated with tissue from animals with bovine spongiform encephalopathy, whether infectious prion protein is present in ruminant muscles is a crucial question. Here we show that experimentally and naturally scrapie-affected sheep accumulate the prion protein PrPSc in a myocyte subset. In naturally infected sheep, PrPSc is detectable in muscle several months before clinical disease onset. The relative amounts of PrPSc suggest a 5,000-fold lower infectivity for muscle as compared to brain.	Ecole Natl Vet Toulouse, UMR INRA ENVT 1225, F-31076 Toulouse, France; CEA Saclay, DRM, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Ecole Natl Vet Toulouse, UMR INRA ENVT 181, F-31076 Toulouse, France; INRA, F-78350 Jouy En Josas, France; INRA, F-31450 Pompertuzat, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; CEA; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE	Andreoletti, O (corresponding author), Ecole Natl Vet Toulouse, UMR INRA ENVT 1225, 23 Chemin Capelles, F-31076 Toulouse, France.	o.andreoletti@envt.fr	FOUCRAS, Gilles/A-3061-2014; Simon, Stephanie/E-4289-2012; Morel, Nathalie/O-9012-2016	FOUCRAS, Gilles/0000-0002-0363-0337; Simon, Stephanie/0000-0002-6071-8255; CORBIERE, Fabien/0000-0003-3006-5561; Ferre, Pierre/0000-0001-6828-1433; TABOURET, Guillaume/0000-0002-7976-4438				Andreoletti O, 2002, J HISTOCHEM CYTOCHEM, V50, P1357, DOI 10.1177/002215540205001009; Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Ferguson NM, 2002, NATURE, V415, P420, DOI 10.1038/nature709; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Kao RR, 2002, SCIENCE, V295, P332, DOI 10.1126/science.1067475; THORNZIG A, 2003, EMBO REP, V4, P530; van Duijn CM, 1998, LANCET, V351, P1081, DOI 10.1016/S0140-6736(97)09468-3; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996; Vilotte JL, 2001, J VIROL, V75, P5977, DOI 10.1128/JVI.75.13.5977-5984.2001; Watanabe Kouichi, 1999, Okajimas Folia Anatomica Japonica, V76, P203	11	114	117	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2004	10	6					591	593		10.1038/nm1055	http://dx.doi.org/10.1038/nm1055			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	825LI	15156203				2022-12-25	WOS:000221759600023
J	Niggeweg, R; Michael, AJ; Martin, C				Niggeweg, R; Michael, AJ; Martin, C			Engineering plants with increased levels of the antioxidant chlorogenic acid	NATURE BIOTECHNOLOGY			English	Article							QUINATE HYDROXYCINNAMOYL TRANSFERASE; TRANSGENIC TOBACCO PLANTS; COENZYME-A; CARDIOVASCULAR-DISEASE; STRESS RESPONSES; OXIDATIVE STRESS; PHENOLIC-ACIDS; GENE; PURIFICATION; METABOLISM	The trend to view many foods not only as sustenance but also as medicine, so-called functional foods, is increasing. Phenolics are the most widespread dietary antioxidants, and among these, chlorogenic acid (CGA) accumulates to high levels in some crop plants. CGA acts as an antioxidant in plants and protects against degenerative, age-related diseases in animals when supplied in their diet. cDNA clones encoding the enzyme that synthesizes CGA, hydroxycinnamoyl-CoA quinate: hydroxycinnamoyl transferase (HQT), were characterized from tomato and tobacco. Gene silencing proved HQT to be the principal route for accumulation of CGA in solanaceous species. Overexpression of HQT in tomato caused plants to accumulate higher levels of CGA, with no side-effects on the levels of other soluble phenolics, and to show improved antioxidant capacity and resistance to infection by a bacterial pathogen. Tomatoes with elevated CGA levels could be used in foods with specific benefits for human health.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Inst Food Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Martin, C (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	cathie.martin@bbsrc.ac.uk						Baker NR, 2001, J EXP BOT, V52, P615, DOI 10.1093/jexbot/52.356.615; Bazzano LA, 2002, AM J CLIN NUTR, V76, P93; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BROADBENT P, 1995, PLANT J, V8, P247, DOI 10.1046/j.1365-313X.1995.08020247.x; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Couteau D, 2001, J APPL MICROBIOL, V90, P873, DOI 10.1046/j.1365-2672.2001.01316.x; DANIELS DGH, 1967, J SCI FOOD AGR, V18, P589, DOI 10.1002/jsfa.2740181209; DANIELS DGH, 1963, J SCI FOOD AGR, V14, P385, DOI 10.1002/jsfa.2740140605; Edwards A, 1999, EUR J BIOCHEM, V266, P724, DOI 10.1046/j.1432-1327.1999.00861.x; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; Franke R, 2002, PLANT J, V30, P33, DOI 10.1046/j.1365-313X.2002.01266.x; Friedman M, 1997, ACS SYM SER, V662, P61, DOI 10.1021/bk-1997-0662.ch005; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fryer MJ, 2002, J EXP BOT, V53, P1249, DOI 10.1093/jexbot/53.372.1249; Hoffmann L, 2003, J BIOL CHEM, V278, P95, DOI 10.1074/jbc.M209362200; Howles PA, 1996, PLANT PHYSIOL, V112, P1617, DOI 10.1104/pp.112.4.1617; Johnson KS, 2001, J CHEM ECOL, V27, P2579, DOI 10.1023/A:1013691802028; LARANJINHA JAN, 1994, BIOCHEM PHARMACOL, V48, P487, DOI 10.1016/0006-2952(94)90278-X; LEATHAM GF, 1980, PHYTOPATHOLOGY, V70, P1134, DOI 10.1094/Phyto-70-1134; LOFTY S, 1992, BIOCHEMISTRY-US, V31, P767; MAHER EA, 1994, P NATL ACAD SCI USA, V91, P7802, DOI 10.1073/pnas.91.16.7802; Mayer MJ, 2001, PLANT CELL, V13, P1669, DOI 10.1105/tpc.13.7.1669; Nardini M, 2002, J AGR FOOD CHEM, V50, P5735, DOI 10.1021/jf0257547; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; PERLTREVES R, 1991, PLANT MOL BIOL, V17, P745, DOI 10.1007/BF00037058; Plumb GW, 1999, J SCI FOOD AGR, V79, P390, DOI 10.1002/(SICI)1097-0010(19990301)79:3&lt;390::AID-JSFA258&gt;3.0.CO;2-0; QUERINEAU F, 1993, PLANT MOL BIOL LABFA, P121; RHODES MJC, 1976, PHYTOCHEMISTRY, V15, P947, DOI 10.1016/S0031-9422(00)84376-9; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; ROBER KC, 1989, BIOCHEM PHYSIOL PFL, V184, P277; Sawa T, 1999, J AGR FOOD CHEM, V47, P397, DOI 10.1021/jf980765e; Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6; Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200; Segasothy M, 1999, QJM-INT J MED, V92, P531, DOI 10.1093/qjmed/92.9.531; SEMLER U, 1987, Z NATURFORSCH C, V42, P1070; Shadle GL, 2003, PHYTOCHEMISTRY, V64, P153, DOI 10.1016/S0031-9422(03)00151-1; Speicher K D, 2000, J Biomol Tech, V11, P74; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; STOCKIGT J, 1974, FEBS LETT, V42, P131, DOI 10.1016/0014-5793(74)80769-6; STRACK D, 1990, PLANT PHYSIOL, V92, P41, DOI 10.1104/pp.92.1.41; Suzuki H, 2003, BIOCHEMISTRY-US, V42, P1764, DOI 10.1021/bi020618g; Tamagnone L, 1998, PLANT CELL, V10, P135, DOI 10.1105/tpc.10.2.135; Tamagnone L, 1998, PLANT CELL, V10, P1801, DOI 10.1105/tpc.10.11.1801; TSANG EWT, 1991, PLANT CELL, V3, P783, DOI 10.1105/tpc.3.8.783; Tsuchiya T, 1996, BIOSCI BIOTECH BIOCH, V60, P765, DOI 10.1271/bbb.60.765; ULBRICH B, 1979, PHYTOCHEMISTRY, V18, P929, DOI 10.1016/S0031-9422(00)91451-1; VILLEGAS RJA, 1986, J BIOL CHEM, V261, P8729; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Waldron KW, 1996, PHYTOCHEM ANALYSIS, V7, P305, DOI 10.1002/(SICI)1099-1565(199611)7:6&lt;305::AID-PCA320&gt;3.0.CO;2-A; Williamson G, 2000, BIOCHEM SOC T, V28, P16, DOI 10.1042/bst0280016	50	534	572	6	132	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2004	22	6					746	754		10.1038/nbt966	http://dx.doi.org/10.1038/nbt966			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	825VA	15107863				2022-12-25	WOS:000221785300037
J	Pennaneach, V; Kolodner, RD				Pennaneach, V; Kolodner, RD			Recombination and the Tel1 and Mec1 checkpoints differentially effect genome rearrangements driven by telomere dysfunction in yeast	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL REARRANGEMENTS; DYSKERATOSIS-CONGENITA; BUDDING YEAST; DNA-DAMAGE; MAINTENANCE; FUSIONS; REPLICATION; INSTABILITY; PATHWAYS	In telomerase-deficient Saccharomyces cerevisiae, telomeres are maintained by recombination. Here we used a S. cerevisiae assay for characterizing gross chromosomal rearrangements (GCRs) to analyze genome instability in post-senescent telomerase-deficient cells. Telomerase-deficient tlc1 and est2 mutants did not have increased GCR rates, but their telomeres could be joined to other DNAs resulting in chromosome fusions. Inactivation of Tell or either the Rad51 or Rad59 recombination pathways in telomerase-deficient cells increased the GCR rate, even though telomeres were maintained. The GCRs were translocations and chromosome fusions formed by nonhomologous end joining. We observed chromosome fusions only in mutant strains expressing Rad51 and Rad55 or when Tel1 was inactivated. In contrast, inactivation of Mec1 resulted in more inversion translocations such as the isochromosomes seen in human tumors. These inversion translocations seemed to be formed by recombination after replication of broken chromosomes.	Univ Calif San Diego, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Ctr Canc, CMME 3058,9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu		Pennaneach, Vincent/0000-0002-2518-0517				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cervantes RB, 2002, CURR OPIN CELL BIOL, V14, P351, DOI 10.1016/S0955-0674(02)00325-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; DuBois ML, 2002, GENETICS, V161, P995; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Liti G, 2003, MOL CELL, V11, P1373, DOI 10.1016/S1097-2765(03)00177-1; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Mieczkowski PA, 2003, P NATL ACAD SCI USA, V100, P10854, DOI 10.1073/pnas.1934561100; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565	30	53	53	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					612	617		10.1038/ng1359	http://dx.doi.org/10.1038/ng1359			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15133512	Bronze			2022-12-25	WOS:000221763700019
J	Ravikumar, B; Vacher, C; Berger, Z; Davies, JE; Luo, SQ; Oroz, LG; Scaravilli, F; Easton, DF; Duden, R; O'Kane, CJ; Rubinsztein, DC				Ravikumar, B; Vacher, C; Berger, Z; Davies, JE; Luo, SQ; Oroz, LG; Scaravilli, F; Easton, DF; Duden, R; O'Kane, CJ; Rubinsztein, DC			Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease	NATURE GENETICS			English	Article							INTRANUCLEAR INCLUSIONS; SYNAPTIC PLASTICITY; CELLULAR GROWTH; TRANSGENIC MICE; DROSOPHILA; MUTATION; PROTEIN; TRANSLATION; NUCLEAR; DEATH	Huntington disease is one of nine inherited neurodegenerative disorders caused by a polyglutamine tract expansion. Expanded polyglutamine proteins accumulate abnormally in intracellular aggregates. Here we show that mammalian target of rapamycin (mTOR) is sequestered in polyglutamine aggregates in cell models, transgenic mice and human brains. Sequestration of mTOR impairs its kinase activity and induces autophagy, a key clearance pathway for mutant huntingtin fragments. This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects. Furthermore, rapamycin protects against neurodegeneration in a fly model of Huntington disease, and the rapamycin analog CCI-779 improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease. Our data provide proof-of-principle for the potential of inducing autophagy to treat Huntington disease.	Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; UCL, Inst Neurol, Div Neuropathol, London, England; Univ Cambridge, Dept Publ Hlth, Genet Epidemiol Unit, Canc Res UK, Cambridge, England; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of London; University College London; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Wellcome MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dcr1000@cus.cam.ac.uk	Duden, Rainer/C-8917-2011; Rubinsztein, David C/C-3472-2011; Duden, Rainer/GXH-3206-2022; O'Kane, Cahir J/C-4413-2011; O'Kane, Cahir/Q-6681-2019	O'Kane, Cahir/0000-0002-3488-2078; Davies, Janet/0000-0002-8853-8328				*BRIT MED ASS ROYA, 2003, BRIT NATL FORUMULARY; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; Gingras AC, 2001, PROG MOLEC, V27, P143; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hennig KM, 2002, GENESIS, V34, P107, DOI 10.1002/gene.10139; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Lione LA, 1999, J NEUROSCI, V19, P10428; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Serkova N, 2001, BRIT J PHARMACOL, V133, P875, DOI 10.1038/sj.bjp.0704142; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; SUPKO JG, 1994, CANCER CHEMOTH PHARM, V33, P325; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Walpoth BH, 2001, EUR J CARDIO-THORAC, V19, P487, DOI 10.1016/S1010-7940(01)00582-6; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	48	1839	1941	9	227	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2004	36	6					585	595		10.1038/ng1362	http://dx.doi.org/10.1038/ng1362			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15146184	Bronze			2022-12-25	WOS:000221763700015
J	Xu, LT; Zhang, L; Yi, YJ; Kang, HK; Datta, SK				Xu, LT; Zhang, L; Yi, YJ; Kang, HK; Datta, SK			Human lupus T cells resist inactivation and escape death by upregulating COX-2	NATURE MEDICINE			English	Article							APOPTOSIS; EXPRESSION; ACTIVATION; SURVIVAL; PROTEIN; ERYTHEMATOSUS; INHIBITORS; PATHWAYS; DEFECTS; LIGAND	Autoimmune T-helper cells drive pathogenic autoantibody production in systemic lupus erythematosus (SLE), but the mechanisms maintaining those T cells are unknown. Autoreactive T cells are normally eliminated by functional inactivation (anergy) and activation-induced cell death (AICD) or apoptosis through death receptor (Fas) signaling(1-3). However, mutations in the genes encoding Fas and its ligand (FasL) are rare in classical SLE4. By gene microarray profiling, validated by functional and biochemical studies, we establish here that activated T cells of lupus patients resist anergy and apoptosis by markedly upregulating and sustaining cyclooxygenase-2 (COX-2) expression. Inhibition of COX-2 caused apoptosis of the anergy-resistant lupus T cells by augmenting Fas signaling and markedly decreasing the survival molecule c-FLIP (cellular homolog of viral FLICE inhibitory protein). Studies with COX-2 inhibitors and Cox-2-deficient mice confirmed that this COX-2/FLIP antiapoptosis program is used selectively by anergy-resistant lupus T cells, and not by cancer cells or other autoimmune T cells. Notably, the gene encoding COX-2 is located in a lupus-susceptibility region on chromosome 1. We also found that only some COX-2 inhibitors were able to suppress the production of pathogenic autoantibodies to DNA by causing autoimmune T-cell apoptosis, an effect that was independent of prostaglandin E 2 (PGE(2)). These findings could be useful in the design of lupus therapies.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Datta, SK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, 303 E Chicago Ave, Chicago, IL 60611 USA.	skd257@northwestern.edu			NIAID NIH HHS [R01-AI41985] Funding Source: Medline; NIAMS NIH HHS [R37-AR39157] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR039157] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; Kaliyaperumal A, 2002, J IMMUNOL, V168, P2530, DOI 10.4049/jimmunol.168.5.2530; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Lander SA, 2002, LUPUS, V11, P340, DOI 10.1191/0961203302lu204oa; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Lin ZS, 2003, LAB INVEST, V83, P765, DOI 10.1097/01.LAB.0000073130.58435.E5; Lu LJ, 1999, J CLIN INVEST, V104, P345, DOI 10.1172/JCI6801; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Pablos JL, 1999, CLIN EXP IMMUNOL, V115, P86; Parfenova H, 2001, AM J PHYSIOL-CELL PH, V281, pC166, DOI 10.1152/ajpcell.2001.281.1.C166; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Schirmer M, 1998, J IMMUNOL, V161, P1018; Sharief MK, 2001, J NEUROIMMUNOL, V119, P358, DOI 10.1016/S0165-5728(01)00389-7; Stack E, 2001, GASTROENTEROL CLIN N, V30, P1001, DOI 10.1016/S0889-8553(05)70225-9; Vaishnaw AK, 1999, ARTHRITIS RHEUM, V42, P1833, DOI 10.1002/1529-0131(199909)42:9<1833::AID-ANR7>3.0.CO;2-Q; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1; Yi YJ, 2000, J IMMUNOL, V165, P6627, DOI 10.4049/jimmunol.165.11.6627; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610; Zhu JX, 2002, JNCI-J NATL CANCER I, V94, P1745	25	109	113	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					411	415		10.1038/nm1005	http://dx.doi.org/10.1038/nm1005			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	14991050				2022-12-25	WOS:000220587000034
J	Gupta, RA; Wang, DZ; Katkuri, S; Wang, HB; Dey, SK; DuBois, RN				Gupta, RA; Wang, DZ; Katkuri, S; Wang, HB; Dey, SK; DuBois, RN			Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth	NATURE MEDICINE			English	Article							PPAR-DELTA; COLORECTAL-CANCER; INFLAMMATION; PROMOTES	We treated Apc(min) mice, which are predisposed to intestinal polyposis, with a selective synthetic agonist of peroxisome proliferator-activated receptor-delta0 (PPAR-delta). Exposure of Apc(min) mice to the PPAR-ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps. The most prominent effect was on polyp size; mice treated with the PPAR-delta activator had a fivefold increase in the number of polyps larger than 2 mm. Our results implicate PPAR-delta in the regulation of intestinal adenoma growth.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat & Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	DuBois, RN (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA.	raymond.dubois@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P0-CA-77839] Funding Source: Medline; NICHD NIH HHS [R37-HD12304, HD 33994] Funding Source: Medline; NIDDK NIH HHS [R37-DK47297, R01DK47279] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kim EC, 1997, GASTROENTEROL CLIN N, V26, P1, DOI 10.1016/S0889-8553(05)70280-6; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	14	244	248	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2004	10	3					245	247		10.1038/nm993	http://dx.doi.org/10.1038/nm993			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	779LH	14758356				2022-12-25	WOS:000189297700034
J	Liu, J; Dehbi, M; Moeck, G; Arhin, F; Bauda, P; Bergeron, D; Callejo, M; Ferretti, V; Ha, NH; Kwan, T; McCarty, J; Srikumar, R; Williams, D; Wu, JZJ; Gros, P; Pelletier, J; DuBow, M				Liu, J; Dehbi, M; Moeck, G; Arhin, F; Bauda, P; Bergeron, D; Callejo, M; Ferretti, V; Ha, NH; Kwan, T; McCarty, J; Srikumar, R; Williams, D; Wu, JZJ; Gros, P; Pelletier, J; DuBow, M			Antimicrobial drug discovery through bacteriophage genomics	NATURE BIOTECHNOLOGY			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; COLI DNAB HELICASE; PROTEIN; GENE; THERAPY; IDENTIFICATION; REPLICATION; INITIATION; VANCOMYCIN; PRIMOSOME	Over evolutionary time bacteriophages have developed unique proteins that arrest critical cellular processes to commit bacterial host metabolism to phage reproduction. Here, we apply this concept of phage-mediated bacterial growth inhibition to antibiotic discovery. We sequenced 26 Staphylococcus aureus phages and identified 31 novel polypeptide families that inhibited growth upon expression in S. aureus. The cellular targets for some of these polypeptides were identified and several were shown to be essential components of the host DNA replication and transcription machineries. The interaction between a prototypic pair, ORF104 of phage 77 and Dnal, the putative helicase loader of S. aureus, was then used to screen for small molecule inhibitors. Several compounds were subsequently found to inhibit both bacterial growth and DNA synthesis. Our results suggest that mimicking the growth-inhibitory effect of phage polypeptides by a chemical compound, coupled with the plethora of phages on earth, will yield new antibiotics to combat infectious diseases.	PhageTech Inc, Ville Saint Laurent, PQ H4S 2A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Liu, J (corresponding author), PhageTech Inc, 7170 Frederick Banting,2nd Floor, Ville Saint Laurent, PQ H4S 2A1, Canada.	jliu@phagetech.com	Bauda, Pascale/AAV-4545-2021	Bauda, Pascale/0000-0001-5072-2069; Moeck, Greg/0000-0001-7827-7227				Ackermann H. W., 1987, VIRUSES PROKARYOTES, V2; Adams MH, 1959, BACTERIOPHAGES; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; Forsyth RA, 2002, MOL MICROBIOL, V43, P1387, DOI 10.1046/j.1365-2958.2002.02832.x; Jana M, 2000, PLASMID, V44, P100, DOI 10.1006/plas.2000.1473; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kaito C, 2002, FEMS MICROBIOL LETT, V210, P157, DOI 10.1111/j.1574-6968.2002.tb11175.x; Kaneko J, 1998, GENE, V215, P57, DOI 10.1016/S0378-1119(98)00278-9; Khare M, 2003, EXPERT OPIN PHARMACO, V4, P165, DOI 10.1517/14656566.4.2.165; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Marsin S, 2001, J BIOL CHEM, V276, P45818, DOI 10.1074/jbc.M101996200; MATHIS G, 1995, CLIN CHEM, V41, P1391; McDevitt D, 2001, TRENDS MICROBIOL, V9, P611, DOI 10.1016/S0966-842X(01)02235-1; Methot N, 1996, MOL CELL BIOL, V16, P5328; Moir DT, 1999, ANTIMICROB AGENTS CH, V43, P439, DOI 10.1128/AAC.43.3.439; *NCCLS, 2000, NCCLS SPEC COLL SUSC; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Odegrip R, 2000, J VIROL, V74, P4057, DOI 10.1128/JVI.74.9.4057-4063.2000; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; Salgado CD, 2003, CLIN INFECT DIS, V36, P131, DOI 10.1086/345436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; SIMPSON RJ, 2002, PROTEINS PROTEOMICS; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stone R, 2002, SCIENCE, V298, P728, DOI 10.1126/science.298.5594.728; Tauriainen S, 1997, APPL ENVIRON MICROB, V63, P4456, DOI 10.1128/AEM.63.11.4456-4461.1997; Tenover FC, 2001, EMERG INFECT DIS, V7, P327, DOI 10.3201/eid0702.010237; Velten M, 2003, MOL CELL, V11, P1009, DOI 10.1016/S1097-2765(03)00130-8; Walsh C., 2003, ANTIBIOTICS ACTIONS; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4	39	164	175	0	40	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					185	191		10.1038/nbt932	http://dx.doi.org/10.1038/nbt932			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14716317				2022-12-25	WOS:000188730500017
J	Bader, JS; Chaudhuri, A; Rothberg, JM; Chant, J				Bader, JS; Chaudhuri, A; Rothberg, JM; Chant, J			Gaining confidence in high-throughput protein interaction networks	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; SMALL-WORLD; CELL-CYCLE; SCALE DATA; DATA SETS; YEAST; IDENTIFICATION; COMPLEXES; ORGANIZATION	Although genome-scale technologies have benefited from statistical measures of data quality, extracting biologically relevant pathways from high-throughput proteomics data remains a challenge. Here we develop a quantitative method for evaluating proteomics data. We present a logistic regression approach that uses statistical and topological descriptors to predict the biological relevance of protein-protein interactions obtained from high-throughput screens for yeast. Other sources of information, including mRNA expression, genetic interactions and database annotations, are subsequently used to validate the model predictions without bias or cross-pollution. Novel topological statistics show hierarchical organization of the network of high-confidence interactions: protein complex interactions extend one to two links, and genetic interactions represent an even finer scale of organization. Knowledge of the maximum number of links that indicates a significant correlation between protein pairs (correlation distance) enables the integrated analysis of proteomics data with data from genetics and gene expression. The type of analysis presented will be essential for analyzing the growing amount of genomic and proteomics data in model organisms and humans.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; CuraGen Corp, New Haven, CT 06511 USA	Johns Hopkins University	Bader, JS (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 201C Clark Hall,3400 N Charles St, Baltimore, MD 21218 USA.		guntain, sodsri/C-5090-2009; Bader, Joel/A-1818-2009	Bader, Joel/0000-0002-6020-4625				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Bader JS, 2003, BIOINFORMATICS, V19, P1869, DOI 10.1093/bioinformatics/btg358; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Deane CM, 2002, MOL CELL PROTEOMICS, V1, P349, DOI 10.1074/mcp.M100037-MCP200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Friedman J., 2001, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-21606-5; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; GIOT L, 2003, SCIENCE; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Matthews LR, 2001, GENOME RES, V11, P2120, DOI 10.1101/gr.205301; McCullagh P., 1989, GEN LINEAR MODELS, V(2nd), DOI [10.1007/978-1-4899-3242-6, https://doi.org/10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wolf YI, 2002, BIOESSAYS, V24, P105, DOI 10.1002/bies.10059; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Zhao LP, 2001, P NATL ACAD SCI USA, V98, P5631, DOI 10.1073/pnas.101013198	41	333	349	0	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					78	85		10.1038/nbt924	http://dx.doi.org/10.1038/nbt924			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704708				2022-12-25	WOS:000187745400030
J	Draper, JS; Smith, K; Gokhale, P; Moore, HD; Maltby, E; Johnson, J; Meisner, L; Zwaka, TP; Thomson, JA; Andrews, PW				Draper, JS; Smith, K; Gokhale, P; Moore, HD; Maltby, E; Johnson, J; Meisner, L; Zwaka, TP; Thomson, JA; Andrews, PW			Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							HUMAN BLASTOCYSTS; PLURIPOTENCY; EXPRESSION; TUMORS; LINES; DIFFERENTIATION; ANTIGENS	We have observed karyotypic changes involving the gain of chromosome 17q in three independent human embryonic stem (hES) cell lines on five independent occasions. A gain of chromosome 12 was seen occasionally. This implies that increased dosage of chromosome 17q and 12 gene(s) provides a selective advantage for the propagation of undifferentiated hES cells. These observations are instructive for the future application of hES cells in transplantation therapies in which the use of aneuploid cells could be detrimental.	Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England; Sheffield Childrens Trust, N Trent Clin Cytogenet Serv, Sheffield S10 2TH, S Yorkshire, England; Univ Sheffield, Royal Hallamshire Hosp, Sect Reprod & Dev Med, Sheffield S10 2SF, S Yorkshire, England; Wisconsin State Lab Hyg, Cytogenet Lab, Madison, WI 53706 USA; Univ Wisconsin, Natl Primate Res Ctr, Sch Med, Madison, WI 53715 USA; Univ Wisconsin, Dept Anat, Sch Med, Madison, WI 53715 USA	University of Sheffield; Sheffield Children's NHS Foundation Trust; University of Sheffield; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Andrews, PW (corresponding author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Gokhale, Paul/0000-0001-7225-4403; Draper, Jonathan/0000-0002-3241-7009; Andrews, Peter/0000-0001-7215-4410				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; ATKIN NB, 1982, LANCET, V2, P1349; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chiou Shiun-Kwei, 2003, Med Sci Monit, V9, pPI25; Draper JS, 2002, J ANAT, V200, P249, DOI 10.1046/j.1469-7580.2002.00030.x; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Liu X, 1997, DEV DYNAM, V209, P85; Longo L, 1997, TRANSGENIC RES, V6, P321, DOI 10.1023/A:1018418914106; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; Skotheim RI, 2002, CANCER RES, V62, P2359; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4	15	748	827	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					53	54		10.1038/nbt922	http://dx.doi.org/10.1038/nbt922			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14661028				2022-12-25	WOS:000187745400026
J	Schramke, V; Luciano, P; Brevet, V; Guillot, S; Corda, Y; Longhese, MP; Gilson, E; Geli, V				Schramke, V; Luciano, P; Brevet, V; Guillot, S; Corda, Y; Longhese, MP; Gilson, E; Geli, V			RPA regulates telomerase action by providing Est1p access to chromosome ends	NATURE GENETICS			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; IN-VIVO; DNA-REPLICATION; SIR PROTEINS; CELL-CYCLE; YEAST KU; S-PHASE; STRAND; REPAIR	Replication protein A (RPA) is a highly conserved single-stranded DNA binding protein involved in DNA replication, recombination and repair. We show here that RPA is present at the telomeres of the budding yeast Saccharomyces cerevisiae, with a maximal association in S phase. A truncation of the N-terminal region of Rfa2p ( associated with the rfa2Delta40 mutated allele) results in severe telomere shortening caused by a defect in the in vivo regulation of telomerase activity. Cells carrying rfa2Delta40 show impaired binding of the protein Est1p, which is required for telomerase action. In addition, normal telomere length can be restored by expressing a Cdc13-Est1p hybrid protein. These findings indicate that RPA activates telomerase by loading Est1p onto telomeres during S phase. We propose a model of in vivo telomerase action that involves synergistic action of RPA and Cdc13p at the G-rich 3' overhang of telomeric DNA.	CNRS, Lab Ingn Syst Macromol, F-13402 Marseille 20, France; Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, Unite Mixte Rech 5161, F-69364 Lyon, France; Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; University of Milano-Bicocca	Geli, V (corresponding author), CNRS, Lab Ingn Syst Macromol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Pia, Maria/AAK-2693-2020	Longhese, Maria Pia/0000-0003-1726-2034; Luciano, Pierre/0000-0002-1394-4129	Telethon [E.1247] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Brush GS, 2001, NUCLEIC ACIDS RES, V29, P4808, DOI 10.1093/nar/29.23.4808; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Craven RJ, 1999, GENETICS, V152, P1531; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Mallory JC, 2003, DNA REPAIR, V2, P1041, DOI 10.1016/S1568-7864(03)00115-0; Maniar HS, 1997, GENETICS, V145, P891; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Price CM, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1216; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; Ritchie KB, 2000, GENETICS, V155, P475; Schramke V, 2001, GENE DEV, V15, P1845, DOI 10.1101/gad.193901; Smith CD, 2003, MOL BIOL CELL, V14, P556, DOI 10.1091/mbc.E02-08-0457; Smith J, 2000, BIOCHIMIE, V82, P71, DOI 10.1016/S0300-9084(00)00183-8; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	37	120	125	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2004	36	1					46	54		10.1038/ng1284	http://dx.doi.org/10.1038/ng1284			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	758TT	14702040	Bronze			2022-12-25	WOS:000187666800013
J	Thiel, K				Thiel, K			Old dogma, new tricks - 21st century phage therapy	NATURE BIOTECHNOLOGY			English	Article								As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage?										Eliopoulos GM, 1998, ANTIMICROB AGENTS CH, V42, P1088, DOI 10.1128/AAC.42.5.1088; Fox JL, 2003, NAT BIOTECHNOL, V21, P1255, DOI 10.1038/nbt904; Scholl D, 2001, J VIROL, V75, P2509, DOI 10.1128/JVI.75.6.2509-2515.2001; TSLODRAS S, 2001, LANCET, V358, P207; *US CDC, 2000, PUBL HLTH ACT PLAN C	5	150	167	0	41	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2004	22	1					31	36		10.1038/nbt0104-31	http://dx.doi.org/10.1038/nbt0104-31			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	759PE	14704699				2022-12-25	WOS:000187745400014
J	Irazoqui, JE; Gladfelter, AS; Lew, DJ				Irazoqui, JE; Gladfelter, AS; Lew, DJ			Scaffold-mediated symmetry breaking by Cdc42p	NATURE CELL BIOLOGY			English	Letter							BUD-SITE-SELECTION; SPONTANEOUS CELL POLARIZATION; EXCHANGE FACTOR CDC24; RHO-TYPE GTPASES; MUTATIONAL ANALYSIS; KINASE CASCADE; PX DOMAIN; YEAST; PROTEINS; GENE	Cell polarization generally occurs along a single well-defined axis that is frequently determined by environmental cues such as chemoattractant gradients or cell-cell contacts, but polarization can also occur spontaneously in the apparent absence of such cues, through a process called symmetry breaking(1-5). In Saccharomyces cerevisiae, cells are born with positional landmarks that mark the poles of the cell and guide subsequent polarization and bud emergence to those sites, but cells lacking such landmarks polarize towards a random cortical site and proliferate normally(6). The landmarks employ a Ras-family GTPase, Rsr1p(7-9), to communicate with the conserved Rho-family GTPase Cdc42p, which is itself polarized and essential for cytoskeletal polarization(10,11). We found that yeast Cdc42p was effectively polarized to a single random cortical site even in the combined absence of landmarks, microtubules and microfilaments. Among a panel of Cdc42p effectors and interacting proteins, we found that the scaffold protein Bem1p was uniquely required for this symmetry-breaking behaviour. Moreover, polarization was dependent on GTP hydrolysis by Cdc42p, suggesting that assembly of a polarization site involves cycling of Cdc42p between GTP- and GDP-bound forms, rather than functioning as a simple on/off switch.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Lew, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	daniel.lew@duke.edu	Irazoqui, Javier E/A-8028-2013	Irazoqui, Javier/0000-0001-6553-1329	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Caviston JP, 2002, P NATL ACAD SCI USA, V99, P12185, DOI 10.1073/pnas.182370299; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Ellson CD, 2002, J CELL SCI, V115, P1099; Endo M, 2003, J BIOL CHEM, V278, P843, DOI 10.1074/jbc.M209714200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GERHART J, 1989, DEVELOPMENT, V107, P37; Gladfelter AS, 2002, J CELL BIOL, V156, P315, DOI 10.1083/jcb.200109062; Gladfelter AS, 2001, MOL BIOL CELL, V12, P1239, DOI 10.1091/mbc.12.5.1239; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Harkins HA, 2001, MOL BIOL CELL, V12, P2497, DOI 10.1091/mbc.12.8.2497; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kirschner M, 2000, CELL, V100, P79, DOI 10.1016/S0092-8674(00)81685-2; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Lechler T, 2001, J CELL BIOL, V155, P261, DOI 10.1083/jcb.200104094; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; Michelitch M, 1996, CURR BIOL, V6, P446, DOI 10.1016/S0960-9822(02)00512-2; Miller PJ, 1997, YEAST, V13, P561; Moore DD, 1995, GLOB MOB SURV; Padmashree CG, 2001, J CELL SCI, V114, P207; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pruyne D, 2000, J CELL SCI, V113, P365; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; van Oudenaarden A, 1999, NAT CELL BIOL, V1, P493, DOI 10.1038/70281; Verkhovsky AB, 1999, CURR BIOL, V9, P11, DOI 10.1016/S0960-9822(99)80042-6; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wedlich-Soldner R, 2003, NAT CELL BIOL, V5, P267, DOI 10.1038/ncb0403-267; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	55	193	194	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1062	1070		10.1038/ncb1068	http://dx.doi.org/10.1038/ncb1068			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14625559				2022-12-25	WOS:000186892900011
J	Ambati, J; Anand, A; Fernandez, S; Sakurai, E; Lynn, BC; Kuziel, WA; Rollins, BJ; Ambati, BK				Ambati, J; Anand, A; Fernandez, S; Sakurai, E; Lynn, BC; Kuziel, WA; Rollins, BJ; Ambati, BK			An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice	NATURE MEDICINE			English	Article							RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; CHLAMYDIA-PNEUMONIAE INFECTION; HIGH-FAT DIET; CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; COMPLEMENT ACTIVATION; TARGETED DISRUPTION; DEPOSIT FORMATION	The study and treatment of age-related macular degeneration (AMD), a leading cause of blindness, has been hampered by a lack of animal models. Here we report that mice deficient either in monocyte chemoattractant protein-1 (Ccl-2; also known as MCP-1) or its cognate C-C chemokine receptor-2 (Ccr-2) develop cardinal features of AMD, including accumulation of lipofuscin in and drusen beneath the retinal pigmented epithelium (RPE), photoreceptor atrophy and choroidal neovascularization (CNV). Complement and IgG deposition in RPE and choroid accompanies senescence in this model, as in human AMD. RPE or choroidal endothelial production of Ccl-2 induced by complement C5a and IgG may mediate choroidal macrophage infiltration into aged wild-type choroids. Wild-type choroidal macrophages degrade C5 and IgG in eye sections of Ccl2(-/-) or Ccr2(-/-) mice. Impaired macrophage recruitment may allow accumulation of C5a and IgG, which induces vascular endothelial growth factor (VEGF) production by RPE, possibly mediating development of CNV. These models implicate macrophage dysfunction in AMD pathogenesis and may be useful as a platform for validating therapies.	Univ Kentucky, Dept Ophthalmol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40506 USA; Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30907 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University System of Georgia; Augusta University	Ambati, J (corresponding author), Univ Kentucky, Dept Ophthalmol, 740 S Limestone St, Lexington, KY 40536 USA.		Mohammed, Imran/J-8271-2012	Mohammed, Imran/0000-0002-8412-0768; Lynn, Bert/0000-0001-8426-3024				Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582; Bian ZM, 1996, J LEUKOCYTE BIOL, V60, P405, DOI 10.1002/jlb.60.3.405; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Brons RH, 2001, ANN RHEUM DIS, V60, P1097, DOI 10.1136/ard.60.12.1097; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496; Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643; Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035; DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; Grossniklaus HE, 2002, MOL VIS, V8, P119; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; GURNE DH, 1991, OPHTHALMOLOGY, V98, P602; Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6; Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629; Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Kothe H, 2000, CIRCULATION, V101, P1760, DOI 10.1161/01.CIR.101.15.1760; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; LEYS A, 1990, GRAEF ARCH CLIN EXP, V228, P499, DOI 10.1007/BF00918479; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936; Meda L, 1996, J IMMUNOL, V157, P1213; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; Roberts WG, 1997, CANCER RES, V57, P765; RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; SCHULZE M, 1993, AM J PATHOL, V142, P179; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	47	489	552	0	34	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2003	9	11					1390	1397		10.1038/nm950	http://dx.doi.org/10.1038/nm950			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	739AH	14566334				2022-12-25	WOS:000186319700029
J	Higa, LAA; Mihaylov, IS; Banks, DP; Zheng, JY; Zhang, H				Higa, LAA; Mihaylov, IS; Banks, DP; Zheng, JY; Zhang, H			Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint	NATURE CELL BIOLOGY			English	Letter							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; LICENSING FACTOR; CELL-CYCLE; INHIBITION; DEGRADATION; REQUIREMENT; INITIATION; GEMININ; PROTEIN	Genomic integrity is maintained by checkpoints that guard against undesired replication after DNA damage. Here, we show that CDT1, a licensing factor of the pre-replication complex (preRC)(1-3,) is rapidly proteolysed after UV- or gamma-irradiation. The preRC assembles on replication origins at the end of mitosis and during G1 to license DNA for replication in S phase. Once the origin recognition complex (ORC) binds to origins, CDC6 and CDT1 associate with ORC and promote loading of the MCM2-7 proteins onto chromatin, generating the preRC. We show that radiation-mediated CDT1 proteolysis is independent of ATM and CHK2 and can occur in G1-phase cells. Loss of the COP9-signalosome (CSN) or CUL4-ROC1 complexes completely suppresses CDT1 proteolysis. CDT1 is specifically polyubiquitinated by CUL4 complexes and the interaction between CDT1 and CUL4 is regulated in part by gamma-irradiation. Our study reveals an evolutionarily conserved and uncharacterized G1 checkpoint that induces CDT1 proteolysis by the CUL4-ROC1 ubiquitin E3 ligase and CSN complexes in response to DNA damage.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University	Zhang, H (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.	hui.zhang@yale.edu		Higa, Leigh Ann/0000-0003-0117-0397	NCI NIH HHS [CA72878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; HENNER WD, 1986, J NATL CANCER I, V76, P1007; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Rialland M, 2002, J CELL SCI, V115, P1435; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	35	241	252	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					1008	1015		10.1038/ncb1061	http://dx.doi.org/10.1038/ncb1061			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14578910				2022-12-25	WOS:000186273100018
J	Weimann, JM; Johansson, CB; Trejo, A; Blau, HM				Weimann, JM; Johansson, CB; Trejo, A; Blau, HM			Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant	NATURE CELL BIOLOGY			English	Article							STEM-CELL; DNA CONTENT; IN-VIVO; DIFFERENTIATED FUNCTIONS; TRANSIENT HETEROKARYONS; MOUSE; LIVER; EXPRESSION; ACTIVATION; FUSION	Heterokaryons are the product of cell fusion without subsequent nuclear or chromosome loss. Decades of research using Sendaivirus or polyethylene glycol (PEG)-mediated fusion in tissue culture showed that the terminally differentiated state of a cell could be altered. But whether stable non-dividing heterokaryons could occur in animals has remained unclear. Here, we show that green fluorescent protein (GFP)-positive bone-marrow-derived cells (BMDCs) contribute to adult mouse Purkinje neurons through cell fusion. The formation of heterokaryons increases in a linear manner over 1.5 years and seems to be stable. The dominant Purkinje neurons caused the BMDC nuclei within the resulting heterokaryons to enlarge, exhibit dispersed chromatin and activate a Purkinje neuron-specific transgene, L7-GFP. The observed reprogrammed heterokaryons that form in brain may provide insights into gene regulation associated with cell-fate plasticity.	Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol,Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Weimann, JM (corresponding author), Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol,Dept Mol Pharmacol, Stanford, CA 94305 USA.				NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG09521, AG20961] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009521, R37AG009521, R01AG020961] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMENGOL JA, 1991, DEV BRAIN RES, V64, P95, DOI 10.1016/0165-3806(91)90213-3; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOHM N, 1981, HISTOCHEMISTRY, V72, P55, DOI 10.1007/BF00496779; DARLINGTON GJ, 1974, SCIENCE, V185, P859, DOI 10.1126/science.185.4154.859; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; EPHRUSSI B, 1965, P NATL ACAD SCI USA, V53, P1040, DOI 10.1073/pnas.53.5.1040; EPSTEIN CJ, 1967, NATURE, V214, P1050, DOI 10.1038/2141050a0; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frisen J, 2002, NEURON, V35, P415, DOI 10.1016/S0896-6273(02)00798-5; GRAHAM DI, 1997, GREENFIELDS NEUROPAT; HARRIS H, 1965, NATURE, V207, P606, DOI 10.1038/207606a0; Harris H., 1970, CELL FUSION DUNHAM L; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; MANN DMA, 1978, J COMP NEUROL, V180, P345, DOI 10.1002/cne.901800210; MANUELIDIS L, 1974, EXP NEUROL, V43, P192, DOI 10.1016/0014-4886(74)90140-X; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Rehen SK, 2001, P NATL ACAD SCI USA, V98, P13361, DOI 10.1073/pnas.231487398; Ringertz Nils R., 1976, CELL HYBRIDS; RUBIN P, 1994, RADIOTHER ONCOL, V31, P51, DOI 10.1016/0167-8140(94)90413-8; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tomomura M, 2001, EUR J NEUROSCI, V14, P57, DOI 10.1046/j.0953-816x.2001.01624.x; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; WRIGHT WE, 1984, EXP CELL RES, V151, P55, DOI 10.1016/0014-4827(84)90355-0; WRIGHT WE, 1984, J CELL BIOL, V98, P427, DOI 10.1083/jcb.98.2.427; [No title captured]	43	353	368	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2003	5	11					959	966		10.1038/ncb1053	http://dx.doi.org/10.1038/ncb1053			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	738EE	14562057				2022-12-25	WOS:000186273100011
J	Wienholds, E; Koudijs, MJ; van Eeden, FJM; Cuppen, E; Plasterk, RHA				Wienholds, E; Koudijs, MJ; van Eeden, FJM; Cuppen, E; Plasterk, RHA			The microRNA-producing enzyme Dicer1 is essential for zebrafish development	NATURE GENETICS			English	Article							RNA-INTERFERENCE; GENES; ELEGANS	MicroRNAs (miRNAs) are produced by the Dicer1 enzyme; the role of Dicer1 in vertebrate development is unknown. Here we report target-selected inactivation of the dicer1 gene in zebrafish. We observed an initial build-up of miRNA levels, produced by maternal Dicer1, in homozygous dicer1 mutants, but miRNA accumulation stopped after a few days. This resulted in developmental arrest around day 10. These results indicate that miRNA-producing Dicer1 is essential for vertebrate development.	Netherlands Inst Dev Biol, Hubrecht Lab, Dept Funct Genom, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Dept Funct Genom, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Van Eeden, Freek/E-6198-2010; Cuppen, Edwin/F-5696-2011; Cuppen, Edwin/H-2389-2016	Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762	10	340	371	0	37	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2003	35	3					217	218		10.1038/ng1251	http://dx.doi.org/10.1038/ng1251			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	738EG	14528306				2022-12-25	WOS:000186273300015
J	Wang, XY; Lee, SR; Arai, K; Lee, SR; Tsuji, K; Rebeck, GW; Lo, EH				Wang, XY; Lee, SR; Arai, K; Lee, SR; Tsuji, K; Rebeck, GW; Lo, EH			Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; METHYL-D-ASPARTATE; EXTRACELLULAR PROTEOLYSIS; PROTEIN; THROMBOLYSIS; EXPRESSION; LRP; INVOLVEMENT; INHIBITION; SCAVENGER	Although thrombolysis with tissue plasminogen activator (tPA) is a stroke therapy approved by the US Food and Drug Administration, its efficacy may be limited by neurotoxic side effects(1,2). Recently, proteolytic damage involving matrix metalloproteinases (MMPs) have been implicated. In experimental embolic stroke models, MMP inhibitors decreased cerebral hemorrhage and injury after treatment with tPA(3,4). MMPs comprise a family of zinc endopeptidases that can modify several components of the extracellular matrix(5,6). In particular, the gelatinases MMP-2 and MMP-9 can degrade neurovascular matrix integrity. MMP-9 promotes neuronal death by disrupting cell-matrix interactions(7), and MMP-9 knockout mice have reduced blood-brain barrier leakage and infarction after cerebral ischemia(8). Hence it is possible that tPA upregulates MMPs in the brain, and that subsequent matrix degradation causes brain injury. Here we show that tPA upregulates MMP-9 in cell culture and in vivo. MMP-9 levels were lower in tPA knockouts compared with wild-type mice after focal cerebral ischemia. In human cerebral microvascular endothelial cells, MMP-9 was upregulated when recombinant tPA was added. RNA interference (RNAi) suggested that this response was mediated by the low-density lipoprotein receptor-related protein (LRP), which avidly binds tPA(9) and possesses signaling properties(10). Targeting the tPA-LRP signaling pathway in brain may offer new approaches for decreasing neurotoxicity and improving stroke therapy.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Georgetown University	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu; lo@helix.mgh.harvard.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037074, R01NS040529, R01NS038731, P50NS010828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014473] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG14473] Funding Source: Medline; NINDS NIH HHS [R01-NS37074, R01-NS38731, R01-NS40529, P50-NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Del Zoppo GJ, 1998, NAT MED, V4, P148, DOI 10.1038/nm0298-148; Fini ME, 1998, BIOL EXTRAC, P299; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hacke W, 1999, NEUROLOGY, V53, pS3; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Mataga N, 2002, P NATL ACAD SCI USA, V99, P7717, DOI 10.1073/pnas.102088899; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Nagai N, 2001, J CEREBR BLOOD F MET, V21, P631, DOI 10.1097/00004647-200106000-00001; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	28	368	399	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2003	9	10					1313	1317		10.1038/nm926	http://dx.doi.org/10.1038/nm926			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	727QK	12960961				2022-12-25	WOS:000185669700044
J	Feuerer, M; Beckhove, P; Garbi, N; Mahnke, Y; Limmer, A; Hommel, M; Hammerling, GJ; Kyewski, B; Hamann, A; Umansky, V; Schirrmacher, V				Feuerer, M; Beckhove, P; Garbi, N; Mahnke, Y; Limmer, A; Hommel, M; Hammerling, GJ; Kyewski, B; Hamann, A; Umansky, V; Schirrmacher, V			Bone marrow as a priming site for T-cell responses to blood-borne antigen	NATURE MEDICINE			English	Article							DENDRITIC CELLS; IN-VIVO; LYMPH-NODES; IMMUNE-RESPONSE; TUMOR-CELLS; MICE; CD8(+); TOLERANCE; TISSUE; NAIVE	Although bone marrow is known as a primary lymphoid organ, its potential to serve as a secondary immune organ has hardly been explored. Here we demonstrate that naive, antigen-specific T cells home to bone marrow, where they can be primed. Antigen presentation to T cells in bone marrow is mediated via resident CD11c(+) dendritic cells. They are highly efficient in taking up exogenous blood-borne antigen and processing it via major histocompatibility complex class I and class II pathways. T-cell activation correlates with dendritic cell-T cell clustering in bone marrow stroma. Primary CD4(+) and CD8(+) T-cell responses generated in bone marrow occur in the absence of secondary lymphoid organs. The responses are not tolerogenic and result in generation of cytotoxic T cells, protective anti-tumor immunity and immunological memory. These findings highlight the uniqueness of bone marrow as an organ important for hemato- and lymphopoiesis and for systemic T cell-mediated immunity.	German Canc Res Ctr DKFZ, Tumor Immunol Program, Heidelberg, Germany; Univ Clin, Inst Mol Med & Expt Immunol, Bonn, Germany; Humboldt Univ, Charite, Dept Expt Rheumatol, Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schirrmacher, V (corresponding author), German Canc Res Ctr DKFZ, Tumor Immunol Program, Heidelberg, Germany.		Garbi, Natalio/H-7666-2014; Garbi, Natalio/B-9147-2009; Hommel, Mirja/C-9791-2019	Hommel, Mirja/0000-0002-4788-6932; Mahnke, Yolanda/0000-0002-2727-9887				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; BAIN BJ, 2001, BONE MARROW PATHOLOG, P114; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Chin R, 2001, NAT MED, V7, P1165, DOI 10.1038/nm1101-1165a; Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; Feuerer M, 2001, NAT MED, V7, P452, DOI 10.1038/86523; Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q; Forg P, 1998, GENE THER, V5, P789, DOI 10.1038/sj.gt.3300628; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hommel M, 2003, J EXP MED, V197, P269, DOI 10.1084/jem.20021512; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kamath AT, 2000, J IMMUNOL, V165, P6762, DOI 10.4049/jimmunol.165.12.6762; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; KRUGER A, 1994, INT J CANCER, V58, P275, DOI 10.1002/ijc.2910580222; Kuroda MJ, 2000, BLOOD, V96, P1474, DOI 10.1182/blood.V96.4.1474.h8001474_1474_1479; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Li M, 2001, J IMMUNOL, V166, P6099, DOI 10.4049/jimmunol.166.10.6099; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Marshall DR, 2001, P NATL ACAD SCI USA, V98, P6313, DOI 10.1073/pnas.101132698; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Muller M, 1998, CANCER RES, V58, P5439; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OSMOND DG, 1994, ADV EXP MED BIOL, V355, P15; Robertson JM, 2000, J IMMUNOL, V164, P4706, DOI 10.4049/jimmunol.164.9.4706; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Tripp RA, 1997, J IMMUNOL, V158, P3716; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907	39	257	264	0	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1151	1157		10.1038/nm914	http://dx.doi.org/10.1038/nm914			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12910264				2022-12-25	WOS:000185061600027
J	Noben-Trauth, K; Zheng, QY; Johnson, KR				Noben-Trauth, K; Zheng, QY; Johnson, KR			Association of cadherin 23 with polygenic inheritance and genetic modification of sensorineural hearing loss	NATURE GENETICS			English	Article							SYNDROME TYPE 1D; INBRED STRAINS; MICE; LOCUS; SUSCEPTIBILITY; STEREOCILIA; MUTATIONS; HARMONIN; MODEL; MOUSE	Age-related hearing loss (AHL) in common inbred mouse strains is a genetically complex quantitative trait. We found a synonymous single-nucleotide polymorphism in exon 7 of Cdh23 that shows significant association with AHL and the deafness modifier mdfw (modifer of deafwaddler). The hypomorphic Cdh23(753A) allele causes in-frame skipping of exon 7. Altered adhesion or reduced stability of CDH23 may confer susceptibility to AHL. Homozygosity at Cdh23(753A) or in combination with heterogeneous secondary factors is a primary determinant of AHL in mice.	Natl Inst Deafness & Other Commun Disorders, Neurogenet Sect, NIH, Rockville, MD 20850 USA; Jackson Lab, Bar Harbor, ME 04609 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Jackson Laboratory	Noben-Trauth, K (corresponding author), Natl Inst Deafness & Other Commun Disorders, Neurogenet Sect, NIH, 5 Res Court, Rockville, MD 20850 USA.		Zheng, Qing/C-1731-2012		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R21DC005846, R01DC009246, R01DC004301, R03DC004376, R01DC005827, Z01DC000036] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC005827, R01 DC005827-03, R01 DC009246, R03 DC004376-01A1, R21 DC005846, R21 DC005846-01A1, R01 DC004301-05, R01 DC004301] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Davis RR, 2001, HEARING RES, V155, P82, DOI 10.1016/S0378-5955(01)00250-7; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; Johnson KR, 2002, GENOMICS, V80, P461, DOI 10.1016/S0888-7543(02)96858-8; Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831; Johnson KR, 2000, GENOMICS, V70, P171, DOI 10.1006/geno.2000.6377; NobenTrauth K, 1997, GENOMICS, V44, P266, DOI 10.1006/geno.1997.4869; Petit C, 2001, ANNU REV GENET, V35, P589, DOI 10.1146/annurev.genet.35.102401.091224; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; von Brederlow B, 2002, HUM MUTAT, V19, P268, DOI 10.1002/humu.10049; Willott JF, 1998, HEARING RES, V115, P162, DOI 10.1016/S0378-5955(97)00189-5; Yamoah EN, 1998, J NEUROSCI, V18, P610; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; Zheng QY, 2001, HEARING RES, V154, P45, DOI 10.1016/S0378-5955(01)00215-5	15	330	346	0	12	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2003	35	1					21	23		10.1038/ng1226	http://dx.doi.org/10.1038/ng1226			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	716FQ	12910270	Green Accepted			2022-12-25	WOS:000185018500006
J	Kramer, BP; Viretta, AU; El Baba, MD; Aubel, D; Weber, W; Fussenegger, M				Kramer, BP; Viretta, AU; El Baba, MD; Aubel, D; Weber, W; Fussenegger, M			An engineered epigenetic transgene switch in mammalian cells	NATURE BIOTECHNOLOGY			English	Article							GENE-EXPRESSION; RESPONSIVE PROMOTERS; ESCHERICHIA-COLI; TOGGLE SWITCH; TRANSCRIPTION; MEMORY; MICE; POLYCOMB; SYSTEMS; VECTORS	In multicellular systems cell identity is imprinted by epigenetic regulation circuits, which determine the global transcriptome of adult cells in a cell phenotype-specific manner(1-3). By combining two repressors, which control each other's expression, we have developed a mammalian epigenetic circuitry able to switch between two stable transgene expression states after transient administration of two alternate drugs. Engineered Chinese hamster ovary cells (CHO-K1) showed toggle switch-specific expression profiles of a human glycoprotein in culture, as well as after microencapsulation and implantation into mice. Switch dynamics and expression stability could be predicted with mathematical models. Epigenetic transgene control through toggle switches is an important tool for engineering artificial gene networks in mammalian cells.	ETH, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; Inst Univ Technol, IUTA, Dept Genie Biol, F-69622 Villeurbanne, France	Swiss Federal Institutes of Technology Domain; ETH Zurich	Fussenegger, M (corresponding author), ETH, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.	fussenegger@biotech.biol.ethz.ch	Weber, Wilfried/B-4732-2012	Weber, Wilfried/0000-0003-4340-4446				Atkinson MR, 2003, CELL, V113, P597, DOI 10.1016/S0092-8674(03)00346-5; Aubel D, 2001, J ANTIBIOT, V54, P44, DOI 10.7164/antibiotics.54.44; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Casadesus J, 2002, BIOESSAYS, V24, P512, DOI 10.1002/bies.10102; Cherry JL, 2000, J THEOR BIOL, V203, P117, DOI 10.1006/jtbi.2000.1068; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ermentrout B., 2002, SIMULATING ANAL ANIM, V14; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P1203, DOI 10.1038/81208; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Kapusnik-Uner J. E., 1996, GOODMAN GILMANS PHAR, P1123; Kohler C, 2002, CURR OPIN CELL BIOL, V14, P773, DOI 10.1016/S0955-0674(02)00394-0; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Moser S, 2000, BIOTECHNOL PROGR, V16, P724, DOI 10.1021/bp000077r; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Rank G, 2002, MOL CELL BIOL, V22, P8026, DOI 10.1128/MCB.22.22.8026-8034.2002; Rivera VM, 1999, P NATL ACAD SCI USA, V96, P8657, DOI 10.1073/pnas.96.15.8657; Schlatter S, 2002, GENE, V282, P19, DOI 10.1016/S0378-1119(01)00824-1; Weber W, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng071; Weber W, 2002, BIOTECHNOL BIOENG, V80, P691, DOI 10.1002/bit.10461; Weber W, 2002, NAT BIOTECHNOL, V20, P901, DOI 10.1038/nbt731; Wegener H.C., 1997, Euro Surveill, V2, P17; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939	28	266	279	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					867	870		10.1038/nbt980	http://dx.doi.org/10.1038/nbt980			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15184906				2022-12-25	WOS:000222533000028
J	Storhoff, JJ; Lucas, AD; Garimella, V; Bao, YP; Muller, UR				Storhoff, JJ; Lucas, AD; Garimella, V; Bao, YP; Muller, UR			Homogeneous detection of unamplified genomic DNA sequences based on colorimetric scatter of gold nanoparticle probes	NATURE BIOTECHNOLOGY			English	Article							HIGHLY FLUORESCENT ANALOGS; REAL-TIME PCR; OPTICAL-PROPERTIES; SUBMICROSCOPIC PARTICLES; BIOLOGICAL APPLICATIONS; OLIGONUCLEOTIDE ARRAYS; TRACER LABELS; POLYNUCLEOTIDES; HYBRIDIZATION; AMPLIFICATION	Nucleic acid diagnostics is dominated by fluorescence-based assays that use complex and expensive enzyme-based target or signal-amplification procedures(1-6). Many clinical diagnostic applications will require simpler, inexpensive assays that can be done in a screening mode. We have developed a 'spot-and-read' colorimetric detection method for identifying nucleic acid sequences based on the distance-dependent optical properties of gold nanoparticles. In this assay, nucleic acid targets are recognized by DNA-modified gold probes, which undergo a color change that is visually detectable when the solutions are spotted onto an illuminated glass waveguide. This scatter-based method enables detection of zeptomole quantities of nucleic acid targets without target or signal amplification when coupled to an improved hybridization method that facilitates probe-target binding in a homogeneous format. In comparison to a previously reported absorbance-based method 7, this method increases detection sensitivity by over four orders of magnitude. We have applied this method to the rapid detection of mecA in methicillin-resistant Staphylococcus aureus genomic DNA samples.	Nanosphere Inc, Dept Appl Sci, Northbrook, IL 60062 USA		Storhoff, JJ (corresponding author), Nanosphere Inc, Dept Appl Sci, 4088 Commercial Ave, Northbrook, IL 60062 USA.	jstorhoff@nanosphere.us			NATIONAL CANCER INSTITUTE [R44CA085008] Funding Source: NIH RePORTER; NCI NIH HHS [R44 CA085008, R44 CA085008-02, 2 R44 CA85008-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernard PS, 2002, CLIN CHEM, V48, P1178; Chambers HF, 1997, CLIN MICROBIOL REV, V10, P781, DOI 10.1128/CMR.10.4.781; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Hall JG, 2000, P NATL ACAD SCI USA, V97, P8272, DOI 10.1073/pnas.140225597; Jenison R, 2001, NAT BIOTECHNOL, V19, P62, DOI 10.1038/83530; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; Kim YJ, 2001, NANO LETT, V1, P165, DOI 10.1021/nl0100116; Kirk BW, 2002, NUCLEIC ACIDS RES, V30, P3295, DOI 10.1093/nar/gkf466; Kwok PY, 2001, ANNU REV GENOM HUM G, V2, P235, DOI 10.1146/annurev.genom.2.1.235; Lazarides AA, 2000, J PHYS CHEM B, V104, P460, DOI 10.1021/jp992179+; Liu JW, 2003, J AM CHEM SOC, V125, P6642, DOI 10.1021/ja034775u; Mackay IM, 2002, NUCLEIC ACIDS RES, V30, P1292, DOI 10.1093/nar/30.6.1292; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Otsuka H, 2001, J AM CHEM SOC, V123, P8226, DOI 10.1021/ja010437m; Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k; Singh-Zocchi M, 2003, P NATL ACAD SCI USA, V100, P7605, DOI 10.1073/pnas.1337215100; Sonnichsen C, 2000, APPL PHYS LETT, V77, P2949, DOI 10.1063/1.1323553; STIMPSON DI, 1995, P NATL ACAD SCI USA, V92, P6379, DOI 10.1073/pnas.92.14.6379; Storhoff JJ, 2000, J AM CHEM SOC, V122, P4640, DOI 10.1021/ja993825l; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639; Thanh NTK, 2002, ANAL CHEM, V74, P1624, DOI 10.1021/ac011127p; WETMUR JG, 1975, BIOPOLYMERS, V14, P2517, DOI 10.1002/bip.1975.360141208; Whelen AC, 1996, ANNU REV MICROBIOL, V50, P349, DOI 10.1146/annurev.micro.50.1.349; Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759; Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760	26	451	476	4	199	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					883	887		10.1038/nbt977	http://dx.doi.org/10.1038/nbt977			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15170215	Green Accepted			2022-12-25	WOS:000222533000031
J	Yanai, K; Sumida, N; Okakura, K; Moriya, T; Watanabe, M; Murakami, T				Yanai, K; Sumida, N; Okakura, K; Moriya, T; Watanabe, M; Murakami, T			Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes	NATURE BIOTECHNOLOGY			English	Article							CHLORAMPHENICOL BIOSYNTHESIS; CHORISMATE MUTASE; P-AMINOBENZOATE; ACID; CLUSTER; IDENTIFICATION; EXPRESSION; CATALYSIS; PATHWAY; PF1022A	PF1022A, a cyclooctadepsipeptide possessing strong anthelmintic properties and produced by the filamentous fungus Rosellinia sp. PF1022, consists of four alternating residues of N-methyl-L-leucine and four residues of D-lactate or D-phenyllactate. PF1022A derivatives obtained through modification of their benzene ring at the para-position with nitro or amino groups act as valuable starting materials for the synthesis of compounds with improved anthelmintic activities. Here we describe the production of such derivatives by fermentation through metabolic engineering of the PF1022A biosynthetic pathway in Rosellinia sp. PF1022. Three genes cloned from Streptomyces venezuelae, and required for the biosynthesis of p-aminophenylpyruvate from chorismate in the chloramphenicol biosynthetic pathway, were expressed in a chorismate mutase-deficient strain derived from Rosellinia sp. PF1022. Liquid chromatography-mass spectrometry and NMR analyses confirmed that this approach facilitated the production of PF1022A derivatives specifically modified at the para-position. This fermentation method is environmentally safe and can be used for the industrial scale production of PF1022A derivatives.	Meiji Seika Kaisha Ltd, Microbiol Resources & Technol Labs, Odawara, Kanagawa 2500852, Japan	Meiji Holdings Co., Ltd.	Yanai, K (corresponding author), Meiji Seika Kaisha Ltd, Microbiol Resources & Technol Labs, 788 Kayama, Odawara, Kanagawa 2500852, Japan.	koji_yanai@meiji.co.jp						ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; Blanc V, 1997, MOL MICROBIOL, V23, P191, DOI 10.1046/j.1365-2958.1997.2031574.x; Brown MP, 1996, MICROBIOL-UK, V142, P1345, DOI 10.1099/13500872-142-6-1345; Campelo AB, 2002, MICROBIOL-SGM, V148, P51, DOI 10.1099/00221287-148-1-51; CANTWELL C, 1992, P ROY SOC B-BIOL SCI, V248, P283, DOI 10.1098/rspb.1992.0073; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD L, 1995, BIO-TECHNOL, V13, P58, DOI 10.1038/nbt0195-58; Cropp TA, 2000, NAT BIOTECHNOL, V18, P980, DOI 10.1038/79479; DALY J, 1968, ARCH BIOCHEM BIOPHYS, V125, P136, DOI 10.1016/0003-9861(68)90647-4; Dosselaere F, 2001, CRIT REV MICROBIOL, V27, P75, DOI 10.1080/20014091096710; DOULL J, 1985, J GEN MICROBIOL, V131, P97; EBERHARD J, 1993, FEBS LETT, V334, P233, DOI 10.1016/0014-5793(93)81718-F; Harder A., 1999, Patent, Patent No. [EP0903347A1, 0903347]; He J, 2001, MICROBIOL-SGM, V147, P2817, DOI 10.1099/00221287-147-10-2817; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; JESCHKE P, 2000, Patent No. 6033879; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; KAWAI S, 1965, ARCH BIOCHEM BIOPHYS, V112, P537, DOI 10.1016/0003-9861(65)90092-5; Kitamoto N, 1998, APPL MICROBIOL BIOT, V50, P85, DOI 10.1007/s002530051260; MIDOH N, 2002, Patent No. 1215281; Miyadoh S., 2000, Nippon Kingakukai Kaiho, V41, P183; MIYAMOTO K, 2003, Patent No. 1291417; MORIYA T, 2002, Patent No. 6403362; Mousdale D. M, 1997, APPL MICROBIAL PHYSL, P165; NISHIYAMA H, 1996, Patent No. 5514773; OHYAMA M, 1999, Patent No. 0930304; PINE SH, 1980, ORGANIC CHEM; SASAKI T, 1992, J ANTIBIOT, V45, P692, DOI 10.7164/antibiotics.45.692; Scherkenbeck Juergen, 2002, Current Topics in Medicinal Chemistry, V2, P759, DOI 10.2174/1568026023393624; SCHMIDHEINI T, 1989, J BACTERIOL, V171, P1245, DOI 10.1128/jb.171.3.1245-1253.1989; UMEZAWA H, 1983, J ANTIBIOT, V36, P1087, DOI 10.7164/antibiotics.36.1087; Watanabe M, 1999, APPL ENVIRON MICROB, V65, P1036; Weckwerth W, 2000, J BIOL CHEM, V275, P17909, DOI 10.1074/jbc.M001084200; YANAI K, 2002, Patent No. 1223215	35	31	44	1	17	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2004	22	7					848	855		10.1038/nbt978	http://dx.doi.org/10.1038/nbt978			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	836CO	15184904				2022-12-25	WOS:000222533000025
J	Irobi, J; Van Impe, K; Seeman, P; Jordanova, A; Dierick, I; Verpoorten, N; Michalik, A; De Vriendt, E; Jacobs, A; Van Gerwen, V; Vennekens, K; Mazanec, R; Tournev, I; Hilton-Jones, D; Talbot, K; Kremensky, N; Van Den Bosch, L; Robberecht, W; Vandekerckhove, J; Van Broeckhoven, C; Gettemans, J; De Jonghe, P; Timmerman, V				Irobi, J; Van Impe, K; Seeman, P; Jordanova, A; Dierick, I; Verpoorten, N; Michalik, A; De Vriendt, E; Jacobs, A; Van Gerwen, V; Vennekens, K; Mazanec, R; Tournev, I; Hilton-Jones, D; Talbot, K; Kremensky, N; Van Den Bosch, L; Robberecht, W; Vandekerckhove, J; Van Broeckhoven, C; Gettemans, J; De Jonghe, P; Timmerman, V			Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy	NATURE GENETICS			English	Article							SPINAL MUSCULAR-ATROPHY; ALPHA-A-CRYSTALLIN; HMN-II; MISSENSE MUTATION; CANDIDATE GENES; UP-REGULATION; PROTEIN; HSP27; MEMBER; SUPERFAMILY	Distal hereditary motor neuropathies are pure motor disorders of the peripheral nervous system resulting in severe atrophy and wasting of distal limb muscles'. In two pedigrees with distal hereditary motor neuropathy type II linked to chromosome 12q24.3, we identified the same mutation (K141N) in small heat-shock 22-kDa protein 8 (encoded by HSPB8; also called HSP22). We found a second mutation (K141E) in two smaller families. Both mutations target the same amino acid, which is essential to the structural and functional integrity of the small heat-shock protein alphaA-crystallin(2). This positively charged residue, when mutated in other small heat-shock proteins, results in various human disorders(.)(3,4) Coimmunoprecipitation experiments showed greater binding of both HSPB8 mutants to the interacting partner HSPB1. Expression of mutant HSPB8 in cultured cells promoted formation of intracellular aggregates. Our findings provide further evidence that mutations in heat-shock proteins have an important role in neurodegenerative disorders.	Univ Instelling Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; Charles Univ Prague, Sch Med 2, Dept Child Neurol, Prague, Czech Republic; Med Univ Sofia, Lab Mol Pathol, Sofia, Bulgaria; Charles Univ Prague, Sch Med 2, Dept Neurol, Prague, Czech Republic; Med Univ Sofia, Dept Neurol, Sofia, Bulgaria; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 2JD, England; Katholieke Univ Leuven, Dept Expt Neurol, Neurobiol Lab, Louvain, Belgium; Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium	Flanders Institute for Biotechnology (VIB); University of Antwerp; Flanders Institute for Biotechnology (VIB); Ghent University; Charles University Prague; Medical University Sofia; Charles University Prague; Medical University Sofia; Radcliffe Infirmary; University of Oxford; KU Leuven; University of Antwerp	Timmerman, V (corresponding author), Univ Instelling Antwerp VIB, Dept Mol Genet, Univ Pl 1, B-2610 Antwerp, Belgium.	vincent.timmerman@ua.ac.be	Van Den Bosch, Ludo/B-7258-2012; Van Broeckhoven, Christine/M-7853-2019; Jordanova, Albena/H-8323-2015; Timmerman, Vincent/O-7283-2019; Van Broeckhoven, Christine/G-8362-2017; Talbot, Kevin/F-7361-2011	Van Broeckhoven, Christine/0000-0003-0183-7665; Jordanova, Albena/0000-0002-3833-3754; Timmerman, Vincent/0000-0002-2162-0933; Van Broeckhoven, Christine/0000-0003-0183-7665; Talbot, Kevin/0000-0001-5490-1697; Van Den Bosch, Ludo/0000-0003-0104-4067				Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; Bera S, 2002, BIOCHEMISTRY-US, V41, P12421, DOI 10.1021/bi0204140; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Fontaine JM, 2003, CELL STRESS CHAPERON, V8, P62, DOI 10.1379/1466-1268(2003)8<62:TSODFP>2.0.CO;2; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; Grohmann K, 2001, NAT GENET, V29, P75, DOI 10.1038/ng703; HARDING AE, 1980, J NEUROL SCI, V45, P337, DOI 10.1016/0022-510X(80)90177-X; Irobi J, 2000, GENOMICS, V65, P34, DOI 10.1006/geno.2000.6149; Irobi J, 2002, J PERIPHER NERV SYST, V7, P87, DOI 10.1046/j.1529-8027.2002.02014.x; Irobi J, 2001, ANN HUM GENET, V65, P517, DOI 10.1017/S0003480001008910; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; TIMMERMAN V, 1992, J NEUROL SCI, V109, P41, DOI 10.1016/0022-510X(92)90091-X; Timmerman V, 1996, HUM MOL GENET, V5, P1065, DOI 10.1093/hmg/5.7.1065; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	30	329	350	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2004	36	6					597	601		10.1038/ng1328	http://dx.doi.org/10.1038/ng1328			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	825MX	15122253	Bronze			2022-12-25	WOS:000221763700016
J	Becskei, A; Boselli, MG; van Oudenaarden, A				Becskei, A; Boselli, MG; van Oudenaarden, A			Amplitude control of cell-cycle waves by nuclear import	NATURE CELL BIOLOGY			English	Letter							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN; TRANSCRIPTION; ACTIVATION; MECHANISMS; TRANSPORT; KINASE; PHOSPHORYLATION; LOCALIZATION	Propagation of waves of biochemical activities through consecutive stages of the cell cycle is essential to execute the steps of cell division in a strict temporal order. Mechanisms that ensure the proper amplitude and timing of these waves are poorly understood(1). Using a synthetic gene circuit, we show that a transcriptional activator driven by yeast cell-cycle promoters propagates transcriptional oscillations with substantial damping. Although regulated nuclear translocation has been implicated in the timing of oscillatory events(2,3), mathematical analysis shows that increasing the rate of nuclear transport is an example of a general regulatory principle, which enhances the fidelity of wave propagation. Indeed, increasing the constitutive import rate of the activator counteracts the damping of waves and concurrently preserves the intensity of the signal. In contrast to the regulatory range of nuclear transport, the range of mRNA turnover considerably limits transcriptional wave propagation. This classification of cellular processes outlines potential regulatory mechanisms that can contribute to faithful transmission of oscillations at different stages of the cell cycle.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	van Oudenaarden, A (corresponding author), MIT, Dept Phys, 13-2008, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019	Becskei, Attila/0000-0002-9462-0934	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068957] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068957] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Audibert A, 2002, MOL CELL BIOL, V22, P6706, DOI 10.1128/MCB.22.19.6706-6718.2002; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Becskei A, 2003, P NATL ACAD SCI USA, V100, P1717, DOI 10.1073/pnas.252766999; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; Breeden LL, 2003, CURR BIOL, V13, pR31, DOI 10.1016/S0960-9822(02)01386-6; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Edgington NP, 2001, J CELL SCI, V114, P4599; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Georgi AB, 2002, CURR BIOL, V12, P105, DOI 10.1016/S0960-9822(01)00662-5; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Hasty J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.148101; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; Makhnevych T, 2003, CELL, V115, P813, DOI 10.1016/S0092-8674(03)00986-3; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Miller ME, 2001, MOL CELL BIOL, V21, P6292, DOI 10.1128/MCB.21.18.6292-6311.2001; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799	41	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2004	6	5					451	+		10.1038/ncb1124	http://dx.doi.org/10.1038/ncb1124			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	821AV	15107861				2022-12-25	WOS:000221432600016
J	Brozovic, S; Nagaishi, T; Yoshida, M; Betz, S; Salas, A; Chen, DH; Kaser, A; Glickman, J; Kuo, T; Little, A; Morrison, J; Corazza, N; Kim, JY; Colgan, SP; Young, SG; Exley, M; Blumberg, RS				Brozovic, S; Nagaishi, T; Yoshida, M; Betz, S; Salas, A; Chen, DH; Kaser, A; Glickman, J; Kuo, T; Little, A; Morrison, J; Corazza, N; Kim, JY; Colgan, SP; Young, SG; Exley, M; Blumberg, RS			CD1d function is regulated by microsomal triglyceride transfer protein	NATURE MEDICINE			English	Article							NKT CELLS; LIVER; RECOGNITION	CD1d is a major histocompatibility complex (MHC) class I-related molecule that functions in glycolipid antigen presentation to distinct subsets of T cells that express natural killer receptors and an invariant T-cell receptor-alpha chain (invariant NKT cells)(1-3). The acquisition of glycolipid antigens by CD1d occurs, in part, in endosomes through the function of resident lipid transfer proteins, namely saposins(4-10). Here we show that microsomal triglyceride transfer protein (MTP), a protein that resides in the endoplasmic reticulum of hepatocytes and intestinal epithelial cells (IECs) and is essential for lipidation of apolipoprotein B-11,B-12, associates with CD1d in hepatocytes. Hepatocytes from animals in which Mttp (the gene encoding MTP) has been conditionally deleted, and IECs in which Mttp gene products have been silenced, are unable to activate invariant NKT cells. Conditional deletion of the Mttp gene in hepatocytes is associated with a redistribution of CD1d expression, and Mttp-deleted mice are resistant to immunopathologies associated with invariant NKT cell-mediated hepatitis and colitis. These studies indicate that the CD1d-regulating function of MTP in the endoplasmic reticulum is complementary to that of the saposins in endosomes in vivo.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Gastroenterol Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94110 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; The J David Gladstone Institutes; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Gastroenterol Div, Boston, MA 02115 USA.	rblumberg@partners.org	Eckhardt, Erik/G-1567-2010; Salas, Azucena/AAN-7035-2020; Colgan, Sean P./B-4573-2009	Salas, Azucena/0000-0003-4572-2907; Young, Stephen/0000-0001-7270-3176; Exley, Mark/0000-0002-5088-1032; Little, Alicia/0000-0003-0066-9372; KIM, JINYONG/0000-0003-2068-7287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319, R37DK044319, R01DK051362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51362, DK44319] Funding Source: Medline; NIGMS NIH HHS [T32 GM007205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Behar SM, 1999, J IMMUNOL, V162, P161; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; Chen DH, 2004, J IMMUNOL, V172, P3535, DOI 10.4049/jimmunol.172.6.3535; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; KANT SJ, 2004, NAT IMMUNOL, V5, P175; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RALF K, 1995, SCIENCE, V269, P1427; Roberts TJ, 2002, J IMMUNOL, V168, P5409, DOI 10.4049/jimmunol.168.11.5409; van de Wal Y, 2003, GASTROENTEROLOGY, V124, P1420, DOI 10.1016/S0016-5085(03)00219-1; Vincent MS, 2003, NAT IMMUNOL, V4, P517, DOI 10.1038/ni0603-517; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Winau F, 2004, NAT IMMUNOL, V5, P169, DOI 10.1038/ni1035; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	30	139	143	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					535	539		10.1038/nm1043	http://dx.doi.org/10.1038/nm1043			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15107843				2022-12-25	WOS:000221242400033
J	Callewaert, N; Van Vlierberghe, H; Van Hecke, A; Laroy, W; Delanghe, J; Contreras, R				Callewaert, N; Van Vlierberghe, H; Van Hecke, A; Laroy, W; Delanghe, J; Contreras, R			Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; ASIALOGLYCOPROTEIN RECEPTOR; BIOCHEMICAL MARKERS; DISEASE; COMPLICATIONS; EXPRESSION; FIBROSIS; BIOPSY	We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers, to generate profiles of serum protein N-glycans of liver disease patients. This technology yielded a biomarker that distinguished compensated cirrhotic from noncirrhotic chronic liver disease patients, with 79% sensitivity and 86% specificity (100% sensitivity and specificity for decompensated cirrhosis). In combination with the clinical chemistry-based Fibrotest biomarker, compensated cirrhosis was detected with 100% specificity and 75% sensitivity. The current 'gold standard' for liver cirrhosis detection is an invasive, costly, often painful liver biopsy. Consequently, the highly specific set of biomarkers presented could obviate biopsy in many cirrhosis patients. This biomarker combination could eventually be used in follow-up examinations of chronic liver disease patients, to yield a warning that cirrhosis has developed and that the risk of complications (such as hepatocellular carcinoma) has increased considerably. Our clinical glycomics technique can easily be implemented in existing molecular diagnostics laboratories.	Univ Ghent, Dept Mol Biomed Res, B-9052 Zwijnaarde, Belgium; VIB, B-9052 Zwijnaarde, Belgium; Ghent Univ Hosp, Dept Gastroenterol & Hepatol, B-9000 Ghent, Belgium; Ghent Univ Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Callewaert, N (corresponding author), Swiss Fed Inst Technol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	natmedcontact@dmbr.Ugent.be		Van Vlierberghe, Hans/0000-0003-0647-9238; Callewaert, Nico/0000-0003-2069-6917; Van Hecke, Annelies/0000-0002-3010-8034				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Callewaert N, 2001, GLYCOBIOLOGY, V11, P275, DOI 10.1093/glycob/11.4.275; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; HENDERSON AR, 1993, ANN CLIN BIOCHEM, V30, P521, DOI 10.1177/000456329303000601; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; Ise H, 2001, BIOCHEM BIOPH RES CO, V285, P172, DOI 10.1006/bbrc.2001.5139; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; Kuper H, 2001, HEPATOLOGY, V34, P714, DOI 10.1053/jhep.2001.28233; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Menon KVN, 2000, MAYO CLIN PROC, V75, P501; Miyoshi E, 1995, HEPATOLOGY, V22, P1847, DOI 10.1002/hep.1840220634; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; Poynard T, 2002, J VIRAL HEPATITIS, V9, P128, DOI 10.1046/j.1365-2893.2002.00341.x; SAWAMURA T, 1984, GASTROENTEROLOGY, V87, P1217; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; STIBLER H, 1991, CLIN CHEM, V37, P2029; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043	22	331	361	5	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2004	10	4					429	434		10.1038/nm1006	http://dx.doi.org/10.1038/nm1006			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	808RU	15152612				2022-12-25	WOS:000220587000037
J	Pajukanta, P; Lilja, HE; Sinsheimer, JS; Cantor, RM; Lusis, AJ; Gentile, M; Duan, XQJ; Soro-Paavonen, A; Naukkarinen, J; Saarela, J; Laakso, M; Ehnholm, C; Taskinen, MR; Peltonen, L				Pajukanta, P; Lilja, HE; Sinsheimer, JS; Cantor, RM; Lusis, AJ; Gentile, M; Duan, XQJ; Soro-Paavonen, A; Naukkarinen, J; Saarela, J; Laakso, M; Ehnholm, C; Taskinen, MR; Peltonen, L			Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1)	NATURE GENETICS			English	Article							DIABETES-SUSCEPTIBILITY GENES; INDEPENDENT REPLICATION; STIMULATORY FACTOR; LINKAGE ANALYSIS; SERUM-LIPIDS; GENOME-WIDE; LOCUS; PEDIGREES; SEARCH; SCAN	Familial combined hyperlipidemia (FCHL), characterized by elevated levels of serum total cholesterol, triglycerides or both(1,2), is observed in about 20% of individuals with premature coronary heart disease(1). We previously identified a locus linked to FCHL on 1q21-q23 in Finnish families with the disease(3). This region has also been linked to FCHL in families from other populations(4-6) as well as to type 2 diabetes mellitus(7-12). These clinical entities have several overlapping phenotypic features, raising the possibility that the same gene may underlie the obtained linkage results. Here, we show that the human gene encoding thioredoxin interacting protein (TXNIP) on 1q, which underlies combined hyperlipidemia in mice(13), is not associated with FCHL. We show that FCHL is linked and associated with the gene encoding upstream transcription factor 1 (USF1) in 60 extended families with FCHL, including 721 genotyped individuals (P = 0.00002), especially in males with high triglycerides (P = 0.0000009). Expression profiles in fat biopsy samples from individuals with FCHL seemed to differ depending on their carrier status for the associated USF1 haplotype. USF1 encodes a transcription factor known to regulate several genes of glucose and lipid metabolism(14-17).	Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Biomedicum, FIN-00290 Helsinki, Finland; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath & Biostat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA DOE, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Finland National Institute for Health & Welfare; University of Helsinki; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland	Pajukanta, P (corresponding author), Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA.	ppajukanta@mednet.ucla.edu; leena.peltonen@ktl.fi	Saarela, Janna S/E-5369-2014; Taskinen, Marja-Riitta/AAN-5432-2020	Taskinen, Marja-Riitta/0000-0002-6229-3588; Saarela, Janna/0000-0002-0853-6219				Allayee H, 2002, CIRC RES, V90, P926, DOI 10.1161/01.RES.0000015885.27134.F0; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Coon H, 2000, ARTERIOSCL THROM VAS, V20, P2275, DOI 10.1161/01.ATV.20.10.2275; Elbein SC, 1999, DIABETES, V48, P1175, DOI 10.2337/diabetes.48.5.1175; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Goring HHH, 2000, AM J HUM GENET, V66, P1298, DOI 10.1086/302846; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; HOSACK DA, 2003, GENOME BIOL, V4; Hsueh WC, 2003, DIABETES, V52, P550, DOI 10.2337/diabetes.52.2.550; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Martin ER, 2003, GENET EPIDEMIOL, V25, P203, DOI 10.1002/gepi.10258; NIKKILA EA, 1973, LANCET, V1, P954; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; Pei WD, 2000, CLIN GENET, V57, P29, DOI 10.1034/j.1399-0004.2000.570105.x; Peltonen L, 1995, BIOL CHEM H-S, V376, P697; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; Sinsheimer JS, 2000, AM J HUM GENET, V66, P1168, DOI 10.1086/302826; Soro A, 2003, J LIPID RES, V44, P1536, DOI 10.1194/jlr.M300069-JLR200; Terwilliger JD, 2000, HUM BIOL, V72, P63; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096; Vakkilainen J, 2002, J LIPID RES, V43, P598; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Watanabe RM, 2000, AM J HUM GENET, V67, P1186; Wiltshire S, 2001, AM J HUM GENET, V69, P553, DOI 10.1086/323249	30	252	262	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2004	36	4					371	376		10.1038/ng1320	http://dx.doi.org/10.1038/ng1320			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	809OY	14991056	Bronze			2022-12-25	WOS:000220647200020
J	Takamiya, K; Kostourou, V; Adams, S; Jadeja, S; Chalepakis, G; Scambler, PJ; Huganir, RL; Adams, RH				Takamiya, K; Kostourou, V; Adams, S; Jadeja, S; Chalepakis, G; Scambler, PJ; Huganir, RL; Adams, RH			A direct functional link between the multi-PDZ domain protein GRIP1 and the Fraser syndrome protein Fras1	NATURE GENETICS			English	Article							EPIDERMOLYSIS-BULLOSA; BLEBBED PHENOTYPE; PROTEOGLYCAN NG2; MOUSE; MICE; DERIVATION; MEMBRANE; MODEL; CELLS	Cell adhesion to extracellular matrix (ECM) proteins is crucial for the structural integrity of tissues and epithelial-mesenchymal interactions mediating organ morphogenesis(1,2). Here we describe how the loss of a cytoplasmic multi-PDZ scaffolding protein, glutamate receptor interacting protein 1 (GRIP1), leads to the formation of subepidermal hemorrhagic blisters, renal agenesis, syndactyly or polydactyly and permanent fusion of eyelids (cryptophthalmos). Similar malformations are characteristic of individuals with Fraser syndrome and animal models of this human genetic disorder, such as mice carrying the blebbed mutation (bl) in the gene encoding the Fras1 ECM protein(3,4). GRIP1 can physically interact with Fras1 and is required for the localization of Fras1 to the basal side of cells. In one animal model of Fraser syndrome, the eye-blebs (eb) mouse, Grip1 is disrupted by a deletion of two coding exons. Our data indicate that GRIP1 is required for normal cell-matrix interactions during early embryonic development and that inactivation of Grip1 causes Fraser syndrome like defects in mice.	Canc Res UK London Res Inst, Vasc Dev Lab, London WC2A 3PX, England; Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece	Cancer Research UK; Howard Hughes Medical Institute; Johns Hopkins University; University of London; University College London; University of Crete	Adams, RH (corresponding author), Canc Res UK London Res Inst, Vasc Dev Lab, London WC2A 3PX, England.	ralf.adams@cancer.org.uk	Adams, Ralf H/AAE-9274-2019; Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Takamiya, Kogo/0000-0001-7240-6307; Kostourou, Vassiliki/0000-0001-7053-6247				Bladt F, 2002, P NATL ACAD SCI USA, V99, P6816, DOI 10.1073/pnas.092130099; Darling S, 1994, Clin Dysmorphol, V3, P91; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Harris BZ, 2001, J CELL SCI, V114, P3219; Heinonen S, 1999, J CELL SCI, V112, P3641; HUMMEL KP, 1971, MOUSE NEWS LETT, V45, P29; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; McGregor L, 2003, NAT GENET, V34, P203, DOI 10.1038/ng1142; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Stegmuller J, 2003, J BIOL CHEM, V278, P3590, DOI 10.1074/jbc.M210010200; Swiergiel JJ, 2000, DEV DYNAM, V219, P21, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1030>3.0.CO;2-S; Tillet E, 1997, J BIOL CHEM, V272, P10769; Vainio S, 2002, NAT REV GENET, V3, P533, DOI 10.1038/nrg842; Vrontou S, 2003, NAT GENET, V34, P209, DOI 10.1038/ng1168; WINTER RM, 1990, CLIN GENET, V37, P494	20	101	107	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2004	36	2					172	177		10.1038/ng1292	http://dx.doi.org/10.1038/ng1292			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	768KT	14730302	Bronze			2022-12-25	WOS:000188542700020
J	Yan, JJ; Jung, JS; Lee, JE; Lee, J; Huh, SO; Kim, HS; Jung, KC; Cho, JY; Nam, JS; Suh, HW; Kim, YH; Song, DK				Yan, JJ; Jung, JS; Lee, JE; Lee, J; Huh, SO; Kim, HS; Jung, KC; Cho, JY; Nam, JS; Suh, HW; Kim, YH; Song, DK			Therapeutic effects of lysophosphatidylcholine in experimental sepsis	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN T-LYMPHOCYTES; HUMAN-MONOCYTES; INDUCED APOPTOSIS; GROWTH-FACTOR; ACTIVATION; MACROPHAGES; MORTALITY; LIGAND; MODEL	Sepsis represents a major cause of death in intensive care units. Here we show that administration of lysophosphatidylcholine (LPC), an endogenous lysophospholipid, protected mice against lethality after cecal ligation and puncture (CLP) or intraperitoneal injection of Escherichia coli. In vivo treatment with LPC markedly enhanced clearance of intraperitoneal bacteria and blocked CLP-induced deactivation of neutrophils. In vitro, LPC increased bactericidal activity of neutrophils, but not macrophages, by enhancing H2O2 production in neutrophils that ingested E. coli. Incubation with an antibody to the LPC receptor, G2A, inhibited LPC-induced protection from CLP lethality and inhibited the effects of LPC in neutrophils. G2A-specific antibody also blocked the inhibitory effects of LPC on certain actions of lipopolysaccharides (LPS), including lethality and the release of tumor necrosis factor-alpha (TNF-alpha) from neutrophils. These results suggest that LPC can effectively prevent and treat sepsis and microbial infections.	Hallym Univ, Inst Nat Med, Coll Med, Dept Pharmacol, Chunchon 200702, Gangwon Do, South Korea; Hallym Univ, Inst Nat Med, Coll Med, Dept Pathol, Chunchon 200702, Gangwon Do, South Korea; Hallym Univ, Biosynergen Inc, Chunchon 200702, Gangwon Do, South Korea	Hallym University; Hallym University; Hallym University	Song, DK (corresponding author), Hallym Univ, Inst Nat Med, Coll Med, Dept Pharmacol, 1 Okchon Dong, Chunchon 200702, Gangwon Do, South Korea.	dksong@hallym.ac.kr	Jung, Kyeong Choen/C-6068-2011	Jung, Kyeong Choen/0000-0002-7741-7184; Suh, HongWon/0000-0001-8691-6797				ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; Ayala A, 1998, BLOOD, V91, P1362, DOI 10.1182/blood.V91.4.1362; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; CORR PB, 1982, AM J PHYSIOL, V243, pH187, DOI 10.1152/ajpheart.1982.243.2.H187; Coutant F, 2002, J IMMUNOL, V169, P1688, DOI 10.4049/jimmunol.169.4.1688; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Drobnik W, 2003, J LIPID RES, V44, P754, DOI 10.1194/jlr.M200401-JLR200; Gomez-Munoz A, 1999, J LIPID RES, V40, P988; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Kabarowski JHS, 2002, BIOCHEM PHARMACOL, V64, P161, DOI 10.1016/S0006-2952(02)01179-6; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Kobold ACM, 2000, INTENS CARE MED, V26, P883, DOI 10.1007/s001340051277; Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Matsumoto T, 1997, FEMS IMMUNOL MED MIC, V17, P171, DOI 10.1016/S0928-8244(97)00005-9; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; Nakahata E, 2001, COMP BIOCHEM PHYS A, V130, P653, DOI 10.1016/S1095-6433(01)00396-8; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NGWENYA BZ, 1986, CANCER IMMUNOL IMMUN, V21, P174; Nishi E, 1998, CIRC RES, V83, P508, DOI 10.1161/01.RES.83.5.508; Nishi E, 1997, CIRC RES, V80, P638, DOI 10.1161/01.RES.80.5.638; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; Okajima F, 1998, BIOCHEM J, V336, P491, DOI 10.1042/bj3360491; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Qureshi M.A., 1995, METHODS IMMUNOTOXICO, V2, P119; Ramos MA, 1998, ARTERIOSCL THROM VAS, V18, P1188, DOI 10.1161/01.ATV.18.7.1188; Remick DG, 2001, CRIT CARE MED, V29, P473, DOI 10.1097/00003246-200103000-00001; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAVAGE JE, 1993, J INVEST DERMATOL, V101, P532, DOI 10.1111/1523-1747.ep12365905; Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179; SOLOMKIN JS, 1981, SURGERY, V90, P319; SZUCS S, 1994, J IMMUNOL METHODS, V167, P245, DOI 10.1016/0022-1759(94)90093-0; Tzianabos AO, 1999, J IMMUNOL, V163, P893; WANG SD, 1994, J IMMUNOL, V152, P5014; Weighardt H, 2002, ANN SURG, V235, P560, DOI 10.1097/00000658-200204000-00015; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Zantl N, 1998, INFECT IMMUN, V66, P2300, DOI 10.1128/IAI.66.5.2300-2309.1998; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	47	255	275	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2004	10	2					161	167		10.1038/nm989	http://dx.doi.org/10.1038/nm989			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	770JN	14716308				2022-12-25	WOS:000188719600035
J	Cosby, K; Partovi, KS; Crawford, JH; Patel, RP; Reiter, CD; Martyr, S; Yang, BK; Waclawiw, MA; Zalos, G; Xu, XL; Huang, KT; Shields, H; Kim-Shapiro, DB; Schechter, AN; Cannon, RO; Gladwin, MT				Cosby, K; Partovi, KS; Crawford, JH; Patel, RP; Reiter, CD; Martyr, S; Yang, BK; Waclawiw, MA; Zalos, G; Xu, XL; Huang, KT; Shields, H; Kim-Shapiro, DB; Schechter, AN; Cannon, RO; Gladwin, MT			Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE RELAXATION; REGIONAL BLOOD-FLOW; S-NITROSOHEMOGLOBIN; SODIUM-NITRITE; XANTHINE-OXIDASE; AUTOCATALYTIC OXIDATION; GLYCERYL TRINITRATE; BIOLOGICAL-SYSTEMS; SYNTHASE ACTIVITY; HUMAN-HEMOGLOBIN	Nitrite anions comprise the largest vascular storage pool of nitric oxide (NO), provided that physiological mechanisms exist to reduce nitrite to NO. We evaluated the vasodilator properties and mechanisms for bioactivation of nitrite in the human forearm. Nitrite infusions of 36 and 0.36 mumol/ min into the forearm brachial artery resulted in supra- and near- physiologic intravascular nitrite concentrations, respectively, and increased forearm blood flow before and during exercise, with or without NO synthase inhibition. Nitrite infusions were associated with rapid formation of erythrocyte iron- nitrosylated hemoglobin and, to a lesser extent, S- nitroso- hemoglobin. NO- modified hemoglobin formation was inversely proportional to oxyhemoglobin saturation. Vasodilation of rat aortic rings and formation of both NO gas and NO- modified hemoglobin resulted from the nitrite reductase activity of deoxyhemoglobin and deoxygenated erythrocytes. This finding links tissue hypoxia, hemoglobin allostery and nitrite bioactivation. These results suggest that nitrite represents a major bioavailable pool of NO, and describe a new physiological function for hemoglobin as a nitrite reductase, potentially contributing to hypoxic vasodilation.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA; NIDDKD, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Off Biostat Res, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Wake Forest Univ, Sch Med, Dept Biomed Engn, Winston Salem, NC 27157 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Wake Forest University; Wake Forest University	Gladwin, MT (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,10 Ctr Dr,Room 7D43, Bethesda, MD 20892 USA.		Kim-Shapiro, Daniel/HGA-2682-2022	Patel, Rakesh/0000-0002-1526-4303; Schechter, Alan N/0000-0002-5235-9408	NHLBI NIH HHS [HL58091, R01 HL058091, R01HL70146] Funding Source: Medline; NIGMS NIH HHS [T32GM08361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005063, R29HL058091, R01HL058091, R37HL058091, R01HL070146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agvald P, 2002, BRIT J PHARMACOL, V135, P373, DOI 10.1038/sj.bjp.0704489; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; Cicinelli E, 1999, CLIN PHYSIOL, V19, P440, DOI 10.1046/j.1365-2281.1999.00200.x; Crawford JH, 2003, BLOOD, V101, P4408, DOI 10.1182/blood-2002-12-3825; Demoncheaux EAG, 2002, CLIN SCI, V102, P77, DOI 10.1042/CS20010232; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Fernandez BO, 2003, INORG CHEM, V42, P2, DOI 10.1021/ic020519r; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; GLADWIN MT, 2002, J BIOL CHEM, V21, P21; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KOSAKA H, 1987, ENVIRON HEALTH PERSP, V73, P147, DOI 10.2307/3430605; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; LAUSTIOLA KE, 1991, PHARMACOL TOXICOL, V68, P60, DOI 10.1111/j.1600-0773.1991.tb01209.x; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; MATSUNAGA K, 1989, J PHARMACOL EXP THER, V248, P687; MCMAHON TJ, 2002, NAT MED, V3, P3; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MILLAR TM, 1997, BIOCHEM SOC T, V25, P528; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; MOULDS RFW, 1981, BRIT J CLIN PHARMACO, V11, P57, DOI 10.1111/j.1365-2125.1981.tb01102.x; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rodriguez J, 2003, P NATL ACAD SCI USA, V100, P336, DOI 10.1073/pnas.0234600100; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Schechter AN, 2002, J CLIN INVEST, V109, P1149, DOI 10.1172/JCI200215637; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; WATANABE S, 1981, ACTA MED OKAYAMA, V35, P173; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	46	1385	1443	4	165	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2003	9	12					1498	1505		10.1038/nm954	http://dx.doi.org/10.1038/nm954			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14595407				2022-12-25	WOS:000186845400033
J	Howard, K				Howard, K			Unlocking the money-making potential of RNAi	NATURE BIOTECHNOLOGY			English	Article																		*FRONT LIN STRAT C, 2003, SIRNA STRAT MARK OUT; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824	2	12	23	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2003	21	12					1441	1446		10.1038/nbt1203-1441	http://dx.doi.org/10.1038/nbt1203-1441			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	748CT	14647324				2022-12-25	WOS:000186845200016
J	Kaseda, K; Higuchi, H; Hirose, K				Kaseda, K; Higuchi, H; Hirose, K			Alternate fast and slow stepping of a heterodimeric kinesin molecule	NATURE CELL BIOLOGY			English	Letter							HAND-OVER-HAND; FORCE GENERATION; MYOSIN-V; MECHANICS; PROTEINS; MOVEMENT; ATPASE; CYCLE	A conventional kinesin molecule travels continuously along a microtubule in discrete 8-nm steps. This processive movement is generally explained by models in which the two identical heads of a kinesin move in a 'hand-over-hand' manner(1-4). Here, we show that a single heterodimeric kinesin molecule (in which one of the two heads is mutated in a nucleotide-binding site) exhibits fast and slow (with the dwell time at least 10 times longer than that of the fast step) 8-nm steps alternately, presumably corresponding to the displacement by the wildtype and mutant heads, respectively. Our results provide the first direct evidence for models in which the roles of the two heads alternate every 8-nm step.	Natl Inst Adv Ind Sci & Technol AIST, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan; JSPS, Tsukuba, Ibaraki 3058562, Japan; Tohoku Univ, Grad Sch Engn, Dept Met, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Sendai, Miyagi 9808579, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Society for the Promotion of Science; Tohoku University; Tohoku University	Hirose, K (corresponding author), Natl Inst Adv Ind Sci & Technol AIST, Gene Funct Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.		Hirose, Keiko/M-5429-2018	Hirose, Keiko/0000-0003-4587-8346				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOCK SM, 1995, BIOPHYS J, V68, pS2305; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; HOWARD J, 1995, BIOPHYS J, V68, pS245; HOWARD J, 1995, BIOPHYS J, V68, pS253; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Kaseda K, 2002, P NATL ACAD SCI USA, V99, P16058, DOI 10.1073/pnas.252409199; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	19	149	153	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2003	5	12					1079	1082		10.1038/ncb1067	http://dx.doi.org/10.1038/ncb1067			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	748ZK	14634664				2022-12-25	WOS:000186892900013
J	Okazaki, T; Tanaka, Y; Nishio, R; Mitsuiye, T; Mizoguchi, A; Wang, J; Ishida, M; Hiai, H; Matsumori, A; Minato, N; Honjo, T				Okazaki, T; Tanaka, Y; Nishio, R; Mitsuiye, T; Mizoguchi, A; Wang, J; Ishida, M; Hiai, H; Matsumori, A; Minato, N; Honjo, T			Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice	NATURE MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; VIRUS MYOCARDITIS; ANTIBODIES; PROTEINS; MODEL; CELLS; IMMUNOADSORPTION; IDENTIFICATION; HYPERTROPHY; MUTATIONS	We recently reported that mice deficient in the programmed cell death- 1 (PD- 1) immunoinhibitory coreceptor develop autoimmune dilated cardiomyopathy (DCM), with production of high- titer autoantibodies against a heart- specific, 30- kDa protein. In this study, we purified the 30- kDa protein from heart extract and identified it as cardiac troponin I (cTnI), encoded by a gene in which mutations can cause familial hypertrophic cardiomyopathy (HCM). Administration of monoclonal antibodies to cTnI induced dilatation and dysfunction of hearts in wild- type mice. Monoclonal antibodies to cTnI stained the surface of cardiomyocytes and augmented the voltage- dependent L- type Ca (2+) current of normal cardiomyocytes. These findings suggest that antibodies to cTnI induce heart dysfunction and dilatation by chronic stimulation of Ca2+ influx in cardiomyocytes.	Kyoto Univ, Dept Med Chem & Mol Biol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ Hosp, Div Emergency Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Physiol & Biophys, Sakyo Ku, Kyoto 6068501, Japan; Mie Univ, Dept Anat, Grad Sch Med, Tsu, Mie 5148507, Japan; Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; Mie University; Kyoto University	Honjo, T (corresponding author), Kyoto Univ, Dept Med Chem & Mol Biol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Okazaki, Taku/0000-0003-4790-1925; Tanaka, Yoshimasa/0000-0002-5024-0614				ALVAREZ FL, 1987, CLIN IMMUNOL IMMUNOP, V43, P129, DOI 10.1016/0090-1229(87)90164-4; Cohn JN, 1997, CIRCULATION, V95, P766; Felix SB, 2002, J AM COLL CARDIOL, V39, P646, DOI 10.1016/S0735-1097(01)01794-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERSKOWITZ A, 1993, J AM COLL CARDIOL, V22, P1385, DOI 10.1016/0735-1097(93)90547-E; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Keffer JH, 1996, AM J CLIN PATHOL, V105, P305; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; MATSUMORI A, 1982, CIRCULATION, V65, P1230, DOI 10.1161/01.CIR.65.6.1230; Matsumori A, 2002, CIRC J, V66, P323, DOI 10.1253/circj.66.323; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; NEU N, 1990, J IMMUNOL, V145, P4094; NEU N, 1987, J IMMUNOL, V139, P3630; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishio R, 2002, J AM COLL CARDIOL, V40, P1506, DOI 10.1016/S0735-1097(02)02166-6; Okazaki T, 2002, CURR OPIN IMMUNOL, V14, P779, DOI 10.1016/S0952-7915(02)00398-9; Pankuweit S, 1997, J MOL CELL CARDIOL, V29, P77, DOI 10.1006/jmcc.1996.0253; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; SCHULTHEISS HP, 1986, ANN NY ACAD SCI, V488, P44; Schulze K, 1999, CARDIOVASC RES, V44, P91, DOI 10.1016/S0008-6363(99)00204-7; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Solaro RJ, 1999, CIRC RES, V84, P122; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Staudt A, 2001, EUR J PHARMACOL, V423, P115, DOI 10.1016/S0014-2999(01)01113-X; Staudt A, 2001, CIRCULATION, V103, P2681; Takagi S, 1998, AM J PHYSIOL-REG I, V274, pR348, DOI 10.1152/ajpregu.1998.274.2.R348; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3	38	480	518	3	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2003	9	12					1477	1483		10.1038/nm955	http://dx.doi.org/10.1038/nm955			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	748CV	14595408				2022-12-25	WOS:000186845400030
J	Oudit, GY; Sun, H; Trivieri, MG; Koch, SE; Dawood, F; Ackerley, C; Yazdanpanah, M; Wilson, GJ; Schwartz, A; Liu, PP; Backx, PH				Oudit, GY; Sun, H; Trivieri, MG; Koch, SE; Dawood, F; Ackerley, C; Yazdanpanah, M; Wilson, GJ; Schwartz, A; Liu, PP; Backx, PH			L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy	NATURE MEDICINE			English	Article							BETA-THALASSEMIA MAJOR; METAL-ION TRANSPORTER; HEREDITARY HEMOCHROMATOSIS; LIPID-PEROXIDATION; CALCIUM CHANNELS; HEART-CELLS; ANTIOXIDANT STATUS; MASS-SPECTROMETRY; CARDIAC MYOCYTES; ALPHA-TOCOPHEROL	Under conditions of iron overload, which are now reaching epidemic proportions worldwide, iron-overload cardiomyopathy is the most important prognostic factor in patient survival. We hypothesize that in iron-overload disorders, iron accumulation in the heart depends on ferrous iron (Fe2+) permeation through the L-type voltage-dependent Ca2+ channel (LVDCC), a promiscuous divalent cation transporter. Iron overload in mice was associated with increased mortality, systolic and diastolic dysfunction, bradycardia, hypotension, increased myocardial fibrosis and elevated oxidative stress. Treatment with LVDCC blockers (CCBs; amlodipine and verapamil) at therapeutic levels inhibited the LVDCC current in cardiomyocytes, attenuated myocardial iron accumulation and oxidative stress, improved survival, prevented hypotension and preserved heart structure and function. Consistent with the role of LVDCCs in myocardial iron uptake, iron-overloaded transgenic mice with cardiac-specific overexpression of the LVDCC alpha(1)-subunit had twofold higher myocardial iron and oxidative stress levels, as well as greater impairment in cardiac function, compared with littermate controls; LVDCC blockade was again protective. Our results indicate that cardiac LVDCCs are key transporters of iron into cardiomyocytes under iron-overloaded conditions, and potentially represent a new therapeutic target to reduce the cardiovascular burden from iron overload.	Univ Toronto, Dept Med, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Physiol, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada; Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1X8, Canada; Univ Cincinnati, Med Ctr, CVRC, Inst Mol Phamracol & Biophys, Cincinnati, OH 45267 USA; Univ Hlth Network, Div Cardiol, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University System of Ohio; University of Cincinnati; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Backx, PH (corresponding author), Univ Toronto, Dept Med, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07382, P01 HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernethy DR, 1999, NEW ENGL J MED, V341, P1447, DOI 10.1056/NEJM199911043411907; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Andrews NC, 2002, CURR OPIN CHEM BIOL, V6, P181, DOI 10.1016/S1367-5931(02)00307-1; Azancot I, 2003, CIRCULATION, V107, P422, DOI 10.1161/01.CIR.0000046488.52939.BF; Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1053/shem.2001.20142; Barton JC, 1996, NAT MED, V2, P394, DOI 10.1038/nm0496-394; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BUJA LM, 1971, AM J MED, V51, P209, DOI 10.1016/0002-9343(71)90240-3; Carvalho M, 2001, BIOPHARM DRUG DISPOS, V22, P383, DOI 10.1002/bdd.282; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CECCHETTI G, 1991, EUR HEART J, V12, P224, DOI 10.1093/oxfordjournals.eurheartj.a059873; Chaston TB, 2003, AM J HEMATOL, V73, P200, DOI 10.1002/ajh.10348; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dilger K, 1999, BRIT J CLIN PHARMACO, V47, P413, DOI 10.1046/j.1365-2125.1999.00910.x; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fuhr U, 2002, EUR J CLIN PHARMACOL, V58, P45, DOI 10.1007/s00228-002-0436-7; Galanello R, 2001, SEMIN HEMATOL, V38, P73, DOI 10.1053/shem.2001.20147; Gharzuddine W S, 2002, Eur J Echocardiogr, V3, P47, DOI 10.1053/euje.2001.0114; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; HERSHKO C, 1987, J LAB CLIN MED, V110, P355; Jensen CE, 1997, EUR J HAEMATOL, V59, P76; KASS RS, 1989, AM J CARDIOL, V64, P351; Kivisto KT, 1997, HUM EXP TOXICOL, V16, P35, DOI 10.1177/0960327197016001071; KREMASTINOS DT, 1993, CIRCULATION, V88, P1127, DOI 10.1161/01.CIR.88.3.1127; KREMASTINOS DT, 1995, CIRCULATION, V91, P66, DOI 10.1161/01.CIR.91.1.66; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Ligon B, 1998, J BIOL CHEM, V273, P13905, DOI 10.1074/jbc.273.22.13905; LINK G, 1985, J LAB CLIN MED, V106, P147; Link G, 1999, J LAB CLIN MED, V133, P179, DOI 10.1016/S0022-2143(99)90011-2; LIU P, 1994, CARDIOVASC DRUG THER, V8, P101, DOI 10.1007/BF00877096; Livrea MA, 1996, BLOOD, V88, P3608, DOI 10.1182/blood.V88.9.3608.bloodjournal8893608; Low LCK, 1997, J PEDIATR ENDOCR MET, V10, P175; LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353; Mason RP, 1999, AM J CARDIOL, V84, p16L; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; MIKUS G, 1990, J PHARMACOL EXP THER, V253, P1042; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016/S0140-6736(00)02357-6; Muhlestein JB, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P297; MULLER FB, 1986, BRIT J CLIN PHARMACO, V21, pS143, DOI 10.1111/j.1365-2125.1986.tb02863.x; Muth JN, 2001, TRENDS PHARMACOL SCI, V22, P526, DOI 10.1016/S0165-6147(00)01797-1; Nawrath H, 1997, N-S ARCH PHARMACOL, V355, P79; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; Palka P, 2002, J AM SOC ECHOCARDIOG, V15, P884, DOI 10.1067/mje.2002.118032; Parkes JG, 1997, TOXICOLOGY, V117, P141, DOI 10.1016/S0300-483X(96)03566-4; Peri R, 2001, J BIOL CHEM, V276, P31667, DOI 10.1074/jbc.M102613200; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; Roy CN, 2001, HUM MOL GENET, V10, P2181, DOI 10.1093/hmg/10.20.2181; Rychkov G, 2001, HEPATOLOGY, V33, P938, DOI 10.1053/jhep.2001.23051; Song LS, 2002, CIRC RES, V90, P174, DOI 10.1161/hh0202.103230; Strohmeyer G, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P268; Templeton DM, 2003, BBA-GEN SUBJECTS, V1619, P113, DOI 10.1016/S0304-4165(02)00497-X; Tsushima RG, 1999, CIRC RES, V84, P1302, DOI 10.1161/01.RES.84.11.1302; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; YOUNG IS, 1994, FREE RADICAL BIO MED, V16, P393, DOI 10.1016/0891-5849(94)90041-8; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	65	356	370	1	27	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2003	9	9					1187	1194		10.1038/nm920	http://dx.doi.org/10.1038/nm920			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	716ZX	12937413				2022-12-25	WOS:000185061600032
